<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<html>
 <body>
  <pmc-articleset>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Retrovirology
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Retrovirology
      </journal-id>
      <journal-title-group>
       <journal-title>
        Retrovirology
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1742-4690
      </issn>
      <publisher>
       <publisher-name>
        BioMed Central
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       26084487
      </article-id>
      <article-id pub-id-type="pmc">
       4472405
      </article-id>
      <article-id pub-id-type="publisher-id">
       178
      </article-id>
      <article-id pub-id-type="doi">
       10.1186/s12977-015-0178-0
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Savarino
         </surname>
         <given-names>
          Andrea
         </given-names>
        </name>
        <address>
         <email>
          andrea.savarino@iss.it
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Shytaj
         </surname>
         <given-names>
          Iart Luca
         </given-names>
        </name>
        <address>
         <email>
          luca.shytaj@iss.it
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <aff id="Aff1">
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.416651.1
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000091206856
         </institution-id>
         <institution>
          Department of Infectious, Parasitic and Immune-Mediated Diseases,
         </institution>
         <institution>
          Istituto Superiore di Sanità,
         </institution>
        </institution-wrap>
        Viale Regina Elena, 299, 00161 Rome, Italy
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        18
       </day>
       <month>
        6
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        18
       </day>
       <month>
        6
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       12
      </volume>
      <elocation-id>
       51
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         11
        </day>
        <month>
         1
        </month>
        <year>
         2015
        </year>
       </date>
       <date date-type="accepted">
        <day>
         30
        </day>
        <month>
         5
        </month>
        <year>
         2015
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © Savarino and Shytaj 2015
       </copyright-statement>
       <license license-type="OpenAccess">
        <license-p>
         <bold>
          Open Access
         </bold>
         This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">
          http://creativecommons.org/publicdomain/zero/1.0/
         </ext-link>
         http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p id="Par1">
        The restoration of the immune system prompted by antiretroviral therapy (ART) has allowed drastically reducing the mortality and morbidity of HIV infection. However, one main source of clinical concern is the persistence of immune hyperactivation in individuals under ART. Chronically enhanced levels of T-cell activation are associated with several deleterious effects which lead to faster disease progression and slower CD4
        <sup>
         +
        </sup>
        T-cell recovery during ART. In this article, we discuss the rationale, and review the results, of the use of antimalarial quinolines, such as chloroquine and its derivative hydroxychloroquine, to counteract immune activation in HIV infection. Despite the promising results of several pilot trials, the most recent clinical data indicate that antimalarial quinolines are unlikely to exert a marked beneficial effect on immune activation. Alternative approaches will likely be required to reproducibly decrease immune activation in the setting of HIV infection. If the quinoline-based strategies should nevertheless be pursued in future studies, particular care must be devoted to the dosage selection, in order to maximize the chances to obtain effective in vivo drug concentrations.
       </p>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Immune activation
       </kwd>
       <kwd>
        HIV latency
       </kwd>
       <kwd>
        Chloroquine
       </kwd>
       <kwd>
        Hydroxychloroquine
       </kwd>
       <kwd>
        Anti-rheumatic
       </kwd>
       <kwd>
        Clinical trials
       </kwd>
       <kwd>
        Auranofin
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © The Author(s) 2015
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Background
     </title>
     <p id="Par21">
      The quest for clinical candidates to counteract immune activation has become a “hot topic” in AIDS research, because HIV infection is characterized by malignant immune hyperactivation which correlates with disease progression and poor response to antiretroviral therapy (ART) [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      –
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ]. Moreover, immune hyperactivation is also regarded as a major obstacle to a cure for AIDS [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ].
     </p>
     <p id="Par22">
      In the beginning of the millennium, an article authored by one of us launched chloroquine as a tool to inhibit viral replication and the related malignant immune activation associated with some viral diseases [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. This article sparked a new wave of studies, in that it extended a theory, previously designed for HIV/AIDS [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ], to other viral diseases characterized by excessive immune activation. As will be discussed below, by accumulating in the acidic organelles, chloroquine exerts both direct antiviral effects on enveloped viruses and decreases activation of several cell types involved in the immune response. Chloroquine has since shown promise in preclinical studies (both in vitro and in vivo), as a therapeutic agent against emerging viruses such as MERS CoV [
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ]. Of note, chloroquine has been indicated as a promising candidate for filovirus treatment [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ], especially during the latest Ebola epidemic [
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ]. In two studies out of three, chloroquine showed antiviral activity in mice at the maximum tolerated dose [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
      ], thus rendering this drug an interesting agent for further testing of combination anti-Ebola therapies. However, the effects of chloroquine and its hydroxyl analogue hydroxychloroquine, on HIV infection, i.e. the initial target for the repurposing of these drugs, have remained controversial. On the one hand, based on the results of some earlier clinical trials, chloroquine/hydroxychloroquine has been recently re-suggested as a promising candidate to restrict the HIV-related immune activation [
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ]. On the other hand, the results from the latest clinical trials indicate that chloroquine/hydroxychloroquine has no beneficial effect on immune activation [
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="CR18">
       18
      </xref>
      ].
     </p>
     <p id="Par23">
      We here provide a state of the art of the studies investigating the use of chloroquine/hydroxychloroquine as a therapeutic tool for HIV/AIDS and suggest the possible biological grounds for the clinical results obtained. Moreover, we describe the reasons why our group decided to proceed further with strategies based on another drug, i.e. auranofin, which shares with chloroquine an anti-rheumatic effect [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ].
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Immune activation in HIV/AIDS
     </title>
     <p id="Par24">
      Several reviews have recently been published on immune activation in HIV infection [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ]. Briefly, immune hyperactivation, commonly measured as the expression levels on peripheral blood lymphocytes of markers such as HLA-DR, CD38, or CD69 correlates with, and also predicts, disease progression (reviewed in [
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
      ,
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      ]). Immune activation gradually decreases following therapy initiation [
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ] and is maintained high in immunological non-responders, who are individuals maintaining low CD4 counts despite prolonged exposure to ART [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. While the initial studies were focused on the relationship between disease progression and activation of CD8
      <sup>
       +
      </sup>
      T-cells [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ], later studies better concluded that there is a broader relationship between disease progression and immune hyperactivation, involving also CD4
      <sup>
       +
      </sup>
      T-cells [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ] and innate immunity [
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
      ].
     </p>
     <p id="Par25">
      Immune activation and viral replication are believed to be mutually enhanced in a vicious circle. The virus, recognized by the immune system as non-self, induces immune activation, which, in turn, fuels viral replication by furnishing to the virus material to synthesize the different viral components. For example, lymphocyte activation increases the cytoplasmic levels of deoxyribonucleotides necessary for viral DNA synthesis by reverse transcriptase [
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      ]. This vicious circle may still persist in anatomical compartments incompletely penetrated by ART.
     </p>
     <p id="Par26">
      HIV-induced immune activation is not limited to specific immunity, but exerts its effects on innate immunity as well. HIV-1 was shown to activate plasmacytoid dendritic cells (pDCs), which, differently from myeloid dendritic cells (the most potent antigen-presenting cells in the body), induce innate antimicrobial immunity by producing type I interferons (Figure
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ) [
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
      ]. pDCs internalize HIV-1 through viral envelope/CD4 interactions, and the internalized virus activates these cells mainly through toll-like receptor 7 (TLR-7) signaling (Figure
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ). Comparative pathology corroborates the hypothesis that over-stimulation of this pathway may be associated with deleterious effects. Sooty mangabeys (
      <italic>
       Cercocebus atys
      </italic>
      ), which can be infected by a simian homolog of HIV (i.e. simian immunodeficiency virus, SIV) but do not develop AIDS, display weak IFN-α production upon stimulation with TLR-7 antagonists [
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      ]. On the contrary, rhesus macaques (
      <italic>
       Macaca mulatta
      </italic>
      ), which do progress to AIDS, produce high amounts of IFN-α when their pDCs are subjected to the same stimuli [
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      ]. Moreover, another species displaying nonpathogenic SIV infection, i.e. the African green monkey (
      <italic>
       Chlorocebus aethiops
      </italic>
      ), is characterized by an efficient control of IFN-α production following acute infection [
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
      ].
      <fig id="Fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Mechanistic model of HIV-induced persistent immune-activation.
         <bold>
          a
         </bold>
         HIV enters CD4-expressing plasmacytoid dendritic cells (pDCs);
         <bold>
          b
         </bold>
         the virus is endocytosed, decapsided and its RNA is recognized by toll-like receptor 7 (TLR-7);
         <bold>
          c
         </bold>
         stimulation of TLR-7 prompts a signaling cascade inducing IFN-α transcription in the nucleus;
         <bold>
          d
         </bold>
         production of IFN-α favors activation of several cell subsets such as T, B and natural killer (NK) lymphocytes. Chloroquine (CQ) is postulated to reduce the efficiency of this mechanism by accumulating in endosomes and decreasing HIV-mediated TLR-7 signaling [
         <xref ref-type="bibr" rid="CR44">
          44
         </xref>
         ].
        </p>
       </caption>
       <graphic id="MO1" xlink:href="12977_2015_178_Fig1_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par27">
      pDCs decrease in peripheral blood during progression to AIDS, because, upon activation, they migrate to the lymphoid tissue [
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ]. As a huge number of cells reside in the gut-associated lymphoid tissue (GALT), according to the microbial translocation theory, the intestinal mucosa damaged by the consequent inflammation may become permeable to products of the gut microbiome which further enhance HIV-related immune hyperactivation [
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
      ,
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
      ].
     </p>
     <p id="Par28">
      Finally, immune activation is one primary driver of both generation and maintenance of the viral reservoir, which is mainly constituted by latently infected, central and transitional memory CD4
      <sup>
       +
      </sup>
      T-cells (henceforth T
      <sub>
       CM
      </sub>
      and T
      <sub>
       TM
      </sub>
      , respectively) [
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ]. Also in this case, comparative pathology has provided clues for understanding this phenomenon. It was shown that CD4
      <sup>
       +
      </sup>
      T
      <sub>
       CM
      </sub>
      cells from sooty mangabeys express, upon activation, low levels of CCR5, the main coreceptor for virus entry into cells, thus limiting infection of this important cellular compartment [
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ]. Instead, activated T
      <sub>
       CM
      </sub>
      cells from AIDS-developing species, such as humans and rhesus macaques, up-regulate the levels of CCR5 to a higher extent than cells from sooty mangabeys, thus facilitating the generation of a consistent viral reservoir [
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ]. After these cells become quiescent, viral replication switches off, and latently infected, HIV-reservoir cells proliferate through low-level antigenic stimulation (T
      <sub>
       CM
      </sub>
      ) or IL-7-driven homeostatic proliferation (T
      <sub>
       TM
      </sub>
      ) [
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ]. Both processes are enhanced by generalized immune activation.
     </p>
    </sec>
    <sec id="Sec3">
     <title>
      Mechanisms of action of chloroquine
     </title>
     <p id="Par29">
      Multiple in vitro effects of chloroquine could support its possible use as a modulator of immune activation in HIV/AIDS:
      <list list-type="order">
       <list-item>
        <p id="Par30">
         Chloroquine and its hydroxyl analogue hydroxychloroquine were shown in several studies to inhibit HIV-1 replication (reviewed in: [
         <xref ref-type="bibr" rid="CR7">
          7
         </xref>
         ]). The effects of these quinolines, mainly due to the induction of a defect in the maturation of the viral envelope glycoprotein gp120 [
         <xref ref-type="bibr" rid="CR35">
          35
         </xref>
         ,
         <xref ref-type="bibr" rid="CR36">
          36
         </xref>
         ], might mimic the effects of broadly neutralizing antibodies directed against the viral envelope, although the effects of these antibodies are weaker than those directed against the CD4-binding site [
         <xref ref-type="bibr" rid="CR37">
          37
         </xref>
         ]. These effects are additive to those of non-nucleosidic reverse transcriptase inhibitors (NNRTIs) and synergistic to those of protease inhibitors (PIs) [
         <xref ref-type="bibr" rid="CR38">
          38
         </xref>
         ]. As quinoline drugs accumulate in lymphoid tissues [
         <xref ref-type="bibr" rid="CR39">
          39
         </xref>
         ], they might decrease ongoing viral replication during ART in anatomical sanctuaries and, consequently switch off one of the main drivers of immune activation. Chloroquine is also an inhibitor of P-glycoprotein (P-gp) and multidrug resistance proteins (MRPs) [
         <xref ref-type="bibr" rid="CR40">
          40
         </xref>
         ,
         <xref ref-type="bibr" rid="CR41">
          41
         </xref>
         ], cell surface glycoproteins which extrude several antiretroviral drugs to the extracellular medium. In line with this evidence, chloroquine was shown to increase the intracellular levels of PIs [
         <xref ref-type="bibr" rid="CR38">
          38
         </xref>
         ]. The effects of chloroquine in combination with NRTIs are instead controversial: some reported an additive effect [
         <xref ref-type="bibr" rid="CR42">
          42
         </xref>
         ], while others did not detect it [
         <xref ref-type="bibr" rid="CR43">
          43
         </xref>
         ]. The combined effects of chloroquine and integrase inhibitors are as yet unknown.
        </p>
       </list-item>
       <list-item>
        <p id="Par31">
         Chloroquine accumulates in phagosomes of pDCs and inhibits their HIV-induced activation [
         <xref ref-type="bibr" rid="CR44">
          44
         </xref>
         ]. It might therefore impact on innate immunity-induced immune hyperactivation.
        </p>
       </list-item>
       <list-item>
        <p id="Par32">
         A recent study showed that hydroxychloroquine selectively induces apoptosis in the memory T-cell compartment (CD45RA
         <sup>
          −
         </sup>
         CD45RO
         <sup>
          +
         </sup>
         ) [
         <xref ref-type="bibr" rid="CR45">
          45
         </xref>
         ]. As, upon activation, naïve T-cells (CD45RA
         <sup>
          +
         </sup>
         CD45RO
         <sup>
          −
         </sup>
         ) acquire a CD45RA
         <sup>
          −
         </sup>
         CD45RO
         <sup>
          +
         </sup>
         phenotype, the “antimemory” effect should limit immune activation (Figure
         <xref ref-type="fig" rid="Fig2">
          2
         </xref>
         ) [
         <xref ref-type="bibr" rid="CR46">
          46
         </xref>
         ]. There is growing consensus that induction of apoptosis in the memory T-cell compartment might have a detrimental effect on the viral reservoir [
         <xref ref-type="bibr" rid="CR47">
          47
         </xref>
         –
         <xref ref-type="bibr" rid="CR49">
          49
         </xref>
         ]. In this light, chloroquine/hydroxychloroquine should have an anti-reservoir potential. This view is supported by another recent study which shows that chloroquine sensitizes to apoptosis the latently infected cells upon viral reactivation, likely by removing the anti-apoptotic effect of the virus structural
         <italic>
          gag
         </italic>
         gene products [
         <xref ref-type="bibr" rid="CR50">
          50
         </xref>
         ]. These effects are potentially interesting, since it has been well demonstrated that viral reactivation from latency does not necessarily result in cell death [
         <xref ref-type="bibr" rid="CR51">
          51
         </xref>
         ].
         <fig id="Fig2">
          <label>
           Figure 2
          </label>
          <caption>
           <p>
            Comparison of the susceptibility to chloroquine/hydroxychloroquine and auranofin of the cellular subsets involved in HIV production and persistence. Shown in the figure is a schematic depiction of
            <bold>
             a
            </bold>
            activation and
            <bold>
             b
            </bold>
            differentiation stages of CD4
            <sup>
             +
            </sup>
            T-lymphocytes and their correlation with viral production, latency and viral reactivation. Both chloroquine/hydroxychloroquine and auranofin can influence these transitions by exerting a pro-apoptotic effect, the efficacy of which is graphically exemplified by the intensity of the
            <italic>
             blue color
            </italic>
            in the corresponding
            <italic>
             rectangles
            </italic>
            . Efficacy gradients are based on data derived from Refs. [
            <xref ref-type="bibr" rid="CR45">
             45
            </xref>
            ,
            <xref ref-type="bibr" rid="CR48">
             48
            </xref>
            ,
            <xref ref-type="bibr" rid="CR50">
             50
            </xref>
            ].
           </p>
          </caption>
          <graphic id="MO2" xlink:href="12977_2015_178_Fig2_HTML">
          </graphic>
         </fig>
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec id="Sec4">
     <title>
      In vivo effects of chloroquine/hydroxychloroquine: preclinical models
     </title>
     <p id="Par33">
      The macaque AIDS model is an important tool for preclinical assessment of strategies aimed at treating HIV/AIDS [
      <xref ref-type="bibr" rid="CR52">
       52
      </xref>
      ]. To our knowledge, chloroquine has been tested in this model on two occasions.
     </p>
     <p id="Par34">
      In a first study, chloroquine (25 mg every other day for 30 days, i.e. a cumulative dosage comparable to that administered to humans with rheumatioid arthritis) was administered to three Chinese rhesus macaques infected with the simian HIV-homologue, SIVmac
      <sub>
       251
      </sub>
      [
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
      ]. Although a decrease in activated pDCs was shown, no effects were seen on viral load and CD4
      <sup>
       +
      </sup>
      and CD8
      <sup>
       +
      </sup>
      T-cell activation (measured as CD38 expression) [
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
      ].
     </p>
     <p id="Par35">
      As the immune activation set point is established during acute infection [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ], Vaccari et al. [
      <xref ref-type="bibr" rid="CR54">
       54
      </xref>
      ] treated with chloroquine (18.7 mg/day for 112 consecutive days) seven SIVmac
      <sub>
       251
      </sub>
      -infected rhesus macaques during the viral load peak that characterizes acute infection. Apart from an unexpected, although transient, increase in the expression of interferon-regulated genes (perhaps not population-relevant as possibly driven by only one animal), no significant differences were reported in viral load and T-cell activation and proliferation (measured as expression of CD69 and Ki67, respectively) [
      <xref ref-type="bibr" rid="CR54">
       54
      </xref>
      ]. A trend was however noticed for maintenance of decreased levels of Ki67, CD69 and CCR5 in the gut of the chloroquine-treated animals, although the differences with values from the control group did not reach statistical significance. The effect of chloroquine in this simian model in the presence of ART is still unknown.
     </p>
    </sec>
    <sec id="Sec5">
     <title>
      In vivo effects of chloroquine/hydroxychloroquine: clinical trials
     </title>
     <p id="Par36">
      Chloroquine and hydroxychloroquine have so far been tested in several HIV clinical trials. The results summarized in Figure
      <xref ref-type="fig" rid="Fig3">
       3
      </xref>
      support the hypothesis that the chloroquine/hydroxychloroquine dosage may be an important driver of at least partial clinical success.
     </p>
     <p id="Par37">
      Suppressive effects on immune activation by chloroquine were shown in the trial conducted by Murray et al. [
      <xref ref-type="bibr" rid="CR55">
       55
      </xref>
      ]. However, in this trial, the dosage administered was not the same for all individuals, some of them receiving 500 mg/die instead of 250 mg/die. It is thus possible that the statistical significance of the effects reported in this study was driven by the higher dosage of the drug. This view is supported by a later study which tested chloroquine at 250 mg/die and failed to show any effect of the drug [
      <xref ref-type="bibr" rid="CR18">
       18
      </xref>
      ].
      <fig id="Fig3">
       <label>
        Figure 3
       </label>
       <caption>
        <p>
         Published clinical studies evaluating the effects of chloroquine/hydroxychloroquine administration, alone or in combination with other drugs, in HIV infected subjects. Highlighted in
         <italic>
          blue
         </italic>
         ,
         <italic>
          red
         </italic>
         or
         <italic>
          white
         </italic>
         are the studies that have reported a positive, negative, or neutral outcome of the therapy respectively.
         <italic>
          CQ
         </italic>
         chloroquine,
         <italic>
          HCQ
         </italic>
         hydroxychloroquine.
        </p>
       </caption>
       <graphic id="MO30" xlink:href="12977_2015_178_Fig3_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par38">
      In two clinical trials conducted in the 1990s, Sperber et al. reported suppressive effects on immune activation (measured at that time as IL-6 production) and viral load in individuals treated with 800 mg of hydroxychloroquine/day (bioequivalent to 500 mg/day of chloroquine) [
      <xref ref-type="bibr" rid="CR56">
       56
      </xref>
      ,
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
      ]. The other clinical trials testing hydroxychloroquine at a lower dosage (i.e. 400 mg/day) led to conflicting results. Earlier studies [
      <xref ref-type="bibr" rid="CR58">
       58
      </xref>
      ,
      <xref ref-type="bibr" rid="CR59">
       59
      </xref>
      ] and the more recent study of Piconi et al. [
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
      ] reported significant effects on viral load [
      <xref ref-type="bibr" rid="CR58">
       58
      </xref>
      ], CD4 counts [
      <xref ref-type="bibr" rid="CR59">
       59
      </xref>
      ], and immune activation. [
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
      ]. Instead, a more recent clinical trial, randomized and double blind, showed disappointing results, even hinting at possibly deleterious effects of hydroxychloroquine on viral load and CD4 counts [
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      ]. This trial was conducted in the absence of ART, and this might explain differences between this study and the study of Piconi et al., which was conducted on individuals under ART [
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
      ]. Another trial in ART-treated patients is currently ongoing and will provide more information on the effects of hydroxychloroquine (ClinicalTrials.gov identifier: NCT01232660).
     </p>
     <p id="Par39">
      The hydroxychloroquine levels show high inter-subject variability and, although individuals receiving the higher hydroxychloroquine dosages (800 and 1,200 mg/day) also showed significantly higher blood levels of the drug than those receiving 400 mg/die, the range of the blood concentrations was in part overlapping in the different dosage groups [
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ]. Chloroquine has similar pharmacokinetics [
      <xref ref-type="bibr" rid="CR62">
       62
      </xref>
      ]; therefore, not only the dosage but also individual differences in drug metabolism and distribution may explain the different conclusions of the aforementioned studies. A large clinical trial has recently been completed (ClinicalTrials.gov Identifier: NCT00819390) and its results can help to better represent the response of a population, thus abolishing the bias due to limited sample size. In this trial, however, chloroquine has been tested at 250 mg/day in the absence of ART; thus, in light of the results of the aforementioned clinical trials and considerations derived from basic science (see next paragraph), it is not surprising that the preliminary results released so far for this trial (
      <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00819390">
       https://clinicaltrials.gov/ct2/show/NCT00819390
      </ext-link>
      ) do not show any significant effect of chloroquine on immune activation, viral load and CD4 counts.
     </p>
    </sec>
    <sec id="Sec6">
     <title>
      Lessons learnt from chloroquine/hydroxychloroquine use in HIV infection
     </title>
     <p id="Par40">
      Chloroquine/hydroxychloroquine-treated individuals display blood concentrations that are highly variable and only rarely exceed 10 or 20 µM, respectively [
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ,
      <xref ref-type="bibr" rid="CR62">
       62
      </xref>
      ]. Therefore, at the steady state levels, these blood concentrations only in part overlap those at which a therapeutic effect is expected. For example, the EC
      <sub>
       50
      </sub>
      of chloroquine on PBMC proliferation upon activation is, in general, ≥10 µM [
      <xref ref-type="bibr" rid="CR63">
       63
      </xref>
      ], and this value can explain the varying results obtained in the different clinical trials, with clearer effects associated with the higher drug dosages. Similarly, the pro-apoptotic effect of hydroxychloroquine on the memory T-cells is only moderate at the concentrations reachable in blood, especially in the lower range [
      <xref ref-type="bibr" rid="CR45">
       45
      </xref>
      ,
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ]. The pro-apoptotic effect of chloroquine described by Li et al. on latently infected cells upon viral reactivation is instead more marked, although still partial, at the upper range of clinically achievable blood concentrations (5–10 µM) [
      <xref ref-type="bibr" rid="CR50">
       50
      </xref>
      ]. This effect could therefore be visible in vivo in terms of viral reservoir reduction, but only treating with high chloroquine dosages in the presence of suppressive ART. Moreover, to maximize the chances to obtain viral reservoir reduction in vivo, chloroquine treatment should be prolonged, as the events of virus reactivation from latency are rather rare (estimated as one event of transition from latency to productive infection every 10 mL of blood each day) [
      <xref ref-type="bibr" rid="CR64">
       64
      </xref>
      ].
     </p>
     <p id="Par41">
      The effect of chloroquine on pDC activation (see Figure
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ) was initially observed in vitro by pre-incubating pDCs with 100 µM of chloroquine for 1 h [
      <xref ref-type="bibr" rid="CR44">
       44
      </xref>
      ]. This treatment results in intracellular concentrations comparable to those observed during chronic in vivo administration [
      <xref ref-type="bibr" rid="CR65">
       65
      </xref>
      ]. In this case, the in vitro effect is in line with the results of two in vivo studies [
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
      ,
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
      ]. The use of chloroquine-related compounds with increased potency is yielding promising results in vitro [
      <xref ref-type="bibr" rid="CR66">
       66
      </xref>
      ], and it will be interesting to test the best-performing candidates in the simian AIDS model.
     </p>
     <p id="Par42">
      The effects of chloroquine/hydroxychloroquine on viral replication have been repeatedly shown in vitro at lower drug levels than those inducing the cellular effects [
      <xref ref-type="bibr" rid="CR35">
       35
      </xref>
      ,
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
      ,
      <xref ref-type="bibr" rid="CR63">
       63
      </xref>
      ,
      <xref ref-type="bibr" rid="CR65">
       65
      </xref>
      ]. The blood concentration/EC
      <sub>
       50
      </sub>
      ratio is however much narrower than those shown by antiretroviral drugs [
      <xref ref-type="bibr" rid="CR63">
       63
      </xref>
      ]. The antiretroviral effects of chloroquine/hydroxychloroquine may though become visible in anatomical sanctuaries of those individuals treated with PI-containing antiretroviral regimens. In any case, we recommend that chloroquine/hydroxychloroquine be tested at the highest recommended dosages in future HIV clinical trials.
     </p>
     <p>
      Alternative/complementary interpretations of the results so far obtained are possible. For example, the effectiveness of the ART regimen employed may play a role in determining the magnitude of the effects (if any) observed following chloroquine/hydroxichloroquine addition. The study of Piconi et al. [
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
      ], showing some benefit in immunological non responders, may indicate that the effects of chloroquine may be visible only in some subsets of individuals with peculiar immunological characteristics, and that these effects can be hindered when immunologically non homogeneous cohorts are studied. In this regard, larger studies, with cohorts stratified according to immunological responsiveness to ART, could provide further information on the effects of chloroquine/hydroxychloroquine.
     </p>
     <p id="Par43">
      Another open question remains the influence of the duration of drug exposure, as it has been shown that chloroquine/hydroxychloroquine has cumulative effects [
      <xref ref-type="bibr" rid="CR67">
       67
      </xref>
      ]. As a proportion of HIV-infected patients in Africa may already be on chloroquine medication to prevent malaria, it might be worth examining the long-term effects of this treatment. In this regard, an ongoing phase III clinical trial will assess the long-term effects of chloroquine and trimethoprim-sulfamethoxazole phrophylaxis on survival and disease control in HIV-infected individuals with suppressed viral load and good clinical response to ART [
      <xref ref-type="bibr" rid="CR68">
       68
      </xref>
      ].
     </p>
    </sec>
    <sec id="Sec7">
     <title>
      Current and future directions: another approach based on antirheumatic therapy
     </title>
     <p id="Par44">
      Given the aforementioned problems in the pharmacokinetics of chloroquine/hydroxychloroquine, our group chose to follow a different, yet partly similar, approach to corroborate treatment of HIV/AIDS. Based on the feedback received from basic science studies and clinical trials that have been published throughout the years, we decided to use drugs the desired effects of which be striking in vitro at concentrations lower than the trough plasma concentrations in vivo. We also decided to re-direct our research on the basis of the plasma concentrations rather than on whole-blood concentrations (widely used for chloroquine/hydroxychloroquine), because we thought that the former might better mimic the tissue culture concentrations. The drug that we selected is the gold-based compound auranofin, the pharmacodynamics and pharmacokinetics of which are well known, due to its decade-long employment for treatment of rheumatoid arthritis [
      <xref ref-type="bibr" rid="CR69">
       69
      </xref>
      ].
     </p>
     <p id="Par45">
      The main rationale for the use of auranofin in our studies was its ability to target the central/transitional memory CD4
      <sup>
       +
      </sup>
      T-cell compartment (Figure
      <xref ref-type="fig" rid="Fig2">
       2
      </xref>
      ) [
      <xref ref-type="bibr" rid="CR48">
       48
      </xref>
      ,
      <xref ref-type="bibr" rid="CR70">
       70
      </xref>
      ], which is known to harbor the main viral reservoir in patients receiving ART [
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ]. Auranofin is drastically active at sub-micromolar (i.e. ≤250 nM) concentrations, which are below those readily achievable in human plasma [
      <xref ref-type="bibr" rid="CR71">
       71
      </xref>
      ]. The administration of auranofin ultimately led to a reduction of the viral reservoir in ART-treated SIVmac251-infected macaques [
      <xref ref-type="bibr" rid="CR70">
       70
      </xref>
      ]. A review on our preclinical studies has recently been published [
      <xref ref-type="bibr" rid="CR46">
       46
      </xref>
      ] and the reader is addressed to it for further detail. Not surprisingly for a drug effective against an autoimmune disease such as rheumatoid arthritis, auranofin may as well be beneficial in terms of reduction of cell activation. In particular, the downregulation of the CD28 molecule induced by auranofin can disrupt the co-stimulatory signal often crucial for lymphocyte activation [
      <xref ref-type="bibr" rid="CR48">
       48
      </xref>
      ]. Moreover, apart from memory CD4
      <sup>
       +
      </sup>
      T-cells, auranofin also targets the memory CD8
      <sup>
       +
      </sup>
      T-cell compartment [
      <xref ref-type="bibr" rid="CR48">
       48
      </xref>
      ], i.e. a cellular subset known to be hyperactivated during HIV infection [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ]. Interestingly, as described for hydroxychloroquine [
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
      ], auranofin was shown to disrupt in various cell lines the TLR-4 signaling [
      <xref ref-type="bibr" rid="CR72">
       72
      </xref>
      ], which is activated by bacterial lipopolysaccharides and likely constitutes another source of immune hyperactivation. In vitro data indicate that the impact of auranofin on lymphocyte activation may be mediated, at least in part, by modulation of oxidative stress [
      <xref ref-type="bibr" rid="CR48">
       48
      </xref>
      ]. Of note, the addition of a potent pro-oxidant drug, such as buthionine sulfoximine (BSO), increases the potency of auranofin, decreasing phytohemagglutinin-induced activation and expression of the α-chain of the IL-2 receptor [
      <xref ref-type="bibr" rid="CR73">
       73
      </xref>
      ]. This is in line with our preliminary data in SIVmac251-infected macaques, in which a combined regimen of ART, auranofin and BSO induced a functional cure-like condition following suspension of all therapies [
      <xref ref-type="bibr" rid="CR74">
       74
      </xref>
      ]. These observations provide proof of concept that drastically decreasing immune hyperactivation arrests SIV disease progression and turns the virus/immune system balance in favor of the latter. Clinical trials will be required to assess the potential of auranofin to decrease immune activation in ART-treated subjects.
     </p>
     <p id="Par46">
      Finally, other drugs used or proposed for treatment of rheumatoid arthritis might find a place in the treatment of HIV/AIDS. For example, the janus kinase inhibitors tofacitinib and ruxolitinib have shown a promising in vitro activity against HIV replication [
      <xref ref-type="bibr" rid="CR75">
       75
      </xref>
      ]. The ongoing in vivo studies on these compounds could provide an opportunity to analyze the effects of this treatment on viral replication and immune activation.
     </p>
    </sec>
    <back>
     <glossary>
      <title>
       Abbreviations
      </title>
      <def-list>
       <def-item>
        <term>
         ART
        </term>
        <def>
         <p id="Par2">
          antiretroviral therapy
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         AIDS
        </term>
        <def>
         <p id="Par3">
          acquired immunodeficiency syndrome
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         BSO
        </term>
        <def>
         <p id="Par4">
          buthionine sulfoximine
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         CCR5
        </term>
        <def>
         <p id="Par5">
          C–C chemokine receptor type 5
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         CD
        </term>
        <def>
         <p id="Par6">
          cluster of designation/differentiation
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         GALT
        </term>
        <def>
         <p id="Par7">
          gut associated lymphoid tissue
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         HIV
        </term>
        <def>
         <p id="Par8">
          human immunodeficiency virus
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         IL
        </term>
        <def>
         <p id="Par9">
          interleukin
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MERS CoV
        </term>
        <def>
         <p id="Par10">
          middle east respiratory syndrome coronavirus
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MRP
        </term>
        <def>
         <p id="Par11">
          multidrug resistance protein
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         NRTI
        </term>
        <def>
         <p id="Par12">
          nucleosidic reverse transcriptase inhibitor
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         NNRTI
        </term>
        <def>
         <p id="Par13">
          non-nucleosidic reverse transcriptase inhibitor
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         pDC
        </term>
        <def>
         <p id="Par14">
          plasmacytoid dendritic cell
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         P-gp
        </term>
        <def>
         <p id="Par15">
          P-glycoprotein
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         PI
        </term>
        <def>
         <p id="Par16">
          protease inhibitor
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         SIV
        </term>
        <def>
         <p id="Par17">
          simian immunodeficiency virus
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         TLR
        </term>
        <def>
         <p id="Par18">
          toll-like receptor
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         T
         <sub>
          CM
         </sub>
        </term>
        <def>
         <p id="Par19">
          central memory T-cell
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         T
         <sub>
          TM
         </sub>
        </term>
        <def>
         <p id="Par20">
          transitional memory T-cell
         </p>
        </def>
       </def-item>
      </def-list>
     </glossary>
     <ack>
      <title>
       Authors’ contributions
      </title>
      <p>
       AS and ILS contributed to the ideas and to the interpretation of the data presented in the manuscript. AS and ILS contributed to manuscript drafting and preparation of the figures. Both authors read and approved the final manuscript.
      </p>
      <sec id="d29e985">
       <title>
        Acknowledgements
       </title>
       <p id="Par47">
        ILS is supported by a fellowship from the “Sapienza” University (Rome, Italy).
       </p>
      </sec>
      <sec id="d29e990">
       <title>
        Compliance with ethical guidelines
       </title>
       <p id="Par48">
        <bold>
         Competing interests
        </bold>
        The Istituto Superiore di Sanità holds a US patent on the use of the auranofin for treatment of HIV/AIDS. AS is the leading inventor of the patent.
       </p>
      </sec>
     </ack>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Giorgi
          </surname>
          <given-names>
           JV
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           HN
          </given-names>
         </name>
         <name>
          <surname>
           Hirji
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Hultin
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <name>
          <surname>
           O’Rourke
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38− CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         1994
        </year>
        <volume>
         170
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         775
        </fpage>
        <lpage>
         781
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/170.4.775
        </pub-id>
        <pub-id pub-id-type="pmid">
         7930717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bofill
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mocroft
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lipman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Medina
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Borthwick
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
         <name>
          <surname>
           Sabin
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Increased numbers of primed activated CD8+ CD38+ CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients
        </article-title>
        <source>
         AIDS
        </source>
        <year>
         1996
        </year>
        <volume>
         10
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         827
        </fpage>
        <lpage>
         834
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/00002030-199607000-00005
        </pub-id>
        <pub-id pub-id-type="pmid">
         8828739
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hunt
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           JN
          </given-names>
         </name>
         <name>
          <surname>
           Sinclair
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Bredt
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Hagos
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Lampiris
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         187
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         1534
        </fpage>
        <lpage>
         1543
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/374786
        </pub-id>
        <pub-id pub-id-type="pmid">
         12721933
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deeks
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
         <name>
          <surname>
           Kitchen
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Gascon
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Narváez
          </surname>
          <given-names>
           AB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load
        </article-title>
        <source>
         Blood
        </source>
        <year>
         2004
        </year>
        <volume>
         104
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         942
        </fpage>
        <lpage>
         947
        </lpage>
        <pub-id pub-id-type="doi">
         10.1182/blood-2003-09-3333
        </pub-id>
        <pub-id pub-id-type="pmid">
         15117761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hunt
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
         <name>
          <surname>
           Brenchley
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sinclair
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           McCune
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Roland
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Page-Shafer
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2008
        </year>
        <volume>
         197
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         126
        </fpage>
        <lpage>
         133
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/524143
        </pub-id>
        <pub-id pub-id-type="pmid">
         18171295
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hatano
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immune activation and HIV persistence: considerations for novel therapeutic interventions
        </article-title>
        <source>
         Curr Opin HIV AIDS
        </source>
        <year>
         2013
        </year>
        <volume>
         8
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         211
        </fpage>
        <lpage>
         216
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/COH.0b013e32835f9788
        </pub-id>
        <pub-id pub-id-type="pmid">
         23454864
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Majori
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of chloroquine on viral infections: an old drug against today’s diseases?
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         3
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         722
        </fpage>
        <lpage>
         727
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(03)00806-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         14592603
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Piette
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         The potential place of chloroquine in the treatment of HIV-1-infected patients
        </article-title>
        <source>
         J Clin Virol
        </source>
        <year>
         2001
        </year>
        <volume>
         20
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         137
        </fpage>
        <lpage>
         140
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1386-6532(00)00140-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         11166662
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wilde
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Jochmans
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Posthuma
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Zevenhoven-Dobbe
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           van Nieuwkoop
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4875
        </fpage>
        <lpage>
         4884
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.03011-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24841269
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madrid
          </surname>
          <given-names>
           PB
          </given-names>
         </name>
         <name>
          <surname>
           Chopra
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Manger
          </surname>
          <given-names>
           ID
          </given-names>
         </name>
         <name>
          <surname>
           Gilfillan
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Keepers
          </surname>
          <given-names>
           TR
          </given-names>
         </name>
         <name>
          <surname>
           Shurtleff
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2013
        </year>
        <volume>
         8
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         e60579
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0060579
        </pub-id>
        <pub-id pub-id-type="pmid">
         23577127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Clercq
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ebola virus (EBOV) infection: therapeutic strategies
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         2015
        </year>
        <volume>
         93
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         1
        </fpage>
        <lpage>
         10
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bcp.2014.11.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         25481298
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="other">
        Long J, Wright E, Molesti E, Temperton N, Barclay W (2015) Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry [v1; ref status: awaiting peer review,
        <ext-link ext-link-type="uri" xlink:href="http://f1000r.es/510">
         http://f1000r.es/510
        </ext-link>
        ]. F1000Research 4:30
       </mixed-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="other">
        Madrid PB, Panchal R, Warren T, Shurtleff A, Endsley A, Green C et al (2015) Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis (in press)
       </mixed-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="other">
        Falzarano D, Safronetz D, Prescott J, Marzi A, Feldmann F, Feldmann H (2015) Lack of protection against Ebola virus from chloroquine in mice and hamsters. Emerg Infect Dis (in press)
       </mixed-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saez-Cirion
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Jacquelin
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Barré-Sinoussi
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Müller-Trutwin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?
        </article-title>
        <source>
         Philos Trans R Soc Lond B Biol Sci
        </source>
        <year>
         2014
        </year>
        <volume>
         369
        </volume>
        <issue>
         1645
        </issue>
        <fpage>
         20130436
        </fpage>
        <pub-id pub-id-type="doi">
         10.1098/rstb.2013.0436
        </pub-id>
        <pub-id pub-id-type="pmid">
         24821922
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rajasuriar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Khoury
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Kamarulzaman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           French
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Cameron
          </surname>
          <given-names>
           PU
          </given-names>
         </name>
         <name>
          <surname>
           Lewin
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Persistent immune activation in chronic HIV infection: do any interventions work?
        </article-title>
        <source>
         AIDS
        </source>
        <year>
         2013
        </year>
        <volume>
         27
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         1199
        </fpage>
        <lpage>
         1208
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/QAD.0b013e32835ecb8b
        </pub-id>
        <pub-id pub-id-type="pmid">
         23324661
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paton
          </surname>
          <given-names>
           NI
          </given-names>
         </name>
         <name>
          <surname>
           Goodall
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Dunn
          </surname>
          <given-names>
           DT
          </given-names>
         </name>
         <name>
          <surname>
           Franzen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Collaco-Moraes
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Gazzard
          </surname>
          <given-names>
           BG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine Trial Team: effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2012
        </year>
        <volume>
         308
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         353
        </fpage>
        <lpage>
         361
        </lpage>
        <pub-id pub-id-type="doi">
         10.1001/jama.2012.6936
        </pub-id>
        <pub-id pub-id-type="pmid">
         22820788
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Routy
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Angel
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kanagaratham
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Radzioch
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Kema
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy
        </article-title>
        <source>
         HIV Med
        </source>
        <year>
         2015
        </year>
        <volume>
         16
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         48
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/hiv.12171
        </pub-id>
        <pub-id pub-id-type="pmid">
         24889179
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           UR
          </given-names>
         </name>
         <name>
          <surname>
           Naidu
          </surname>
          <given-names>
           MU
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           TR
          </given-names>
         </name>
         <name>
          <surname>
           Shobha
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Askar
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis—a double blind study
        </article-title>
        <source>
         J Rheumatol
        </source>
        <year>
         1995
        </year>
        <volume>
         22
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1235
        </fpage>
        <lpage>
         1240
        </lpage>
        <pub-id pub-id-type="pmid">
         7562751
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klatt
          </surname>
          <given-names>
           NR
          </given-names>
         </name>
         <name>
          <surname>
           Chomont
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Douek
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Deeks
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immune activation and HIV persistence: implications for curative approaches to HIV infection
        </article-title>
        <source>
         Immunol Rev
        </source>
        <year>
         2013
        </year>
        <volume>
         254
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         326
        </fpage>
        <lpage>
         342
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/imr.12065
        </pub-id>
        <pub-id pub-id-type="pmid">
         23772629
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paiardini
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Müller-Trutwin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         HIV-associated chronic immune activation
        </article-title>
        <source>
         Immunol Rev
        </source>
        <year>
         2013
        </year>
        <volume>
         254
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         78
        </fpage>
        <lpage>
         101
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/imr.12079
        </pub-id>
        <pub-id pub-id-type="pmid">
         23772616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lederman
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Funderburg
          </surname>
          <given-names>
           NT
          </given-names>
         </name>
         <name>
          <surname>
           Sekaly
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
         <name>
          <surname>
           Klatt
          </surname>
          <given-names>
           NR
          </given-names>
         </name>
         <name>
          <surname>
           Hunt
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Residual immune dysregulation syndrome in treated HIV infection
        </article-title>
        <source>
         Adv Immunol
        </source>
        <year>
         2013
        </year>
        <volume>
         119
        </volume>
        <fpage>
         51
        </fpage>
        <lpage>
         83
        </lpage>
        <pub-id pub-id-type="pmid">
         23886064
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lichtfuss
          </surname>
          <given-names>
           GF
          </given-names>
         </name>
         <name>
          <surname>
           Hoy
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Rajasuriar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Kramski
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Crowe
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Lewin
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection
        </article-title>
        <source>
         Biomark Med
        </source>
        <year>
         2011
        </year>
        <volume>
         5
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         171
        </fpage>
        <lpage>
         186
        </lpage>
        <pub-id pub-id-type="doi">
         10.2217/bmm.11.15
        </pub-id>
        <pub-id pub-id-type="pmid">
         21473720
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Autran
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Carcelain
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           TS
          </given-names>
         </name>
         <name>
          <surname>
           Blanc
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Mathez
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Tubiana
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Positive effects of combined antiretroviral therapy on CD4+ Tcell homeostasis and function in advanced HIV disease
        </article-title>
        <source>
         Science
        </source>
        <year>
         1997
        </year>
        <volume>
         277
        </volume>
        <issue>
         5322
        </issue>
        <fpage>
         112
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.277.5322.112
        </pub-id>
        <pub-id pub-id-type="pmid">
         9204894
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Giorgi
          </surname>
          <given-names>
           JV
          </given-names>
         </name>
         <name>
          <surname>
           Hultin
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <name>
          <surname>
           McKeating
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           TD
          </given-names>
         </name>
         <name>
          <surname>
           Owens
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Jacobson
          </surname>
          <given-names>
           LP
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         1999
        </year>
        <volume>
         179
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         859
        </fpage>
        <lpage>
         870
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/314660
        </pub-id>
        <pub-id pub-id-type="pmid">
         10068581
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Beignon
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           McKenna
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Skoberne
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Manches
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           DaSilva
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Kavanagh
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         2005
        </year>
        <volume>
         115
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         3265
        </fpage>
        <lpage>
         3275
        </lpage>
        <pub-id pub-id-type="doi">
         10.1172/JCI26032
        </pub-id>
        <pub-id pub-id-type="pmid">
         16224540
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           WY
          </given-names>
         </name>
         <name>
          <surname>
           Cara
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Gallo
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name>
          <surname>
           Lori
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         1993
        </year>
        <volume>
         90
        </volume>
        <issue>
         19
        </issue>
        <fpage>
         8925
        </fpage>
        <lpage>
         8928
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.90.19.8925
        </pub-id>
        <pub-id pub-id-type="pmid">
         7692440
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mandl
          </surname>
          <given-names>
           JN
          </given-names>
         </name>
         <name>
          <surname>
           Barry
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Vanderford
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <name>
          <surname>
           Kozyr
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Chavan
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Klucking
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections
        </article-title>
        <source>
         Nat Med
        </source>
        <year>
         2008
        </year>
        <volume>
         14
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         1077
        </fpage>
        <lpage>
         1087
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm.1871
        </pub-id>
        <pub-id pub-id-type="pmid">
         18806803
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jacquelin
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Mayau
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Targat
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Liovat
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Kunkel
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Petitjean
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         2009
        </year>
        <volume>
         119
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         3544
        </fpage>
        <lpage>
         3555
        </lpage>
        <pub-id pub-id-type="pmid">
         19959873
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sachdeva
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Asthana
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Brewer
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <name>
          <surname>
           Garcia
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Asthana
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impaired restoration of plasmacytoid dendritic cells in HIV-1-infected patients with poor CD4 T cell reconstitution is associated with decrease in capacity to produce IFN-alpha but not proinflammatory cytokines
        </article-title>
        <source>
         J Immunol
        </source>
        <year>
         2008
        </year>
        <volume>
         181
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         2887
        </fpage>
        <lpage>
         2897
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.181.4.2887
        </pub-id>
        <pub-id pub-id-type="pmid">
         18684980
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lederman
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Funderburg
          </surname>
          <given-names>
           NT
          </given-names>
         </name>
         <name>
          <surname>
           Sekaly
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
         <name>
          <surname>
           Klatt
          </surname>
          <given-names>
           NR
          </given-names>
         </name>
         <name>
          <surname>
           Hunt
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Residual immune dysregulation syndrome in treated HIV infection
        </article-title>
        <source>
         Adv Immunol
        </source>
        <year>
         2013
        </year>
        <volume>
         119
        </volume>
        <fpage>
         51
        </fpage>
        <lpage>
         83
        </lpage>
        <pub-id pub-id-type="pmid">
         23886064
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marchetti
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Tincati
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Silvestri
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Microbial translocation in the pathogenesis of HIV infection and AIDS
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <year>
         2013
        </year>
        <volume>
         26
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         2
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CMR.00050-12
        </pub-id>
        <pub-id pub-id-type="pmid">
         23297256
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chomont
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           El-Far
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ancuta
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Trautmann
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Procopio
          </surname>
          <given-names>
           FA
          </given-names>
         </name>
         <name>
          <surname>
           Yassine-Diab
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
        </article-title>
        <source>
         Nat Med
        </source>
        <year>
         2009
        </year>
        <volume>
         15
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         893
        </fpage>
        <lpage>
         900
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm.1972
        </pub-id>
        <pub-id pub-id-type="pmid">
         19543283
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paiardini
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cervasi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Reyes-Aviles
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Micci
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Ortiz
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Chahroudi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Low levels of SIV infection in sooty mangabey central memory CD4+ T cells are associated with limited CCR5 expression
        </article-title>
        <source>
         Nat Med
        </source>
        <year>
         2011
        </year>
        <volume>
         17
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         830
        </fpage>
        <lpage>
         836
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm.2395
        </pub-id>
        <pub-id pub-id-type="pmid">
         21706028
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsai
          </surname>
          <given-names>
           WP
          </given-names>
         </name>
         <name>
          <surname>
           Nara
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
         <name>
          <surname>
           Kung
          </surname>
          <given-names>
           HF
          </given-names>
         </name>
         <name>
          <surname>
           Oroszlan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of human immunodeficiency virus infectivity by chloroquine
        </article-title>
        <source>
         AIDS Res Hum Retroviruses
        </source>
        <year>
         1990
        </year>
        <volume>
         6
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         481
        </fpage>
        <lpage>
         489
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/aid.1990.6.481
        </pub-id>
        <pub-id pub-id-type="pmid">
         1692728
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Naarding
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Baan
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Pollakis
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Paxton
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes
        </article-title>
        <source>
         Retrovirology
        </source>
        <year>
         2007
        </year>
        <volume>
         4
        </volume>
        <fpage>
         6
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1742-4690-4-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         17263871
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Forsman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Beirnaert
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Aasa-Chapman
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Hoorelbeke
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Hijazi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Koh
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         12069
        </fpage>
        <lpage>
         12081
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01379-08
        </pub-id>
        <pub-id pub-id-type="pmid">
         18842738
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lucia
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           ter Heine
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Rastrelli
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Rutella
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Majori
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Quinoline antimalarials as investigational drugs for HIV-1/AIDS: in vitro effects on HIV-1 replication, HIV-1 response to antiretroviral drugs, and intracellular antiretroviral drug concentrations
        </article-title>
        <source>
         Drug Dev Res
        </source>
        <year>
         2006
        </year>
        <volume>
         67
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         806
        </fpage>
        <lpage>
         817
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/ddr.20147
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aguirre-Cruz
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Torres
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name>
          <surname>
           Jung-Cook
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Fortuny
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Sánchez
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Soda-Mehry
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects
        </article-title>
        <source>
         AIDS Res Hum Retroviruses
        </source>
        <year>
         2010
        </year>
        <volume>
         26
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         339
        </fpage>
        <lpage>
         342
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/aid.2009.0129
        </pub-id>
        <pub-id pub-id-type="pmid">
         20334568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klohs
          </surname>
          <given-names>
           WD
          </given-names>
         </name>
         <name>
          <surname>
           Steinkampf
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of lysosomotropic agents and secretory inhibitors on anthracycline retention and activity in multiple drug-resistant cells
        </article-title>
        <source>
         Mol Pharmacol
        </source>
        <year>
         1988
        </year>
        <volume>
         34
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         180
        </fpage>
        <lpage>
         185
        </lpage>
        <pub-id pub-id-type="pmid">
         2901030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vezmar
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Georges
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         2000
        </year>
        <volume>
         59
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         1245
        </fpage>
        <lpage>
         1252
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0006-2952(00)00270-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         10736425
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antiretroviral treatment
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         1998
        </year>
        <volume>
         352
        </volume>
        <issue>
         9135
        </issue>
        <fpage>
         1224
        </fpage>
        <lpage>
         1225
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(05)60566-1
        </pub-id>
        <pub-id pub-id-type="pmid">
         9777866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Torres
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name>
          <surname>
           Reyes-Terán
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Sotelo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Jung-Cook
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Aguirre-Cruz
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influence of quinacrine and chloroquine on the in vitro 3′-azido-3′-deoxythymidine antiretroviral effect
        </article-title>
        <source>
         AIDS Res Ther
        </source>
        <year>
         2015
        </year>
        <volume>
         12
        </volume>
        <fpage>
         7
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12981-015-0048-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         25788967
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martinson
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Montoya
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Usuga
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Ronquillo
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Landay
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Desai
          </surname>
          <given-names>
           SN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2010
        </year>
        <volume>
         54
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         871
        </fpage>
        <lpage>
         881
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.01246-09
        </pub-id>
        <pub-id pub-id-type="pmid">
         19949061
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45.
       </label>
       <mixed-citation publication-type="other">
        van Loosdregt J, Spreafico R, Rossetti M, Prakken BJ, Lotz M, Albani S (2013) Hydroxychloroquine preferentially induces apoptosis of CD45RO + effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells. J Allergy Clin Immunol 131(5):1443–6.e1
       </mixed-citation>
      </ref>
      <ref id="CR46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shytaj
          </surname>
          <given-names>
           IL
          </given-names>
         </name>
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         A cure for AIDS: a matter of timing?
        </article-title>
        <source>
         Retrovirology
        </source>
        <year>
         2013
        </year>
        <volume>
         10
        </volume>
        <fpage>
         145
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1742-4690-10-145
        </pub-id>
        <pub-id pub-id-type="pmid">
         24267982
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chomont
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           DaFonseca
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Vandergeeten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Ancuta
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Sékaly
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV
        </article-title>
        <source>
         Curr Opin HIV AIDS
        </source>
        <year>
         2011
        </year>
        <volume>
         6
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         30
        </fpage>
        <lpage>
         36
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/COH.0b013e3283413775
        </pub-id>
        <pub-id pub-id-type="pmid">
         21242891
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chirullo
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Sgarbanti
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Limongi
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Shytaj
          </surname>
          <given-names>
           IL
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Das
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A candidate anti-HIV reservoir compound, auranofin, exerts a selective ‘anti-memory’ effect by exploiting the baseline oxidative status of lymphocytes
        </article-title>
        <source>
         Cell Death Dis
        </source>
        <year>
         2013
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e944
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/cddis.2013.473
        </pub-id>
        <pub-id pub-id-type="pmid">
         24309931
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           XY
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Plasmodium infection reduces the volume of the viral reservoir in SIV-infected rhesus macaques receiving antiretroviral therapy
        </article-title>
        <source>
         Retrovirology
        </source>
        <year>
         2014
        </year>
        <volume>
         11
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         112
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12977-014-0112-x
        </pub-id>
        <pub-id pub-id-type="pmid">
         25487036
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50.
       </label>
       <mixed-citation publication-type="other">
        Li H, Hatfield G, Pauza CD (2014) Gag-mediated autophagy promotes CD4 T cell survival: a possible mechanism for HIV reservoir persistence. XX international AIDS conference, towards an HIV cure symposium; Melbourne, Australia. PE18 LB
       </mixed-citation>
      </ref>
      <ref id="CR51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shan
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Shroff
          </surname>
          <given-names>
           NS
          </given-names>
         </name>
         <name>
          <surname>
           Durand
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Rabi
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           HC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation
        </article-title>
        <source>
         Immunity
        </source>
        <year>
         2012
        </year>
        <volume>
         36
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         491
        </fpage>
        <lpage>
         501
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.immuni.2012.01.014
        </pub-id>
        <pub-id pub-id-type="pmid">
         22406268
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Evans
          </surname>
          <given-names>
           DT
          </given-names>
         </name>
         <name>
          <surname>
           Silvestri
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nonhuman primate models in AIDS research
        </article-title>
        <source>
         Curr Opin HIV AIDS
        </source>
        <year>
         2013
        </year>
        <volume>
         8
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         255
        </fpage>
        <lpage>
         261
        </lpage>
        <pub-id pub-id-type="pmid">
         23615116
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           GH
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           LG
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           YT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibitory effects of chloroquine on the activation of plasmacytoid dendritic cells in SIVmac239-infected Chinese rhesus macaques
        </article-title>
        <source>
         Cell Mol Immunol
        </source>
        <year>
         2012
        </year>
        <volume>
         9
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         410
        </fpage>
        <lpage>
         416
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/cmi.2012.22
        </pub-id>
        <pub-id pub-id-type="pmid">
         22885523
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vaccari
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Fenizia
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           ZM
          </given-names>
         </name>
         <name>
          <surname>
           Hryniewicz
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Boasso
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Doster
          </surname>
          <given-names>
           MN
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques
        </article-title>
        <source>
         AIDS Res Hum Retroviruses
        </source>
        <year>
         2014
        </year>
        <volume>
         30
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         355
        </fpage>
        <lpage>
         362
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/aid.2013.0218
        </pub-id>
        <pub-id pub-id-type="pmid">
         24251542
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murray
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Down
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Boulware
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Stauffer
          </surname>
          <given-names>
           WM
          </given-names>
         </name>
         <name>
          <surname>
           Cavert
          </surname>
          <given-names>
           WP
          </given-names>
         </name>
         <name>
          <surname>
           Schacker
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Reduction of immune activation with chloroquine therapy during chronic HIV infection
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2010
        </year>
        <volume>
         84
        </volume>
        <issue>
         22
        </issue>
        <fpage>
         12082
        </fpage>
        <lpage>
         12086
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01466-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         20844049
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Louie
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kraus
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Proner
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sapira
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1
        </article-title>
        <source>
         Clin Ther
        </source>
        <year>
         1995
        </year>
        <volume>
         17
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         622
        </fpage>
        <lpage>
         636
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0149-2918(95)80039-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         8565026
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Ross
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Chusid
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Gonchar
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1
        </article-title>
        <source>
         Clin Ther
        </source>
        <year>
         1997
        </year>
        <volume>
         19
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         913
        </fpage>
        <lpage>
         923
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0149-2918(97)80045-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         9385480
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paton
          </surname>
          <given-names>
           NI
          </given-names>
         </name>
         <name>
          <surname>
           Aboulhab
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Karim
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2002
        </year>
        <volume>
         359
        </volume>
        <issue>
         9318
        </issue>
        <fpage>
         1667
        </fpage>
        <lpage>
         1668
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(02)08557-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         12020529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paton
          </surname>
          <given-names>
           NI
          </given-names>
         </name>
         <name>
          <surname>
           Aboulhab
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks
        </article-title>
        <source>
         HIV Med
        </source>
        <year>
         2005
        </year>
        <volume>
         6
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         13
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1468-1293.2005.00259.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         15670247
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Piconi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Parisotto
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Rizzardini
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Passerini
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Terzi
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Argenteri
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders
        </article-title>
        <source>
         Blood
        </source>
        <year>
         2011
        </year>
        <volume>
         118
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         3263
        </fpage>
        <lpage>
         3272
        </lpage>
        <pub-id pub-id-type="doi">
         10.1182/blood-2011-01-329060
        </pub-id>
        <pub-id pub-id-type="pmid">
         21576701
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Gibbs
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Baethge
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Botstein
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
         <name>
          <surname>
           Caldwell
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2002
        </year>
        <volume>
         46
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         1460
        </fpage>
        <lpage>
         1469
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/art.10307
        </pub-id>
        <pub-id pub-id-type="pmid">
         12115175
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Augustijns
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Geusens
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Verbeke
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis
        </article-title>
        <source>
         Eur J Clin Pharmacol
        </source>
        <year>
         1992
        </year>
        <volume>
         42
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         429
        </fpage>
        <lpage>
         433
        </lpage>
        <pub-id pub-id-type="pmid">
         1307690
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR63">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Gennero
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           HC
          </given-names>
         </name>
         <name>
          <surname>
           Serrano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Malavasi
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity
        </article-title>
        <source>
         AIDS
        </source>
        <year>
         2001
        </year>
        <volume>
         15
        </volume>
        <issue>
         17
        </issue>
        <fpage>
         2221
        </fpage>
        <lpage>
         2229
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/00002030-200111230-00002
        </pub-id>
        <pub-id pub-id-type="pmid">
         11698694
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR64">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rong
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Perelson
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy
        </article-title>
        <source>
         PLoS Comput Biol
        </source>
        <year>
         2009
        </year>
        <volume>
         5
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         e1000533
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pcbi.1000533
        </pub-id>
        <pub-id pub-id-type="pmid">
         19834532
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR65">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kalb
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Banerjee
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Mayer
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes
        </article-title>
        <source>
         AIDS Res Hum Retroviruses
        </source>
        <year>
         1993
        </year>
        <volume>
         9
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         91
        </fpage>
        <lpage>
         98
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/aid.1993.9.91
        </pub-id>
        <pub-id pub-id-type="pmid">
         8427717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR66">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Royle
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Tsai
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Tabarrini
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Massari
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Aquino
          </surname>
          <given-names>
           VN
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Modulation of HIV-1-induced activation of plasmacytoid dendritic cells by 6-desfluoroquinolones
        </article-title>
        <source>
         AIDS Res Hum Retroviruses
        </source>
        <year>
         2014
        </year>
        <volume>
         30
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         345
        </fpage>
        <lpage>
         354
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/aid.2013.0154
        </pub-id>
        <pub-id pub-id-type="pmid">
         24229417
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR67">
       <label>
        67.
       </label>
       <mixed-citation publication-type="other">
        Tsang AC, Ahmadi Pirshahid S, Virgili G, Gottlieb CC, Hamilton J, Coupland SG (2015) Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test. Ophthalmology [Epub ahead of print]
       </mixed-citation>
      </ref>
      <ref id="CR68">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mehraj
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Jenabian
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Vyboh
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Routy
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immune suppression by myeloid cells in HIV infection: new targets for immunotherapy
        </article-title>
        <source>
         Open AIDS J
        </source>
        <year>
         2014
        </year>
        <volume>
         8
        </volume>
        <fpage>
         66
        </fpage>
        <lpage>
         78
        </lpage>
        <pub-id pub-id-type="doi">
         10.2174/1874613601408010066
        </pub-id>
        <pub-id pub-id-type="pmid">
         25624956
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR69">
       <label>
        69.
       </label>
       <mixed-citation publication-type="other">
        Suarez-Almazor ME, Spooner CH, Belseck E, Shea B (2000) Auranofin versus placebo in rheumatoid arthritis. Cochrane Database Syst Rev. (2):CD002048
        <bold>
         (Review)
        </bold>
       </mixed-citation>
      </ref>
      <ref id="CR70">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lewis
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           DaFonseca
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Chomont
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Palamara
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name>
          <surname>
           Tardugno
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mai
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension
        </article-title>
        <source>
         AIDS
        </source>
        <year>
         2011
        </year>
        <volume>
         25
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1347
        </fpage>
        <lpage>
         1356
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/QAD.0b013e328347bd77
        </pub-id>
        <pub-id pub-id-type="pmid">
         21505294
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR71">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lewis
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Capell
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <name>
          <surname>
           McNeil
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Iqbal
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           WE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gold levels produced by treatment with auranofin and sodium aurothiomalate
        </article-title>
        <source>
         Ann Rheum Dis
        </source>
        <year>
         1983
        </year>
        <volume>
         42
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         566
        </fpage>
        <lpage>
         570
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/ard.42.5.566
        </pub-id>
        <pub-id pub-id-type="pmid">
         6414387
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR72">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Youn
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Saitoh
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
         <name>
          <surname>
           Miyake
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hwang
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <year>
         2006
        </year>
        <volume>
         350
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         866
        </fpage>
        <lpage>
         871
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2006.09.097
        </pub-id>
        <pub-id pub-id-type="pmid">
         17034761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR73">
       <label>
        73.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vint
          </surname>
          <given-names>
           IA
          </given-names>
         </name>
         <name>
          <surname>
           Chain
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Foreman
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <article-title>
         The interaction of auranofin and buthionine sulfoximine blocks activation of human peripheral T lymphocytes
        </article-title>
        <source>
         Cell Immunol
        </source>
        <year>
         1993
        </year>
        <volume>
         152
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         152
        </fpage>
        <lpage>
         161
        </lpage>
        <pub-id pub-id-type="doi">
         10.1006/cimm.1993.1275
        </pub-id>
        <pub-id pub-id-type="pmid">
         8242758
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR74">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shytaj
          </surname>
          <given-names>
           IL
          </given-names>
         </name>
         <name>
          <surname>
           Chirullo
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Wagner
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Ferrari
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Sgarbanti
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Corte
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS
        </article-title>
        <source>
         Retrovirology
        </source>
        <year>
         2013
        </year>
        <volume>
         10
        </volume>
        <fpage>
         71
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1742-4690-10-71
        </pub-id>
        <pub-id pub-id-type="pmid">
         23866829
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR75">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gavegnano
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Detorio
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Montero
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Bosque
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Planelles
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Schinazi
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         1977
        </fpage>
        <lpage>
         1986
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.02496-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24419350
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Int J Antimicrob Agents
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Int. J. Antimicrob. Agents
      </journal-id>
      <journal-title-group>
       <journal-title>
        International Journal of Antimicrobial Agents
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0924-8579
      </issn>
      <issn pub-type="epub">
       1872-7913
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V. and the International Society of Chemotherapy.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       17629679
      </article-id>
      <article-id pub-id-type="pmc">
       7126847
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0924-8579(07)00258-0
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.ijantimicag.2007.05.015
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Rolain
         </surname>
         <given-names>
          Jean-Marc
         </given-names>
        </name>
        <email>
         jm.rolain@medecine.univ-mrs.fr
        </email>
        <xref ref-type="corresp" rid="cor1">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Colson
         </surname>
         <given-names>
          Philippe
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Raoult
         </surname>
         <given-names>
          Didier
         </given-names>
        </name>
       </contrib>
      </contrib-group>
      <aff>
       Unité des Rickettsies, CNRS UMR 6020, Université de la Méditerranée, Faculté de Médecine et de Pharmacie, 27 Boulevard Jean Moulin, 13385 Marseille Cedex 5, France
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ⁎
        </label>
        Corresponding author. Tel.: +33 491 38 55 17; fax: +33 491 83 03 90.
        <email>
         jm.rolain@medecine.univ-mrs.fr
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        16
       </day>
       <month>
        7
       </month>
       <year>
        2007
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        10
       </month>
       <year>
        2007
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        16
       </day>
       <month>
        7
       </month>
       <year>
        2007
       </year>
      </pub-date>
      <volume>
       30
      </volume>
      <issue>
       4
      </issue>
      <fpage>
       297
      </fpage>
      <lpage>
       308
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2007
       </copyright-year>
       <copyright-holder>
        Elsevier B.V. and the International Society of Chemotherapy
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Chloroquine (CQ) and its hydroxyl analogue hydroxychloroquine (HCQ) are weak bases with a half-century long use as antimalarial agents. Apart from this antimalarial activity, CQ and HCQ have gained interest in the field of other infectious diseases. One of the most interesting mechanisms of action is that CQ leads to alkalinisation of acid vesicles that inhibit the growth of several intracellular bacteria and fungi. The proof of concept of this effect was first used to restore intracellular pH allowing antibiotic efficacy for
        <italic>
         Coxiella burnetii
        </italic>
        , the agent of Q fever, and doxycycline plus HCQ is now the reference treatment for chronic Q fever. There is also strong evidence of a similar effect in vitro against
        <italic>
         Tropheryma whipplei
        </italic>
        , the agent of Whipple's disease, and a clinical trial is in progress. Other bacteria and fungi multiply in an acidic environment and encouraging in vitro data suggest that this concept may be generalised for all intracellular organisms that multiply in an acidic environment. For viruses, CQ led to inhibition of uncoating and/or alteration of post-translational modifications of newly synthesised proteins, especially inhibition of glycosylation. These effects have been well described in vitro for many viruses, with human immunodeficiency virus (HIV) being the most studied. Preliminary in vivo clinical trials suggest that CQ alone or in combination with antiretroviral drugs might represent an interesting way to treat HIV infection. In conclusion, our review re-emphasises the paradigm that activities mediated by lysosomotropic agents may offer an interesting weapon to face present and future infectious diseases worldwide.
       </p>
      </abstract>
      <kwd-group>
       <title>
        Keywords
       </title>
       <kwd>
        Chloroquine
       </kwd>
       <kwd>
        Hydroxychloroquine
       </kwd>
       <kwd>
        Lysosomotropic agents
       </kwd>
       <kwd>
        Alkalinisation
       </kwd>
       <kwd>
        Q fever
       </kwd>
       <kwd>
        Whipple's disease
       </kwd>
       <kwd>
        HIV
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="section0005">
     <label>
      1
     </label>
     <title>
      Introduction: general effects of chloroquine (CQ) and hydroxychloroquine (HCQ)
     </title>
     <p id="para0005">
      CQ is a 9-aminoquinoline known since 1934, which emerged during the first part of the 20th century as an effective quinine substitute and the drug of choice against malaria
      <xref ref-type="bibr" rid="bib1">
       [1]
      </xref>
      . It proved to be among the most successful antimalarial drugs on a worldwide scale owing to its wide deployment coinciding with the geographical distribution of
      <italic>
       Plasmodium
      </italic>
      and its high intrinsic antiparasitic efficacy and low toxicity. Concomitant with a gradual decrease in its use for therapy and prophylaxis of
      <italic>
       Plasmodium
      </italic>
      -induced disease worldwide, related to the emergence of CQ-resistant parasites, CQ and its hydroxyl analogue HCQ have gained interest in the field of other infectious diseases
      <xref ref-type="bibr" rid="bib2">
       [2]
      </xref>
      . The mechanism of action of CQ is multiple, differing according to the pathogen, and has not been well elucidated for all microorganisms. CQ and HCQ enter cells as non-protonated forms where they become protonated according to the Henderson–Hasselbach law, i.e. in a manner inversely proportional to the pH
      <xref ref-type="bibr" rid="bib2">
       [2]
      </xref>
      . They therefore concentrate within acidic organelles, including endosomes, lysosomes and Golgi vesicles, in which they increase the pH
      <xref ref-type="bibr" rid="bib3">
       [3]
      </xref>
      . Over the last decade, two main mechanisms of action of CQ have been well described, i.e. alkalinisation of acid vesicles in cells infected by intracellular bacteria and fungi, and alteration of post-translational modifications of newly synthesised proteins in cells infected by viruses. The proof of concept of the use of CQ as an anti-infectious agent, other than an antimalarial agent, has been fully demonstrated for the first time in vitro and in vivo with the model of chronic Q fever. This concept was initially based on cellular biology findings, mainly by manipulation of the pH of acidic vacuoles where
      <italic>
       Coxiella burnetii
      </italic>
      , the agent of Q fever, live and multiply. Demonstration of a negative effect on growth of
      <italic>
       C. burnetii
      </italic>
      by lysosomotropic agents
      <xref ref-type="bibr" rid="bib4">
       [4]
      </xref>
      was the first step, followed by demonstration that alkalinising
      <italic>
       C. burnetii
      </italic>
      -containing vacuoles could restore the intracellular activity of antibiotics (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      )
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      . This paradigm was later used to demonstrate the clinical efficacy of an association of doxycycline and HCQ in the treatment of chronic Q fever endocarditis and this regimen is now the reference treatment and is to date the only model of confirmed clinical efficacy (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      )
      <xref ref-type="bibr" rid="bib6">
       [6]
      </xref>
      . There is strong evidence of such an effect in other intracellular bacteria, especially for
      <italic>
       Tropheryma whipplei
      </italic>
      , the agent of Whipple's disease, which multiply in phagosomes, since agents that increase the intravacuolar pH decrease bacterial viability
      <xref ref-type="bibr" rid="bib7">
       [7]
      </xref>
      . By analogy with
      <italic>
       C. burnetii
      </italic>
      , HCQ restores the intracellular activity of doxycycline in vitro
      <xref ref-type="bibr" rid="bib8">
       [8]
      </xref>
      and a clinical trial using this regimen is under evaluation. Several other bacteria and fungi live and multiply in acidic vacuoles and preliminary in vitro data are encouraging for the usefulness of CQ in such infections. For viruses, CQ led to an inhibition of low-pH-dependent entry steps or alteration of post-translational modifications of newly synthesised proteins, especially via inhibition of glycosylation. These effects have been well described in vitro for many viruses, with human immunodeficiency virus type-1 (HIV-1) being the most studied. Moreover, preliminary in vivo clinical trials have suggested that CQ alone or in combination with antiretroviral drugs might represent an interesting way to treat HIV infection.
      <fig id="fig1">
       <label>
        Fig. 1
       </label>
       <caption>
        <p>
         Concept on the use of chloroquine (CQ) and hydroxychloroquine for intracellular bacteria and fungi: the
         <italic>
          Coxiella burnetii
         </italic>
         paradigm.
        </p>
       </caption>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
     </p>
     <p id="para0010">
      Here we review available in vitro and in vivo data on the effects of CQ/HCQ on bacterial, fungal and viral infections, with the concept that manipulation of the intracellular pH in cells and modification of glycosylation of proteins by lysosomotropic agents instead of antimicrobial compounds is a powerful approach as new therapeutic strategies for the prevention and therapeutic management of several infectious diseases, including some of great public health concern worldwide. CQ/HCQ also have anti-inflammatory properties, however these will not be discussed in this review.
     </p>
    </sec>
    <sec id="section0010">
     <label>
      2
     </label>
     <title>
      CQ/HCQ efficacy against bacterial infections
     </title>
     <p id="para0015">
      The intracellular location of several bacteria and fungi has been known for decades as a critical point to explain failure of antibiotic treatment to eradicate these pathogens from host cells
      <xref ref-type="bibr" rid="bib9">
       [9]
      </xref>
      . Intracellular pathogens evade the first-line antimicrobial defence, which includes attack by phagocytes (
      <xref ref-type="fig" rid="fig2">
       Fig. 2
      </xref>
      ). After being internalised by the cell, usually there is formation of a phagosome that rapidly fuses with lysosomes. The bacteria are then killed by oxygen-dependent and oxygen-independent killing mechanisms, which leads to acidification of the phagolysosome (pH 4.5) and acidic activation of lysosomal enzymes. Intracellular pathogens may evade this lysosomal pathway by several mechanisms: (i) lifestyle in lysosome free-cells such as erythrocytes (
      <italic>
       Bartonella
      </italic>
      spp.); (ii) escape from the phagosome before fusion with lysosomes and multiplication in the cytosol (
      <italic>
       Rickettsia
      </italic>
      and
      <italic>
       Shigella
      </italic>
      ) (
      <xref ref-type="fig" rid="fig2">
       Fig. 2
      </xref>
      ); (iii) inhibition of phagolysosomal fusion and multiplication in the phagosome (
      <italic>
       Chlamydia
      </italic>
      ,
      <italic>
       Ehrlichia
      </italic>
      ,
      <italic>
       Legionella
      </italic>
      ,
      <italic>
       Salmonella
      </italic>
      ,
      <italic>
       Yersinia
      </italic>
      ,
      <italic>
       Brucella
      </italic>
      ,
      <italic>
       Mycobacterium
      </italic>
      ,
      <italic>
       Francisella
      </italic>
      ,
      <italic>
       Histoplasma capsulatum
      </italic>
      and
      <italic>
       Aspergillus fumigatus
      </italic>
      ) (
      <xref ref-type="fig" rid="fig2">
       Fig. 2
      </xref>
      ); and (iv) survival and multiplication in phagolysosomes (
      <italic>
       C. burnetii, T. whipplei, Staphylococcus aureus, Candida albicans
      </italic>
      and
      <italic>
       Cryptococcus neoformans
      </italic>
      ) (
      <xref ref-type="fig" rid="fig2">
       Fig. 2
      </xref>
      )
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib9">
       [9]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       [10]
      </xref>
      . There are many arguments suggesting that the low pH environment within phagosomal compartments of the cell is critical for many intracellular pathogens to access cellular iron for growth
      <xref ref-type="bibr" rid="bib11">
       [11]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib12">
       [12]
      </xref>
      . CQ treatment of different cells, including macrophages, could inhibit the growth of several of these intracellular bacteria by neutralising the phagolysosomal pH (
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      ;
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      ,
      <xref ref-type="fig" rid="fig2">
       Fig. 2
      </xref>
      ). Thus, two main mechanisms can explain intracellular bacterial inhibition by CQ: pH-dependent iron deprivation
      <xref ref-type="bibr" rid="bib11">
       [11]
      </xref>
      ; and direct toxicity by increasing the phagolysosomal pH, which is harmful for the growth of several intracellular pathogens such as
      <italic>
       C. burnetii
      </italic>
      <xref ref-type="bibr" rid="bib13">
       [13]
      </xref>
      and
      <italic>
       T. whipplei
      </italic>
      <xref ref-type="bibr" rid="bib7">
       [7]
      </xref>
      .
      <fig id="fig2">
       <label>
        Fig. 2
       </label>
       <caption>
        <p>
         Strategy for replication of intracellular bacteria and fungi known to be inhibited by chloroquine and/or hydroxychloroquine.
        </p>
       </caption>
       <graphic xlink:href="gr2_lrg">
       </graphic>
      </fig>
      <table-wrap id="tbl1" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Bacteria, fungi and viruses inhibited by chloroquine and/or hydroxychloroquine (in vitro data)
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Bacteria
          </th>
          <th align="left">
           Reference
          </th>
          <th align="left">
           Fungi
          </th>
          <th align="left">
           Reference
          </th>
          <th align="left">
           Virus
          </th>
          <th align="left">
           Reference
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           <italic>
            Coxiella burnetii
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib5">
            [5]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib13">
            [13]
           </xref>
          </td>
          <td align="left">
           <italic>
            Histoplasma capsulatum
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib24">
            [24]
           </xref>
          </td>
          <td align="left">
           HIV
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib2">
            [2]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib29">
            [29]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib30">
            [30]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib31">
            [31]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib32">
            [32]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Tropheryma whipplei
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib7">
            [7]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib8">
            [8]
           </xref>
          </td>
          <td align="left">
           <italic>
            Cryptococcus neoformans
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib15">
            [15]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib25">
            [25]
           </xref>
          </td>
          <td align="left">
           SARS-CoV
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib33">
            [33]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib34">
            [34]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Legionella pneumophila
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib11">
            [11]
           </xref>
          </td>
          <td align="left">
           <italic>
            Paracoccidioides brasiliensis
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib26">
            [26]
           </xref>
          </td>
          <td align="left">
           Influenza viruses
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib35">
            [35]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib36">
            [36]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib37">
            [37]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib38">
            [38]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Francisella tularensis
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib12">
            [12]
           </xref>
          </td>
          <td align="left">
           <italic>
            Penicillium marneffei
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib15">
            [15]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib27">
            [27]
           </xref>
          </td>
          <td align="left">
           Flavivirus, including yellow fever virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib39">
            [39]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Mycobacterium tuberculosis
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib14">
            [14]
           </xref>
          </td>
          <td align="left">
           <italic>
            Aspergillus fumigatus
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib28">
            [28]
           </xref>
          </td>
          <td align="left">
           Rubella virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib40">
            [40]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib41">
            [41]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Mycobacterium avium
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib15">
            [15]
           </xref>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           HAV
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib42">
            [42]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Salmonella
           </italic>
           Typhi
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib16">
            [16]
           </xref>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           HBV
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib43">
            [43]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib44">
            [44]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Escherichia coli
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib17">
            [17]
           </xref>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           HCV
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib45">
            [45]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Bacillus anthracis
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib18">
            [18]
           </xref>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Arenavirus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib46">
            [46]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Bacillus subtilis
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib19">
            [19]
           </xref>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Borrelia burgdorferi
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib20">
            [20]
           </xref>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Lymphocytic choriomeningitis virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib47">
            [47]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Brucella abortus
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib21">
            [21]
           </xref>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Rabies virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib48">
            [48]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Staphylococcus aureus
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib22">
            [22]
           </xref>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Varicella–Zoster virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib49">
            [49]
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Listeria monocytogenes
           </italic>
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib23">
            [23]
           </xref>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Respiratory syncytial virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib50">
            [50]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Sindbis virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib51">
            [51]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Herpes simplex viruses
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib41">
            [41]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib52">
            [52]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib53">
            [53]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Epstein–Barr virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib54">
            [54]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Polioviruses
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib55">
            [55]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib56">
            [56]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib57">
            [57]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Newcastle disease virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib58">
            [58]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Borna disease virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib59">
            [59]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Vesicular stomatitis virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib37">
            [37]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib60">
            [60]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib61">
            [61]
           </xref>
           ,
           <xref ref-type="bibr" rid="bib62">
            [62]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Vaccinia virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib63">
            [63]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Murine RNA tumour virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib64">
            [64]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           FMDV
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib65">
            [65]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Mayaro virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib66">
            [66]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Feline calicivirus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib67">
            [67]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           African swine fever virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib68">
            [68]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Bovine leukaemia virus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib69">
            [69]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Canine parvovirus
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib70">
            [70]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td align="left">
           Minute Virus of Mice
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib71">
            [71]
           </xref>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          HIV, human immunodeficiency virus; SARS-CoV, SARS coronavirus; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; FMDV, foot and mouth disease virus.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <sec id="section0015">
      <label>
       2.1
      </label>
      <title>
       In vitro activity of HCQ/CQ against C. burnetii
      </title>
      <p id="para0020">
       <italic>
        Coxiella burnetii
       </italic>
       is the agent of Q fever and is a strict intracellular bacterium that is able to survive in phagolysosomes where a low pH (pH 4.5) is necessary for its metabolism
       <xref ref-type="bibr" rid="bib4">
        [4]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib72">
        [72]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib73">
        [73]
       </xref>
       . Q fever includes acute manifestations (mainly pneumonitis and hepatitis) and chronic forms (mainly endocarditis)
       <xref ref-type="bibr" rid="bib74">
        [74]
       </xref>
       . Usually a regimen of doxycycline 200 mg per day for 3 weeks is recommended for patients with acute Q fever. Presently, this treatment of acute Q fever is not sufficient to prevent the development of chronic Q fever
       <xref ref-type="bibr" rid="bib75">
        [75]
       </xref>
       . Thus, reliable antibiotic therapy for chronic infection is a more challenging problem since antibiotics are not bactericidal in vitro against
       <italic>
        C. burnetii
       </italic>
       <xref ref-type="bibr" rid="bib74">
        [74]
       </xref>
       . When the pH of
       <italic>
        C. burnetii
       </italic>
       -containing phagolysosomes was raised using basic lysosomotropic agents such as CQ, methylamine and ammonium chloride, bacterial multiplication was inhibited, showing a direct negative effect on growth by lysosomotropic agents, including CQ
       <xref ref-type="bibr" rid="bib4">
        [4]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib13">
        [13]
       </xref>
       . An original killing assay model developed by Maurin et al.
       <xref ref-type="bibr" rid="bib5">
        [5]
       </xref>
       demonstrated that doxycycline, pefloxacin and rifampicin did not show any significant bactericidal activity. Conversely, it was shown that in vitro intracellular antibiotic activity was restored and was correlated with modification of the pH by lysosomotropic agents (
       <xref ref-type="fig" rid="fig3">
        Fig. 3
       </xref>
       ). The lack of bactericidal activity was probably due to inactivation by the low pH of the phagolysosomes in which
       <italic>
        C. burnetii
       </italic>
       survives. Addition of a lysosomotropic alkalinising agent, i.e. CQ, to antibiotics improved the activities of doxycycline and pefloxacin, which then became bactericidal
       <xref ref-type="bibr" rid="bib5">
        [5]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib13">
        [13]
       </xref>
       . The model in which bacteria actively multiply only at acidic pH is a good paradigm to demonstrate that lack of bactericidal effect of antibiotics is due to intraphagolysosomal acidity.
       <fig id="fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Phagolysosomal alkalinisation and bactericidal effect of antibiotics (adapted from Maurin et al.
          <xref ref-type="bibr" rid="bib5">
           [5]
          </xref>
          ). Colours are those of universal colours used in pH paper. RVB, residual viable bacteria. [Awaiting permission from J Infect Dis.].
         </p>
        </caption>
        <graphic xlink:href="gr3_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="section0020">
      <label>
       2.2
      </label>
      <title>
       In vivo activity of HCQ/CQ against C. burnetii
      </title>
      <p id="para0025">
       These in vitro findings have now been evaluated in many in vivo studies of the treatment of patients with chronic Q fever endocarditis using a combination of doxycycline and HCQ (at 1 μg/mL in serum) for 18–36 months. Indeed, prior to this treatment, patients were treated with a long-term tetracycline and quinolone regimen for at least 4 years, with a high percentage of relapses
       <xref ref-type="bibr" rid="bib6">
        [6]
       </xref>
       . This regimen was compared with a combination of doxycycline and hydroxychloroquine sulphate in patients suffering from Q fever endocarditis
       <xref ref-type="bibr" rid="bib6">
        [6]
       </xref>
       . Of 14 patients treated with a doxycycline and quinolone combination, 1 died, 7 relapsed (3 were re-treated and 4 switched to the new regimen), 1 was still being treated and 5 were considered cured using this regimen only. The mean duration of therapy for cure in this group was 55 months (median 60 months)
       <xref ref-type="bibr" rid="bib6">
        [6]
       </xref>
       . Twenty-one patients received the doxycycline and HCQ regimen: 1 patient died of a surgical complication, 2 were still being treated, 17 were cured and 1 was currently being evaluated. Two patients treated for 12 months but none of the patients treated for &gt;18 months relapsed
       <xref ref-type="bibr" rid="bib6">
        [6]
       </xref>
       . The mean duration of treatment in this group was 31 months (median 26 months). This regimen allowed a reduction in the duration of therapy to 18 months for many patients and also reduced the relapse rate to &lt;5%
       <xref ref-type="bibr" rid="bib6">
        [6]
       </xref>
       . This regimen is now the current therapy for the treatment of chronic Q fever. CQ used at therapeutic dosages may have some deleterious effects, including the risk of retinopathy, necessitating a regular ophthalmological examination
       <xref ref-type="bibr" rid="bib74">
        [74]
       </xref>
       . CQ levels in serum should be monitored to ensure that they are maintained at 1 ± 0.2 mg/L. Similarly, an HIV-infected patient with Q fever endocarditis was successfully treated with valvular replacement and a combination of doxycycline and HCQ
       <xref ref-type="bibr" rid="bib76">
        [76]
       </xref>
       . This combined treatment is probably also indicated in cases of
       <italic>
        C. burnetii
       </italic>
       vascular graft infection, as reported recently
       <xref ref-type="bibr" rid="bib77">
        [77]
       </xref>
       . Similarly, a retrospective study of patients diagnosed as having Q fever during 1985–2000 evaluated the risk of developing endocarditis according to the regimen of antibiotics given to the patients
       <xref ref-type="bibr" rid="bib75">
        [75]
       </xref>
       . When these regimens were compared, 6 (75%) of 8 patients who did not receive treatment developed a chronic infection, 5 of 10 developed a chronic infection when receiving doxycycline alone for 2 weeks to 6 months, and none of the 12 who received doxycycline and HCQ for 1–15 months developed chronic infection. The regimen containing HCQ was found to be significantly superior in preventing Q fever endocarditis compared with doxycycline alone (
       <italic>
        P
       </italic>
       = 0.009)
       <xref ref-type="bibr" rid="bib75">
        [75]
       </xref>
       . No significant differences were found between treatment with doxycycline alone and no treatment
       <xref ref-type="bibr" rid="bib75">
        [75]
       </xref>
       . It is now established that development of Q fever endocarditis may be prevented by searching for minor valvulopathies with echocardiography following diagnosis of acute Q fever
       <xref ref-type="bibr" rid="bib78">
        [78]
       </xref>
       and by treatment with a combination of doxycycline and HCQ for 1 year
       <xref ref-type="bibr" rid="bib79">
        [79]
       </xref>
       . Finally, four cases of Q fever osteoarticular infection (two tenosynovitis and two spondylodiscitis complicated by paravertebral abscess) were eventually cured using the combination of doxycycline and HCQ
       <xref ref-type="bibr" rid="bib80">
        [80]
       </xref>
       .
      </p>
     </sec>
     <sec id="section0025">
      <label>
       2.3
      </label>
      <title>
       Tropheryma whipplei
      </title>
      <p id="para0030">
       Whipple's disease was invariably fatal before the advent of antibiotics. However, current therapeutic recommendations are not based on therapeutic trials or adjusted according to the susceptibility of
       <italic>
        T. whipplei
       </italic>
       to various antimicrobial agents, since the bacteria was only isolated in 2000
       <xref ref-type="bibr" rid="bib81">
        [81]
       </xref>
       . Following isolation of the bacteria, it has been shown that vacuole acidification is critical to the survival of
       <italic>
        T. whipplei
       </italic>
       in phagosomes, since agents that increase the intravacuolar pH decrease bacterial viability (
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       )
       <xref ref-type="bibr" rid="bib7">
        [7]
       </xref>
       . By analogy with
       <italic>
        C. burnetii
       </italic>
       , we have demonstrated that doxycycline alone was not bactericidal against
       <italic>
        T. whipplei
       </italic>
       in an in vitro cell model and that alkalinisation with HCQ may restore activity
       <xref ref-type="bibr" rid="bib8">
        [8]
       </xref>
       . A regimen based on this observation (doxycycline and HCQ) has thus far been the only successful bactericidal regimen against
       <italic>
        T. whipplei
       </italic>
       in vitro. Whether this regimen will work in a general clinical setting remains to be established, but it has been successful in four of our patients: two with classic Whipple's disease and two with blood culture-negative endocarditis
       <xref ref-type="bibr" rid="bib82">
        [82]
       </xref>
       .
      </p>
     </sec>
     <sec id="section0030">
      <label>
       2.4
      </label>
      <title>
       Staphylococcus aureus
      </title>
      <p id="para0035">
       <italic>
        Staphylococcus aureus
       </italic>
       is a facultative intracellular bacterium that resides within phagolysosomes
       <xref ref-type="bibr" rid="bib83">
        [83]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib84">
        [84]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib85">
        [85]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib86">
        [86]
       </xref>
       . The intracellular location of certain strains of
       <italic>
        S. aureus
       </italic>
       serves as a reservoir of bacteria that is thought to be important in therapy of recurrent infections in humans and in chronic staphylococcal mastitis in dairy cows
       <xref ref-type="bibr" rid="bib87">
        [87]
       </xref>
       . Although aminoglycosides are bactericidal for extracellular staphylococci, they are ineffective in reducing the intracellular form of the microorganism
       <xref ref-type="bibr" rid="bib88">
        [88]
       </xref>
       . It was hypothesised that diminished susceptibility of intracellular
       <italic>
        S. aureus
       </italic>
       may be related to the acidic pH within phagolysosomes
       <xref ref-type="bibr" rid="bib88">
        [88]
       </xref>
       . It has been demonstrated that alkalinising
       <italic>
        S. aureus
       </italic>
       -containing vacuoles could restore the intracellular activity of aminoglycosides
       <xref ref-type="bibr" rid="bib89">
        [89]
       </xref>
       . Furthermore, intracellular killing of
       <italic>
        S. aureus
       </italic>
       correlated well with increased lysosomal pH due to lysosomotropic alkalinising agents
       <xref ref-type="bibr" rid="bib89">
        [89]
       </xref>
       . Recently, it has been demonstrated that CQ and ammonium chloride significantly enhanced intracellular killing by levofloxacin
       <xref ref-type="bibr" rid="bib22">
        [22]
       </xref>
       . The bactericidal activity of levofloxacin was partially restored when the pH was neutralised from 5.0 to 7.4
       <xref ref-type="bibr" rid="bib22">
        [22]
       </xref>
       . The bactericidal activity of moxifloxacin, abolished in the intracellular salt medium, was partially restored when the pH was raised from 5.0 to 7.4
       <xref ref-type="bibr" rid="bib22">
        [22]
       </xref>
       . Similarly, alkalinisation of phagolysosomes significantly enhanced intracellular killing by moxifloxacin
       <xref ref-type="bibr" rid="bib90">
        [90]
       </xref>
       . In a model of bovine mastitis due to
       <italic>
        S. aureus
       </italic>
       , it has been clearly demonstrated that low intraphagolysosomal pH affects the ability of an antibiotic to kill intracellular bacteria, since the activity of rifampicin was enhanced at pH 5.0
       <xref ref-type="bibr" rid="bib91">
        [91]
       </xref>
       . Similar reasoning probably explains why rifampicin, which both penetrates within eukaryotic cells
       <xref ref-type="bibr" rid="bib92">
        [92]
       </xref>
       and is more active at acidic pH
       <xref ref-type="bibr" rid="bib87">
        [87]
       </xref>
       , displays bactericidal activity against intracellular
       <italic>
        S. aureus
       </italic>
       <xref ref-type="bibr" rid="bib93">
        [93]
       </xref>
       .
      </p>
     </sec>
     <sec id="section0035">
      <label>
       2.5
      </label>
      <title>
       Other bacteria with in vitro data on the effectiveness of CQ/HCQ
      </title>
      <sec id="section0040">
       <label>
        2.5.1
       </label>
       <title>
        Legionella pneumophila
       </title>
       <p id="para0040">
        <italic>
         Legionella pneumophila
        </italic>
        is a strict intracellular bacterium that multiplies in human mononuclear phagocytes and is responsible for Legionnaire's disease
        <xref ref-type="bibr" rid="bib94">
         [94]
        </xref>
        . Cellular iron metabolism is of critical importance to
        <italic>
         L. pneumophila
        </italic>
        since its multiplication is dependent upon the availability of intracellular iron. It has been demonstrated that CQ and ammonium chloride inhibit the intracellular multiplication of
        <italic>
         L. pneumophila
        </italic>
        by limiting the availability of iron to the bacterium
        <xref ref-type="bibr" rid="bib11">
         [11]
        </xref>
        . Thus, CQ may interfere with intracellular iron metabolism by recycling iron from ferritin by blocking degradation of ferritin by acid proteases
        <xref ref-type="bibr" rid="bib11">
         [11]
        </xref>
        .
       </p>
      </sec>
      <sec id="section0045">
       <label>
        2.5.2
       </label>
       <title>
        Francisella tularensis
       </title>
       <p id="para0045">
        <italic>
         Francisella tularensis
        </italic>
        bv.
        <italic>
         tularensis
        </italic>
        and
        <italic>
         F. tularensis
        </italic>
        bv.
        <italic>
         palearctica
        </italic>
        are facultative intracellular bacteria responsible for tularaemia. It has been demonstrated that
        <italic>
         F. tularensis
        </italic>
        finds a successful niche for replication in an acidified vacuole where iron is concentrated
        <xref ref-type="bibr" rid="bib12">
         [12]
        </xref>
        . Growth of
        <italic>
         F. tularensis
        </italic>
        in murine macrophages has been shown to be dramatically inhibited in vitro by CQ in a dose-dependent manner
        <xref ref-type="bibr" rid="bib12">
         [12]
        </xref>
        . Intracellular localisation in an acidic vesicle, which facilitates the availability of iron essential for
        <italic>
         Francisella
        </italic>
        growth, is a survival tactic of this bacterium and iron depletion is one mechanism that macrophages use to inhibit its growth
        <xref ref-type="bibr" rid="bib12">
         [12]
        </xref>
        .
       </p>
      </sec>
      <sec id="section0050">
       <label>
        2.5.3
       </label>
       <title>
        Mycobacterium spp.
       </title>
       <p id="para0050">
        CQ has been reported to inhibit the intracellular multiplication of
        <italic>
         Mycobacterium tuberculosis
        </italic>
        both in human monocyte-derived macrophages and mouse peritoneal macrophages
        <xref ref-type="bibr" rid="bib11">
         [11]
        </xref>
        . It seems possible that CQ inhibits
        <italic>
         M. tuberculosis
        </italic>
        intracellular multiplication by raising intracellular pH and limiting the availability of iron to this bacterium, as it does for
        <italic>
         L. pneumophila
        </italic>
        . Similarly, it has been demonstrated that addition of CQ results in a significant reduction of the intracellular growth of
        <italic>
         Mycobacterium avium
        </italic>
        in bone marrow-derived macrophages
        <xref ref-type="bibr" rid="bib11">
         [11]
        </xref>
        .
       </p>
      </sec>
      <sec id="section0055">
       <label>
        2.5.4
       </label>
       <title>
        Miscellaneous
       </title>
       <p id="para0055">
        In vitro activity of CQ and/or HCQ has been demonstrated for other bacteria, including
        <italic>
         Salmonella enterica
        </italic>
        serovar Typhi,
        <italic>
         Escherichia coli
        </italic>
        ,
        <italic>
         Bacillus anthracis
        </italic>
        ,
        <italic>
         Bacillus subtilis
        </italic>
        ,
        <italic>
         Borrelia burgdorferi
        </italic>
        ,
        <italic>
         Brucella abortus
        </italic>
        and
        <italic>
         Listeria monocytogenes
        </italic>
        (
        <xref ref-type="table" rid="tbl1">
         Table 1
        </xref>
        ;
        <xref ref-type="fig" rid="fig1">
         Fig. 1
        </xref>
        ). These bacteria may be good candidates for clinical use of CQ/HCQ.
       </p>
      </sec>
     </sec>
    </sec>
    <sec id="section0060">
     <label>
      3
     </label>
     <title>
      CQ/HCQ efficacy against fungal infections
     </title>
     <p id="para0060">
      Recent in vitro studies indicate that CQ may also have interesting activity against fungal diseases (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      ;
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      ), including mainly
      <italic>
       H. capsulatum
      </italic>
      <xref ref-type="bibr" rid="bib95">
       [95]
      </xref>
      and
      <italic>
       C. neoformans
      </italic>
      <xref ref-type="bibr" rid="bib96">
       [96]
      </xref>
      . Intracellular
      <italic>
       H. capsulatum
      </italic>
      is adapted to survive within the mammalian phagolysosome and resides within a membrane-bound phagosome that does not fully acidify.
      <italic>
       Histoplasma capsulatum
      </italic>
      is able to maintain a phagosomal pH of 6.5
      <xref ref-type="bibr" rid="bib97">
       [97]
      </xref>
      by inhibition of phagolysosomal fusion
      <xref ref-type="bibr" rid="bib98">
       [98]
      </xref>
      and by expression of a unique endogenous H
      <sup>
       +
      </sup>
      -ATPase that buffers the phagosomal pH
      <xref ref-type="bibr" rid="bib99">
       [99]
      </xref>
      . It has been demonstrated that CQ induces an antihistoplasmal state in macrophages by restricting the pH-dependent release of iron within the phagolysosome
      <xref ref-type="bibr" rid="bib24">
       [24]
      </xref>
      . Similarly, CQ has been shown to kill
      <italic>
       C. neoformans
      </italic>
      , but by a mechanism independent of iron deprivation
      <xref ref-type="bibr" rid="bib15">
       [15]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib25">
       [25]
      </xref>
      . Indeed, unlike
      <italic>
       H. capsulatum, C. neoformans
      </italic>
      is able to maintain a phagolysosome milieu at ca. pH 5.1
      <xref ref-type="bibr" rid="bib100">
       [100]
      </xref>
      and addition of CQ increases the phagolysosomal pH allowing inhibition of growth at alkaline pH
      <xref ref-type="bibr" rid="bib25">
       [25]
      </xref>
      . It has been reported that
      <italic>
       A. fumigatus
      </italic>
      has the ability to inhibit fusion of the phagosome with the lysosome and that CQ may increase killing of this fungus in macrophages by a pH-dependent mechanism
      <xref ref-type="bibr" rid="bib28">
       [28]
      </xref>
      . CQ has been shown to inhibit the intramacrophagic growth of
      <italic>
       Penicillium marneffei
      </italic>
      <xref ref-type="bibr" rid="bib15">
       [15]
      </xref>
      , an opportunistic fungus that causes disseminated infection in acquired immune deficiency syndrome (AIDS) patients by increasing the intravacuolar pH and disrupting pH-dependent metabolic processes
      <xref ref-type="bibr" rid="bib27">
       [27]
      </xref>
      . The decrease in the intracellular iron concentration results in impaired functionality of several cellular enzymes with a subsequent deleterious effect on critical steps such as replication of cellular DNA or gene expression
      <xref ref-type="bibr" rid="bib27">
       [27]
      </xref>
      . Finally, the effect of CQ on multiplication of
      <italic>
       Paracoccidioides brasiliensis
      </italic>
      has been studied in human monocytes and in a murine paracoccidioidomycosis model
      <xref ref-type="bibr" rid="bib26">
       [26]
      </xref>
      . CQ was demonstrated to be able to kill
      <italic>
       P. brasiliensis
      </italic>
      grown in human monocytes. The effect of CQ was reversed by FeNTA, an iron compound that is soluble at neutral to alkaline pH, but not by holotransferrin, which releases iron only in an acidic environment. Thus, CQ inhibits
      <italic>
       P. brasiliensis
      </italic>
      survival in human monocytes by iron deprivation
      <xref ref-type="bibr" rid="bib26">
       [26]
      </xref>
      .
     </p>
    </sec>
    <sec id="section0065">
     <label>
      4
     </label>
     <title>
      CQ/HCQ efficacy against viral infections (
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      )
     </title>
     <sec id="section0070">
      <label>
       4.1
      </label>
      <title>
       Mechanisms of antiviral activity (
       <xref ref-type="fig" rid="fig4">
        Fig. 4
       </xref>
       )
      </title>
      <p id="para0065">
       The pH increase induced by CQ/HCQ within acidic organelles, including endosomes, lysosomes and Golgi vesicles, is involved in its antiviral activity via two main mechanisms.
       <fig id="fig4">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          Viruses inhibited by chloroquine (CQ) and/or hydroxychloroquine (HCQ). HCV, hepatitis C virus; HAV, hepatitis A virus; HIV, human immunodeficiency virus; HSV-1, herpes simplex virus type-1; SARS-CoV, severe acute respiratory syndrome-associated coronavirus.
         </p>
        </caption>
        <graphic xlink:href="gr4_lrg">
        </graphic>
       </fig>
      </p>
      <p id="para0070">
       First, these drugs might be responsible for inhibition of viruses requiring a pH-dependent step for entry into their host cell. Indeed, many viruses have a low-pH-dependent conformational change that triggers fusion, penetration and/or uncoating, and for these viruses endocytosis is crucial due to acidification that occurs within the endosomal pathway
       <xref ref-type="bibr" rid="bib101">
        [101]
       </xref>
       . Thus, in this mechanism the antiviral effect is dependent on the extent to which the virus uses endosomes for entry
       <xref ref-type="bibr" rid="bib59">
        [59]
       </xref>
       . For instance, Shibata et al.
       <xref ref-type="bibr" rid="bib35">
        [35]
       </xref>
       found that CQ might prevent the uncoating of influenza B virus by increasing the lysosomal pH above the critical value required for inducing fusion between the virus envelope and the lysosomal membrane. CQ was also found to inhibit uncoating of the hepatitis A virus (HAV)
       <xref ref-type="bibr" rid="bib42">
        [42]
       </xref>
       .
      </p>
      <p id="para0075">
       Second, CQ/HCQ might inhibit post-translational modifications of the virus envelope glycoproteins by proteases and glycosyltransferases within the trans-Golgi network and endoplasmic vesicles. Indeed, some of these enzymes require a low pH for their activity and CQ/HCQ might therefore lead to decreased viral infectivity through impaired envelope maturation. Flaviviridae are examples of viruses for which CQ could act as an antiviral by inhibiting their envelope maturation pathway through alteration of the proteolytic processing of the prM protein
       <xref ref-type="bibr" rid="bib39">
        [39]
       </xref>
       .
      </p>
      <p id="para0080">
       Also, a putative mechanism for anti-HIV-1 activity is through alteration of the glycosylation pattern and amino acid charge within several regions of the gp120 viral envelope protein
       <xref ref-type="bibr" rid="bib2">
        [2]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib102">
        [102]
       </xref>
       . For instance, a reduction in the number of potential N-linked glycosylation sites within the V3 region of gp120, which might provide for altered immune escape and broadening of the antibody repertoire, has been observed
       <xref ref-type="bibr" rid="bib102">
        [102]
       </xref>
       . Savarino et al.
       <xref ref-type="bibr" rid="bib2">
        [2]
       </xref>
       previously found that CQ decreased the infectivity of newly produced HIV-1 as well as the ability of HIV-1-infected cells to form syncitia, and this was associated with structural changes in gp120. Recent data further suggest that CQ may be responsible for inhibition of the biosynthesis of sialic acid. Indeed, it was recently observed that this drug inhibited cellular enzymes involved in sialic acid biosynthesis
       <xref ref-type="bibr" rid="bib103">
        [103]
       </xref>
       . This might represent a major antiviral mechanism, since sialic acids are a component of HIV-1 envelope glycoproteins.
      </p>
      <p id="para0085">
       CQ/HCQ may also have indirect antiviral effects. Indeed, CQ was found to be effective in preventing the spread of severe acute respiratory syndrome (SARS)-associated coronavirus (CoV) in cell culture by interfering with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2 (ACE2)
       <xref ref-type="bibr" rid="bib33">
        [33]
       </xref>
       ; and sialic acids, biosynthesis of which might be inhibited by CQ/HCQ, are component of receptors of SARS-CoV and orthomyxoviruses
       <xref ref-type="bibr" rid="bib36">
        [36]
       </xref>
       .
      </p>
      <p id="para0090">
       In addition to these two main mechanisms, other possible mechanisms such as immunomodulatory and anti-inflammatory properties have been suggested, however these will not be discussed in the present review.
      </p>
     </sec>
     <sec id="section0075">
      <label>
       4.2
      </label>
      <title>
       Activity of HCQ/CQ against viruses
      </title>
      <p id="para0095">
       In vitro activity of HCQ/CQ has been reported for a wide range of viruses, most frequently in experiments aiming to study the cycle replication pathways using CQ, especially the mechanism by which viruses penetrate host cells (
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       ;
       <xref ref-type="fig" rid="fig4">
        Fig. 4
       </xref>
       ).
      </p>
      <p id="para0100">
       Inhibitory concentrations of CQ fell within the 0.5–10 μmol/L range, depending on antiviral CQ doses, the viruses that were targeted and the assays used for assessment of the antiviral effect. Importantly, these concentrations are in the range that is clinically achieved in plasma during malaria therapy, varying from 1.6 μmol/L to 12.5 μmol/L
       <xref ref-type="bibr" rid="bib104">
        [104]
       </xref>
       . The most studied in vitro effect of CQ/HCQ has been against HIV. Moreover, in vivo studies quasi-exclusively concerned HIV-1. This is probably due to the high morbidity and mortality related to HIV-1 worldwide and the need for low-cost antiretroviral therapies in resource-poor countries.
      </p>
     </sec>
     <sec id="section0080">
      <label>
       4.3
      </label>
      <title>
       In vitro anti-HIV activity of HCQ/CQ
      </title>
      <p id="para0105">
       CQ/HCQ have largely been shown to inhibit HIV replication in vitro. Importantly, this inhibition was observed in several cell line models, but also in lymphocytes and monocytes from peripheral blood
       <xref ref-type="bibr" rid="bib29">
        [29]
       </xref>
       . An anti-HIV effect has been demonstrated either in the presence of high concentrations of CQ/HCQ prior to infection of HIV-1-permissive cells
       <xref ref-type="bibr" rid="bib29">
        [29]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib30">
        [30]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib102">
        [102]
       </xref>
       or during incubation of HIV-infected cells with CQ concentrations similar to those found in peripheral blood from individuals chronically treated with CQ
       <xref ref-type="bibr" rid="bib31">
        [31]
       </xref>
       . Thus, these data suggest both a preventive and curative effect of this drug against HIV. The concentration inhibiting 50% of viral replication (IC
       <sub>
        50
       </sub>
       ) ranged between 1 μmol/L and 10 μmol/L for various HIV strains and culture cells in the studies of Savarino et al.
       <xref ref-type="bibr" rid="bib2">
        [2]
       </xref>
       . Boelaert et al.
       <xref ref-type="bibr" rid="bib105">
        [105]
       </xref>
       described an additional inhibition of HIV-1 replication with hydroxyurea plus didanosine (ddI) or zidovudine, with a CQ IC
       <sub>
        50
       </sub>
       of 0.4–0.9 μmol/L for the cell lines and 0.2–0.9 μmol/L for the primary cells; no CQ-induced toxicity or apoptosis was noted. Interestingly, according to in vitro data, CQ/HCQ also appears to be active against HIV-2, which mostly circulates in West Africa, as well as against HIV-1 of different subtypes
       <xref ref-type="bibr" rid="bib2">
        [2]
       </xref>
       . This deserves attention since HIV-2 strains have established or suggested natural resistance to several antiretroviral drugs, such as non-nucleoside reverse transcriptase inhibitors and likely some protease inhibitors (PIs)
       <xref ref-type="bibr" rid="bib106">
        [106]
       </xref>
       .
      </p>
     </sec>
     <sec id="section0085">
      <label>
       4.4
      </label>
      <title>
       In vivo anti-HIV activity of HCQ/CQ
      </title>
      <p id="para0110">
       Anti-HIV-1 activity of CQ/HCQ has been observed in a few in vivo studies since 1995
       <xref ref-type="bibr" rid="bib107">
        [107]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib108">
        [108]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib109">
        [109]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib110">
        [110]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib111">
        [111]
       </xref>
       . Two small, phase II, randomised, double-blind studies, including 40 and 72 patients with CD4 cell counts of 200–500 cells/mm
       <sup>
        3
       </sup>
       , compared reduction of plasma HIV-1 RNA levels in individuals treated with HCQ versus either placebo or zidovudine
       <xref ref-type="bibr" rid="bib107">
        [107]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib108">
        [108]
       </xref>
       . In both trials, more than two-thirds of patients were antiretroviral-naive. In the first trial, 8 weeks of treatment with 800 mg HCQ per day resulted in a significant mean 0.6 log
       <sub>
        10
       </sub>
       reduction of HIV-1 load (
       <italic>
        P
       </italic>
       = 0.022), whereas no significant decrease was observed in the placebo arm (20 patients in each arm)
       <xref ref-type="bibr" rid="bib107">
        [107]
       </xref>
       . Concomitantly, the percentage of CD4
       <sup>
        +
       </sup>
       lymphocytes remained stable in the HCQ group, whereas it significantly decreased in the placebo arm (
       <italic>
        P
       </italic>
       = 0.032). In the second trial, 35 and 37 patients received HCQ or zidovudine, respectively, for 16 weeks
       <xref ref-type="bibr" rid="bib108">
        [108]
       </xref>
       . HIV-1 load was significantly reduced in both groups (by 0.4 log
       <sub>
        10
       </sub>
       copies/mL and 0.6 log
       <sub>
        10
       </sub>
       copies/mL, respectively) and, interestingly, 0 of 35 patients in the HCQ group versus 8 of 37 patients in the zidovudine group showed an increase in HIV-1 RNA levels. Two other recent non-controlled studies have been reported. In Singapore, 22 patients with HIV-1 load &lt;100 000 copies/mL and CD4 cell count &gt;150 cells/mm
       <sup>
        3
       </sup>
       received HCQ (200 mg), hydroxyurea and ddI twice daily for 48 weeks, resulting in a 1.3 log
       <sub>
        10
       </sub>
       decrease in plasma HIV-1 RNA levels
       <xref ref-type="bibr" rid="bib109">
        [109]
       </xref>
       . HIV-1 RNA levels were further reduced compared with baseline (mean decrease 1.6 log
       <sub>
        10
       </sub>
       copies/mL) in all 14 patients who completed a 144-week course of therapy, with drug resistance mutations detected in 4 patients at this time point
       <xref ref-type="bibr" rid="bib110">
        [110]
       </xref>
       . In another study in India, 18 patients with CD4 counts &gt;350/mm
       <sup>
        3
       </sup>
       received lamivudine, hydroxyurea and CQ (250 mg) twice daily for 6 months
       <xref ref-type="bibr" rid="bib111">
        [111]
       </xref>
       . HIV-1 load reduction was significant (−2.0 log
       <sub>
        10
       </sub>
       ), reaching undetectable levels in 10 patients, and the median rise in CD4 count was 78 cells/mm
       <sup>
        3
       </sup>
       . Altogether, these in vivo data in patients with non-severe immunosuppression (CD4 cell count &gt;200/mm
       <sup>
        3
       </sup>
       ) at least suggest that HIV-1 resistance to CQ/HCQ alone or in combination with antiretroviral drugs might not develop easily
       <xref ref-type="bibr" rid="bib36">
        [36]
       </xref>
       . In contrast, addition of CQ to a zidovudine and ddI regimen provided no significant improvement in viro-immunological parameters in 21 HIV-1-infected children in a recent study from Thailand
       <xref ref-type="bibr" rid="bib112">
        [112]
       </xref>
       .
      </p>
      <p id="para0115">
       It is interesting to note that a 243-fold accumulation of CQ in colostrum cells of African mothers taking 100 mg of CQ per day has been observed. This suggests that this drug could be potentially active as an adjuvant to post-natal antiretroviral prophylaxis of mother-to-child transmission by decreasing HIV-1 load in milk in geographical areas where vertical transmission is of great concern
       <xref ref-type="bibr" rid="bib113">
        [113]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib114">
        [114]
       </xref>
       .
      </p>
     </sec>
    </sec>
    <sec id="section0090">
     <label>
      5
     </label>
     <title>
      Additive or synergistic effects of HCQ/CQ with antiretroviral drugs
     </title>
     <p id="para0120">
      In several settings, CQ/HCQ should be used in combination with other antiviral drugs, questioning whether associations may be additive or synergistic. The additive effect of CQ and zidovudine has been shown, and might also exist in association with ddI or hydroxyurea
      <xref ref-type="bibr" rid="bib105">
       [105]
      </xref>
      . Furthermore, the combined effect of CQ and PIs is synergistic in a dose-independent manner
      <xref ref-type="bibr" rid="bib2">
       [2]
      </xref>
      . Savarino et al. showed that CQ in combination with PIs carries out a combined inhibitory effect on P-glycoprotein and multidrug resistance protein 1, which is involved in efflux of PIs, a major class of antiretrovirals. Interestingly, the synergism between CQ and PIs was associated with a decreased threshold of susceptibility to PIs in resistant isolates
      <xref ref-type="bibr" rid="bib2">
       [2]
      </xref>
      . Of note, CQ is a major substrate of cytochrome CYP3A4
      <xref ref-type="bibr" rid="bib116">
       [116]
      </xref>
      , and nevirapine (a non-nucleoside HIV-1 reverse transcriptase inhibitor) and HIV PIs are well recognised CYP3A4 inducers and inhibitors, respectively
      <xref ref-type="bibr" rid="bib115">
       [115]
      </xref>
      . Thus, these latter drugs might subsequently decrease or increase the levels/effects of CQ.
     </p>
     <sec id="section0095">
      <label>
       5.1
      </label>
      <title>
       Activity of HCQ/CQ on SARS-CoV and orthomyxoviruses
      </title>
      <p id="para0125">
       It has been shown that endosomal transport is needed for human coronavirus HCoV-229E and that cells treated with CQ displayed reduced expression of viral antigens
       <xref ref-type="bibr" rid="bib114">
        [114]
       </xref>
       . More recently, CQ was found to have strong antiviral effects on SARS-CoV infection in cell cultures when they were treated either before or after exposure to the virus (even 3–5 h following infection), suggesting both prophylactic and therapeutic effects
       <xref ref-type="bibr" rid="bib33">
        [33]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib34">
        [34]
       </xref>
       . In Keyaerts et al.'s study
       <xref ref-type="bibr" rid="bib34">
        [34]
       </xref>
       , CQ inhibited viral replication with a 50% effective concentration (EC
       <sub>
        50
       </sub>
       ) of 8.8 μmol/L. Of note, the dose inducing 50% cytostatic activity was much higher (261.3 μmol/L). Potential mechanisms of action of CQ against coronaviruses are through underglycosylation of ACE2, which has been identified as a functional cellular receptor of SARS-CoV spike protein
       <xref ref-type="bibr" rid="bib33">
        [33]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib117">
        [117]
       </xref>
       . Alteration by CQ of the SARS-CoV spike protein is controversial
       <xref ref-type="bibr" rid="bib33">
        [33]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib118">
        [118]
       </xref>
       . A pH-related reduction of the transduction of SARS-CoV pseudotype viruses has also been suggested
       <xref ref-type="bibr" rid="bib33">
        [33]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib119">
        [119]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib120">
        [120]
       </xref>
       . Of note, Biot et al.
       <xref ref-type="bibr" rid="bib121">
        [121]
       </xref>
       recently reported the design and synthesis of hydroxyferroquine derivatives with antimalarial, anti-HIV and anti-SARS-CoV activities.
      </p>
      <p id="para0130">
       The activity of CQ against Orthomyxoviridae (influenza A and B viruses) has been described for several decades
       <xref ref-type="bibr" rid="bib35">
        [35]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib37">
        [37]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib122">
        [122]
       </xref>
       and in vitro assays on avian influenza virus strains are ongoing
       <xref ref-type="bibr" rid="bib36">
        [36]
       </xref>
       . Shibata et al.'s
       <xref ref-type="bibr" rid="bib35">
        [35]
       </xref>
       results suggested that CQ prevents the uncoating of influenza B virus. Ooi et al.
       <xref ref-type="bibr" rid="bib38">
        [38]
       </xref>
       found that the IC
       <sub>
        50
       </sub>
       values of CQ against influenza A viruses H1N1 and H3N2 were 3.6 μmol/L and 0.84 μmol/L, respectively.
      </p>
     </sec>
     <sec id="section0100">
      <label>
       5.2
      </label>
      <title>
       Activity of HCQ/CQ on hepatitis viruses
      </title>
      <p id="para0135">
       In a recent study, Blanchard et al.
       <xref ref-type="bibr" rid="bib45">
        [45]
       </xref>
       found that pre-treating target cells with CQ inhibited hepatitis C virus (HCV) clone JFH-1 propagation in cell culture, which suggests that HCV, like flaviviruses and pestiviruses, enters cells through clathrin-mediated endocytosis and fusion within an acidic endosomal compartment. CQ was also found to be active against hepatitis B virus (HBV) and duck HBV
       <xref ref-type="bibr" rid="bib43">
        [43]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib44">
        [44]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib123">
        [123]
       </xref>
       , contrasting with another study in which infection of human hepatocyte cultures with HBV was found to be unaffected by CQ
       <xref ref-type="bibr" rid="bib124">
        [124]
       </xref>
       . Seven patients with histologically proven chronic active hepatitis B have been treated with 150–450 mg of CQ for a median of 12 months
       <xref ref-type="bibr" rid="bib125">
        [125]
       </xref>
       . In all patients, alanine aminotransferase (ALT) returned to normal values and prothrombin time improved. Interestingly, ALT increased in three patients following inadvertent CQ withdrawal and returned to prior levels on re-administration. In four patients, a repeat liver biopsy 1 year later revealed inactive cirrhosis. Recently, an enhancement by CQ of human CD8
       <sup>
        +
       </sup>
       T-cell cell response to HBV antigen has been observed
       <xref ref-type="bibr" rid="bib126">
        [126]
       </xref>
       . Inhibition by CQ of hepatitis A virus (HAV) uncoating and replication has also been described
       <xref ref-type="bibr" rid="bib42">
        [42]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib60">
        [60]
       </xref>
       .
      </p>
     </sec>
     <sec id="section0105">
      <label>
       5.3
      </label>
      <title>
       Toxicity and therapeutic range
      </title>
      <p id="para0140">
       A major advantage of CQ/HCQ is their limited and preventable toxicity. Long experience of the use of these drugs in the treatment of malaria has already demonstrated the safety of short-term administration to humans. Moreover, CQ/HCQ have been widely used for chronic administration in rheumatic diseases, chronic Q fever and for antimalarial prophylaxis for up to several years with only a low incidence of adverse effects even during pregnancy
       <xref ref-type="bibr" rid="bib114">
        [114]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib127">
        [127]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib128">
        [128]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib129">
        [129]
       </xref>
       . The main adverse effect reported in long-term administration of these drugs was macular retinopathy due to the cumulative dose, which could be prevented with regular visual monitoring during the course of treatment
       <xref ref-type="bibr" rid="bib6">
        [6]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib130">
        [130]
       </xref>
       .
      </p>
     </sec>
    </sec>
    <sec id="section0110">
     <label>
      6
     </label>
     <title>
      Conclusion
     </title>
     <p id="para0145">
      In summary, CQ/HCQ have several advantages as antimicrobial agents, including multiple potential mechanisms and a broad spectrum of activity at clinically achievable plasma concentrations, together with well known and limited toxicity and low cost. Two major concepts have emerged to explain the activity of CQ/HCQ, namely alkalinisation of phagolysosomes for intracellular bacteria and fungi, and inhibition of entry steps and protein glycosylation for viruses. The pioneer and the only model of an infectious disease that could be treated by manipulation of intracellular pH by a lysosomotropic agent was chronic Q fever. This review re-emphasises that the
      <italic>
       C. burnetii
      </italic>
      paradigm and activities mediated by lysosomotropic agents could be generalised for other intracellular pathogens living in acidic vacuoles or that require a low pH for multiplication. This may offer an interesting weapon to face present and future infectious diseases worldwide.
     </p>
     <p id="para0150">
      <italic>
       Funding
      </italic>
      : None.
     </p>
     <p id="para0155">
      <italic>
       Competing interests
      </italic>
      : None declared.
     </p>
     <p id="para0160">
      <italic>
       Ethical approval
      </italic>
      : Not required.
     </p>
    </sec>
    <back>
     <ref-list id="bibliography0005">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wellems
          </surname>
          <given-names>
           T.E.
          </given-names>
         </name>
         <name>
          <surname>
           Plowe
          </surname>
          <given-names>
           C.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine-resistant malaria
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         184
        </volume>
        <year>
         2001
        </year>
        <fpage>
         770
        </fpage>
        <lpage>
         776
        </lpage>
        <pub-id pub-id-type="pmid">
         11517439
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lucia
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
         <name>
          <surname>
           Rastrelli
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors
        </article-title>
        <source>
         J Acquir Immune Defic Syndr
        </source>
        <volume>
         35
        </volume>
        <year>
         2004
        </year>
        <fpage>
         223
        </fpage>
        <lpage>
         232
        </lpage>
        <pub-id pub-id-type="pmid">
         15076236
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O’Neill
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
         <name>
          <surname>
           Bray
          </surname>
          <given-names>
           P.G.
          </given-names>
         </name>
         <name>
          <surname>
           Hawley
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           B.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         4-Aminoquinolines—past, present, and future: a chemical perspective
        </article-title>
        <source>
         Pharmacol Ther
        </source>
        <volume>
         77
        </volume>
        <year>
         1998
        </year>
        <fpage>
         29
        </fpage>
        <lpage>
         58
        </lpage>
        <pub-id pub-id-type="pmid">
         9500158
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hackstadt
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Biochemical stratagem for obligate parasitism of eukaryotic cells by
         <italic>
          Coxiella burnetii
         </italic>
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         78
        </volume>
        <year>
         1981
        </year>
        <fpage>
         3240
        </fpage>
        <lpage>
         3244
        </lpage>
        <pub-id pub-id-type="pmid">
         6942430
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maurin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Benoliel
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Bongrand
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the
         <italic>
          Coxiella burnetii
         </italic>
         paradigm
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         166
        </volume>
        <year>
         1992
        </year>
        <fpage>
         1097
        </fpage>
        <lpage>
         1102
        </lpage>
        <pub-id pub-id-type="pmid">
         1402021
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Houpikian
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Tissot Dupont
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Riss
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Arditi-Djiane
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of Q fever endocarditis: comparison of two regimens containing doxycycline and ofloxacin or hydroxychloroquine
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         159
        </volume>
        <year>
         1999
        </year>
        <fpage>
         167
        </fpage>
        <lpage>
         173
        </lpage>
        <pub-id pub-id-type="pmid">
         9927100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ghigo
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Capo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Aurouze
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Survival of
         <italic>
          Tropheryma whipplei
         </italic>
         , the agent of Whipple's disease, requires phagosome acidification
        </article-title>
        <source>
         Infect Immun
        </source>
        <volume>
         70
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1501
        </fpage>
        <lpage>
         1506
        </lpage>
        <pub-id pub-id-type="pmid">
         11854238
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boulos
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibiotic susceptibility of
         <italic>
          Tropheryma whipplei
         </italic>
         in MRC5 cells
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         48
        </volume>
        <year>
         2004
        </year>
        <fpage>
         747
        </fpage>
        <lpage>
         752
        </lpage>
        <pub-id pub-id-type="pmid">
         14982759
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maurin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Optimum treatment of intracellular infection
        </article-title>
        <source>
         Drugs
        </source>
        <volume>
         52
        </volume>
        <year>
         1996
        </year>
        <fpage>
         45
        </fpage>
        <lpage>
         59
        </lpage>
        <pub-id pub-id-type="pmid">
         8799684
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maurin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intracellular organisms
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <volume>
         9
        </volume>
        <year>
         1997
        </year>
        <fpage>
         61
        </fpage>
        <lpage>
         70
        </lpage>
        <pub-id pub-id-type="pmid">
         18611821
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Byrd
          </surname>
          <given-names>
           T.F.
          </given-names>
         </name>
         <name>
          <surname>
           Horwitz
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibits the intracellular multiplication of
         <italic>
          Legionella pneumophila
         </italic>
         by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens
        </article-title>
        <source>
         J Clin Invest
        </source>
        <volume>
         88
        </volume>
        <year>
         1991
        </year>
        <fpage>
         351
        </fpage>
        <lpage>
         357
        </lpage>
        <pub-id pub-id-type="pmid">
         2056129
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fortier
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Leiby
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Growth of
         <italic>
          Francisella tularensis
         </italic>
         LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth
        </article-title>
        <source>
         Infect Immun
        </source>
        <volume>
         63
        </volume>
        <year>
         1995
        </year>
        <fpage>
         1478
        </fpage>
        <lpage>
         1483
        </lpage>
        <pub-id pub-id-type="pmid">
         7890413
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Drancourt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Vestris
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bactericidal effect of doxycycline associated with lysosomotropic agents on
         <italic>
          Coxiella burnetii
         </italic>
         in P388D1 cells
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         34
        </volume>
        <year>
         1990
        </year>
        <fpage>
         1512
        </fpage>
        <lpage>
         1514
        </lpage>
        <pub-id pub-id-type="pmid">
         2221859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crowle
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           May
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         34
        </volume>
        <year>
         1990
        </year>
        <fpage>
         2217
        </fpage>
        <lpage>
         2222
        </lpage>
        <pub-id pub-id-type="pmid">
         2127346
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Appelberg
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Gomes
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Experimental results on chloroquine and AIDS-related opportunistic infections
        </article-title>
        <source>
         J Acquir Immune Defic Syndr
        </source>
        <volume>
         26
        </volume>
        <year>
         2001
        </year>
        <fpage>
         300
        </fpage>
        <lpage>
         301
        </lpage>
        <pub-id pub-id-type="pmid">
         11242206
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Horowitz
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Carbonaro
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of the
         <italic>
          Salmonella typhi
         </italic>
         oral vaccine strain, Ty21a, by mefloquine and chloroquine
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         166
        </volume>
        <year>
         1992
        </year>
        <fpage>
         1462
        </fpage>
        <lpage>
         1464
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wiseman
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of pH on the inhibitory activity of chloroquine against
         <italic>
          Escherichia coli
         </italic>
        </article-title>
        <source>
         J Pharm Pharmacol
        </source>
        <volume>
         24
        </volume>
        <issue>
         Suppl.
        </issue>
        <year>
         1972
        </year>
        <fpage>
         162P
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Artenstein
          </surname>
          <given-names>
           A.W.
          </given-names>
         </name>
         <name>
          <surname>
           Opal
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cristofaro
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine enhances survival in
         <italic>
          Bacillus anthracis
         </italic>
         intoxication
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         190
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1655
        </fpage>
        <lpage>
         1660
        </lpage>
        <pub-id pub-id-type="pmid">
         15478072
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           K.T.
          </given-names>
         </name>
         <name>
          <surname>
           Dawes
          </surname>
          <given-names>
           I.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The preferential inhibition of
         <italic>
          Bacillus subtilis
         </italic>
         spore outgrowth by chloroquine
        </article-title>
        <source>
         Arch Microbiol
        </source>
        <volume>
         152
        </volume>
        <year>
         1989
        </year>
        <fpage>
         251
        </fpage>
        <lpage>
         257
        </lpage>
        <pub-id pub-id-type="pmid">
         2476100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brorson
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Brorson
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An in vitro study of the susceptibility of mobile and cystic forms of
         <italic>
          Borrelia burgdorferi
         </italic>
         to hydroxychloroquine
        </article-title>
        <source>
         Int Microbiol
        </source>
        <volume>
         5
        </volume>
        <year>
         2002
        </year>
        <fpage>
         25
        </fpage>
        <lpage>
         31
        </lpage>
        <pub-id pub-id-type="pmid">
         12102233
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Detilleux
          </surname>
          <given-names>
           P.G.
          </given-names>
         </name>
         <name>
          <surname>
           Deyoe
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Cheville
          </surname>
          <given-names>
           N.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of endocytic and metabolic inhibitors on the internalization and intracellular growth of
         <italic>
          Brucella abortus
         </italic>
         in Vero cells
        </article-title>
        <source>
         Am J Vet Res
        </source>
        <volume>
         52
        </volume>
        <year>
         1991
        </year>
        <fpage>
         1658
        </fpage>
        <lpage>
         1664
        </lpage>
        <pub-id pub-id-type="pmid">
         1767988
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Grellet
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Paillard
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Dubois
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Quentin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Saux
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors influencing the intracellular activity of fluoroquinolones: a study using levofloxacin in a
         <italic>
          Staphylococcus aureus
         </italic>
         THP-1 monocyte model
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <volume>
         57
        </volume>
        <year>
         2006
        </year>
        <fpage>
         883
        </fpage>
        <lpage>
         890
        </lpage>
        <pub-id pub-id-type="pmid">
         16533826
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prada-Delgado
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Carrasco-Marin
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Pena-Macarro
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of Rab5a exchange activity is a key step for
         <italic>
          Listeria monocytogenes
         </italic>
         survival
        </article-title>
        <source>
         Traffic
        </source>
        <volume>
         6
        </volume>
        <year>
         2005
        </year>
        <fpage>
         252
        </fpage>
        <lpage>
         265
        </lpage>
        <pub-id pub-id-type="pmid">
         15702993
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Newman
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Gootee
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Brunner
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Deepe
          </surname>
          <given-names>
           G.S.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
        </person-group>
        <article-title>
         Chloroquine induces human macrophage killing of
         <italic>
          Histoplasma capsulatum
         </italic>
         by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis
        </article-title>
        <source>
         J Clin Invest
        </source>
        <volume>
         93
        </volume>
        <year>
         1994
        </year>
        <fpage>
         1422
        </fpage>
        <lpage>
         1429
        </lpage>
        <pub-id pub-id-type="pmid">
         8163646
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Levitz
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <name>
          <surname>
           Tabuni
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine induces human mononuclear phagocytes to inhibit and kill
         <italic>
          Cryptococcus neoformans
         </italic>
         by a mechanism independent of iron deprivation
        </article-title>
        <source>
         J Clin Invest
        </source>
        <volume>
         100
        </volume>
        <year>
         1997
        </year>
        <fpage>
         1640
        </fpage>
        <lpage>
         1646
        </lpage>
        <pub-id pub-id-type="pmid">
         9294133
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dias-Melicio FPetruzzielloL.A.
          </surname>
         </name>
         <name>
          <surname>
           Moreira
          </surname>
          <given-names>
           A.P.
          </given-names>
         </name>
         <name>
          <surname>
           Calvi
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Soares
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibits
         <italic>
          Paracoccidioides brasiliensis
         </italic>
         survival within human monocytes by limiting the availability of intracellular iron
        </article-title>
        <source>
         Microbiol Immunol
        </source>
        <volume>
         50
        </volume>
        <year>
         2006
        </year>
        <fpage>
         307
        </fpage>
        <lpage>
         314
        </lpage>
        <pub-id pub-id-type="pmid">
         16625052
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Taramelli
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tognazioli
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ravagnani
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Leopardi
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Giannulis
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of intramacrophage growth of
         <italic>
          Penicillium marneffei
         </italic>
         by 4-aminoquinolines
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         45
        </volume>
        <year>
         2001
        </year>
        <fpage>
         1450
        </fpage>
        <lpage>
         1455
        </lpage>
        <pub-id pub-id-type="pmid">
         11302809
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jahn
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Langfelder
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Schneider
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Schindel
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Brakhage
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         PKSP-dependent reduction of phagolysosome fusion and intracellular kill of
         <italic>
          Aspergillus fumigatus
         </italic>
         conidia by human monocyte-derived macrophages
        </article-title>
        <source>
         Cell Microbiol
        </source>
        <volume>
         4
        </volume>
        <year>
         2002
        </year>
        <fpage>
         793
        </fpage>
        <lpage>
         803
        </lpage>
        <pub-id pub-id-type="pmid">
         12464010
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kalb
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Banerjee
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Mayer
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes
        </article-title>
        <source>
         AIDS Res Hum Retroviruses
        </source>
        <volume>
         9
        </volume>
        <year>
         1993
        </year>
        <fpage>
         91
        </fpage>
        <lpage>
         98
        </lpage>
        <pub-id pub-id-type="pmid">
         8427717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           D.F.
          </given-names>
         </name>
         <name>
          <surname>
           Santo
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Rebello
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rebello
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Weak bases affect late stages of Mayaro virus replication cycle in vertebrate cells
        </article-title>
        <source>
         J. Med. Microbiol.
        </source>
        <volume>
         49
        </volume>
        <issue>
         4
        </issue>
        <year>
         2000
        </year>
        <fpage>
         313
        </fpage>
        <lpage>
         318
        </lpage>
        <pub-id pub-id-type="pmid">
         10755624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pardridge
          </surname>
          <given-names>
           W.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Diagne
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes
        </article-title>
        <source>
         Immunol Lett
        </source>
        <volume>
         64
        </volume>
        <year>
         1998
        </year>
        <fpage>
         45
        </fpage>
        <lpage>
         47
        </lpage>
        <pub-id pub-id-type="pmid">
         9865601
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Sassaroli
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Louie
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine
        </article-title>
        <source>
         Clin Ther
        </source>
        <volume>
         18
        </volume>
        <year>
         1996
        </year>
        <fpage>
         1080
        </fpage>
        <lpage>
         1092
        </lpage>
        <pub-id pub-id-type="pmid">
         9001825
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bergeron
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Benjannet
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         2
        </volume>
        <year>
         2005
        </year>
        <fpage>
         69
        </fpage>
        <pub-id pub-id-type="pmid">
         16115318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Maes
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Neyts
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Van
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <volume>
         323
        </volume>
        <year>
         2004
        </year>
        <fpage>
         264
        </fpage>
        <lpage>
         268
        </lpage>
        <pub-id pub-id-type="pmid">
         15351731
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shibata
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Aoki
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsurumi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         64
        </volume>
        <year>
         1983
        </year>
        <fpage>
         1149
        </fpage>
        <lpage>
         1156
        </lpage>
        <pub-id pub-id-type="pmid">
         6842189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Di
          </surname>
          <given-names>
           T.L.
          </given-names>
         </name>
         <name>
          <surname>
           Donatelli
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         New insights into the antiviral effects of chloroquine
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         6
        </volume>
        <year>
         2006
        </year>
        <fpage>
         67
        </fpage>
        <lpage>
         69
        </lpage>
        <pub-id pub-id-type="pmid">
         16439323
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lenard
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antihistaminics, local anesthetics, and other amines as antiviral agents
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         78
        </volume>
        <year>
         1981
        </year>
        <fpage>
         3605
        </fpage>
        <lpage>
         3609
        </lpage>
        <pub-id pub-id-type="pmid">
         6115382
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Chew
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Loh
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Chua
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro inhibition of human influenza A virus replication by chloroquine
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         3
        </volume>
        <year>
         2006
        </year>
        <fpage>
         39
        </fpage>
        <pub-id pub-id-type="pmid">
         16729896
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Randolph
          </surname>
          <given-names>
           V.B.
          </given-names>
         </name>
         <name>
          <surname>
           Winkler
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Stollar
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acidotropic amines inhibit proteolytic processing of flavivirus prM protein
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         174
        </volume>
        <year>
         1990
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         458
        </lpage>
        <pub-id pub-id-type="pmid">
         2154882
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Petruzziello
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Orsi
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Macchia
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rieti
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Frey
          </surname>
          <given-names>
           T.K.
          </given-names>
         </name>
         <name>
          <surname>
           Mastromarino
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathway of rubella virus infectious entry into Vero cells
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         77
        </volume>
        <issue>
         Pt 2
        </issue>
        <year>
         1996
        </year>
        <fpage>
         303
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         8627234
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nakhasi
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Callahan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Dave
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rubella virus: mechanism of attenuation in the vaccine strain (HPV77)
        </article-title>
        <source>
         Virus Res
        </source>
        <volume>
         13
        </volume>
        <issue>
         3
        </issue>
        <year>
         1989
        </year>
        <fpage>
         231
        </fpage>
        <lpage>
         243
        </lpage>
        <pub-id pub-id-type="pmid">
         2773598
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bishop
          </surname>
          <given-names>
           N.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Examination of potential inhibitors of hepatitis A virus uncoating
        </article-title>
        <source>
         Intervirology
        </source>
        <volume>
         41
        </volume>
        <year>
         1998
        </year>
        <fpage>
         261
        </fpage>
        <lpage>
         271
        </lpage>
        <pub-id pub-id-type="pmid">
         10325536
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Offensperger
          </surname>
          <given-names>
           W.B.
          </given-names>
         </name>
         <name>
          <surname>
           Offensperger
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Walter
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Blum
          </surname>
          <given-names>
           H.E.
          </given-names>
         </name>
         <name>
          <surname>
           Gerok
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of duck hepatitis B virus infection by lysosomotropic agents
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         183
        </volume>
        <year>
         1991
        </year>
        <fpage>
         415
        </fpage>
        <lpage>
         418
        </lpage>
        <pub-id pub-id-type="pmid">
         2053292
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Civitico
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Luscombe
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         31
        </volume>
        <year>
         1990
        </year>
        <fpage>
         90
        </fpage>
        <lpage>
         97
        </lpage>
        <pub-id pub-id-type="pmid">
         1696959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Blanchard
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Belouzard
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Goueslain
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis C virus entry depends on clathrin-mediated endocytosis
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         80
        </volume>
        <year>
         2006
        </year>
        <fpage>
         6964
        </fpage>
        <lpage>
         6972
        </lpage>
        <pub-id pub-id-type="pmid">
         16809302
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glushakova
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lukashevich
          </surname>
          <given-names>
           I.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early events in arenavirus replication are sensitive to lysosomotropic compounds
        </article-title>
        <source>
         Arch Virol
        </source>
        <volume>
         104
        </volume>
        <year>
         1989
        </year>
        <fpage>
         157
        </fpage>
        <lpage>
         161
        </lpage>
        <pub-id pub-id-type="pmid">
         2923547
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Borrow
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Oldstone
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanism of lymphocytic choriomeningitis virus entry into cells
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         198
        </volume>
        <issue>
         1
        </issue>
        <year>
         1994
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         8259643
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Superti
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ammonium chloride and chloroquine inhibit rabies virus infection in neuroblastoma cells Brief report
        </article-title>
        <source>
         Arch Virol
        </source>
        <volume>
         81
        </volume>
        <year>
         1984
        </year>
        <fpage>
         377
        </fpage>
        <lpage>
         382
        </lpage>
        <pub-id pub-id-type="pmid">
         6148053
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pontesilli
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Carotenuto
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Levin
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Suez
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hayward
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Processing and presentation of cell-associated varicella–zoster virus antigens by human monocytes
        </article-title>
        <source>
         Clin Exp Immunol
        </source>
        <volume>
         70
        </volume>
        <year>
         1987
        </year>
        <fpage>
         127
        </fpage>
        <lpage>
         135
        </lpage>
        <pub-id pub-id-type="pmid">
         2826056
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lindemans
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Coffer
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Schellens
          </surname>
          <given-names>
           I.M.
          </given-names>
         </name>
         <name>
          <surname>
           de Graaff
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kimpen
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Koenderman
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-κB-dependent mechanism
        </article-title>
        <source>
         J Immunol
        </source>
        <volume>
         176
        </volume>
        <year>
         2006
        </year>
        <fpage>
         5529
        </fpage>
        <lpage>
         5537
        </lpage>
        <pub-id pub-id-type="pmid">
         16622022
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cassell
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           D.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of lysosomotropic weak bases on infection of BHK-21 cells by Sindbis virus
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         52
        </volume>
        <year>
         1984
        </year>
        <fpage>
         857
        </fpage>
        <lpage>
         864
        </lpage>
        <pub-id pub-id-type="pmid">
         6492263
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sidhu
          </surname>
          <given-names>
           G.S.
          </given-names>
         </name>
         <name>
          <surname>
           Friedman
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Maheshwari
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanism of enhancement of the antiviral action of interferon against herpes simplex virus-1 by chloroquine
        </article-title>
        <source>
         J Interferon Cytokine Res
        </source>
        <volume>
         16
        </volume>
        <year>
         1996
        </year>
        <fpage>
         725
        </fpage>
        <lpage>
         731
        </lpage>
        <pub-id pub-id-type="pmid">
         8887057
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Koyama
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Uchida
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of multiplication of herpes simplex virus type 1 by ammonium chloride and chloroquine
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         138
        </volume>
        <issue>
         2
        </issue>
        <year>
         1984
        </year>
        <fpage>
         332
        </fpage>
        <lpage>
         335
        </lpage>
        <pub-id pub-id-type="pmid">
         6093369
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hutt-Fletcher
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epstein–Barr virus enters B cells and epithelial cells by different routes
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         66
        </volume>
        <year>
         1992
        </year>
        <fpage>
         3409
        </fpage>
        <lpage>
         3414
        </lpage>
        <pub-id pub-id-type="pmid">
         1316456
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zeichhardt
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wetz
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Willingmann
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Habermehl
          </surname>
          <given-names>
           K.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Entry of poliovirus type 1 and Mouse Elberfeld (ME) virus into HEp-2 cells: receptor-mediated endocytosis and endosomal or lysosomal uncoating
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         66
        </volume>
        <year>
         1985
        </year>
        <fpage>
         483
        </fpage>
        <lpage>
         492
        </lpage>
        <pub-id pub-id-type="pmid">
         2857762
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kronenberger
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Vrijsen
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Boeye
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine induces empty capsid formation during poliovirus eclipse
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         65
        </volume>
        <year>
         1991
        </year>
        <fpage>
         7008
        </fpage>
        <lpage>
         7011
        </lpage>
        <pub-id pub-id-type="pmid">
         1658391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madshus
          </surname>
          <given-names>
           I.H.
          </given-names>
         </name>
         <name>
          <surname>
           Olsnes
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sandvig
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanism of entry into the cytosol of poliovirus type 1: requirement for low pH
        </article-title>
        <source>
         J Cell Biol
        </source>
        <volume>
         98
        </volume>
        <issue>
         4
        </issue>
        <year>
         1984
        </year>
        <fpage>
         1194
        </fpage>
        <lpage>
         1200
        </lpage>
        <pub-id pub-id-type="pmid">
         6325467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yoshida
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Takao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kiyotani
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Sakaguchi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Endoproteolytic activation of Newcastle disease virus fusion proteins requires an intracellular acidic environment
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         170
        </volume>
        <year>
         1989
        </year>
        <fpage>
         571
        </fpage>
        <lpage>
         574
        </lpage>
        <pub-id pub-id-type="pmid">
         2728349
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gonzalez-Dunia
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Cubitt
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           de la Torre
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanism of Borna disease virus entry into cells
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         72
        </volume>
        <year>
         1998
        </year>
        <fpage>
         783
        </fpage>
        <lpage>
         788
        </lpage>
        <pub-id pub-id-type="pmid">
         9420287
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lenard
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of vesicular stomatitis virus infection by spike glycoprotein.
        </article-title>
        <source>
         Evidence for an intracellular, G protein-requiring step. J Cell Biol
        </source>
        <volume>
         84
        </volume>
        <issue>
         2
        </issue>
        <year>
         1980
        </year>
        <fpage>
         430
        </fpage>
        <lpage>
         437
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fredericksen
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Whitt
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         240
        </volume>
        <year>
         1998
        </year>
        <fpage>
         349
        </fpage>
        <lpage>
         358
        </lpage>
        <pub-id pub-id-type="pmid">
         9454708
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dille
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of vesicular stomatitis virus glycoprotein expression by chloroquine
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         62
        </volume>
        <year>
         1982
        </year>
        <fpage>
         91
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="pmid">
         6290597
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib63">
       <label>
        63
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Janeczko
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Esteban
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Studies on the mechanism of entry of vaccinia virus in animal cells
        </article-title>
        <source>
         Arch Virol
        </source>
        <volume>
         92
        </volume>
        <year>
         1987
        </year>
        <fpage>
         135
        </fpage>
        <lpage>
         150
        </lpage>
        <pub-id pub-id-type="pmid">
         3800657
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib64">
       <label>
        64
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pazmino
          </surname>
          <given-names>
           N.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuhas
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tennant
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of murine RNA tumor virus replication and oncogenesis by chloroquine
        </article-title>
        <source>
         Int J Cancer
        </source>
        <volume>
         14
        </volume>
        <year>
         1974
        </year>
        <fpage>
         379
        </fpage>
        <lpage>
         385
        </lpage>
        <pub-id pub-id-type="pmid">
         4459273
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib65">
       <label>
        65
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carrillo
          </surname>
          <given-names>
           E.C.
          </given-names>
         </name>
         <name>
          <surname>
           Giachetti
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Campos
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early steps in FMDV replication: further analysis on the effects of chloroquine
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         147
        </volume>
        <year>
         1985
        </year>
        <fpage>
         118
        </fpage>
        <lpage>
         125
        </lpage>
        <pub-id pub-id-type="pmid">
         2998059
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib66">
       <label>
        66
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferreira
          </surname>
          <given-names>
           D.F.
          </given-names>
         </name>
         <name>
          <surname>
           Santo
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Rebello
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rebello
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Weak bases affect late stages of Mayaro virus replication cycle in vertebrate cells
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <volume>
         49
        </volume>
        <year>
         2000
        </year>
        <fpage>
         313
        </fpage>
        <lpage>
         318
        </lpage>
        <pub-id pub-id-type="pmid">
         10755624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib67">
       <label>
        67
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stuart
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           T.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Entry of feline calicivirus is dependent on clathrin-mediated endocytosis and acidification in endosomes
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         80
        </volume>
        <year>
         2006
        </year>
        <fpage>
         7500
        </fpage>
        <lpage>
         7509
        </lpage>
        <pub-id pub-id-type="pmid">
         16840330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib68">
       <label>
        68
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Geraldes
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Valdeira
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of chloroquine on African swine fever virus infection
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         66
        </volume>
        <issue>
         Pt 5
        </issue>
        <year>
         1985
        </year>
        <fpage>
         1145
        </fpage>
        <lpage>
         1148
        </lpage>
        <pub-id pub-id-type="pmid">
         3998709
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib69">
       <label>
        69
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mager
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Masengo
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Mammerickx
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Letesson
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         T cell proliferative response to bovine leukaemia virus (BLV): identification of T cell epitopes on the major core protein (p24) in BLV-infected cattle with normal haematological values
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         75
        </volume>
        <year>
         1994
        </year>
        <fpage>
         2223
        </fpage>
        <lpage>
         2231
        </lpage>
        <pub-id pub-id-type="pmid">
         7521391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib70">
       <label>
        70
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Basak
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious entry pathway for canine parvovirus
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         186
        </volume>
        <year>
         1992
        </year>
        <fpage>
         368
        </fpage>
        <lpage>
         376
        </lpage>
        <pub-id pub-id-type="pmid">
         1733094
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib71">
       <label>
        71
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ros
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Burckhardt
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kempf
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         76
        </volume>
        <issue>
         24
        </issue>
        <year>
         2002
        </year>
        <fpage>
         12634
        </fpage>
        <lpage>
         12645
        </lpage>
        <pub-id pub-id-type="pmid">
         12438589
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib72">
       <label>
        72
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hackstadt
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         pH dependence of the
         <italic>
          Coxiella burnetii
         </italic>
         glutamate transport system
        </article-title>
        <source>
         J Bacteriol
        </source>
        <volume>
         154
        </volume>
        <year>
         1983
        </year>
        <fpage>
         598
        </fpage>
        <lpage>
         603
        </lpage>
        <pub-id pub-id-type="pmid">
         6132912
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib73">
       <label>
        73
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mege
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Maurin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Capo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Coxiella burnetii
         </italic>
         : the ‘query’ fever bacterium. A model of immune subversion by a strictly intracellular microorganism
        </article-title>
        <source>
         FEMS Microbiol Rev
        </source>
        <volume>
         19
        </volume>
        <year>
         1997
        </year>
        <fpage>
         209
        </fpage>
        <lpage>
         217
        </lpage>
        <pub-id pub-id-type="pmid">
         9167255
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib74">
       <label>
        74
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maurin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Q fever
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <volume>
         12
        </volume>
        <year>
         1999
        </year>
        <fpage>
         518
        </fpage>
        <lpage>
         553
        </lpage>
        <pub-id pub-id-type="pmid">
         10515901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib75">
       <label>
        75
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fenollar
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Fournier
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Carrieri
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Habib
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Messana
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risks factors and prevention of Q fever endocarditis
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         33
        </volume>
        <year>
         2001
        </year>
        <fpage>
         312
        </fpage>
        <lpage>
         316
        </lpage>
        <pub-id pub-id-type="pmid">
         11438895
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib76">
       <label>
        76
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madariaga
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Pulvirenti
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sekosan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Paddock
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Q fever endocarditis in HIV-infected patient
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         501
        </fpage>
        <lpage>
         504
        </lpage>
        <pub-id pub-id-type="pmid">
         15109422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib77">
       <label>
        77
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Senn
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Franciolli
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Coxiella burnetii
         </italic>
         vascular graft infection
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <volume>
         5
        </volume>
        <year>
         2005
        </year>
        <fpage>
         109
        </fpage>
        <pub-id pub-id-type="pmid">
         16336642
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib78">
       <label>
        78
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fenollar
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Thuny
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Xeridat
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Lepidi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Endocarditis after acute Q fever in patients with previously undiagnosed valvulopathies
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         42
        </volume>
        <year>
         2006
        </year>
        <fpage>
         818
        </fpage>
        <lpage>
         821
        </lpage>
        <pub-id pub-id-type="pmid">
         16477559
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib79">
       <label>
        79
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Landais
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fenollar
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Thuny
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         From acute Q fever to endocarditis: serological follow-up strategy
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         44
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1337
        </fpage>
        <lpage>
         1340
        </lpage>
        <pub-id pub-id-type="pmid">
         17443471
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib80">
       <label>
        80
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Landais
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fenollar
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Constantin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Q fever osteoarticular infection: four new cases and a review of the literature
        </article-title>
        <source>
         Eur J Clin Microbiol Infect Dis
        </source>
        <volume>
         26
        </volume>
        <year>
         2007
        </year>
        <fpage>
         341
        </fpage>
        <lpage>
         347
        </lpage>
        <pub-id pub-id-type="pmid">
         17401591
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib81">
       <label>
        81
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Birg
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           La Scola
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cultivation of the bacillus of Whipple's disease
        </article-title>
        <source>
         New Engl J Med
        </source>
        <volume>
         342
        </volume>
        <year>
         2000
        </year>
        <fpage>
         620
        </fpage>
        <lpage>
         625
        </lpage>
        <pub-id pub-id-type="pmid">
         10699161
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib82">
       <label>
        82
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fenollar
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Puechal
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Whipple's disease
        </article-title>
        <source>
         New Engl J Med
        </source>
        <volume>
         256
        </volume>
        <year>
         2007
        </year>
        <fpage>
         55
        </fpage>
        <lpage>
         66
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib83">
       <label>
        83
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rogers
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Tompsett
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The survival of staphylococci within human leukocytes
        </article-title>
        <source>
         J Exp Med
        </source>
        <volume>
         95
        </volume>
        <year>
         1952
        </year>
        <fpage>
         209
        </fpage>
        <lpage>
         230
        </lpage>
        <pub-id pub-id-type="pmid">
         14907971
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib84">
       <label>
        84
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kapral
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
         <name>
          <surname>
           Shayegani
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intracellular survival of staphylococci
        </article-title>
        <source>
         J Exp Med
        </source>
        <volume>
         110
        </volume>
        <year>
         1959
        </year>
        <fpage>
         123
        </fpage>
        <pub-id pub-id-type="pmid">
         13664874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib85">
       <label>
        85
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Craven
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Field
          </surname>
          <given-names>
           T.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bunch
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Mayer
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bourne
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The influence of extracellular and phagolysosomal pH changes on the bactericidal activity of bovine neutrophils against
         <italic>
          Staphylococcus aureus
         </italic>
        </article-title>
        <source>
         Vet Immunol Immunopathol
        </source>
        <volume>
         13
        </volume>
        <year>
         1986
        </year>
        <fpage>
         97
        </fpage>
        <lpage>
         110
        </lpage>
        <pub-id pub-id-type="pmid">
         3765370
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib86">
       <label>
        86
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Styrt
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Klempner
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Modification of interactions between neutrophils and staphylococci by lysosomotropic week bases
        </article-title>
        <source>
         Infect Immun
        </source>
        <volume>
         50
        </volume>
        <year>
         1985
        </year>
        <fpage>
         415
        </fpage>
        <lpage>
         419
        </lpage>
        <pub-id pub-id-type="pmid">
         2997038
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib87">
       <label>
        87
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yancey
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Sanchez
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ford
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activity of antibiotics against
         <italic>
          Staphylococcus aureus
         </italic>
         within polymorphonuclear neutrophils
        </article-title>
        <source>
         Eur J Clin Microbiol Infect Dis
        </source>
        <volume>
         10
        </volume>
        <year>
         1991
        </year>
        <fpage>
         107
        </fpage>
        <lpage>
         113
        </lpage>
        <pub-id pub-id-type="pmid">
         1864272
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib88">
       <label>
        88
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Mathison
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of low intraphagolysosomal pH on antimicrobial activity of antibiotics against ingested staphylococci
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <volume>
         16
        </volume>
        <year>
         1983
        </year>
        <fpage>
         309
        </fpage>
        <lpage>
         316
        </lpage>
        <pub-id pub-id-type="pmid">
         6876137
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib89">
       <label>
        89
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maurin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Phagolysosomal alkalinization and intracellular killing of
         <italic>
          Staphylococcus aureus
         </italic>
         by amikacin
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         169
        </volume>
        <year>
         1994
        </year>
        <fpage>
         330
        </fpage>
        <lpage>
         336
        </lpage>
        <pub-id pub-id-type="pmid">
         8106766
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib90">
       <label>
        90
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Grellet
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Dubois
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Saux
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Quentin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors compromising the activity of moxifloxacin against intracellular
         <italic>
          Staphylococcus aureus
         </italic>
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <volume>
         59
        </volume>
        <year>
         2007
        </year>
        <fpage>
         755
        </fpage>
        <lpage>
         758
        </lpage>
        <pub-id pub-id-type="pmid">
         17353222
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib91">
       <label>
        91
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sanchez
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ford
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Yancey
          </surname>
          <given-names>
           R.J.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
        </person-group>
        <article-title>
         Evaluation of antibiotic effectiveness against
         <italic>
          Staphylococcus aureus
         </italic>
         surviving within the bovine mammary gland macrophage
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <volume>
         21
        </volume>
        <year>
         1988
        </year>
        <fpage>
         773
        </fpage>
        <lpage>
         786
        </lpage>
        <pub-id pub-id-type="pmid">
         3410801
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib92">
       <label>
        92
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tulkens
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intracellular distribution and activity of antibiotics
        </article-title>
        <source>
         Eur J Clin Microbiol Infect Dis
        </source>
        <volume>
         10
        </volume>
        <year>
         1991
        </year>
        <fpage>
         100
        </fpage>
        <lpage>
         106
        </lpage>
        <pub-id pub-id-type="pmid">
         1864271
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib93">
       <label>
        93
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mandell
          </surname>
          <given-names>
           G.L.
          </given-names>
         </name>
         <name>
          <surname>
           Vest
          </surname>
          <given-names>
           T.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Killing of intraleukocytic
         <italic>
          Staphylococcus aureus
         </italic>
         by rifampin: in vitro and in vivo studies
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         125
        </volume>
        <year>
         1972
        </year>
        <fpage>
         486
        </fpage>
        <lpage>
         490
        </lpage>
        <pub-id pub-id-type="pmid">
         5023643
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib94">
       <label>
        94
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stout
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           V.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Legionellosis
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         337
        </volume>
        <year>
         1997
        </year>
        <fpage>
         682
        </fpage>
        <lpage>
         687
        </lpage>
        <pub-id pub-id-type="pmid">
         9278466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib95">
       <label>
        95
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Levitz
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and the fungal phagosome
        </article-title>
        <source>
         Curr Opin Microbiol
        </source>
        <volume>
         3
        </volume>
        <year>
         2000
        </year>
        <fpage>
         349
        </fpage>
        <lpage>
         353
        </lpage>
        <pub-id pub-id-type="pmid">
         10972492
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib96">
       <label>
        96
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Simons
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Levitz
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Determination of the pH of the
         <italic>
          Cryptococcus neoformans
         </italic>
         vacuole
        </article-title>
        <source>
         Med Mycol
        </source>
        <volume>
         40
        </volume>
        <year>
         2002
        </year>
        <fpage>
         329
        </fpage>
        <lpage>
         332
        </lpage>
        <pub-id pub-id-type="pmid">
         12146766
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib97">
       <label>
        97
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eissenberg
          </surname>
          <given-names>
           L.G.
          </given-names>
         </name>
         <name>
          <surname>
           Goldman
          </surname>
          <given-names>
           W.E.
          </given-names>
         </name>
         <name>
          <surname>
           Schlesinger
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Histoplasma capsulatum
         </italic>
         modulates the acidification of phagolysosomes
        </article-title>
        <source>
         J Exp Med
        </source>
        <volume>
         177
        </volume>
        <year>
         1995
        </year>
        <fpage>
         1605
        </fpage>
        <lpage>
         1611
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib98">
       <label>
        98
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Strasser
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Newman
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ciraolo
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Howell
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dean
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Regulation of the macrophage vacuolar ATPase and phagosome–lysosome fusion by
         <italic>
          Histoplasma capsulatum
         </italic>
        </article-title>
        <source>
         J Immunol
        </source>
        <volume>
         162
        </volume>
        <year>
         1999
        </year>
        <fpage>
         6148
        </fpage>
        <lpage>
         6154
        </lpage>
        <pub-id pub-id-type="pmid">
         10229858
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib99">
       <label>
        99
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schafer
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Dean
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cloning and sequence analysis of an H(+)-ATPase-encoding gene from the human dimorphic pathogen
         <italic>
          Histoplasma capsulatum
         </italic>
        </article-title>
        <source>
         Gene
        </source>
        <volume>
         136
        </volume>
        <year>
         1993
        </year>
        <fpage>
         295
        </fpage>
        <lpage>
         300
        </lpage>
        <pub-id pub-id-type="pmid">
         7916725
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib100">
       <label>
        100
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Levitz
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Nong
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Seetoo
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <name>
          <surname>
           Speizer
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Simons
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Cryptococcus neoformans
         </italic>
         resides in an acidic phagolysosome of human macrophages
        </article-title>
        <source>
         Infect Immun
        </source>
        <volume>
         67
        </volume>
        <year>
         1999
        </year>
        <fpage>
         885
        </fpage>
        <lpage>
         890
        </lpage>
        <pub-id pub-id-type="pmid">
         9916104
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib101">
       <label>
        101
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sieczkarski
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dissecting virus entry via endocytosis
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         83
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1535
        </fpage>
        <lpage>
         1545
        </lpage>
        <pub-id pub-id-type="pmid">
         12075072
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib102">
       <label>
        102
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Naarding
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Baan
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Pollakis
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Paxton
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes
        </article-title>
        <source>
         Retrovirology
        </source>
        <volume>
         4
        </volume>
        <year>
         2007
        </year>
        <fpage>
         6
        </fpage>
        <pub-id pub-id-type="pmid">
         17263871
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib103">
       <label>
        103
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kwiek
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Haystead
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rudolph
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         43
        </volume>
        <year>
         2004
        </year>
        <fpage>
         4538
        </fpage>
        <lpage>
         4547
        </lpage>
        <pub-id pub-id-type="pmid">
         15078100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib104">
       <label>
        104
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ducharme
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Farinotti
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements
        </article-title>
        <source>
         Clin Pharmacokinet
        </source>
        <volume>
         31
        </volume>
        <year>
         1996
        </year>
        <fpage>
         257
        </fpage>
        <lpage>
         274
        </lpage>
        <pub-id pub-id-type="pmid">
         8896943
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib105">
       <label>
        105
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Piette
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <volume>
         61
        </volume>
        <year>
         2001
        </year>
        <fpage>
         1531
        </fpage>
        <lpage>
         1535
        </lpage>
        <pub-id pub-id-type="pmid">
         11377382
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib106">
       <label>
        106
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Witvrouw
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pannecouque
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Switzer
          </surname>
          <given-names>
           W.M.
          </given-names>
         </name>
         <name>
          <surname>
           Folks
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           De
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
         <name>
          <surname>
           Heneine
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis
        </article-title>
        <source>
         Antivir Ther
        </source>
        <volume>
         9
        </volume>
        <year>
         2004
        </year>
        <fpage>
         57
        </fpage>
        <lpage>
         65
        </lpage>
        <pub-id pub-id-type="pmid">
         15040537
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib107">
       <label>
        107
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Louie
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kraus
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1
        </article-title>
        <source>
         Clin Ther
        </source>
        <volume>
         17
        </volume>
        <year>
         1995
        </year>
        <fpage>
         622
        </fpage>
        <lpage>
         636
        </lpage>
        <pub-id pub-id-type="pmid">
         8565026
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib108">
       <label>
        108
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1
        </article-title>
        <source>
         Clin Ther
        </source>
        <volume>
         19
        </volume>
        <year>
         1997
        </year>
        <fpage>
         913
        </fpage>
        <lpage>
         923
        </lpage>
        <pub-id pub-id-type="pmid">
         9385480
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib109">
       <label>
        109
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paton
          </surname>
          <given-names>
           N.I.
          </given-names>
         </name>
         <name>
          <surname>
           Aboulhab
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Karim
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         359
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1667
        </fpage>
        <lpage>
         1668
        </lpage>
        <pub-id pub-id-type="pmid">
         12020529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib110">
       <label>
        110
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paton
          </surname>
          <given-names>
           N.I.
          </given-names>
         </name>
         <name>
          <surname>
           Aboulhab
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks
        </article-title>
        <source>
         HIV Med
        </source>
        <volume>
         6
        </volume>
        <year>
         2005
        </year>
        <fpage>
         13
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="pmid">
         15670247
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib111">
       <label>
        111
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Joshi
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Butala
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Patwardhan
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Daver
          </surname>
          <given-names>
           N.G.
          </given-names>
         </name>
         <name>
          <surname>
           Kelkar
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy
        </article-title>
        <source>
         J Assoc Physicians India
        </source>
        <volume>
         52
        </volume>
        <year>
         2004
        </year>
        <fpage>
         597
        </fpage>
        <lpage>
         598
        </lpage>
        <pub-id pub-id-type="pmid">
         15645995
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib112">
       <label>
        112
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Engchanil
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kosalaraksa
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lumbiganon
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children
        </article-title>
        <source>
         J Med Assoc Thai
        </source>
        <volume>
         89
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1229
        </fpage>
        <lpage>
         1236
        </lpage>
        <pub-id pub-id-type="pmid">
         17048434
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib113">
       <label>
        113
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kourtis
          </surname>
          <given-names>
           A.P.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           F.K.
          </given-names>
         </name>
         <name>
          <surname>
           Abrams
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jamieson
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bulterys
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mother-to-child transmission of HIV-1: timing and implications for prevention
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         6
        </volume>
        <year>
         2006
        </year>
        <fpage>
         726
        </fpage>
        <lpage>
         732
        </lpage>
        <pub-id pub-id-type="pmid">
         17067921
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib114">
       <label>
        114
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Majori
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of chloroquine on viral infections: an old drug against today's diseases?
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         3
        </volume>
        <year>
         2003
        </year>
        <fpage>
         722
        </fpage>
        <lpage>
         727
        </lpage>
        <pub-id pub-id-type="pmid">
         14592603
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib115">
       <label>
        115
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malaty
          </surname>
          <given-names>
           L.I.
          </given-names>
         </name>
         <name>
          <surname>
           Kuper
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drug interactions of HIV protease inhibitors
        </article-title>
        <source>
         Drug Saf
        </source>
        <volume>
         20
        </volume>
        <issue>
         2
        </issue>
        <year>
         1999
        </year>
        <fpage>
         147
        </fpage>
        <lpage>
         169
        </lpage>
        <pub-id pub-id-type="pmid">
         10082072
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib116">
       <label>
        116
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Projean
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Baune
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Farinotti
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing
         <italic>
          N
         </italic>
         -desethylchloroquine formation
        </article-title>
        <source>
         Drug Metab Dispos
        </source>
        <volume>
         31
        </volume>
        <year>
         2003
        </year>
        <fpage>
         748
        </fpage>
        <lpage>
         754
        </lpage>
        <pub-id pub-id-type="pmid">
         12756207
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib117">
       <label>
        117
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib118">
       <label>
        118
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Escarmis
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Buchmeier
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Alteration of the pH dependence of coronavirus-induced cell fusion: effect of mutations in the spike glycoprotein
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         65
        </volume>
        <year>
         1991
        </year>
        <fpage>
         1916
        </fpage>
        <lpage>
         1928
        </lpage>
        <pub-id pub-id-type="pmid">
         1848311
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib119">
       <label>
        119
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Reeves
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rennekamp
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Amberg
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Piefer
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bates
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         101
        </volume>
        <year>
         2004
        </year>
        <fpage>
         4240
        </fpage>
        <lpage>
         4245
        </lpage>
        <pub-id pub-id-type="pmid">
         15010527
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib120">
       <label>
        120
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ganesh
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         78
        </volume>
        <year>
         2004
        </year>
        <fpage>
         5642
        </fpage>
        <lpage>
         5650
        </lpage>
        <pub-id pub-id-type="pmid">
         15140961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib121">
       <label>
        121
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Biot
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Daher
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Chavain
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities
        </article-title>
        <source>
         J Med Chem
        </source>
        <volume>
         49
        </volume>
        <year>
         2006
        </year>
        <fpage>
         2845
        </fpage>
        <lpage>
         2849
        </lpage>
        <pub-id pub-id-type="pmid">
         16640347
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib122">
       <label>
        122
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yoshimura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kuroda
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kawasaki
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yamashina
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Maeda
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ohnishi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious cell entry mechanism of influenza virus
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         43
        </volume>
        <year>
         1982
        </year>
        <fpage>
         284
        </fpage>
        <lpage>
         293
        </lpage>
        <pub-id pub-id-type="pmid">
         7109028
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib123">
       <label>
        123
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hirschman
          </surname>
          <given-names>
           S.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Garfinkel
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of hepatitis B DNA polymerase by intercalating agents
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         271
        </volume>
        <year>
         1978
        </year>
        <fpage>
         681
        </fpage>
        <lpage>
         683
        </lpage>
        <pub-id pub-id-type="pmid">
         625339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib124">
       <label>
        124
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hagelstein
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Fathinejad
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Stremmel
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Galle
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         pH-independent uptake of hepatitis B virus in primary human hepatocytes
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         229
        </volume>
        <year>
         1997
        </year>
        <fpage>
         292
        </fpage>
        <lpage>
         294
        </lpage>
        <pub-id pub-id-type="pmid">
         9123873
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib125">
       <label>
        125
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kouroumalis
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Koskinas
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report
        </article-title>
        <source>
         Ann Acad Med Singapore
        </source>
        <volume>
         15
        </volume>
        <year>
         1986
        </year>
        <fpage>
         149
        </fpage>
        <lpage>
         152
        </lpage>
        <pub-id pub-id-type="pmid">
         3752892
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib126">
       <label>
        126
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Accapezzato
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Visco
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Francavilla
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo
        </article-title>
        <source>
         J Exp Med
        </source>
        <volume>
         202
        </volume>
        <year>
         2005
        </year>
        <fpage>
         817
        </fpage>
        <lpage>
         828
        </lpage>
        <pub-id pub-id-type="pmid">
         16157687
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib127">
       <label>
        127
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Mallet
          </surname>
          <given-names>
           M.N.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Correlation between serum levels of doxycycline and serology evolution in patients treated for
         <italic>
          Coxiella burnetii
         </italic>
         endocarditis
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         9
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1322
        </fpage>
        <lpage>
         1325
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib128">
       <label>
        128
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Boulos
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Mallet
          </surname>
          <given-names>
           M.N.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         49
        </volume>
        <year>
         2005
        </year>
        <fpage>
         2673
        </fpage>
        <lpage>
         2676
        </lpage>
        <pub-id pub-id-type="pmid">
         15980335
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib129">
       <label>
        129
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klinger
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Morad
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Westall
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         358
        </volume>
        <year>
         2001
        </year>
        <fpage>
         813
        </fpage>
        <lpage>
         814
        </lpage>
        <pub-id pub-id-type="pmid">
         11564493
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib130">
       <label>
        130
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bernstein
          </surname>
          <given-names>
           H.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         75
        </volume>
        <year>
         1983
        </year>
        <fpage>
         25
        </fpage>
        <lpage>
         34
        </lpage>
        <pub-id pub-id-type="pmid">
         6869408
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Int J Antimicrob Agents
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Int. J. Antimicrob. Agents
      </journal-id>
      <journal-title-group>
       <journal-title>
        International Journal of Antimicrobial Agents
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0924-8579
      </issn>
      <issn pub-type="epub">
       1872-7913
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V. and International Society of Chemotherapy.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32234468
      </article-id>
      <article-id pub-id-type="pmc">
       7138178
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0924-8579(20)30105-9
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.ijantimicag.2020.105955
      </article-id>
      <article-id pub-id-type="publisher-id">
       105955
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The epidemiology, diagnosis and treatment of COVID-19
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0001">
        <name>
         <surname>
          Zhai
         </surname>
         <given-names>
          Pan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0002">
        <name>
         <surname>
          Ding
         </surname>
         <given-names>
          Yanbing
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0003">
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          Xia
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0004">
        <name>
         <surname>
          Long
         </surname>
         <given-names>
          Junke
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Zhong
         </surname>
         <given-names>
          Yanjun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0004">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0006">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Yiming
         </given-names>
        </name>
        <email>
         lym-fly@whu.edu.cn
        </email>
        <xref ref-type="aff" rid="aff0005">
         e
        </xref>
        <xref ref-type="corresp" rid="cor0001">
         ⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0001">
       <label>
        a
       </label>
       Department of Neurology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430073, Hubei, China
      </aff>
      <aff id="aff0002">
       <label>
        b
       </label>
       Department of Respiratory Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430073, Hubei, China
      </aff>
      <aff id="aff0003">
       <label>
        c
       </label>
       Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
      </aff>
      <aff id="aff0004">
       <label>
        d
       </label>
       ICU Center, The Second Xiangya Hospital, Central South University, Furong, Changsha, Hunan, 41001, China
      </aff>
      <aff id="aff0005">
       <label>
        e
       </label>
       Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China
      </aff>
      <author-notes>
       <corresp id="cor0001">
        <label>
         ⁎
        </label>
        <bold>
         Corresponding author.
        </bold>
        Yiming Li, Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China.
        <email>
         lym-fly@whu.edu.cn
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        28
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        28
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       105955
      </elocation-id>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="author-highlights" id="abs0001">
       <title>
        Highlights
       </title>
       <p>
        <list id="celist0001" list-type="simple">
         <list-item id="celistitem0001">
          <label>
           •
          </label>
          <p id="para0001">
           The mean incubation period is 2-14 days, and the basic reproduction number is 2.24-3.58.
          </p>
         </list-item>
         <list-item id="celistitem0002">
          <label>
           •
          </label>
          <p id="para0002">
           COVID-19 infection should be diagnosed clinically with typical respiratory syndromes coupled with recent exposure.
          </p>
         </list-item>
         <list-item id="celistitem0003">
          <label>
           •
          </label>
          <p id="para0003">
           Chest computerized tomography (CT) could facilitate early diagnosis.
          </p>
         </list-item>
         <list-item id="celistitem0004">
          <label>
           •
          </label>
          <p id="para0004">
           Public health measures, such as isolation, quarantine, social distancing and community containment, can curb COVID-19.
          </p>
         </list-item>
         <list-item id="celistitem0005">
          <label>
           •
          </label>
          <p id="para0005">
           Clinical trials assessing antivirals, chloroquine, hydroxychloroquine, glucocorticoids, convalescent plasma transfusion against COVID-19.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <abstract id="abs0002">
       <p>
        In December 2019, the outbreak of the novel coronavirus disease (COVID-19) in China spread worldwide, becoming an emergency of major international concern. SARS-CoV-2 infection causes clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus. Human-to-human transmission via droplets, contaminated hands or surfaces has been described, with incubation times of 2-14 days. Early diagnosis, quarantine, and supportive treatments are essential to cure patients. This paper reviews the literature on all available information about the epidemiology, diagnosis, isolation and treatments of COVID-19. Treatments, including antiviral agents, chloroquine and hydroxychloroquine, corticosteroids, antibodies, convalescent plasma transfusion and vaccines, are discussed in this article. In addition, registered trials investigating treatment options for COVID-19 infection are listed.
       </p>
      </abstract>
      <kwd-group id="keys0001">
       <title>
        Keywords
       </title>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        Pandemic
       </kwd>
       <kwd>
        Diagnosis
       </kwd>
       <kwd>
        Isolation
       </kwd>
       <kwd>
        Remdesivir
       </kwd>
       <kwd>
        Clinical trials
       </kwd>
      </kwd-group>
     </article-meta>
     <notes>
      <p id="misc0001">
       Editor: Jean-Marc Rolain
      </p>
     </notes>
    </front>
    <sec id="sec0001">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="para0006">
      There is a current worldwide outbreak of a new type of coronavirus (COVID-19), which originated from Wuhan, China and has now spread to 140 other countries, including Japan, Korea and Italy. The World Health Organization (WHO) declared that COVID-19 has become a global health concern, causing severe respiratory tract infections in humans. Current evidence indicates that SARS-CoV-2 spread to humans via transmission from wild animals illegally sold in the Huanan Seafood Wholesale Market. Phylogenetic analysis shows that SARS-CoV-2 is a new member of the Coronaviridae family but is distinct from SARS-CoV (identity of approximately 79%) and MERS-CoV (identity of approximately 50%)
      <xref ref-type="bibr" rid="bib0001">
       [1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0002">
       2]
      </xref>
      . Knowing the origin of such a pathogen is critical to developing the means to block further transmission and vaccines
      <xref ref-type="bibr" rid="bib0003">
       [3]
      </xref>
      . Notably, SARS-CoV-2 shares a high level of genetic similarity (96.3%) with the bat coronavirus RaTG13, which was obtained from bats in Yunnan in 2013; however, bats are not the immediate source of SARS-CoV-2
      <xref ref-type="bibr" rid="bib0004">
       [4]
      </xref>
      .
     </p>
     <p id="para0007">
      The typical symptoms of COVID-19 are fever, sore throat, fatigue, cough or dyspnea coupled with recent exposure. As of March 16, 2020, the outbreak of COVID-19 generated 168 826 confirmed cases, including 6503 deaths worldwide. In China during the outbreak of the pandemic, 42 000 doctors and nurses from all over the country supported Wuhan. Moreover, the government shared the updated genome sequence of COVID-19 to the public, and scientists from China and overseas are working closely and efficiently on this public health emergency
      <xref ref-type="bibr" rid="bib0005">
       [5
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0006">
       6]
      </xref>
      . Due to interventions and control measures from the government (shutting down public transportation and implementing a treatment strategy) and the change in personal behaviors (wearing masks and reducing contact with others), the number of confirmed and suspected cases in China has started to decrease.
     </p>
     <p id="para0008">
      However, the transmission of pneumonia associated with SARS-CoV-2 has not yet been eliminated. The COVID-19 outbreak is still a major challenge for clinicians. The aim of this article is to describe the epidemiology, diagnosis, isolation, and treatment of COVID-19.
     </p>
    </sec>
    <sec id="sec0002">
     <label>
      2
     </label>
     <title>
      Epidemiology
     </title>
     <sec id="sec0003">
      <label>
       2.1
      </label>
      <title>
       Incubation period
      </title>
      <p id="para0009">
       A study of early transmission dynamics of COVID-19 revealed that the mean incubation period was 5.2 days (95% confidence interval [CI], 4.1-7.0), with the 95th percentile of the distribution at 12.5 days
       <xref ref-type="bibr" rid="bib0007">
        [7]
       </xref>
       . A later study using the travel history and symptom onset of 88 confirmed cases showed a similar mean incubation period of 6.4 days (95% CI, 5.6-7.7)
       <xref ref-type="bibr" rid="bib0008">
        [8]
       </xref>
       . An unusual case was also reported in which the incubation period was as long as 19 days
       <xref ref-type="bibr" rid="bib0009">
        [9]
       </xref>
       . Notably, a long incubation time means adjustments in screening and control policies
       <xref ref-type="bibr" rid="bib0010">
        [10]
       </xref>
       . The 19-day incubation period is a low probability event, and experts suggest 14 days for quarantine.
      </p>
     </sec>
     <sec id="sec0004">
      <label>
       2.2
      </label>
      <title>
       Basic reproduction number
      </title>
      <p id="para0010">
       The basic reproduction number is model-based, largely depends on the epidemiological setting, and is the most important parameter to determine intrinsic transmissibility. The early outbreak data largely follow exponential growth. Different models based on the clinical progression of the disease were devised to estimate the basic reproduction number. In the early stages of COVID-19, the pandemic doubled in size every 7.4 days, and the basic reproduction number was estimated to be 2.2
       <xref ref-type="bibr" rid="bib0007">
        [7]
       </xref>
       . Another study estimated the basic reproduction number as ranging from 2.24 to 3.58
       <xref ref-type="bibr" rid="bib0011">
        [11]
       </xref>
       . However, a deterministic compartmental model based on the likelihood and a model analysis showed that the control reproduction number may be as high as 6.47
       <xref ref-type="bibr" rid="bib0012">
        [12]
       </xref>
       . The authors noted that this basic reproduction number was higher because the estimate accounts for 3-4 generations of viral transmission and intensive social contacts. The basic reproduction number estimated by the majority of studies ranges from 2.24 to 3.58
       <xref ref-type="bibr" rid="bib0013">
        [13]
       </xref>
       , which is slightly higher than that of SARS.
      </p>
     </sec>
    </sec>
    <sec id="sec0005">
     <label>
      3
     </label>
     <title>
      Diagnosis
     </title>
     <p id="para0011">
      Rapid and accurate detection of COVID-19 is crucial to control outbreaks in the community and in hospitals
      <xref ref-type="bibr" rid="bib0014">
       [14]
      </xref>
      . Current diagnostic tests for coronavirus include reverse-transcription polymerase chain reaction (RT-PCR), real‐time RT-PCR (rRT‐PCR), and reverse transcription loop‐mediated isothermal amplification (RT‐LAMP)
      <xref ref-type="bibr" rid="bib0015">
       [15
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0016">
       16]
      </xref>
      . RT-LAMP has similar sensitivity to rRT-PCR, is highly specific and is used to detect MERS-CoV
      <xref ref-type="bibr" rid="bib0017">
       [17
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0018">
       18]
      </xref>
      . According to current diagnostic criteria founded by the China National Health Commission, laboratory examinations, including nasopharyngeal and oropharyngeal swab tests, have become a standard assessment for diagnosis of COVID-19 infection. To identify patients earlier, two one-step quantitative RT-PCR (qRT-PCR) assays were developed to detect two different regions (ORF1b and N) of the SARS-CoV-2 genome
      <xref ref-type="bibr" rid="bib0019">
       [19]
      </xref>
      . Three novel RT-PCR assays targeting the RNA-dependent RNA polymerase (RdRp)/helicase (Hel), spike (S), and nucleocapsid (N) genes of SARS-CoV-2 were developed. Among the three novel assays, the COVID-19-RdRp/Hel assay had the lowest limit of detection in vitro; highly sensitive and specific assays may help to improve the laboratory diagnosis of COVID-19
      <xref ref-type="bibr" rid="bib0020">
       [20]
      </xref>
      . The SARS-CoV E gene assay was more sensitive than the RdRp gene assay combined with the one-step RT-PCR system
      <xref ref-type="bibr" rid="bib0021">
       [21]
      </xref>
      . The E gene PCR was sufficient to diagnose a SARS-CoV-2 infection but the RdRp protocol was recommended to confirm a positive result
      <xref ref-type="bibr" rid="bib0022">
       [22
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0023">
       23]
      </xref>
      . The overall positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan was 38%
      <xref ref-type="bibr" rid="bib0024">
       [24]
      </xref>
      . The positive rate of PCR for oropharyngeal swabs is not very high: only 53.3% of COVID-19-confirmed patients had positive oral swabs tests
      <xref ref-type="bibr" rid="bib0025">
       [25]
      </xref>
      . In a series of 51 patients with confirmed COVID-19 infection, 71% patients were RT-PCR positive at the first time of testing of throat swab or sputum samples
      <xref ref-type="bibr" rid="bib0026">
       [26]
      </xref>
      . The RT-PCR results usually become positive after several days (2-8 days)
      <xref ref-type="bibr" rid="bib0027">
       [27]
      </xref>
      . Automated solutions for molecular diagnostics can handle large numbers of samples and can be scaled to keep pace with fluctuating demand
      <xref ref-type="bibr" rid="bib0028">
       [28]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0029">
       [29]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0030">
       [30]
      </xref>
      . The good analytical performance of a molecular assay for the detection of SARS-CoV-2 on a high-throughput platform, the cobas 6800, was observed with minimal hands-on time, while offering fast and reliable results
      <xref ref-type="bibr" rid="bib0031">
       [31
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0032">
       32]
      </xref>
      .
     </p>
     <p id="para0011s">
      The current laboratory test is time-consuming, and a shortage of commercial kits delays diagnosis. For patients suffering from fever, sore throat, fatigue, coughing or dyspnea that is coupled with recent exposure, COVID-19 infection should be diagnosed with typical chest computerized tomography (CT) characteristics despite negative RT-PCR results
      <xref ref-type="bibr" rid="bib0033">
       [33]
      </xref>
      . Of 1014 patients, 59% had positive RT-PCR results, and 88% had positive chest CT scans
      <xref ref-type="bibr" rid="bib0034">
       [34]
      </xref>
      . COVID-19 belongs to the Coronaviridae family; therefore, it is not surprising that COVID-19 has imaging findings that are similar to those for SARS-CoV and MERS-CoV
      <xref ref-type="bibr" rid="bib0035">
       [35]
      </xref>
      . Typical CT findings included bilateral pulmonary parenchymal ground-glass and consolidative pulmonary opacities, sometimes with a rounded morphology and peripheral lung distribution
      <xref ref-type="bibr" rid="bib0033">
       [33]
      </xref>
      . Eighty-six percent of patients showed ground-glass opacities or consolidation, and more than one lobe (71%) with bilateral involvement (76%) was affected in the 21 initial chest CT scans
      <xref ref-type="bibr" rid="bib0036">
       [36]
      </xref>
      . Notably, lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent
      <xref ref-type="bibr" rid="bib0036">
       [36]
      </xref>
      . Lung abnormalities on chest CT scan were most severe approximately 10 days after the initial onset of symptoms
      <xref ref-type="bibr" rid="bib0037">
       [37]
      </xref>
      . Chest CT scans can be used to assess the severity of COVID-19. COVID-19 also manifests with chest CT imaging abnormalities in asymptomatic patients, with rapid evolution from focal unilateral to diffuse bilateral ground-glass opacities that progressed to or co-existed with consolidations within 1-3 weeks. Combining assessment of imaging features with clinical and laboratory findings could facilitate early diagnosis of COVID-19 pneumonia
      <xref ref-type="bibr" rid="bib0038">
       [38]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0039">
       [39]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0040">
       [40]
      </xref>
      . As the diagnostic criteria expanded from laboratory examination to chest CT imaging, more than 14 000 patients were diagnosed on February 12, 2020.
     </p>
    </sec>
    <sec id="sec0006">
     <label>
      4
     </label>
     <title>
      Isolation
     </title>
     <p id="para0012">
      Classical public health measures, including isolation, quarantine, social distancing and community containment, can be used to curb the pandemic of this respiratory disease
      <xref ref-type="bibr" rid="bib0041">
       [41]
      </xref>
      . China has been preparing since 2003 to contain future pandemics by applying lessons learned from SARS
      <xref ref-type="bibr" rid="bib0042">
       [42]
      </xref>
      . In the COVID-19 pandemic, China issued the largest quarantine in history. All the residents living in mainland China were locked-in, and city public transportation, including buses, trains, ferries, and airports, were shutdown. Given the trajectory of this outbreak, the Chinese government scaled up such efforts to keep pace with the rapid increase in cases and geographical spread. The Wuhan government made full use of the gym and two convention centers and transformed them into makeshift hospitals with 3400 beds in only one night to isolate COVID-19 patients from healthy controls. More makeshift hospitals are under construction. Isolation beds were quickly expanded from only 137 at the beginning of the outbreak of COVID-19 to 56 000 to separate infected patients from non-infected individuals. The swift and decisive response of China contributed to reducing the control reproduction number and transmission risk. Due to the powerful and effective isolation measures taken by the Chinese government, the increase in COVID-19 began to slow down on February 14, 2020, according to the data released by the China National Health Commission.
     </p>
    </sec>
    <sec id="sec0007">
     <label>
      5
     </label>
     <title>
      Treatments
     </title>
     <sec id="sec0008">
      <label>
       5.1
      </label>
      <title>
       Antiviral agents
      </title>
      <p id="para0013">
       There is no current evidence from randomized controlled trials (RCTs) to recommend any specific anti-SARS-CoV-2 treatment for patients with a suspected or confirmed COVID-19 infection. Lopinavir (LPV) inhibits the protease activity of coronavirus in vitro and in animal studies. A retrospective, matched-cohort study including 1052 SARS patients showed that LPV/ritonavir as initial treatment was associated with a reduced death rate (2.3% vs. 11.0%)
       <xref ref-type="bibr" rid="bib0043">
        [43]
       </xref>
       . The protease inhibitor LPV is an effective treatment based on the experience accumulated from the SARS and MERS outbreaks, indicating it is a potential treatment option for COVID‐19
       <xref ref-type="bibr" rid="bib0044">
        [44]
       </xref>
       . Ribavirin, a guanosine analogue, is an antiviral compound used to treat several virus infections, including respiratory syncytial virus, hepatitis C virus, and some viral hemorrhagic fevers. Promising results were obtained with ribavirin in a MERS-CoV rhesus macaque model
       <xref ref-type="bibr" rid="bib0045">
        [45]
       </xref>
       . In addition, SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) model is targeted by ribavirin after sequence analysis, modeling, and docking to build the model. This feature increases its potential as an antiviral against SARS-CoV-2
       <xref ref-type="bibr" rid="bib0046">
        [46]
       </xref>
       .
      </p>
      <p id="para0014">
       The antiviral agent, remdesivir was designed for the Ebola virus disease
       <xref ref-type="bibr" rid="bib0047">
        [47]
       </xref>
       . Remdesivir shows broad-spectrum antiviral activity against several RNA viruses, and it may compete for RdRp
       <xref ref-type="bibr" rid="bib0048">
        [48]
       </xref>
       . Remdesivir and IFNb have superior antiviral activity to LPV and ritonavir in vitro
       <xref ref-type="bibr" rid="bib0049">
        [49]
       </xref>
       . In a mouse model of SARS-CoV pathogenesis, both prophylactic and therapeutic remdesivir improved pulmonary function and reduced lung viral loads and severe lung pathology
       <xref ref-type="bibr" rid="bib0050">
        [50]
       </xref>
       . In a rhesus macaque model of MERS-CoV infection, prophylactic remdesivir treatment was initiated 24 h prior to inoculation, and MERS-CoV did not induce clinical disease and did not replicate in respiratory tissues, thus preventing the formation of lung lesions
       <xref ref-type="bibr" rid="bib0051">
        [51]
       </xref>
       . In cell-based assays, the triphosphate form of remdesivir incorporated at position i, and RNA chain termination was delayed, which explained the high potency of remdesivir against RNA
       <xref ref-type="bibr" rid="bib0052">
        [52]
       </xref>
       . Remdesivir was used to treat the first case of COVID-19 infection in the United States: the patient's clinical condition improved after only one day of remdesivir treatment
       <xref ref-type="bibr" rid="bib0053">
        [53]
       </xref>
       . A phase II clinical trial of remdesivir was performed by the University of Nebraska Medical Center, and a phase III clinical trial was performed by the China-Japan Friendship Hospital. The results of these clinical trials will be revealed in April 2020. Remdesivir improved pulmonary function, reduced lung viral loads, and ameliorated severe lung pathology. In contrast, prophylactic LPV/RTV-IFNb only slightly reduced viral loads and did not impact other disease parameters, and therapeutic LPV/RTV-IFNb improved pulmonary function, but did not reduce virus replication or severe lung pathology [49]. Overall, these results indicated that remdesivir showed more potential than LPV/RTV-IFNb
       <xref ref-type="bibr" rid="bib0054">
        [54]
       </xref>
       . In a case report, lopinavir/ritonavir (Kaletra®) and arbidol were associated with significant improvements in COVID-19 patients
       <xref ref-type="bibr" rid="bib0055">
        [55]
       </xref>
       . The efficacy and safety of these antiviral agents for COVID-19 will be assessed in further clinical trials. Thirty-four trials of antiviral agents in patients with COVID‐19 have been registered up to March 15, 2020 (
       <xref ref-type="table" rid="tbl0001">
        Table 1
       </xref>
       ).
       <table-wrap id="tbl0001" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Clinical trials of antiviral agents in patients with COVID-19.
         </p>
        </caption>
        <alt-text id="alt0001">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th valign="top">
            Register number
           </th>
           <th valign="top">
            Title
           </th>
           <th valign="top">
            Group 1 (sample size)
           </th>
           <th valign="top">
            Group 2 (sample size)
           </th>
           <th valign="top">
            Group 3 (sample size)
           </th>
           <th valign="top">
            Primary indicator
           </th>
           <th valign="top">
            Primary sponsor
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td valign="top">
            ChiCTR2000029621
           </td>
           <td valign="top">
            Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Arbidol tablets + basic treatment (190 patients)
           </td>
           <td align="left" valign="top">
            Basic treatment (190 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029308
           </td>
           <td valign="top">
            A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and 50 mg of ritonavir), twice a day, 2 tablets at a time (80 patients)
           </td>
           <td align="left" valign="top">
            Conventional standardized treatment (80 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Clinical improvement time of 28 days after randomization, 7-point scale
           </td>
           <td valign="top">
            Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029387
           </td>
           <td valign="top">
            Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus pneumonia
           </td>
           <td valign="top">
            Ribavirin + Interferon alpha-1b (36 patients)
           </td>
           <td valign="top">
            Lopinavir / ritonavir + interferon alpha-1b (36 patients)
           </td>
           <td valign="top">
            Ribavirin + LPV/r+Interferon alpha-1b (36 patients)
           </td>
           <td valign="top">
            Time to 2019-nCoV RNA negativity in patients
           </td>
           <td valign="top">
            Chongqing Public Health Medical Center
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029468
           </td>
           <td valign="top">
            A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Lopinavir/ritonavir (LPV/r)+ emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination (60 patients)
           </td>
           <td valign="top">
            LPV/r (60 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Survival rate
           </td>
           <td valign="top">
            Institute of Emergency Medicine and Disaster Medicine Sichuan People's Hospital, Sichuan Academy of Medical Sciences
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029539
           </td>
           <td valign="top">
            A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Conventional standardized treatment and Lopinavir-Ritonavir (164 patients)
           </td>
           <td align="left" valign="top">
            Conventional standardized treatment (164 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Incidence of adverse outcome within 14 days after admission: Patients with conscious dyspnea, SpO2 ≤94% or respiratory frequency ≥ 24 times/min in the state of resting without oxygen inhalation
           </td>
           <td valign="top">
            Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029541
           </td>
           <td valign="top">
            A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            DRV/c (800 mg/150 mg QD) + conventional treatment containing thymosin (40 patients)
           </td>
           <td align="left" valign="top">
            LPV/r (400 mg/100 mg bid) + conventional treatment containing thymosin (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time to conversion of 2019-nCoV RNA result from RI sample
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029548
           </td>
           <td valign="top">
            Randomized, open-label, controlled trial for evaluating the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients
           </td>
           <td valign="top">
            BaloxavirMarboxil: 80 mg on day1, 80 mg on day 4; and 80 mg on day 7 as necessary (10 patients)
           </td>
           <td valign="top">
            Favipiravir: 600 mg tid with 160 0mg first loading dosage for no more than 14 days (10 patients)
           </td>
           <td valign="top">
            Lopinavir-Ritonavir: 2(200mg/50 mg), twice daily, for 14days (10 patients)
           </td>
           <td valign="top">
            Time to viral negativity by RT-PCR,Time to clinical improvement
           </td>
           <td valign="top">
            The First Affiliated Hospital, Zhejiang University School of Medicine
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029600
           </td>
           <td valign="top">
            Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Alpha-Interferon atomization (30 patients)
           </td>
           <td valign="top">
            Lopinavir and Ritonavir + alpha-Interferon atomization (30 patients)
           </td>
           <td valign="top">
            Favipiravir + alpha-Interferon atomization(30 patients)
           </td>
           <td valign="top">
            Negative time of novel Coronavirus by PCR, chest imaging, incidence rate of kidney damage
           </td>
           <td valign="top">
            The Third People's Hospital of Shenzhen
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029603
           </td>
           <td valign="top">
            A randomized, open-label, multi-centre clinical trial evaluating and comparing the safety and efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for confirmed cases of novel Coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Conventional standardized treatment and ASC09/Ritonavir (80 patients)
           </td>
           <td align="left" valign="top">
            Conventional standardized treatment and Lopinavir/Ritonavir (80 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            The incidence of composite adverse outcome
           </td>
           <td valign="top">
            The First Affiliated Hospital of Zhejiang University School of Medicine
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029853
           </td>
           <td valign="top">
            A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Oral administration of 5 tablets of 1 mg azvudine daily (10 patients)
           </td>
           <td align="left" valign="top">
            Control group (10 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Temperature, improvement of respiratory symptoms
           </td>
           <td valign="top">
            People's Hospital of Guangshan County
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029996
           </td>
           <td valign="top">
            A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Tablets; 200 mg; oral; twice a day; adult dose is 1600 mg per time on first day (20 patients)
           </td>
           <td valign="top">
            Tablets; 200 mg; orally; twice a day; adult dose is 1800 mg per time on first day (20 patients)
           </td>
           <td valign="top">
            Tablets; 200 mg; oral; twice a day; adult dose is 2400 mg per time on first day (20 patients)
           </td>
           <td valign="top">
            Time to clinical recovery
           </td>
           <td valign="top">
            Beijing Chaoyang Hospital, Capital Medical University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030041
           </td>
           <td valign="top">
            A single-arm, single-center clinical trial for azvudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Azvudine tablets (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            The novel coronavirus nucleic acid negative rate
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030113
           </td>
           <td valign="top">
            Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir
           </td>
           <td valign="top">
            Ritonavir/ritonavir treatment (15 patients)
           </td>
           <td valign="top">
            Favipiravir (15 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Blood routine tests, Liver function examination, Renal function examination, Blood gas analysis, Chest CT examination
           </td>
           <td valign="top">
            The Third People's Hospital of Shenzhen
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030254
           </td>
           <td valign="top">
            A randomized, open-controlled trial for farpiravir tablets in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Farpiravir tablets (120 patients)
           </td>
           <td align="left" valign="top">
            Abidole tablets (120 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Pulse oxygen saturation parameters, respiratory support Nucleic acid test of novel coronavirus
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030259
           </td>
           <td valign="top">
            Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial
           </td>
           <td valign="top">
            Danorevir sodium tablets/ritonavir oral (30 patients)
           </td>
           <td valign="top">
            Symptomatic treatment (30 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Rate of composite adverse outcomes: SpO2, PaO2/FiO2, respiratory rate
           </td>
           <td valign="top">
            Shanghai Changzheng Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030424
           </td>
           <td valign="top">
            A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Azvudine Tablet: D1: 10 mg/day,QD
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Negative conversion rate of the new coronavirus nucleic acid
           </td>
           <td valign="top">
            Henan Provincial People's Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030472
           </td>
           <td valign="top">
            An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Ganovo/ritonavir oral + conventional treatment (10 patients)
           </td>
           <td valign="top">
            Conventional treatment (10 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Rate of composite adverse outcomes: SPO2, PaO2/FiO2 and respiratory rate
           </td>
           <td valign="top">
            Shenyang Sixth People's Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030487
           </td>
           <td valign="top">
            A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Azvudine Tablet: D1: 10 mg/day, QD
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Negative conversion rate of the new coronavirus nucleic acid
           </td>
           <td valign="top">
            The First Affiliated Hospital of Henan University of CM
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04244591
           </td>
           <td valign="top">
            Glucocorticoid therapy for novel Coronavirus critically ill patients with severe acute respiratory failure (Steroids-SARI)
           </td>
           <td valign="top">
            Methylprednisolone therapy and standard care
           </td>
           <td valign="top">
            Standard care
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Lower Murray lung injury score
           </td>
           <td valign="top">
            Peking Union Medical College Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04252274
           </td>
           <td valign="top">
            Efficacy and safety of Darunavir and Cobicistat for treatment of pneumonia caused by 2019-nCoV (DACO-nCoV)
           </td>
           <td valign="top">
            Darunavir, Cobicistat and conventional treatments
           </td>
           <td align="left" valign="top">
            Conventional treatments
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7
           </td>
           <td valign="top">
            Shanghai Public Health Clinical Center
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04252664
           </td>
           <td valign="top">
            A Phase 3 randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of remdesivir in hospitalized adult patients with mild and moderate 2019-nCoV respiratory disease
           </td>
           <td valign="top">
            Remdesivir
           </td>
           <td valign="top">
            Remdesivir placebo
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            All cause mortality
           </td>
           <td valign="top">
            Capital Medical University
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04254874
           </td>
           <td valign="top">
            A prospective/retrospective, randomized controlled clinical study of interferon atomization in the 2019-nCoV pneumonia
           </td>
           <td valign="top">
            Abidol hydrochloride
           </td>
           <td align="left" valign="top">
            Abidol Hydrochloride combined with Interferon atomization
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Rate of disease remission, Time for lung recovery
           </td>
           <td valign="top">
            Tongji Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04255017
           </td>
           <td valign="top">
            A prospective/retrospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia
           </td>
           <td valign="top">
            Abidol hydrochloride
           </td>
           <td valign="top">
            Oseltamivir
           </td>
           <td valign="top">
            Lopinavir/ritonavir
           </td>
           <td valign="top">
            Rate of disease remission
           </td>
           <td valign="top">
            Tongji Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04257656
           </td>
           <td valign="top">
            Severe 2019-nCoV Remdesivir randomized controlled trial (RCT)
           </td>
           <td valign="top">
            Remdesivir
           </td>
           <td valign="top">
            Remdesivir placebo
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time to Clinical Improvement (TTCI)
           </td>
           <td valign="top">
            Capital Medical University
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04260594
           </td>
           <td valign="top">
            Clinical study of arbidol hydrochloride tablets in the treatment of pneumonia caused by novel Coronavirus
           </td>
           <td valign="top">
            Arbidol
           </td>
           <td valign="top">
            Basic treatment
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Virus negative conversion rate in the first week
           </td>
           <td valign="top">
            Jieming QU
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04261270
           </td>
           <td valign="top">
            A randomized, open, controlled clinical study to evaluate the efficacy of ASC09F and Ritonavir for 2019-nCoV pneumonia
           </td>
           <td valign="top">
            ASC09F + Oseltamivir
           </td>
           <td valign="top">
            Ritonavir + Oseltamivir
           </td>
           <td valign="top">
            Oseltamivir
           </td>
           <td valign="top">
            Rate of comprehensive adverse outcome
           </td>
           <td valign="top">
            Tongji Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04261270
           </td>
           <td valign="top">
            A randomized, open, controlled clinical study to evaluate the efficacy of ASC09F and Ritonavir for 2019-nCoV pneumonia
           </td>
           <td valign="top">
            ASC09F + Oseltamivir
           </td>
           <td align="left" valign="top">
            Ritonavir + Oseltamivir
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Rate of comprehensive adverse outcome
           </td>
           <td valign="top">
            Tongji Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04261517
           </td>
           <td valign="top">
            Efficacy and safety of hydroxychloroquine for treatment of pneumonia caused by 2019-nCoV (HC-nCoV)
           </td>
           <td valign="top">
            Hydroxychloroquine and conventional treatments
           </td>
           <td align="left" valign="top">
            Conventional treatments
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions
           </td>
           <td valign="top">
            Shanghai Public Health Clinical Center
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04261907
           </td>
           <td valign="top">
            Evaluating and comparing the safety and efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for novel Coronavirus infection
           </td>
           <td valign="top">
            ASC09/ritonavir
           </td>
           <td valign="top">
            Lopinavir/ritonavir
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            The incidence of composite adverse outcome
           </td>
           <td valign="top">
            First Affiliated Hospital of Zhejiang University
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04276688
           </td>
           <td valign="top">
            Lopinavir/ Ritonavir, Ribavirin and IFN-beta combination for nCoV treatment
           </td>
           <td valign="top">
            Lopinavir/ritonavir
           </td>
           <td valign="top">
            Ribavirin
           </td>
           <td valign="top">
            Interferon Beta-1B
           </td>
           <td valign="top">
            Time to negative NPS 2019-n-CoV RT-PCR
           </td>
           <td valign="top">
            The University of Hong Kong
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04292730
           </td>
           <td valign="top">
            Study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with moderate Coronavirus disease (COVID-19) compared to standard of care treatment
           </td>
           <td valign="top">
            Remdesivir
           </td>
           <td valign="top">
            Standard of care
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Proportion of participants discharged by Day 14
           </td>
           <td valign="top">
            Gilead Sciences
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04292899
           </td>
           <td valign="top">
            Study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with severe Coronavirus disease (COVID-19)
           </td>
           <td valign="top">
            Remdesivir
           </td>
           <td valign="top">
            Standard of care
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Proportion of participants With normalization of fever and oxygen saturation through Day 14
           </td>
           <td valign="top">
            Gilead Sciences
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04304053
           </td>
           <td valign="top">
            Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID-19 epidemic
           </td>
           <td valign="top">
            Antiviral treatment and prophylaxis
           </td>
           <td align="left" valign="top">
            Standard Public Health measures
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases
           </td>
           <td valign="top">
            Lihir Medical Centre
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04307693
           </td>
           <td valign="top">
            Comparison of Lopinavir/Ritonavir or hydroxychloroquine in patients with mild Coronavirus disease (COVID-19)
           </td>
           <td valign="top">
            Lopinavir / Ritonavir tablet
           </td>
           <td align="left" valign="top">
            Hydroxychloroquine sulfate tablet
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Viral load
           </td>
           <td valign="top">
            Asan Medical Center
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec0009">
      <label>
       5.2
      </label>
      <title>
       Chloroquine and hydroxychloroquine
      </title>
      <p id="para0015">
       Chloroquine is a widely-used antimalarial and autoimmune disease drug that has been reported to be a potential broad-spectrum antiviral drug
       <xref ref-type="bibr" rid="bib0056">
        [56]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0057">
        [57]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0058">
        [58]
       </xref>
       . Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV
       <xref ref-type="bibr" rid="bib0059">
        [59]
       </xref>
       . The first results obtained from more than 100 patients showed the apparent efficacy of chloroquine in terms of reduction of exacerbation of pneumonia, duration of symptoms and delay of viral clearance, all in the absence of severe side effects
       <xref ref-type="bibr" rid="bib0060">
        [60]
       </xref>
       . Chloroquine was included in the recommendations for the prevention and treatment of COVID-19 pneumonia
       <xref ref-type="bibr" rid="bib0060">
        [60
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0061">
        61]
       </xref>
       . The optimal dosage of chloroquine for SARS-CoV-2 will need to be assessed in future trials
       <xref ref-type="bibr" rid="bib0062">
        [62]
       </xref>
       .
      </p>
      <p id="para0016">
       Hydroxychloroquine is a chloroquine analog for which there are fewer concerns about drug-drug interactions
       <xref ref-type="bibr" rid="bib0063">
        [63]
       </xref>
       . In the previous SARS outbreak, hydroxychloroquine was reported to have anti-SARS-CoV activity in vitro
       <xref ref-type="bibr" rid="bib0064">
        [64]
       </xref>
       . Using physiologically-based pharmacokinetic (PBPK) models, hydroxychloroquine was found to be more potent than chloroquine in SARS-CoV-2-infected Vero cells
       <xref ref-type="bibr" rid="bib0065">
        [65]
       </xref>
       . Cytokines IL-6 and IL-10 have been reported to be increased in response to SARS-CoV-2 infection
       <xref ref-type="bibr" rid="bib0066">
        [66
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0067">
        67]
       </xref>
       . This may progress to a cytokine storm, followed by multiorgan failure and death. Both chloroquine and hydroxychloroquine have immunomodulatory effects and can suppress the immune response
       <xref ref-type="bibr" rid="bib0068">
        [68
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0069">
        69]
       </xref>
       . Therefore, 21 clinical studies were launched by Chinese hospitals and the University of Oxford to evaluate the efficacy of these agents in COVID-19 infection (
       <xref ref-type="table" rid="tbl0002">
        Table 2
       </xref>
       ). It is also necessary to determine whether the benefit of chloroquine therapy depends on the age of the patient and the clinical presentation or stage of the disease
       <xref ref-type="bibr" rid="bib0070">
        [70]
       </xref>
       . If clinical data confirm the biological results, chloroquine and hydroxychloroquine may be used in prophylaxis as well as curative treatment for individuals exposed to SARS-CoV-2
       <xref ref-type="bibr" rid="bib0071">
        [71]
       </xref>
       .
       <table-wrap id="tbl0002" position="float">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Clinical trials of chloroquine and hydroxychloroquine in patients with COVID-19.
         </p>
        </caption>
        <alt-text id="alt0002">
         Table 2
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th valign="top">
            Register number
           </th>
           <th valign="top">
            Title
           </th>
           <th valign="top">
            Group 1 (sample size)
           </th>
           <th valign="top">
            Group 2 (sample size)
           </th>
           <th valign="top">
            Group 3 (sample size)
           </th>
           <th valign="top">
            Primary indicator
           </th>
           <th valign="top">
            Primary sponsor
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td valign="top">
            ChiCTR2000029898
           </td>
           <td valign="top">
            Evaluation of the efficacy and safety of hydroxychloroquine sulfate in comparison with phosphate chloroquine in severe patients with novel Coronavirus pneumonia (COVID-19): a randomized, open-label, parallel, controlled trial
           </td>
           <td valign="top">
            Hydroxychloroquine sulfate Day1: first dose: 6 tablets (0.1 g/tablet) , second dose: 6 tablets (0.1 g/tablet) after 6 h ;Day2~5: 2 tablets (0.1 g/tablet), BID (50 patients)
           </td>
           <td valign="top">
            Phosphate chloroquine Day 1-3:500 mg, BID Day 4-5:250 mg, BID (50 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            TTCI (Time to Clinical Improvement)
           </td>
           <td valign="top">
            Peking University Third Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029988
           </td>
           <td valign="top">
            Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)
           </td>
           <td valign="top">
            Chloroquine phosphate (40 patients)
           </td>
           <td valign="top">
            None (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time to Clinical Recovery
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029542
           </td>
           <td valign="top">
            Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Chloroquine (10 patients)
           </td>
           <td align="left" valign="top">
            Conventional management (10 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Viral-negative transforming time 30-day cause-specific mortality
           </td>
           <td valign="top">
            Sun Yat sen Memorial Hospital of Sun Yat sen University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029559
           </td>
           <td valign="top">
            Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Hydroxychloroquine 0.1 oral 2/day (100 patients)
           </td>
           <td valign="top">
            Hydroxychloroquine 0.2 oral 2/day (100 patients)
           </td>
           <td valign="top">
            Starch pill oral 2/day (100 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Renmin Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029609
           </td>
           <td valign="top">
            A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Oral chloroquine phosphate (59 mild-moderate patients and 14 severe patients)
           </td>
           <td valign="top">
            Oral Lopinavir/ritonavir (59 mild-moderate patients and 14 severe patients)
           </td>
           <td valign="top">
            Chloroquine phosphate plus Lopinavir/ritonavir (59 mild-moderate patients)
           </td>
           <td valign="top">
            Virus nucleic acid-negative transforming time
           </td>
           <td valign="top">
            The Fifth Affiliated Hospital of Sun Yat-Sen University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029740
           </td>
           <td valign="top">
            Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients (randomized open-label control clinical trial)
           </td>
           <td valign="top">
            Oral intake hydroxycholoroquine 0.2 twice a day (54 patients)
           </td>
           <td valign="top">
            Conventional therapy (24 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Oxygen index, lung radiography, temperature
           </td>
           <td valign="top">
            The First Hospital of Peking University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029741
           </td>
           <td valign="top">
            Compare the efficacy and safety of chloroquine and lopinavir/ritonavir in patients with mild/general CoVID-19 infection, and establish a standardized treatment plan.
           </td>
           <td valign="top">
            Chloroquine phosphate (56 patients)
           </td>
           <td valign="top">
            Control group (56 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Length of stay, oxygenation index during treatment, all-cause mortality in 28 days
           </td>
           <td valign="top">
            The Fifth Affiliated Hospital Sun Yat-Sen University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029803
           </td>
           <td valign="top">
            A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)
           </td>
           <td valign="top">
            Hydroxychloroquine, small dose and high dose (80 patients/group)
           </td>
           <td align="left" valign="top">
            Abidol hydrochloride, small dose and high dose (80 patients/group)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Number of patients who have progressed to suspected or confirmed within 24 days of exposure to new coronavirus
           </td>
           <td valign="top">
            Renmin Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029826
           </td>
           <td valign="top">
            A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            2 tablets phosphoric chloroquine BID (80 patients)
           </td>
           <td align="left" valign="top">
            2 tablets placebo BID (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Mortality rate
           </td>
           <td valign="top">
            Jingzhou Central Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029837
           </td>
           <td valign="top">
            A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            2 tablets phosphoric chloroquine BID (80 patients)
           </td>
           <td align="left" valign="top">
            2 tablets placebo BID (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time of conversion to negative novel coronavirus nucleic acid
           </td>
           <td valign="top">
            Jingzhou Central Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029868
           </td>
           <td valign="top">
            Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a multicenter, randomized controlled trial
           </td>
           <td valign="top">
            Oral hydroxychloroquine sulfate tablets (100 patients)
           </td>
           <td align="left" valign="top">
            Conventional treatment meeting the Guideline (100 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Viral nucleic acid test
           </td>
           <td valign="top">
            Ruijin Hospital, Shanghai Jiaotong University School of Medicine
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029898
           </td>
           <td valign="top">
            Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Common Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial
           </td>
           <td valign="top">
            Hydroxychloroquine sulfate Day1: first dose: 6 tablets (0.1 g/tablet) , second dose: 6 tablets (0.1 g/tablet) after 6 h ;Day 2~5: 2 tablets (0.1 g/tablet), BID (50 patients)
           </td>
           <td valign="top">
            Phosphate chloroquine Day 1-3:500 mg, BID Day 4-5:250 mg, BID (50 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time to Clinical Recovery, TTCR
           </td>
           <td valign="top">
            Peking University Third Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029935
           </td>
           <td valign="top">
            A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)
           </td>
           <td align="left" valign="top">
            Conventional treatment combined with Chloroquine Phosphate (100 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Length of hospital stay
           </td>
           <td valign="top">
            HwaMei Hospital, University of Chinese Academy of Sciences
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029939
           </td>
           <td valign="top">
            A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)
           </td>
           <td valign="top">
            Conventional treatment (50 patients)
           </td>
           <td align="left" valign="top">
            conventional treatment combined with Chloroquine Phosphate (50 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Length of hospital stay
           </td>
           <td valign="top">
            HwaMei Hospital, University of Chinese Academy of Sciences
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029988
           </td>
           <td valign="top">
            Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)
           </td>
           <td valign="top">
            Chloroquine phosphate (40 patients)
           </td>
           <td valign="top">
            None (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time to clinical recovery
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029992
           </td>
           <td valign="top">
            A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Chloroquine phosphate 1.0 g x 2 days for the first dose, 0.5 g x 12 days from the third day (40 patients)
           </td>
           <td valign="top">
            Hydroxychloroquine sulfate 0.2 g bid x 14 days (40 patients)
           </td>
           <td valign="top">
            Recommended treatment plan for novel coronavirus pneumonia severe and critical cases (20 patients)
           </td>
           <td valign="top">
            Clinical recovery time, changes in viral load of upper and lower respiratory tract samples compared with the baseline
           </td>
           <td valign="top">
            Zhongshan Hospital Affiliated to Xiamen University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030031
           </td>
           <td valign="top">
            A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            2 tablets phosphoric chloroquine BID 80 patients)
           </td>
           <td align="left" valign="top">
            2 tablets placebo BID (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time of conversion to negative novel coronavirus nucleic acid
           </td>
           <td valign="top">
            The Sixth Affiliated Hospital of Guangzhou Medical University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030054
           </td>
           <td valign="top">
            A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19)
           </td>
           <td valign="top">
            Hydroxychloroquine sulfate 0.2 g bid x 14 days a day (30 patients)
           </td>
           <td valign="top">
            First dose of chloroquine phosphate 1 g x 2 days, and the third day was 0.5 g x 12 days (30 patients)
           </td>
           <td valign="top">
            Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan (20 patients)
           </td>
           <td valign="top">
            Clinical recovery time
           </td>
           <td valign="top">
            Zhongshan Hospital Affiliated to Xiamen University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030417
           </td>
           <td valign="top">
            Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Chloroquine phosphate aerosol inhalation solution (15 patients)
           </td>
           <td align="left" valign="top">
            Water for injection atomization inhalation (15 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Temperature, respiratory symptoms
           </td>
           <td valign="top">
            Harbin infectious diseases hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030718
           </td>
           <td valign="top">
            Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Chloroquine phosphate (40 patients)
           </td>
           <td align="left" valign="top">
            Regular treatment (40 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Time to clinical recovery
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04303507
           </td>
           <td valign="top">
            Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting
           </td>
           <td valign="top">
            Chloroquine
           </td>
           <td valign="top">
            Placebo
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Number of symptomatic COVID-19 infections
           </td>
           <td valign="top">
            University of Oxford
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec0010">
      <label>
       5.3
      </label>
      <title>
       Corticosteroids
      </title>
      <p id="para0017">
       In a study of 41 COVID-19 patients, 21% received corticosteroids, which could suppress lung inflammation
       <xref ref-type="bibr" rid="bib0066">
        [66]
       </xref>
       . The administered dose of methylprednisolone varied depending on disease severity. Current interim guidance from the WHO on the clinical management of severe acute respiratory infection when SARS-CoV-2 infection is suspected (released January 28, 2020) advises against the use of corticosteroids unless indicated for another reason. The clinical outcomes of coronavirus and similar outbreaks do not support the use of corticosteroids. In a retrospective observational study of 309 adults who were critically ill with MERS, patients who were given corticosteroids were more likely to require mechanical ventilation, vasopressors, and renal replacement therapy
       <xref ref-type="bibr" rid="bib0072">
        [72]
       </xref>
       . For the management of SARS, corticosteroid treatment was more associated with psychosis, diabetes and avascular necrosis
       <xref ref-type="bibr" rid="bib0073">
        [73
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0074">
        74]
       </xref>
       . Overall, there is no unique reason to expect that patients with COVID-19 infection will benefit from corticosteroids, and such treatment may be harmful
       <xref ref-type="bibr" rid="bib0075">
        [75]
       </xref>
       . However, according to our clinical experience, corticosteroids could be prescribed at the right time for the right patients. The clinical trials involving corticosteroids are shown in
       <xref ref-type="table" rid="tbl0003">
        Table 3
       </xref>
       .
       <table-wrap id="tbl0003" position="float">
        <label>
         Table 3
        </label>
        <caption>
         <p>
          Clinical trials of corticosteroids in patients with COVID-19.
         </p>
        </caption>
        <alt-text id="alt0003">
         Table 3
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th valign="top">
            Register number
           </th>
           <th valign="top">
            Title
           </th>
           <th valign="top">
            Group 1 (sample size)
           </th>
           <th valign="top">
            Group 2 (sample size)
           </th>
           <th valign="top">
            Group 3 (sample size)
           </th>
           <th valign="top">
            Primary indicator
           </th>
           <th valign="top">
            Primary sponsor
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td valign="top">
            ChiCTR2000029386
           </td>
           <td valign="top">
            Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: a randomized controlled trial
           </td>
           <td valign="top">
            Methylprednisolone, intravenous injection, 1-2 mg/kg·d for 3 days (24 patients)
           </td>
           <td valign="top">
            Without any glucocorticoid therapy (24 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            SOFA score
           </td>
           <td valign="top">
            Chongqing Public Health Medical Center
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029656
           </td>
           <td valign="top">
            A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Standard treatment and methylprednisolone for injection (50 patients)
           </td>
           <td align="left" valign="top">
            Standard treatment (50 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Chest imaging, complications
           </td>
           <td valign="top">
            Wuhan Pulmonary Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030481
           </td>
           <td valign="top">
            The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial
           </td>
           <td valign="top">
            Early corticosteroid intervention (75 patients)
           </td>
           <td valign="top">
            Middle-late corticosteroid intervention (75 patients)
           </td>
           <td valign="top">
            No corticosteroid (50 patients)
           </td>
           <td valign="top">
            Time of duration of COVID-19 nucleic acid RT-PCR test results of respiratory specimens change to negative
           </td>
           <td valign="top">
            Zhongnan Hospital of Wuhan University
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT0424459
           </td>
           <td valign="top">
            The efficacy of different hormone doses in 2019-nCoV severe pneumonia
           </td>
           <td valign="top">
            Methylprednisolone (&lt;40 mg/d intravenous drip for 7 days)
           </td>
           <td valign="top">
            Methylprednisolone (40~80 mg/d intravenous drip for 7 days)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Rate of disease remission, rate and time of entering the critical stage
           </td>
           <td valign="top">
            Tongji Hospital
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec0011">
      <label>
       5.4
      </label>
      <title>
       Antibodies
      </title>
      <p id="para0018">
       The development of vaccines and therapeutic antibodies against COVID-19 has important implications. Considering the relatively high identity of the receptor-binding domain (RBD) in SARS-CoV-2 and SARS-CoV, the cross-reactivity of anti-SARS-CoV antibodies with the COVID-19 spike protein was assessed. The spike protein is the major inducer of neutralizing antibodies. Fortunately, the SARS-CoV-specific human monoclonal antibody CR3022 binds potently with the COVID-19 RBD
       <xref ref-type="bibr" rid="bib0076">
        [76]
       </xref>
       . However, other SARS-CoV RBD-directed antibodies 230, m396 and 80R cannot bind to the COVID-19 RBD
       <xref ref-type="bibr" rid="bib0077">
        [77]
       </xref>
       . CR3022 may be a potential therapeutic candidate, alone or in combination with other neutralizing antibodies, for the prevention and treatment of COVID-19 infections. Antibodies MAb114 and REGN-EB3 were designed for treatment of Ebola virus infection and significantly reduce mortality from Ebola virus disease
       <xref ref-type="bibr" rid="bib0047">
        [47]
       </xref>
       . Monoclonal antibodies can only recognize a single antigen epitope, which limits the use of MAb114 and REGN-EB3 in the treatment of COVID-19. However, the development of COVID-19-specific antibodies requires a long time. It is not easy to apply monoclonal antibodies for new pathogens to clinical practice in a short time.
      </p>
     </sec>
     <sec id="sec0012">
      <label>
       5.5
      </label>
      <title>
       Convalescent plasma transfusion
      </title>
      <p id="para0019">
       Convalescent plasma was administered early after symptom onset in the treatment of SARS, and the pooled odds of mortality following treatment was reduced compared with placebo or no therapy (odds ratio, 0.25)
       <xref ref-type="bibr" rid="bib0078">
        [78]
       </xref>
       . However, in Ebola virus disease, the transfusion of up to 500 mL of convalescent plasma in 84 patients was not associated with a significant improvement in survival
       <xref ref-type="bibr" rid="bib0079">
        [79]
       </xref>
       . In a laboratory test, the COVID-19 virus was isolated from the bronchoalveolar lavage fluid of a critically ill patient, and it could be neutralized by sera from several patients
       <xref ref-type="bibr" rid="bib0080">
        [80]
       </xref>
       . Current clinical trials involving convalescent plasma transfusion are shown in
       <xref ref-type="table" rid="tbl0004">
        Table 4
       </xref>
       . The National Health Commission of China appealed to convalescent patients to donate blood for the treatment of COVID-19 infection. Convalescent plasma should be collected within two weeks after recovery to ensure a high neutralization antibody titer. The difficulty in obtaining plasma during convalescence limits its clinical application. Well-designed clinical trials are needed to further evaluate the efficacy and safety of convalescent plasma therapy in patients with COVID-19 infection.
       <table-wrap id="tbl0004" position="float">
        <label>
         Table 4
        </label>
        <caption>
         <p>
          Clinical trials of convalescent plasma transfusion in patients with COVID-19Searched on
          <ext-link ext-link-type="uri" id="interref2a" xlink:href="http://www.chictr.org.cn/">
           http://www.chictr.org.cn/
          </ext-link>
          and
          <ext-link ext-link-type="uri" id="interref2b" xlink:href="https://clinicaltrials.gov/">
           https://clinicaltrials.gov/
          </ext-link>
          . As of March 15, 2020.
         </p>
        </caption>
        <alt-text id="alt0004">
         Table 4
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th valign="top">
            Register number
           </th>
           <th valign="top">
            Title
           </th>
           <th valign="top">
            Group 1 (sample size)
           </th>
           <th valign="top">
            Group 2 (sample size)
           </th>
           <th valign="top">
            Primary indicator
           </th>
           <th valign="top">
            Primary sponsor
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td valign="top">
            ChiCTR2000030039
           </td>
           <td valign="top">
            Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Conventional therapy with infusion of convalescent plasma: 200-500 mL (30 patients)
           </td>
           <td valign="top">
            Conventional therapy (30 patients)
           </td>
           <td valign="top">
            Viral load, SARS-CoV-2 antibody levels
           </td>
           <td valign="top">
            Affiliated Hospital of Xuzhou Medical University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029757
           </td>
           <td valign="top">
            Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial
           </td>
           <td valign="top">
            Conventional treatment and convalescent plasma therapy (100 patients)
           </td>
           <td valign="top">
            Conventional treatment (100 patients)
           </td>
           <td valign="top">
            Number of days between randomized grouping and clinical improvement
           </td>
           <td valign="top">
            China-Japan Friendship Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000029850
           </td>
           <td valign="top">
            Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Standardized comprehensive treatment combined with convalescent plasma treatment (10 patients)
           </td>
           <td valign="top">
            Standardized comprehensive treatment (10 patients)
           </td>
           <td valign="top">
            Fatality rate
           </td>
           <td valign="top">
            The First Affiliated Hospital of Zhejiang University School of Medicine
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030010
           </td>
           <td valign="top">
            A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)
           </td>
           <td valign="top">
            Anti-SARS-CoV-2 virus-inactivated plasma (50 patients)
           </td>
           <td valign="top">
            Ordinary plasma (50 patients)
           </td>
           <td valign="top">
            Improvement of clinical symptoms
           </td>
           <td valign="top">
            Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030046
           </td>
           <td valign="top">
            A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)
           </td>
           <td valign="top">
            Anti-2019-nCoV virus-inactivated plasma (10 patients)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Changes to clinical symptoms, laboratory and radiological data
           </td>
           <td valign="top">
            First People's Hospital of Jiangxia District
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030179
           </td>
           <td valign="top">
            Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)
           </td>
           <td valign="top">
            Routine treatment + plasma treatment (50 patients)
           </td>
           <td valign="top">
            Routine treatment (50 patients)
           </td>
           <td valign="top">
            Cure rate, mortality
           </td>
           <td valign="top">
            The First Affiliated Hospital of Nanchang University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030381
           </td>
           <td valign="top">
            A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2-inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient
           </td>
           <td valign="top">
            Conventional treatment and anti-SARS-CoV-2 virus-inactivated plasma (20 patients)
           </td>
           <td valign="top">
            Conventional treatment and ordinary plasma (20 patients)
           </td>
           <td valign="top">
            Clinical symptom improvement
           </td>
           <td valign="top">
            First People's Hospital of Jiangxi District, Wuhan
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030627
           </td>
           <td valign="top">
            Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases
           </td>
           <td valign="top">
            Convalescent plasma therapy + routine treatment (15 patients)
           </td>
           <td valign="top">
            Routine treatment (15 patients)
           </td>
           <td valign="top">
            Temperature, virus nucleic acid detection
           </td>
           <td valign="top">
            The First Affiliated Hospital of Zhengzhou University
           </td>
          </tr>
          <tr>
           <td valign="top">
            ChiCTR2000030702
           </td>
           <td valign="top">
            Plasma of the convalescent in the treatment of novel coronavirus pneumonia (COVID-19) common patient: a prospective clinical trial
           </td>
           <td valign="top">
            Conventional treatment and convalescent plasma therapy (25 patients)
           </td>
           <td valign="top">
            Conventional treatment (25 patients)
           </td>
           <td valign="top">
            Time to clinical recovery after randomization
           </td>
           <td valign="top">
            China-Japan Friendship Hospital
           </td>
          </tr>
          <tr>
           <td valign="top">
            NCT04292340
           </td>
           <td valign="top">
            Anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of COVID-19
           </td>
           <td align="left" valign="top">
            Anti-SARS-CoV-2-inactivated convalescent plasma
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            Virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions
           </td>
           <td valign="top">
            Shanghai Public Health Clinical Center
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec0013">
      <label>
       5.6
      </label>
      <title>
       Vaccines
      </title>
      <p id="para0020">
       The structure of SARS-CoV-2 S protein has been revealed, and this should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis
       <xref ref-type="bibr" rid="bib0077">
        [77]
       </xref>
       . These findings provide the basis for further studies to optimize vaccination strategies for this emerging infection. The majority of the vaccines being developed for coronaviruses target the spike glycoprotein or S protein
       <xref ref-type="bibr" rid="bib0081">
        [81]
       </xref>
       . Vaccine development is a long process, and no vaccines are available at the time of a pandemic outbreak. For example, the Ebola epidemic outbreak occurred in 2013, and three years later, the rVSV Ebola Vaccine was selected for phase I clinical trials for its safety and immunogenicity in Africa and Europe
       <xref ref-type="bibr" rid="bib0082">
        [82]
       </xref>
       . In November 2019, the European Commission granted marketing authorization to Merck Sharp and Dohme B.V. in Europe for their Ebola vaccine, Ervebo. Fortunately, Moderna company announced on February 24, 2020 that the company's experimental mRNA COVID-19 vaccine, known as mRNA-1273, is ready for human testing. It is a remarkably fast development cycle to develop an initial vaccine just weeks after identifying the SARS-CoV-2 genetic sequence. The clinical trial of safety and immunogenicity of mRNA-1273 in the treatment of COVID-19 is under investigation (ClinicalTrials.gov Identifier: NCT04283461). Moreover, a new oral SARS-CoV-2 vaccine has been successfully developed at Tianjin University, which uses food-grade safe
       <italic>
        Saccharomyces cerevisiae
       </italic>
       as a carrier and targets the S protein. There are 18 biotechnology companies and universities in China working on SARS-CoV-2 vaccines. Vaccines for SARS-CoV-2 have been developed much faster than those for Ebola because of the collaborative efforts of scientists around the world and the fast-track approval of SARS-CoV-2 vaccine development efforts by the Chinese health organizations.
      </p>
     </sec>
    </sec>
    <sec id="sec0014">
     <label>
      6
     </label>
     <title>
      Conclusions
     </title>
     <p id="para0021">
      Bats have been recognized as a natural reservoir and vectors of a variety of coronaviruses, and these viruses have crossed species barriers to infect humans and many different kinds of animals, including avians, rodents, and chiropters
      <xref ref-type="bibr" rid="bib0083">
       [83
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0084">
       84]
      </xref>
      . While the origin of COVID-19 is still being investigated, COVID-19 has features typical of the Coronaviridae family and was classified in the beta-coronavirus 2b lineage. COVID-19 can be transmitted between humans. Interventions, including intensive contact tracing followed by quarantine and isolation, can effectively reduce the spread of COVID-19, with the effect of travel restrictions. Wearing masks, washing hands and disinfecting surfaces contribute to reducing the risk of infection. Human coronaviruses can be efficiently inactivated within 1 min using surface disinfection procedures with 62-71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite
      <xref ref-type="bibr" rid="bib0085">
       [85]
      </xref>
      .
     </p>
     <p id="para0022">
      Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, control the pandemic, and reduce the economic impact of COVID-19 on China and the world. In acute respiratory infection, RT-PCR is routinely used to detect causative viruses from respiratory secretions. The positive rate of PCR from oropharyngeal swabs is not very high. In this situation, more swab testing is needed to clarify diagnosis. Typical CT findings can help early screening of suspected cases and diagnosis of COVID-19.
     </p>
     <p id="para0023">
      The COVID-19 infection has a clustering onset and is more likely to affect older males (average age 51 years) with comorbidities
      <xref ref-type="bibr" rid="bib0086">
       [86]
      </xref>
      . No evidence supports adverse birth outcomes, intrauterine infection, or vertical transmission of COVID-19
      <xref ref-type="bibr" rid="bib0087">
       [87]
      </xref>
      . However, viral infections can be acquired when the infant passes through the birth canal during vaginal delivery or through postpartum breastfeeding
      <xref ref-type="bibr" rid="bib0088">
       [88]
      </xref>
      . The most common symptoms were fever, cough, expectoration, headache, myalgia or fatigue, diarrhea, and hemoptysis
      <xref ref-type="bibr" rid="bib0089">
       [89]
      </xref>
      . Some people may experience severe acute respiratory distress syndrome. Histological examination of lung biopsy samples showed bilateral diffuse alveolar damage with cellular fibromyxoid exudates
      <xref ref-type="bibr" rid="bib0090">
       [90]
      </xref>
      . Other organs are also susceptible to COVID-19. The single-cell RNA-seq data was used to analyse receptor ACE2 expression to reveal the potential risk of different human organs to COVID-19 infection
      <xref ref-type="bibr" rid="bib0091">
       [91]
      </xref>
      . COVID-19 uses the same cell entry receptor as SARS-CoV, ACE2, which regulates both cross-species and human-to-human transmissions
      <xref ref-type="bibr" rid="bib0080">
       [80]
      </xref>
      . Proximal tubular cells also express higher levels of the ACE2 receptor, which leads to susceptibility to COVID-19
      <xref ref-type="bibr" rid="bib0091">
       [91]
      </xref>
      and induces kidney injury. Data from 33 patients with a complete clinical course were analysed, and the levels of blood urea and creatinine were higher in non-survivors than in survivors
      <xref ref-type="bibr" rid="bib0092">
       [92]
      </xref>
      .
     </p>
     <p id="para0024">
      All patients with COVID-19-infected pneumonia received antibacterial agents, 90% received antiviral therapy, and 45% received methylprednisolone
      <xref ref-type="bibr" rid="bib0092">
       [92]
      </xref>
      . Clinical trials are underway to investigate the efficacy of new antiviral drugs, convalescent plasma transfusion, and vaccines. Most of the trials were initiated by investigators and the study period is 1 to 11 months. Although the final results of these studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for therapy
      <xref ref-type="bibr" rid="bib0093">
       [93]
      </xref>
      .
     </p>
     <p id="para0025">
      The COVID-19 pandemic is a public health emergency of international concern, and all countries need a coordinated international effort to fight COVID-19. The transmission of pneumonia associated with SARS-CoV-2 has not yet been eliminated. In the absence of vaccines and antivirals, isolation and quarantine are achieving remarkable results. It is necessary to strengthen the monitoring of COVID-19 and to develop drugs and vaccines against the COVID-19 infection as soon as possible.
     </p>
    </sec>
    <back>
     <ref-list id="cebibl1">
      <title>
       References
      </title>
      <ref id="bib0001">
       <label>
        1
       </label>
       <element-citation id="sbref0001" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus from patients with pneumonia in China, 2019
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         382
        </volume>
        <year>
         2020
        </year>
        <fpage>
         727
        </fpage>
        <lpage>
         733
        </lpage>
        <pub-id pub-id-type="pmid">
         31978945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0002">
       <label>
        2
       </label>
       <element-citation id="sbref0002" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         565
        </fpage>
        <lpage>
         574
        </lpage>
        <pub-id pub-id-type="pmid">
         32007145
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0003">
       <label>
        3
       </label>
       <element-citation id="sbref0003" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         HIV-1 did not contribute to the 2019-nCoV genome
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        <volume>
         9
        </volume>
        <year>
         2020
        </year>
        <fpage>
         378
        </fpage>
        <lpage>
         381
        </lpage>
        <pub-id pub-id-type="pmid">
         32056509
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0004">
       <label>
        4
       </label>
       <element-citation id="sbref0004" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paraskevis
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kostaki
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
         <name>
          <surname>
           Magiorkinis
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Panayiotakopoulos
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Sourvinos
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Tsiodras
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event
        </article-title>
        <source>
         Infect Genet Evol
        </source>
        <volume>
         79
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         104212
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0005">
       <label>
        5
       </label>
       <element-citation id="sbref0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harcourt
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Kamili
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sakthivel
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Murray
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe Acute Respiratory Syndrome Coronavirus 2 from patient with 2019 novel Coronavirus disease, United States
        </article-title>
        <source>
         Emerging Infect Dis
        </source>
        <volume>
         26
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0006">
       <label>
        6
       </label>
       <element-citation id="sbref0006" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           Z.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new coronavirus associated with human respiratory disease in China
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         579
        </volume>
        <year>
         2020
        </year>
        <fpage>
         265
        </fpage>
        <lpage>
         269
        </lpage>
        <pub-id pub-id-type="pmid">
         32015508
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0007">
       <label>
        7
       </label>
       <element-citation id="sbref0007" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         382
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1199
        </fpage>
        <lpage>
         1207
        </lpage>
        <pub-id pub-id-type="pmid">
         31995857
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0008">
       <label>
        8
       </label>
       <element-citation id="sbref0008" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Backer
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Klinkenberg
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wallinga
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0009">
       <label>
        9
       </label>
       <element-citation id="sbref0009" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Presumed asymptomatic carrier transmission of COVID-19
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <label>
        10
       </label>
       <element-citation id="sbref0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Rayner
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Does SARS-CoV-2 has a longer incubation period than SARS and MERS?
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         92
        </volume>
        <year>
         2020
        </year>
        <fpage>
         476
        </fpage>
        <lpage>
         478
        </lpage>
        <pub-id pub-id-type="pmid">
         32056235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0011">
       <label>
        11
       </label>
       <element-citation id="sbref0011" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Ran
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Musa
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        <volume>
         92
        </volume>
        <year>
         2020
        </year>
        <fpage>
         214
        </fpage>
        <lpage>
         217
        </lpage>
        <pub-id pub-id-type="pmid">
         32007643
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0012">
       <label>
        12
       </label>
       <element-citation id="sbref0012" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Bragazzi
          </surname>
          <given-names>
           N.L.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimation of the transmission risk of the 2019-nCoV and Its implication for public health interventions
        </article-title>
        <source>
         J Clin Med
        </source>
        <volume>
         9
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0013">
       <label>
        13
       </label>
       <element-citation id="sbref0013" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Shih
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hsueh
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         105924
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0014">
       <label>
        14
       </label>
       <element-citation id="sbref0014" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           O.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chik-Yan Yip
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.M.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Consistent detection of 2019 novel coronavirus in saliva
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <label>
        15
       </label>
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bhadra
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ellington
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         10
        </volume>
        <year>
         2015
        </year>
        <object-id pub-id-type="publisher-id">
         e0123126
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0016">
       <label>
        16
       </label>
       <element-citation id="sbref0016" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           G.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tee
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and evaluation of novel real-time reverse transcription-PCR Assays with locked nucleic acid probes targeting leader sequences of human-pathogenic Coronaviruses
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         53
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2722
        </fpage>
        <lpage>
         2726
        </lpage>
        <pub-id pub-id-type="pmid">
         26019210
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0017">
       <label>
        17
       </label>
       <element-citation id="sbref0017" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A Rapid and Specific Assay for the Detection of MERS-CoV
        </article-title>
        <source>
         Front Microbiol
        </source>
        <volume>
         9
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1101
        </fpage>
        <pub-id pub-id-type="pmid">
         29896174
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0018">
       <label>
        18
       </label>
       <element-citation id="sbref0018" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Baek
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           Y.K.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ahn
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         One-pot reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) for detecting MERS-CoV
        </article-title>
        <source>
         Front Microbiol
        </source>
        <volume>
         7
        </volume>
        <year>
         2016
        </year>
        <fpage>
         2166
        </fpage>
        <pub-id pub-id-type="pmid">
         28119682
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0019">
       <label>
        19
       </label>
       <element-citation id="sbref0019" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           S.M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           K.P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Krishnan
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular diagnosis of a novel Coronavirus (2019-nCoV) causing an outbreak of pneumonia
        </article-title>
        <source>
         Clin Chem
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <label>
        20
       </label>
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0021">
       <label>
        21
       </label>
       <element-citation id="sbref0021" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Konrad
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Eberle
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Dangel
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Treis
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Berger
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bengs
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0022">
       <label>
        22
       </label>
       <element-citation id="sbref0022" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cordes
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Heim
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid random access detection of the novel SARS-coronavirus-2 (SARS-CoV-2, previously 2019-nCoV) using an open access protocol for the Panther Fusion
        </article-title>
        <source>
         J Clin Virol
        </source>
        <volume>
         125
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         104305
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0023">
       <label>
        23
       </label>
       <element-citation id="sbref0023" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Landt
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Kaiser
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Molenkamp
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Meijer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0024">
       <label>
        24
       </label>
       <element-citation id="sbref0024" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020
        </article-title>
        <source>
         Clin Chim Acta
        </source>
        <volume>
         505
        </volume>
        <year>
         2020
        </year>
        <fpage>
         172
        </fpage>
        <lpage>
         175
        </lpage>
        <pub-id pub-id-type="pmid">
         32156607
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <label>
        25
       </label>
       <element-citation id="sbref0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           X.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        <volume>
         9
        </volume>
        <year>
         2020
        </year>
        <fpage>
         386
        </fpage>
        <lpage>
         389
        </lpage>
        <pub-id pub-id-type="pmid">
         32065057
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0026">
       <label>
        26
       </label>
       <element-citation id="sbref0026" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ying
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sensitivity of chest CT for COVID-19: comparison to RT-PCR
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         200432
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0027">
       <label>
        27
       </label>
       <element-citation id="sbref0027" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of chest CT in combination with negative RT-PCR assay for the 2019 novel Coronavirus but high clinical suspicion
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         200330
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0028">
       <label>
        28
       </label>
       <element-citation id="sbref0028" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cobb
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Simon
          </surname>
          <given-names>
           C.O.
          </given-names>
         </name>
         <name>
          <surname>
           Stramer
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Body
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
         <name>
          <surname>
           Reisch
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The cobas(R) 6800/8800 system: a new era of automation in molecular diagnostics
        </article-title>
        <source>
         Expert Rev Mol Diagn
        </source>
        <volume>
         17
        </volume>
        <year>
         2017
        </year>
        <fpage>
         167
        </fpage>
        <lpage>
         180
        </lpage>
        <pub-id pub-id-type="pmid">
         28043179
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0029">
       <label>
        29
       </label>
       <element-citation id="sbref0029" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marlowe
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hardy
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Krevolin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gohl
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Arcenas
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         High-throughput testing of urogenital and extragenital specimens for detection of Chlamydia trachomatis and Neisseria gonorrhoeae with Cobas((R)) CT/NG
        </article-title>
        <source>
         Eur J Microbiol Immunol (Bp)
        </source>
        <volume>
         7
        </volume>
        <year>
         2017
        </year>
        <fpage>
         176
        </fpage>
        <lpage>
         186
        </lpage>
        <pub-id pub-id-type="pmid">
         29034107
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <label>
        30
       </label>
       <element-citation id="sbref0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greub
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Sahli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Brouillet
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Jaton
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ten years of R&amp;D and full automation in molecular diagnosis
        </article-title>
        <source>
         Future Microbiol
        </source>
        <volume>
         11
        </volume>
        <year>
         2016
        </year>
        <fpage>
         403
        </fpage>
        <lpage>
         425
        </lpage>
        <pub-id pub-id-type="pmid">
         27028061
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0031">
       <label>
        31
       </label>
       <element-citation id="sbref0031" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eigner
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Reucher
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hefner
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Staffa-Peichl
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kolb
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Betz
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical evaluation of multiplex RT-PCR assays for the detection of influenza A/B and respiratory syncytial virus using a high throughput system
        </article-title>
        <source>
         J Virol Methods
        </source>
        <volume>
         269
        </volume>
        <year>
         2019
        </year>
        <fpage>
         49
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="pmid">
         30946852
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0032">
       <label>
        32
       </label>
       <element-citation id="sbref0032" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pfefferle
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Reucher
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Nörz
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lütgehetmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         25
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0033">
       <label>
        33
       </label>
       <element-citation id="sbref0033" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         200343
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0034">
       <label>
        34
       </label>
       <element-citation id="sbref0034" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ai
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Correlation of chest CT and RT-PCR testing in Coronavirus disease 2019 (COVID-19) in China: A Report of 1014 Cases
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         200642
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0035">
       <label>
        35
       </label>
       <element-citation id="sbref0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Das
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           E.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Al Jawder
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Enani
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Skakni
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute Middle East Respiratory Syndrome Coronavirus: temporal lung changes observed on the chest radiographs of 55 patients
        </article-title>
        <source>
         AJR Am J Roentgenol
        </source>
        <volume>
         205
        </volume>
        <year>
         2015
        </year>
        <fpage>
         W267
        </fpage>
        <lpage>
         W274
        </lpage>
        <pub-id pub-id-type="pmid">
         26102309
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0036">
       <label>
        36
       </label>
       <element-citation id="sbref0036" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bernheim
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Mei
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         CT imaging features of 2019 novel Coronavirus (2019-nCoV)
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         200230
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0037">
       <label>
        37
       </label>
       <element-citation id="sbref0037" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gui
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Time course of lung changes on chest CT During recovery from 2019 novel Coronavirus (COVID-19) pneumonia
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         200370
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0038">
       <label>
        38
       </label>
       <element-citation id="sbref0038" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Alwalid
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         20
        </volume>
        <year>
         2020
        </year>
        <fpage>
         425
        </fpage>
        <lpage>
         434
        </lpage>
        <pub-id pub-id-type="pmid">
         32105637
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0039">
       <label>
        39
       </label>
       <element-citation id="sbref0039" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2
        </article-title>
        <source>
         Eur J Nucl Med Mol Imaging
        </source>
        <volume>
         47
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1275
        </fpage>
        <lpage>
         1280
        </lpage>
        <pub-id pub-id-type="pmid">
         32107577
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <label>
        40
       </label>
       <element-citation id="sbref0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0041">
       <label>
        41
       </label>
       <element-citation id="sbref0041" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           D.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         27
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0042">
       <label>
        42
       </label>
       <element-citation id="sbref0042" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           G.Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pandemic planning in China: applying lessons from severe acute respiratory syndrome
        </article-title>
        <source>
         Respirology
        </source>
        <volume>
         13
        </volume>
        <issue>
         Suppl 1
        </issue>
        <year>
         2008
        </year>
        <fpage>
         S33
        </fpage>
        <lpage>
         S35
        </lpage>
        <pub-id pub-id-type="pmid">
         18366527
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0043">
       <label>
        43
       </label>
       <element-citation id="sbref0043" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tsui
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           M.M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study
        </article-title>
        <source>
         Hong Kong Med J
        </source>
        <volume>
         9
        </volume>
        <year>
         2003
        </year>
        <fpage>
         399
        </fpage>
        <lpage>
         406
        </lpage>
        <pub-id pub-id-type="pmid">
         14660806
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0044">
       <label>
        44
       </label>
       <element-citation id="sbref0044" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           T.-T.
          </given-names>
         </name>
         <name>
          <surname>
           Qian
          </surname>
          <given-names>
           J.-D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           W.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           G.-Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0045">
       <label>
        45
       </label>
       <element-citation id="sbref0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques
        </article-title>
        <source>
         Nat Med
        </source>
        <volume>
         19
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1313
        </fpage>
        <lpage>
         1317
        </lpage>
        <pub-id pub-id-type="pmid">
         24013700
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0046">
       <label>
        46
       </label>
       <element-citation id="sbref0046" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Elfiky
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
        </article-title>
        <source>
         Life Sci
        </source>
        <volume>
         248
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         117477
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0047">
       <label>
        47
       </label>
       <element-citation id="sbref0047" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mulangu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Dodd
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Davey
          </surname>
          <given-names>
           R.T.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Tshiani Mbaya
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Proschan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Mukadi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A randomized, controlled trial of Ebola virus disease therapeutics
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         381
        </volume>
        <year>
         2019
        </year>
        <fpage>
         2293
        </fpage>
        <lpage>
         2303
        </lpage>
        <pub-id pub-id-type="pmid">
         31774950
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0048">
       <label>
        48
       </label>
       <element-citation id="sbref0048" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tchesnokov
          </surname>
          <given-names>
           E.P.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Porter
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Gotte
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanism of inhibition of Ebola virus RNA-dependent RNA Polymerase by remdesivir
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         11
        </volume>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="bib0049">
       <label>
        49
       </label>
       <element-citation id="sbref0049" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Leist
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Schafer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Won
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
        </article-title>
        <source>
         Nat Commun
        </source>
        <volume>
         11
        </volume>
        <year>
         2020
        </year>
        <fpage>
         222
        </fpage>
        <pub-id pub-id-type="pmid">
         31924756
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0050">
       <label>
        50
       </label>
       <element-citation id="sbref0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Case
          </surname>
          <given-names>
           J.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
        </article-title>
        <source>
         Sci Transl Med
        </source>
        <volume>
         9
        </volume>
        <year>
         2017
        </year>
       </element-citation>
      </ref>
      <ref id="bib0051">
       <label>
        51
       </label>
       <element-citation id="sbref0051" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Cronin
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Jordan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         117
        </volume>
        <year>
         2020
        </year>
        <fpage>
         6771
        </fpage>
        <lpage>
         6776
        </lpage>
        <pub-id pub-id-type="pmid">
         32054787
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0052">
       <label>
        52
       </label>
       <element-citation id="sbref0052" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gordon
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tchesnokov
          </surname>
          <given-names>
           E.P.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Porter
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Gotte
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0053">
       <label>
        53
       </label>
       <element-citation id="sbref0053" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holshue
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           DeBolt
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lindquist
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lofy
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wiesman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bruce
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First case of 2019 novel Coronavirus in the United States
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         382
        </volume>
        <year>
         2020
        </year>
        <fpage>
         929
        </fpage>
        <lpage>
         936
        </lpage>
        <pub-id pub-id-type="pmid">
         32004427
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0054">
       <label>
        54
       </label>
       <element-citation id="sbref0054" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martinez
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Compounds with therapeutic potential against novel respiratory 2019 coronavirus
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0055">
       <label>
        55
       </label>
       <element-citation id="sbref0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment
        </article-title>
        <source>
         Biosci Trends
        </source>
        <volume>
         14
        </volume>
        <year>
         2020
        </year>
        <fpage>
         64
        </fpage>
        <lpage>
         68
        </lpage>
        <pub-id pub-id-type="pmid">
         32037389
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0056">
       <label>
        56
       </label>
       <element-citation id="sbref0056" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Di Trani
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Donatelli
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         New insights into the antiviral effects of chloroquine
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         6
        </volume>
        <year>
         2006
        </year>
        <fpage>
         67
        </fpage>
        <lpage>
         69
        </lpage>
        <pub-id pub-id-type="pmid">
         16439323
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0057">
       <label>
        57
       </label>
       <element-citation id="sbref0057" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model
        </article-title>
        <source>
         Cell Res
        </source>
        <volume>
         23
        </volume>
        <year>
         2013
        </year>
        <fpage>
         300
        </fpage>
        <lpage>
         302
        </lpage>
        <pub-id pub-id-type="pmid">
         23208422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0058">
       <label>
        58
       </label>
       <element-citation id="sbref0058" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <volume>
         30
        </volume>
        <year>
         2007
        </year>
        <fpage>
         297
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         17629679
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0059">
       <label>
        59
       </label>
       <element-citation id="sbref0059" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bergeron
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Benjannet
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Erickson
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         2
        </volume>
        <year>
         2005
        </year>
        <fpage>
         69
        </fpage>
        <pub-id pub-id-type="pmid">
         16115318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0060">
       <label>
        60
       </label>
       <element-citation id="sbref0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
        </article-title>
        <source>
         Biosci Trends
        </source>
        <volume>
         14
        </volume>
        <year>
         2020
        </year>
        <fpage>
         72
        </fpage>
        <lpage>
         73
        </lpage>
        <pub-id pub-id-type="pmid">
         32074550
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0061">
       <label>
        61
       </label>
       <element-citation id="sbref0061" publication-type="journal">
        <article-title>
         [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua Jie He He Hu Xi Za Zhi
        </source>
        <volume>
         43
        </volume>
        <year>
         2020
        </year>
        <fpage>
         185
        </fpage>
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="pmid">
         32164085
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0062">
       <label>
        62
       </label>
       <element-citation id="sbref0062" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lagier
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         105932
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0063">
       <label>
        63
       </label>
       <element-citation id="sbref0063" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jallouli
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Galicier
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zahr
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Aumaitre
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Frances
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Le Guern
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus
        </article-title>
        <source>
         Arthritis Rheumatol
        </source>
        <volume>
         67
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2176
        </fpage>
        <lpage>
         2184
        </lpage>
        <pub-id pub-id-type="pmid">
         25989906
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0064">
       <label>
        64
       </label>
       <element-citation id="sbref0064" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Biot
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Daher
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Chavain
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fandeur
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Khalife
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Dive
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities
        </article-title>
        <source>
         J Med Chem
        </source>
        <volume>
         49
        </volume>
        <year>
         2006
        </year>
        <fpage>
         2845
        </fpage>
        <lpage>
         2849
        </lpage>
        <pub-id pub-id-type="pmid">
         16640347
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0065">
       <label>
        65
       </label>
       <element-citation id="sbref0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0066">
       <label>
        66
       </label>
       <element-citation id="sbref0066" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0067">
       <label>
        67
       </label>
       <element-citation id="sbref0067" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.G.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Shang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua Jie He He Hu Xi Za Zhi
        </source>
        <volume>
         43
        </volume>
        <year>
         2020
        </year>
        <fpage>
         203
        </fpage>
        <lpage>
         208
        </lpage>
        <pub-id pub-id-type="pmid">
         32164089
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0068">
       <label>
        68
       </label>
       <element-citation id="sbref0068" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schrezenmeier
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Dorner
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
        </article-title>
        <source>
         Nat Rev Rheumatol
        </source>
        <volume>
         16
        </volume>
        <year>
         2020
        </year>
        <fpage>
         155
        </fpage>
        <lpage>
         166
        </lpage>
        <pub-id pub-id-type="pmid">
         32034323
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0069">
       <label>
        69
       </label>
       <element-citation id="sbref0069" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Majori
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of chloroquine on viral infections: an old drug against today's diseases
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         3
        </volume>
        <year>
         2003
        </year>
        <fpage>
         722
        </fpage>
        <lpage>
         727
        </lpage>
        <pub-id pub-id-type="pmid">
         14592603
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0070">
       <label>
        70
       </label>
       <element-citation id="sbref0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Touret
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           de Lamballerie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Of chloroquine and COVID-19
        </article-title>
        <source>
         Antiviral Res
        </source>
        <volume>
         177
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         104762
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0071">
       <label>
        71
       </label>
       <element-citation id="sbref0071" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine for the 2019 novel coronavirus SARS-CoV-2
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         105923
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0072">
       <label>
        72
       </label>
       <element-citation id="sbref0072" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Mandourah
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hameed
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Sindi
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Almekhlafi
          </surname>
          <given-names>
           G.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hussein
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         197
        </volume>
        <year>
         2018
        </year>
        <fpage>
         757
        </fpage>
        <lpage>
         767
        </lpage>
        <pub-id pub-id-type="pmid">
         29161116
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0073">
       <label>
        73
       </label>
       <element-citation id="sbref0073" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Allen Chan
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients
        </article-title>
        <source>
         J Clin Virol
        </source>
        <volume>
         31
        </volume>
        <year>
         2004
        </year>
        <fpage>
         304
        </fpage>
        <lpage>
         309
        </lpage>
        <pub-id pub-id-type="pmid">
         15494274
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0074">
       <label>
        74
       </label>
       <element-citation id="sbref0074" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           D.T.
          </given-names>
         </name>
         <name>
          <surname>
           Wing
          </surname>
          <given-names>
           Y.K.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           H.C.
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           Y.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yiu
          </surname>
          <given-names>
           G.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         39
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1247
        </fpage>
        <lpage>
         1249
        </lpage>
        <pub-id pub-id-type="pmid">
         15486852
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0075">
       <label>
        75
       </label>
       <element-citation id="sbref0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Millar
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Baillie
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         473
        </fpage>
        <lpage>
         475
        </lpage>
        <pub-id pub-id-type="pmid">
         32043983
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0076">
       <label>
        76
       </label>
       <element-citation id="sbref0076" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        <volume>
         9
        </volume>
        <year>
         2020
        </year>
        <fpage>
         382
        </fpage>
        <lpage>
         385
        </lpage>
        <pub-id pub-id-type="pmid">
         32065055
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0077">
       <label>
        77
       </label>
       <element-citation id="sbref0077" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wrapp
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Abiona
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
        </article-title>
        <source>
         Science
        </source>
        <volume>
         367
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1260
        </fpage>
        <lpage>
         1263
        </lpage>
        <pub-id pub-id-type="pmid">
         32075877
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0078">
       <label>
        78
       </label>
       <element-citation id="sbref0078" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mair-Jenkins
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Saavedra-Campos
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Baillie
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Cleary
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Khaw
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         211
        </volume>
        <year>
         2015
        </year>
        <fpage>
         80
        </fpage>
        <lpage>
         90
        </lpage>
        <pub-id pub-id-type="pmid">
         25030060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0079">
       <label>
        79
       </label>
       <element-citation id="sbref0079" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Griensven
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           de Lamballerie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Semple
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Gallian
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Baize
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of convalescent plasma for Ebola virus disease in Guinea
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         374
        </volume>
        <year>
         2016
        </year>
        <fpage>
         33
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="pmid">
         26735992
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0080">
       <label>
        80
       </label>
       <element-citation id="sbref0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A pneumonia outbreak associated with a new coronavirus of probable bat origin
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         579
        </volume>
        <year>
         2020
        </year>
        <fpage>
         270
        </fpage>
        <lpage>
         273
        </lpage>
        <pub-id pub-id-type="pmid">
         32015507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0081">
       <label>
        81
       </label>
       <element-citation id="sbref0081" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The spike protein of SARS-CoV–a target for vaccine and therapeutic development
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        <volume>
         7
        </volume>
        <year>
         2009
        </year>
        <fpage>
         226
        </fpage>
        <lpage>
         236
        </lpage>
        <pub-id pub-id-type="pmid">
         19198616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0082">
       <label>
        82
       </label>
       <element-citation id="sbref0082" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agnandji
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Huttner
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Zinser
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Njuguna
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Dahlke
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandes
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Phase 1 Trials of rVSV Ebola vaccine in Africa and Europe
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         374
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1647
        </fpage>
        <lpage>
         1660
        </lpage>
        <pub-id pub-id-type="pmid">
         25830326
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0083">
       <label>
        83
       </label>
       <element-citation id="sbref0083" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent advances in the detection of respiratory virus infection in humans
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         92
        </volume>
        <year>
         2020
        </year>
        <fpage>
         408
        </fpage>
        <lpage>
         417
        </lpage>
        <pub-id pub-id-type="pmid">
         31944312
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0084">
       <label>
        84
       </label>
       <element-citation id="sbref0084" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackenzie
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jeggo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reservoirs and vectors of emerging viruses
        </article-title>
        <source>
         Curr Opin Virol
        </source>
        <volume>
         3
        </volume>
        <year>
         2013
        </year>
        <fpage>
         170
        </fpage>
        <lpage>
         179
        </lpage>
        <pub-id pub-id-type="pmid">
         23491947
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0085">
       <label>
        85
       </label>
       <element-citation id="sbref0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Todt
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pfaender
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Steinmann
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         104
        </volume>
        <year>
         2020
        </year>
        <fpage>
         246
        </fpage>
        <lpage>
         251
        </lpage>
        <pub-id pub-id-type="pmid">
         32035997
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0086">
       <label>
        86
       </label>
       <element-citation id="sbref0086" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0087">
       <label>
        87
       </label>
       <element-citation id="sbref0087" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         809
        </fpage>
        <lpage>
         815
        </lpage>
        <pub-id pub-id-type="pmid">
         32151335
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0088">
       <label>
        88
       </label>
       <element-citation id="sbref0088" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potential maternal and infant outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting pregnant women: Lessons from SARS, MERS, and other human Coronavirus infections
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         12
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0089">
       <label>
        89
       </label>
       <element-citation id="sbref0089" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           X.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           X.X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           X.G.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ying
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         368
        </volume>
        <year>
         2020
        </year>
        <fpage>
         m606
        </fpage>
        <pub-id pub-id-type="pmid">
         32075786
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0090">
       <label>
        90
       </label>
       <element-citation id="sbref0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathological findings of COVID-19 associated with acute respiratory distress syndrome
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0091">
       <label>
        91
       </label>
       <element-citation id="sbref0091" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection
        </article-title>
        <source>
         Front Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0092">
       <label>
        92
       </label>
       <element-citation id="sbref0092" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0093">
       <label>
        93
       </label>
       <element-citation id="sbref0093" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical trial analysis of 2019-nCoV therapy registered in China
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0001">
      <title>
       Declarations
      </title>
      <p>
       <bold>
        Funding:
       </bold>
       This work was supported by the Professional Development Research Project of the National Chinese Medicine Clinical Research Base of the
       <funding-source id="gs00001">
        State Administration of Traditional Chinese Medicine
       </funding-source>
       (No. JDZX2015295) and the
       <funding-source id="gs00002">
        National Natural Science Foundation of China
       </funding-source>
       (No. 81701962).
      </p>
      <p>
       <bold>
        Competing Interests:
       </bold>
       The authors declare no competing interests.
      </p>
      <p>
       <bold>
        Ethical Approval:
       </bold>
       Not required
      </p>
     </ack>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Clin Rev Allergy Immunol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Clin Rev Allergy Immunol
      </journal-id>
      <journal-title-group>
       <journal-title>
        Clinical Reviews in Allergy &amp; Immunology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1080-0549
      </issn>
      <issn pub-type="epub">
       1559-0267
      </issn>
      <publisher>
       <publisher-name>
        Humana Press Inc
       </publisher-name>
       <publisher-loc>
        New York
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       21221847
      </article-id>
      <article-id pub-id-type="pmc">
       7091063
      </article-id>
      <article-id pub-id-type="publisher-id">
       8243
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/s12016-010-8243-x
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Hydroxychloroquine: From Malaria to Autoimmunity
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ben-Zvi
         </surname>
         <given-names>
          Ilan
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kivity
         </surname>
         <given-names>
          Shaye
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Langevitz
         </surname>
         <given-names>
          Pnina
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Shoenfeld
         </surname>
         <given-names>
          Yehuda
         </given-names>
        </name>
        <address>
         <email>
          shoenfel@post.tau.ac.il
         </email>
        </address>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.413795.d
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000121072845
         </institution-id>
         <institution>
          Rheumatology Unit, Zabludowicz Center for Autoimmune Diseases and Department of Internal Medicine F,
         </institution>
         <institution>
          Sheba Medical Center,
         </institution>
        </institution-wrap>
        Tel-Hashomer, 52621 Israel
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.413795.d
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000121072845
         </institution-id>
         <institution>
          Rheumatology Unit, Zabludowicz Center for Autoimmune Diseases and Department of Internal Medicine A and C,
         </institution>
         <institution>
          Sheba Medical Center,
         </institution>
        </institution-wrap>
        Tel-Hashomer, 52621 Israel
       </aff>
       <aff id="Aff3">
        <label>
         3
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.413795.d
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000121072845
         </institution-id>
         <institution>
          Rheumatology Unit, Zabludowicz Center for Autoimmune Diseases,
         </institution>
         <institution>
          Sheba Medical Center,
         </institution>
        </institution-wrap>
        Tel-Hashomer, 52621 Israel
       </aff>
       <aff id="Aff4">
        <label>
         4
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.413795.d
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000121072845
         </institution-id>
         <institution>
          Zabludowicz Center for Autoimmune Diseases and Department of Internal Medicine B,
         </institution>
         <institution>
          Sheba Medical Center,
         </institution>
        </institution-wrap>
        Tel-Hashomer, 52621 Israel
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        8
       </day>
       <month>
        1
       </month>
       <year>
        2011
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <year>
        2012
       </year>
      </pub-date>
      <volume>
       42
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       145
      </fpage>
      <lpage>
       153
      </lpage>
      <permissions>
       <copyright-statement>
        © Springer Science+Business Media, LLC 2011
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p>
        Quinine was first recognized as a potent antimalarial agent hundreds of years ago. Since then, the beneficial effects of quinine and its more advanced synthetic forms, chloroquine and hydroxychloroquine, have been increasingly recognized in a myriad of other diseases in addition to malaria. In recent years, antimalarials were shown to have various immunomodulatory effects, and currently have an established role in the management of rheumatic diseases, such as systemic lupus erythematosus and rheumatoid arthritis, skin diseases, and in the treatment of chronic Q fever. Lately, additional metabolic, cardiovascular, antithrombotic, and antineoplastic effects of antimalarials were shown. In this review, we discuss the known various immunomodulatory mechanisms of antimalarials and the current evidence for their beneficial effects in various diseases and in potential novel applications.
       </p>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Chloroquine
       </kwd>
       <kwd>
        Hydroxychloroquine
       </kwd>
       <kwd>
        Antimalarial
       </kwd>
       <kwd>
        Novel
       </kwd>
       <kwd>
        Therapy
       </kwd>
       <kwd>
        Lupus
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Springer Science+Business Media, LLC 2012
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <p>
     Hydroxychloroquine (HCQ) belongs to the group of antimalarial agents, which recognition of its benefit in other diseases except malaria dates back to 1894, when Payne reported that quinine was effective in cutaneous lupus [
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     ]. Since then, therapeutic effects of antimalarial agents were shown in a myriad of other diseases and the evidence for its potential benefit continues to grow.
    </p>
    <p>
     The first use of quinine as a drug is traditionally attributed to the Incan descendents in Peru, who cured the countess of Chinchon from a febrile illness with a mysterious bark powder in 1630 [
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
     ,
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     ]. Hundreds of years later, the alkaloids from the bark were extracted when chloroquine was one of a large series of 4-aminoquinolines which were investigated, beginning in 1943, as part of the extensive cooperative program of antimalarial research in the USA during World War II when thousands of compounds were synthesized and tested for activity. Chloroquine eventually proved most promising and was released for field trial. When hostilities ceased, it was discovered that the compound had been synthesized and studied as early as 1934 by the Germans but rejected because of toxicity in avian models.
    </p>
    <p>
     During the Second World War, millions of soldiers took antimalarial prophylaxis, and the observation that antimalarial improved the soldiers’ rashes and inflammatory arthritis led to the first trial that showed the efficacy of antimalarials in systemic lupus erythematosus (SLE) [
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
     ]. Since then, the role of antimalarials in rheumatic diseases was established and today its use is widespread in SLE and in rheumatoid arthritis (RA) [
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
     –
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ]. The synthetic form of HCQ was introduced in 1955 and differs from chloroquine only by a hydroxyl group, decreasing its toxicity while conserving its efficacy.
    </p>
    <p>
     Hydroxychloroquine has numerous known immunomodulatory effects [
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
     ], but its specific mechanism in individual diseases is not clear. The major proposed mechanisms of action of antimalarials on the immune system include: (1) interference with lysosomal acidification and inhibition of proteolysis, chemotaxis, phagocytosis, and antigen presentation [
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
     ,
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
     ]; (2) decreasing macrophage-mediated cytokine production, especially interleukin (IL)-1 and IL-6 [
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     ]; (3) inhibition of phospholipase A2 and thereby antagonizing the effects of prostaglandins [
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
     ,
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     ]; (4) absorption and blocking of UV light cutaneous reactions [
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ]; (5) binding and stabilizing DNA [
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
     ]; (6) inhibition of T and B-cell receptors calcium signaling [
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
     ]; and (7) inhibition of matrix metalloproteinases [
     <xref ref-type="bibr" rid="CR17">
      17
     </xref>
     ]. It was recently recognized that HCQ also inhibits toll-like receptors signaling [
     <xref ref-type="bibr" rid="CR18">
      18
     </xref>
     ], highlighting a new and important effect, which might play a part in numerous pathways and may contribute to our understanding of its usefulness in many autoimmune and other diseases. The various major known immunomodulatory mechanisms of HCQ is schematically drawn in Fig.
     <xref ref-type="fig" rid="Fig1">
      1
     </xref>
     .
     <fig id="Fig1">
      <label>
       Fig. 1
      </label>
      <caption>
       <p>
        The various inhibitory and immunomodulatory effects of HCQ are schematically drawn.
        <italic>
         PLA2
        </italic>
        phospholipase A2,
        <italic>
         IL
        </italic>
        interleukin,
        <italic>
         TLR
        </italic>
        toll like receptor,
        <italic>
         UV
        </italic>
        ultraviolet
       </p>
      </caption>
      <graphic id="MO1" xlink:href="12016_2010_8243_Fig1_HTML">
      </graphic>
     </fig>
    </p>
    <p>
     In addition to its established efficacy in SLE and RA, antimalarials were also found to be beneficial in other rheumatic and skin diseases, including palindromic rheumatism [
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ], eosinophilic fasciitis [
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
     ], dermatomyositis [
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
     ], Sjögren’s syndrome [
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     ], porphyria cutanea tarda [
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ], polymorphous light eruption [
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
     ], granuloma annulare [
     <xref ref-type="bibr" rid="CR26">
      26
     </xref>
     ], lichen planus [
     <xref ref-type="bibr" rid="CR27">
      27
     </xref>
     ], lupus panniculitis [
     <xref ref-type="bibr" rid="CR28">
      28
     </xref>
     ], and discoid lupus [
     <xref ref-type="bibr" rid="CR29">
      29
     </xref>
     ]. The traditional indications for the use of HCQ are summarized in Table
     <xref ref-type="table" rid="Tab1">
      1
     </xref>
     .
     <table-wrap id="Tab1">
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Traditional indications and doses for the use of hydroxychloroquine
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th>
          Indication
         </th>
         <th>
          Dose
         </th>
         <th>
          Study
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td>
          Malaria (acute)
         </td>
         <td>
          800 mg followed by 400 mg at 6, 24, and 48 h
         </td>
         <td>
          CDC guidelines[
          <xref ref-type="bibr" rid="CR111">
           111
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td>
          Rheumatoid arthritis
         </td>
         <td>
          400–600 mg/day
         </td>
         <td>
          Clark et al. [
          <xref ref-type="bibr" rid="CR5">
           5
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td>
          SLE
         </td>
         <td>
          200–400 mg/day
         </td>
         <td>
          Tsakonas et al. [
          <xref ref-type="bibr" rid="CR7">
           7
          </xref>
          ], Molad et al. [
          <xref ref-type="bibr" rid="CR6">
           6
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td>
          Palindromic rheumatism
         </td>
         <td>
          200–400 mg/day
         </td>
         <td>
          Youssef et al. [
          <xref ref-type="bibr" rid="CR19">
           19
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td>
          Eosinophilic fasciitis
         </td>
         <td>
          400 mg/day
         </td>
         <td>
          Lakhanpal et al. [
          <xref ref-type="bibr" rid="CR20">
           20
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td>
          Dermatomyositis
         </td>
         <td>
          400 mg/day
         </td>
         <td>
          Woo et al. [
          <xref ref-type="bibr" rid="CR21">
           21
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td>
          Sjögren’s syndrome
         </td>
         <td>
          6–7 mg/kg/day
         </td>
         <td>
          Fox et al. [
          <xref ref-type="bibr" rid="CR22">
           22
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td>
          Porphyria cutanea tarda
         </td>
         <td>
          250–500 mg/week
         </td>
         <td>
          Ashton et al. [
          <xref ref-type="bibr" rid="CR23">
           23
          </xref>
          ], Valls et al. [
          <xref ref-type="bibr" rid="CR24">
           24
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td>
          Polymorphous light eruption
         </td>
         <td>
          200–400 mg/day
         </td>
         <td>
          Murphy et al. [
          <xref ref-type="bibr" rid="CR25">
           25
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td>
          Granuloma annulare
         </td>
         <td>
          2–9 mg/gk/day
         </td>
         <td>
          Cannistraci et al. [
          <xref ref-type="bibr" rid="CR26">
           26
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td>
          Lichen planus
         </td>
         <td>
          200–400 mg/day
         </td>
         <td>
          Eisen [
          <xref ref-type="bibr" rid="CR27">
           27
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td>
          Lupus panniculitis
         </td>
         <td>
          200–400 mg/day
         </td>
         <td>
          Chung et al. [
          <xref ref-type="bibr" rid="CR28">
           28
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td>
          Discoid lupus
         </td>
         <td>
          400 mg/day
         </td>
         <td>
          Jessop et al. [
          <xref ref-type="bibr" rid="CR29">
           29
          </xref>
          ]
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        <italic>
         SLE
        </italic>
        systemic lupus erythematosus
       </p>
      </table-wrap-foot>
     </table-wrap>
    </p>
    <p>
     Recently, antimalarials were shown to have potential beneficial effects in many other diseases, including diseases of the immune, cardiovascular, and hematological systems, as well as malignant and infectious diseases other than malaria. Here, we review the current evidence for novel applications of the antimalarials, mainly chloroquine and HCQ.
    </p>
    <sec id="Sec1">
     <title>
      Antimicrobial Effects
     </title>
     <p>
      In addition to its antimalarial effect, HCQ was found to be effective against bacterial and viral infections. Its antibacterial and antiviral effects are attributed to the alkalinization of intracellular acidic organelles infected by bacteria and to the inhibition of entry steps and viral proteins glycosylation [
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ]. The most recognized antibacterial effect of HCQ is in
      <italic>
       Coxiella burnetii
      </italic>
      infections, where the treatment of choice for chronic Q-fever endocarditis consists of HCQ together with doxycycline for 18–36 months.
     </p>
     <p>
      In the human immunodeficiency virus (HIV), HCQ was shown to inhibit virus replication in T cells, by inhibiting the surface envelope glycoprotein 120 [
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
      –
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ]. This anti-HIV mechanism lacks cross-resistance with other antiretroviral drugs and was novel in the armamentarium of anti-HIV drugs. Paton et al. [
      <xref ref-type="bibr" rid="CR35">
       35
      </xref>
      ] showed that combined treatment with HCQ, hydroxyurea, and didanosine in antiretroviral naïve HIV patients with low viral load, decreased viral replication, and increased the CD4 count. However, in the current era of the highly active anti-retroviral therapy for HIV, the use of non anti-retroviral drugs such as HCQ is probably redundant.
     </p>
     <p>
      Human corona virus (hCoV) caused a near pandemic of severe acute respiratory syndrome in 2002–2003. To date, no specific antiviral drugs for the prevention or treatment of hCoV infection are available. Recently, chloroquine was shown to inhibit the replication and spread of corona virus in vitro [
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
      ,
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ] and to prevent infection with hCoV in newborn mice [
      <xref ref-type="bibr" rid="CR38">
       38
      </xref>
      ], showing promise as a potential therapy of this resistant virus.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Metabolic and Cardiovascular Effects
     </title>
     <p>
      The hypoglycemic effect of chloroquine was first demonstrated in a patient with insulin resistance in 1984 [
      <xref ref-type="bibr" rid="CR39">
       39
      </xref>
      ]. Later on, a clinical trial of non-insulin dependent diabetic patients who were treated with a short course of chloroquine exhibited a significant improvement in glucose tolerance in these patients [
      <xref ref-type="bibr" rid="CR40">
       40
      </xref>
      ]. When HCQ was combined with insulin for 6 months, the glycated hemoglobin decreased significantly compared to placebo, and the insulin dose had to be reduced by 30% in the HCQ group [
      <xref ref-type="bibr" rid="CR41">
       41
      </xref>
      ]. In another study, diabetic patients who did not respond to sulfonylurea were successfully treated with HCQ and their glycated hemoglobin was reduced by 1% [
      <xref ref-type="bibr" rid="CR42">
       42
      </xref>
      ]. The presumed anti-diabetic mechanism of chloroquine is by a decrease in the insulin clearance and degradation rate and an increase in the secretion of C-peptide [
      <xref ref-type="bibr" rid="CR43">
       43
      </xref>
      ,
      <xref ref-type="bibr" rid="CR44">
       44
      </xref>
      ]. Although HCQ was shown to have hypoglycemic effects, it should be noted the current treatment options for diabetes mellitus (DM) are varied and effective, so a role for antimalarials in diabetes treatment is unlikely.
     </p>
     <p>
      The use of HCQ may also be beneficial for reducing cardiovascular risk by improving glycemic control in RA and SLE patients; Shojania et al. [
      <xref ref-type="bibr" rid="CR45">
       45
      </xref>
      ] described a case of induction of hypoglycemia in a patient with DM and polyarthritis treated with HCQ. Later, in a cohort of patients with SLE or RA, treatment with HCQ was associated with lower levels of fasting blood glucose [
      <xref ref-type="bibr" rid="CR46">
       46
      </xref>
      ] and significantly lowered the risk to develop DM in RA patients [
      <xref ref-type="bibr" rid="CR47">
       47
      </xref>
      ]. It was recently shown that HCQ significantly reduces glycosylated hemoglobin in diabetes patients [
      <xref ref-type="bibr" rid="CR48">
       48
      </xref>
      ]. This observed association between HCQ treatment and lower risk of DM in rheumatic patients needs further clinical and pharmacological studies to assess HCQ’s effect on blood sugar before becoming common clinical practice.
     </p>
     <p>
      Hydroxychloroquine was also shown to have a favorable effect on lipid profile in patients with rheumatic diseases. Wallace et al. [
      <xref ref-type="bibr" rid="CR49">
       49
      </xref>
      ] showed that in RA and SLE, treatment with HCQ lowered the levels of cholesterol, triglycerides and LDL, irrespective of concomitant steroid administration, diet, or weight. Later studies confirmed this observation and suggested that this should be taken into account in rheumatic patients with significant cardiovascular risk factors and in ameliorating the adverse effects of corticosteroid therapy on lipid profile [
      <xref ref-type="bibr" rid="CR50">
       50
      </xref>
      –
      <xref ref-type="bibr" rid="CR52">
       52
      </xref>
      ]. However, a different study in Chinese SLE patients did not show significant effect on serum lipid profile, but these patients had mild or absent disease-activity and used low corticosteroid dose [
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
      ]. Of note, in addition to its metabolic effects on blood sugar and lipids, HCQ was recently also shown to improve endothelial function and to protect against thrombovascular events in lupus patients [
      <xref ref-type="bibr" rid="CR54">
       54
      </xref>
      –
      <xref ref-type="bibr" rid="CR56">
       56
      </xref>
      ].
     </p>
    </sec>
    <sec id="Sec3">
     <title>
      Antithrombotic Effects
     </title>
     <p>
      Approximately 30 years ago, HCQ was shown to prevent thromboembolic events in patients going total hip replacement [
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
      ]. The mechanism was unknown at the time, but it was later shown that HCQ inhibits platelet aggregation and the release of arachidonic acid from stimulated platelets [
      <xref ref-type="bibr" rid="CR58">
       58
      </xref>
      ]. Treatment with HCQ was also shown to be protective against thrombosis in lupus patients with antiphospholipid syndrome (APS) [
      <xref ref-type="bibr" rid="CR59">
       59
      </xref>
      ,
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
      ] and to reduce the risk of plaque formation in these patients [
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ]. Furthermore, HCQ seemed to be protective against thrombus formation in a group of anti-phospholipid (aPL) antibodies carriers without lupus [
      <xref ref-type="bibr" rid="CR62">
       62
      </xref>
      ].
     </p>
     <p>
      The antithrombotic mechanism of HCQ in APS is not completely understood, but some novel observations were recently made; Edwards et al. [
      <xref ref-type="bibr" rid="CR63">
       63
      </xref>
      ] found that HCQ decrease thrombus size and shortens the time to thrombus clearance in mice injected with human aPL antibodies. More recently, Espinola et al. [
      <xref ref-type="bibr" rid="CR64">
       64
      </xref>
      ] showed that HCQ inhibits platelets activation by aPL antibodies and Rand et al. showed that HCQ significantly reduces the binding of aPL-beta2-glycoprotein I complexes to phospholipid surfaces and also protects against the disruption of the potent anticoagulant annexin A5 by aPL antibodies in vitro and in patients’ plasma [
      <xref ref-type="bibr" rid="CR65">
       65
      </xref>
      ,
      <xref ref-type="bibr" rid="CR66">
       66
      </xref>
      ]. These finding suggest that HCQ should be an integral part of the treatment of APS, especially in patients with concomitant SLE.
     </p>
    </sec>
    <sec id="Sec4">
     <title>
      Antineoplastic Effects
     </title>
     <p>
      The antineoplastic effect of antimalarials was first observed when a program of chloroquine prophylaxis against malaria in Tanzania was associated with a reduction in the incidence of Burkitt lymphoma [
      <xref ref-type="bibr" rid="CR67">
       67
      </xref>
      ]. Later, chloroquine was shown to prevent spontaneous lymphoma development in mice models of human Burkitt lymphoma and ataxia telangiectasia, through the suppression of autophagy and an induction of p53-dependent cell death pathway [
      <xref ref-type="bibr" rid="CR68">
       68
      </xref>
      ]. Hydroxychloroquine was also shown to induce apoptosis of malignant B-cells from patients with chronic lymphocytic leukemia (CLL), through the activation of caspase-3 and modulation of Bcl-2/bax ratio [
      <xref ref-type="bibr" rid="CR69">
       69
      </xref>
      ,
      <xref ref-type="bibr" rid="CR70">
       70
      </xref>
      ]. Recently, a biodegradable nanoparticle drug delivery system loaded with HCQ was shown to produce a strong apoptotic effect on B-CLL cells in vitro [
      <xref ref-type="bibr" rid="CR71">
       71
      </xref>
      ].
     </p>
     <p>
      Except for its effect on hematological malignancies, HCQ was also shown to have antineoplastic effects on solid tumors: (1) An anti breast-cancer effect was shown by demonstration of its antiproliferative effect on the human breast tumor cell models MCF-7 and Bcap-37 [
      <xref ref-type="bibr" rid="CR72">
       72
      </xref>
      –
      <xref ref-type="bibr" rid="CR74">
       74
      </xref>
      ]. (2) An antiproliferative effect on mouse colon cancer cell line was shown, as well as a reduction in tumor volume in vivo with chloroquine treatment [
      <xref ref-type="bibr" rid="CR75">
       75
      </xref>
      ]. Chloroquine was also shown to potentiate the antiproliferative effect of 5-fluorouracil on the human colorectal cell line HT-29 [
      <xref ref-type="bibr" rid="CR76">
       76
      </xref>
      ]. (3) Chloroquine was shown to inhibit growth and induce cell death of A549 lung cancer cells [
      <xref ref-type="bibr" rid="CR77">
       77
      </xref>
      ]. (4) In a randomized, double-blind, placebo-controlled trial, patients with glioblastoma multiforme who were treated with chloroquine had a much better survival rate compared with non-treated patients [
      <xref ref-type="bibr" rid="CR78">
       78
      </xref>
      ].
     </p>
     <p>
      In addition to its independent antineoplastic effects, chloroquine was shown to effectively sensitize cancer cells to radiation and chemotherapy, without enhancing normal cells vulnerability [
      <xref ref-type="bibr" rid="CR79">
       79
      </xref>
      ,
      <xref ref-type="bibr" rid="CR80">
       80
      </xref>
      ]. Although these preliminary studies look promising, the potential role for antimalarials in the treatment paradigm of malignancies still remains to be established.
     </p>
    </sec>
    <sec id="Sec5">
     <title>
      Additional Effects
     </title>
     <p>
      In addition to its immunomodulatory effects described above, HCQ was also shown to inhibit the T cell response to foreign minor and major histocompatibility antigens and therefore inhibit the development of graft versus host disease (GVHD) in mice [
      <xref ref-type="bibr" rid="CR81">
       81
      </xref>
      ]. A phase II trial in patients who received bone marrow transplantation, showed better GVHD free survival and lower incidence of high-grade GVHD in patients who were treated with HCQ in addition to the traditional immunosuppressive drugs [
      <xref ref-type="bibr" rid="CR82">
       82
      </xref>
      ]. However, a phase III trial failed to exhibit additional benefit in GVHD prevention when HCQ was added to monotherpay with cyclosporine A [
      <xref ref-type="bibr" rid="CR83">
       83
      </xref>
      ].
     </p>
     <p>
      Additional beneficial effects of HCQ were also shown anecdotally in other diseases: (1) Hydroxychloroquine was shown to be very effective in Kikuchi–Fujimoto disease, a benign disease characterized by lymphadenopathy and fever, usually occurring in young women [
      <xref ref-type="bibr" rid="CR84">
       84
      </xref>
      ,
      <xref ref-type="bibr" rid="CR85">
       85
      </xref>
      ]. (2) Skeletal and metabolic effects of sarcoidosis were successfully treated with HCQ in patients who were not candidates for glucocorticoid treatment [
      <xref ref-type="bibr" rid="CR86">
       86
      </xref>
      –
      <xref ref-type="bibr" rid="CR88">
       88
      </xref>
      ]. (3) Hydroxychloroquine enabled steroid cessation in patients with subglottic stenosis who were steroid dependent due to edema and granulation tissue [
      <xref ref-type="bibr" rid="CR89">
       89
      </xref>
      ]. (4) Hydroxychloroquine in combination with azathioprine prompted a major recovery in a patient with sensory neuropathy syndrome [
      <xref ref-type="bibr" rid="CR90">
       90
      </xref>
      ]. (5) Exposure to HCQ during pregnancy in mothers with SLE who carried anti-Ro/La antibodies was associated with a decreased risk of fetal development of cardiac neonatal lupus, compared to mothers who were not treated with HCQ [
      <xref ref-type="bibr" rid="CR91">
       91
      </xref>
      ,
      <xref ref-type="bibr" rid="CR92">
       92
      </xref>
      ]. (6) Hydroxychloroquine was shown to enhance the production of hemoglobin F, showing a therapeutic potential for hemoglobinopathies [
      <xref ref-type="bibr" rid="CR93">
       93
      </xref>
      ].
     </p>
    </sec>
    <sec id="Sec6">
     <title>
      Antimalarials Toxicity
     </title>
     <p>
      Antimalarials are contraindicated in known hypersensitivity and in patients with a history of retinopathy. Taken in proper doses, chloroquine is an extraordinarily safe drug; however, its safety margin is narrow, and a single dose of 30 mg/kg may be fatal [
      <xref ref-type="bibr" rid="CR94">
       94
      </xref>
      ]. Caution should be used in patients with neuromuscular disorders such as myasthenia gravis and in patients with psychotic disorders. Patients with glucose-6-phosphate deficiency should be carefully monitored for hemolysis, although this is extremely rare in therapeutic doses.
     </p>
     <p>
      Acute chloroquine toxicity is encountered most frequently when therapeutic or high doses are administered too rapidly by parenteral routes. Toxic manifestations relate primarily to the cardiovascular system and the central nervous system (CNS). Cardiovascular effects include hypotension, vasodilation, suppressed myocardial function, cardiac arrhythmias, and eventual cardiac arrest. CNS side-effects may include confusion, convulsions, and coma. Doses of chloroquine used for oral therapy of acute malarial attack and for rheumatic and skin diseases may cause GI upset, headache, visual disturbances, urticaria, and pruritus. Prolonged use may occasionally cause headache, blurred vision, diplopia, confusion, convulsions, lichenoid skin eruptions, bleaching of hair, widening of the QRS interval, and T wave abnormalities. These complications are rare and usually disappear soon after the drug is withheld. Rare instances of hemolysis and blood dyscrasias have been reported [
      <xref ref-type="bibr" rid="CR95">
       95
      </xref>
      ]. Chloroquine may also cause discoloration of nail beds and mucous membranes [
      <xref ref-type="bibr" rid="CR96">
       96
      </xref>
      ].
     </p>
     <p>
      Irreversible retinopathy and ototoxicity can result from high daily doses (&gt;250 mg) of chloroquine or HCQ that lead to cumulative total doses of more than 1 g of base per kilogram body weight [
      <xref ref-type="bibr" rid="CR97">
       97
      </xref>
      –
      <xref ref-type="bibr" rid="CR99">
       99
      </xref>
      ]. Retinopathy presumably is related to drug accumulation in melanin-rich tissues and can be avoided if the daily dose is 250 mg or less. Prolonged therapy with high doses can also cause toxic myopathy, cardiopathy, and peripheral neuropathy [
      <xref ref-type="bibr" rid="CR100">
       100
      </xref>
      –
      <xref ref-type="bibr" rid="CR103">
       103
      </xref>
      ]; these reactions improve if the drug is withdrawn promptly [
      <xref ref-type="bibr" rid="CR104">
       104
      </xref>
      ].
     </p>
     <p>
      Hydroxychloroquine crosses the placenta as fetus levels were shown to be equivalent to maternal levels [
      <xref ref-type="bibr" rid="CR105">
       105
      </xref>
      ]. However, no fetal toxicity was evident in subsequent studies and no congenital abnormalities were seen in pregnant patients treated with HCQ during the first trimester of pregnancy [
      <xref ref-type="bibr" rid="CR106">
       106
      </xref>
      ,
      <xref ref-type="bibr" rid="CR107">
       107
      </xref>
      ]. During lactation, the amount of HCQ transferred to children seems very low and does not confer a risk of toxicity to the child [
      <xref ref-type="bibr" rid="CR108">
       108
      </xref>
      ,
      <xref ref-type="bibr" rid="CR109">
       109
      </xref>
      ]. Accordingly, continuation of HCQ use during pregnancy is recommended and there’s no evidence to advice against breastfeeding during treatment [
      <xref ref-type="bibr" rid="CR110">
       110
      </xref>
      ]. A summary of antimalarials toxicity and main adverse effects is presented in Table
      <xref ref-type="table" rid="Tab2">
       2
      </xref>
      .
      <table-wrap id="Tab2">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Main adverse effects of chloroquine and HCQ treatment
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th colspan="2">
           Type
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           Ocular
          </td>
          <td>
           Retinopathy (early changes reversible, may progress despite discontinuation if advanced), blurred vision, corneal changes/deposits
          </td>
         </tr>
         <tr>
          <td>
           Neuromuscular and skeletal
          </td>
          <td>
           Myopathy, palsy, or neuromyopathy leading to progressive weakness and atrophy of proximal muscle groups (may be associated with mild sensory changes, loss of deep tendon reflexes, and abnormal nerve conduction)
          </td>
         </tr>
         <tr>
          <td>
           Cardiovascular
          </td>
          <td>
           Cardiomyopathy (rare, relationship to HCQ unclear)
          </td>
         </tr>
         <tr>
          <td>
           Central nervous system
          </td>
          <td>
           Ataxia, dizziness, emotional changes, headache, irritability, lassitude, nervousness, nightmares, psychosis, seizure, vertigo
          </td>
         </tr>
         <tr>
          <td>
           Gastrointestinal
          </td>
          <td>
           Abdominal cramping, anorexia, nausea, vomiting, diarrhea, abnormal liver function
          </td>
         </tr>
         <tr>
          <td>
           Cutaneous
          </td>
          <td>
           Alopecia, angioedema, bleaching of hair, pigmentation changes (skin and mucosal; black-blue color), rash, pruritus
          </td>
         </tr>
         <tr>
          <td>
           Otic
          </td>
          <td>
           Deafness, tinnitus
          </td>
         </tr>
         <tr>
          <td>
           Respiratory
          </td>
          <td>
           Bronchospasm, respiratory failure (myopathy-related)
          </td>
         </tr>
         <tr>
          <td>
           Hematological
          </td>
          <td>
           Agranulocytosis, aplastic anemia, hemolysis (in patients with glucose-6-phosphate deficiency), leukopenia, thrombocytopenia
          </td>
         </tr>
         <tr>
          <td>
           Other
          </td>
          <td>
           Exacerbation of psoriasis
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
     <p>
      In conclusion, since the first use of antimalarial agents nearly a century ago, their effects on diseases in nearly all major branches of medicine have been increasingly recognized, including the fields of immunology, oncology, hematology, dermatology, cardiology, and infectious diseases. A summary of the effects of antimalarials is shown in Table
      <xref ref-type="table" rid="Tab3">
       3
      </xref>
      . To date, antimalarials have an established role in treatment of SLE, RA, chronic Q fever, and various skin diseases. They may also have a role in the treatment of antiphospholipid syndrome. There are currently many ongoing clinical trials studying the effects of antimalarials in other diseases, such as malignant neoplasms of the lung, breast, prostate, pancreas and colon, melanoma, renal cell carcinoma, CLL, multiple myeloma, influenza, HIV infection, osteoarthritis, and the metabolic syndrome, as can be seen by browsing the website
      <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">
       clinicaltrials.gov
      </ext-link>
      . The mechanism of action of HCQ and its effectiveness in these diseases and in other potential conditions still remains to be demonstrated in the future.
      <table-wrap id="Tab3">
       <label>
        Table 3
       </label>
       <caption>
        <p>
         A summary of the effects of antimalarials in various conditions
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Effect
          </th>
          <th>
           Disease/state
          </th>
          <th>
           Mechanism
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td rowspan="3">
           Antimicrobial
          </td>
          <td>
           Chronic Q fever endocarditis
          </td>
          <td>
           Alkalinization of phagosome
          </td>
         </tr>
         <tr>
          <td>
           Human immunodeficiency virus
          </td>
          <td>
           Inhibition of virus replication
          </td>
         </tr>
         <tr>
          <td>
           Human corona virus
          </td>
          <td>
           Inhibition of replication
          </td>
         </tr>
         <tr>
          <td rowspan="3">
           Metabolic and cardiovascular
          </td>
          <td>
           Hypoglycemic in diabetes mellitus
          </td>
          <td rowspan="3">
           Decreasing insulin clearance and increasing secretion of C-peptide
          </td>
         </tr>
         <tr>
          <td>
           Improves lipid profile in SLE and RA and in steroid use
          </td>
         </tr>
         <tr>
          <td>
           Improve endothelial function
          </td>
         </tr>
         <tr>
          <td rowspan="3">
           Antithrombotic
          </td>
          <td>
           Prevention of thromboembolism in immobilized patients
          </td>
          <td rowspan="2">
           Inhibition of platelet aggregation and arachidonic acid release
          </td>
         </tr>
         <tr>
          <td rowspan="2">
           Prevention of thrombosis in antiphospholipid syndrome
          </td>
         </tr>
         <tr>
          <td>
           Inhibition of platelets activation by aPL antibodies, reducing binding of aPL-beta2-GPI to antiphospholipids and disruption of annexin A5 by aPL antibodies
          </td>
         </tr>
         <tr>
          <td rowspan="4">
           Antineoplastic
          </td>
          <td>
           Prevention of lymphoma in mice
          </td>
          <td>
           Induction of p53-dependentcell death
          </td>
         </tr>
         <tr>
          <td>
           Induction of apoptosis in CLL cells
          </td>
          <td rowspan="3">
           Activation of caspase-3
          </td>
         </tr>
         <tr>
          <td>
           Solid tumors: e.g., breast, colon, glioblastoma multiforme, lung
          </td>
         </tr>
         <tr>
          <td>
           Sensitization of cancer cells to radiation and chemotherapy
          </td>
         </tr>
         <tr>
          <td rowspan="6">
           Other
          </td>
          <td>
           Prevention of GVHD disease
          </td>
          <td rowspan="6">
           Inhibition of T cell response to MHC antigens
          </td>
         </tr>
         <tr>
          <td>
           Kikuchi–Fujimoto disease
          </td>
         </tr>
         <tr>
          <td>
           Sarcoidosis
          </td>
         </tr>
         <tr>
          <td>
           Subglottic stenosis
          </td>
         </tr>
         <tr>
          <td>
           Sensory neuropathy
          </td>
         </tr>
         <tr>
          <td>
           Decreases risk of fetal cardiac lupus
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         Where known, the mechanism is described
        </p>
        <p>
         <italic>
          aPL
         </italic>
         antiphospholipid,
         <italic>
          GP
         </italic>
         glycoprotein,
         <italic>
          CLL
         </italic>
         chronic lymphocytic leukemia,
         <italic>
          GVHD
         </italic>
         graft versus host disease,
         <italic>
          MHC
         </italic>
         major histocompatibility complex
        </p>
       </table-wrap-foot>
      </table-wrap>
     </p>
    </sec>
    <back>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <name>
          <surname>
           Cyr
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The history of lupus erythematosus. From Hippocrates to Osler
        </article-title>
        <source>
         Rheum Dis Clin North Am
        </source>
        <year>
         1988
        </year>
        <volume>
         14
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         1
        </fpage>
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="pmid">
         3041483
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mates
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Nesher
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Zevin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Quinines—past and present
        </article-title>
        <source>
         Harefuah
        </source>
        <year>
         2007
        </year>
        <volume>
         146
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         560
        </fpage>
        <lpage>
         562
        </lpage>
        <pub-id pub-id-type="pmid">
         17803173
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wallace
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The history of antimalarials
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         1996
        </year>
        <volume>
         5
        </volume>
        <issue>
         Suppl 1
        </issue>
        <fpage>
         S2
        </fpage>
        <lpage>
         S3
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/096120339600500102
        </pub-id>
        <pub-id pub-id-type="pmid">
         8803902
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Page
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of lupus erythematosus with mepacrine
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         1951
        </year>
        <volume>
         2
        </volume>
        <issue>
         6687
        </issue>
        <fpage>
         755
        </fpage>
        <lpage>
         758
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(51)91643-1
        </pub-id>
        <pub-id pub-id-type="pmid">
         14874500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Clark
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Casas
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Tugwell
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Medina
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Gheno
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Tenorio
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <year>
         1993
        </year>
        <volume>
         119
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1067
        </fpage>
        <lpage>
         1071
        </lpage>
        <pub-id pub-id-type="pmid">
         8239224
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Molad
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Gorshtein
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wysenbeek
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Guedj
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Majadla
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Weinberger
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         2002
        </year>
        <volume>
         11
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         356
        </fpage>
        <lpage>
         361
        </lpage>
        <pub-id pub-id-type="doi">
         10.1191/0961203302lu203ra
        </pub-id>
        <pub-id pub-id-type="pmid">
         12139373
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsakonas
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Joseph
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Esdaile
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Choquette
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Senecal
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Cividino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         1998
        </year>
        <volume>
         7
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         80
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="doi">
         10.1191/096120398678919778
        </pub-id>
        <pub-id pub-id-type="pmid">
         9541091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kalia
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Dutz
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
        </person-group>
        <article-title>
         New concepts in antimalarial use and mode of action in dermatology
        </article-title>
        <source>
         Dermatol Ther
        </source>
        <year>
         2007
        </year>
        <volume>
         20
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         160
        </fpage>
        <lpage>
         174
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1529-8019.2007.00131.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         17970883
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohkuma
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Poole
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         1978
        </year>
        <volume>
         75
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         3327
        </fpage>
        <lpage>
         3331
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.75.7.3327
        </pub-id>
        <pub-id pub-id-type="pmid">
         28524
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ziegler
          </surname>
          <given-names>
           HK
          </given-names>
         </name>
         <name>
          <surname>
           Unanue
          </surname>
          <given-names>
           ER
          </given-names>
         </name>
        </person-group>
        <article-title>
         Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         1982
        </year>
        <volume>
         79
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         175
        </fpage>
        <lpage>
         178
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.79.1.175
        </pub-id>
        <pub-id pub-id-type="pmid">
         6798568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Quraishi
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Kalb
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <name>
          <surname>
           Panja
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Mayer
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells
        </article-title>
        <source>
         J Rheumatol
        </source>
        <year>
         1993
        </year>
        <volume>
         20
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         803
        </fpage>
        <lpage>
         808
        </lpage>
        <pub-id pub-id-type="pmid">
         8336306
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Loffler
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Bohn
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Hesse
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Kunze
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver
        </article-title>
        <source>
         Biochim Biophys Acta
        </source>
        <year>
         1985
        </year>
        <volume>
         835
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         448
        </fpage>
        <lpage>
         455
        </lpage>
        <pub-id pub-id-type="pmid">
         4016141
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Manku
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Horrobin
          </surname>
          <given-names>
           DF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         1976
        </year>
        <volume>
         2
        </volume>
        <issue>
         7995
        </issue>
        <fpage>
         1115
        </fpage>
        <lpage>
         1117
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(76)91090-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         62951
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lester
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Burnham
          </surname>
          <given-names>
           TK
          </given-names>
         </name>
         <name>
          <surname>
           Fine
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Murray
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. I. The mechanism of action of hydroxychloroquine
        </article-title>
        <source>
         Arch Dermatol
        </source>
        <year>
         1967
        </year>
        <volume>
         96
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         1
        </fpage>
        <lpage>
         10
        </lpage>
        <pub-id pub-id-type="doi">
         10.1001/archderm.1967.01610010007001
        </pub-id>
        <pub-id pub-id-type="pmid">
         5298279
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           SN
          </given-names>
         </name>
         <name>
          <surname>
           Yielding
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spectrophotometric studies of the interaction of chloroquine with deoxyribonucleic acid
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         1965
        </year>
        <volume>
         240
        </volume>
        <fpage>
         3123
        </fpage>
        <lpage>
         3131
        </lpage>
        <pub-id pub-id-type="pmid">
         14342342
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goldman
          </surname>
          <given-names>
           FD
          </given-names>
         </name>
         <name>
          <surname>
           Gilman
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Hollenback
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Kato
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Premack
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Rawlings
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties
        </article-title>
        <source>
         Blood
        </source>
        <year>
         2000
        </year>
        <volume>
         95
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         3460
        </fpage>
        <lpage>
         3466
        </lpage>
        <pub-id pub-id-type="pmid">
         10828029
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lesiak
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Narbutt
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sysa-Jedrzejowska
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lukamowicz
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           McCauliffe
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name>
          <surname>
           Wozniacka
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         2010
        </year>
        <volume>
         19
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         683
        </fpage>
        <lpage>
         688
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/0961203309356455
        </pub-id>
        <pub-id pub-id-type="pmid">
         20064914
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kyburz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Brentano
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Gay
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mode of action of hydroxychloroquine in RA—evidence of an inhibitory effect on toll-like receptor signaling
        </article-title>
        <source>
         Nat Clin Pract Rheumatol
        </source>
        <year>
         2006
        </year>
        <volume>
         2
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         458
        </fpage>
        <lpage>
         459
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/ncprheum0292
        </pub-id>
        <pub-id pub-id-type="pmid">
         16951696
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Youssef
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Palindromic rheumatism: a response to chloroquine
        </article-title>
        <source>
         J Rheumatol
        </source>
        <year>
         1991
        </year>
        <volume>
         18
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         35
        </fpage>
        <lpage>
         37
        </lpage>
        <pub-id pub-id-type="pmid">
         2023196
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lakhanpal
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Ginsburg
          </surname>
          <given-names>
           WW
          </given-names>
         </name>
         <name>
          <surname>
           Michet
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Doyle
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           SB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases
        </article-title>
        <source>
         Semin Arthritis Rheum
        </source>
        <year>
         1988
        </year>
        <volume>
         17
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         221
        </fpage>
        <lpage>
         231
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0049-0172(88)90008-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         3232080
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           TY
          </given-names>
         </name>
         <name>
          <surname>
           Callen
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Voorhees
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Bickers
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Hanno
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Hawkins
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine
        </article-title>
        <source>
         J Am Acad Dermatol
        </source>
        <year>
         1984
        </year>
        <volume>
         10
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         592
        </fpage>
        <lpage>
         600
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0190-9622(84)80263-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         6715608
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fox
          </surname>
          <given-names>
           RI
          </given-names>
         </name>
         <name>
          <surname>
           Dixon
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Guarrasi
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Krubel
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of primary Sjogren’s syndrome with hydroxychloroquine: a retrospective, open-label study
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         1996
        </year>
        <volume>
         5
        </volume>
        <issue>
         Suppl 1
        </issue>
        <fpage>
         S31
        </fpage>
        <lpage>
         S36
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/096120339600500108
        </pub-id>
        <pub-id pub-id-type="pmid">
         8803908
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ashton
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <name>
          <surname>
           Hawk
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Magnus
          </surname>
          <given-names>
           IA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Low-dose oral chloroquine in the treatment of porphyria cutanea tarda
        </article-title>
        <source>
         Br J Dermatol
        </source>
        <year>
         1984
        </year>
        <volume>
         111
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         609
        </fpage>
        <lpage>
         613
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1365-2133.1984.tb06632.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         6498093
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Valls
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Ena
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Enriquez-De-Salamanca
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Low-dose oral chloroquine in patients with porphyria cutanea tarda and low–moderate iron overload
        </article-title>
        <source>
         J Dermatol Sci
        </source>
        <year>
         1994
        </year>
        <volume>
         7
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         169
        </fpage>
        <lpage>
         175
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0923-1811(94)90092-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         7918235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name>
          <surname>
           Hawk
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Magnus
          </surname>
          <given-names>
           IA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring
        </article-title>
        <source>
         Br J Dermatol
        </source>
        <year>
         1987
        </year>
        <volume>
         116
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         379
        </fpage>
        <lpage>
         386
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1365-2133.1987.tb05852.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         3552020
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cannistraci
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Lesnoni La Parola
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Falchi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Picardo
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of generalized granuloma annulare with hydroxychloroquine
        </article-title>
        <source>
         Dermatology
        </source>
        <year>
         2005
        </year>
        <volume>
         211
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         167
        </fpage>
        <lpage>
         168
        </lpage>
        <pub-id pub-id-type="doi">
         10.1159/000086452
        </pub-id>
        <pub-id pub-id-type="pmid">
         16088169
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eisen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial
        </article-title>
        <source>
         J Am Acad Dermatol
        </source>
        <year>
         1993
        </year>
        <volume>
         28
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         609
        </fpage>
        <lpage>
         612
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0190-9622(93)70082-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         8463463
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Hann
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine
        </article-title>
        <source>
         J Dermatol
        </source>
        <year>
         1997
        </year>
        <volume>
         24
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         569
        </fpage>
        <lpage>
         572
        </lpage>
        <pub-id pub-id-type="pmid">
         9350102
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="other">
        Jessop S, Whitelaw DA, Delamere FM (2009) Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. (4):CD002954
       </mixed-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2007
        </year>
        <volume>
         30
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         297
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ijantimicag.2007.05.015
        </pub-id>
        <pub-id pub-id-type="pmid">
         17629679
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Majori
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of chloroquine on viral infections: an old drug against today’s diseases?
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         3
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         722
        </fpage>
        <lpage>
         727
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(03)00806-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         14592603
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Gennero
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
        </person-group>
        <article-title>
         The anti-HIV-1 activity of chloroquine
        </article-title>
        <source>
         J Clin Virol
        </source>
        <year>
         2001
        </year>
        <volume>
         20
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         131
        </fpage>
        <lpage>
         135
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1386-6532(00)00139-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         11166661
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lucia
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Rastrelli
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Rutella
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Golotta
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Morra
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors
        </article-title>
        <source>
         J Acquir Immune Defic Syndr
        </source>
        <year>
         2004
        </year>
        <volume>
         35
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         223
        </fpage>
        <lpage>
         232
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/00126334-200403010-00002
        </pub-id>
        <pub-id pub-id-type="pmid">
         15076236
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kalb
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Banerjee
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Mayer
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes
        </article-title>
        <source>
         AIDS Res Hum Retroviruses
        </source>
        <year>
         1993
        </year>
        <volume>
         9
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         91
        </fpage>
        <lpage>
         98
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/aid.1993.9.91
        </pub-id>
        <pub-id pub-id-type="pmid">
         8427717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paton
          </surname>
          <given-names>
           NI
          </given-names>
         </name>
         <name>
          <surname>
           Aboulhab
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks
        </article-title>
        <source>
         HIV Med
        </source>
        <year>
         2005
        </year>
        <volume>
         6
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         13
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1468-1293.2005.00259.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         15670247
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Maes
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Neyts
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Van Ranst
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <year>
         2004
        </year>
        <volume>
         323
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         264
        </fpage>
        <lpage>
         268
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2004.08.085
        </pub-id>
        <pub-id pub-id-type="pmid">
         15351731
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Bergeron
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Benjannet
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Erickson
          </surname>
          <given-names>
           BR
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
        </article-title>
        <source>
         Virol J
        </source>
        <year>
         2005
        </year>
        <volume>
         2
        </volume>
        <fpage>
         69
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1743-422X-2-69
        </pub-id>
        <pub-id pub-id-type="pmid">
         16115318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Rysman
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Verbeeck
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Van Ranst
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2009
        </year>
        <volume>
         53
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         3416
        </fpage>
        <lpage>
         3421
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.01509-08
        </pub-id>
        <pub-id pub-id-type="pmid">
         19506054
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Blazar
          </surname>
          <given-names>
           BR
          </given-names>
         </name>
         <name>
          <surname>
           Whitley
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <name>
          <surname>
           Kitabchi
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Tsai
          </surname>
          <given-names>
           MY
          </given-names>
         </name>
         <name>
          <surname>
           Santiago
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           White
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance
        </article-title>
        <source>
         Diabetes
        </source>
        <year>
         1984
        </year>
        <volume>
         33
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         1133
        </fpage>
        <lpage>
         1137
        </lpage>
        <pub-id pub-id-type="doi">
         10.2337/diabetes.33.12.1133
        </pub-id>
        <pub-id pub-id-type="pmid">
         6094290
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           GD
          </given-names>
         </name>
         <name>
          <surname>
           Amos
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Mahler
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Peters
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of chloroquine on insulin and glucose homoeostasis in normal subjects and patients with non-insulin-dependent diabetes mellitus
        </article-title>
        <source>
         Br Med J (Clin Res Ed)
        </source>
        <year>
         1987
        </year>
        <volume>
         294
        </volume>
        <issue>
         6570
        </issue>
        <fpage>
         465
        </fpage>
        <lpage>
         467
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/bmj.294.6570.465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Quatraro
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Consoli
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Magno
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Caretta
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Nardozza
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ceriello
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug?
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <year>
         1990
        </year>
        <volume>
         112
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         678
        </fpage>
        <lpage>
         681
        </lpage>
        <pub-id pub-id-type="pmid">
         2110430
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gerstein
          </surname>
          <given-names>
           HC
          </given-names>
         </name>
         <name>
          <surname>
           Thorpe
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <name>
          <surname>
           Haynes
          </surname>
          <given-names>
           RB
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas—a randomized trial
        </article-title>
        <source>
         Diabetes Res Clin Pract
        </source>
        <year>
         2002
        </year>
        <volume>
         55
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         209
        </fpage>
        <lpage>
         219
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0168-8227(01)00325-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         11850097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Emami
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Pasutto
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
         <name>
          <surname>
           Mercer
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Jamali
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats
        </article-title>
        <source>
         Life Sci
        </source>
        <year>
         1999
        </year>
        <volume>
         64
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         325
        </fpage>
        <lpage>
         335
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0024-3205(98)00568-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         10072192
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Powrie
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           GD
          </given-names>
         </name>
         <name>
          <surname>
           Shojaee-Moradie
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Sonksen
          </surname>
          <given-names>
           PH
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus
        </article-title>
        <source>
         Am J Physiol
        </source>
        <year>
         1991
        </year>
        <volume>
         260
        </volume>
        <issue>
         6 Pt 1
        </issue>
        <fpage>
         E897
        </fpage>
        <lpage>
         E904
        </lpage>
        <pub-id pub-id-type="pmid">
         2058666
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shojania
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Koehler
          </surname>
          <given-names>
           BE
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis
        </article-title>
        <source>
         J Rheumatol
        </source>
        <year>
         1999
        </year>
        <volume>
         26
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         195
        </fpage>
        <lpage>
         196
        </lpage>
        <pub-id pub-id-type="pmid">
         9918262
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Penn
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Schott
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Toledo
          </surname>
          <given-names>
           FG
          </given-names>
         </name>
         <name>
          <surname>
           Kuller
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus
        </article-title>
        <source>
         J Rheumatol
        </source>
        <year>
         2010
        </year>
        <volume>
         37
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         1136
        </fpage>
        <lpage>
         1142
        </lpage>
        <pub-id pub-id-type="doi">
         10.3899/jrheum.090994
        </pub-id>
        <pub-id pub-id-type="pmid">
         20436082
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wasko
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Hubert
          </surname>
          <given-names>
           HB
          </given-names>
         </name>
         <name>
          <surname>
           Lingala
          </surname>
          <given-names>
           VB
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Luggen
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Fries
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2007
        </year>
        <volume>
         298
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         187
        </fpage>
        <lpage>
         193
        </lpage>
        <pub-id pub-id-type="doi">
         10.1001/jama.298.2.187
        </pub-id>
        <pub-id pub-id-type="pmid">
         17622600
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rekedal
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
         <name>
          <surname>
           Massarotti
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Garg
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Bhatia
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Gleeson
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2010
        </year>
        <volume>
         62
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         3569
        </fpage>
        <lpage>
         3573
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/art.27703
        </pub-id>
        <pub-id pub-id-type="pmid">
         20722019
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wallace
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Metzger
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Turnbull
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Kern
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1990
        </year>
        <volume>
         89
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         322
        </fpage>
        <lpage>
         326
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0002-9343(90)90345-E
        </pub-id>
        <pub-id pub-id-type="pmid">
         2393036
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hodis
          </surname>
          <given-names>
           HN
          </given-names>
         </name>
         <name>
          <surname>
           Quismorio
          </surname>
          <given-names>
           FP
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Wickham
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Blankenhorn
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
        </person-group>
        <article-title>
         The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus
        </article-title>
        <source>
         J Rheumatol
        </source>
        <year>
         1993
        </year>
        <volume>
         20
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         661
        </fpage>
        <lpage>
         665
        </lpage>
        <pub-id pub-id-type="pmid">
         8496861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munro
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Morrison
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           McDonald
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
         <name>
          <surname>
           Hunter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Madhok
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Capell
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis
        </article-title>
        <source>
         Ann Rheum Dis
        </source>
        <year>
         1997
        </year>
        <volume>
         56
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         374
        </fpage>
        <lpage>
         377
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/ard.56.6.374
        </pub-id>
        <pub-id pub-id-type="pmid">
         9227167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rahman
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Gladman
          </surname>
          <given-names>
           DD
          </given-names>
         </name>
         <name>
          <surname>
           Urowitz
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hallett
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Bruce
          </surname>
          <given-names>
           IN
          </given-names>
         </name>
        </person-group>
        <article-title>
         The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs
        </article-title>
        <source>
         J Rheumatol
        </source>
        <year>
         1999
        </year>
        <volume>
         26
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         325
        </fpage>
        <lpage>
         330
        </lpage>
        <pub-id pub-id-type="pmid">
         9972966
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           EK
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Tomlinson
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         2000
        </year>
        <volume>
         9
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         413
        </fpage>
        <lpage>
         416
        </lpage>
        <pub-id pub-id-type="doi">
         10.1191/096120300678828541
        </pub-id>
        <pub-id pub-id-type="pmid">
         10981644
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bengtsson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Andersson
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Edvinsson
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Edvinsson
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Sturfelt
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Nived
          </surname>
          <given-names>
           O
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of medication on microvascular vasodilatation in patients with systemic lupus erythematosus
        </article-title>
        <source>
         Basic Clin Pharmacol Toxicol
        </source>
        <year>
         2010
        </year>
        <volume>
         107
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         919
        </fpage>
        <lpage>
         924
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1742-7843.2010.00604.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         20560926
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Bobba
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Shariati-Sarabi
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Gladman
          </surname>
          <given-names>
           DD
          </given-names>
         </name>
         <name>
          <surname>
           Urowitz
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2010
        </year>
        <volume>
         62
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         863
        </fpage>
        <lpage>
         868
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/art.27289
        </pub-id>
        <pub-id pub-id-type="pmid">
         20131232
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tanay
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Leibovitz
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Frayman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Zimlichman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Shargorodsky
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Gavish
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment
        </article-title>
        <source>
         Ann NY Acad Sci
        </source>
        <year>
         2007
        </year>
        <volume>
         1108
        </volume>
        <fpage>
         24
        </fpage>
        <lpage>
         34
        </lpage>
        <pub-id pub-id-type="doi">
         10.1196/annals.1422.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         17893967
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Charnley
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty
        </article-title>
        <source>
         Clin Orthop Relat Res
        </source>
        <year>
         1979
        </year>
        <volume>
         144
        </volume>
        <fpage>
         174
        </fpage>
        <lpage>
         177
        </lpage>
        <pub-id pub-id-type="pmid">
         535221
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nosal
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Jancinova
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Petrikova
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibits stimulated platelets at the arachidonic acid pathway
        </article-title>
        <source>
         Thromb Res
        </source>
        <year>
         1995
        </year>
        <volume>
         77
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         531
        </fpage>
        <lpage>
         542
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0049-3848(95)00028-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         7624839
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Petri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective
        </article-title>
        <source>
         Scand J Rheumatol
        </source>
        <year>
         1996
        </year>
        <volume>
         25
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         191
        </fpage>
        <lpage>
         193
        </lpage>
        <pub-id pub-id-type="doi">
         10.3109/03009749609069986
        </pub-id>
        <pub-id pub-id-type="pmid">
         8792794
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tektonidou
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Laskari
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Panagiotakos
          </surname>
          <given-names>
           DB
          </given-names>
         </name>
         <name>
          <surname>
           Moutsopoulos
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2009
        </year>
        <volume>
         61
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         29
        </fpage>
        <lpage>
         36
        </lpage>
        <pub-id pub-id-type="pmid">
         19116963
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belizna
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Richard
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Thuillez
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Levesque
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Shoenfeld
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Insights into atherosclerosis therapy in antiphospholipid syndrome
        </article-title>
        <source>
         Autoimmun Rev
        </source>
        <year>
         2007
        </year>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         46
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.autrev.2007.06.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         17967725
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Erkan
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Yazici
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Peterson
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Sammaritano
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lockshin
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome
        </article-title>
        <source>
         Rheumatology (Oxford)
        </source>
        <year>
         2002
        </year>
        <volume>
         41
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         924
        </fpage>
        <lpage>
         929
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/rheumatology/41.8.924
        </pub-id>
        <pub-id pub-id-type="pmid">
         12154210
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR63">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Pierangeli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Barker
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Harris
          </surname>
          <given-names>
           EN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice
        </article-title>
        <source>
         Circulation
        </source>
        <year>
         1997
        </year>
        <volume>
         96
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         4380
        </fpage>
        <lpage>
         4384
        </lpage>
        <pub-id pub-id-type="pmid">
         9416907
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR64">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Espinola
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         <name>
          <surname>
           Pierangeli
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Gharavi
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Harris
          </surname>
          <given-names>
           EN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies
        </article-title>
        <source>
         Thromb Haemost
        </source>
        <year>
         2002
        </year>
        <volume>
         87
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         518
        </fpage>
        <lpage>
         522
        </lpage>
        <pub-id pub-id-type="pmid">
         11916085
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR65">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rand
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           XX
          </given-names>
         </name>
         <name>
          <surname>
           Quinn
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Ashton
          </surname>
          <given-names>
           AW
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           PP
          </given-names>
         </name>
         <name>
          <surname>
           Hathcock
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug
        </article-title>
        <source>
         Blood
        </source>
        <year>
         2010
        </year>
        <volume>
         115
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         2292
        </fpage>
        <lpage>
         2299
        </lpage>
        <pub-id pub-id-type="doi">
         10.1182/blood-2009-04-213520
        </pub-id>
        <pub-id pub-id-type="pmid">
         19965621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR66">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rand
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           XX
          </given-names>
         </name>
         <name>
          <surname>
           Quinn
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           PP
          </given-names>
         </name>
         <name>
          <surname>
           Hathcock
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Taatjes
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers
        </article-title>
        <source>
         Blood
        </source>
        <year>
         2008
        </year>
        <volume>
         112
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         1687
        </fpage>
        <lpage>
         1695
        </lpage>
        <pub-id pub-id-type="doi">
         10.1182/blood-2008-03-144204
        </pub-id>
        <pub-id pub-id-type="pmid">
         18577708
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR67">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Geser
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Brubaker
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Draper
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of a malaria suppression program on the incidence of African Burkitt’s lymphoma
        </article-title>
        <source>
         Am J Epidemiol
        </source>
        <year>
         1989
        </year>
        <volume>
         129
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         740
        </fpage>
        <lpage>
         752
        </lpage>
        <pub-id pub-id-type="pmid">
         2923122
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR68">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maclean
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Dorsey
          </surname>
          <given-names>
           FC
          </given-names>
         </name>
         <name>
          <surname>
           Cleveland
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Kastan
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         2008
        </year>
        <volume>
         118
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         79
        </fpage>
        <lpage>
         88
        </lpage>
        <pub-id pub-id-type="doi">
         10.1172/JCI33700
        </pub-id>
        <pub-id pub-id-type="pmid">
         18097482
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR69">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lagneaux
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Delforge
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Carlier
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Massy
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Bernier
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Bron
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors
        </article-title>
        <source>
         Br J Haematol
        </source>
        <year>
         2001
        </year>
        <volume>
         112
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         344
        </fpage>
        <lpage>
         352
        </lpage>
        <pub-id pub-id-type="doi">
         10.1046/j.1365-2141.2001.02553.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         11167827
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR70">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lagneaux
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Delforge
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dejeneffe
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Massy
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Bernier
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Bron
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio
        </article-title>
        <source>
         Leuk Lymphoma
        </source>
        <year>
         2002
        </year>
        <volume>
         43
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         1087
        </fpage>
        <lpage>
         1095
        </lpage>
        <pub-id pub-id-type="pmid">
         12148891
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR71">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mansilla
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Marin
          </surname>
          <given-names>
           GH
          </given-names>
         </name>
         <name>
          <surname>
           Nunez
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Drago
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Sturla
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Mertz
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The lysosomotropic agent, hydroxychloroquine, delivered in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro
        </article-title>
        <source>
         Cancer Biother Radiopharm
        </source>
        <year>
         2010
        </year>
        <volume>
         25
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         97
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/cbr.2009.0655
        </pub-id>
        <pub-id pub-id-type="pmid">
         20187802
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR72">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           PD
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           YL
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           XQ
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Mao
          </surname>
          <given-names>
           YQ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cell growth inhibition, G2/M cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Bcap-37
        </article-title>
        <source>
         Cell Physiol Biochem
        </source>
        <year>
         2008
        </year>
        <volume>
         22
        </volume>
        <issue>
         5–6
        </issue>
        <fpage>
         431
        </fpage>
        <lpage>
         440
        </lpage>
        <pub-id pub-id-type="doi">
         10.1159/000185488
        </pub-id>
        <pub-id pub-id-type="pmid">
         19088425
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR73">
       <label>
        73.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rahim
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Strobl
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells
        </article-title>
        <source>
         Anticancer Drugs
        </source>
        <year>
         2009
        </year>
        <volume>
         20
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         736
        </fpage>
        <lpage>
         745
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/CAD.0b013e32832f4e50
        </pub-id>
        <pub-id pub-id-type="pmid">
         19584707
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR74">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           McCracken
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Strobl
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Control of mammary tumor cell growth in vitro by novel cell differentiation and apoptosis agents
        </article-title>
        <source>
         Breast Cancer Res Treat
        </source>
        <year>
         2002
        </year>
        <volume>
         75
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         107
        </fpage>
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="doi">
         10.1023/A:1019698807564
        </pub-id>
        <pub-id pub-id-type="pmid">
         12243503
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR75">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           YL
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Mao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Chloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis
        </article-title>
        <source>
         Cancer Invest
        </source>
        <year>
         2009
        </year>
        <volume>
         27
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         286
        </fpage>
        <lpage>
         292
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/07357900802427927
        </pub-id>
        <pub-id pub-id-type="pmid">
         19194831
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR76">
       <label>
        76.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sasaki
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Tsuno
          </surname>
          <given-names>
           NH
          </given-names>
         </name>
         <name>
          <surname>
           Sunami
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Tsurita
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Kawai
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Okaji
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells
        </article-title>
        <source>
         BMC Cancer
        </source>
        <year>
         2010
        </year>
        <volume>
         10
        </volume>
        <fpage>
         370
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1471-2407-10-370
        </pub-id>
        <pub-id pub-id-type="pmid">
         20630104
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR77">
       <label>
        77.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Miao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibits cell growth and induces cell death in A549 lung cancer cells
        </article-title>
        <source>
         Bioorg Med Chem
        </source>
        <year>
         2006
        </year>
        <volume>
         14
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         3218
        </fpage>
        <lpage>
         3222
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bmc.2005.12.035
        </pub-id>
        <pub-id pub-id-type="pmid">
         16413786
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR78">
       <label>
        78.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sotelo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Briceno
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Lopez-Gonzalez
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <year>
         2006
        </year>
        <volume>
         144
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         337
        </fpage>
        <lpage>
         343
        </lpage>
        <pub-id pub-id-type="pmid">
         16520474
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR79">
       <label>
        79.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Solomon
          </surname>
          <given-names>
           VR
          </given-names>
         </name>
         <name>
          <surname>
           Ulibarri
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine
        </article-title>
        <source>
         Bioorg Med Chem
        </source>
        <year>
         2008
        </year>
        <volume>
         16
        </volume>
        <issue>
         17
        </issue>
        <fpage>
         7888
        </fpage>
        <lpage>
         7893
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bmc.2008.07.076
        </pub-id>
        <pub-id pub-id-type="pmid">
         18691894
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR80">
       <label>
        80.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Solomon
          </surname>
          <given-names>
           VR
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies
        </article-title>
        <source>
         Eur J Pharmacol
        </source>
        <year>
         2009
        </year>
        <volume>
         625
        </volume>
        <issue>
         1–3
        </issue>
        <fpage>
         220
        </fpage>
        <lpage>
         233
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ejphar.2009.06.063
        </pub-id>
        <pub-id pub-id-type="pmid">
         19836374
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR81">
       <label>
        81.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schultz
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Gilman
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
        </person-group>
        <article-title>
         The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease
        </article-title>
        <source>
         Leuk Lymphoma
        </source>
        <year>
         1997
        </year>
        <volume>
         24
        </volume>
        <issue>
         3–4
        </issue>
        <fpage>
         201
        </fpage>
        <lpage>
         210
        </lpage>
        <pub-id pub-id-type="pmid">
         9156650
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR82">
       <label>
        82.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khoury
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Trinkaus
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Adkins
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Vij
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation
        </article-title>
        <source>
         Biol Blood Marrow Transplant
        </source>
        <year>
         2003
        </year>
        <volume>
         9
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         714
        </fpage>
        <lpage>
         721
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbmt.2003.08.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         14652855
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR83">
       <label>
        83.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fong
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Trinkaus
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Adkins
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Vij
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Devine
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Tomasson
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation
        </article-title>
        <source>
         Biol Blood Marrow Transplant
        </source>
        <year>
         2007
        </year>
        <volume>
         13
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         1201
        </fpage>
        <lpage>
         1206
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbmt.2007.06.012
        </pub-id>
        <pub-id pub-id-type="pmid">
         17889357
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR84">
       <label>
        84.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           PH
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           YF
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Wann
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           HT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kikuchi–Fujimoto disease: an amazing response to hydroxychloroquine
        </article-title>
        <source>
         Eur J Pediatr
        </source>
        <year>
         2010
        </year>
        <volume>
         169
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         1557
        </fpage>
        <lpage>
         1559
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00431-010-1256-x
        </pub-id>
        <pub-id pub-id-type="pmid">
         20645108
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR85">
       <label>
        85.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rezai
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kuchipudi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Chundi
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Ariga
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Loew
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sha
          </surname>
          <given-names>
           BE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kikuchi–Fujimoto disease: hydroxychloroquine as a treatment
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         39
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         e124
        </fpage>
        <lpage>
         e126
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/426144
        </pub-id>
        <pub-id pub-id-type="pmid">
         15578393
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR86">
       <label>
        86.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeSimone
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name>
          <surname>
           Brilliant
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
         <name>
          <surname>
           Basile
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           NH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Granulomatous infiltration of the talus and abnormal vitamin D and calcium metabolism in a patient with sarcoidosis: successful treatment with hydroxychloroquine
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1989
        </year>
        <volume>
         87
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         694
        </fpage>
        <lpage>
         696
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0002-9343(89)80409-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         2589406
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR87">
       <label>
        87.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O’Leary
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lohnes
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Cohanim
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Yendt
          </surname>
          <given-names>
           ER
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effects of chloroquine on serum 1, 25-dihydroxyvitamin D and calcium metabolism in sarcoidosis
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         1986
        </year>
        <volume>
         315
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         727
        </fpage>
        <lpage>
         730
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJM198609183151203
        </pub-id>
        <pub-id pub-id-type="pmid">
         3755800
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR88">
       <label>
        88.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shimoni
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hershcovici
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Mekhmandarov
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Maor-Kendler
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Beigel
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Skeletal sarcoidosis: successful treatment with hydroxychloroquine
        </article-title>
        <source>
         Isr Med Assoc J
        </source>
        <year>
         2000
        </year>
        <volume>
         2
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         558
        </fpage>
        <lpage>
         559
        </lpage>
        <pub-id pub-id-type="pmid">
         10979339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR89">
       <label>
        89.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hirshoren
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Eliashar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Weinberger
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine for subglottic stenosis: a novel therapy in the battle for air
        </article-title>
        <source>
         Laryngoscope
        </source>
        <year>
         2010
        </year>
        <volume>
         120
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         743
        </fpage>
        <lpage>
         744
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/lary.20848
        </pub-id>
        <pub-id pub-id-type="pmid">
         20155800
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR90">
       <label>
        90.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hussain
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Scelsa
          </surname>
          <given-names>
           SN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sensory neuronopathy with Ro antibodies: response to combination immunosuppression
        </article-title>
        <source>
         J Clin Neuromuscul Dis
        </source>
        <year>
         2010
        </year>
        <volume>
         11
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         120
        </fpage>
        <lpage>
         123
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/CND.0b013e3181d05980
        </pub-id>
        <pub-id pub-id-type="pmid">
         20215984
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR91">
       <label>
        91.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Izmirly PM
          </surname>
          <given-names>
           CP
          </given-names>
         </name>
         <name>
          <surname>
           Kim MY
          </surname>
          <given-names>
           DF
          </given-names>
         </name>
         <name>
          <surname>
           Llanos
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           C-C
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine and prevention of anti-SSA/Ro associated cardiac disease in mothers with a previous child with Neonatal Lupus
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2010
        </year>
        <volume>
         62
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         S306
        </fpage>
       </element-citation>
      </ref>
      <ref id="CR92">
       <label>
        92.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Izmirly
          </surname>
          <given-names>
           PM
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           MY
          </given-names>
         </name>
         <name>
          <surname>
           Llanos
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Le
          </surname>
          <given-names>
           PU
          </given-names>
         </name>
         <name>
          <surname>
           Guerra
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Askanase
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine
        </article-title>
        <source>
         Ann Rheum Dis
        </source>
        <year>
         2010
        </year>
        <pub-id pub-id-type="pmid">
         20447951
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR93">
       <label>
        93.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iyamu
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Perdew
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Woods
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Growth inhibitory and differentiation effects of chloroquine and its analogue on human leukemic cells potentiate fetal hemoglobin production by targeting the polyamine pathway
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         2009
        </year>
        <volume>
         77
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         1021
        </fpage>
        <lpage>
         1028
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bcp.2008.11.016
        </pub-id>
        <pub-id pub-id-type="pmid">
         19073155
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR94">
       <label>
        94.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           WR
          </given-names>
         </name>
         <name>
          <surname>
           White
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial drug toxicity: a review
        </article-title>
        <source>
         Drug Saf
        </source>
        <year>
         2004
        </year>
        <volume>
         27
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         25
        </fpage>
        <lpage>
         61
        </lpage>
        <pub-id pub-id-type="doi">
         10.2165/00002018-200427010-00003
        </pub-id>
        <pub-id pub-id-type="pmid">
         14720085
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR95">
       <label>
        95.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hochstein
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Glucose-6-phosphate dehydrogenase deficiency: mechanisms of drug-induced hemolysis
        </article-title>
        <source>
         Exp Eye Res
        </source>
        <year>
         1971
        </year>
        <volume>
         11
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         389
        </fpage>
        <lpage>
         395
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0014-4835(71)80051-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         4941679
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR96">
       <label>
        96.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kleinegger
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
         <name>
          <surname>
           Hammond
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
         <name>
          <surname>
           Finkelstein
          </surname>
          <given-names>
           MW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Oral mucosal hyperpigmentation secondary to antimalarial drug therapy
        </article-title>
        <source>
         Oral Surg Oral Med Oral Pathol Oral Radiol Endod
        </source>
        <year>
         2000
        </year>
        <volume>
         90
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         189
        </fpage>
        <lpage>
         194
        </lpage>
        <pub-id pub-id-type="doi">
         10.1067/moe.2000.106340
        </pub-id>
        <pub-id pub-id-type="pmid">
         10936838
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR97">
       <label>
        97.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bortoli
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Santiago
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine ototoxicity
        </article-title>
        <source>
         Clin Rheumatol
        </source>
        <year>
         2007
        </year>
        <volume>
         26
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1809
        </fpage>
        <lpage>
         1810
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s10067-007-0662-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         17594118
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR98">
       <label>
        98.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tehrani
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Ostrowski
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Hariman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Jay
          </surname>
          <given-names>
           WM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular toxicity of hydroxychloroquine
        </article-title>
        <source>
         Semin Ophthalmol
        </source>
        <year>
         2008
        </year>
        <volume>
         23
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         201
        </fpage>
        <lpage>
         209
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/08820530802049962
        </pub-id>
        <pub-id pub-id-type="pmid">
         18432546
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR99">
       <label>
        99.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wolfe
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Marmor
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus
        </article-title>
        <source>
         Arthritis Care Res (Hoboken)
        </source>
        <year>
         2010
        </year>
        <volume>
         62
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         775
        </fpage>
        <lpage>
         784
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/acr.20133
        </pub-id>
        <pub-id pub-id-type="pmid">
         20535788
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR100">
       <label>
        100.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Costedoat-Chalumeau
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Hulot
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Amoura
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Delcourt
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Maisonobe
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Dorent
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cardiomyopathy related to antimalarial therapy with illustrative case report
        </article-title>
        <source>
         Cardiology
        </source>
        <year>
         2007
        </year>
        <volume>
         107
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         73
        </fpage>
        <lpage>
         80
        </lpage>
        <pub-id pub-id-type="doi">
         10.1159/000094079
        </pub-id>
        <pub-id pub-id-type="pmid">
         16804295
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR101">
       <label>
        101.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keating
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Bhatia
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Amin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Sinak
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           WD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction
        </article-title>
        <source>
         J Am Soc Echocardiogr
        </source>
        <year>
         2005
        </year>
        <volume>
         18
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         981
        </fpage>
        <pub-id pub-id-type="pmid">
         16153529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR102">
       <label>
        102.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kwon
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <name>
          <surname>
           Kleiner
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ishida
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Godown
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ciafaloni
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Looney
          </surname>
          <given-names>
           RJ
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine-induced myopathy
        </article-title>
        <source>
         J Clin Rheumatol
        </source>
        <year>
         2010
        </year>
        <volume>
         16
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         28
        </fpage>
        <lpage>
         31
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/RHU.0b013e3181c47ec8
        </pub-id>
        <pub-id pub-id-type="pmid">
         20051753
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR103">
       <label>
        103.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siddiqui
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <name>
          <surname>
           Huberfeld
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
         <name>
          <surname>
           Weidenheim
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Einberg
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Efferen
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine-induced toxic myopathy causing respiratory failure
        </article-title>
        <source>
         Chest
        </source>
        <year>
         2007
        </year>
        <volume>
         131
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         588
        </fpage>
        <lpage>
         590
        </lpage>
        <pub-id pub-id-type="doi">
         10.1378/chest.06-1146
        </pub-id>
        <pub-id pub-id-type="pmid">
         17296665
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR104">
       <label>
        104.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Estes
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Ewing-Wilson
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Mitsumoto
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Hanson
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Shirey
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Chloroquine neuromyotoxicity. Clinical and pathologic perspective
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1987
        </year>
        <volume>
         82
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         447
        </fpage>
        <lpage>
         455
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0002-9343(87)90444-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         3826099
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR105">
       <label>
        105.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Costedoat-Chalumeau
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Amoura
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Aymard
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Le
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <name>
          <surname>
           Wechsler
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Vauthier
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evidence of transplacental passage of hydroxychloroquine in humans
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2002
        </year>
        <volume>
         46
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         1123
        </fpage>
        <lpage>
         1124
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/art.10150
        </pub-id>
        <pub-id pub-id-type="pmid">
         11953993
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR106">
       <label>
        106.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Clowse
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Magder
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Witter
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Petri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine in lupus pregnancy
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2006
        </year>
        <volume>
         54
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         3640
        </fpage>
        <lpage>
         3647
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/art.22159
        </pub-id>
        <pub-id pub-id-type="pmid">
         17075810
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR107">
       <label>
        107.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Levy
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Buskila
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Gladman
          </surname>
          <given-names>
           DD
          </given-names>
         </name>
         <name>
          <surname>
           Urowitz
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Koren
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pregnancy outcome following first trimester exposure to chloroquine
        </article-title>
        <source>
         Am J Perinatol
        </source>
        <year>
         1991
        </year>
        <volume>
         8
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         174
        </fpage>
        <lpage>
         178
        </lpage>
        <pub-id pub-id-type="doi">
         10.1055/s-2007-999371
        </pub-id>
        <pub-id pub-id-type="pmid">
         2029276
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR108">
       <label>
        108.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klinger
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Morad
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Westall
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Laskin
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Spitzer
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Koren
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2001
        </year>
        <volume>
         358
        </volume>
        <issue>
         9284
        </issue>
        <fpage>
         813
        </fpage>
        <lpage>
         814
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(01)06004-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         11564493
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR109">
       <label>
        109.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Motta
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Tincani
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Faden
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Zinzini
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Lojacono
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Marchesi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation
        </article-title>
        <source>
         J Perinatol
        </source>
        <year>
         2005
        </year>
        <volume>
         25
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         86
        </fpage>
        <lpage>
         89
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/sj.jp.7211208
        </pub-id>
        <pub-id pub-id-type="pmid">
         15496869
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR110">
       <label>
        110.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Costedoat-Chalumeau
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Amoura
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Huong
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Lechat
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Piette
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature
        </article-title>
        <source>
         Autoimmun Rev
        </source>
        <year>
         2005
        </year>
        <volume>
         4
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         111
        </fpage>
        <lpage>
         115
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.autrev.2004.11.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         15722258
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR111">
       <label>
        111.
       </label>
       <mixed-citation publication-type="other">
        cdc.gov [online] [database on the Internet]. Available from:
        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/malaria/resources/pdf/treatmenttable73109.pdf">
         http://www.cdc.gov/malaria/resources/pdf/treatmenttable73109.pdf
        </ext-link>
        . Accessed 22 Nov 2010
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Interferon Cytokine Res
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Interferon Cytokine Res
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       jir
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Interferon &amp; Cytokine Research
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1079-9907
      </issn>
      <issn pub-type="epub">
       1557-7465
      </issn>
      <publisher>
       <publisher-name>
        Mary Ann Liebert, Inc.
       </publisher-name>
       <publisher-loc>
        140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25321315
      </article-id>
      <article-id pub-id-type="pmc">
       4350140
      </article-id>
      <article-id pub-id-type="publisher-id">
       10.1089/jir.2014.0038
      </article-id>
      <article-id pub-id-type="doi">
       10.1089/jir.2014.0038
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research Reports
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Hydroxychloroquine-Inhibited Dengue Virus Is Associated with Host Defense Machinery
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Li-Fong
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1,
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="fn1">
         <sup>
          *
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          You-Sheng
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2,
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="fn1">
         <sup>
          *
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          Nan-Chieh
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yu
         </surname>
         <given-names>
          Chia-Yi
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         <sup>
          4,
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="fn2">
         <sup>
          †
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tsai
         </surname>
         <given-names>
          Wei-Lun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff5">
         <sup>
          5
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          Jih-Jung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff6">
         <sup>
          6
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kubota
         </surname>
         <given-names>
          Toru
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff7">
         <sup>
          7
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Matsuoka
         </surname>
         <given-names>
          Mayumi
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff8">
         <sup>
          8
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          Siang-Ru
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Chih-Shiang
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          Ruo-Wei
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          Yi-Ling
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         <sup>
          4
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Chang
         </surname>
         <given-names>
          Tsung-Hsien
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2,
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff6">
         <sup>
          6
         </sup>
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         <sup>
          1
         </sup>
        </label>
        Division of Allergy, Immunology, and Rheumatology,
        <institution>
         Kaohsiung Veterans General Hospital
        </institution>
        , Kaohsiung,
        <country>
         Taiwan
        </country>
        .
       </aff>
       <aff id="aff2">
        <label>
         <sup>
          2
         </sup>
        </label>
        Department of Medical Education and Research,
        <institution>
         Kaohsiung Veterans General Hospital
        </institution>
        , Kaohsiung,
        <country>
         Taiwan
        </country>
        .
       </aff>
       <aff id="aff3">
        <label>
         <sup>
          3
         </sup>
        </label>
        Department of Family Medicine,
        <institution>
         Zuoying Branch of Kaohsiung Armed Forces General Hospital
        </institution>
        , Kaohsiung,
        <country>
         Taiwan
        </country>
        .
       </aff>
       <aff id="aff4">
        <label>
         <sup>
          4
         </sup>
        </label>
        <institution>
         Institute of Biomedical Sciences
        </institution>
        , Academia Sinica, Taipei,
        <country>
         Taiwan
        </country>
        .
       </aff>
       <aff id="aff5">
        <label>
         <sup>
          5
         </sup>
        </label>
        Division of Gastroenterology, Department of Internal Medicine,
        <institution>
         Kaohsiung Veterans General Hospital
        </institution>
        , Kaohsiung,
        <country>
         Taiwan
        </country>
        .
       </aff>
       <aff id="aff6">
        <label>
         <sup>
          6
         </sup>
        </label>
        Graduate Institute of Pharmaceutical Technology,
        <institution>
         Tajen University
        </institution>
        , Pingtung,
        <country>
         Taiwan
        </country>
        .
       </aff>
       <aff id="aff7">
        <label>
         <sup>
          7
         </sup>
        </label>
        Department of Virology III,
        <institution>
         National Institute of Infectious Diseases
        </institution>
        , Tokyo,
        <country>
         Japan
        </country>
        .
       </aff>
       <aff id="aff8">
        <label>
         <sup>
          8
         </sup>
        </label>
        Department of Bacteriology II,
        <institution>
         National Institute of Infectious Diseases
        </institution>
        , Tokyo,
        <country>
         Japan
        </country>
        .
       </aff>
      </contrib-group>
      <author-notes>
       <fn fn-type="equal" id="fn1">
        <label>
         <sup>
          *
         </sup>
        </label>
        <p>
         These authors equally contributed to this work.
        </p>
       </fn>
       <fn fn-type="present-address" id="fn2">
        <label>
         <sup>
          †
         </sup>
        </label>
        <p>
         Present address: Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan City, Taiwan.
        </p>
       </fn>
       <corresp>
        <addr-line>
         Address correspondence to:
        </addr-line>
        <addr-line>
         <italic>
          Dr. Tsung-Hsien Chang
         </italic>
        </addr-line>
        <addr-line>
         <italic>
          Department of Medical Education and Research
         </italic>
        </addr-line>
        <institution>
         <italic>
          Kaohsiung Veterans General Hospital
         </italic>
        </institution>
        <addr-line>
         <italic>
          Kaohsiung 813
         </italic>
        </addr-line>
        <country>
         Taiwan
        </country>
        <break>
        </break>
        <italic>
         E-mail:
        </italic>
        <email xlink:href="mailto:changth@vghks.gov.tw">
         changth@vghks.gov.tw
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <day>
        01
       </day>
       <month>
        3
       </month>
       <year>
        2015
       </year>
       <!--string-date: March 2015-->
      </pub-date>
      <volume>
       35
      </volume>
      <issue>
       3
      </issue>
      <fpage>
       143
      </fpage>
      <lpage>
       156
      </lpage>
      <history>
       <date date-type="received">
        <day>
         18
        </day>
        <month>
         2
        </month>
        <year>
         2014
        </year>
        <!--string-date: Received 18 February 2014-->
       </date>
       <date date-type="accepted">
        <day>
         02
        </day>
        <month>
         8
        </month>
        <year>
         2014
        </year>
        <!--string-date: Accepted 2 August 2014-->
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright 2015, Mary Ann Liebert, Inc.
       </copyright-statement>
       <copyright-year>
        2015
       </copyright-year>
      </permissions>
      <self-uri content-type="pdf" xlink:href="jir.2014.0038.pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <p>
        Hydroxychloroquine (HCQ) is an antimalarial drug also used in treating autoimmune diseases. Its antiviral activity was demonstrated in restricting HIV infection
        <italic>
         in vitro
        </italic>
        ; however, the clinical implications remain controversial. Infection with dengue virus (DENV) is a global public health problem, and we lack an antiviral drug for DENV. Here, we evaluated the anti-DENV potential of treatment with HCQ. Immunofluorescence assays demonstrated that HCQ could inhibit DENV serotype 1–4 infection
        <italic>
         in vitro
        </italic>
        . RT-qPCR analysis of HCQ-treated cells showed induced expression of interferon (IFN)-related antiviral proteins and certain inflammatory cytokines. Mechanistic study suggested that HCQ activated the innate immune signaling pathways of IFN-β, AP-1, and NFκB. Knocking down mitochondrial antiviral signaling protein (MAVS), inhibiting TANK binding kinase 1 (TBK1)/inhibitor-κB kinase ɛ (IKKɛ), and blocking type I IFN receptor reduced the efficiency of HCQ against DENV-2 infection. Furthermore, HCQ significantly induced cellular production of reactive oxygen species (ROS), which was involved in the host defense system. Suppression of ROS production attenuated the innate immune activation and anti-DENV-2 effect of HCQ. In summary, HCQ triggers the host defense machinery by inducing ROS- and MAVS-mediated innate immune activation against DENV infection and may be a candidate drug for DENV infection.
       </p>
      </abstract>
      <counts>
       <fig-count count="6">
       </fig-count>
       <table-count count="2">
       </table-count>
       <ref-count count="68">
       </ref-count>
       <page-count count="14">
       </page-count>
      </counts>
     </article-meta>
    </front>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Mayo Clin Proc
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Mayo Clin. Proc
      </journal-id>
      <journal-title-group>
       <journal-title>
        Mayo Clinic Proceedings
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0025-6196
      </issn>
      <issn pub-type="epub">
       1942-5546
      </issn>
      <publisher>
       <publisher-name>
        Mayo Foundation for Medical Education and Research
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7141471
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0025-6196(20)30313-X
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.mayocp.2020.03.024
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Giudicessi
         </surname>
         <given-names>
          John R.
         </given-names>
        </name>
        <degrees>
         MD, PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Noseworthy
         </surname>
         <given-names>
          Peter A.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Friedman
         </surname>
         <given-names>
          Paul A.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Ackerman
         </surname>
         <given-names>
          Michael J.
         </given-names>
        </name>
        <degrees>
         MD, PhD
        </degrees>
        <email>
         ackerman.michael@mayo.edu
        </email>
        <email>
         @MJAckermanMDPhD
        </email>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Department of Cardiovascular Medicine, Clinician-Investigator Training Program, Mayo Clinic, Rochester, MN
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        <bold>
         Correspondence:
        </bold>
        Address to Michael J. Ackerman, MD, PhD, Mayo Clinic Windland Smith Rice Genetic Heart Rhythm Clinic, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
        <email>
         ackerman.michael@mayo.edu
        </email>
        <email>
         @MJAckermanMDPhD
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        7
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        7
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <permissions>
       <copyright-statement>
        © 2020 Mayo Foundation for Medical Education and Research.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <p>
        As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the “off-label” repurposing of drugs such as hydroxychloroquine and lopinavir/ritonavir, which has the potential for unwanted QT-interval prolongation and a risk of drug-induced sudden cardiac death. With the possibility that a considerable proportion of the world’s population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Abbreviations and Acronyms
       </title>
       <kwd>
        COVID-19, coronavirus disease 19
       </kwd>
       <kwd>
        DI-SCD, drug-induced sudden cardiac death
       </kwd>
       <kwd>
        DI-TdP, drug-induced torsades de pointes
       </kwd>
       <kwd>
        ECG, electrocardiogram
       </kwd>
       <kwd>
        FDA, Food and Drug Administration
       </kwd>
       <kwd>
        LQTS, long QT syndrome
       </kwd>
       <kwd>
        PPE, personal protective equipment
       </kwd>
       <kwd>
        SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p id="p0010">
     Since its emergence from the Wuhan province of China in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease 2019 (COVID-19) respiratory illness, has already claimed the lives of more than 20,000 individuals worldwide.
     <xref ref-type="bibr" rid="bib1">
      <sup>
       1
      </sup>
     </xref>
     <sup>
      ,
     </sup>
     <xref ref-type="bibr" rid="bib2">
      <sup>
       2
      </sup>
     </xref>
     With the number of COVID-19 cases and deaths increasing with each passing day, there is perhaps no more pressing need in medicine than to identify safe and efficacious therapies to prevent SARS-CoV-2 infections as well as to attenuate the severity of the resulting COVID-19 respiratory illness.
     <xref ref-type="bibr" rid="bib2">
      <sup>
       2
      </sup>
     </xref>
     Although there are no US Food and Drug Administration (FDA)–approved drugs to prevent or treat COVID-19, a number of promising novel (ie, remdesivir) and repurposed (ie, hydroxychloroquine, potentially together with azithromycin) pharmacological agents, reported to inhibit the growth of SARS-CoV-2 in vitro,
     <xref ref-type="bibr" rid="bib3">
      <sup>
       3
      </sup>
     </xref>
     <sup>
      ,
     </sup>
     <xref ref-type="bibr" rid="bib4">
      <sup>
       4
      </sup>
     </xref>
     are being evaluated in randomized clinical trials.
    </p>
    <p id="p0015">
     In advance of more definitive evidence, clinicians on the front lines of the pandemic have begun to use these medications under “off-label” or “compassionate-use” circumstances with anecdotal success.
     <xref ref-type="bibr" rid="bib5">
      <sup>
       5
      </sup>
     </xref>
     <sup>
      ,
     </sup>
     <xref ref-type="bibr" rid="bib6">
      <sup>
       6
      </sup>
     </xref>
     In light of (1) the need for this practice to continue in the absence of viable, evidence-based therapies and (2) the proclivity of many promising COVID-19 pharmacotherapies—specifically antimalarial agents such as hydroxychloroquine—to prolong the QTc, thereby increasing the risk of drug-induced torsades de pointes (DI-TdP) and drug induced-sudden cardiac death (DI-SCD), this document was assembled to help health care professionals safely use these medications and minimize concomitant risks.
    </p>
    <sec id="sec1">
     <title>
      Pharmacodynamics and QTc-Prolonging/Torsadogenic Potential of the Antimalarial Medications Chloroquine and Hydroxychloroquine
     </title>
     <p id="p0020">
      Chloroquine and its analogue hydroxychloroquine have been used for nearly 80 years as prophylactic pharmacotherapies for malaria. Although still used as antimalarial agents in parts of the world with chloroquine-sensitive
      <italic>
       Plasmodium falciparum
      </italic>
      protozoa, hydroxychloroquine has found new life as a disease-modifying antirheumatic drug for the management of conditions such as systemic lupus erythematosus and rheumatoid arthritis.
     </p>
     <p id="p0025">
      At the cellular level, these antimalarial drugs accumulate in intracellular vesicles such as endosomes and lysosomes where they are protonated, leading to increased vesicular pH.
      <xref ref-type="bibr" rid="bib7">
       <sup>
        7
       </sup>
      </xref>
      This process in turn inhibits the activity of the pH-dependent proteases involved in the intracellular processing of secretory proteins with a number of immunologic and nonimmunologic effects, including tumor necrosis factor α and interleukin 6.
      <xref ref-type="bibr" rid="bib7">
       <sup>
        7
       </sup>
      </xref>
      Collectively, a reduction in these secretory proteins is believed to result in (1) the accumulation of cytotoxic heme that poisons
      <italic>
       P falciparum
      </italic>
      protozoa and (2) modulation of immune cell behavior in a manner that attenuates inflammatory processes.
      <xref ref-type="bibr" rid="bib7">
       <sup>
        7
       </sup>
      </xref>
     </p>
     <p id="p0030">
      In addition, chloroquine and hydroxychloroquine possess antiviral properties in vitro.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib7">
       <sup>
        7
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib8">
       <sup>
        8
       </sup>
      </xref>
      Both chloroquine and hydroxychloroquine are believed to act on the entry and postentry stages of severe acute respiratory syndrome coronavirus and SARS-CoV-2 infection, likely via effects on endosomal pH and the resulting underglycosylation of angiotensin-converting enzyme 2 receptors that are required for viral entry.
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib8">
       <sup>
        8
       </sup>
      </xref>
     </p>
     <p id="p0035">
      Based on this in vitro data, it has been hypothesized that hydroxychloroquine, more so than chloroquine, may have therapeutic efficacy in the COVID-19 pandemic by (1) preventing SARS-CoV-2 infection by inhibiting angiotensin-converting enzyme 2–mediated viral entry (ie, preinfection prophylaxis) and (2) attenuating the postviral cytokine storm observed in severe COVID-19 cases via a multitude of immunomodulatory mechanisms (ie, treatment of active infection/postviral sequelae). Promising in vitro data
      <xref ref-type="bibr" rid="bib3">
       <sup>
        3
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib4">
       <sup>
        4
       </sup>
      </xref>
      as well as anecdotal in vivo evidence of therapeutic benefit
      <xref ref-type="bibr" rid="bib5">
       <sup>
        5
       </sup>
      </xref>
      have led many institutions, including Mayo Clinic, to consider the use of hydroxychloroquine as a first-line COVID-19 pharmacotherapy for the time being and spurred an array of clinical trials designed to assess the efficacy of repurposed hydroxychloroquine in both the prevention and treatment of COVID-19.
     </p>
     <p id="p0040">
      Although the collective safety profiles of chloroquine and hydroxychloroquine are relatively favorable, both drugs block the
      <italic>
       KCNH2-
      </italic>
      encoded HERG/K
      <sub>
       v
      </sub>
      11.1 potassium channel and potentially can prolong the QTc. In at-risk individuals, these so-called HERG blockers can precipitate DI-TdP or, worse, DI-SCD, especially with long-term use (
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      ). As a result, the number of DI-SCDs attributable to hydroxychloroquine in particular is not trivial (
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      ). With the theoretical possibility that a substantial proportion of the world population could receive hydroxychloroquine as first-line prophylaxis or treatment, including an estimated 3 million individuals with congenital long QT syndrome (LQTS), the number of hydroxychloroquine-mediated DI-SCDs could increase precipitously unless appropriate QTc monitoring algorithms are instituted. This risk of DI-SCD could be further amplified if multiple medications, each with their own QTc-prolonging/torsadogenic potential (ie, chloroquine/hydroxychloroquine plus azithromycin and/or lopinavir/ritonavir), are used in combination (
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      ).
      <table-wrap id="tbl1" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Torsadogenic Potential and Postmarketing Adverse Events Associated With Possible COVID-19 Repurposed Pharmacotherapies
         <xref ref-type="table-fn" rid="tbl1fna">
          a
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Possible COVID-19 therapy
          </th>
          <th>
           In vitro inhibition of SARS-CoV-2
          </th>
          <th>
           CredibleMeds classification
          </th>
          <th>
           VT/VF/TdP/LQTS in FAERS
           <xref ref-type="table-fn" rid="tbl1fnb">
            b
           </xref>
          </th>
          <th>
           Cardiac arrest in FAERS
           <xref ref-type="table-fn" rid="tbl1fnb">
            b
           </xref>
          </th>
          <th>
           References
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td colspan="6">
           Repurposed antimalarial agents
          </td>
         </tr>
         <tr>
          <td>
           Chloroquine
          </td>
          <td>
           Yes
          </td>
          <td>
           Known TdP risk
          </td>
          <td align="char">
           72
          </td>
          <td align="char">
           54
          </td>
          <td align="char">
           3, 9, 10
          </td>
         </tr>
         <tr>
          <td>
           Hydroxychloroquine
          </td>
          <td>
           Yes
          </td>
          <td>
           Known TdP risk
          </td>
          <td align="char">
           222
          </td>
          <td align="char">
           105
          </td>
          <td align="char">
           4, 11
          </td>
         </tr>
         <tr>
          <td colspan="6">
           Repurposed antiviral agents
          </td>
         </tr>
         <tr>
          <td>
           Lopinavir/ritonavir
          </td>
          <td>
           Unknown
           <xref ref-type="table-fn" rid="tbl1fnc">
            c
           </xref>
          </td>
          <td>
           Possible TdP risk
          </td>
          <td align="char">
           27
          </td>
          <td align="char">
           48
          </td>
          <td>
           12-14
          </td>
         </tr>
         <tr>
          <td colspan="6">
           Adjunctive agents
          </td>
         </tr>
         <tr>
          <td>
           Azithromycin
          </td>
          <td>
           Unknown
          </td>
          <td>
           Known TdP risk
          </td>
          <td align="char">
           396
          </td>
          <td align="char">
           251
          </td>
          <td>
           15, 16
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="tbl1fna">
         <label>
          a
         </label>
         <p id="ntpara0020">
          COVID-19 = coronavirus disease 2019; FAERS = US Food and Drug Administration Adverse Event Reporting System; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; TdP = torsades de pointes.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tbl1fnb">
         <label>
          b
         </label>
         <p id="ntpara0025">
          Adverse event reporting from postmarketing surveillance does not account for prescription volume and is often subjected to substantial bias from confounding variables, quality of reported data, duplication, and underreporting of events.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tbl1fnc">
         <label>
          c
         </label>
         <p id="ntpara0030">
          Lopinavir/ritonavir has been found to inhibit other severe acute respiratory syndrome viruses in vitro. However, a recent randomized trial found no benefit in COVID-19.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
    </sec>
    <sec id="sec2">
     <title>
      Mitigating the Potential Risk of DI-TdP and DI-SCD Associated With Widespread Use of Chloroquine/Hydroxychloroquine in the COVID-19 Pandemic
     </title>
     <p id="p0045">
      Although some might argue that DI-SCDs in the setting of widespread chloroquine/hydroxychloroquine use represents acceptable “friendly fire” in the war on SARS-CoV-2/COVID-19, we believe that with the institution of a few simple and safe precautions, the risk of DI-TdP and DI-SCD can be mitigated. Ultimately, it comes down to identifying the small subset of individuals who, either secondary to an underlying genetic predisposition (such as congenital LQTS, which is present in 1 in 2000 people) and/or by virtue of the presence of multiple modifiable and nonmodifiable QTc risk factors (
      <xref ref-type="table" rid="tbl2">
       Table 2
      </xref>
      ),
      <xref ref-type="bibr" rid="bib17">
       <sup>
        17
       </sup>
      </xref>
      have excessive baseline QTc prolongation (QTc ≥500 ms) and/or have an inherent tendency for development of an exaggerated QTc response (ie, ΔQTc ≥60 ms) following exposure to medications with the adverse effect of potential QTc prolongation (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ). Although the percentage of individuals at risk is small, given the pandemic nature of COVID-19, in absolute terms the number of individuals potentially at risk for lethal adverse drug effects is large (at least 4000 individuals of the &gt;400,000 COVID-19–positive patients worldwide are expected to be at increased risk for DI-TdP/DI-SCD if treated with these medications). This issue would be especially true if these medications are adopted for postexposure prophylaxis.
      <table-wrap id="tbl2" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Modifiable and Nonmodifiable Risk Factors for Drug-Induced Long QT Syndrome/Torsades de Pointes
         <xref ref-type="table-fn" rid="tbl2fna">
          a
         </xref>
         <sup>
          ,
         </sup>
         <xref ref-type="table-fn" rid="tbl2fnb">
          b
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <tbody>
         <tr>
          <td>
           Modifiable risk factors
          </td>
         </tr>
         <tr>
          <td>
           Electrolyte disturbances
          </td>
         </tr>
         <tr>
          <td>
           Hypocalcemia (calcium &lt;4.65 mg/dL)
          </td>
         </tr>
         <tr>
          <td>
           Hypokalemia (potassium &lt;3.4 mmol/L)
          </td>
         </tr>
         <tr>
          <td>
           Hypomagnesemia (magnesium &lt;1.7 mg/dL)
          </td>
         </tr>
         <tr>
          <td>
           QT-prolonging medication polypharmacy
          </td>
         </tr>
         <tr>
          <td>
           Concurrent use of ≥1 medication from
           <ext-link ext-link-type="uri" id="intref0030" xlink:href="http://www.crediblemeds.com">
            www.crediblemeds.com
           </ext-link>
          </td>
         </tr>
         <tr>
          <td>
           Nonmodifiable risk factors
          </td>
         </tr>
         <tr>
          <td>
           Common diagnoses
          </td>
         </tr>
         <tr>
          <td>
           Acute coronary syndrome
          </td>
         </tr>
         <tr>
          <td>
           Anorexia nervosa or starvation
          </td>
         </tr>
         <tr>
          <td>
           Bradyarrhythmias (heart rate &lt;45 beats/min)
          </td>
         </tr>
         <tr>
          <td>
           Cardiac heart failure (ejection fraction &lt;40%; uncompensated)
          </td>
         </tr>
         <tr>
          <td>
           Congenital long QT syndrome or other genetic susceptibility
          </td>
         </tr>
         <tr>
          <td>
           Chronic renal failure requiring dialysis
          </td>
         </tr>
         <tr>
          <td>
           Diabetes mellitus (types 1 and 2)
          </td>
         </tr>
         <tr>
          <td>
           Hypertrophic cardiomyopathy
          </td>
         </tr>
         <tr>
          <td>
           Hypoglycemia (documented and in the absence of diabetes)
          </td>
         </tr>
         <tr>
          <td>
           Pheochromocytoma
          </td>
         </tr>
         <tr>
          <td>
           Cardiac arrest within preceding 24 h
          </td>
         </tr>
         <tr>
          <td>
           Syncope or seizure within preceding 24 h
          </td>
         </tr>
         <tr>
          <td>
           Stroke, subarachnoid hemorrhage, or other head trauma within preceding 7 d
          </td>
         </tr>
         <tr>
          <td>
           Clinical history
          </td>
         </tr>
         <tr>
          <td>
           Personal or family history of QT-interval prolongation or sudden unexplained death in the absence of a clinical or genetic diagnosis
          </td>
         </tr>
         <tr>
          <td>
           Demographic
          </td>
         </tr>
         <tr>
          <td>
           Elderly (&gt;65 y)
          </td>
         </tr>
         <tr>
          <td>
           Female sex
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="tbl2fna">
         <label>
          a
         </label>
         <p id="ntpara0035">
          A “pro-QTc” score of ≥4 based on risk factors similar to those listed above was an independent predictor of mortality in patients with QT-interval prolongation.
          <xref ref-type="bibr" rid="bib17">
           <sup>
            17
           </sup>
          </xref>
          Unfortunately, the predictive value of these risk factors in patients with normal or borderline QT intervals has not been assessed.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tbl2fnb">
         <label>
          b
         </label>
         <p id="ntpara0040">
          SI conversion factors: To convert calcium values to mmol/L, multiply by 0.25; to convert magnesium values to mmol/L, multiply by 0.411.
         </p>
        </fn>
       </table-wrap-foot>
       <attrib>
        Adapted from
        <italic>
         Neurogastroenterol Motil
        </italic>
        ,
        <xref ref-type="bibr" rid="bib18">
         <sup>
          18
         </sup>
        </xref>
        with permission. © 2018 John Wiley &amp; Sons Ltd.
       </attrib>
      </table-wrap>
      <fig id="fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Approach to mitigating the risk of drug-induced torsades de pointes (TdP)/drug-induced sudden cardiac death in patients with coronavirus disease 19 (COVID-19) treated following a hypothetical treatment algorithm with “off-label” hydroxychloroquine alone or in combination with azithromycin. Both medications are known HERG blockers with both QTc- prolonging and torsadogenic potential. The estimated 99th percentile QTc values (derived from otherwise healthy individuals), which places a patient in the “green light” category, are less than 460 ms before puberty, less than 470 ms in men, and less than 480 ms in women. We estimate that the baseline QTc assessment will place 90% of patients in green light, 9% in yellow light, and 1% in red light status. ∗Severe COVID-19 cases are defined as a respiratory rate of greater than 30 breaths/min (adults) or 40 breaths/min (children), oxygen saturation of 93% or less, Pa
         <sc>
          O
         </sc>
         <sub>
          2
         </sub>
         to fraction of inspired oxygen ratio less than 300, or lung infiltrates involving more than 50% of the lung field after 24 to 48 hours.
         <sup>
          #
         </sup>
         Hydroxychloroquine inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and reduced viral burden in a small French study. No randomized controlled trial data are available to support the clinical efficacy of hydroxychloroquine use in COVID-19, and its use remains “off label” presently.
         <sup>
          ¥
         </sup>
         Repurposed antiviral alternatives such as lopinavir/ritonavir also have QTc-prolonging effects. BID = twice daily; CHF = congestive heart failure; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; CV = cardiovascular; ECG = electrocardiography; ICU = intensive care unit; IV = intravenous; NIAID = National Institute of Allergy and Infectious Diseases; PO = by mouth.
        </p>
       </caption>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0050">
      Traditionally, the QTc is calculated from either lead II or V
      <sub>
       5
      </sub>
      of the 12-lead electrocardiogram (ECG) and corrected for heart rate using the Bazett or Fridericia formula before any intraindividual or interindividual QTc comparisons are made. Unfortunately, in the context of the COVID-19 pandemic, acquisition of the patient’s QTc by the 12-lead ECG, which requires additional personnel exposure (ie, ECG technician), and a necessity for serial ECGs, which requires exposure of complex equipment (multiple ECG wires), could further strain the already limited supply of personal protective equipment (PPE) in many countries. Alternatively, some FDA-approved consumer mobile ECG devices are capable of generating accurate QTc measurements.
      <xref ref-type="bibr" rid="bib19">
       <sup>
        19
       </sup>
      </xref>
      To this end, AliveCor, Inc, just received emergency clearance from the FDA for use of the KardiaMobile 6L device (FDA-approved for atrial fibrillation detection) for QTc monitoring of patients with COVID-19 treated with QT-prolonging medications such as chloroquine/hydroxychloroquine (March 20, 2020, 1:15
      <sc>
       PM
      </sc>
      CST). Similarly, many telemetry systems are equipped with real-time QTc monitoring features that could be used for hospitalized patients.
     </p>
     <p id="p0055">
      For patients with COVID-19 about to be treated with medications with the increased potential for DI-TdP/DI-SCD (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ), baseline QTc status should be obtained either by a traditional 12-lead ECG or perhaps preferably with the use of a smartphone-enabled mobile QTc meter using the simple infection control measures outlined in
      <xref ref-type="fig" rid="fig2">
       Figure 2
      </xref>
      to limit personnel exposures and conserve critical PPE. On average, the QTc values for otherwise healthy postpubertal males and females are around 410 ms and 420 ms, respectively. In contrast, a QTc value that exceeds the 99th percentile value for otherwise healthy individuals (ie, 460 ms in both sexes before puberty, 470 ms in postpubertal males, and 480 ms in postpubertal females), in the absence of any exogenous QTc-aggravating factors, may signal an individual at increased risk for QT-related ventricular arrhythmias.
      <xref ref-type="bibr" rid="bib20">
       <sup>
        20
       </sup>
      </xref>
      <sup>
       ,
      </sup>
      <xref ref-type="bibr" rid="bib21">
       <sup>
        21
       </sup>
      </xref>
      In contrast and as a frame of reference, the average QTc value was 470 ms for the more than 1400 patients with congenital LQTS who have been cared for in Mayo Clinic’s Windland Smith Rice Genetic Heart Rhythm Clinic. Furthermore, with very few exceptions (amiodarone being one), patients with a resting QTc
      <underline>
       of
      </underline>
      500 ms or more, whether secondary to congenital LQTS or acquired (QTc-prolonging drugs, QTc-prolonging electrolyte abnormalities such as hypokalemia, or QTc-prolonging disease states as detailed in
      <xref ref-type="table" rid="tbl2">
       Table 2
      </xref>
      ), have a considerably greater risk for both DI-TdP and DI-SCD.
      <xref ref-type="bibr" rid="bib22">
       22
      </xref>
      ,
      <xref ref-type="bibr" rid="bib23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="bib24">
       24
      </xref>
      <fig id="fig2">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Protocols for the possible inpatient and outpatient use of a smartphone-enabled mobile electrocardiogram (ECG) to assess and monitor QTc values in patients with coronavirus disease 19. A, Inpatient protocol using dedicated institutional smartphone/tablet and mobile ECG device. Whenever possible, we strongly recommend the use of a dedicated institutional Bluetooth-enabled smartphone or tablet device that is not used for personal use (ie, phone calls or other activities) to limit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). B, Inpatient or outpatient protocol using personal (or institutionally loaned) smartphone/tablet and mobile ECG device. ∗Currently, the only smartphone-enabled mobile ECG with US Food and Drug Administration approval for QTc monitoring is the AliveCor KardiaMobile 6L device. PPE = personal protective equipment.
        </p>
       </caption>
       <graphic xlink:href="gr2_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0060">
      Accordingly, the baseline QTc value can be used to roughly approximate the patient’s risk of DI-TdP/DI-SCD following initiation of a medication with QTc-prolonging potential. For patients with QTc values less than the 99th percentile for age/sex (ie, 460 ms in prepubertal males/females, 470 ms in postpubertal males, and 480 ms in postpubertal females [
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      “green light” status]), the risk of DI-TdP/DI-LQTS is low, and chloroquine/hydroxychloroquine (or other QTc-prolonging COVID-19 pharmacotherapies) should be initiated without delay as outlined in the QTc monitoring algorithm. Remember, whether by 12-lead ECG, telemetry, or smartphone-enabled acquisition of the ECG, if the noted QT interval is less than one-half the preceding RR interval, then the calculated QTc will always be less than 460 ms and the patient can be “green light go” for COVID-19 treatments that may have QTc-prolonging potential.
     </p>
     <p id="p0065">
      In contrast, those patients with a baseline QTc
      <underline>
       of
      </underline>
      500 ms or greater are at increased risk for DI-TdP/DI-SCD (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      “red light” status) and every effort should be made to (1) assess and correct for contributing electrolyte abnormalities (hypocalcemia, hypokalemia, and/or hypomagnesemia), (2) review and discontinue other unnecessary QTc-prolonging medications if present or transition to alternatives with less QTc liability, and/or (3) proceed with closer monitoring (telemetry) or even consideration of more advanced countermeasures such as equipping the patient with a wearable defibrillator (eg, LifeVest [ZOLL Medical Corporation]) if the decision is made to commence therapy.
     </p>
     <p id="p0070">
      In the setting of a QTc value
      <underline>
       of
      </underline>
      500 ms or greater, navigating and circumventing this QTc liability depends greatly on the risk-benefit calculus, and the decision rests with the treating clinician and patient. For example, in younger patients with COVID-19 (ie, &lt;40 years) who have only mild symptoms and a QTc
      <underline>
       of
      </underline>
      500 ms or greater, it may be reasonable to avoid treatment altogether because the arrhythmia risk may outweigh the risk of development of COVID-19–related acute respiratory distress syndrome. However, in patients with a QTc
      <underline>
       of
      </underline>
      500 ms or greater presenting with progressively worsening respiratory symptoms or at greater risk (ie, &gt;65 years of age, immunosuppressed, and/or high-risk comorbid conditions) for respiratory complications, the potential benefit of QTc-prolonging COVID-19 pharmacotherapies may exceed the arrhythmia risk. Therefore, the ultimate goal of QTc surveillance in the COVID-19 pandemic should
      <bold>
       <underline>
        NOT
       </underline>
      </bold>
      be to identify those who cannot receive these medications but to identify those with compromised or reduced “repolarization reserve” in whom increased QTc countermeasures can and should be taken to mitigate the risk of drug-related death from DI-TdP/DI-SCD.
      <xref ref-type="bibr" rid="bib25">
       <sup>
        25
       </sup>
      </xref>
     </p>
     <p id="p0075">
      Ultimately, much of the risk-benefit calculus awaits determination of the therapeutic efficacy of hydroxychloroquine, with or without concomitant azithromycin. Until such information is available, if the decision has been made to treat a patient with a red light designation (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ) based on their baseline QTc
      <underline>
       of
      </underline>
      500 ms or greater, it seems prudent to start with hydroxychloroquine alone, rather than combination drug therapy with azithromycin. In addition, if combination drug therapy, with hydroxychloroquine and azithromycin, was initiated in a patient with an initial green light/yellow light QTc status and the individual transitions to red light status after self-identification as a “QTc reactor” with a ΔQTc
      <underline>
       of
      </underline>
      60 ms or greater, then consideration should be given to discontinuing azithromycin, optimizing electrolyte status, or intensifying countermeasures further (placing on telemetry for continuous rhythm assessment).
     </p>
    </sec>
    <sec id="sec3">
     <title>
      Frequency of QTc Surveillance and Adjustments in the Setting of Wide QRS Complex
     </title>
     <p id="p0080">
      Ideally, following a baseline QTc assessment, therapy may be initiated with either QTc reassurance (low risk for the vast majority [90%] of patients) or varying QTc countermeasures in place for those flagged as at increased risk. The timing of on-therapy QTc surveillance will be dictated not only by the pharmacokinetics of the COVID-19 therapies used but also by the practical logistics of an institution’s method of QTc monitoring. For the 12-lead ECG approach, if QTc surveillance is deemed important, then one machine should be designated for acquisition of the data and a limited number of ECG technicians/personnel should be used to minimize PPE utilization and personnel exposure. Also, the number of on-therapy QTc assessments should be constrained to minimize personnel exposure risk and PPE consumption. In this scenario, for those placed in red light status because their baseline QTc
      <underline>
       is
      </underline>
      500 ms or greater, an initial on-therapy QTc should be obtained around 2 to 4 hours after the first dose and then again at 48 hours and 96 hours following treatment initiation. Patients receiving either green light or yellow light status can probably forego the early QTc assessment and wait until 48 hours and 96 hours for their on-drug QTc determination. If the on-therapy QTc is 500 ms or greater or the patient self-identified as a QTc reactor with a ΔQTc
      <underline>
       of
      </underline>
      60 ms or greater, then the QTc countermeasures need to be reexamined or the medications stopped in an effort to neutralize the increased potential for DI-TdP and DI-SCD (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ).
     </p>
     <p id="p0085">
      In contrast, for medical centers able to implement the FDA emergency-approved, smartphone-enabled approach (
      <xref ref-type="fig" rid="fig2">
       Figure 2
      </xref>
      ) or to determine the QTc from the telemetry strips, ECG technician exposure risk and consumption of PPE by those individuals would be eliminated and the patient’s QTc could be obtained by the health care team already present, for example, with the QTc obtained per shift as another vital sign.
      <xref ref-type="bibr" rid="bib26">
       <sup>
        26
       </sup>
      </xref>
      Such increased QTc surveillance would enable discovery of the QTc reactor and implementation of countermeasures sooner and hopefully would thereby circumvent the potentially preventable tragedy of DI-SCD (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ).
     </p>
     <p id="p0090">
      Finally, for patients with a wide QRS complex from either ventricular pacing or right/left bundle branch block, a wide QRS complex QTc adjustment will need to be made. Otherwise, patients will receive a red light signal inappropriately, resulting in therapy delay, discontinuation, or avoidance altogether. In this setting, the simplest approach is to maintain the previously indicated QTc green, yellow, and red light thresholds and apply a simple formula to account for the wide QRS complex (wide QRS complex–adjusted QTc = QTc – [QRS − 100 ms]). For example, if a patient’s left bundle branch block has yielded a QRS complex of 200 ms and a QTc of 520 ms, this scenario would appear to activate the red light pathway (
      <xref ref-type="fig" rid="fig1">
       Figure 1
      </xref>
      ). However, the wide QRS complex–adjusted QTc would be 520 ms – (200 − 100 ms) = 520 − 100 = 420 ms, which is not red light status at all but rather “green light go” status with much QTc reassurance that the patient is at low risk for DI-SCD.
     </p>
    </sec>
    <sec id="sec4">
     <title>
      Conclusion
     </title>
     <p id="p0095">
      As this coronavirus pandemic continues to spread and wreak havoc, economic loss, and more importantly, the tragic deaths of thousands throughout the world, we must all do our part in this war on COVID-19. Washing hands and physical distancing are core components of containment efforts to “flatten the curve.” Development of a coronavirus vaccine is progressing at unprecedented speed but is still at least 12 to 18 months away. In the meantime, there is hope that a long-ago discovered antimalarial drug, hydroxychloroquine, may have lifesaving therapeutic efficacy against COVID-19. And if it does, we hope that this simple QTc surveillance strategy, enabled by innovation and the FDA’s emergency approval, will help prevent altogether or at least substantially reduce the number of drug-induced ventricular arrhythmias and sudden cardiac deaths, particularly if there is widespread adoption and utilization of these medications for COVID-19.
     </p>
    </sec>
    <sec id="sec5">
     <title>
      Uncited References
     </title>
     <p id="p0100">
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="bib11">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bib13">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="bib14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="bib15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="bib16">
       16
      </xref>
      .
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sref1" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in
         <italic>
          Lancet
         </italic>
         . 2020;395(10223):496]
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sref2" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shah
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kashyap
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Tosh
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Sampathkumar
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           O'Horo
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Guide to understanding the 2019 novel coronavirus [published online ahead of print February 28, 2020]
        </article-title>
        <comment>
         <italic>
          Mayo Clin Proc
         </italic>
        </comment>
        <ext-link ext-link-type="doi" id="intref0010" xlink:href="10.1016/j.mayocp.2020.02.003">
         https://doi.org/10.1016/j.mayocp.2020.02.003
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </article-title>
        <source>
         Cell Res
        </source>
        <volume>
         30
        </volume>
        <issue>
         3
        </issue>
        <year>
         2020
        </year>
        <fpage>
         269
        </fpage>
        <lpage>
         271
        </lpage>
        <pub-id pub-id-type="pmid">
         32020029
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sref4" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [published online ahead of print March 9, 2020]
        </article-title>
        <comment>
         Clin Infect Dis
        </comment>
        <ext-link ext-link-type="doi" id="intref0015" xlink:href="10.1093/cid/ciaa237">
         https://doi.org/10.1093/cid/ciaa237
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gautret
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lagier
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Parola
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine and azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial
        </article-title>
        <source>
         medRxiv
        </source>
        <volume>
         03
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sref6" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lagier
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 [published online ahead of print March 4, 2020]
        </article-title>
        <comment>
         <italic>
          Int J Antimicrob Agents
         </italic>
        </comment>
        <ext-link ext-link-type="doi" id="intref0020" xlink:href="10.1016/j.ijantimicag.2020.105932">
         https://doi.org/10.1016/j.ijantimicag.2020.105932
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Majori
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of chloroquine on viral infections: an old drug against today's diseases?
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         3
        </volume>
        <issue>
         11
        </issue>
        <year>
         2003
        </year>
        <fpage>
         722
        </fpage>
        <lpage>
         727
        </lpage>
        <pub-id pub-id-type="pmid">
         14592603
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sref8" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bergeron
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Benjannet
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         2
        </volume>
        <year>
         2005
        </year>
        <fpage>
         69
        </fpage>
        <pub-id pub-id-type="pmid">
         16115318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sref9" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Traebert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dumotier
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Meister
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Dominguez-Estevez
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Suter
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells
        </article-title>
        <source>
         Eur J Pharmacol
        </source>
        <volume>
         484
        </volume>
        <issue>
         1
        </issue>
        <year>
         2004
        </year>
        <fpage>
         41
        </fpage>
        <lpage>
         48
        </lpage>
        <pub-id pub-id-type="pmid">
         14729380
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stas
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Faes
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Noyens
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine
        </article-title>
        <source>
         Int J Cardiol
        </source>
        <volume>
         127
        </volume>
        <issue>
         2
        </issue>
        <year>
         2008
        </year>
        <fpage>
         e80
        </fpage>
        <lpage>
         e82
        </lpage>
        <pub-id pub-id-type="pmid">
         17590456
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           F.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia
        </article-title>
        <source>
         Clin Toxicol (Phila)
        </source>
        <volume>
         44
        </volume>
        <issue>
         2
        </issue>
        <year>
         2006
        </year>
        <fpage>
         173
        </fpage>
        <lpage>
         175
        </lpage>
        <pub-id pub-id-type="pmid">
         16615675
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
        </article-title>
        <source>
         J Clin Virol
        </source>
        <volume>
         31
        </volume>
        <issue>
         1
        </issue>
        <year>
         2004
        </year>
        <fpage>
         69
        </fpage>
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="pmid">
         15288617
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sref13" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wen
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 [published online ahead of print March 18, 2020]
        </article-title>
        <comment>
         N Engl J Med
        </comment>
        <ext-link ext-link-type="doi" id="intref0025" xlink:href="10.1056/NEJMoa2001282">
         https://doi.org/10.1056/NEJMoa2001282
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soliman
          </surname>
          <given-names>
           E.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Lundgren
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Roediger
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations
        </article-title>
        <source>
         AIDS
        </source>
        <volume>
         25
        </volume>
        <issue>
         3
        </issue>
        <year>
         2011
        </year>
        <fpage>
         367
        </fpage>
        <lpage>
         377
        </lpage>
        <pub-id pub-id-type="pmid">
         21150558
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Giudicessi
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Ackerman
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused?
        </article-title>
        <source>
         Cleve Clin J Med
        </source>
        <volume>
         80
        </volume>
        <issue>
         9
        </issue>
        <year>
         2013
        </year>
        <fpage>
         539
        </fpage>
        <lpage>
         544
        </lpage>
        <pub-id pub-id-type="pmid">
         24001961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arellano-Rodrigo
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           García
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Mont
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Roqué
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome [in Spanish]
        </article-title>
        <source>
         Med Clin (Barc)
        </source>
        <volume>
         117
        </volume>
        <issue>
         3
        </issue>
        <year>
         2001
        </year>
        <fpage>
         118
        </fpage>
        <lpage>
         119
        </lpage>
        <pub-id pub-id-type="pmid">
         11459586
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haugaa
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Bos
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tarrell
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Morlan
          </surname>
          <given-names>
           B.W.
          </given-names>
         </name>
         <name>
          <surname>
           Caraballo
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ackerman
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Institution-wide QT alert system identifies patients with a high risk of mortality
        </article-title>
        <source>
         Mayo Clin Proc
        </source>
        <volume>
         88
        </volume>
        <issue>
         4
        </issue>
        <year>
         2013
        </year>
        <fpage>
         315
        </fpage>
        <lpage>
         325
        </lpage>
        <pub-id pub-id-type="pmid">
         23541006
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Giudicessi
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Ackerman
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Camilleri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cardiovascular safety of prokinetic agents: a focus on drug-induced arrhythmias
        </article-title>
        <source>
         Neurogastroenterol Motil
        </source>
        <volume>
         30
        </volume>
        <issue>
         6
        </issue>
        <year>
         2018
        </year>
        <fpage>
         e13302
        </fpage>
        <pub-id pub-id-type="pmid">
         29441683
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Garabelli
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Stavrakis
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Albert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of QT interval readings in normal sinus rhythm between a smartphone heart monitor and a 12-lead ECG for healthy volunteers and inpatients receiving sotalol or dofetilide
        </article-title>
        <source>
         J Cardiovasc Electrophysiol
        </source>
        <volume>
         27
        </volume>
        <issue>
         7
        </issue>
        <year>
         2016
        </year>
        <fpage>
         827
        </fpage>
        <lpage>
         832
        </lpage>
        <pub-id pub-id-type="pmid">
         27027653
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sharma
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Drezner
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Baggish
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         International recommendations for electrocardiographic interpretation in athletes
        </article-title>
        <source>
         Eur Heart J
        </source>
        <volume>
         39
        </volume>
        <issue>
         16
        </issue>
        <year>
         2018
        </year>
        <fpage>
         1466
        </fpage>
        <lpage>
         1480
        </lpage>
        <pub-id pub-id-type="pmid">
         28329355
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sref21" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vink
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Neumann
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Lieve
          </surname>
          <given-names>
           K.V.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Determination and interpretation of the QT interval
        </article-title>
        <source>
         Circulation
        </source>
        <volume>
         138
        </volume>
        <issue>
         21
        </issue>
        <year>
         2018
        </year>
        <fpage>
         2345
        </fpage>
        <lpage>
         2358
        </lpage>
        <pub-id pub-id-type="pmid">
         30571576
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sref22" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goldenberg
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Moss
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Peterson
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome
        </article-title>
        <source>
         Circulation
        </source>
        <volume>
         117
        </volume>
        <issue>
         17
        </issue>
        <year>
         2008
        </year>
        <fpage>
         2184
        </fpage>
        <lpage>
         2191
        </lpage>
        <pub-id pub-id-type="pmid">
         18427136
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hobbs
          </surname>
          <given-names>
           J.B.
          </given-names>
         </name>
         <name>
          <surname>
           Peterson
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Moss
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         296
        </volume>
        <issue>
         10
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1249
        </fpage>
        <lpage>
         1254
        </lpage>
        <pub-id pub-id-type="pmid">
         16968849
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sauer
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Moss
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           McNitt
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Long QT syndrome in adults
        </article-title>
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         49
        </volume>
        <issue>
         3
        </issue>
        <year>
         2007
        </year>
        <fpage>
         329
        </fpage>
        <lpage>
         337
        </lpage>
        <pub-id pub-id-type="pmid">
         17239714
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roden
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Long QT syndrome: reduced repolarization reserve and the genetic link
        </article-title>
        <source>
         J Intern Med
        </source>
        <volume>
         259
        </volume>
        <issue>
         1
        </issue>
        <year>
         2006
        </year>
        <fpage>
         59
        </fpage>
        <lpage>
         69
        </lpage>
        <pub-id pub-id-type="pmid">
         16336514
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Giudicessi
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Noseworthy
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ackerman
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The QT interval
        </article-title>
        <source>
         Circulation
        </source>
        <volume>
         139
        </volume>
        <issue>
         24
        </issue>
        <year>
         2019
        </year>
        <fpage>
         2711
        </fpage>
        <lpage>
         2713
        </lpage>
        <pub-id pub-id-type="pmid">
         31180747
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <fn-group>
      <fn id="d32e653">
       <p id="ntpara0010">
        <bold>
         Grant Support:
        </bold>
        This work was supported by the
        <funding-source id="gs1">
         Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program
        </funding-source>
        .
       </p>
      </fn>
      <fn id="d32e660">
       <p id="ntpara0015">
        <bold>
         Potential Competing Interests:
        </bold>
        Dr Ackerman is a consultant for Abbott, Audentes Therapeutics, BIOTRONIK SE &amp; Co. KG, Boston Scientific Corporation, Invitae Corporation, LQT Therapeutics Inc, Medtronic, and MyoKardia. Drs Noseworthy, Friedman, and Ackerman and Mayo Clinic are involved in an equity/royalty relationship with AliveCor, Inc (not involved in this study). Dr Giudicessi reports no competing interests.
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Toxicol Environ Health B Crit Rev
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J Toxicol Environ Health B Crit Rev
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       UTEB
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       uteb20
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Toxicology and Environmental Health. Part B, Critical Reviews
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1093-7404
      </issn>
      <issn pub-type="epub">
       1521-6950
      </issn>
      <publisher>
       <publisher-name>
        Taylor &amp; Francis
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32281481
      </article-id>
      <article-id pub-id-type="pmc">
       7157945
      </article-id>
      <article-id pub-id-type="publisher-id">
       1752340
      </article-id>
      <article-id pub-id-type="doi">
       10.1080/10937404.2020.1752340
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review
       </article-title>
       <alt-title alt-title-type="running-authors">
        B. B. PEREIRA
       </alt-title>
       <alt-title alt-title-type="running-title">
        JOURNAL OF TOXICOLOGY &amp; ENVIRONMENTAL HEALTH, PART B
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0002-2633-9067
        </contrib-id>
        <name>
         <surname>
          Pereira
         </surname>
         <given-names>
          Boscolli Barbosa
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">
        </xref>
        <xref ref-type="aff" rid="AFF0002">
        </xref>
        <xref ref-type="corresp" rid="AN0001">
        </xref>
       </contrib>
       <aff id="AFF0001">
        <label>
         1
        </label>
        <institution>
         Institute of Geography, Department of Environmental Health, Federal University of Uberlândia, Santa Mônica Campus
        </institution>
        , Uberlândia,
        <country>
         Brazil
        </country>
       </aff>
       <aff id="AFF0002">
        <label>
         2
        </label>
        <institution>
         Institute of Biotechnology, Department of Genetics and Biochemistry, Federal University of Uberlândia, Umuarama Campus
        </institution>
        , Uberlândia,
        <country>
         Brazil
        </country>
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="AN0001">
        CONTACT Boscolli Barbosa Pereira
        <email xlink:href="boscolli86@hotmail.com">
         boscolli86@hotmail.com
        </email>
        <institution>
         Federal University of Uberlândia, Institute of Geography, Department of Environmental Health, Santa Mônica Campus, Avenida João Naves de Ávila
        </institution>
        , 2121, 38.408-100, Uberlândia, Minas Gerais, Brazil.
        <country>
         Phone +55 34 3291 5989
        </country>
        .
       </corresp>
      </author-notes>
      <pub-date pub-type="collection">
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        12
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       0
      </volume>
      <issue>
       0
      </issue>
      <fpage seq="1">
       1
      </fpage>
      <lpage>
       5
      </lpage>
      <permissions>
       <copyright-statement>
        © 2020 Taylor &amp; Francis
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Taylor &amp; Francis
       </copyright-holder>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
        </license-p>
       </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="UTEB_A_1752340.pdf">
      </self-uri>
      <abstract>
       <title>
        ABSTRACT
       </title>
       <p>
        As a result of the 2019 coronavirus disease pandemic (COVID-19), there has been an urgent worldwide demand for treatments. Due to factors such as history of prescription for other infectious diseases, availability, and relatively low cost, the use of chloroquine (CQ) and hydroxychloroquine (HCQ) has been tested
        <italic>
         in vivo
        </italic>
        and
        <italic>
         in vitro
        </italic>
        for the ability to inhibit the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, even though investigators noted the therapeutic potential of these drugs, it is important to consider the toxicological risks and necessary care for rational use of CQ and HCQ. This study provides information on the main toxicological and epidemiological aspects to be considered for prophylaxis or treatment of COVID-19 using CQ but mainly HCQ, which is a less toxic derivative than CQ, and was shown to produce better results in inhibiting proliferation of SARS-CoV-2 based upon preliminary tests.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <title>
        KEYWORDS
       </title>
       <kwd>
        Toxicology
       </kwd>
       <kwd>
        screening
       </kwd>
       <kwd>
        health care
       </kwd>
       <kwd>
        retinopathy
       </kwd>
       <kwd>
        public health
       </kwd>
      </kwd-group>
      <counts>
       <fig-count count="1">
       </fig-count>
       <ref-count count="26">
       </ref-count>
       <page-count count="5">
       </page-count>
      </counts>
     </article-meta>
    </front>
    <sec id="S0001" sec-type="intro">
     <title>
      Introduction
     </title>
     <p>
      The coronavirus disease 2019 (COVID-19) pandemic has produced significant impacts on public health and global economy, due to hospitalizations, deaths, high complexity of clinical care and long quarantine periods required to control the spread of the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
     </p>
     <p>
      In a scenario of high infection rate and occurrence of severe cases that may result in death, the demand for effective drugs to treat and control the COVID-19 pandemic was given top priority by the health and political authorities. Among the drugs currently tested
      <italic>
       in vitro
      </italic>
      and
      <italic>
       in vivo
      </italic>
      , remdesivir, ribavirin, chloroquine (CQ) and hydroxychloroquine (HCQ) have shown promising clinical results in inhibiting the viral replication of SARS-CoV-2 (Zhang et al.
      <xref rid="CIT0025">
       2020
      </xref>
      ). However, while the molecular mechanisms underlying therapeutic actions and clinical benefits remain to still be explored, the search for information regarding CQ and HCQ toxicity is a priority, since it can directly contribute to the design of randomized clinical trials (Cabral et al.
      <xref rid="CIT0002">
       2019
      </xref>
      ; Jorge et al.
      <xref rid="CIT0007">
       2018
      </xref>
      ; Liu et al.
      <xref rid="CIT0010">
       2020
      </xref>
      ; Stokkermans and Trichonas
      <xref rid="CIT0020">
       2019
      </xref>
      ; Yam and Kwok
      <xref rid="CIT0023">
       2006
      </xref>
      ; Zhang et al.
      <xref rid="CIT0026">
       2015
      </xref>
      ).
     </p>
     <p>
      Although research concerning the use of CQ and HCQ in control of COVID-19 is still preliminary, the potential use of these drugs is supported by factors including availability, low cost, and history of use in treatment of rheumatic and infectious diseases such as malaria and amebiasis (Stokkermans and Trichonas
      <xref rid="CIT0020">
       2019
      </xref>
      ). In addition, there is a growing trend of preference for HCQ, which is a less toxic derivative of CQ, and was found to yield better results in inhibiting proliferation of SARS-CoV-2 (Liu et al.
      <xref rid="CIT0010">
       2020
      </xref>
      ).
     </p>
     <p>
      With respect to adverse effects, there is a recognition that HCQ produces toxicity to retina tissue, which may consequently result in irreversible retinopathy (Marmor et al.
      <xref rid="CIT0011">
       2002
      </xref>
      ), especially in cases of prolonged exposure to the drug (Wolf and Marmor
      <xref rid="CIT0022">
       2010
      </xref>
      ). In less recurrent cases, usually after prolonged exposure to HCQ, cardiotoxicity, and toxicological effects were reported in the central nervous system with neuromyopathy symptoms (skeletal muscle weakness) and gastrointestinal changes (Stein, Bell, and Ang
      <xref rid="CIT0019">
       2000
      </xref>
      ).
     </p>
     <p>
      Although there is evidence of damage to the genetic material of liver cells
      <italic>
       in vitro
      </italic>
      produced by antimalarial drugs (Guo et al
      <xref rid="CIT0006">
       2019
      </xref>
      ), there are few apparent studies available that address the genotoxicity of these drugs, with only a few pointing to low potential for DNA damage by CQ in tests performed
      <italic>
       in vitro
      </italic>
      (Riccio et al.
      <xref rid="CIT0018">
       2001
      </xref>
      ).
     </p>
     <p>
      Considering the urgency of conducting clinical research that results in safe and effective protocols for the therapeutic use of CQ and HCQ, this timely review aimed to present and discuss relevant aspects for the prevention of toxicological effects during and after treatment of COVID-19.
     </p>
    </sec>
    <sec id="S0002">
     <title>
      Pharmacological, therapeutic, and toxicological properties of chloroquine and hydroxychloroquine
     </title>
     <p>
      General aspects to be considered for prophylaxis or treatment of COVID-19 using CQ and HCQ are summarized in
      <xref rid="F0001">
       Figure 1
      </xref>
      .
      <xref rid="F0001">
       Figure 1(a
      </xref>
      ) emphasizes the physicochemical properties of chloroquine (CQ) and hydroxychloroquine (HCQ). CQ and HCQ are synthetic antimalarials developed from the bark of cinchona (Rubiaceae), which are soluble in water (HCQ is more soluble because it possesses a hydroxyl group), are rapidly fast absorbed with a long plasma elimination half-life of 900 and 1300 hr, respectively (Kalia and Dutz
      <xref rid="CIT0008">
       2007
      </xref>
      ). This leads to tissue bioaccumulation after chronic treatments (Stokkermans and Trichonas
      <xref rid="CIT0020">
       2019
      </xref>
      ).
      <fig fig-type="figure" id="F0001" orientation="portrait" position="float">
       <object-id pub-id-type="doi">
        10.1080/10937404.2020.1752340-F0001
       </object-id>
       <label>
        Figure 1.
       </label>
       <caption>
        <p>
         Toxicological and epidemiological aspects to be considered for prophylaxis or treatment of COVID-19 using CQ and HCQ. (a) Physicochemical properties of chloroquine (CQ) and hydroxychloroquine (HCQ); (b) Incidence of side effects in patients on long-term HCQ therapy; (c) Prescription of CQ | HCQ and patient-care in treatment of COVID-19.
        </p>
        <p specific-use="attrib">
         <xref rid="F0001">
          Figure 1B
         </xref>
         . * In all studies the most important predictor of hydroxychloroquine retinal toxicity was the duration of use (cumulative dose).
        </p>
       </caption>
       <graphic xlink:href="UTEB_A_1752340_F0001_OC">
       </graphic>
      </fig>
     </p>
     <p>
      The cytochrome P450 complex is responsible for the metabolism of CQ and HCQ in the liver, with approximately 50% of metabolites excreted without modification by the kidneys (Kalia and Dutz
      <xref rid="CIT0008">
       2007
      </xref>
      ). CQ and HCQ may also be transported across the placenta. Both drugs were detected in breast milk (Rainsford et al.
      <xref rid="CIT0017">
       2015
      </xref>
      ).
     </p>
     <p>
      To be successful in replication, viruses need a host intracellular medium with a stable acidic pH in endosomes, lysosomes, and Golgi complex. The antiviral properties of CQ and HCQ are attributed to the accumulation of aminoquinolines that raise the pH of the medium in lysosomes and other intracellular acidic compartments and organelles (Plantone and Koudriavtseva
      <xref rid="CIT0016">
       2018
      </xref>
      ).
     </p>
     <p>
      It is important to emphasize that treatment of COVID-19 consists not only of inhibiting the viral replication of SARS-CoV-2, but also of controlling inflammatory processes by reducing the production of pro-inflammatory cytokines and other mediators (Al-Bari and Alim
      <xref rid="CIT0001">
       2017
      </xref>
      ).
     </p>
     <p>
      Regarding side effects, the main toxicological outcomes initiated by CQ and HCQ reported in the medical-scientific literature are related to retinopathy, neuromyopathy, and cardiomyopathy. In the retinal pigment epithelium, CQ and HCQ have an affinity for the melanin molecules, producing effects on macular cones (outside of the fovea). More specifically, the retinal pigmented cells react to the accumulation of external segments of the photoreceptors triggered by CQ and HCQ resulting in a decrease in phagocytic activity of lysosomes on the external segments of the photoreceptor, migrating to central and peripheral regions of the tissue and inducing epithelial atrophy with irreversible changes in its photoreceptors (Yam and Kwok
      <xref rid="CIT0023">
       2006
      </xref>
      ).
     </p>
     <p>
      As mentioned previously due to the long plasma elimination half-life of CQ and HCQ, these drugs are slowly excreted. Thus, even after treatment is stopped, it is necessary to monitor side effects, since pruritus to corneal deposition (keratopathy) and continued maculopathy on the retina may be delayed in occurrence.
     </p>
     <p>
      Regarding the occurrence of cardiomyopathy and neuromyopathy, the metabolic mechanisms underlying histological damage mediated by HCQ are similar. Because it is a basic compound, in the intracellular medium of muscle tissues, HCQ enters lysosomes by diffusion, since these organelles have acidic pH. Within lysosomes, HCQ is protonated and accumulates, inhibiting the action of lysosomal phospholipases, resulting in vacuolization of cardiac and skeletal muscle cells (Yogasundaram et al.
      <xref rid="CIT0024">
       2014
      </xref>
      ).
     </p>
     <p>
      Liu et al. (
      <xref rid="CIT0009">
       2018
      </xref>
      ) performed a meta-analysis to investigate the effects of using CQ and HCQ in 16,679 (pooled) patients with rheumatic diseases, but their effects on the cardiomyopathy and neuromyopathy were not confirmed. Chatre et al. (
      <xref rid="CIT0004">
       2018
      </xref>
      ) examined cardiac complications attributed to CQ and HCQ in a systematic review of the literature and noted that CQ- or HCQ-related cardiac disorders were rare but severe adverse events occurred after long-term administration.
     </p>
    </sec>
    <sec id="S0003">
     <title>
      Epidemiology of CQ and HCQ retinal toxicity
     </title>
     <p>
      While controlled clinical studies are still lacking to epidemiologically clarify the incidence of cardiomyopathy and neuromyopathy, the toxicity produced in retinal cells was more comprehensively explored (Melles and Marmor
      <xref rid="CIT0014">
       2014
      </xref>
      ). As shown in
      <xref rid="F0001">
       Figure 1(b
      </xref>
      ), the incidence of CQ and HCQ retinal toxicity increases with chronic treatment, which reinforces the hypothesis of bioaccumulation. Considering that the daily doses of CQ and HCQ prescribed vary around 400 mg, after 7 years of treatment, the patient will have received 1 kg of the drug.
     </p>
     <p>
      Although most investigators found the incidence of retinopathy lower than 2% (Mavrikakis et al.
      <xref rid="CIT0013">
       2003
      </xref>
      ), two aspects need to be considered when using CQ and HCQ to treat COVID-19: (1) it is a pandemic and, therefore, millions of people will receive treatment and, (2) the doses used in an acute approach to viral infection are often much higher when compared to utilization of CQ and HCQ for treatment of chronic rheumatic diseases (Touret de Lamballerie
      <xref rid="CIT0021">
       2020
      </xref>
      ). In addition, another very important epidemiological consideration is the fact that retinopathy is more common in Asian patients (Melles and Marmor
      <xref rid="CIT0015">
       2015
      </xref>
      ).
     </p>
    </sec>
    <sec id="S0004">
     <title>
      Prescription of CQ, HCQ, and patient-care
     </title>
     <p>
      From the analysis of results obtained in research that investigated the risks of toxicity associated with the use of CQ and HCQ (Castrejón et al.
      <xref rid="CIT0003">
       2014
      </xref>
      ; Gossec et al.
      <xref rid="CIT0005">
       2019
      </xref>
      ), it is evident that some care needs to be considered when prescribing CQ and/or HCQ in treatment of COVID-19, such that side effects are prevented or reduced (
      <xref rid="F0001">
       Figure 1(c
      </xref>
      )). Thus, the main challenge is to consider as many epidemiological and clinical aspects as possible before starting treatment.
     </p>
     <p>
      In this sense, it is important to know the history of previous (or ongoing) use of CQ and HCQ in patients infected with malaria, amebiasis, or individuals with chronic diseases as rheumatoid arthritis and systemic lupus. It is also relevant to remember that Asian patients are at a higher risk of developing retinopathy. Patients with or without vision problems or cardiovascular diseases need to be periodically monitored during and after treatment with CQ and HCQ. It is possible to perform simple tests to measure central and peripheral visual acuity. In addition, symptoms such as ocular pruritus and early signs of cardiac arrhythmias need to be identified.
     </p>
     <p>
      As for possible drug interactions, the scientific literature describes that Kaolin clay and antacids interact with CQ and HCQ, which may reduce antiviral and anti-inflammatory activity. On the other hand, CQ and HCQ diminish the activity of antibiotics and immunosuppressants, such as ampicillin and cyclosporin. Patients who are being treated with mefloquine are at increased risk of convulsions.
     </p>
     <p>
      Current recommendations emphasized the fact that toxicity is related to the dose calculated by real weight. Hence, the prescription of daily doses of CQ and HCQ needs to be suitable for patients who are at high risk of presenting adverse effects, considering that cumulative doses above 2.3 mg/kg body weight/day are considered high risk (Marmor et al.
      <xref rid="CIT0012">
       2016
      </xref>
      ).
     </p>
     <p>
      There is no evidence that the use of CQ and HCQ has a preventive effect on the effects of COVID-19. Thus, clear information regarding the risk/benefit ratio of CQ and HCQ prescription needs to be shared among health professionals and extended to patients and the population. While researchers around the world are looking to develop target-specific drugs against the SARS-CoV-2 virus, current approaches need to be grounded in practices of patient care minimizing risk by rigorous screening and measuring of doses.
     </p>
    </sec>
    <back>
     <sec>
      <title>
       Acknowledgments
      </title>
      <p>
       Financial support is acknowledged to “Coordenação de Aperfeiçoamento de Pessoal de Nível Superior” (CAPES).
      </p>
     </sec>
     <ref-list>
      <title>
       References
      </title>
      <ref id="CIT0001">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Al-Bari
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Alim
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <year>
         2017
        </year>
        <article-title>
         Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases
        </article-title>
        .
        <source>
         <italic>
          Pharmacol. Res. Pers.
         </italic>
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         13
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1002/prp2.293
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0002">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cabral
          </surname>
          <given-names>
           R. T. S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Klumb
          </surname>
          <given-names>
           E. M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Couto
          </surname>
          <given-names>
           M. I. N. N.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Carneiro
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <year>
         2019
        </year>
        <article-title>
         Evaluation of toxic retinopathy caused by antimalarial medications with spectral domain optical coherence tomography
        </article-title>
        .
        <source>
         <italic>
          Arq. Bras. Oftalmol.
         </italic>
        </source>
        <volume>
         82
        </volume>
        :
        <fpage>
         12
        </fpage>
        –
        <lpage>
         17
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.5935/0004-2749.20190002
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         30403262
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0003">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Castrejón
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tani
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jolly
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Mosca
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        <article-title>
         Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care
        </article-title>
        .
        <source>
         <italic>
          Clin. Exp. Rheumatol.
         </italic>
        </source>
        <volume>
         32
        </volume>
        (
        <issue>
         5 Suppl 85
        </issue>
        ):
        <fpage>
         S85
        </fpage>
        –
        <lpage>
         S95
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24528649
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0004">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chatre
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Roubille
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Vernhet
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jorgensen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Pers
          </surname>
          <given-names>
           Y. M.
          </given-names>
         </name>
        </person-group>
        <year>
         2018
        </year>
        <article-title>
         Cardiac complications attributed to chloroquine and hydroxychloroquine: A systematic review of the literature
        </article-title>
        .
        <source>
         <italic>
          Drug Saf.
         </italic>
        </source>
        <volume>
         41
        </volume>
        :
        <fpage>
         919
        </fpage>
        –
        <lpage>
         31
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1007/s40264-018-0689-4
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         29858838
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0005">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gossec
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Molto
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Romand
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Puyraimond-Zemmour
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lavielle
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Beauvais
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Senbel
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Flipo
          </surname>
          <given-names>
           R. M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pouplin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Richez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         , et al
        </person-group>
        <year>
         2019
        </year>
        <article-title>
         Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus
        </article-title>
        .
        <source>
         <italic>
          Joint Bone Spine
         </italic>
        </source>
        <volume>
         86
        </volume>
        :
        <fpage>
         13
        </fpage>
        –
        <lpage>
         19
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.jbspin.2018.08.006
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         30243782
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0006">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Guo
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Seo
          </surname>
          <given-names>
           J. E.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Mei
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <year>
         2020
        </year>
        <article-title>
         Genetic toxicity assessment using liver cell models: Past, present, and future
        </article-title>
        .
        <source>
         <italic>
          J. Toxicol. Environ. Health B
         </italic>
        </source>
        <volume>
         23
        </volume>
        :
        <fpage>
         27
        </fpage>
        –
        <lpage>
         50
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1080/10937404.2019.1692744
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0007">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jorge
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ung
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Young
          </surname>
          <given-names>
           L. H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Melles
          </surname>
          <given-names>
           R. B.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Choi
          </surname>
          <given-names>
           H. K.
          </given-names>
         </name>
        </person-group>
        <year>
         2018
        </year>
        <article-title>
         Hydroxychloroquine retinopathy - implications of research advances for rheumatology care
        </article-title>
        .
        <source>
         <italic>
          Nature Rev. Rheumatol.
         </italic>
        </source>
        <volume>
         14
        </volume>
        :
        <fpage>
         693
        </fpage>
        –
        <lpage>
         703
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1038/s41584-018-0111-8
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         30401979
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0008">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kalia
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Dutz
          </surname>
          <given-names>
           J. P.
          </given-names>
         </name>
        </person-group>
        <year>
         2007
        </year>
        <article-title>
         New concepts in antimalarial use and mode of action in dermatology
        </article-title>
        .
        <source>
         <italic>
          Dermatol. Ther.
         </italic>
        </source>
        <volume>
         2
        </volume>
        :
        <fpage>
         160
        </fpage>
        –
        <lpage>
         74
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1111/j.1529-8019.2007.00131.x
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0009">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kwong
          </surname>
          <given-names>
           J. S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Xu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sun
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tian
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         , et al
        </person-group>
        <year>
         2018
        </year>
        <article-title>
         Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: A systematic review and meta-analysis
        </article-title>
        .
        <source>
         <italic>
          Drug Des. Dev. Ther.
         </italic>
        </source>
        <volume>
         11
        </volume>
        :
        <fpage>
         1685
        </fpage>
        –
        <lpage>
         95
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.2147/DDDT.S166893
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0010">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Xu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhong
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <year>
         2020
        </year>
        <article-title>
         Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
        </article-title>
        .
        <source>
         <italic>
          Cell Dis.
         </italic>
        </source>
        <volume>
         18
        </volume>
        :
        <fpage>
         16
        </fpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1038/s41421-020-0156-0
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0011">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Marmor
          </surname>
          <given-names>
           M. F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Carr
          </surname>
          <given-names>
           R. E.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Easterbrook
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Mieler
          </surname>
          <given-names>
           W. F.
          </given-names>
         </name>
         ,
         <collab>
          American Academy of Ophthalmology
         </collab>
        </person-group>
        <year>
         2002
        </year>
        <article-title>
         Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: A report by the American Academy of Ophthalmology
        </article-title>
        .
        <source>
         <italic>
          Ophthalmology
         </italic>
        </source>
        <volume>
         109
        </volume>
        :
        <fpage>
         1377
        </fpage>
        –
        <lpage>
         82
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/S0161-6420(02)01168-5
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         12093666
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0012">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Marmor
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kellner
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lai
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Melles
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mieler
          </surname>
          <given-names>
           W.F.
          </given-names>
         </name>
         ,
         <collab>
          American Academy of Ophthalmology
         </collab>
        </person-group>
        <year>
         2016
        </year>
        <article-title>
         Recommendations on screening for chloroquine and hydroxychloroquine retinopathy
        </article-title>
        .
        <source>
         <italic>
          Ophthalmology
         </italic>
        </source>
        <volume>
         123
        </volume>
        :
        <fpage>
         1386
        </fpage>
        –
        <lpage>
         94
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.ophtha.2016.01.058
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         26992838
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0013">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Mavrikakis
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sfikakis
          </surname>
          <given-names>
           P. P.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mavrikakis
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rougas
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nikolaou
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kostopoulos
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Mavrikakis
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <year>
         2003
        </year>
        <article-title>
         The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: A reappraisal
        </article-title>
        .
        <source>
         <italic>
          Ophthalmology
         </italic>
        </source>
        <volume>
         110
        </volume>
        :
        <fpage>
         1321
        </fpage>
        –
        <lpage>
         26
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/S0161-6420(03)00409-3
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         12867385
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0014">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Melles
          </surname>
          <given-names>
           R. B.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Marmor
          </surname>
          <given-names>
           M. F.
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        <article-title>
         The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy
        </article-title>
        .
        <source>
         <italic>
          J. Am. Med. Assoc. Ophthalmol.
         </italic>
        </source>
        <volume>
         132
        </volume>
        :
        <fpage>
         1453
        </fpage>
        –
        <lpage>
         60
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0015">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Melles
          </surname>
          <given-names>
           R. B.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Marmor
          </surname>
          <given-names>
           M. F.
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         Pericentral retinopathy and racial differences in hydroxychloroquine toxicity
        </article-title>
        .
        <source>
         <italic>
          Ophthalmology
         </italic>
        </source>
        <volume>
         122
        </volume>
        :
        <fpage>
         110
        </fpage>
        –
        <lpage>
         16
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.ophtha.2014.07.018
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25182842
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0016">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Plantone
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Koudriavtseva
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <year>
         2018
        </year>
        <article-title>
         Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: A mini-review
        </article-title>
        .
        <source>
         <italic>
          Clin. Drug Investig.
         </italic>
        </source>
        <volume>
         38
        </volume>
        :
        <fpage>
         653
        </fpage>
        –
        <lpage>
         71
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1007/s40261-018-0656-y
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0017">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rainsford
          </surname>
          <given-names>
           K. D.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Parke
          </surname>
          <given-names>
           A. L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Clifford-Rashotte
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Kean
          </surname>
          <given-names>
           W. F.
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases
        </article-title>
        .
        <source>
         <italic>
          Inflammopharmacology
         </italic>
        </source>
        <volume>
         23
        </volume>
        :
        <fpage>
         231
        </fpage>
        –
        <lpage>
         69
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26246395
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0018">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Riccio
          </surname>
          <given-names>
           E. S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lee
          </surname>
          <given-names>
           P. S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Winegar
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Krogstad
          </surname>
          <given-names>
           D. J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           De
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Mirsalis
          </surname>
          <given-names>
           J. C.
          </given-names>
         </name>
        </person-group>
        <year>
         2001
        </year>
        <article-title>
         Genetic toxicology testing of the antimalarial drugs chloroquine and a new analog, AQ-13
        </article-title>
        .
        <source>
         <italic>
          Environ. Mol. Mutagen.
         </italic>
        </source>
        <volume>
         38
        </volume>
        :
        <fpage>
         69
        </fpage>
        –
        <lpage>
         79
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1002/em.1052
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         11473390
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0019">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Stein
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bell
          </surname>
          <given-names>
           M. J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Ang
          </surname>
          <given-names>
           L. C.
          </given-names>
         </name>
        </person-group>
        <year>
         2000
        </year>
        <article-title>
         Hydroxychloroquine neuromyotoxicity
        </article-title>
        .
        <source>
         <italic>
          J. Rheumatol.
         </italic>
        </source>
        <volume>
         27
        </volume>
        :
        <fpage>
         2927
        </fpage>
        –
        <lpage>
         31
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11128688
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0020">
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Stokkermans
          </surname>
          <given-names>
           T. J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Trichonas
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <year>
         2019
        </year>
        <source>
         <italic>
          Chloroquine and Hydroxychloroquine Toxicity
         </italic>
        </source>
        .
        <publisher-name>
         Stat Pearls. Stat Pearls Publishing, LLC
        </publisher-name>
        <fpage>
         10
        </fpage>
        <comment>
         Gen 22; NBK 537086
        </comment>
       </mixed-citation>
      </ref>
      <ref id="CIT0021">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Touret
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           de Lamballerie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <year>
         2020
        </year>
        <article-title>
         Of chloroquine and COVID-19
        </article-title>
        .
        <source>
         <italic>
          Antiviral Res.
         </italic>
        </source>
        <volume>
         177
        </volume>
        :
        <fpage>
         104762
        </fpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2020.104762
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         32147496
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0022">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wolfe
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Marmor
          </surname>
          <given-names>
           M. F.
          </given-names>
         </name>
        </person-group>
        <year>
         2010
        </year>
        <article-title>
         Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus
        </article-title>
        .
        <source>
         <italic>
          Arthritis Care Res. (Hoboken)
         </italic>
        </source>
        <volume>
         62
        </volume>
        :
        <fpage>
         775
        </fpage>
        –
        <lpage>
         84
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1002/acr.20133
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         20535788
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0023">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yam
          </surname>
          <given-names>
           J. C.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Kwok
          </surname>
          <given-names>
           A. K.
          </given-names>
         </name>
        </person-group>
        <year>
         2006
        </year>
        <article-title>
         Ocular toxicity of hydroxychloroquine
        </article-title>
        .
        <source>
         <italic>
          Hong Kong Med. J.
         </italic>
        </source>
        <volume>
         12
        </volume>
        :
        <fpage>
         294
        </fpage>
        –
        <lpage>
         304
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16912357
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0024">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yogasundaram
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Putko
          </surname>
          <given-names>
           B. N.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tien
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Paterson
          </surname>
          <given-names>
           D. I.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cujec
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ringrose
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Oudit
          </surname>
          <given-names>
           G. Y.
          </given-names>
         </name>
        </person-group>
        <year>
         2014
        </year>
        <article-title>
         Hydroxychloroquine-induced cardiomyopathy: Case report, pathophysiology, diagnosis, and treatment
        </article-title>
        .
        <source>
         <italic>
          Can. J. Cardiol.
         </italic>
        </source>
        <volume>
         30
        </volume>
        :
        <fpage>
         1706
        </fpage>
        –
        <lpage>
         15
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1016/j.cjca.2014.08.016
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25475472
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0025">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zheng
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Dai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <year>
         2020
        </year>
        <article-title>
         Controversial treatments: An updated understanding of the Coronavirus Disease 2019
        </article-title>
        .
        <source>
         <italic>
          J. Med. Virol.
         </italic>
        </source>
        doi:
        <pub-id pub-id-type="doi">
         10.1002/jmv.25788
        </pub-id>
        <comment>
         Epub ahead of print
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0026">
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Liao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           L. J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Xiao
          </surname>
          <given-names>
           H. T.
          </given-names>
         </name>
        </person-group>
        <year>
         2015
        </year>
        <article-title>
         The utility of chloroquine in cancer therapy
        </article-title>
        .
        <source>
         <italic>
          Curr. Med. Res. Opin.
         </italic>
        </source>
        <volume>
         31
        </volume>
        :
        <fpage>
         1009
        </fpage>
        –
        <lpage>
         13
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1185/03007995.2015.1025731
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25734693
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Int J Antimicrob Agents
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Int. J. Antimicrob. Agents
      </journal-id>
      <journal-title-group>
       <journal-title>
        International Journal of Antimicrobial Agents
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0924-8579
      </issn>
      <issn pub-type="epub">
       1872-7913
      </issn>
      <publisher>
       <publisher-name>
        Published by Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32205204
      </article-id>
      <article-id pub-id-type="pmc">
       7102549
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0924-8579(20)30099-6
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.ijantimicag.2020.105949
      </article-id>
      <article-id pub-id-type="publisher-id">
       105949
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0001">
        <name>
         <surname>
          Gautret
         </surname>
         <given-names>
          Philippe
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
        <xref ref-type="fn" rid="fn1">
         $
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0002">
        <name>
         <surname>
          Lagier
         </surname>
         <given-names>
          Jean-Christophe
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
        <xref ref-type="fn" rid="fn1">
         $
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0003">
        <name>
         <surname>
          Parola
         </surname>
         <given-names>
          Philippe
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0004">
        <name>
         <surname>
          Hoang
         </surname>
         <given-names>
          Van Thuan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
        <xref ref-type="aff" rid="aff0004">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Meddeb
         </surname>
         <given-names>
          Line
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0006">
        <name>
         <surname>
          Mailhe
         </surname>
         <given-names>
          Morgane
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0007">
        <name>
         <surname>
          Doudier
         </surname>
         <given-names>
          Barbara
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0008">
        <name>
         <surname>
          Courjon
         </surname>
         <given-names>
          Johan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0005">
         e
        </xref>
        <xref ref-type="aff" rid="aff0006">
         f
        </xref>
        <xref ref-type="aff" rid="aff0007">
         g
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0009">
        <name>
         <surname>
          Giordanengo
         </surname>
         <given-names>
          Valérie
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0008">
         h
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0010">
        <name>
         <surname>
          Vieira
         </surname>
         <given-names>
          Vera Esteves
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0011">
        <name>
         <surname>
          Dupont
         </surname>
         <given-names>
          Hervé Tissot
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0012">
        <name>
         <surname>
          Honoré
         </surname>
         <given-names>
          Stéphane
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0009">
         i
        </xref>
        <xref ref-type="aff" rid="aff0010">
         j
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0013">
        <name>
         <surname>
          Colson
         </surname>
         <given-names>
          Philippe
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0014">
        <name>
         <surname>
          Chabrière
         </surname>
         <given-names>
          Eric
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0015">
        <name>
         <surname>
          La Scola
         </surname>
         <given-names>
          Bernard
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0016">
        <name>
         <surname>
          Rolain
         </surname>
         <given-names>
          Jean-Marc
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0017">
        <name>
         <surname>
          Brouqui
         </surname>
         <given-names>
          Philippe
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0018">
        <name>
         <surname>
          Raoult
         </surname>
         <given-names>
          Didier
         </given-names>
        </name>
        <email>
         Didier.raoult@gmail.com
        </email>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
        <xref ref-type="corresp" rid="cor0001">
         ⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0001">
       <label>
        a
       </label>
       IHU-Méditerranée Infection, Marseille, France
      </aff>
      <aff id="aff0002">
       <label>
        b
       </label>
       Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France
      </aff>
      <aff id="aff0003">
       <label>
        c
       </label>
       Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France
      </aff>
      <aff id="aff0004">
       <label>
        d
       </label>
       Thai Binh University of Medicine and Pharmacy, Thai Binh, Viet Nam
      </aff>
      <aff id="aff0005">
       <label>
        e
       </label>
       Infectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France
      </aff>
      <aff id="aff0006">
       <label>
        f
       </label>
       Université Côte d'Azur, Nice, France
      </aff>
      <aff id="aff0007">
       <label>
        g
       </label>
       U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Virulence Microbienne et Signalisation Inflammatoire, INSERM, Nice, France
      </aff>
      <aff id="aff0008">
       <label>
        h
       </label>
       Department of Virology, Biological and Pathological Center, Centre Hospitalier Universitaire de Nice, 06200 Nice, France
      </aff>
      <aff id="aff0009">
       <label>
        i
       </label>
       Service Pharmacie, Hôpital Timone, AP-HM, Marseille, France
      </aff>
      <aff id="aff0010">
       <label>
        j
       </label>
       Laboratoire de Pharmacie Clinique, Aix Marseille Université, Marseille, France
      </aff>
      <author-notes>
       <corresp id="cor0001">
        <label>
         ⁎
        </label>
        Corresponding author.
        <email>
         Didier.raoult@gmail.com
        </email>
       </corresp>
       <fn id="fn1">
        <label>
         $
        </label>
        <p id="notep0001">
         equal work
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        20
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        20
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       105949
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         16
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         17
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Published by Elsevier B.V.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0001">
       <sec>
        <title>
         Background
        </title>
        <p>
         Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads.
        </p>
       </sec>
       <sec>
        <title>
         Patients and methods
        </title>
        <p>
         French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16
         <sup>
          th
         </sup>
         , to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p>
         Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms.
        </p>
        <p>
         Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.
        </p>
       </sec>
       <sec>
        <title>
         Conclusion
        </title>
        <p>
         Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
        </p>
       </sec>
      </abstract>
      <kwd-group id="keys0001">
       <title>
        Key words
       </title>
       <kwd>
        2019-nCoV
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        hydroxychloroquine
       </kwd>
       <kwd>
        azithomycin
       </kwd>
       <kwd>
        clinical trial
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec0001">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="para0007">
      In late December 2019, an outbreak of an emerging disease (COVID-19) due to a novel coronavirus (named SARS-CoV-2 latter) started in Wuhan, China and rapidly spread in China and outside [
      <xref ref-type="bibr" rid="bib0001">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0002">
       2
      </xref>
      ]. The WHO declared the epidemic of COVID-19 as a pandemic on March 12
      <sup>
       th
      </sup>
      2020
      <xref ref-type="bibr" rid="bib0003">
       [3]
      </xref>
      . According to a recent Chinese stud, about 80% of patients present with mild disease and the overall case-fatality rate is about 2.3% but reaches 8.0% in patients aged 70 to 79 years and 14.8% in those aged ≥80 years
      <xref ref-type="bibr" rid="bib0004">
       [4]
      </xref>
      . However, there is probably an important number of asymptomatic carriers in the population, and thus the mortality rate is probably overestimated. France is now facing the COVID-19 wave with more than 4500 cases, as of March 14
      <sup>
       th
      </sup>
      2020
      <xref ref-type="bibr" rid="bib0005">
       [5]
      </xref>
      . Thus, there is an urgent need for an effective treatment to treat symptomatic patients but also to decrease the duration of virus carriage in order to limit the transmission in the community. Among candidate drugs to treat COVID-19, repositioning of old drugs for use as antiviral treatment is an interesting strategy because knowledge on safety profile, side effects, posology and drug interactions are well known [
      <xref ref-type="bibr" rid="bib0006">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0007">
       7
      </xref>
      ].
     </p>
     <p id="para0008">
      A recent paper reported an inhibitor effect of remdesivir (a new antiviral drug) and chloroquine (an old antimalarial drug) on the growth of SARS-CoV-2
      <italic>
       in vitro,
      </italic>
      <xref ref-type="bibr" rid="bib0008">
       [8]
      </xref>
      and an early clinical trial conducted in COVID-19 Chinese patients, showed that chloroquine had a significant effect, both in terms of clinical outcome and viral clearance, when comparing to controls groups [
      <xref ref-type="bibr" rid="bib0009">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0010">
       10
      </xref>
      ]. Chinese experts recommend that patients diagnosed as mild, moderate and severe cases of COVID-19 pneumonia and without contraindications to chloroquine, be treated with 500 mg chloroquine twice a day for ten days
      <xref ref-type="bibr" rid="bib0011">
       [11]
      </xref>
      .
     </p>
     <p id="para0009">
      Hydroxychloroquine (an analogue of chloroquine) has been demonstrated to have an anti-SARS-CoV activity
      <italic>
       in vitro
      </italic>
      <xref ref-type="bibr" rid="bib0012">
       [12]
      </xref>
      . Hydroxychloroquine clinical safety profile is better than that of chloroquine (during long-term use) and allows higher daily dose
      <xref ref-type="bibr" rid="bib0013">
       [13]
      </xref>
      and has fewer concerns about drug-drug interactions
      <xref ref-type="bibr" rid="bib0014">
       [14]
      </xref>
      . Our team has a very comprehensive experience in successfully treating patients with chronic diseases due to intracellular bacteria (Q fever due to
      <italic>
       Coxiella burnetii
      </italic>
      and Whipple's disease due to
      <italic>
       Tropheryma whipplei
      </italic>
      ) with long-term hydroxychloroquine treatment (600 mg/day for 12 to 18 months) since more than 20 years. [
      <xref ref-type="bibr" rid="bib0015">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0016">
       16
      </xref>
      ] We therefore started to conduct a clinical trial aiming at assessing the effect of hydroxychloroquine on SARS-CoV-2-infected patients after approval by the French Ministry of Health. In this report we describe our early results, focusing on virological data in patients receiving hydroxychloroquine as compared to a control group.
     </p>
    </sec>
    <sec id="sec0002">
     <label>
      2
     </label>
     <title>
      Study population and Methods
     </title>
     <sec id="sec0003">
      <label>
       2.1
      </label>
      <title>
       Setting
      </title>
      <p id="para0010">
       This ongoing study is coordinated by The Méditerranée Infection University Hospital Institute in Marseille. Patients who were proposed a treatment with hydroxychloroquine were recruited and managed in Marseille centre. Controls without hydroxychloroquine treatment were recruited in Marseille, Nice, Avignon and Briançon centers, all located in South France.
      </p>
     </sec>
     <sec id="sec0004">
      <label>
       2.2
      </label>
      <title>
       Patients
      </title>
      <p id="para0011">
       Hospitalized patients with confirmed COVID-19 were included in this study if they fulfilled two primary criteria: i) age &gt;12 years; ii) PCR documented SARS-CoV-2 carriage in nasopharyngeal sample at admission whatever their clinical status.
      </p>
      <p id="para0012">
       Patients were excluded if they had a known allergy to hydroxychloroquine or chloroquine or had another known contraindication to treatment with the study drug, including retinopathy, G6PD deficiency and QT prolongation. Breastfeeding and pregnant patients were excluded based on their declaration and pregnancy test results when required.
      </p>
     </sec>
     <sec id="sec0005">
      <label>
       2.3
      </label>
      <title>
       Informed consent
      </title>
      <p id="para0013">
       Before being included in the study, patients meeting inclusion criteria had to give their consent to participate to the study. Written informed signed consent was obtained from adult participants (≥ 18 years) or from parents or legal guardians for minors (&lt;18 years). An information document that clearly indicates the risks and the benefits associated with the participation to the study was given to each patient. Patients received information about their clinical status during care regardless of whether they participate in the study or not. Regarding patient identification, a study number was assigned sequentially to included participants, according to the range of patient numbers allocated to each study centre. The study was conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines of good clinical practice, the Helsinki Declaration, and applicable standard operating procedures.
      </p>
      <p id="para0014">
       The protocol, appendices and any other relevant documentation were submitted to the French National Agency for Drug Safety (ANSM) (2020-000890-25) and to the French Ethic Committee (CPP Ile de France) (20.02.28.99113) for reviewing and approved on 5
       <sup>
        th
       </sup>
       and 6
       <sup>
        th
       </sup>
       March, 2020, respectively. This trial is registered with EU Clinical Trials Register, number 2020-000890-25.
      </p>
     </sec>
     <sec id="sec0006">
      <label>
       2.4
      </label>
      <title>
       Procedure
      </title>
      <p id="para0015">
       Patients were seen at baseline for enrolment, initial data collection and treatment at day-0, and again for daily follow-up during 14 days. Each day, patients received a standardized clinical examination and when possible, a nasopharyngeal sample was collected. All clinical data were collected using standardized questionnaires. All patients in Marseille center were proposed oral hydroxychloroquine sulfate 200 mg, three times per day during ten days (in this preliminary phase,we did not enrolled children in the treatment group based in data indicating that children develop mild symptoms of COVID-19
       <xref ref-type="bibr" rid="bib0004">
        [4]
       </xref>
       ). Patients who refused the treatment or had an exclusion criteria, served as controls in Marseille centre. Patients in other centers did not receive hydroxychloroquine and served as controls. Symptomatic treatment and antibiotics as a measure to prevent bacterial super-infection was provided by investigators based on clinical judgment. Hydroxychloroquine was provided by the National Pharmacy of France on nominative demand.
      </p>
     </sec>
     <sec id="sec0007">
      <label>
       2.5
      </label>
      <title>
       Clinical classification
      </title>
      <p id="para0016">
       Patients were grouped into three categories: asymptomatic, upper respiratory tract infection (URTI) when presenting with rhinitis, pharyngitis, or isolated low-grade fever and myalgia, and lower respiratory tract infections (LRTI) when presenting with symptoms of pneumonia or bronchitis.
      </p>
     </sec>
     <sec id="sec0008">
      <label>
       2.6
      </label>
      <title>
       PCR assay
      </title>
      <p id="para0017">
       SARS-CoV-2 RNA was assessed by real-time reverse transcription-PCR
       <xref ref-type="bibr" rid="bib0017">
        [17]
       </xref>
       .
      </p>
     </sec>
     <sec id="sec0009">
      <label>
       2.7
      </label>
      <title>
       Hydroxychloroquine dosage
      </title>
      <p id="para0018">
       Native hydroxychloroquine has been dosed from patients’ serum samples by UHPLC-UV using a previously described protocol
       <xref ref-type="bibr" rid="bib0018">
        [18]
       </xref>
       . The peak of the chromatogram at 1.05 min of retention corresponds to hydroxychloroquine metabolite. The serum concentration of this metabolite is deduced from UV absorption, as for hydroxychloroquine concentration. Considering both concentrations provides an estimation of initial serum hydroxychloroquine concentration.
      </p>
     </sec>
     <sec id="sec0010">
      <label>
       2.8
      </label>
      <title>
       Culture
      </title>
      <p id="para0019">
       For all patients, 500 µL of the liquid collected from the nasopharyngeal swab were passed through 0.22-µm pore sized centrifugal filter (Merck millipore, Darmstadt, Germany), then were inoculated in wells of 96-well culture microplates, of which 4 wells contained Vero E6 cells (ATCC CRL-1586) in Minimum Essential Medium culture medium with 4% fetal calf serum and 1% glutamine. After centrifigation at 4,000 g, microplates were incubated at 37°C. Plates were observed daily for evidence of cytopathogenic effect. Presumptive detection of virus in supernatant was done using SU5000 SEM (Hitachi) then confirmed by specific RT-PCR.
      </p>
     </sec>
     <sec id="sec0011">
      <label>
       2.9
      </label>
      <title>
       Outcome
      </title>
      <p id="para0020">
       The primary endpoint was virological clearance at day-6 post-inclusion. Secondary outcomes were virological clearance overtime during the study period, clinical follow-up (body temperature, respiratory rate, long of stay at hospital and mortality), and occurrence of side-effects.
      </p>
     </sec>
     <sec id="sec0012">
      <label>
       2.10
      </label>
      <title>
       Statistics
      </title>
      <p id="para0021">
       Assuming a 50% efficacy of hydroxychloroquine in reducing the viral load at day 7, a 85% power, a type I error rate of 5% and 10% loss to follow-up, we calculated that a total of 48 COVID-19 patients (ie, 24 cases in the hydroxychloroquine group and 24 in the control group) would be required for the analysis (Fleiss with CC). Statistical differences were evaluated by Pearson's chi-square or Fisher's exact tests as categorical variables, as appropriate. Means of quantitative data were compared using Student's t-test. Analyses were performed in Stata version 14.2.
      </p>
     </sec>
    </sec>
    <sec id="sec0013" sec-type="supplementary-material">
     <label>
      3
     </label>
     <title>
      Results (detailed results are available in supplementary Table 1)
     </title>
     <sec id="sec0014">
      <label>
       3.1
      </label>
      <title>
       Demographics and clinical presentation
      </title>
      <p id="para0022">
       We enrolled 36 out of 42 patients meeting the inclusion criteria in this study that had at least six days of follow-up at the time of the present analysis. A total of 26 patients received hydroxychloroquine and 16 were control patients. Six hydroxychloroquine-treated patients were lost in follow-up during the survey because of early cessation of treatment. Reasons are as follows: three patients were transferred to intensive care unit, including one transferred on day2 post-inclusion who was PCR-positive on day1, one transferred on day3 post-inclusion who was PCR-positive on days1-2 and one transferred on day4 post-inclusion who was PCR-positive on day1 and day3; one patient died on day3 post inclusion and was PCR-negative on day2; one patient decided to leave the hospital on day3 post-inclusion and was PCR-negative on days1-2; finally, one patient stopped the treatment on day3 post-inclusion because of nausea and was PCR-positive on days1-2-3. The results presented here are therefore those of 36 patients (20 hydroxychloroquine-treated patients and 16 control patients). None of the control patients was lost in follow-up. Basic demographics and clinical status are presented in
       <xref ref-type="table" rid="tbl0001">
        Table 1
       </xref>
       . Overall, 15 patients were male (41.7%), with a mean age of 45.1 years. The proportion of asymptomatic patients was 16.7%, that of patients with URTI symptoms was 61.1% and that of patients with LRTI symptoms was 22.2%). All patients with LRTI symptoms, had confirmed pneumonia by CTScan. Hydroxychloroquine-treated patients were older than control patients (51.2 years vs. 37.3 years). No significant difference was observed between hydroxychloroquine-treated patients and control patients with regard to gender, clinical status and duration of symptoms prior to inclusion (
       <xref ref-type="table" rid="tbl0001">
        Table 1
       </xref>
       ). Among hydroxychloroquine-treated patients six patients received azithromycin (500mg on day1 followed by 250mg per day, the next four days) to prevent bacterial super-infection under daily electrocardiogram control. Clinical follow-up and occurrence of side-effects will be described in a further paper at the end of the trial.
       <table-wrap id="tbl0001" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Characteristics of the study population.
         </p>
        </caption>
        <alt-text id="alt0003">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th valign="top">
           </th>
           <th align="left" colspan="3" valign="top">
            Age (years)
           </th>
           <th align="left" colspan="2" valign="top">
            Male gender
           </th>
           <th align="left" colspan="4" valign="top">
            Clinical status
           </th>
           <th align="left" colspan="3" valign="top">
            Time between onset of symptoms and inclusion (days)
           </th>
          </tr>
          <tr>
           <th valign="top">
           </th>
           <th valign="top">
            Mean ± SD
           </th>
           <th valign="top">
            t
           </th>
           <th valign="top">
            p-value
           </th>
           <th valign="top">
            n (%)
           </th>
           <th valign="top">
            p-value
           </th>
           <th valign="top">
            Asymptomatic
           </th>
           <th valign="top">
            URTI
           </th>
           <th valign="top">
            LRTI
           </th>
           <th valign="top">
            p-value
           </th>
           <th valign="top">
            Mean ± SD
           </th>
           <th valign="top">
            t
           </th>
           <th valign="top">
            p-value
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td valign="top">
            Hydroxychloroquine treated patients (N=20)
           </td>
           <td valign="top">
            51.2 ± 18.7
           </td>
           <td valign="top">
            -1.95
           </td>
           <td valign="top">
            0.06
           </td>
           <td valign="top">
            9 (45.0)
           </td>
           <td valign="top">
            0.65
           </td>
           <td valign="top">
            2 (10.0)
           </td>
           <td valign="top">
            12 (60.0)
           </td>
           <td valign="top">
            6 (30.0)
           </td>
           <td valign="top">
            0.30
           </td>
           <td valign="top">
            4.1 ± 2.6
           </td>
           <td valign="top">
            -0.15
           </td>
           <td valign="top">
            0.88
           </td>
          </tr>
          <tr>
           <td valign="top">
            Control patients (N=16)
           </td>
           <td valign="top">
            37.3 ± 24.0
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            6 (37.5)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            4 (25.0)
           </td>
           <td valign="top">
            10 (62.5)
           </td>
           <td valign="top">
            2 (12.5)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            3.9 ± 2.8
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
          </tr>
          <tr>
           <td valign="top">
            All patients (36)
           </td>
           <td valign="top">
            45.1 ± 22.0
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            15 (41.7)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            6 (16.7)
           </td>
           <td valign="top">
            22 (61.1)
           </td>
           <td valign="top">
            8 (22.2)
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            4.0 ± 2.6
           </td>
           <td valign="top">
           </td>
           <td valign="top">
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           URTI: upper tract respiratory infection, LRTI: lower tract respiratory infection
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec0015">
      <label>
       3.2
      </label>
      <title>
       Hydroxychloroquine dosage
      </title>
      <p id="para0023">
       Mean hydroxychloroquine serum concentration was 0.46 µg/ml±0.2 (N=20).
      </p>
     </sec>
     <sec id="sec0016">
      <label>
       3.3
      </label>
      <title>
       Effect of hydroxychloroquine on viral load
      </title>
      <p id="para0024">
       The proportion of patients that had negative PCR results in nasopharyngeal samples significantly differed between treated patients and controls at days 3-4-5 and 6 post-inclusion (
       <xref ref-type="table" rid="tbl0002">
        Table 2
       </xref>
       ). At day6 post-inclusion, 70% of hydroxychloroquine-treated patients were virologicaly cured comparing with 12.5% in the control group (p= 0.001).
       <table-wrap id="tbl0002" position="float">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Proportion of patients with virological cure (negative nasopharyngeal PCR) by day, in COVID-19 patients treated with hydroxychloroquine and in COVID-19 control patients.
         </p>
        </caption>
        <alt-text id="alt0004">
         Table 2
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th valign="top">
           </th>
           <th align="left" colspan="3" valign="top">
            Day3 post inclusion
           </th>
           <th align="left" colspan="3" valign="top">
            Day4 post inclusion
           </th>
           <th align="left" colspan="3" valign="top">
            Day5 post inclusion
           </th>
           <th align="left" colspan="3" valign="top">
            Day6 post inclusion
           </th>
          </tr>
          <tr>
           <th valign="top">
           </th>
           <th valign="top">
            Number of negative patients/total number of patients
           </th>
           <th valign="top">
            %
           </th>
           <th valign="top">
            p-value
           </th>
           <th valign="top">
            Number of negative patients/total number of patients
           </th>
           <th valign="top">
            %
           </th>
           <th valign="top">
            p-value
           </th>
           <th valign="top">
            Number of negative patients/total number of patients
           </th>
           <th valign="top">
            %
           </th>
           <th valign="top">
            p-value
           </th>
           <th valign="top">
            Number of negative patients/total number of patients
           </th>
           <th valign="top">
            %
           </th>
           <th valign="top">
            p-value
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td valign="top">
            Hydroxychloroquine treated patients (N=20)
           </td>
           <td valign="top">
            10/20
           </td>
           <td valign="top">
            50.0
           </td>
           <td valign="top">
            0.005
           </td>
           <td valign="top">
            12/20
           </td>
           <td valign="top">
            60.0
           </td>
           <td valign="top">
            0.04
           </td>
           <td valign="top">
            13/20
           </td>
           <td valign="top">
            65.0
           </td>
           <td valign="top">
            0.006
           </td>
           <td valign="top">
            14/20
           </td>
           <td valign="top">
            70.0
           </td>
           <td valign="top">
            0.001
           </td>
          </tr>
          <tr>
           <td valign="top">
            Control patients (N=16)
           </td>
           <td valign="top">
            1/16
           </td>
           <td valign="top">
            6.3
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            4/16
           </td>
           <td valign="top">
            25.0
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            3/16
           </td>
           <td valign="top">
            18.8
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            2/16
           </td>
           <td valign="top">
            12.5
           </td>
           <td valign="top">
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           <sup>
            a
           </sup>
           control patients from centers other than Marseille did not underwent daily sampling, but were sampled every other day in most cases, they were considered positive for PCR when actually positive the day(s) before and the day(s) after the day(s) with missing data.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p id="para0025">
       When comparing the effect of hydroxychloroquine treatment as a single drug and the effect of hydroxychloroquine and azithromyc in combination, the proportion of patients that had negative PCR results in nasopharyngeal samples was significantly different between the two groups at days 3-4-5 and 6 post-inclusion (
       <xref ref-type="table" rid="tbl0003">
        Table 3
       </xref>
       ). At day6 post-inclusion, 100% of patients treated with hydroxychloroquine and azithromycin combination were virologicaly cured comparing with 57.1% in patients treated with hydroxychloroquine only, and 12.5% in the control group (p&lt;0.001). These results are summarized in
       <xref ref-type="fig" rid="fig0001">
        Figure 1
       </xref>
       ,
       <xref ref-type="fig" rid="fig0002">
        Figure 2
       </xref>
       . Drug effect was significantly higher in patients with symptoms of URTI and LRTI, as compared to asymptomatic patients with p&lt;0.05 (data not show).
       <table-wrap id="tbl0003" position="float">
        <label>
         Table 3
        </label>
        <caption>
         <p>
          Proportion of patients with virological cure (negative nasopharyngeal PCR) by day, in COVID-19 patients treated with hydroxychloroquine only, in COVID-19 patients treated with hydroxychloroquine and azithomycin combination, and in COVID-19 control patients.
         </p>
        </caption>
        <alt-text id="alt0005">
         Table 3
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th valign="top">
           </th>
           <th align="left" colspan="3" valign="top">
            Day3 post inclusion
           </th>
           <th align="left" colspan="3" valign="top">
            Day4 post inclusion
           </th>
           <th align="left" colspan="3" valign="top">
            Day5 post inclusion
           </th>
           <th align="left" colspan="3" valign="top">
            Day6 post inclusion
           </th>
          </tr>
          <tr>
           <th valign="top">
           </th>
           <th valign="top">
            Number of negative patients/total number of patients
           </th>
           <th valign="top">
            %
           </th>
           <th valign="top">
            p-value
           </th>
           <th valign="top">
            Number of negative patients/total number of patients
           </th>
           <th valign="top">
            %
           </th>
           <th valign="top">
            p-value
           </th>
           <th valign="top">
            Number of negative patients/total number of patients
           </th>
           <th valign="top">
            %
           </th>
           <th valign="top">
            p-value
           </th>
           <th valign="top">
            Number of negative patients/total number of patients
           </th>
           <th valign="top">
            %
           </th>
           <th valign="top">
            p-value
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td valign="top">
            Control patients
           </td>
           <td valign="top">
            1/16
           </td>
           <td valign="top">
            6.3
           </td>
           <td valign="top">
            0.002
           </td>
           <td valign="top">
            4/16
           </td>
           <td valign="top">
            25.0
           </td>
           <td valign="top">
            0.05
           </td>
           <td valign="top">
            3/16
           </td>
           <td valign="top">
            18.8
           </td>
           <td valign="top">
            0.002
           </td>
           <td valign="top">
            2/16
           </td>
           <td valign="top">
            12.5
           </td>
           <td valign="top">
            &lt;0.001
           </td>
          </tr>
          <tr>
           <td valign="top">
            Hydroxychloroquine treatment only
           </td>
           <td valign="top">
            5/14
           </td>
           <td valign="top">
            35.7
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            7/14
           </td>
           <td valign="top">
            50.0
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            7/14
           </td>
           <td valign="top">
            50.0
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            8/14
           </td>
           <td valign="top">
            57.1
           </td>
           <td valign="top">
           </td>
          </tr>
          <tr>
           <td valign="top">
            Hydroxychloroquine and azithromycin combined treatment
           </td>
           <td valign="top">
            5/6
           </td>
           <td valign="top">
            83.3
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            5/6
           </td>
           <td valign="top">
            83.3
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            6/6
           </td>
           <td valign="top">
            100
           </td>
           <td valign="top">
           </td>
           <td valign="top">
            6/6
           </td>
           <td valign="top">
            100
           </td>
           <td valign="top">
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
       <fig id="fig0001">
        <label>
         Figure 1
        </label>
        <caption>
         <p>
          Percentage of patients with PCR-positive nasopharyngeal samples from inclusion to day6 post-inclusion in COVID-19 patients treated with hydroxychloroquine and in COVID-19 control patients.
         </p>
        </caption>
        <alt-text id="alt0001">
         Figure 1
        </alt-text>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
       <fig id="fig0002">
        <label>
         Figure 2
        </label>
        <caption>
         <p>
          Percentage of patients with PCR-positive nasopharyngeal samples from inclusion to day6 post-inclusion in COVID-19 patients treated with hydroxychloroquine only, in COVID-19 patients treated with hydroxychloroquine and azithomycin combination, and in COVID-19 control patients.
         </p>
        </caption>
        <alt-text id="alt0002">
         Figure 2
        </alt-text>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
      </p>
      <p id="para0026">
       Of note, one patient who was still PCR-positive at day6-post inclusion under hydroxychloroquine treatment only, received azithromycin in addition to hydroxychloroquine at day8-post inclusion and cured her infection at day-9 post infection. In contrast, one of the patients under hydroxychloroquine and azithromycin combination who tested negative at day6 post-inclusion was tested positive at low titer at day8 post-inclusion.
      </p>
     </sec>
     <sec id="sec0017">
      <label>
       3.4
      </label>
      <title>
       Cultures
      </title>
      <p id="para0027">
       We could isolate SARS-CoV-2 in 19 out of 25 clinical samples from patients.
      </p>
     </sec>
    </sec>
    <sec id="sec0018">
     <label>
      4
     </label>
     <title>
      Discussion
     </title>
     <p id="para0028">
      For ethical reasons and because our first results are so significant and evident we decide to share our findings with the medical community, given the urgent need for an effective drug against SARS-CoV-2 in the current pandemic context.
     </p>
     <p id="para0029">
      We show here that hydroxychloroquine is efficient in clearing viral nasopharyngeal carriage of SARS-CoV-2 in COVID-19 patients in only three to six days, in most patients. A significant difference was observed between hydroxychloroquine-treated patients and controls starting even on day3 post-inclusion. These results are of great importance because a recent paper has shown that the mean duration of viral shedding in patients suffering from COVID-19 in China was 20 days (even 37 days for the longest duration)
      <xref ref-type="bibr" rid="bib0019">
       [19]
      </xref>
     </p>
     <p id="para0030">
      Very recently, a Chinese team published results of a study demonstrating that chloroquine and hydroxychloroquine inhibit SARS-CoV-2
      <italic>
       in vitro
      </italic>
      with hydroxychloroquine (EC50=0.72%µM) found to be more potent than chloroquine (EC50=5.47%µM)
      <xref ref-type="bibr" rid="bib0014">
       [14]
      </xref>
      . These
      <italic>
       in vitro
      </italic>
      results corroborate our clinical results. The target values indicated in this paper
      <xref ref-type="bibr" rid="bib0014">
       [14]
      </xref>
      were reached in our experiments. The safer dose-dependent toxicity profile of hydroxychloroquine in humans, compared to that of chloroquine
      <xref ref-type="bibr" rid="bib0013">
       [13]
      </xref>
      allows using clinical doses of hydroxychloroquine that will be over its EC50 observed
      <italic>
       in vitro
      </italic>
      <xref ref-type="bibr" rid="bib0014">
       [14]
      </xref>
      .
     </p>
     <p id="para0031">
      Our preliminary results also suggest a synergistic effect of the combination of hydroxychloroquine and azithromycin. Azithromycin has been shown to be active
      <italic>
       in vitro
      </italic>
      against Zika and Ebola viruses
      <xref ref-type="bibr" rid="bib0020">
       [20]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0021">
       [21]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0022">
       [22]
      </xref>
      and to prevent severe respiratory tract infections when administrated to patients suffering viral infection
      <xref ref-type="bibr" rid="bib0023">
       [23]
      </xref>
      . This finding should be further explored to know whether a combination is more effective especially in severe cases. Speculated potential risk of severe QT prolongation induced by the association of the two drugs has not been established yet but should be considered. As for each treatment, the cost benefits of the risk should be evaluated individually. Further studies on this combination are needed, since such combination may both act as an antiviral therapy against SARS-CoV-2 and prevent bacterial super-infections.
     </p>
     <p id="para0032">
      The cause of failure for hydroxychloroquine treatment should be investigated by testing the isolated SARS-CoV-2 strains of the non-respondents and analyzing their genome, and by analyzing the host factors that may be associated with the metabolism of hydroxychloroquine. The existence of hydroxychloroquine failure in two patients (mother and son) is more suggestive of the last mechanism of resistance.
     </p>
     <p id="para0033">
      Such results are promising and open the possibility of an international strategy to decision-makers to fight this emerging viral infection in real-time even if other strategies and research including vaccine development could be also effective, but only in the future. We therefore recommend that COVID-19 patients be treated with hydroxychloroquine and azithromycin to cure their infection and to limit the transmission of the virus to other people in order to curb the spread of COVID-19 in the world. Further works are also warranted to determine if these compounds could be useful as chemoprophylaxis to prevent the transmission of the virus, especially for healthcare workers. Our study has some limitations including a small sample size, limited long-term outcome follow-up, and dropout of six patients from the study, however in the current context, we believe that our results should be shared with the scientific community.
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Declaration of Competing Interest
     </title>
     <p id="para0035">
      N/A
     </p>
    </sec>
    <back>
     <ref-list id="cebibl1">
      <title>
       References
      </title>
      <ref id="bib0001">
       <label>
        1
       </label>
       <element-citation id="sbref0001" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Shih
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           WC
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Hsueh
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020 Feb 17
        </year>
        <object-id pub-id-type="publisher-id">
         105924
        </object-id>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0002">
       <label>
        2
       </label>
       <element-citation id="sbref0002" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           YR
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           QQ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence”
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0003">
       <label>
        3
       </label>
       <mixed-citation id="othref0001" publication-type="other">
        WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020]
       </mixed-citation>
      </ref>
      <ref id="bib0004">
       <label>
        4
       </label>
       <element-citation id="sbref0003" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           McGoogan
          </surname>
          <given-names>
           JM.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020 Feb 24
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0005">
       <label>
        5
       </label>
       <mixed-citation id="othref0002" publication-type="other">
        Santé Publique France. Infection au nouveau Coronavirus (SARS-CoV-2), COVID-19, France et Monde [
        <ext-link ext-link-type="uri" id="interref0002" xlink:href="https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/articles/infection-au-nouveau-coronavirus-sars-cov-2-covid-19-france-et-monde">
         https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/articles/infection-au-nouveau-coronavirus-sars-cov-2-covid-19-france-et-monde
        </ext-link>
        ]
       </mixed-citation>
      </ref>
      <ref id="bib0006">
       <label>
        6
       </label>
       <element-citation id="sbref0004" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine for the 2019 novel coronavirus SARS-CoV-2
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020 Feb 15
        </year>
        <object-id pub-id-type="publisher-id">
         105923
        </object-id>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0007">
       <label>
        7
       </label>
       <element-citation id="sbref0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Lagier
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0008">
       <label>
        8
       </label>
       <element-citation id="sbref0006" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </article-title>
        <source>
         Cell Res
        </source>
        <year>
         2020
        </year>
        <fpage>
         10
        </fpage>
        <lpage>
         0282
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0009">
       <label>
        9
       </label>
       <element-citation id="sbref0007" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
        </article-title>
        <source>
         Biosci Trends
        </source>
        <year>
         2020 Feb 19
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <label>
        10
       </label>
       <mixed-citation id="othref0003" publication-type="other">
        Chinese Clinical Trial Registry. http://www.chictr.org.cn/ searchproj.aspx?title=%E6%B0%AF%E5%96%B9&amp;offi cialname=&amp;subjectid=&amp;secondaryid=&amp;applier=&amp;study leader=&amp;ethicalcommitteesanction=&amp;sponsor=&amp;studya ilment=&amp;studyailmentcode=&amp;studytype=0&amp;studystage= 0&amp;studydesign=0&amp;minstudyexecutetime=&amp;maxstudyexe cutetime=&amp;recruitmentstatus=0&amp;gender=0&amp;agreetosign =&amp;secsponsor=&amp;regno=&amp;regstatus=0&amp;country=&amp;prov ince=&amp;city=&amp;institution=&amp;institutionlevel=&amp;measure= &amp;intercode=&amp;sourceofspends=&amp;createyear=0&amp;isupload rf=&amp;whetherpublic=&amp;btngo=btn&amp;verifycode=&amp;page=1.
       </mixed-citation>
      </ref>
      <ref id="bib0011">
       <label>
        11
       </label>
       <element-citation id="sbref0008" publication-type="journal">
        <article-title>
         Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua Jie He He Hu Xi Za Zhi
        </source>
        <volume>
         43
        </volume>
        <issue>
         3
        </issue>
        <year>
         2020 Mar 12
        </year>
        <fpage>
         185
        </fpage>
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="pmid">
         32164085
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0012">
       <label>
        12
       </label>
       <element-citation id="sbref0009" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Biot
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Daher
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Chavain
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Fandeur
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Khalife
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Dive
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities
        </article-title>
        <source>
         J Med Chem
        </source>
        <volume>
         49
        </volume>
        <year>
         2006
        </year>
        <fpage>
         2845
        </fpage>
        <lpage>
         2849
        </lpage>
        <pub-id pub-id-type="pmid">
         16640347
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0013">
       <label>
        13
       </label>
       <element-citation id="sbref0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marmor
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Kellner
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           TY
          </given-names>
         </name>
         <name>
          <surname>
           Melles
          </surname>
          <given-names>
           RB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)
        </article-title>
        <source>
         Ophthalmology
        </source>
        <issue>
         6
        </issue>
        <year>
         2016 Jun;123
        </year>
        <fpage>
         1386
        </fpage>
        <lpage>
         1394
        </lpage>
        <comment>
         Epub 2016 Mar 16
        </comment>
        <pub-id pub-id-type="pmid">
         26992838
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0014">
       <label>
        14
       </label>
       <element-citation id="sbref0011" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2020 Mar 9
        </year>
        <comment>
         pii: ciaa237[Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <label>
        15
       </label>
       <element-citation id="sbref0012" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Houpikian
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Tissot Dupont
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Riss
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Arditi-Djiane
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         159
        </volume>
        <issue>
         2
        </issue>
        <year>
         1999 Jan 25
        </year>
        <fpage>
         167
        </fpage>
        <lpage>
         173
        </lpage>
        <pub-id pub-id-type="pmid">
         9927100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0016">
       <label>
        16
       </label>
       <element-citation id="sbref0013" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lagier
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Whipple's disease and
         <italic>
          Tropheryma whipplei
         </italic>
         infections: when to suspect them and how to diagnose and treat them
        </article-title>
        <source>
         Curr Opin Infect Dis
        </source>
        <volume>
         31
        </volume>
        <issue>
         6
        </issue>
        <year>
         2018 Dec
        </year>
        <fpage>
         463
        </fpage>
        <lpage>
         470
        </lpage>
        <comment>
         [x] Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188. doi: 10.3760/cma.j.issn.1001-0939.2020.03.009
        </comment>
        <pub-id pub-id-type="pmid">
         30299363
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0017">
       <label>
        17
       </label>
       <element-citation id="sbref0014" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amrane
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Tissot-Dupont
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Doudier
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Eldin
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Hocquart
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mailhe
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot
        </article-title>
        <source>
         Travel Med Infect Dis.
        </source>
        <year>
         2020
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0018">
       <label>
        18
       </label>
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Armstrong
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Richez
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Chabriere
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Simultaneous UHPLC-UV analysis of hydroxychloroquine, minocycline and doxycycline from serum samples for the therapeutic drug monitoring of Q fever and Whipple's disease
        </article-title>
        <source>
         J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
        </source>
        <volume>
         1060
        </volume>
        <year>
         2017
        </year>
        <fpage>
         166
        </fpage>
        <lpage>
         172
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0019">
       <label>
        19
       </label>
       <element-citation id="sbref0016" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020 Mar 11
        </year>
        <comment>
         pii: S0140-6736(20)30566-3[Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <label>
        20
       </label>
       <element-citation id="sbref0017" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Retallack
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Di Lullo
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Arias
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Knopp
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Laurie
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <name>
          <surname>
           Sandoval-Espinosa
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Zika virus cell tropism in the developing human brain and inhibition by azithromycin
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         113
        </volume>
        <issue>
         50
        </issue>
        <year>
         2016 Dec 13
        </year>
        <fpage>
         14408
        </fpage>
        <lpage>
         14413
        </lpage>
        <comment>
         Epub 2016 Nov 29
        </comment>
        <pub-id pub-id-type="pmid">
         27911847
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0021">
       <label>
        21
       </label>
       <element-citation id="sbref0018" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madrid
          </surname>
          <given-names>
           PB
          </given-names>
         </name>
         <name>
          <surname>
           Panchal
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         <name>
          <surname>
           Warren
          </surname>
          <given-names>
           TK
          </given-names>
         </name>
         <name>
          <surname>
           Shurtleff
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name>
          <surname>
           Endsley
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
         <name>
          <surname>
           Kolokoltsov
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of Ebola Virus Inhibitors for Drug Repurposing
        </article-title>
        <source>
         ACS Infect Dis
        </source>
        <volume>
         1
        </volume>
        <issue>
         7
        </issue>
        <year>
         2015 Jul 10
        </year>
        <fpage>
         317
        </fpage>
        <lpage>
         326
        </lpage>
        <comment>
         Epub 2015 May 11
        </comment>
        <pub-id pub-id-type="pmid">
         27622822
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0022">
       <label>
        22
       </label>
       <element-citation id="sbref0019" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosseboeuf
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Aubry
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Nhan
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           de Pina
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Azithromycin inhibits the replication of Zika virus
        </article-title>
        <source>
         J Antivirals Antiretrovirals
        </source>
        <volume>
         10
        </volume>
        <issue>
         1
        </issue>
        <year>
         2018
        </year>
        <fpage>
         6
        </fpage>
        <lpage>
         11
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0023">
       <label>
        23
       </label>
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bacharier
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
         <name>
          <surname>
           Guilbert
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
         <name>
          <surname>
           Mauger
          </surname>
          <given-names>
           DT
          </given-names>
         </name>
         <name>
          <surname>
           Boehmer
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Beigelman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Fitzpatrick
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: A randomized clinical trial
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         314
        </volume>
        <issue>
         19
        </issue>
        <year>
         2015 Nov 17
        </year>
        <fpage>
         2034
        </fpage>
        <lpage>
         2044
        </lpage>
        <pub-id pub-id-type="pmid">
         26575060
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="sec0023" sec-type="supplementary-material">
      <label>
       Appendix
      </label>
      <title>
       Supplementary materials
      </title>
      <p id="para0034a">
       <supplementary-material content-type="local-data" id="ecom0001">
        <media xlink:href="mmc1.docx">
         <alt-text>
          Image, application 1
         </alt-text>
        </media>
       </supplementary-material>
      </p>
     </sec>
     <ack id="ack0001">
      <sec id="sec0019">
       <title>
        Acknowledgements
       </title>
       <p id="para0036">
        We thank Céline Boschi, Stéphanie Branger, Véronique Filosa, Géraldine Gonfier, Nadège Palmero, Magali Richez and all the clinical, technical and paramedical staffs of the hospitalization units and laboratories for their support in this difficult context.
       </p>
      </sec>
      <sec id="sec0020">
       <title>
        Funding
       </title>
       <p id="para0037">
        This work was supported by the French Government under the « Investissements d'avenir » (Investments for the Future) program managed by the Agence Nationale de la Recherche (ANR, fr: National Agency for Research), (reference: Méditerranée Infection 10-IAHU-03)
       </p>
      </sec>
      <sec id="sec0021">
       <title>
        Ethical Approval
       </title>
       <p id="para0038">
        French Ethic Committee (CPP Ile de France) (20.02.28.99113)
       </p>
      </sec>
     </ack>
     <fn-group>
      <fn fn-type="supplementary-material" id="sec0022">
       <p id="para0007a">
        Supplementary material associated with this article can be found, in the online version, at
        <ext-link ext-link-type="uri" id="interref0001" xlink:href="https://doi.org/10.1016/j.ijantimicag.2020.105949">
         doi:10.1016/j.ijantimicag.2020.105949
        </ext-link>
        .
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Diabetes Metab Syndr
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Diabetes Metab Syndr
      </journal-id>
      <journal-title-group>
       <journal-title>
        Diabetes &amp; Metabolic Syndrome
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1871-4021
      </issn>
      <issn pub-type="epub">
       1878-0334
      </issn>
      <publisher>
       <publisher-name>
        Diabetes India. Published by Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32247211
      </article-id>
      <article-id pub-id-type="pmc">
       7102587
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1871-4021(20)30051-5
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.dsx.2020.03.011
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Singh
         </surname>
         <given-names>
          Awadhesh Kumar
         </given-names>
        </name>
        <email>
         draksingh_2001@yahoo.com
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Singh
         </surname>
         <given-names>
          Akriti
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Shaikh
         </surname>
         <given-names>
          Altamash
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Singh
         </surname>
         <given-names>
          Ritu
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au5">
        <name>
         <surname>
          Misra
         </surname>
         <given-names>
          Anoop
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
        <xref ref-type="aff" rid="aff5">
         e
        </xref>
        <xref ref-type="aff" rid="aff6">
         f
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       G. D Hospital &amp; Diabetes Institute, Kolkata, India
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       College of Medicine &amp; JNM Hospital, Kalyani, Nadia, West Bengal, India
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Saifee Hospital, Mumbai, India
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       Fortis CDOC Hospital for Diabetes and Allied Sciences, Chirag Enclave, New Delhi, India
      </aff>
      <aff id="aff5">
       <label>
        e
       </label>
       National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India
      </aff>
      <aff id="aff6">
       <label>
        f
       </label>
       Diabetes Foundation (India), New Delhi, India
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding author.
        <email>
         draksingh_2001@yahoo.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        26
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date iso-8601-date="2020-06-01" pub-type="ppub">
       <season>
        May-June
       </season>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        26
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       14
      </volume>
      <issue>
       3
      </issue>
      <fpage>
       241
      </fpage>
      <lpage>
       246
      </lpage>
      <history>
       <date date-type="received">
        <day>
         21
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         22
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         22
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Diabetes India
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <sec>
        <title>
         Background and aims
        </title>
        <p>
         No drugs are currently approved for Coronavirus Disease-2019 (COVID-19), although some have been tried. In view of recent studies and discussion on chloroquine and hydroxychloroquine (HCQ), we aimed to review existing literature and relevant websites regarding these drugs and COVID-19, adverse effects related to drugs, and related guidelines.
        </p>
       </sec>
       <sec>
        <title>
         Aims and methods
        </title>
        <p>
         We systematically searched the PubMed database up till March 21, 2020 and retrieved all the articles published on chloroquine and HCQ and COVID-19.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p>
         Two small human studies have been conducted with both these drugs in COVID-19, and have shown significant improvement in some parameters in patients with COVID-19.
        </p>
       </sec>
       <sec>
        <title>
         Conclusion
        </title>
        <p>
         Considering minimal risk upon use, a long experience of use in other diseases, cost-effectiveness and easy availability across India, we propose that both these drugs are worthy of fast track clinical trial for treatment, and may be carefully considered for clinical use as experimental drugs. Since HCQ has been approved for treatment of diabetes in India, it should be further researched in diabetes and COVID-19, a subgroup where significant mortality has been shown.
        </p>
       </sec>
      </abstract>
      <abstract abstract-type="author-highlights" id="abs0015">
       <title>
        Highlights
       </title>
       <p>
        <list id="ulist0010" list-type="simple">
         <list-item id="u0010">
          <label>
           •
          </label>
          <p id="p0010">
           Some drugs have been tried for Coronavirus Disease-2019 (COVID-19).
          </p>
         </list-item>
         <list-item id="u0015">
          <label>
           •
          </label>
          <p id="p0015">
           Chloroquine and Hydroxychloroquine has shown some promise in treatment of COVID-19 and should be fast tracked for further research.
          </p>
         </list-item>
         <list-item id="u0020">
          <label>
           •
          </label>
          <p id="p0020">
           We present available guidelines and propose use of these drugs in COVID-19.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Keywords
       </title>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        Chloroquine
       </kwd>
       <kwd>
        Hydroxychloroquine
       </kwd>
       <kwd>
        Diabetes
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0025">
      Novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the (Corona Virus Disease 2019) COVID-19, emerged in Wuhan, Hubei province, China. On 11th March 2020, The World Health Organization (WHO) declared this disease as pandemic [
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ]. Chinese Centre for Disease Control and Prevention showed an increased mortality in people with diabetes (2.3%
      <italic>
       vs
      </italic>
      . 7.3%; overall
      <italic>
       vs
      </italic>
      . in patients with diabetes respectively) from a report of 72,314 cases of COVID-19 [
      <xref ref-type="bibr" rid="bib2">
       2
      </xref>
      ]. People with diabetes and COVID-19 may need special attention and clinical care [
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ]. In the absence of any known efficient therapy and because of the situation of a “public-health emergency”, many drugs have been tried recently in the treatment for COVID-19 that includes a low-cost antimalarial drug chloroquine and its derivative hydroxychloroquine (HCQ), along with several other antiviral drugs. Because HCQ has been approved in the treatment of type 2 diabetes in India since 2014 as a third- or fourth-line drug, it would be interesting to research its impact in patients with diabetes, infected with COVID-19.
     </p>
     <p id="p0030">
      Reports gathered so far have suggested that a number of drugs could be potential candidates for the treatment of COVID-19, although the clinical effectiveness of these drugs have not yet been fully evaluated. The list of these drugs has been summarized in
      <xref ref-type="table" rid="tbl1">
       Table 1
      </xref>
      [
      <xref ref-type="bibr" rid="bib4">
       [4]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib5">
       [5]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib6">
       [6]
      </xref>
      ].
      <table-wrap id="tbl1" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Drugs in pipeline for COVID-19
         <xref ref-type="bibr" rid="bib4">
          [4]
         </xref>
         ,
         <xref ref-type="bibr" rid="bib5">
          [5]
         </xref>
         ,
         <xref ref-type="bibr" rid="bib6">
          [6]
         </xref>
        </p>
       </caption>
       <alt-text id="alttext0010">
        Table 1
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Drugs
          </th>
          <th>
           Types
          </th>
          <th>
           Mechanisms of action
          </th>
          <th>
           Past evidences
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           4-aminoquinoline
          </td>
          <td align="left">
           Not clearly known, changes the pH of endosomes and believed to prevent viral entry, transport and post-entry events
          </td>
          <td align="left">
           Inhibits infection of cells by SARS-CoV-2
           <italic>
            in vitro
           </italic>
           , approved for malaria treatment and prophylaxis
          </td>
         </tr>
         <tr>
          <td align="left">
           Hydroxychloroquine
          </td>
          <td align="left">
           4-aminoquinoline
          </td>
          <td align="left">
           Not clearly known, changes the pH of endosomes and believed to prevents viral entry, transport and post-entry events
          </td>
          <td align="left">
           Inhibits infection of cells by SARS-CoV-2
           <italic>
            in vitro,
           </italic>
           approved for malaria prophylaxis and autoimmune disease (e.g. rheumatic diseases). Approved for treatment of T2DM in India
          </td>
         </tr>
         <tr>
          <td align="left">
           Remdesivir
          </td>
          <td align="left">
           Adenosine nucleotide analogues
          </td>
          <td align="left">
           Inhibits viral application
          </td>
          <td align="left">
           Effective against SARS and MERS
          </td>
         </tr>
         <tr>
          <td align="left">
           Ribavirin
          </td>
          <td align="left">
           Nucleoside analogue
          </td>
          <td align="left">
           Inhibits viral RNA synthesis and mRNA capping
          </td>
          <td align="left">
           No evidence in SARS (potential harm) and MERS
          </td>
         </tr>
         <tr>
          <td align="left">
           Ribavirin plus Interferon
          </td>
          <td>
          </td>
          <td align="left">
           Inhibits viral replication
          </td>
          <td align="left">
           Mixed result against MERS
          </td>
         </tr>
         <tr>
          <td align="left">
           Camostat Mesilate
          </td>
          <td align="left">
           Protease inhibitors
          </td>
          <td align="left">
           Blocks viral maturation and entry to cells
          </td>
          <td align="left">
           Effectively blocked SARS-CoV-2 in lung cells
           <italic>
            in vitro
           </italic>
          </td>
         </tr>
         <tr>
          <td align="left">
           Lopinavir/Ritonavir
          </td>
          <td align="left">
           Protease inhibitors
          </td>
          <td align="left">
           Blocks viral cellular entry
          </td>
          <td align="left">
           Effective against SARS-CoV-1 both
           <italic>
            in vitro
           </italic>
           and human studies, approved for HIV-1 treatment
          </td>
         </tr>
         <tr>
          <td align="left">
           Darunavir/Cobicistat
          </td>
          <td align="left">
           Protease inhibitors
          </td>
          <td align="left">
           Blocks viral cellular entry
          </td>
          <td align="left">
           Established anti-HIV medication. No activity against coronaviruses or other respiratory viruses.
           <break>
           </break>
           No
           <italic>
            in vitro
           </italic>
           or clinical data.
          </td>
         </tr>
         <tr>
          <td align="left">
           Favipiravir
          </td>
          <td align="left">
           RNA polymerase inhibitors
          </td>
          <td align="left">
           Inhibits viral RNA-dependent polymerase
          </td>
          <td align="left">
           Broad-spectrum anti-viral against influenza, arenavirus, bunyavirus and filovirus
          </td>
         </tr>
         <tr>
          <td align="left">
           Umifenovir
          </td>
          <td align="left">
           Fusion inhibitor
          </td>
          <td align="left">
           Inhibits fusion between viral and cellular membrane
          </td>
          <td align="left">
           Antiviral against other Corona viruses
          </td>
         </tr>
         <tr>
          <td align="left">
           Interferon-β1
          </td>
          <td align="left">
           Cytokines
          </td>
          <td align="left">
           Stimulate innate antiviral immunity.
          </td>
          <td align="left">
           MERS-CoV appears to be more sensitive than SARS-CoV
           <italic>
            in vitro
           </italic>
           studies. Anti-MERS-CoV action noted in animal studies.
          </td>
         </tr>
         <tr>
          <td align="left">
           Interferon beta plus Lopinavir/Ritonavir
          </td>
          <td>
          </td>
          <td align="left">
           Interferon beta inhibits viral replication
          </td>
          <td align="left">
           Ongoing study for SARS-Cov-2 and MIRACLE trial for MERS
          </td>
         </tr>
         <tr>
          <td align="left">
           Aerosolized interferon α
          </td>
          <td align="left">
           Cytokines
          </td>
          <td align="left">
           Stimulate innate antiviral immunity.
          </td>
          <td align="left">
           Case report suggested benefit in MERS
          </td>
         </tr>
         <tr>
          <td align="left">
           Oseltamivir
          </td>
          <td align="left">
           Neuraminidase inhibitor
          </td>
          <td align="left">
           Inhibits viral replication
          </td>
          <td align="left">
           No effect in SARS
           <italic>
            in vitro
           </italic>
           studies. No evidence in SARS and MERS
          </td>
         </tr>
         <tr>
          <td align="left">
           Baloxivir marboxil
          </td>
          <td align="left">
           Viral endonuclease inhibitor
          </td>
          <td align="left">
           Inhibits influenza virus multiplication
          </td>
          <td align="left">
           Approved for uncomplicated influenza only. Oral route.
          </td>
         </tr>
         <tr>
          <td align="left">
           Tocilizumab,
           <break>
           </break>
           Sarilumab
           <break>
           </break>
           Eculizumab
          </td>
          <td align="left">
           Monoclonal antibody
          </td>
          <td align="left">
           IL-6 inhibitor, blocks cytokine storm.
          </td>
          <td align="left">
           No data on SARS or MERS. Tocilizumab reduced fever and oxygen requirement in COVID-19, approved for rheumatoid arthritis.
          </td>
         </tr>
         <tr>
          <td align="left">
           SARS-Cov-2 specific protease drug candidate
          </td>
          <td align="left">
           Protease inhibitors
          </td>
          <td align="left">
           Blocks viral infectivity
          </td>
          <td align="left">
           No data available
          </td>
         </tr>
         <tr>
          <td align="left">
           SARS-Cov-2 specific antibodies
          </td>
          <td align="left">
           Antibody
          </td>
          <td align="left">
           Binds to virus and block infection, binds to infected cells and change the immune system
          </td>
          <td align="left">
           Inhibits SARS-CoV-2 entry into cells
           <italic>
            in vitro
           </italic>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          SARS- severe acute respiratory syndrome, MERS- Middle-East respiratory syndrome, HIV- Human Immunodeficiency syndrome, T2DM – type 2 diabetes, COVID-19- Corona virus disease 19.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="p0035">
      In this review article, we have systematically searched the medical data base until March 21, 2020 and collated all the available evidences that have emerged so far on the efficacy of chloroquine and hydroxychloroquine, in the treatment of patients with COVID-19, with or without diabetes and present a perspective on both these compounds. Additionally, we have also pooled the currently on-going trials with both these compounds against the COVID-19.
     </p>
    </sec>
    <sec id="sec2">
     <label>
      2
     </label>
     <title>
      Methods
     </title>
     <p id="p0040">
      We systematically searched the PubMed database up till March 21, 2020 using key words chloroquine AND COVID-19, and hydroxychloroquine AND COVID-19 and retrieved a total of 13 articles. The two articles that were written in Chinese were excluded. In addition, we also accessed and retrieved the full text of the cross references of importance from these 11 articles written in English. Moreover, we also accessed the currently ongoing trials with both these compounds from
      <ext-link ext-link-type="uri" id="intref0010" xlink:href="http://ClinicalTrials.gov">
       ClinicalTrials.gov
      </ext-link>
      .
     </p>
    </sec>
    <sec id="sec3">
     <label>
      3
     </label>
     <title>
      Results
     </title>
     <sec id="sec3.1">
      <label>
       3.1
      </label>
      <title>
       Studies of chloroquine and hydroxychloroquine conducted
       <italic>
        in vitro
       </italic>
      </title>
      <p id="p0045">
       Experimental studies have suggested that chloroquine is a proven anti-malarial drug that has the capability of inhibiting the replication of several intracellular micro-organisms including coronaviruses
       <italic>
        in vitro
       </italic>
       . It is also believed that chloroquine may have a varied mechanism of action which may differ depending upon the pathogen studied. It has been increasingly learnt that the anti-viral and anti-inflammatory activities of chloroquine may have a role in the treatment of patients with novel COVID-19. Chloroquine increases endosomal pH and interferes with the glycosylation of cellular receptor of SARS-CoV and thereby it has the potential to block viral infection [
       <xref ref-type="bibr" rid="bib7">
        7
       </xref>
       ]. In addition, chloroquine also inhibits the quinone reductase-2, which is involved in sialic acid biosynthesis (an acidic monosaccharides of cell transmembrane proteins required for ligand recognition) that makes this agent a broad antiviral agent. It is important to note that both human coronavirus HCoV-O43 and orthomyxoviruses uses sialic acid moieties as a receptor. Moreover, chloroquine changes the pH of lysosomes and likely inhibits cathepsins, that leads to the formation of the autophagosome which cleaves SARS-CoV-2 spike protein. Furthermore, chloroquine through the inhibition of MAP-kinase interferes with SARS-CoV-2 molecular crosstalk, besides altering the virion assembly, budding and interfering with the proteolytic processing of the M protein [
       <xref ref-type="bibr" rid="bib7">
        7
       </xref>
       ,
       <xref ref-type="bibr" rid="bib8">
        8
       </xref>
       ]. Previous experimental studies have also demonstrated that chloroquine has potent anti-SARS-CoV-1 effects
       <italic>
        in vitro
       </italic>
       , primarily attributable to a deficit in the glycosylation receptors at the virus cell surface, so that it cannot bind to the angiotensin-converting enzyme 2 (ACE2) expressed in lung, heart, kidney and intestine. Since SARS-CoV-2 utilizes the similar surface receptor ACE2, it is believed that chloroquine can also interfere with ACE2 receptor glycosylation thus prevents SARS-CoV-2 attachment to the target cells [
       <xref ref-type="bibr" rid="bib6">
        [6]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib7">
        [7]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib8">
        [8]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib9">
        [9]
       </xref>
       ]. Chinese researchers who studied the effect of chloroquine
       <italic>
        in vitro
       </italic>
       (using Vero E6 cell line infected by SARS-CoV-2) found chloroquine to be highly effective in reducing viral replication that can be easily achievable with standard dosing due to its favorable penetration in tissues including the lung [
       <xref ref-type="bibr" rid="bib6">
        6
       </xref>
       ,
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ].
      </p>
      <p id="p0050">
       Since the structure and mechanism of action of chloroquine and hydroxychloroquine (HCQ) are exactly same except an additional hydroxy moiety in one terminal in HCQ, both act as a weak base that can change the pH of acidic intracellular organelles including endosomes/lysosomes, essential for the membrane fusion. It is believed that both the agents could be effective tools against SARS-CoV-1 and SARS-CoV-2 [
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ]. However, an important question that still remains is whether HCQ has a similar effect on SARS-CoV-2 infection. Some data show HCQ effectively inhibited both the entry, transport and the post-entry stages of SARS-CoV-2, similar to the chloroquine and one study found HCQ to be a more potent agent than chloroquine in inhibiting SARS-CoV-2
       <italic>
        in vitro
       </italic>
       [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib13">
        13
       </xref>
       ]. In addition, HCQ acts effectively on other intracellular bacterial infections such as Coxiella burnetii (Q fever) and Tropheryma whipplei (Whipple’s disease) [
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
       ]. Addition of hydroxyl molecule makes HCQ less permeable to blood-retinal barrier and allows faster clearance from retinal pigment cell, thereby suggesting a lesser risk of retinal toxicity with HCQ, as compared to chloroquine [
       <xref ref-type="bibr" rid="bib16">
        16
       </xref>
       ]. Furthermore, the narrow therapeutic and safety index margin with chloroquine makes HCQ a safer option than chloroquine.
      </p>
      <p id="p0055">
       An additional issue to be considered in severely sick patients is cytokine storm associated with disease severity of SARS-CoV-2 [
       <xref ref-type="bibr" rid="bib17">
        17
       </xref>
       ].The significant decrease in the production of pro-inflammatory markers and cytokines with HCQ has made this agent a successful disease modifying anti-inflammatory agent in the treatment of various autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus and Sjogren’s syndrome. Long-term clinical safety profile of HCQ is better than that of chloroquine, that allows higher daily dose of HCQ with less drug-drug interactions.
      </p>
     </sec>
     <sec id="sec3.2">
      <label>
       3.2
      </label>
      <title>
       Studies conducted with chloroquine and hydroxychloroquine in human COVID-19
      </title>
      <p id="p0060">
       The anti-viral and anti-inflammatory actions of chloroquine have led to numerous trials urgently in the face of global health emergency. A Chinese study involving more than 100 patients of COVID-19 found chloroquine superior to the control group in reducing symptom duration, exacerbation of pneumonia including radiological improvement and promoting virus-negative seroconversion without any severe side effects [
       <xref ref-type="bibr" rid="bib18">
        18
       </xref>
       ]. This represents the first human trial ever conducted with chloroquine against COVID-19. Although the detailed results of this trial are not yet published and only available in a letter form, interestingly, this early result led China to include chloroquine in the prevention and treatment of COVID-19 pneumonia. Moreover, The National Health Commission of the People’s Republic of China recommended inclusion of chloroquine in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19. In this study, chloroquine was given in dose of 500 mg of chloroquine twice daily in mild to severe COVID-19 pneumonia (see
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       ).
      </p>
      <p id="p0065">
       The second human study which is currently available was conducted with HCQ. In an open-label, non-randomized trial (n = 36) conducted in Marseille, France, Gautret et al. found that HCQ alone and combination of HCQ plus azithromycin was highly and significantly effective in clearing viral nasopharyngeal carriage (measured by polymerase chain reaction [PCR]) in only three-to six days in COVID-19 subjects, compared to control. The virological clearance day-6 post-inclusion (primary outcome) with HCQ
       <italic>
        vs.
       </italic>
       control was 70.0% versus 12.5%, respectively (p = 0.001). In addition, the virological clearance at day-6 post-inclusion in HCQ plus azithromycin, HCQ and control arm was 100%, 57.1% and 12.5% respectively (p &lt; 0.001). This data suggests a synergistic effect of azithromycin with HCQ. Indeed, azithromycin has shown an antiviral effect against Zika and Ebola viruses in
       <italic>
        in vitro
       </italic>
       studies; however, it is not yet known whether it has any action against COVID-19 as well [
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ]. These results of converting a potential carrier to a seronegative patient are of importance with regards to preventing community transmission of COVID-19. Since the data from Wuhan, China showed that some patients were carrier as long as up to 37 days (usually around 20 days), results of this study are very encouraging in the context of converting a patient to a seronegative subject within 6 days. Interestingly, this study also showed that the effect of HCQ was significantly higher (p &lt; 0.05) in symptomatic patients as compared to asymptomatic patients with COVID-19. The authors have acknowledged limitations of the study; a small sample size, dropout of six patients and limited follow-up, apart from the non-randomized and open-label nature of the trial. A close look in to this study also suggests that the Cycle threshold (Ct) value for nasopharyngeal swab PCR to call it as a sample negative, was lower (Ct value &gt; 35 was deemed as negative for virus) compared to conventional Ct threshold of &gt;40. Ct is defined as the number of cycles to be run for the PCR test to turn positive. In other words, lower the number of Ct denotes more virus is present and lesser number of cycles are required to hit the threshold. Moreover, nasopharyngeal swab PCR is a less sensitive tool, compared to PCR of Broncho-alveolar lavage and sputum in COVID-19. Furthermore, exclusion of five patients (26%) receiving HCQ from the overall analysis, exaggerate the final results of this study.
      </p>
      <p id="p0070">
       Nevertheless, based on limited available evidences to date, and given the prevailing pandemic of COVID-19, some of the institutions and or organizations have already recognized the utility of chloroquine and HCQ [
       <xref ref-type="bibr" rid="bib20">
        20
       </xref>
       ]. The expert consensus from the Department of Science and Technology and Health Commission of Guangdong province published on 20th February (based on
       <italic>
        in vitro
       </italic>
       evidence and still unpublished clinical experience) chloroquine phosphate tablet at a dose of 500 mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of SARS-CoV-2 pneumonia in the absence of contraindication to the drug [
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       ]. A Central Clinical Task Force from Korea who have treated 27 cases of COVID-19 recommend using lopinavir 400mg/Ritonavir 100 mg BID or Chloroquine 500 mg orally per day or Hydroxychloroquine 400 mg orally per day for 7–10 days, in moderate to severe case of COVID-19 [
       <xref ref-type="bibr" rid="bib22">
        22
       </xref>
       ]. Similarly, The Dutch Center of Disease control in a public document on its website, also suggested the use of chloroquine in those having severe COVID-19 infection admitted in the intensive care unit [
       <xref ref-type="bibr" rid="bib23">
        23
       </xref>
       ].
       <xref ref-type="table" rid="tbl2">
        Table 2
       </xref>
       summarizes the recommendation and dosing from all the various groups [
       <xref ref-type="bibr" rid="bib21">
        [21]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        [22]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib23">
        [23]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib24">
        [24]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib25">
        [25]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib26">
        [26]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib27">
        [27]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib28">
        [28]
       </xref>
       ].
       <table-wrap id="tbl2" position="float">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Available Guidelines (as of March 21, 2020) in the treatment of COVID-19 for Chloroquine and Hydroxychloroquine.
          <xref ref-type="bibr" rid="bib19">
           <sup>
            19
           </sup>
          </xref>
          <sup>
           ,
          </sup>
          <xref ref-type="bibr" rid="bib21">
           [21]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib22">
           [22]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib23">
           [23]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib24">
           [24]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib25">
           [25]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib26">
           [26]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib27">
           [27]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib28">
           [28]
          </xref>
         </p>
        </caption>
        <alt-text id="alttext0015">
         Table 2
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Study/Guidelines/Country
           </th>
           <th>
            Dose (adults)
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left">
            Expert consensus from Department of Science and Technology and Health Commission of Guangdong province, China
            <xref ref-type="bibr" rid="bib21">
             <sup>
              21
             </sup>
            </xref>
           </td>
           <td align="left">
            Chloroquine phosphate 500 mg BID for 10 days.
           </td>
          </tr>
          <tr>
           <td align="left">
            Central Clinical Task Force, Korea
            <xref ref-type="bibr" rid="bib22">
             <sup>
              22
             </sup>
            </xref>
           </td>
           <td align="left">
            <underline>
             Moderate to severe COVID-19:
            </underline>
            <break>
            </break>
            Lopinavir 400mg/Ritonavir 100 mg BID or Chloroquine 500 mg orally per day or Hydroxychloroquine 400 mg orally per day for 7–10 days.
           </td>
          </tr>
          <tr>
           <td align="left" rowspan="2">
            Centre for Disease Control and Prevention, Atlanta, MICC Version 1 (March 12, 2020)
            <xref ref-type="bibr" rid="bib23">
             <sup>
              23
             </sup>
            </xref>
           </td>
           <td align="left">
            <underline>
             URTI plus positive PCR:
            </underline>
            <list id="ulist0015" list-type="simple">
             <list-item id="u0025">
              <label>
               •
              </label>
              <p id="p0130">
               Chloroquine phosphate 500 mg BID for 5 days.
              </p>
             </list-item>
             <list-item id="u0030">
              <label>
               •
              </label>
              <p id="p0135">
               Oseltamivir 150 mg BID for 5 days.
              </p>
             </list-item>
            </list>
           </td>
          </tr>
          <tr>
           <td align="left">
            <underline>
             COVID-19 Pneumonia:
            </underline>
            <list id="ulist0020" list-type="simple">
             <list-item id="u0035">
              <label>
               •
              </label>
              <p id="p0140">
               Chloroquine phosphate 500 mg BID for 5 days plus Darunavir 800 mg/Cobicistat 150 mg OD for 2 weeks.
              </p>
             </list-item>
             <list-item id="u0040">
              <label>
               •
              </label>
              <p id="p0145">
               Atazanavir 400 mg OD for 2 weeks plus Oseltamivir 150 mg BID for 5 days.
              </p>
             </list-item>
            </list>
           </td>
          </tr>
          <tr>
           <td align="left">
            The Dutch Center of Disease Control
            <xref ref-type="bibr" rid="bib24">
             <sup>
              24
             </sup>
            </xref>
           </td>
           <td align="left">
            600 mg of Chloroquine base followed by 300 mg after 12 h on day 1, then 300 mg × 2/day per person on days 2–5.
           </td>
          </tr>
          <tr>
           <td align="left">
            Italian Society of Infectious and Tropical Diseases (Lombardy Section)
            <xref ref-type="bibr" rid="bib25">
             <sup>
              25
             </sup>
            </xref>
           </td>
           <td align="left">
            <underline>
             Mild to moderate COVID-19
            </underline>
            :
            <break>
            </break>
            Lopinavir/ritonavir plus Chloroquine 500 mg × 2/day or Hydroxychloroquine 200 mg per day for 10 days.
            <break>
            </break>
            <underline>
             Severe or critical COVID-19
            </underline>
            :
            <break>
            </break>
            Remdesivir plus Chloroquine 500 mg × 2/day or Hydroxychloroquine 200 mg per day for 10–20 days.
           </td>
          </tr>
          <tr>
           <td align="left">
            Mount Sinai Health System, Canada
            <xref ref-type="bibr" rid="bib26">
             <sup>
              26
             </sup>
            </xref>
           </td>
           <td align="left">
            <underline>
             Moderate to severe COVID-19:
            </underline>
            <break>
            </break>
            Hydroxychloroquine 400 mg BID x 2 doses then 12 h later start 400 mg OD for 5–10 days.
           </td>
          </tr>
          <tr>
           <td align="left">
            Surviving Sepsis Campaign, The Society of Critical Care Medicine and the European Society of Intensive Care Medicine.
            <xref ref-type="bibr" rid="bib27">
             <sup>
              27
             </sup>
            </xref>
           </td>
           <td align="left">
            Insufficient evidence to issue a recommendation on the use of chloroquine or hydroxychloroquine in critically ill adults with COVID-19 at this point of time.
           </td>
          </tr>
          <tr>
           <td align="left">
            Clinical guidance for patients with suspected or confirmed COVID-19 in Belgium
            <xref ref-type="bibr" rid="bib28">
             <sup>
              28
             </sup>
            </xref>
           </td>
           <td align="left">
            <underline>
             Mild/Moderate/Severe COVID-19
            </underline>
            :
            <break>
            </break>
            Hydroxychloroquine 400 mg at diagnosis, 400 mg 12 h later, followed by 200 mg BID for 5 days,
            <break>
            </break>
            Or,
            <break>
            </break>
            Chloroquine 600 mg at diagnosis and 300 mg 12 h later followed by 300 mg BID for 5 days (Consider lopinavir 400 mg/ritonavir 100 mg BID for 14 days as a second choice only if HCQ and chloroquine is contraindicated, provided it can be administered within 10 days after onset of symptoms)
            <break>
            </break>
            <underline>
             Critical COVID-19
            </underline>
            :
            <break>
            </break>
            Remdesivir 200 mg loading dose i.v within 30 min followed by 100 mg OD for 2–10 days (Hydroxychloroquine is second option if Remdesivir is unavailable)
           </td>
          </tr>
          <tr>
           <td align="left">
            Clinical guidance for patients with suspected or confirmed COVID-19 in Netherland
            <xref ref-type="bibr" rid="bib28">
             <sup>
              28
             </sup>
            </xref>
           </td>
           <td align="left">
            <underline>
             Mild/moderate/severe COVID-19
            </underline>
            :
            <break>
            </break>
            Chloroquine 600 mg on day 1, then 300 mg BID for 5 days (lopinavir/ritonavir as second option)
            <break>
            </break>
            <underline>
             Critical COVID-19
            </underline>
            :
            <break>
            </break>
            Remdesivir for 10 days plus chloroquine for 5 day
           </td>
          </tr>
          <tr>
           <td align="left">
            Gautret et al., Marseille, France
            <xref ref-type="bibr" rid="bib19">
             <sup>
              19
             </sup>
            </xref>
           </td>
           <td align="left">
            Hydroxychloroquine 200 mg TID for 10 days.
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           OD-once daily, BID-twice daily, TID-thrice daily, URTI- upper respiratory tract infection, PCR-polymerase chain reaction, i.v - intravenous.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
    </sec>
    <sec id="sec4">
     <label>
      4
     </label>
     <title>
      Discussion
     </title>
     <p id="p0075">
      The antiviral activity of chloroquine and HCQ have been identified in the
      <italic>
       in vitro
      </italic>
      studies and the growth of many different viruses have been inhibited in the cell culture line by both the agents, including the SARS coronavirus. Mice studies have also demonstrated activity of these agents against human coronavirus OC43, enterovirus EV-A71, Zika virus and influenza A H5N1. However, no benefit of chloroquine was seen in the prevention of influenza and dengue infection in a randomized, double-blind, placebo-controlled, clinical trial [
      <xref ref-type="bibr" rid="bib29">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="bib30">
       30
      </xref>
      ]. Similarly, chloroquine was active in
      <italic>
       ex vivo
      </italic>
      studies but not in the
      <italic>
       in vivo
      </italic>
      studies against ebolavirus, nipah and influenza viruses [
      <xref ref-type="bibr" rid="bib31">
       [31]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib32">
       [32]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib33">
       [33]
      </xref>
      ]. Data of chloroquine against chikungunya virus is even more intriguing. While chloroquine had satisfactory antiviral activity against chikungunya
      <italic>
       in vitro
      </italic>
      , animal studies showed increase in virus replication, aggravation of fever and incomplete viral clearance [
      <xref ref-type="bibr" rid="bib34">
       34
      </xref>
      ]. Human trials of chloroquine showed no improvement in chikungunya acute illness and rather an increase in chronic arthralgia was observed during post-illness period, compared to the controls [
      <xref ref-type="bibr" rid="bib35">
       35
      </xref>
      ]. The role of chloroquine against Human Immunodeficiency Virus was inconclusive [
      <xref ref-type="bibr" rid="bib36">
       36
      </xref>
      ]. The only viral disease where chloroquine was modestly effective so far before COVID-19 era was chronic hepatitis C suggesting an increased virological response to pegylated interferon plus ribavirin [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ]. Therefore, the results of chloroquine and HCQ so far done against COVID-19, more promising than previous trial in other viral diseases. Moreover, these drugs are of low cost, reasonably safe (see below), and widely available in countries where malaria is endemic.
     </p>
     <sec id="sec4.1">
      <label>
       4.1
      </label>
      <title>
       Cautions and contraindication with chloroquine and hydroxychloroquine
      </title>
      <p id="p0080">
       Expectedly, some precautions will be needed while using both these drugs that include frequent monitoring of hematological parameters (RBC, WBC and platelet counts), measurement of serum electrolytes, blood glucose (because of hypoglycemic potential of HCQ) and hepatic as well as renal functions. Since both these drugs have the potential to prolong QTc, routine electrocardiography is essential prior to starting these drugs. Co-administration of other drugs known to prolong the QTc interval (such as anti-arrhythmic, anti-depressants, anti-psychotics, anti-histaminic, teneligliptin, ondansetron and moxifloxacin etc.) must be avoided [
       <xref ref-type="bibr" rid="bib38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="bib39">
        39
       </xref>
       ]. Moreover, addition of azithromycin to HCQ as done in French trial by Gautret et al. may increase the risk of QTc prolongation. Perform ECG daily if QTc is 450–500 msec. Additionally, hypoglycemia must be looked for in patients with diabetes especially with concurrent use of chloroquine/HCQ and lopinavir/ritonavir. Chloroquine and HCQ should not be used concurrently with lopinavir/ritonavir and remdisivir for anticipated QTc prolongation. Finally, pharmacovigilance on visual and mental disturbance is also closely required.
      </p>
      <p id="p0085">
       Although there are sporadic case reports of chloroquine-induced cardiomyopathy and reversible heart failure in the literature, many studies and large meta-analysis conducted in patients with rheumatoid arthritis pointed to a reduced cardiovascular risk with both these compounds [
       <xref ref-type="bibr" rid="bib40">
        40
       </xref>
       ]. Nevertheless, since both the drug has potential to prolog QTc, a baseline ECG should be done in patients with established cardiovascular disease.
      </p>
      <p id="p0090">
       All clinicians using these drugs must know contraindication to both these compounds; hypersensitivity to these agents, retinopathy, porphyria, epilepsy, pre-existing maculopathy, G6PD deficiency, recent myocardial infarction and QTc &gt;500 msec. Chloroquine is not contraindicated in pregnancy.
      </p>
     </sec>
    </sec>
    <sec id="sec5">
     <label>
      5
     </label>
     <title>
      Conclusion
     </title>
     <p id="p0095">
      Although evidence of chloroquine and HCQ is limited (based on the experimental data and only two small human trials), considering the potentially favorable benefit-risk balance of chloroquine and HCQ in absence of any other valid treatment option, we believe that such treatment could be useful in the current context of pandemic COVID-19 outbreak. We have summarized current consideration and proposed line of management in
      <xref ref-type="table" rid="tbl3">
       Table 3
      </xref>
      . The low cost of chloroquine and HCQ could also be an effective strategy to counter COVID-19 (especially in patients with diabetes and other co-morbidities in whom mortality is high) in resource constrained and COVID-19 overburdened heath care systems in middle- and low-income counties including India.
      <table-wrap id="tbl3" position="float">
       <label>
        Table 3
       </label>
       <caption>
        <p>
         Based on the available evidence so far (including
         <italic>
          in vitro
         </italic>
         ,
         <italic>
          ex vivo
         </italic>
         and
         <italic>
          in vivo
         </italic>
         studies – both experimental and two human studies) and considering the benefit-risk ratio as well as the low cost of chloroquine and hydroxychloroquine in Indian context, we propose the following regime, until more evidence is available -
        </p>
       </caption>
       <alt-text id="alttext0020">
        Table 3
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Timing of intervention
          </th>
          <th>
           Proposed
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           Chemoprophylaxis
          </td>
          <td align="left">
           <list id="ulist0025" list-type="simple">
            <list-item id="u0045">
             <label>
              •
             </label>
             <p id="p0150">
              No conclusive evidence so far; however, chloroquine or HCQ could be researched as a prophylactic agent in endemic areas. Recent guidelines from Indian Council of Medical Research recommend it as prophylactic agent (see reference 42 for indication and dose)
             </p>
            </list-item>
            <list-item id="u0050">
             <label>
              •
             </label>
             <p id="p0155">
              Note: HCQ can be used as an adjunct to control glycemia in adult patients with type 2 diabetes (approved for treatment in India). However, role of such adjunctive treatment for testing its potential role as a prophylaxis of COVID-19 in diabetes, has not been researched but could be attempted (in view of above) considering a higher mortality in patients with diabetes, as compared to non-diabetic subjects with COVID-19.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           Confirmed COVID-19
          </td>
          <td align="left">
           A. Chloroquine phosphate:
           <sup>
            @$
           </sup>
           <break>
           </break>
           1. COVID-19 URTI: 500 mg BID for 5 days.
           <break>
           </break>
           2. COVID-19 LRTI: 500 mg BID for 10 days.
           <break>
           </break>
           B. Hydroxychloroquine:
           <sup>
            @$
           </sup>
           <break>
           </break>
           Loading dose: 400 mg BID day 1, then
           <break>
           </break>
           Maintenance dose: 200 mg BID for 5–10 days.
           <break>
           </break>
           C. Monitor and watch for side effects∗
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          @ watch for hypoglycemia in diabetes especially with concurrent use of lopinavir/ritonavir, $ should not be used concurrently with lopinavir/ritonavir and remdisivir due to increased QTc prolongation, ∗ complete blood count, renal, hepatic profile and ECG – watch for QTc prolongation, URTI- upper respiratory tract infection, LRTI- lower respiratory tract infection, HCQ-hydroxychloroquine, BID – twice daily.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="tbl4" position="float">
       <label>
        Table 4
       </label>
       <caption>
        <p>
         Ongoing trials with chloroquine and hydroxychloroquine as of March 21, 2020.
        </p>
       </caption>
       <alt-text id="alttext0025">
        Table 4
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Study title
          </th>
          <th>
           Types of intervention
          </th>
          <th>
           Intervention vs. comparator
          </th>
          <th>
           n
          </th>
          <th>
           Country
          </th>
          <th>
           ClinicalTrial.Org identifier
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquine for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19)
          </td>
          <td align="left">
           Treatment
          </td>
          <td align="left">
           Antiviral drugs plus Chloroquine PBO
          </td>
          <td align="left">
           80
          </td>
          <td align="left">
           Thailand
          </td>
          <td align="left">
           NCT04303299
          </td>
         </tr>
         <tr>
          <td align="left">
           Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV)
          </td>
          <td align="left">
           Prophylaxis
          </td>
          <td align="left">
           Chloroquine PBO
          </td>
          <td align="left">
           10,000
          </td>
          <td align="left">
           UK
          </td>
          <td align="left">
           NCT04303507
          </td>
         </tr>
         <tr>
          <td align="left">
           Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic (HCQ4COV19)
          </td>
          <td align="left">
           Treatment and prophylaxis in two separate groups
          </td>
          <td align="left">
           Darunavir/Cobicistat plus Chloroquine PBO
          </td>
          <td align="left">
           3040
          </td>
          <td align="left">
           Germany
          </td>
          <td align="left">
           NCT04304053
          </td>
         </tr>
         <tr>
          <td align="left">
           The Clinical Study of Carrimycin on Treatment Patients With COVID-19
          </td>
          <td align="left">
           Treatment
          </td>
          <td align="left">
           Carrimycin Lopinavir/ritonavir Arbidol Chloroquine PBO
          </td>
          <td align="left">
           520
          </td>
          <td align="left">
           China
          </td>
          <td align="left">
           NCT04286503
          </td>
         </tr>
         <tr>
          <td align="left">
           Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients with Mild Coronavirus Disease (COVID-19)
          </td>
          <td align="left">
           Treatment
          </td>
          <td align="left">
           Lopinavir/ritonavir HCQ
          </td>
          <td align="left">
           150
          </td>
          <td align="left">
           Korea
          </td>
          <td align="left">
           NCT04307693
          </td>
         </tr>
         <tr>
          <td align="left">
           Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV)
          </td>
          <td align="left">
           Treatment
          </td>
          <td align="left">
           HCQ PBO
          </td>
          <td align="left">
           30
          </td>
          <td align="left">
           China
          </td>
          <td align="left">
           NCT04261517
          </td>
         </tr>
         <tr>
          <td align="left">
           Post-exposure Prophylaxis for SARS-Coronavirus-2
          </td>
          <td align="left">
           Post exposure prophylaxis
          </td>
          <td align="left">
           HCQ PBO
          </td>
          <td align="left">
           1500
          </td>
          <td align="left">
           United States
          </td>
          <td align="left">
           NCT04308668
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          HCQ-hydroxychloroquine, PBO- placebo, N - number.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="p0100">
      Future directions:
      <list id="olist0010" list-type="simple">
       <list-item id="o0010">
        <label>
         1.
        </label>
        <p id="p0105">
         Intervention trials planned for COVID-19: Several trials are currently underway with both chloroquine and HCQ in patients with COVID-19 at different doses. A search of The
         <ext-link ext-link-type="uri" id="intref0015" xlink:href="http://ClinicalTrial.org">
          ClinicalTrial.org
         </ext-link>
         database dated March 21, 2020 showed 4 trials with chloroquine and 3 trials with HCQ which is currently under progress and have been summarized in
         <xref ref-type="table" rid="tbl4">
          Table 4
         </xref>
         . A list of 23 trials are already enlisted with both compounds at Chinese Clinical Trial Registry (
         <ext-link ext-link-type="uri" id="intref0020" xlink:href="http://www.chictr.org.cn">
          http://www.chictr.org.cn
         </ext-link>
         ) [
         <xref ref-type="bibr" rid="bib41">
          41
         </xref>
         ]. We believe that it would be wise to conduct a quick interim analysis from these trials as soon as possible to find out the results that can be applied to the masses across the globe to curb the menace of COVID-19 pandemic.
        </p>
       </list-item>
       <list-item id="o0015">
        <label>
         2.
        </label>
        <p id="p0110">
         Research for resistance to drugs in already mutating virus strains: Another area which needs to be explored further is resistance to chloroquine and HCQ that may be present with different strains of the virus.
        </p>
       </list-item>
       <list-item id="o0020">
        <label>
         3.
        </label>
        <p id="p0115">
         Role of these drugs in COVID-19 chemoprophylaxis: Another knowledge gap that still remains is about role of these drugs in chemoprophylaxis. We still do not know whether these compounds can be useful to prevent the transmission of the virus, especially for healthcare workers. This needs to be tested in further studies.
        </p>
       </list-item>
       <list-item id="o0025">
        <label>
         4.
        </label>
        <p id="p0120">
         Use of HCQ in patients with diabetes in India where it is already approved for treatment: It would be interesting to research COVID-19 infection in patients with diabetes who are already on HCQ for treatment of diabetes. Further, the effect of HCQ on glycemia, cardiovascular function and viral load, in patients with diabetes needs to be researched.
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Declaration of competing interest
     </title>
     <p id="p0125">
      We hereby declare that we have no conflict of interest related to this article.
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sref1" publication-type="other">
        <article-title>
         WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020
        </article-title>
        <ext-link ext-link-type="uri" id="intref0025" xlink:href="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-atthe-media-briefing-on-covid-19---11-march-2020">
         https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-atthe-media-briefing-on-covid-19---11-march-2020
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sref2" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           McGoogan
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention
        </article-title>
        <source>
         J Am Med Assoc
        </source>
        <year>
         2020 Feb 24
        </year>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gupta
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ghosh
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Misra
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical considerations for patients with diabetes in times of COVID-19 epidemic
        </article-title>
        <source>
         Diabetes, Metab Syndrome Clin Res Rev
        </source>
        <volume>
         14
        </volume>
        <issue>
         3
        </issue>
        <year>
         2020 Mar 10
        </year>
        <fpage>
         211
        </fpage>
        <lpage>
         212
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sref4" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Hsueh
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yen
          </surname>
          <given-names>
           M.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths
        </article-title>
        <source>
         J Microbiol Immunol Infect
        </source>
        <issue>
         20
        </issue>
        <year>
         2020 Mar 4
        </year>
        <fpage>
         30040
        </fpage>
        <lpage>
         30042
        </lpage>
        <comment>
         pii: S1684-1182, [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           LiuW
          </surname>
         </name>
         <name>
          <surname>
           Morse
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lalonde
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV
        </article-title>
        <source>
         Chembiochem
        </source>
        <volume>
         4
        </volume>
        <year>
         2020 Feb
        </year>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Hsueh
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yen
          </surname>
          <given-names>
           M.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drug treatment options for the 2019-new coronavirus (2019-nCoV)
        </article-title>
        <source>
         Biosci Trends
        </source>
        <year>
         2020 Jan 28
        </year>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </article-title>
        <source>
         Cell Res
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sref8" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine for the 2019 novel coronavirus
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020 Feb 17
        </year>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sref9" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         291
        </volume>
        <year>
         2016
        </year>
        <fpage>
         9218e32
        </fpage>
        <pub-id pub-id-type="pmid">
         26953343
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lagier
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020 Mar 4
        </year>
        <fpage>
         105932
        </fpage>
        <comment>
         [Epub ahead of print]
        </comment>
        <pub-id pub-id-type="pmid">
         32145363
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Biot
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Daher
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Chavain
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fandeur
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Khalife
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Dive
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities
        </article-title>
        <source>
         J Med Chem
        </source>
        <volume>
         49
        </volume>
        <year>
         2006
        </year>
        <fpage>
         2845
        </fpage>
        <lpage>
         2849
        </lpage>
        <pub-id pub-id-type="pmid">
         16640347
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
        </article-title>
        <source>
         Cell Discov
        </source>
        <volume>
         6
        </volume>
        <year>
         2020
        </year>
        <fpage>
         16
        </fpage>
        <pub-id pub-id-type="pmid">
         32194981
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sref13" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2020 Mar 9
        </year>
        <comment>
         pii: ciaa237, [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Drancourt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Vestris
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         34
        </volume>
        <year>
         1990
        </year>
        <fpage>
         1512
        </fpage>
        <lpage>
         1514
        </lpage>
        <pub-id pub-id-type="pmid">
         2221859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <mixed-citation id="sref15" publication-type="other">
        Boulos A, Rolain JM, Raoult D. Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob Agents.
       </mixed-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sref16" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marmor
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Kellner
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Melles
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
         <name>
          <surname>
           Mieler
          </surname>
          <given-names>
           W.F.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         American academy of ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy
        </chapter-title>
        <year>
         2016
        </year>
        <comment>
         Revision
        </comment>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020 Feb 15
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <comment>
         Epub 2020 Jan 24. Ophthalmology. 2016 Jun;123(6):1386-94. doi:10.1016/j.ophtha.2016.01.058. Epub 2016 Mar 16
        </comment>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
        </article-title>
        <source>
         Biosci Trends
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gautret
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lagiera
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Parolaa
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Hoanga
          </surname>
          <given-names>
           V.T.
          </given-names>
         </name>
         <name>
          <surname>
           Meddeba
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Mailhea
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         17 March 2020
        </year>
        <comment>
         In Press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Touret
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           de Lamballerie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Of chloroquine and COVID-19
        </article-title>
        <source>
         Antivir Res
        </source>
        <volume>
         177
        </volume>
        <year>
         2020 Mar 5
        </year>
        <fpage>
         104762
        </fpage>
        <comment>
         [Epub ahead of print]
        </comment>
        <pub-id pub-id-type="pmid">
         32147496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sref21" publication-type="journal">
        <article-title>
         Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua Jiehe He Huxi Zazhi
        </source>
        <volume>
         43
        </volume>
        <issue>
         3
        </issue>
        <year>
         2020 Mar 12
        </year>
        <fpage>
         185
        </fpage>
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="pmid">
         32164085
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sref22" publication-type="other">
        <article-title>
         Korea biomedical review website
        </article-title>
        <ext-link ext-link-type="uri" id="intref0030" xlink:href="http://www.koreabiomed.com/news/articleView.html?idxno=7428">
         http://www.koreabiomed.com/news/articleView.html?idxno=7428
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sref23" publication-type="other">
        <ext-link ext-link-type="uri" id="intref0035" xlink:href="https://www.medcampus.io/mnotes/protocol-for-treatment-of-confirmed-covid-19-5e5e2781e86c5d0001f77303">
         https://www.medcampus.io/mnotes/protocol-for-treatment-of-confirmed-covid-19-5e5e2781e86c5d0001f77303
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sref24" publication-type="other">
        <ext-link ext-link-type="uri" id="intref0040" xlink:href="https://lci.rivm.nl/covid-19/bijlage/behandeladvies">
         https://lci.rivm.nl/covid-19/bijlage/behandeladvies
        </ext-link>
        <comment>
         Accessed on 20th March 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sref25" publication-type="other">
        <ext-link ext-link-type="uri" id="intref0045" xlink:href="http://www.simit.org/medias/1555-covid19-linee-guida-trattamento-01mar.pdf">
         http://www.simit.org/medias/1555-covid19-linee-guida-trattamento-01mar.pdf
        </ext-link>
        <comment>
         Last accessed on 20th March 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sref26" publication-type="other">
        <article-title>
         Mount Sinai health system treatment guidelines for SARS-CoV-2 infection (COVID-19)
        </article-title>
        <ext-link ext-link-type="uri" id="intref0050" xlink:href="https://www.mountsinai.org/health-library/diseases-conditions/2019-novel-coronavirus-2019-ncov">
         https://www.mountsinai.org/health-library/diseases-conditions/2019-novel-coronavirus-2019-ncov
        </ext-link>
        <comment>
         Last accessed on 20th March 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sref27" publication-type="other">
        <ext-link ext-link-type="uri" id="intref0055" xlink:href="https://www.esicm.org/ssc-covid19-guidelines/">
         https://www.esicm.org/ssc-covid19-guidelines/
        </ext-link>
        <comment>
         Last accessed on 20th March 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sref28" publication-type="other">
        <article-title>
         Interim clinical guidelines for patients suspected of/confirmed with COVID-19 infection
        </article-title>
        <ext-link ext-link-type="uri" id="intref0060" xlink:href="https://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf">
         https://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paton
          </surname>
          <given-names>
           N.I.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           Y.B.
          </given-names>
         </name>
         <name>
          <surname>
           Archuleta
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         11
        </volume>
        <issue>
         9
        </issue>
        <year>
         2011 Sep
        </year>
        <fpage>
         677
        </fpage>
        <lpage>
         683
        </lpage>
        <pub-id pub-id-type="pmid">
         21550310
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tricou
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Minh
          </surname>
          <given-names>
           N.N.
          </given-names>
         </name>
         <name>
          <surname>
           Van
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Farrar
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wills
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults
        </article-title>
        <source>
         PLoS Neglected Trop Dis
        </source>
        <volume>
         4
        </volume>
        <year>
         2010
        </year>
        <fpage>
         e785
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Safronetz
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Prescott
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Marzi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lack of protection against ebola virus from chloroquine in mice and hamsters
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         21
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1065
        </fpage>
        <lpage>
         1067
        </lpage>
        <pub-id pub-id-type="pmid">
         25988934
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sref32" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vigerust
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           McCullers
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine is effective against influenza A virus in vitro but not in vivo
        </article-title>
        <source>
         Influenza Other Respir Viruses
        </source>
        <volume>
         1
        </volume>
        <year>
         2007
        </year>
        <fpage>
         189
        </fpage>
        <lpage>
         192
        </lpage>
        <pub-id pub-id-type="pmid">
         19453426
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pallister
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Middleton
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Klein
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine administration does not prevent Nipah virus infection and disease in ferrets
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         83
        </volume>
        <year>
         2009
        </year>
        <fpage>
         11979
        </fpage>
        <lpage>
         11982
        </lpage>
        <pub-id pub-id-type="pmid">
         19759137
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sref34" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seth
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Man
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Banaudha
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Madhavan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sidhu
          </surname>
          <given-names>
           G.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acceleration of viral replication and up-regulation of cytokine levels by antimalarials: implications in malaria-endemic areas
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <volume>
         61
        </volume>
        <year>
         1999
        </year>
        <fpage>
         180
        </fpage>
        <lpage>
         186
        </lpage>
        <pub-id pub-id-type="pmid">
         10463664
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sref35" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roques
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Thiberville
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Dupuis-Maguiraga
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lum
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
         <name>
          <surname>
           Labadie
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Martinon
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         10
        </volume>
        <issue>
         5
        </issue>
        <year>
         2018 May 17
        </year>
        <comment>
         pii: E268
        </comment>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sref36" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chauhan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tikoo
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The enigma of the clandestine association between chloroquine and HIV-1 infection
        </article-title>
        <source>
         HIV Med
        </source>
        <volume>
         16
        </volume>
        <year>
         2015
        </year>
        <fpage>
         585
        </fpage>
        <lpage>
         590
        </lpage>
        <pub-id pub-id-type="pmid">
         26238012
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sref37" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Helal
          </surname>
          <given-names>
           G.K.
          </given-names>
         </name>
         <name>
          <surname>
           Gad
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Abd-Ellah
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Eid
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         88
        </volume>
        <issue>
         12
        </issue>
        <year>
         2016
        </year>
        <fpage>
         2170
        </fpage>
        <lpage>
         2178
        </lpage>
        <pub-id pub-id-type="pmid">
         27183377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sref38" publication-type="other">
        <article-title>
         Chloroquine US prescribing information
        </article-title>
        <comment>
         (Last accessed March 21, 2020)
        </comment>
        <ext-link ext-link-type="uri" id="intref0065" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/006002s044lbl.pdf">
         https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/006002s044lbl.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sref39" publication-type="other">
        <article-title>
         Chloroquine US prescribing information
        </article-title>
        <comment>
         (Last accessed March 21, 2020)
        </comment>
        <ext-link ext-link-type="uri" id="intref0070" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf">
         https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation id="sref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kwong
          </surname>
          <given-names>
           J.S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis
        </article-title>
        <source>
         Drug Des Dev Ther
        </source>
        <volume>
         12
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1685
        </fpage>
        <lpage>
         1695
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation id="sref41" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cortegiani
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ingoglia
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ippolito
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Giarratano
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Einav
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
        </article-title>
        <source>
         J Crit Care
        </source>
        <issue>
         20
        </issue>
        <year>
         2020 Mar 10
        </year>
        <fpage>
         30390
        </fpage>
        <lpage>
         30397
        </lpage>
        <comment>
         pii: S0883-9441
        </comment>
        <ext-link ext-link-type="uri" id="intref0075" xlink:href="https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf">
         https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf
        </ext-link>
        <comment>
         [Epub ahead of print]. 42: Recommendations for empiric use of hydroxychloroquine for prophylaxis of SARS CoV-2 infection
        </comment>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Clin Microbiol Rev
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Clin. Microbiol. Rev
      </journal-id>
      <journal-id journal-id-type="hwp">
       cmr
      </journal-id>
      <journal-id journal-id-type="pmc">
       cmr
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       CMR
      </journal-id>
      <journal-title-group>
       <journal-title>
        Clinical Microbiology Reviews
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0893-8512
      </issn>
      <issn pub-type="epub">
       1098-6618
      </issn>
      <publisher>
       <publisher-name>
        American Society for Microbiology
       </publisher-name>
       <publisher-loc>
        1752 N St., N.W., Washington, DC
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25810418
      </article-id>
      <article-id pub-id-type="pmc">
       4402954
      </article-id>
      <article-id pub-id-type="publisher-id">
       00102-14
      </article-id>
      <article-id pub-id-type="doi">
       10.1128/CMR.00102-14
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Reviews
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease
       </article-title>
       <alt-title alt-title-type="running-head">
        Middle East Respiratory Syndrome Coronavirus
       </alt-title>
       <alt-title alt-title-type="short-authors">
        Chan et al.
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          Jasper F. W.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e53">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lau
         </surname>
         <given-names>
          Susanna K. P.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e76">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          To
         </surname>
         <given-names>
          Kelvin K. W.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e105">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cheng
         </surname>
         <given-names>
          Vincent C. C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e131">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Woo
         </surname>
         <given-names>
          Patrick C. Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e151">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          Kwok-Yung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e171">
         *
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         a
        </label>
        State Key Laboratory of Emerging Infectious Diseases and Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, China
       </aff>
       <aff id="aff2">
        <label>
         b
        </label>
        Carol Yu Centre for Infection, Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, China
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address correspondence to Kwok-Yung Yuen,
        <email>
         kyyuen@hku.hk
        </email>
        .
       </corresp>
       <fn fn-type="other">
        <p>
         <bold>
          Citation
         </bold>
         Chan JFW, Lau SKP, To KKW, Cheng VCC, Woo PCY, Yuen K-Y. 25 March 2015. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev doi:
         <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/CMR.00102-14">
          10.1128/CMR.00102-14
         </ext-link>
         .
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        25
       </day>
       <month>
        3
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        4
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       28
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       465
      </fpage>
      <lpage>
       522
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2015, American Society for Microbiology. All Rights Reserved.
       </copyright-statement>
       <copyright-year>
        2015
       </copyright-year>
       <copyright-holder>
        American Society for Microbiology
       </copyright-holder>
      </permissions>
      <self-uri content-type="pdf" xlink:href="zcm002152507465.pdf">
      </self-uri>
      <abstract>
       <title>
        SUMMARY
       </title>
       <p>
        The source of the severe acute respiratory syndrome (SARS) epidemic was traced to wildlife market civets and ultimately to bats. Subsequent hunting for novel coronaviruses (CoVs) led to the discovery of two additional human and over 40 animal CoVs, including the prototype lineage C betacoronaviruses,
        <named-content content-type="genus-species">
         Tylonycteris
        </named-content>
        bat CoV HKU4 and
        <named-content content-type="genus-species">
         Pipistrellus
        </named-content>
        bat CoV HKU5; these are phylogenetically closely related to the Middle East respiratory syndrome (MERS) CoV, which has affected more than 1,000 patients with over 35% fatality since its emergence in 2012. All primary cases of MERS are epidemiologically linked to the Middle East. Some of these patients had contacted camels which shed virus and/or had positive serology. Most secondary cases are related to health care-associated clusters. The disease is especially severe in elderly men with comorbidities. Clinical severity may be related to MERS-CoV's ability to infect a broad range of cells with DPP4 expression, evade the host innate immune response, and induce cytokine dysregulation. Reverse transcription-PCR on respiratory and/or extrapulmonary specimens rapidly establishes diagnosis. Supportive treatment with extracorporeal membrane oxygenation and dialysis is often required in patients with organ failure. Antivirals with potent
        <italic>
         in vitro
        </italic>
        activities include neutralizing monoclonal antibodies, antiviral peptides, interferons, mycophenolic acid, and lopinavir. They should be evaluated in suitable animal models before clinical trials. Developing an effective camel MERS-CoV vaccine and implementing appropriate infection control measures may control the continuing epidemic.
       </p>
      </abstract>
      <counts>
       <fig-count count="10">
       </fig-count>
       <table-count count="12">
       </table-count>
       <equation-count count="0">
       </equation-count>
       <ref-count count="345">
       </ref-count>
       <page-count count="58">
       </page-count>
       <word-count count="46818">
       </word-count>
      </counts>
     </article-meta>
    </front>
   </article>
   <article article-type="brief-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Nat Rev Rheumatol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Nat Rev Rheumatol
      </journal-id>
      <journal-title-group>
       <journal-title>
        Nature Reviews. Rheumatology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1759-4790
      </issn>
      <issn pub-type="epub">
       1759-4804
      </issn>
      <publisher>
       <publisher-name>
        Nature Publishing Group UK
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       20046202
      </article-id>
      <article-id pub-id-type="pmc">
       7097534
      </article-id>
      <article-id pub-id-type="publisher-id">
       BFnrrheum2009235
      </article-id>
      <article-id pub-id-type="doi">
       10.1038/nrrheum.2009.235
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Hydroxychloroquine in SLE: old drug, new perspectives
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Dörner
         </surname>
         <given-names>
          Thomas
         </given-names>
        </name>
        <address>
         <email>
          thomas.doerner@charite.de
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
        <bio>
         <p id="Par1">
          Thomas Dörner is a Professor of Rheumatology and Clinical Immunology, and leads the hemostaseology group at the Charité University Medicine, Berlin, and the immune memory group at the German Rheumatology Research Center, Berlin. His major scientific interests are the role and differentiation of B cells in autoimmune diseases, innovative immune therapies for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome, and the relationship between inflammation and coagulation. He serves on several editorial boards of international journals, such as
          <italic>
           Annals of the Rheumatic Diseases, Arthritis Research &amp; Therapy
          </italic>
          , and
          <italic>
           Rheumatology Reviews
          </italic>
          .
         </p>
        </bio>
       </contrib>
       <aff id="Aff1">
        Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum, Charitéplatz 01, Berlin, 10098 Germany
       </aff>
      </contrib-group>
      <pub-date pub-type="ppub">
       <year>
        2010
       </year>
      </pub-date>
      <volume>
       6
      </volume>
      <issue>
       1
      </issue>
      <fpage>
       10
      </fpage>
      <lpage>
       11
      </lpage>
      <permissions>
       <copyright-statement>
        © Nature Publishing Group 2010
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="Standfirst" id="Abs1">
       <p id="Par2">
        Antimalarial agents have long been used in the treatment of autoimmune diseases, despite uncertainty regarding the exact mechanisms underlying their various effects. Growing evidence that these drugs offer protection from major infections could stimulate more research into these mechanisms, with possible implications for therapy.
       </p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
       <title>
        Subject terms
       </title>
       <kwd>
        Clinical pharmacology
       </kwd>
       <kwd>
        Systemic lupus erythematosus
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Springer Nature Limited 2010
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <p id="Par3">
     Chloroquine, together with its hydroxyl derivative hydroxychloroquine, was initially used as an antimalarial agent, but is also useful in the treatment of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (SLE). Chloroquine and hydroxychloroquine are approved for the treatment of SLE and have been shown to reduce the frequency of disease flares (particularly of lupus nephritis), contribute to the maintenance of remission, prolong the onset of disease and reduce the risk of complications.
     <sup>
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
     </sup>
     Beyond their immunomodulatory effects in SLE, these agents have also been shown to protect against thrombotic events,
     <sup>
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
     </sup>
     improve glucose and lipid profiles, and prevent renal damage,
     <sup>
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
     </sup>
     apparently resulting in reduced cardiovascular risk, for which SLE is an independent risk factor. Ultimately, an increased rate of survival has been reported in SLE patients taking antimalarial agents.
     <sup>
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
     </sup>
    </p>
    <p id="Par4">
     Antimalarial agents are inexpensive, especially compared with treatments used more recently in SLE patients, and also have a good overall tolerability profile, with the exception of a risk of retinal toxicity. To date, antimalarial agents have not been reliably linked to an increased incidence of infections as has been known to occur with use of other immunosuppressive drugs. In this context, and surprisingly, a recent nested case–control study aiming to identify factors predictive of infectious complications
     <sup>
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
     </sup>
     reported that SLE patients treated with antimalarial agents had a lower risk of major infections (odds ratio [OR] 0.06, 95% CI 0.02–0.18), whereas prednisone treatment (OR 1.12, 95% CI 1.04–1.19) and lung involvement (OR 4.41, 95% CI 1.06–18.36) increased this risk. Interestingly, the median dose of prednisone in patients with major infections was 7.5 mg per day, and each 10 mg per day dose increase led to an 11-fold increase in infection risk. Cyclophosphamide exposure and overt lupus nephritis were not associated with enhanced infection risk in this study, probably because an insufficient number of patients was included.
    </p>
    <p id="Par5">
     Although this study by Ruiz-Irastorza and colleagues
     <sup>
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
     </sup>
     was limited by the inclusion of only 83 cases of SLE and 166 controls, it did show that the risk of major infections is 16 times lower in patients treated with antimalarial agents than those who were not. This effect of antimalarials is consistent with observations from two previous studies in SLE.
     <sup>
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
     </sup>
     One retrospective study of patients with lupus nephritis identified a lower frequency of infections among patients previously treated with antimalarial agents.
     <sup>
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
     </sup>
     Another study in patients with SLE
     <sup>
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
     </sup>
     found that hydroxychloroquine treatment led to a lower risk of major infections, giving an OR of 0.05 (95% CI 0.01–0.23); this is comparable to that of the study by Ruiz-Irastorza and colleagues
     <sup>
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
     </sup>
     which was partly corrected for disease activity.
    </p>
    <p id="Par6">
     Although prospective studies are needed to confirm these data, an assessment of the value of antimalarial agents, especially hydroxychloroquine, requires a re-evaluation of their underlying mechanisms of action. Beyond their benefits of clinical prevention of lupus flares, increased patient survival, prevention of severe organ damage, thrombosis and bone mass loss, and possible use in pregnant patients, indicators for reduced major infections might shed new light on antimalarial agents as a 'magic therapeutic bullet'. Most noteworthy, a similar reduction in infections with hydroxychloroquine use has been observed in patients with rheumatoid arthritis, which suggests that the reduction of infections might not be restricted to SLE.
     <sup>
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
     </sup>
    </p>
    <p id="Par7">
     Usually, a key factor in considering immunosuppressive therapy for the treatment of patients with SLE is a substantially increased risk of infections. Immunosuppressive drugs, most notably steroids, as well as SLE activity, the presence of lupus nephritis or low serum complement levels have all been shown to increase the rate of infections. Although the intimate interrelationship between disease activity and choice of therapy intensity is critical in systemic autoimmune disease, one rule of clinical practice says that intensive therapy in patients with very active disease increases the risk of infections. How are antimalarial agents able to break this rule?
    </p>
    <p id="Par8">
     Even if the data by Ruiz-Istorza
     <italic>
      et al
     </italic>
     .
     <sup>
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
     </sup>
     can be confirmed in clinical prospective studies, we are still left with uncertainty about the unique underlying immunomodulatory and anti-infective effects of antimalarial agents. Originally used as antiparasitic agents, antimalarial drugs have also been shown to have antimicrobial effects,
     <sup>
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
     </sup>
     at least
     <italic>
      in vitro
     </italic>
     , against bacteria, such as
     <italic>
      Tropheryma whippelii
     </italic>
     ,
     <italic>
      Staphylococcus aureus
     </italic>
     ,
     <italic>
      Legionella pneumophila
     </italic>
     ,
     <italic>
      Mycobacterium
     </italic>
     species,
     <italic>
      Salmonella typhi
     </italic>
     ,
     <italic>
      Escherichia coli
     </italic>
     and
     <italic>
      Borrelia burgdorferi
     </italic>
     , fungi,
     <sup>
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
     </sup>
     and viruses including HIV, severe acute respiratory syndrome (SARS) coronavirus and others.
     <sup>
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
     </sup>
     This remarkable combination of immunomodulatory effects and effects against a variety of microbes is noteworthy and indicates hitherto unknown pathways of immune intervention and protection, respectively.
    </p>
    <p id="Par9">
     Two major concepts have been postulated to explain the mechanisms of action of antimalarial agents. First, alkalinization of phagolysosomes kills intracellular bacteria and fungi and, second, blockade of several steps of viral entry and protein glycosylation prevents the spread of viruses.
     <sup>
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
     </sup>
     The antibacterial and antifungal effects of antimalarial agents appear to be linked to interference with antigen presentation, which is mediated by pH-dependent iron deprivation and by increasing the phagolysosomal pH; this ultimately leads to reduced immune system activation and inhibits the growth of intracellular organisms.
     <sup>
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
     </sup>
     Moreover, the basic intracellular pH induced by antimalarial agents could have antiviral effects and result in the blockade of hydrolases and post-translational modifications, including inhibition of glycosylation of newly synthesized proteins. Notably, glycosylation inhibition might lead to interactions of chloroquine with sugar-modifying enzymes or glycosyltransferases and could account for effects on a number of processes that are sialic-acid dependent, including intracellular as well as extracellular functions (for example, binding to surface receptors).
    </p>
    <p id="Par10">
     A third and rather appealing concept hypothesizes that interference with innate immune activation, that is, by blocking Toll-like receptor (TLR) 3, TLR7 and TLR9, could be responsible for a number of effects of antimalarial agents. Thus, antimalarial agents can interfere with intracellular recognition of nucleic-acid-binding by TLR7 and TLR9, which are harbored in intracellular compartments and block the activation of interferon in SLE. Since TLR recognition is also involved in protection against infection, a tempting idea is that antimalarial agents lead to prominent TLR inhibition by changing the intracellular pH.
    </p>
    <p id="Par11">
     Despite reports of the valuable clinical effects of antimalarial agents in SLE, we still need additional confirmation from clinical studies as well as more-detailed basic studies to decipher their mechanisms of action. Since only about 40–50% of patients with SLE are treated with antimalarial agents, the available data on these drugs demand reconsideration of their pleiotropic effects in SLE patients where not contraindicated. Ultimately, a better understanding of the individual effects of antimalarial agents could pave the way for innovative drugs that combine immunomodulatory and anti-infective potency, or that even provide new etiopathogenic insights into SLE.
    </p>
    <back>
     <notes notes-type="COI-statement">
      <title>
       Competing interests
      </title>
      <p id="Par12">
       The author declares no competing financial interests.
      </p>
     </notes>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           James
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         2007
        </year>
        <volume>
         16
        </volume>
        <fpage>
         401
        </fpage>
        <lpage>
         409
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/0961203307078579
        </pub-id>
        <pub-id pub-id-type="pmid">
         17664230
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kaiser
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Cleveland
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Criswell
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort
        </article-title>
        <source>
         Ann. Rheum. Dis.
        </source>
        <year>
         2009
        </year>
        <volume>
         68
        </volume>
        <fpage>
         238
        </fpage>
        <lpage>
         241
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/ard.2008.093013
        </pub-id>
        <pub-id pub-id-type="pmid">
         18782792
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ruiz-Irastorza
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         2006
        </year>
        <volume>
         15
        </volume>
        <fpage>
         577
        </fpage>
        <lpage>
         583
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/0961203306071872
        </pub-id>
        <pub-id pub-id-type="pmid">
         17080912
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siso
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Previous antimalarial therapy in patients diagnosed with lupus nephiritis: influence on outcomes and survival
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         2008
        </year>
        <volume>
         17
        </volume>
        <fpage>
         281
        </fpage>
        <lpage>
         288
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/0961203307086503
        </pub-id>
        <pub-id pub-id-type="pmid">
         18413408
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsakonas
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         1998
        </year>
        <volume>
         7
        </volume>
        <fpage>
         80
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="doi">
         10.1191/096120398678919778
        </pub-id>
        <pub-id pub-id-type="pmid">
         9541091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pons-Estel
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort
        </article-title>
        <source>
         Arthritis Rheum.
        </source>
        <year>
         2009
        </year>
        <volume>
         61
        </volume>
        <fpage>
         830
        </fpage>
        <lpage>
         839
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/art.24538
        </pub-id>
        <pub-id pub-id-type="pmid">
         19479701
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ruiz-Irastorza
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Egurbide
          </surname>
          <given-names>
           MV
          </given-names>
         </name>
         <name>
          <surname>
           Olivares
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Martinez-Berriotxoa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Aguirre
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences
        </article-title>
        <source>
         Rheumatology (Oxford)
        </source>
        <year>
         2008
        </year>
        <volume>
         47
        </volume>
        <fpage>
         920
        </fpage>
        <lpage>
         923
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/rheumatology/ken121
        </pub-id>
        <pub-id pub-id-type="pmid">
         18411213
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bultink
          </surname>
          <given-names>
           IEM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus
        </article-title>
        <source>
         Arthritis Res. Ther.
        </source>
        <year>
         2006
        </year>
        <volume>
         8
        </volume>
        <fpage>
         R183
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/ar2095
        </pub-id>
        <pub-id pub-id-type="pmid">
         17166254
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smitten
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
        </person-group>
        <article-title>
         The risk of hospitalized infection in patients with rheumatoid arthritis
        </article-title>
        <source>
         J. Rheumatol.
        </source>
        <year>
         2008
        </year>
        <volume>
         35
        </volume>
        <fpage>
         387
        </fpage>
        <lpage>
         393
        </lpage>
        <pub-id pub-id-type="pmid">
         18260176
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century
        </article-title>
        <source>
         Int. J. Antimicrob. Agents
        </source>
        <year>
         2007
        </year>
        <volume>
         30
        </volume>
        <fpage>
         297
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ijantimicag.2007.05.015
        </pub-id>
        <pub-id pub-id-type="pmid">
         17629679
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Int J Antimicrob Agents
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Int. J. Antimicrob. Agents
      </journal-id>
      <journal-title-group>
       <journal-title>
        International Journal of Antimicrobial Agents
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0924-8579
      </issn>
      <issn pub-type="epub">
       1872-7913
      </issn>
      <publisher>
       <publisher-name>
        The Author(s). Published by Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32171740
      </article-id>
      <article-id pub-id-type="pmc">
       7118659
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0924-8579(20)30088-1
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.ijantimicag.2020.105938
      </article-id>
      <article-id pub-id-type="publisher-id">
       105938
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0001">
        <name>
         <surname>
          Devaux
         </surname>
         <given-names>
          Christian A.
         </given-names>
        </name>
        <email>
         christian.devaux@mediterranee-infection.com
        </email>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
        <xref ref-type="corresp" rid="cor0001">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0002">
        <name>
         <surname>
          Rolain
         </surname>
         <given-names>
          Jean-Marc
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0003">
        <name>
         <surname>
          Colson
         </surname>
         <given-names>
          Philippe
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0004">
        <name>
         <surname>
          Raoult
         </surname>
         <given-names>
          Didier
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0001">
       <label>
        a
       </label>
       Aix-Marseille Université, IRD, APHM, MEPHI, IHU–Méditerranée Infection, Marseille, France
      </aff>
      <aff id="aff0002">
       <label>
        b
       </label>
       CNRS, Marseille, France
      </aff>
      <aff id="aff0003">
       <label>
        c
       </label>
       IHU–Méditerranée Infection, 19–21 boulevard Jean Moulin, 13005 Marseille, France
      </aff>
      <author-notes>
       <corresp id="cor0001">
        <label>
         ⁎
        </label>
        Corresponding author. Present address: IHU–Méditerranée Infection, 19–21 Boulevard Jean Moulin, 13385 Marseille, France. Tel.: +33 4 13 73 20 51; fax: +33 4 13 73 20 52.
        <email>
         christian.devaux@mediterranee-infection.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        12
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        12
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       105938
      </elocation-id>
      <permissions>
       <copyright-statement>
        © 2020 The Authors
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0001">
       <p>
        Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. In the absence of a known efficient therapy and because of the situation of a public-health emergency, it made sense to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2 since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle.
       </p>
      </abstract>
      <kwd-group id="keys0001">
       <title>
        Keywords
       </title>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        Chloroquine
       </kwd>
      </kwd-group>
     </article-meta>
     <notes>
      <p id="msc0010">
       Editor: Jose Fernando Oliveira
      </p>
     </notes>
    </front>
    <sec id="sec0001">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="para0001">
      Chloroquine is an amine acidotropic form of quinine that was synthesised in Germany by Bayer in 1934 and emerged approximately 70 years ago as an effective substitute for natural quinine
      <xref ref-type="bibr" rid="bib0001">
       [1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0002">
       2]
      </xref>
      . Quinine is a compound found in the bark of
      <italic>
       Cinchona
      </italic>
      trees native to Peru and was the previous drug of choice against malaria
      <xref ref-type="bibr" rid="bib0003">
       [3]
      </xref>
      . For decades, chloroquine was a front-line drug for the treatment and prophylaxis of malaria and is one of the most prescribed drugs worldwide
      <xref ref-type="bibr" rid="bib0004">
       [4]
      </xref>
      . Chloroquine and the 4-aminoquinoline drug hydroxychloroquine belong to the same molecular family. Hydroxychloroquine differs from chloroquine by the presence of a hydroxyl group at the end of the side chain: the
      <italic>
       N
      </italic>
      -ethyl substituent is β-hydroxylated. This molecule is available for oral administration in the form of hydroxychloroquine sulfate. Hydroxychloroquine has pharmacokinetics similar to that of chloroquine, with rapid gastrointestinal absorption and renal elimination. However, the clinical indications and toxic doses of these drugs slightly differ. In malaria, the indication for chloroquine was a high dose for a short period of time (due to its toxicity at high doses) or a low dose for a long period of time. Hydroxychloroquine was reported to be as active as chloroquine against
      <italic>
       Plasmodium falciparum
      </italic>
      malaria and less toxic, but it is much less active than chloroquine against chloroquine-resistant
      <italic>
       P. falciparum
      </italic>
      owing to its physicochemical properties. What is advantageous with hydroxychloroquine is that it can be used in high doses for long periods with very good tolerance. Unfortunately, the efficacy of chloroquine gradually declined due to the continuous emergence of chloroquine-resistant
      <italic>
       P. falciparum
      </italic>
      strains
      <xref ref-type="bibr" rid="bib0005">
       [5]
      </xref>
      . Chloroquine is also utilised in the treatment of autoimmune diseases
      <xref ref-type="bibr" rid="bib0006">
       [6]
      </xref>
      . Yet the activity of the molecule is not limited to malaria and the control of inflammatory processes, as illustrated by its broad-spectrum activity against a range of bacterial, fungal and viral infections
      <xref ref-type="bibr" rid="bib0007">
       [7]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0008">
       [8]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0009">
       [9]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0010">
       [10]
      </xref>
      . Indeed, in the mid-1990s, due to its tolerability, rare toxicity reports, inexpensive cost and immunomodulatory properties
      <xref ref-type="bibr" rid="bib0011">
       [11]
      </xref>
      , chloroquine repurposing was explored against human immunodeficiency virus (HIV) and other viruses associated with inflammation and was found to be efficient in inhibiting their replication cycle
      <xref ref-type="bibr" rid="bib0012">
       [12]
      </xref>
      .
     </p>
     <p id="para0002">
      Recently, a novel coronavirus emerged in the Chinese city of Wuhan in December 2019. After human coronavirus 229E (HCoV-229E) (classified in the genus
      <italic>
       Alphacoronavirus
      </italic>
      ) and HCoV-OC43 (
      <italic>
       Betacoronavirus
      </italic>
      lineage 2a member) described in the 1960s, SARS-CoV-1 (
      <italic>
       Betacoronavirus
      </italic>
      lineage 2b member) that emerged in March 2003, HCoV-NL63 (
      <italic>
       Alphacoronavirus
      </italic>
      lineage 1b member) described in 2004, HCoV-HKU1 (
      <italic>
       Betacoronavirus
      </italic>
      lineage 2a member) discovered in 2005, and finally MERS-CoV that emerged in 2012 (classified in
      <italic>
       Betacoronavirus
      </italic>
      lineage 2c), the novel coronavirus is the seventh human coronavirus described to date as being responsible for respiratory infection. Evidence was rapidly reported that patients were suffering from an infection with a novel
      <italic>
       Betacoronavirus
      </italic>
      tentatively named 2019 novel coronavirus (2019-nCoV)
      <xref ref-type="bibr" rid="bib0013">
       [13
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0014">
       14]
      </xref>
      . Despite drastic containment measures, the spread of 2019-nCoV, now officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is ongoing. Phylogenetic analysis of this virus indicated that it is different (~80% nucleotide identity) but related to SARS-CoV-1
      <xref ref-type="bibr" rid="bib0015">
       [15]
      </xref>
      . Because the world is threatened by the possibility of a SARS-CoV-2 pandemic, the broad-spectrum antiviral effects of chloroquine warranted particular attention for repurposing this drug in the therapy of the disease caused by SARS-CoV-2, named coronavirus disease 2019 (COVID-19).
     </p>
    </sec>
    <sec id="sec0002">
     <label>
      2
     </label>
     <title>
      Antiviral properties of chloroquine
     </title>
     <p id="para0003">
      In vitro, chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus
      <xref ref-type="bibr" rid="bib0016">
       [16]
      </xref>
      , poliovirus
      <xref ref-type="bibr" rid="bib0017">
       [17]
      </xref>
      , HIV
      <xref ref-type="bibr" rid="bib0012">
       [12
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0018">
       [18]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0019">
       [19]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0020">
       [20]
      </xref>
      , hepatitis A virus
      <xref ref-type="bibr" rid="bib0021">
       [21
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0022">
       22]
      </xref>
      , hepatitis C virus
      <xref ref-type="bibr" rid="bib0023">
       [23]
      </xref>
      , influenza A and B viruses
      <xref ref-type="bibr" rid="bib0024">
       [24]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0025">
       [25]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0026">
       [26]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0027">
       [27]
      </xref>
      , influenza A H5N1 virus
      <xref ref-type="bibr" rid="bib0028">
       [28]
      </xref>
      , Chikungunya virus
      <xref ref-type="bibr" rid="bib0029">
       [29]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0030">
       [30]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0031">
       [31]
      </xref>
      , Dengue virus
      <xref ref-type="bibr" rid="bib0032">
       [32
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0033">
       33]
      </xref>
      , Zika virus
      <xref ref-type="bibr" rid="bib0034">
       [34]
      </xref>
      , Lassa virus
      <xref ref-type="bibr" rid="bib0035">
       [35]
      </xref>
      , Hendra and Nipah viruses
      <xref ref-type="bibr" rid="bib0036">
       [36
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0037">
       37]
      </xref>
      , Crimean–Congo hemorrhagic fever virus
      <xref ref-type="bibr" rid="bib0038">
       [38]
      </xref>
      and Ebola virus
      <xref ref-type="bibr" rid="bib0039">
       [39]
      </xref>
      , as well as various DNA viruses such as hepatitis B virus
      <xref ref-type="bibr" rid="bib0040">
       [40]
      </xref>
      and herpes simplex virus
      <xref ref-type="bibr" rid="bib0041">
       [41]
      </xref>
      .The antiviral properties of chloroquine described in vitro have sometimes been confirmed during treatment of virus-infected patients but have not always been reproduced in clinical trials depending on the disease, the concentration of chloroquine used, the duration of treatment and the clinical team in charge of the trial.
     </p>
     <p id="para0004">
      Regarding coronaviruses, the potential therapeutic benefits of chloroquine were notably reported for SARS-CoV-1
      <xref ref-type="bibr" rid="bib0011">
       [11
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0042">
       42]
      </xref>
      . Chloroquine was also reported to inhibit in vitro the replication of HCoV-229E in epithelial lung cell cultures
      <xref ref-type="bibr" rid="bib0043">
       [43
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0044">
       44]
      </xref>
      . In 2009, it was reported that lethal infections of newborn mice with the HCoV-O43 coronavirus could be averted by administering chloroquine through the mother's milk. In vitro experiments also showed a strong antiviral effect of chloroquine on a recombinant HCoV-O43 coronavirus
      <xref ref-type="bibr" rid="bib0045">
       [45]
      </xref>
      . Although chloroquine was reported to be active against Middle East respiratory syndrome coronavirus (MERS-CoV) in vitro
      <xref ref-type="bibr" rid="bib0046">
       [46]
      </xref>
      , this observation remains controversial
      <xref ref-type="bibr" rid="bib0047">
       [47]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0003">
     <label>
      3
     </label>
     <title>
      Potential antiviral effect of chloroquine against SARS-CoV-2
     </title>
     <p id="para0005">
      Because of its broad spectrum of action against viruses, including most coronaviruses and particularly its close relative SARS-CoV-1, and because coronavirus cell entry occurs through the endolysosomal pathway
      <xref ref-type="bibr" rid="bib0048">
       [48]
      </xref>
      , it made sense in a situation of a public-health emergency and the absence of any known efficient therapy to investigate the possible effect of chloroquine against SARS-CoV-2. A recent paper reported that both chloroquine and the antiviral drug remdesivir inhibited SARS-CoV-2 in vitro and suggested these drugs be assessed in human patients suffering from COVID-19
      <xref ref-type="bibr" rid="bib0049">
       [49]
      </xref>
      .
     </p>
     <p id="para0006">
      Recently, the China National Center for Biotechnology Development indicated that chloroquine is one of the three drugs with a promising profile against the new SARS-CoV-2 coronavirus that causes COVID-19. Chloroquine repurposing was investigated in hospitals in Beijing, in central China's Hunan Province and South China's Guangdong Province. According to preliminary reports
      <xref ref-type="bibr" rid="bib0050">
       [50
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0051">
       51]
      </xref>
      from the Chinese authorities suggesting that approximately 100 infected patients treated with chloroquine experienced a more rapid decline in fever and improvement of lung computed tomography (CT) images and required a shorter time to recover compared with control groups, with no obvious serious adverse effects, the Chinese medical advisory board has suggested chloroquine inclusion in the SARS-CoV-2 treatment guidelines. As a result, chloroquine is probably the first molecule to be used in China and abroad on the front line for the treatment of severe SARS-CoV-2 infections. Although the long use of this drug in malaria therapy demonstrates the safety of acute chloroquine administration to humans, one cannot ignore the minor risk of macular retinopathy, which depends on the cumulative dose
      <xref ref-type="bibr" rid="bib0052">
       [52]
      </xref>
      , and the existence of some reports on cardiomyopathy as a severe adverse effect caused by chloroquine
      <xref ref-type="bibr" rid="bib0053">
       [53
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0054">
       54]
      </xref>
      . A survey of SARS-CoV-2-infected patients for adverse effects of chloroquine therapy remains to be performed. However, chloroquine is currently among the best available candidates to impact the severity of SARS-CoV-2 infections in humans. Currently, at least ten clinical trials are testing chloroquine as an anti-COVID-19 therapy
      <xref ref-type="bibr" rid="bib0055">
       [55]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0004">
     <label>
      4
     </label>
     <title>
      Mode of action of chloroquine
     </title>
     <p id="para0007">
      Chloroquine has multiple mechanisms of action that may differ according to the pathogen studied.
     </p>
     <p id="para0008">
      Chloroquine can inhibit a pre-entry step of the viral cycle by interfering with viral particles binding to their cellular cell surface receptor. Chloroquine was shown to inhibit quinone reductase 2
      <xref ref-type="bibr" rid="bib0056">
       [56]
      </xref>
      , a structural neighbour of UDP-
      <italic>
       N
      </italic>
      -acetylglucosamine 2-epimerases
      <xref ref-type="bibr" rid="bib0057">
       [57]
      </xref>
      that are involved in the biosynthesis of sialic acids. The sialic acids are acidic monosaccharides found at the extremity of sugar chains present on cell transmembrane proteins and are critical components of ligand recognition. The possible interference of chloroquine with sialic acid biosynthesis could account for the broad antiviral spectrum of that drug since viruses such as the human coronavirus HCoV-O43 and the orthomyxoviruses use sialic acid moieties as receptors
      <xref ref-type="bibr" rid="bib0058">
       [58]
      </xref>
      . The potent anti-SARS-CoV-1 effects of chloroquine in vitro were considered attributable to a deficit in the glycosylation of a virus cell surface receptor, the angiotensin-converting enzyme 2 (ACE2) on Vero cells
      <xref ref-type="bibr" rid="bib0059">
       [59]
      </xref>
      .
     </p>
     <p id="para0009">
      Chloroquine can also impair another early stage of virus replication by interfering with the pH-dependent endosome-mediated viral entry of enveloped viruses such as Dengue virus or Chikungunya virus
      <xref ref-type="bibr" rid="bib0060">
       [60
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0061">
       61]
      </xref>
      . Due to the alkalisation of endosomes, chloroquine was an effective in vitro treatment against Chikungunya virus when added to Vero cells prior to virus exposure
      <xref ref-type="bibr" rid="bib0030">
       [30]
      </xref>
      . The mechanism of inhibition likely involved the prevention of endocytosis and/or rapid elevation of the endosomal pH and abrogation of virus–endosome fusion. A pH-dependant mechanism of entry of coronavirus into target cells was also reported for SARS-CoV-1 after binding of the DC-SIGN receptor
      <xref ref-type="bibr" rid="bib0062">
       [62]
      </xref>
      . The activation step that occurs in endosomes at acidic pH results in fusion of the viral and endosomal membranes leading to the release of the viral SARS-CoV-1 genome into the cytosol
      <xref ref-type="bibr" rid="bib0063">
       [63]
      </xref>
      . In the absence of antiviral drug, the virus is targeted to the lysosomal compartment where the low pH, along with the action of enzymes, disrupts the viral particle, thus liberating the infectious nucleic acid and, in several cases, enzymes necessary for its replication
      <xref ref-type="bibr" rid="bib0064">
       [64]
      </xref>
      . Chloroquine-mediated inhibition of hepatitis A virus was found to be associated with uncoating, thus blocking its entire replication cycle
      <xref ref-type="bibr" rid="bib0022">
       [22]
      </xref>
      .
     </p>
     <p id="para0010">
      Chloroquine can also interfere with the post-translational modification of viral proteins. These post-translational modifications, which involve proteases and glycosyltransferases, occur within the endoplasmic reticulum or the trans-Golgi network vesicles and may require a low pH. For HIV, the antiretroviral effect of chloroquine is attributable to a post-transcriptional inhibition of glycosylation of the gp120 envelope glycoprotein, and the neosynthesised virus particles are non-infectious
      <xref ref-type="bibr" rid="bib0019">
       [19
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0065">
       65]
      </xref>
      . Chloroquine also inhibits the replication Dengue-2 virus by affecting the normal proteolytic processing of the flavivirus prM protein to M protein
      <xref ref-type="bibr" rid="bib0032">
       [32]
      </xref>
      . As a result, viral infectivity is impaired. In the herpes simplex virus (HSV) model, chloroquine inhibited budding with accumulation of non-infectious HSV-1 particles in the trans-Golgi network
      <xref ref-type="bibr" rid="bib0066">
       [66]
      </xref>
      . Using non-human coronavirus, it was shown that the intracellular site of coronavirus budding is determined by the localisation of its membrane M proteins that accumulate in the Golgi complex beyond the site of virion budding
      <xref ref-type="bibr" rid="bib0067">
       [67]
      </xref>
      , suggesting a possible action of chloroquine on SARS-CoV-2 at this step of the replication cycle. It was recently reported that the C-terminal domain of the MERS-CoV M protein contains a trans-Golgi network localisation signal
      <xref ref-type="bibr" rid="bib0068">
       [68]
      </xref>
      .
     </p>
     <p id="para0011">
      Beside affecting the virus maturation process, pH modulation by chloroquine can impair the proper maturation of viral protein
      <xref ref-type="bibr" rid="bib0032">
       [32]
      </xref>
      and the recognition of viral antigen by dendritic cells, which occurs through a Toll-like receptor-dependent pathway that requires endosomal acidification
      <xref ref-type="bibr" rid="bib0069">
       [69]
      </xref>
      . On the contrary, other proposed effects of chloroquine on the immune system include increasing the export of soluble antigens into the cytosol of dendritic cells and the enhancement of human cytotoxic CD8
      <sup>
       +
      </sup>
      T-cell responses against viral antigens
      <xref ref-type="bibr" rid="bib0070">
       [70]
      </xref>
      . In the influenza virus model, it was reported that chloroquine improve the cross-presentation of non-replicating virus antigen by dendritic cells to CD8
      <sup>
       +
      </sup>
      T-cells recruited to lymph nodes draining the site of infection, eliciting a broadly protective immune response
      <xref ref-type="bibr" rid="bib0071">
       [71]
      </xref>
      .
     </p>
     <p id="para0012">
      Chloroquine can also act on the immune system through cell signalling and regulation of pro-inflammatory cytokines. Chloroquine is known to inhibit phosphorylation (activation) of the p38 mitogen-activated protein kinase (MAPK) in THP-1 cells as well as caspase-1
      <xref ref-type="bibr" rid="bib0072">
       [72]
      </xref>
      . Activation of cells via MAPK signalling is frequently required by viruses to achieve their replication cycle
      <xref ref-type="bibr" rid="bib0073">
       [73]
      </xref>
      . In the model of HCoV-229 coronavirus, chloroquine-induced virus inhibition occurs through inhibition of p38 MAPK
      <xref ref-type="bibr" rid="bib0044">
       [44]
      </xref>
      . Chloroquine is a well-known immunomodulatory agent capable of mediating an anti-inflammatory response
      <xref ref-type="bibr" rid="bib0011">
       [11]
      </xref>
      . Therefore, there are clinical applications of this drug in inflammatory diseases such as rheumatoid arthritis
      <xref ref-type="bibr" rid="bib0074">
       [74]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0075">
       [75]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0076">
       [76]
      </xref>
      , lupus erythematosus
      <xref ref-type="bibr" rid="bib0006">
       [6
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0077">
       77]
      </xref>
      and sarcoidosis
      <xref ref-type="bibr" rid="bib0078">
       [78]
      </xref>
      . Chloroquine inhibits interleukin-1 beta (IL-1β) mRNA expression in THP-1 cells and reduces IL-1β release
      <xref ref-type="bibr" rid="bib0072">
       [72]
      </xref>
      . Chloroquine-induced reduction of IL-1 and IL-6 cytokines was also found in monocytes/macrophages
      <xref ref-type="bibr" rid="bib0079">
       [79]
      </xref>
      . Chloroquine-induced inhibition of tumour necrosis factor-alpha (TNFα) production by immune cells was reported to occur either through disruption of cellular iron metabolism
      <xref ref-type="bibr" rid="bib0080">
       [80]
      </xref>
      , blockade of the conversion of pro-TNF into soluble mature TNFα molecules
      <xref ref-type="bibr" rid="bib0081">
       [81]
      </xref>
      and/or inhibition of TNFα mRNA expression
      <xref ref-type="bibr" rid="bib0072">
       [72
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0082">
       82
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0083">
       83]
      </xref>
      . Inhibition of the TNFα receptor was also reported in U937 monocytic cells treated with chloroquine
      <xref ref-type="bibr" rid="bib0084">
       [84]
      </xref>
      . In the Dengue virus model, chloroquine was found to inhibit interferon-alpha (IFNα), IFNβ, IFNγ, TNFα, IL-6 and IL-12 gene expression in U937 cells infected with Dengue-2 virus
      <xref ref-type="bibr" rid="bib0033">
       [33]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0005">
     <label>
      5
     </label>
     <title>
      Conclusion
     </title>
     <p id="para0013">
      Chloroquine has been shown to be capable of inhibiting the in vitro replication of several coronaviruses. Recent publications support the hypothesis that chloroquine can improve the clinical outcome of patients infected by SARS-CoV-2. The multiple molecular mechanisms by which chloroquine can achieve such results remain to be further explored. Since SARS-CoV-2 was found a few days ago to utilise the same cell surface receptor ACE2 (expressed in lung, heart, kidney and intestine) as SARS-CoV-1
      <xref ref-type="bibr" rid="bib0085">
       [85
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0086">
       86]
      </xref>
      (
      <xref ref-type="table" rid="tbl0001">
       Table 1
      </xref>
      ), it may be hypothesised that chloroquine also interferes with ACE2 receptor glycosylation thus preventing SARS-CoV-2 binding to target cells. Wang and Cheng reported that SARS-CoV and MERS-CoV upregulate the expression of ACE2 in lung tissue, a process that could accelerate their replication and spread
      <xref ref-type="bibr" rid="bib0085">
       [85]
      </xref>
      . Although the binding of SARS-CoV to sialic acids has not been reported so far (it is expected that
      <italic>
       Betacoronavirus
      </italic>
      adaptation to humans involves progressive loss of hemagglutinin-esterase lectin activity), if SARS-CoV-2 like other coronaviruses targets sialic acids on some cell subtypes, this interaction will be affected by chloroquine treatment
      <xref ref-type="bibr" rid="bib0087">
       [87
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0088">
       88]
      </xref>
      . Today, preliminary data indicate that chloroquine interferes with SARS-CoV-2 attempts to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein
      <xref ref-type="bibr" rid="bib0089">
       [89]
      </xref>
      , a prerequisite to the formation of the autophagosome
      <xref ref-type="bibr" rid="bib0049">
       [49]
      </xref>
      . Obviously, it can be hypothesised that SARS-CoV-2 molecular crosstalk with its target cell can be altered by chloroquine through inhibition of kinases such as MAPK. Chloroquine could also interfere with proteolytic processing of the M protein and alter virion assembly and budding (
      <xref ref-type="fig" rid="fig0001">
       Fig. 1
      </xref>
      ). Finally, in COVID-19 disease this drug could act indirectly through reducing the production of pro-inflammatory cytokines and/or by activating anti-SARS-CoV-2 CD8
      <sup>
       +
      </sup>
      T-cells.
      <table-wrap id="tbl0001" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Human coronavirus (HCoV) receptors/co-receptors as possible targets for chloroquine-induced inhibition of the virus replication cycle
        </p>
       </caption>
       <alt-text id="alt0002">
        Table 1
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th valign="top">
           Coronavirus
          </th>
          <th valign="top">
           Receptor
           <xref ref-type="table-fn" rid="tb1fn1">
            a
           </xref>
          </th>
          <th valign="top">
           May also bind
          </th>
          <th valign="top">
           Replication cycle inhibited by chloroquine
           <xref ref-type="table-fn" rid="tb1fn2">
            b
           </xref>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="4" valign="top">
           <italic>
            Alphacoronavirus
           </italic>
          </td>
         </tr>
         <tr>
          <td valign="top">
           HCoV-229E
          </td>
          <td valign="top">
           Aminopeptidase N (APN)/CD13
          </td>
          <td valign="top">
          </td>
          <td valign="top">
           Yes
          </td>
         </tr>
         <tr>
          <td valign="top">
           HCoV-NL63
          </td>
          <td valign="top">
           Angiotensin-converting enzyme 2 (ACE2)
          </td>
          <td align="left" valign="top">
          </td>
          <td align="left" valign="top">
           ?
          </td>
         </tr>
         <tr>
          <td valign="top">
          </td>
          <td valign="top">
           Heparan sulfate proteoglycans
           <xref ref-type="table-fn" rid="tb1fn3">
            c
           </xref>
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="4" valign="top">
           <italic>
            Betacoronavirus
           </italic>
          </td>
         </tr>
         <tr>
          <td valign="top">
           HCoV-OC43
          </td>
          <td valign="top">
           HLA class I
           <xref ref-type="table-fn" rid="tb1fn4">
            d
           </xref>
           , IFN-inducible transmembrane (IFITM) proteins in endocytic vesicles
           <xref ref-type="table-fn" rid="tb1fn5">
            e
           </xref>
          </td>
          <td valign="top">
           Sialic acid (
           <italic>
            O
           </italic>
           -acetylated sialic acid)
           <xref ref-type="table-fn" rid="tb1fn6">
            f
           </xref>
          </td>
          <td valign="top">
           Yes
          </td>
         </tr>
         <tr>
          <td valign="top">
           SARS-CoV-1
          </td>
          <td valign="top">
           Angiotensin-converting enzyme 2 (ACE2)
          </td>
          <td valign="top">
           DC-SIGN/CD209, DC-SIGNr, DC-SIGN-related lectin LSECtin
           <xref ref-type="table-fn" rid="tb1fn7">
            g
           </xref>
          </td>
          <td valign="top">
           Yes
          </td>
         </tr>
         <tr>
          <td valign="top">
           HCoV-HKU1
          </td>
          <td valign="top">
           HLA class I
           <xref ref-type="table-fn" rid="tb1fn8">
            h
           </xref>
          </td>
          <td valign="top">
           Sialic acid (
           <italic>
            O
           </italic>
           -acetylated sialic acid)
          </td>
          <td valign="top">
           ?
          </td>
         </tr>
         <tr>
          <td valign="top">
           MERS-CoV
           <xref ref-type="table-fn" rid="tb1fn9">
            i
           </xref>
          </td>
          <td valign="top">
           Dipeptidyl peptidase 4 (DPP4)/CD26
          </td>
          <td valign="top">
          </td>
          <td valign="top">
           Yes
          </td>
         </tr>
         <tr>
          <td valign="top">
           SARS-CoV-2
          </td>
          <td valign="top">
           ACE2
           <xref ref-type="table-fn" rid="tb1fn9">
            i
           </xref>
          </td>
          <td valign="top">
           Sialic acid?
          </td>
          <td valign="top">
           Yes
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          HLA, human leukocyte antigen.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tb1fn1">
         <label>
          a
         </label>
         <p id="notep0002">
          Adapted from Graham et al.
          <xref ref-type="bibr" rid="bib0091">
           [91]
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tb1fn2">
         <label>
          b
         </label>
         <p id="notep0003">
          Chloroquine could interfere with receptor (ACE2) glycosylation and/or sialic acid biosynthesis.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tb1fn3">
         <label>
          c
         </label>
         <p id="notep0004">
          According to Milewska et al.
          <xref ref-type="bibr" rid="bib0092">
           [92]
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tb1fn4">
         <label>
          d
         </label>
         <p id="notep0005">
          According to Collins
          <xref ref-type="bibr" rid="bib0093">
           [93]
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tb1fn5">
         <label>
          e
         </label>
         <p id="notep0006">
          According to Zhao et al.
          <xref ref-type="bibr" rid="bib0094">
           [94]
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tb1fn6">
         <label>
          f
         </label>
         <p id="notep0007">
          According to Vlasak et al.
          <xref ref-type="bibr" rid="bib0095">
           [95]
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tb1fn7">
         <label>
          g
         </label>
         <p id="notep0008">
          According to Huang et al.
          <xref ref-type="bibr" rid="bib0096">
           [96]
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tb1fn8">
         <label>
          h
         </label>
         <p id="notep0009">
          According to Chan et al.
          <xref ref-type="bibr" rid="bib0097">
           [97]
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tb1fn9">
         <label>
          i
         </label>
         <p id="notep0010">
          It is worth noting that different host cell proteases are required to activate the spike (S) protein for coronaviruses, such as SARS-CoV-1 S protein that requires activation by cathepsin L
          <xref ref-type="bibr" rid="bib0089">
           [89]
          </xref>
          , or MERS-CoV that requires furin-mediated activation of the S protein
          <xref ref-type="bibr" rid="bib0098">
           [98]
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <fig id="fig0001">
       <label>
        Fig. 1
       </label>
       <caption>
        <p>
         Schematic representation of the possible effects of chloroquine on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication cycle. SARS-CoV2, like other human coronaviruses, harbours three envelope proteins, the spike (S) protein (180–220 kDa), the membrane (M) protein (25–35 kDa) and the envelope (E) protein (10–12 kDa), which are required for entry of infectious virions into target cells. The virion also contains the nucleocapsid (N), capable of binding to viral genomic RNA, and nsp3, a key component of the replicase complex. A subset of betacoronaviruses use a hemagglutinin-esterase (65 kDa) that binds sialic acids at the surface of glycoproteins. The S glycoprotein determines the host tropism. There is indication that SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) expressed on pneumocytes
         <xref ref-type="bibr" rid="bib0085">
          [85
         </xref>
         ,
         <xref ref-type="bibr" rid="bib0099">
          99]
         </xref>
         . Binding to ACE2 is expected to trigger conformational changes in the S glycoprotein allowing cleavage by the transmembrane protease TMPRSS2 of the S protein and the release of S fragments into the cellular supernatant that inhibit virus neutralisation by antibodies
         <xref ref-type="bibr" rid="bib0100">
          [100]
         </xref>
         . The virus is then transported into the cell through the early and late endosomes where the host protease cathepsin L further cleaves the S protein at low pH, leading to fusion of the viral envelope and phospholipidic membrane of the endosomes resulting in release of the viral genome into the cell cytoplasm. Replication then starts and the positive-strand viral genomic RNA is transcribed into a negative RNA strand that is used as a template for the synthesis of viral mRNA. Synthesis of the negative RNA strand peaks earlier and falls faster than synthesis of the positive strand. Infected cells contain between 10 and 100 times more positive strands than negative strands. The ribosome machinery of the infected cells is diverted in favour of the virus, which then synthesises its non-structural proteins (NSPs) that assemble into the replicase-transcriptase complex to favour viral subgenomic mRNA synthesis (see the review by Fehr and Perlman for details
         <xref ref-type="bibr" rid="bib0101">
          [101]
         </xref>
         ). Following replication, the envelope proteins are translated and inserted into the endoplasmic reticulum and then move to the Golgi compartment. Viral genomic RNA is packaged into the nucleocapsid and then envelope proteins are incorporated during the budding step to form mature virions. The M protein, which localises to the trans-Golgi network, plays an essential role during viral assembly by interacting with the other proteins of the virus. Following assembly, the newly formed viral particles are transported to the cell surface in vesicles and are released by exocytosis. It is possible that chloroquine interferes with ACE2 receptor glycosylation, thus preventing SARS-CoV-2 binding to target cells. Chloroquine could also possibly limit the biosynthesis of sialic acids that may be required for cell surface binding of SARS-CoV-2. If binding of some viral particles is achieved, chloroquine may modulate the acidification of endosomes thereby inhibiting formation of the autophagosome. Through reduction of cellular mitogen-activated protein (MAP) kinase activation, chloroquine may also inhibit virus replication. Moreover, chloroquine could alter M protein maturation and interfere with virion assembly and budding. With respect to the effect of chloroquine on the immune system, see the elegant review by Savarino et al.
         <xref ref-type="bibr" rid="bib0011">
          [11]
         </xref>
         . ERGIC, ER-Golgi intermediate compartment.
        </p>
       </caption>
       <alt-text id="alt0001">
        Fig 1
       </alt-text>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
     </p>
     <p id="para0014">
      Already in 2007, some of us emphasised in this journal the possibility of using chloroquine to fight orphan viral infections
      <xref ref-type="bibr" rid="bib0010">
       [10]
      </xref>
      . The worldwide ongoing trials, including those involving the care of patients in our institute
      <xref ref-type="bibr" rid="bib0090">
       [90]
      </xref>
      , will verify whether the hopes raised by chloroquine in the treatment of COVID-19 can be confirmed.
     </p>
    </sec>
    <back>
     <ref-list id="cebibl1">
      <title>
       References
      </title>
      <ref id="bib0001">
       <label>
        1
       </label>
       <element-citation id="sbref0001" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Winzeler
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Malaria research in the post-genomic era
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         455
        </volume>
        <year>
         2008
        </year>
        <fpage>
         751
        </fpage>
        <lpage>
         756
        </lpage>
        <pub-id pub-id-type="pmid">
         18843360
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0002">
       <label>
        2
       </label>
       <element-citation id="sbref0002" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parhizgar
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Tahghighi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review
        </article-title>
        <source>
         Iran J Med Sci
        </source>
        <volume>
         42
        </volume>
        <year>
         2017
        </year>
        <fpage>
         115
        </fpage>
        <lpage>
         128
        </lpage>
        <pub-id pub-id-type="pmid">
         28360437
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0003">
       <label>
        3
       </label>
       <element-citation id="sbref0003" publication-type="book">
        <comment>
         editor
        </comment>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Bruce-Chwatt
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <source>
         Chemotherapy of malaria
        </source>
        <edition>
         2nd ed.
        </edition>
        <year>
         1981
        </year>
        <publisher-name>
         WHO
        </publisher-name>
        <publisher-loc>
         Geneva, Switzerland
        </publisher-loc>
        <comment>
         WHO Monograph Series 27
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0004">
       <label>
        4
       </label>
       <element-citation id="sbref0004" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           White
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
         <name>
          <surname>
           Pukrittayakamee
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hien
          </surname>
          <given-names>
           T.T.
          </given-names>
         </name>
         <name>
          <surname>
           Faiz
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Mokuolu
          </surname>
          <given-names>
           O.A.
          </given-names>
         </name>
         <name>
          <surname>
           Dondorp
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Malaria
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         383
        </volume>
        <year>
         2014
        </year>
        <fpage>
         723
        </fpage>
        <lpage>
         735
        </lpage>
        <pub-id pub-id-type="pmid">
         23953767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0005">
       <label>
        5
       </label>
       <element-citation id="sbref0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wellems
          </surname>
          <given-names>
           T.E.
          </given-names>
         </name>
         <name>
          <surname>
           Plowe
          </surname>
          <given-names>
           C.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine-resistant malaria
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         184
        </volume>
        <year>
         2001
        </year>
        <fpage>
         770
        </fpage>
        <lpage>
         776
        </lpage>
        <pub-id pub-id-type="pmid">
         11517439
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0006">
       <label>
        6
       </label>
       <element-citation id="sbref0006" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Silverman
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bargman
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of antimalarial agents in the treatment of SLE and lupus nephritis
        </article-title>
        <source>
         Nat Rev Nephrol
        </source>
        <volume>
         7
        </volume>
        <year>
         2011
        </year>
        <fpage>
         718
        </fpage>
        <lpage>
         729
        </lpage>
        <pub-id pub-id-type="pmid">
         22009248
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0007">
       <label>
        7
       </label>
       <element-citation id="sbref0007" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Drancourt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Vestris
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bactericidal effect of doxycycline associated with lysosomotropic agents on
         <italic>
          Coxiella burnetii
         </italic>
         in P388D1 cells
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         34
        </volume>
        <year>
         1990
        </year>
        <fpage>
         1512
        </fpage>
        <lpage>
         1514
        </lpage>
        <pub-id pub-id-type="pmid">
         2221859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0008">
       <label>
        8
       </label>
       <element-citation id="sbref0008" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Houpikian
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Tissot
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           Riss
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Arditi-Djiane
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         159
        </volume>
        <year>
         1999
        </year>
        <fpage>
         167
        </fpage>
        <lpage>
         173
        </lpage>
        <pub-id pub-id-type="pmid">
         9927100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0009">
       <label>
        9
       </label>
       <element-citation id="sbref0009" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boulos
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibiotic susceptibility of
         <italic>
          Tropheryma whipplei
         </italic>
         in MRC5 cells
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         48
        </volume>
        <year>
         2004
        </year>
        <fpage>
         747
        </fpage>
        <lpage>
         752
        </lpage>
        <pub-id pub-id-type="pmid">
         14982759
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <label>
        10
       </label>
       <element-citation id="sbref0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infection in the 21st century
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <volume>
         30
        </volume>
        <year>
         2007
        </year>
        <fpage>
         297
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         17629679
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0011">
       <label>
        11
       </label>
       <element-citation id="sbref0011" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Majori
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of chloroquine on viral infections: an old drug against today's diseases?
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         3
        </volume>
        <year>
         2003
        </year>
        <fpage>
         722
        </fpage>
        <lpage>
         727
        </lpage>
        <pub-id pub-id-type="pmid">
         14592603
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0012">
       <label>
        12
       </label>
       <element-citation id="sbref0012" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Piette
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The potential place of chloroquine in the treatment of HIV-1-infected patients
        </article-title>
        <source>
         J Clin Virol
        </source>
        <volume>
         20
        </volume>
        <year>
         2001
        </year>
        <fpage>
         137
        </fpage>
        <lpage>
         140
        </lpage>
        <pub-id pub-id-type="pmid">
         11166662
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0013">
       <label>
        13
       </label>
       <element-citation id="sbref0013" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0014">
       <label>
        14
       </label>
       <element-citation id="sbref0014" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus from patients with pneumonia in China, 2019
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         382
        </volume>
        <year>
         2020
        </year>
        <fpage>
         727
        </fpage>
        <lpage>
         733
        </lpage>
        <pub-id pub-id-type="pmid">
         31978945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <label>
        15
       </label>
       <mixed-citation id="othref0001" publication-type="other">
        Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv2020 Jan 23. doi:
        <pub-id pub-id-type="doi">
         10.1101/2020.01.22.914952
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="bib0016">
       <label>
        16
       </label>
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Superti
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ammonium chloride and chloroquine inhibit rabies virus infection in neuroblastoma cells
        </article-title>
        <source>
         Arch Virol
        </source>
        <volume>
         81
        </volume>
        <year>
         1984
        </year>
        <fpage>
         377
        </fpage>
        <lpage>
         382
        </lpage>
        <pub-id pub-id-type="pmid">
         6148053
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0017">
       <label>
        17
       </label>
       <element-citation id="sbref0016" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kronenberger
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Vrijsen
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Boeyé
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine induces empty capsid formation during poliovirus eclipse
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         65
        </volume>
        <year>
         1991
        </year>
        <fpage>
         7008
        </fpage>
        <lpage>
         7011
        </lpage>
        <pub-id pub-id-type="pmid">
         1658391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0018">
       <label>
        18
       </label>
       <element-citation id="sbref0017" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsai
          </surname>
          <given-names>
           W.P.
          </given-names>
         </name>
         <name>
          <surname>
           Nara
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Kung
          </surname>
          <given-names>
           H.F.
          </given-names>
         </name>
         <name>
          <surname>
           Oroszlan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of human immunodeficiency virus infectivity by chloroquine
        </article-title>
        <source>
         AIDS Res Hum Retroviruses
        </source>
        <volume>
         6
        </volume>
        <year>
         1990
        </year>
        <fpage>
         481
        </fpage>
        <lpage>
         489
        </lpage>
        <pub-id pub-id-type="pmid">
         1692728
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0019">
       <label>
        19
       </label>
       <element-citation id="sbref0018" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gennero
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The anti-HIV-1 activity of chloroquine
        </article-title>
        <source>
         J Clin Virol
        </source>
        <volume>
         20
        </volume>
        <year>
         2001
        </year>
        <fpage>
         131
        </fpage>
        <lpage>
         135
        </lpage>
        <pub-id pub-id-type="pmid">
         11166661
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <label>
        20
       </label>
       <element-citation id="sbref0019" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Romanelli
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hoven
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity
        </article-title>
        <source>
         Curr Pharm Des
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         2643
        </fpage>
        <lpage>
         2648
        </lpage>
        <pub-id pub-id-type="pmid">
         15320751
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0021">
       <label>
        21
       </label>
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Superti
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Seganti
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Orsi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Divizia
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gabrieli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Pana
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of lipophilic amines on the growth of hepatitis A virus in Frp/3 cells
        </article-title>
        <source>
         Arch Virol
        </source>
        <volume>
         96
        </volume>
        <year>
         1987
        </year>
        <fpage>
         289
        </fpage>
        <lpage>
         296
        </lpage>
        <pub-id pub-id-type="pmid">
         2821967
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0022">
       <label>
        22
       </label>
       <element-citation id="sbref0021" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bishop
          </surname>
          <given-names>
           N.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Examination of potential inhibitors of hepatitis A virus uncoating
        </article-title>
        <source>
         Intervirology
        </source>
        <volume>
         41
        </volume>
        <year>
         1998
        </year>
        <fpage>
         261
        </fpage>
        <lpage>
         271
        </lpage>
        <pub-id pub-id-type="pmid">
         10325536
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0023">
       <label>
        23
       </label>
       <element-citation id="sbref0022" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mizui
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yamashina
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tanida
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Takei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ueno
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Sakamoto
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy
        </article-title>
        <source>
         J Gastroenterol
        </source>
        <volume>
         45
        </volume>
        <year>
         2010
        </year>
        <fpage>
         195
        </fpage>
        <lpage>
         203
        </lpage>
        <pub-id pub-id-type="pmid">
         19760134
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0024">
       <label>
        24
       </label>
       <element-citation id="sbref0023" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lenard
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antihistaminics, local anesthetics, and other amines as antiviral agents
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         78
        </volume>
        <year>
         1981
        </year>
        <fpage>
         3605
        </fpage>
        <lpage>
         3609
        </lpage>
        <pub-id pub-id-type="pmid">
         6115382
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <label>
        25
       </label>
       <element-citation id="sbref0024" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shibata
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Aoki
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsurumi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Sugiura
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Nishiyama
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         64
        </volume>
        <year>
         1983
        </year>
        <fpage>
         1149
        </fpage>
        <lpage>
         1156
        </lpage>
        <pub-id pub-id-type="pmid">
         6842189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0026">
       <label>
        26
       </label>
       <element-citation id="sbref0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Chew
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Loh
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Chua
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro inhibition of human influenza A virus replication by chloroquine
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         3
        </volume>
        <year>
         2006
        </year>
        <fpage>
         39
        </fpage>
        <pub-id pub-id-type="pmid">
         16729896
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0027">
       <label>
        27
       </label>
       <element-citation id="sbref0026" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paton
          </surname>
          <given-names>
           N.I.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           Y.B.
          </given-names>
         </name>
         <name>
          <surname>
           Archuleta
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         11
        </volume>
        <year>
         2011
        </year>
        <fpage>
         677
        </fpage>
        <lpage>
         683
        </lpage>
        <pub-id pub-id-type="pmid">
         21550310
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0028">
       <label>
        28
       </label>
       <element-citation id="sbref0027" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model
        </article-title>
        <source>
         Cell Res
        </source>
        <volume>
         23
        </volume>
        <year>
         2013
        </year>
        <fpage>
         300
        </fpage>
        <lpage>
         302
        </lpage>
        <pub-id pub-id-type="pmid">
         23208422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0029">
       <label>
        29
       </label>
       <element-citation id="sbref0028" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Lamballerie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Boisson
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Reynier
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Enault
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Charrel
          </surname>
          <given-names>
           R.N.
          </given-names>
         </name>
         <name>
          <surname>
           Flahault
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         On Chikungunya acute infection and chloroquine treatment
        </article-title>
        <source>
         Vector Borne Zoonotic Dis
        </source>
        <volume>
         8
        </volume>
        <year>
         2008
        </year>
        <fpage>
         837
        </fpage>
        <lpage>
         840
        </lpage>
        <pub-id pub-id-type="pmid">
         18620511
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <label>
        30
       </label>
       <element-citation id="sbref0029" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Santhosh
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Tiwari
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lakshmana Rao
          </surname>
          <given-names>
           P.V.
          </given-names>
         </name>
         <name>
          <surname>
           Parida
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in Vero cells
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         82
        </volume>
        <year>
         2010
        </year>
        <fpage>
         817
        </fpage>
        <lpage>
         824
        </lpage>
        <pub-id pub-id-type="pmid">
         20336760
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0031">
       <label>
        31
       </label>
       <element-citation id="sbref0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Delogu
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           de Lamballerie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chikungunya disease and chloroquine treatment
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         83
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1058
        </fpage>
        <lpage>
         1059
        </lpage>
        <pub-id pub-id-type="pmid">
         21503920
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0032">
       <label>
        32
       </label>
       <element-citation id="sbref0031" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Randolph
          </surname>
          <given-names>
           V.B.
          </given-names>
         </name>
         <name>
          <surname>
           Winkler
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Stollar
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acidotropic amines inhibit proteolytic processing of flavivirus prM protein
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         174
        </volume>
        <year>
         1990
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         458
        </lpage>
        <pub-id pub-id-type="pmid">
         2154882
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0033">
       <label>
        33
       </label>
       <element-citation id="sbref0032" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Farias
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Machado
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
         <name>
          <surname>
           de Almeida Junior
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           de Aquino
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           da Fonseca
          </surname>
          <given-names>
           B.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine interferes with dengue-2 virus replication in U937 cells
        </article-title>
        <source>
         Microbiol Immunol
        </source>
        <volume>
         58
        </volume>
        <year>
         2014
        </year>
        <fpage>
         318
        </fpage>
        <lpage>
         326
        </lpage>
        <pub-id pub-id-type="pmid">
         24773578
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0034">
       <label>
        34
       </label>
       <element-citation id="sbref0033" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Delvecchio
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Higa
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Pezzuto
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Valadao
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Garcez
          </surname>
          <given-names>
           P.P.
          </given-names>
         </name>
         <name>
          <surname>
           Monteiro
          </surname>
          <given-names>
           F.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         8
        </volume>
        <year>
         2016
        </year>
        <fpage>
         E322
        </fpage>
        <pub-id pub-id-type="pmid">
         27916837
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0035">
       <label>
        35
       </label>
       <element-citation id="sbref0034" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glushakova
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lukashevich
          </surname>
          <given-names>
           I.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early events in arenavirus replication are sensitive to lysosomotropic compounds
        </article-title>
        <source>
         Arch Virol
        </source>
        <volume>
         104
        </volume>
        <year>
         1989
        </year>
        <fpage>
         157
        </fpage>
        <lpage>
         161
        </lpage>
        <pub-id pub-id-type="pmid">
         2923547
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0036">
       <label>
        36
       </label>
       <element-citation id="sbref0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Porotto
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Orefice
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Yokoyama
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Mungall
          </surname>
          <given-names>
           B.A.
          </given-names>
         </name>
         <name>
          <surname>
           Realubit
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Sganga
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Simulating
         <italic>
          Henipavirus
         </italic>
         multicycle replication in a screening assay leads to identification of a promising candidate for therapy
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         83
        </volume>
        <year>
         2009
        </year>
        <fpage>
         5148
        </fpage>
        <lpage>
         5155
        </lpage>
        <pub-id pub-id-type="pmid">
         19264786
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0037">
       <label>
        37
       </label>
       <element-citation id="sbref0036" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Freiberg
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Worthy
          </surname>
          <given-names>
           M.N.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Holbrook
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         91
        </volume>
        <year>
         2010
        </year>
        <fpage>
         765
        </fpage>
        <lpage>
         772
        </lpage>
        <pub-id pub-id-type="pmid">
         19889926
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0038">
       <label>
        38
       </label>
       <element-citation id="sbref0037" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferraris
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Moroso
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pernet
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Emonet
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrier Rembert
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Paranhos-Baccala
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of Crimean–Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules
        </article-title>
        <source>
         Antiviral Res
        </source>
        <volume>
         118
        </volume>
        <year>
         2015
        </year>
        <fpage>
         75
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="pmid">
         25796972
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0039">
       <label>
        39
       </label>
       <element-citation id="sbref0038" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dowall
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Bosworth
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Bewley
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Rayner
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         96
        </volume>
        <year>
         2015
        </year>
        <fpage>
         3484
        </fpage>
        <lpage>
         3492
        </lpage>
        <pub-id pub-id-type="pmid">
         26459826
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <label>
        40
       </label>
       <element-citation id="sbref0039" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kouroumalis
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Koskinas
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report
        </article-title>
        <source>
         Ann Acad Med Singapore
        </source>
        <volume>
         15
        </volume>
        <year>
         1986
        </year>
        <fpage>
         149
        </fpage>
        <lpage>
         152
        </lpage>
        <pub-id pub-id-type="pmid">
         3752892
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0041">
       <label>
        41
       </label>
       <element-citation id="sbref0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Koyama
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Uchida
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of multiplication of herpes simplex virus type 1 by ammonium chloride and chloroquine
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         138
        </volume>
        <year>
         1984
        </year>
        <fpage>
         332
        </fpage>
        <lpage>
         335
        </lpage>
        <pub-id pub-id-type="pmid">
         6093369
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0042">
       <label>
        42
       </label>
       <element-citation id="sbref0041" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Rysman
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Verbeeck
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Van Ranst
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         53
        </volume>
        <year>
         2009
        </year>
        <fpage>
         3416
        </fpage>
        <lpage>
         3421
        </lpage>
        <pub-id pub-id-type="pmid">
         19506054
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0043">
       <label>
        43
       </label>
       <element-citation id="sbref0042" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Blau
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Human coronavirus HCoV-229E enters susceptible cells via the endocytic pathway
        </chapter-title>
        <comment>
         editors
        </comment>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Lavi
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hingley
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
        </person-group>
        <source>
         The nidoviruses (coronaviruses and arteriviruses)
        </source>
        <year>
         2001
        </year>
        <publisher-name>
         Kluwer
        </publisher-name>
        <publisher-loc>
         New York, NY
        </publisher-loc>
        <fpage>
         193
        </fpage>
        <lpage>
         197
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0044">
       <label>
        44
       </label>
       <element-citation id="sbref0043" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kono
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tatsumi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Saito
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kuriyama
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Shirasawa
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK
        </article-title>
        <source>
         Antiviral Res
        </source>
        <volume>
         77
        </volume>
        <year>
         2008
        </year>
        <fpage>
         150
        </fpage>
        <lpage>
         152
        </lpage>
        <pub-id pub-id-type="pmid">
         18055026
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0045">
       <label>
        45
       </label>
       <element-citation id="sbref0044" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Safe and sensitive antiviral screening platform based on recombinant human coronavirus OC43 expressing the luciferase reporter gene
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         60
        </volume>
        <year>
         2016
        </year>
        <fpage>
         5492
        </fpage>
        <lpage>
         5503
        </lpage>
        <pub-id pub-id-type="pmid">
         27381385
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0046">
       <label>
        46
       </label>
       <element-citation id="sbref0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wilde
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Jochmans
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Posthuma
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Zevenhoven-Dobbe
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           van Nieuwkoop
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         58
        </volume>
        <year>
         2014
        </year>
        <fpage>
         4875
        </fpage>
        <lpage>
         4884
        </lpage>
        <pub-id pub-id-type="pmid">
         24841269
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0047">
       <label>
        47
       </label>
       <element-citation id="sbref0046" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Fisher
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of treatment modalities for Middle East respiratory syndrome
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <volume>
         71
        </volume>
        <year>
         2016
        </year>
        <fpage>
         3340
        </fpage>
        <lpage>
         3350
        </lpage>
        <pub-id pub-id-type="pmid">
         27585965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0048">
       <label>
        48
       </label>
       <element-citation id="sbref0047" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burkard
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Verheije
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wicht
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           van Kasteren
          </surname>
          <given-names>
           S.I.
          </given-names>
         </name>
         <name>
          <surname>
           van Kuppeveld
          </surname>
          <given-names>
           F.J.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <volume>
         10
        </volume>
        <year>
         2014
        </year>
        <object-id pub-id-type="publisher-id">
         e1004502
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0049">
       <label>
        49
       </label>
       <element-citation id="sbref0048" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </article-title>
        <source>
         Cell Res
        </source>
        <volume>
         30
        </volume>
        <year>
         2020
        </year>
        <fpage>
         269
        </fpage>
        <lpage>
         271
        </lpage>
        <pub-id pub-id-type="pmid">
         32020029
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0050">
       <label>
        50
       </label>
       <element-citation id="sbref0049" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
        </article-title>
        <source>
         Biosci Trends
        </source>
        <year>
         Feb 2020
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0051">
       <label>
        51
       </label>
       <element-citation id="sbref0050" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia
         </collab>
        </person-group>
        <article-title>
         Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia [in Chinese]
        </article-title>
        <source>
         Zhonghua Jie He He Hu Xi Za Zhi
        </source>
        <volume>
         43
        </volume>
        <year>
         2020
        </year>
        <fpage>
         E019
        </fpage>
        <pub-id pub-id-type="pmid">
         32075365
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0052">
       <label>
        52
       </label>
       <element-citation id="sbref0051" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bernstein
          </surname>
          <given-names>
           H.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular safety of hydroxychloroquine
        </article-title>
        <source>
         Ann Ophthalmol
        </source>
        <volume>
         23
        </volume>
        <year>
         1991
        </year>
        <fpage>
         292
        </fpage>
        <lpage>
         296
        </lpage>
        <pub-id pub-id-type="pmid">
         1952638
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0053">
       <label>
        53
       </label>
       <element-citation id="sbref0052" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ratliff
          </surname>
          <given-names>
           N.B.
          </given-names>
         </name>
         <name>
          <surname>
           Estes
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Myles
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Shirey
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
         <name>
          <surname>
           McMahon
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         316
        </volume>
        <year>
         1987
        </year>
        <fpage>
         191
        </fpage>
        <lpage>
         193
        </lpage>
        <pub-id pub-id-type="pmid">
         3796692
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0054">
       <label>
        54
       </label>
       <element-citation id="sbref0053" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cubero
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Rodriguez Reguero
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Rojo Ortega
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Restrictive cardiomyopathy caused by chloroquine
        </article-title>
        <source>
         Br Heart J
        </source>
        <volume>
         69
        </volume>
        <year>
         1993
        </year>
        <fpage>
         451
        </fpage>
        <lpage>
         452
        </lpage>
        <pub-id pub-id-type="pmid">
         8518071
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0055">
       <label>
        55
       </label>
       <element-citation id="sbref0054" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus puts drug repurposing on the fast track
        </article-title>
        <source>
         Nature Biotechnology
        </source>
        <year>
         2020 Feb 27
        </year>
       </element-citation>
      </ref>
      <ref id="bib0056">
       <label>
        56
       </label>
       <element-citation id="sbref0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kwiek
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Haystead
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rudolph
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         43
        </volume>
        <year>
         2004
        </year>
        <fpage>
         4538
        </fpage>
        <lpage>
         4547
        </lpage>
        <pub-id pub-id-type="pmid">
         15078100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0057">
       <label>
        57
       </label>
       <element-citation id="sbref0056" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Varki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sialic acids as ligands in recognition phenomena
        </article-title>
        <source>
         FASEB J
        </source>
        <volume>
         11
        </volume>
        <year>
         1997
        </year>
        <fpage>
         248
        </fpage>
        <lpage>
         255
        </lpage>
        <pub-id pub-id-type="pmid">
         9068613
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0058">
       <label>
        58
       </label>
       <element-citation id="sbref0057" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Olofsson
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kumlin
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Dimock
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Arnberg
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Avian influenza and sialic acid receptors: more than meets the eye?
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         5
        </volume>
        <year>
         2005
        </year>
        <fpage>
         184
        </fpage>
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="pmid">
         15766653
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0059">
       <label>
        59
       </label>
       <element-citation id="sbref0058" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bergeron
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Benjannet
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Erickson
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         2
        </volume>
        <year>
         2005
        </year>
        <fpage>
         69
        </fpage>
        <pub-id pub-id-type="pmid">
         16115318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0060">
       <label>
        60
       </label>
       <element-citation id="sbref0059" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tricou
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Minh
          </surname>
          <given-names>
           N.N.
          </given-names>
         </name>
         <name>
          <surname>
           Van
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Farrar
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wills
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults
        </article-title>
        <source>
         PLoS Negl Trop Dis
        </source>
        <volume>
         4
        </volume>
        <year>
         2010
        </year>
        <fpage>
         e785
        </fpage>
        <pub-id pub-id-type="pmid">
         20706626
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0061">
       <label>
        61
       </label>
       <element-citation id="sbref0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gay
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Bernard
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Solignat
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chazal
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Devaux
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Briant
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         pH-dependent entry of Chikungunya virus into
         <italic>
          Aedes albopictus
         </italic>
         cells
        </article-title>
        <source>
         Infect Genet Evol
        </source>
        <volume>
         12
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1275
        </fpage>
        <lpage>
         1281
        </lpage>
        <pub-id pub-id-type="pmid">
         22386853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0062">
       <label>
        62
       </label>
       <element-citation id="sbref0061" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ganesh
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           W.P.
          </given-names>
         </name>
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         78
        </volume>
        <year>
         2004
        </year>
        <fpage>
         5642
        </fpage>
        <lpage>
         5650
        </lpage>
        <pub-id pub-id-type="pmid">
         15140961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0063">
       <label>
        63
       </label>
       <element-citation id="sbref0062" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway
        </article-title>
        <source>
         Cell Res
        </source>
        <volume>
         18
        </volume>
        <year>
         2008
        </year>
        <fpage>
         290
        </fpage>
        <lpage>
         301
        </lpage>
        <pub-id pub-id-type="pmid">
         18227861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0064">
       <label>
        64
       </label>
       <element-citation id="sbref0063" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cassell
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           D.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of lysosomotropic weak bases on infection of BHK-21 cells by Sindbis virus
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         52
        </volume>
        <year>
         1984
        </year>
        <fpage>
         857
        </fpage>
        <lpage>
         864
        </lpage>
        <pub-id pub-id-type="pmid">
         6492263
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0065">
       <label>
        65
       </label>
       <element-citation id="sbref0064" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lucia
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
         <name>
          <surname>
           Rastrelli
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Rutella
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Golotta
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Morra
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors
        </article-title>
        <source>
         J Acquir Immune Defic Syndr
        </source>
        <volume>
         35
        </volume>
        <year>
         1996
        </year>
        <fpage>
         223
        </fpage>
        <lpage>
         232
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0066">
       <label>
        66
       </label>
       <element-citation id="sbref0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harley
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Dasgupta
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           D.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of herpes simplex virus-containing organelles by subcellular fractionation: role for organelle acidification in assembly of infectious particles
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         75
        </volume>
        <year>
         2001
        </year>
        <fpage>
         1236
        </fpage>
        <lpage>
         1251
        </lpage>
        <pub-id pub-id-type="pmid">
         11152497
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0067">
       <label>
        67
       </label>
       <element-citation id="sbref0066" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klumperman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Locker
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Meijer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Horzinek
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Geuze
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         68
        </volume>
        <year>
         1994
        </year>
        <fpage>
         6523
        </fpage>
        <lpage>
         6534
        </lpage>
        <pub-id pub-id-type="pmid">
         8083990
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0068">
       <label>
        68
       </label>
       <element-citation id="sbref0067" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perrier
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bonnin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Desmarets
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Danneels
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Goffard
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Rouillé
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         294
        </volume>
        <year>
         2019
        </year>
        <fpage>
         14406
        </fpage>
        <lpage>
         14421
        </lpage>
        <pub-id pub-id-type="pmid">
         31399512
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0069">
       <label>
        69
       </label>
       <element-citation id="sbref0068" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Diebold
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kaisho
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Hemmi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Akira
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Reis e Sousa
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
        </article-title>
        <source>
         Science
        </source>
        <volume>
         303
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1529
        </fpage>
        <lpage>
         1531
        </lpage>
        <pub-id pub-id-type="pmid">
         14976261
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0070">
       <label>
        70
       </label>
       <element-citation id="sbref0069" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Accapezzato
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Visco
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Francavilla
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Molette
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Donato
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Paroli
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine enhances human CD8
         <sup>
          +
         </sup>
         T cell responses against soluble antigens in vivo
        </article-title>
        <source>
         J Exp Med
        </source>
        <volume>
         202
        </volume>
        <year>
         2005
        </year>
        <fpage>
         817
        </fpage>
        <lpage>
         828
        </lpage>
        <pub-id pub-id-type="pmid">
         16157687
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0071">
       <label>
        71
       </label>
       <element-citation id="sbref0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Garulli
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Di Mario
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Sciaraffia
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Accapezzato
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Barnaba
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Castrucci
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         31
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1717
        </fpage>
        <lpage>
         1724
        </lpage>
        <pub-id pub-id-type="pmid">
         23380456
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0072">
       <label>
        72
       </label>
       <element-citation id="sbref0071" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Steiz
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Valbracht
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Quach
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lotz
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms
        </article-title>
        <source>
         J Clin Immunol
        </source>
        <volume>
         23
        </volume>
        <year>
         2003
        </year>
        <fpage>
         477
        </fpage>
        <lpage>
         484
        </lpage>
        <pub-id pub-id-type="pmid">
         15031635
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0073">
       <label>
        73
       </label>
       <element-citation id="sbref0072" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Briant
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Robert-Hebmann
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Acquaviva
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pelchen-Matthews
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Marsh
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Devaux
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The protein tyrosine kinase p56
         <italic>
          <sup>
           lck
          </sup>
         </italic>
         is required for triggering NF-κB activation upon interaction of human immunodeficiency virus type 1 envelope glycoprotein gp120 with cell surface CD4
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         72
        </volume>
        <year>
         1998
        </year>
        <fpage>
         6207
        </fpage>
        <lpage>
         6214
        </lpage>
        <pub-id pub-id-type="pmid">
         9621091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0074">
       <label>
        74
       </label>
       <element-citation id="sbref0073" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fuld
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Horwich
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of rheumatoid arthritis with chloroquine
        </article-title>
        <source>
         Br Med J
        </source>
        <volume>
         15
        </volume>
        <year>
         1958
        </year>
        <fpage>
         1199
        </fpage>
        <lpage>
         1201
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0075">
       <label>
        75
       </label>
       <element-citation id="sbref0074" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackenzie
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial drugs for rheumatoid arthritis
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         75
        </volume>
        <year>
         1983
        </year>
        <fpage>
         48
        </fpage>
        <lpage>
         58
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0076">
       <label>
        76
       </label>
       <element-citation id="sbref0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sharma
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <name>
          <surname>
           Do
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wasko
          </surname>
          <given-names>
           M.C.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-malarials: are there benefits beyond mild disease?
        </article-title>
        <source>
         Curr Treat Options Rheumatol
        </source>
        <volume>
         2
        </volume>
        <year>
         2016
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         12
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0077">
       <label>
        77
       </label>
       <element-citation id="sbref0076" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wozniacka
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lesiak
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Narbutt
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           McCauliffe
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Sysa-Jedrzejowska
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients
        </article-title>
        <source>
         Lupus
        </source>
        <volume>
         15
        </volume>
        <year>
         2006
        </year>
        <fpage>
         268
        </fpage>
        <lpage>
         275
        </lpage>
        <pub-id pub-id-type="pmid">
         16761500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0078">
       <label>
        78
       </label>
       <element-citation id="sbref0077" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sharma
          </surname>
          <given-names>
           O.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement
        </article-title>
        <source>
         Arch Neurol
        </source>
        <volume>
         55
        </volume>
        <year>
         1998
        </year>
        <fpage>
         1248
        </fpage>
        <lpage>
         1254
        </lpage>
        <pub-id pub-id-type="pmid">
         9740120
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0079">
       <label>
        79
       </label>
       <element-citation id="sbref0078" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jang
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Byun
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jue
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes
        </article-title>
        <source>
         Rheumatology
        </source>
        <volume>
         45
        </volume>
        <year>
         2006
        </year>
        <fpage>
         703
        </fpage>
        <lpage>
         710
        </lpage>
        <pub-id pub-id-type="pmid">
         16418198
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0080">
       <label>
        80
       </label>
       <element-citation id="sbref0079" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Picot
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Peyron
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Donadille
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Vuillez
          </surname>
          <given-names>
           J.-P.
          </given-names>
         </name>
         <name>
          <surname>
           Barbe
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ambroise-Thomas
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism
        </article-title>
        <source>
         Immunology
        </source>
        <volume>
         80
        </volume>
        <year>
         1993
        </year>
        <fpage>
         127
        </fpage>
        <lpage>
         133
        </lpage>
        <pub-id pub-id-type="pmid">
         8244453
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0081">
       <label>
        81
       </label>
       <element-citation id="sbref0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jeong
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Jue
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages
        </article-title>
        <source>
         J Immunol
        </source>
        <volume>
         158
        </volume>
        <year>
         1997
        </year>
        <fpage>
         4901
        </fpage>
        <lpage>
         4907
        </lpage>
        <pub-id pub-id-type="pmid">
         9144507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0082">
       <label>
        82
       </label>
       <element-citation id="sbref0081" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ertel
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Ayala
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Morrison
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Perrin
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chaudry
          </surname>
          <given-names>
           I.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibits macrophage tumour necrosis factor-α mRNA transcription
        </article-title>
        <source>
         Immunology
        </source>
        <volume>
         80
        </volume>
        <year>
         1993
        </year>
        <fpage>
         122
        </fpage>
        <lpage>
         126
        </lpage>
        <pub-id pub-id-type="pmid">
         8244452
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0083">
       <label>
        83
       </label>
       <element-citation id="sbref0082" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Levitz
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine interferes with lipopolysaccharide-induced TNF-α gene expression by a nonlysosomotropic mechanism
        </article-title>
        <source>
         J Immunol
        </source>
        <volume>
         165
        </volume>
        <year>
         2000
        </year>
        <fpage>
         1534
        </fpage>
        <lpage>
         1540
        </lpage>
        <pub-id pub-id-type="pmid">
         10903761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0084">
       <label>
        84
       </label>
       <element-citation id="sbref0083" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jeong
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Jeon
          </surname>
          <given-names>
           K.I.
          </given-names>
         </name>
         <name>
          <surname>
           Jue
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells
        </article-title>
        <source>
         Immunology
        </source>
        <volume>
         105
        </volume>
        <year>
         2002
        </year>
        <fpage>
         83
        </fpage>
        <lpage>
         91
        </lpage>
        <pub-id pub-id-type="pmid">
         11849318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0085">
       <label>
        85
       </label>
       <mixed-citation id="othref0002" publication-type="other">
        Wang P.H., Cheng Y.Increasing host cellular receptor—angiotensin-converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV infection. bioRxiv2020 Feb 27. doi:
        <pub-id pub-id-type="doi">
         10.1101/2020.02.24.963348
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="bib0086">
       <label>
        86
       </label>
       <element-citation id="sbref0084" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Qiao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV
        </article-title>
        <source>
         J Infect
        </source>
        <year>
         2020 Feb 21
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0087">
       <label>
        87
       </label>
       <element-citation id="sbref0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Langereis
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           van Vliet
          </surname>
          <given-names>
           A.L.W.
          </given-names>
         </name>
         <name>
          <surname>
           Huizinga
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         105
        </volume>
        <year>
         2008
        </year>
        <fpage>
         9065
        </fpage>
        <lpage>
         9069
        </lpage>
        <pub-id pub-id-type="pmid">
         18550812
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0088">
       <label>
        88
       </label>
       <element-citation id="sbref0086" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bakkers
          </surname>
          <given-names>
           M.J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Lang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Feistsma
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hulswit
          </surname>
          <given-names>
           R.J.G.
          </given-names>
         </name>
         <name>
          <surname>
           de Poot
          </surname>
          <given-names>
           S.A.H.
          </given-names>
         </name>
         <name>
          <surname>
           van Vliet
          </surname>
          <given-names>
           A.L.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Betacoronavirus
         </italic>
         adaptation to humans involved progressive loss of hemagglutinin-esterase lectin activity
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <volume>
         21
        </volume>
        <year>
         2017
        </year>
        <fpage>
         356
        </fpage>
        <lpage>
         366
        </lpage>
        <pub-id pub-id-type="pmid">
         28279346
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0089">
       <label>
        89
       </label>
       <element-citation id="sbref0087" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Glowacka
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Steffen
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Chaipan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Agudelo
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Different host cell proteases activate the SARS-coronavirus spike-protein for cell–cell and virus–cell fusion
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         413
        </volume>
        <year>
         2011
        </year>
        <fpage>
         265
        </fpage>
        <lpage>
         274
        </lpage>
        <pub-id pub-id-type="pmid">
         21435673
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0090">
       <label>
        90
       </label>
       <element-citation id="sbref0088" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lagier
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020 Mar 4
        </year>
        <object-id pub-id-type="publisher-id">
         105932
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0091">
       <label>
        91
       </label>
       <element-citation id="sbref0089" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A decade after SARS: strategies to control emerging coronaviruses
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        <volume>
         11
        </volume>
        <year>
         2013
        </year>
        <fpage>
         836
        </fpage>
        <lpage>
         848
        </lpage>
        <pub-id pub-id-type="pmid">
         24217413
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0092">
       <label>
        92
       </label>
       <element-citation id="sbref0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Milewska
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Zarebski
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nowak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Stozek
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Potempa
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         88
        </volume>
        <year>
         2014
        </year>
        <fpage>
         13221
        </fpage>
        <lpage>
         13230
        </lpage>
        <pub-id pub-id-type="pmid">
         25187545
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0093">
       <label>
        93
       </label>
       <element-citation id="sbref0091" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         HLA class I antigen serves as a receptor for human coronavirus OC43
        </article-title>
        <source>
         Immunol Invest
        </source>
        <volume>
         22
        </volume>
        <year>
         1993
        </year>
        <fpage>
         95
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="pmid">
         8505072
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0094">
       <label>
        94
       </label>
       <element-citation id="sbref0092" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Cuconati
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Block
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interferon induction of IFITM proteins promotes infection by human coronavirus OC43
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         111
        </volume>
        <year>
         2014
        </year>
        <fpage>
         6756
        </fpage>
        <lpage>
         6761
        </lpage>
        <pub-id pub-id-type="pmid">
         24753610
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0095">
       <label>
        95
       </label>
       <element-citation id="sbref0093" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vlasak
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Luytjes
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Spaan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Palese
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         85
        </volume>
        <year>
         1988
        </year>
        <fpage>
         4526
        </fpage>
        <lpage>
         4529
        </lpage>
        <pub-id pub-id-type="pmid">
         3380803
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0096">
       <label>
        96
       </label>
       <element-citation id="sbref0094" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Milewska
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Golda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Q.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus HKU1 spike protein uses
         <italic>
          O
         </italic>
         -acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         89
        </volume>
        <year>
         2015
        </year>
        <fpage>
         7202
        </fpage>
        <lpage>
         7213
        </lpage>
        <pub-id pub-id-type="pmid">
         25926653
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0097">
       <label>
        97
       </label>
       <element-citation id="sbref0095" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         83
        </volume>
        <year>
         2009
        </year>
        <fpage>
         1026
        </fpage>
        <lpage>
         1035
        </lpage>
        <pub-id pub-id-type="pmid">
         18987136
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0098">
       <label>
        98
       </label>
       <element-citation id="sbref0096" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Millet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         111
        </volume>
        <year>
         2014
        </year>
        <fpage>
         15214
        </fpage>
        <lpage>
         15219
        </lpage>
        <pub-id pub-id-type="pmid">
         25288733
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0099">
       <label>
        99
       </label>
       <mixed-citation id="othref0003" publication-type="other">
        Zhao Y., Zhao Z., Wang Y., Zhou Y., Ma Y., Zuo W.Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv2020 Jan 26. doi:
        <pub-id pub-id-type="doi">
         10.1101/2020.01.26.919985
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="bib0100">
       <label>
        100
       </label>
       <element-citation id="sbref0097" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glowacka
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Soilleux
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Pfefferle
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         85
        </volume>
        <year>
         2011
        </year>
        <fpage>
         4122
        </fpage>
        <lpage>
         4134
        </lpage>
        <pub-id pub-id-type="pmid">
         21325420
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0101">
       <label>
        101
       </label>
       <element-citation id="sbref0098" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: an overview of their replication and pathogenesis
        </article-title>
        <source>
         Methods Mol Biol
        </source>
        <volume>
         1282
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         25720466
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0001">
      <title>
       Acknowledgment
      </title>
      <p>
       The figure was designed using the Servier Medical Art supply of images available under a Creative Commons CC BY 3.0 license.
      </p>
      <p>
       <bold>
        Funding:
       </bold>
       This study was supported by IHU–Méditerranée Infection, University of Marseille and CNRS (Marseille, France). This work has benefited from French state support, managed by the Agence nationale de la recherche (ANR), including the ‘Programme d'investissement d'avenir’ under the reference Méditerranée Infection 10-1AHU-03.
      </p>
      <p>
       <bold>
        Competing interests:
       </bold>
       None declared.
      </p>
      <p>
       <bold>
        Ethical approval:
       </bold>
       Not required.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Int J Antimicrob Agents
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Int. J. Antimicrob. Agents
      </journal-id>
      <journal-title-group>
       <journal-title>
        International Journal of Antimicrobial Agents
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0924-8579
      </issn>
      <issn pub-type="epub">
       1872-7913
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V. and International Society of Chemotherapy.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32251731
      </article-id>
      <article-id pub-id-type="pmc">
       7128678
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0924-8579(20)30110-2
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.ijantimicag.2020.105960
      </article-id>
      <article-id pub-id-type="publisher-id">
       105960
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0001">
        <name>
         <surname>
          Fantini
         </surname>
         <given-names>
          Jacques
         </given-names>
        </name>
        <email>
         jacques.fantini@univ-amu.fr
        </email>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
        <xref ref-type="corresp" rid="cor0001">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0002">
        <name>
         <surname>
          Di Scala
         </surname>
         <given-names>
          Coralie
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0003">
        <name>
         <surname>
          Chahinian
         </surname>
         <given-names>
          Henri
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0004">
        <name>
         <surname>
          Yahi
         </surname>
         <given-names>
          Nouara
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0001">
       <label>
        a
       </label>
       INSERM UMR_S 1072, Marseille, France
      </aff>
      <aff id="aff0002">
       <label>
        b
       </label>
       Department of Biology, Aix-Marseille Université, Marseille, France
      </aff>
      <aff id="aff0003">
       <label>
        c
       </label>
       INMED, INSERM U1249, Parc Scientifique de Luminy, Marseille, France
      </aff>
      <author-notes>
       <corresp id="cor0001">
        <label>
         ⁎
        </label>
        Corresponding author. Address: INSERM UMR_S 1072, Boulevard Pierre Dramard, 13015 Marseille, France.
        <email>
         jacques.fantini@univ-amu.fr
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        3
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        3
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       105960
      </elocation-id>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Elsevier B.V. and International Society of Chemotherapy
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="author-highlights" id="abs0001">
       <title>
        Highlights
       </title>
       <p>
        <list id="celist0001" list-type="simple">
         <list-item id="celistitem0001">
          <label>
           •
          </label>
          <p id="para0001">
           The COVID‐19 pandemic caused by SARS‐CoV‐2 poses a global health emergency.
          </p>
         </list-item>
         <list-item id="celistitem0002">
          <label>
           •
          </label>
          <p id="para0002">
           Promising results suggest that chloroquine could stop the spread of SARS‐CoV‐2.
          </p>
         </list-item>
         <list-item id="celistitem0003">
          <label>
           •
          </label>
          <p id="para0003">
           In-silico studies confirm the antiviral properties of chloroquine.
          </p>
         </list-item>
         <list-item id="celistitem0004">
          <label>
           •
          </label>
          <p id="para0004">
           New mechanism of action of chloroquine elucidated.
          </p>
         </list-item>
         <list-item id="celistitem0005">
          <label>
           •
          </label>
          <p id="para0005">
           Hydroxychloroquine is more potent than chloroquine.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <abstract id="abs0002">
       <p>
        The recent emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) is responsible for a worldwide pandemic. Given the global health emergency, drug repositioning is the most reliable option to design an efficient therapy for infected patients without delay. The first step of the viral replication cycle [i.e. attachment to the surface of respiratory cells, mediated by the spike (S) viral protein] offers several potential therapeutic targets. The S protein uses the angiotension-converting enzyme-2 (ACE-2) receptor for entry, but also sialic acids linked to host cell surface gangliosides. Using a combination of structural and molecular modelling approaches, this study showed that chloroquine (CLQ), one of the drugs currently under investigation for SARS-CoV-2 treatment, binds sialic acids and gangliosides with high affinity. A new type of ganglioside-binding domain at the tip of the N-terminal domain of the SARS-CoV-2 S protein was identified. This domain (111–158), which is fully conserved among clinical isolates worldwide, may improve attachment of the virus to lipid rafts and facilitate contact with the ACE-2 receptor. This study showed that, in the presence of CLQ [or its more active derivative, hydroxychloroquine (CLQ-OH)], the viral S protein is no longer able to bind gangliosides. The identification of this new mechanism of action of CLQ and CLQ-OH supports the use of these repositioned drugs to cure patients infected with SARS-CoV-2. The in-silico approaches used in this study might also be used to assess the efficiency of a broad range of repositioned and/or innovative drug candidates before clinical evaluation.
       </p>
      </abstract>
      <abstract abstract-type="graphical" id="abs0003">
       <title>
        Graphical Abstract
       </title>
       <p>
        <fig id="fig0011" position="anchor">
         <alt-text id="alttx001">
          Image, graphical abstract
         </alt-text>
         <graphic xlink:href="fx1_lrg">
         </graphic>
        </fig>
       </p>
      </abstract>
      <kwd-group id="keys0001">
       <title>
        Keywords
       </title>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        Pandemic
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        Ganglioside
       </kwd>
       <kwd>
        Spike
       </kwd>
       <kwd>
        Chloroquine
       </kwd>
      </kwd-group>
     </article-meta>
     <notes>
      <p id="misc0001">
       Editor: Jean-Marc Rolain
      </p>
     </notes>
    </front>
    <sec id="sec0001">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="para0006">
      The recent emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) is responsible for a global pandemic
      <xref ref-type="bibr" rid="bib0001">
       [1]
      </xref>
      , and there is an urgent need to identify active antiviral agents. Given the global health emergency, drug repositioning is the most reliable option to design an efficient therapy for infected patients without delay
      <xref ref-type="bibr" rid="bib0002">
       [2
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0003">
       3]
      </xref>
      . Several drugs have already been tested, among which chloroquine (CLQ), a well-known antimalarial drug, is one of the most promising as it has shown apparent efficacy in the treatment of COVID-19-associated pneumonia in recent clinical studies
      <xref ref-type="bibr" rid="bib0004">
       [4]
      </xref>
      . However, the mechanism of action of CLQ against SARS-CoV-2 is unclear as the drug seems to exert a broad range of potential antiviral effects
      <xref ref-type="bibr" rid="bib0005">
       [5]
      </xref>
      . Therefore, although CLQ is classically considered as an inhibitor of endocytic pathways through elevation of endosomal pH
      <xref ref-type="bibr" rid="bib0006">
       [6]
      </xref>
      , its detailed molecular mechanism of action as an antiviral compound remains unclear
      <xref ref-type="bibr" rid="bib0003">
       [3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0005">
       5]
      </xref>
      . Interestingly, CLQ has been shown to interfere with the terminal glycosylation of angiotensin-converting enzyme-2 (ACE-2)
      <xref ref-type="bibr" rid="bib0007">
       [7]
      </xref>
      , which acts as a plasma membrane receptor for both SARS-CoV
      <xref ref-type="bibr" rid="bib0008">
       [8]
      </xref>
      and SARS-CoV-2
      <xref ref-type="bibr" rid="bib0009">
       [9]
      </xref>
      , and CLQ could act at several steps of the coronavirus replication cycle
      <xref ref-type="bibr" rid="bib0007">
       [7]
      </xref>
      . These data suggest the interesting and mostly unexplored possibility that CLQ could prevent viral attachment through a direct effect on host cell surface molecules.
     </p>
     <p id="para0007">
      One important characteristic of human coronaviruses is that besides their protein membrane receptor, they also depend upon sialic-acid-containing glycoproteins and gangliosides that act as primary attachment factors along the respiratory tract
      <xref ref-type="bibr" rid="bib0010">
       [10]
      </xref>
      . The present study used a combination of structural and molecular modelling approaches
      <xref ref-type="bibr" rid="bib0011">
       [11]
      </xref>
      to investigate the potential interaction between CLQ and sialic acids. A ganglioside-binding site in the N-terminal domain (NTD) of the spike (S) glycoprotein of SARS-CoV-2 was identified, and CLQ was shown to be a potential blocker of the S–ganglioside interaction which occurs in the first step of the viral replication cycle (i.e. attachment to the surface of respiratory cells, mediated by the S protein). In addition, the antiviral potential of CLQ and its derivative hydroxychloroquine (CLQ-OH) against SARS-CoV-2 were compared. Overall, this study found that CLQ and CLQ-OH may be used to fight pathogenic human coronaviruses
      <xref ref-type="bibr" rid="bib0003">
       [3]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0004">
       [4]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0005">
       [5]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0006">
       [6]
      </xref>
      , including SARS-CoV-2
      <xref ref-type="bibr" rid="bib0012">
       [12]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0002">
     <label>
      2
     </label>
     <title>
      Materials and methods
     </title>
     <p id="para0008">
      In-silico analyses were performed using Hyperchem and Molegro Molecular viewer as described
      <xref ref-type="bibr" rid="bib0011">
       [11
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0013">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0014">
       14]
      </xref>
      . The initial coordinates of GM1 were obtained from CHARMM-GUI Glycolipid Modeler (
      <ext-link ext-link-type="uri" id="interref0001" xlink:href="http://www.charmmgui.org/?doc=input/glycolipid">
       http://www.charmmgui.org/?doc=input/glycolipid
      </ext-link>
      ;
      <xref ref-type="bibr" rid="bib0015">
       [15]
      </xref>
      ), which uses the internal coordinate information of common glycosidic torsion angle values, orients the ganglioside perpendicular to the membrane, and performs Langevin dynamics with a cylindrical restraint potential to keep the whole GM1 molecule cylindrical, especially the membrane-embedded ceramide part. In the next step, the ganglioside was included in a periodic box solvated with 1128 water molecules. The system was energy-minimized six times, switching between runs using the steepest descent gradients and runs using Polak–Ribière conjugate gradients until convergence to machine precision. The ganglioside was subsequently merged with the NTD domain of SARS-CoV-2 S protein as obtained from pdb file # 6VSB
      <xref ref-type="bibr" rid="bib0016">
       [16]
      </xref>
      . Initial conditions corresponded to minimized structures obtained with the Polak–Ribière algorithm. Docked complexes were subsequently submitted to iterative cycles of molecular dynamics using the CHARMM36 force field optimized for carbohydrates
      <xref ref-type="bibr" rid="bib0017">
       [17]
      </xref>
      . Interaction energies were calculated from stable complexes using the Ligand Energy Inspector function of Molegro
      <xref ref-type="bibr" rid="bib0013">
       [13]
      </xref>
      .
     </p>
     <p id="para0009">
      N-acetylneuraminic acid (Neu5Ac) was generated with the Hyperchem database. 9-O-acetyl-N-acetylneuraminic acid (9-O-SIA) was retrieved from pdb file 6Q06
      <xref ref-type="bibr" rid="bib0018">
       [18]
      </xref>
      . CLQ is N-(7-chloroquinolin-4-yl)-N,N-diéthyl-pentane-1,4-diamine. Its three-dimensioanl structure was retrieved from pdb file # 4V2O
      <xref ref-type="bibr" rid="bib0019">
       [19]
      </xref>
      . CLQ-OH is (RS)-2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol. CLQ-OH was generated by hydroxylation of CLQ with Hyperchem. Both CLQ and CLQ-OH were energy-minimized and merged with water molecules as described below.
     </p>
    </sec>
    <sec id="sec0003">
     <label>
      3
     </label>
     <title>
      Results
     </title>
     <sec id="sec0004">
      <label>
       3.1
      </label>
      <title>
       Structural and conformational analysis of CLQ and CLQ-OH in water
      </title>
      <p id="para0010">
       The chemical structures of CLQ and CLQ-OH are shown in
       <xref ref-type="fig" rid="fig0001">
        Fig. 1
       </xref>
       (a,b). The only difference between the two molecules is the presence of a terminal hydroxyl group in CLQ-OH. This OH group has a marked influence on the conformation and water-solubilization properties of the drug. CLQ-OH may adopt a wide range of conformations, the most stable being the extended one shown in
       <xref ref-type="fig" rid="fig0001">
        Fig. 1
       </xref>
       (c). When immersed in a periodic box of 31.5 Å
       <sup>
        2
       </sup>
       with 1042 water molecules, the system reached, at equilibrium, an estimated energy of interaction of -92 kJ.mol
       <sup>
        −1
       </sup>
       , accounting for 56 water molecules solvating CLQ-OH
       <xref ref-type="fig" rid="fig0001">
        Fig. 1
       </xref>
       (d). In contrast, due to an intramolecular hydrophobic effect, CLQ appeared to be more condensed than CLQ-OH
       <xref ref-type="fig" rid="fig0001">
        Fig. 1
       </xref>
       (e). At equilibrium, CLQ was surrounded by 58 water molecules with an energy of interaction of -79 kJ.mol
       <sup>
        −1
       </sup>
       <xref ref-type="fig" rid="fig0001">
        Fig. 1
       </xref>
       (f).
       <fig id="fig0001">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Chemical structure of chloroquine (CLQ) and hydroxychloroquine (CLQ-OH). (a) CLQ. (b) CLQ-OH. (c) CLQ-OH extended conformer. (d) CLQ-OH in water. (e) Typical condensed conformer of CLQ. (f) CLQ in water. The molecules in (c–f) are shown in either tube or sphere rendering (carbon, green; nitrogen, blue; oxygen, red; hydrogen, white). In (c) and (e), the chlorine atom of CLQ and CLQ-OH is indicated by an arrow.
         </p>
        </caption>
        <alt-text id="alt0001">
         Fig 1
        </alt-text>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
      <p id="para0011">
       These water-compatible conformations of CLQ and CLQ-OH were used as initial conditions for studying the interaction of these drugs with sialic acids and gangliosides.
      </p>
     </sec>
     <sec id="sec0005">
      <label>
       3.2
      </label>
      <title>
       Sialic acids as molecular targets of CLQ and CLQ-OH
      </title>
      <p id="para0012">
       Neu5Ac is the predominant sialic acid found in human glycoproteins and gangliosides. When CLQ was merged with Neu5Ac, a quasi-instantaneous fit occurred between the two molecules, whose global shapes in water are geometrically complementary
       <xref ref-type="fig" rid="fig0002">
        Fig. 2
       </xref>
       (a). This is particularly obvious in the views of the CLQ–Neu5Ac complex in mixed surface/balls and sticks rendition
       <xref ref-type="fig" rid="fig0002">
        Fig. 2
       </xref>
       (a,b). The interaction was driven by the positioning of the negative charge of the carboxylate group of Neu5Ac and one of the two cationic charges of CLQ (pKa 10.2)
       <xref ref-type="fig" rid="fig0002">
        Fig. 2
       </xref>
       (c). The energy of interaction of this complex was estimated to be -47 kJ.mol
       <sup>
        −1
       </sup>
       . As coronaviruses preferentially interact with 9-O-acetyl-N-acetylneuraminic acid (9-O-SIA)
       <xref ref-type="bibr" rid="bib0010">
        [10]
       </xref>
       , this study used a similar molecular modelling approach to assess whether CLQ could also interact with this specific sialic acid. A good fit between CLQ and 9-O-SIA was obtained
       <xref ref-type="fig" rid="fig0002">
        Fig. 2
       </xref>
       (d–f), with an energy of interaction of -45 kJ.mol
       <sup>
        −1
       </sup>
       . In this case, the carboxylate group of the sialic acid interacted with the cationic group of the nitrogen-containing ring of CLQ (pKa 8.1)
       <xref ref-type="fig" rid="fig0002">
        Fig. 2
       </xref>
       (d). The complex was further stabilized by OH-π and van der Waals interactions.
       <fig id="fig0002">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Molecular modelling of chloroquine (CLQ) interaction with sialic acids. (a,b) Surface representation of the CLQ–sialic acid (Neu5Ac) complex. Two opposite views of the complex are shown. Note the geometric complementarity between the L-shape conformer of CLQ dissolved in water (in blue) and Neu5Ac (in red). (c) Neu5Ac bound to CLQ via a combination of CH-π and electrostatic interactions with one of the cationic groups of CLQ (+). (d) Molecular modelling of CLQ bound to N-acetyl-9-O-acetylneuraminic acid (9-O-SIA). From right to left, the dashed lines indicate a series of van der Waals, OH-π and electrostatic contacts with both cationic groups of CLQ (+). (e,f) Surface representations of the CLQ–9-O-SIA complex.
         </p>
        </caption>
        <alt-text id="alt0002">
         Fig 2
        </alt-text>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
      </p>
      <p id="para0013">
       Next, CLQ-OH was tested to assess whether it could, as CLQ, bind to 9-O-SIA (
       <xref ref-type="fig" rid="fig0003">
        Fig. 3
       </xref>
       ). The complex obtained with CLQ-OH was very similar to that obtained with CLQ [compare
       <xref ref-type="fig" rid="fig0003">
        Fig. 3
       </xref>
       (a,b) with
       <xref ref-type="fig" rid="fig0002">
        Fig. 2
       </xref>
       (e,f), although several conformational adjustments occurred during the simulations. Interestingly, the OH group of CLQ-OH reinforced the binding of CLQ to sialic acid through establishment of a hydrogen bond
       <xref ref-type="fig" rid="fig0003">
        Fig. 3
       </xref>
       (c,d). Overall, this hydrogen bond compensated for the slight loss of energy caused by the conformational rearrangement, and the energy of interaction of the complex was estimated to be -46 kJ.mol
       <sup>
        −1
       </sup>
       , which is very close to the value obtained for CLQ (-45 kJ.mol
       <sup>
        −1
       </sup>
       ).
       <fig id="fig0003">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Molecular modelling of hydroxychloroquine (CLQ-OH) interaction with sialic acids. (a,b) Surface representation of CLQ-OH bound to N-acetyl-9-O-acetylneuraminic acid (9-O-SIA). Two opposite views of the complex are shown. Note the geometric complementarity between CLQ-OH (in blue) and 9-O-SIA (in red). (c,d) Molecular mechanism of CLQ-OH binding to 9-O-SIA: combination of electrostatic interactions and hydrogen bonding.
         </p>
        </caption>
        <alt-text id="alt0003">
         Fig 3
        </alt-text>
        <graphic xlink:href="gr3_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="sec0006">
      <label>
       3.3
      </label>
      <title>
       Molecular recognition of gangliosides by CLQ and CLQ-OH
      </title>
      <p id="para0014">
       In the respiratory tract, sialic acids are usually part of glycoproteins and gangliosides. Molecular modelling approaches were used to assess whether CLQ and CLQ-OH can recognize sialic acid units in their natural molecular environment. In these simulations, ganglioside GM1 was chosen as a representative example of human plasma membrane gangliosides. A first series of simulations was performed with CLQ. When merged with the ganglioside, CLQ had two distinct binding sites, both located in the polar saccharide part of GM1. The first site was located at the tip of the saccharide moiety of the ganglioside
       <xref ref-type="fig" rid="fig0004">
        Fig. 4
       </xref>
       (a,b). The energy of interaction was estimated to be -47 kJ.mol
       <sup>
        −1
       </sup>
       . CLQ retained the typical L-shape structure of the water-soluble conformer bound to isolated sialic acids [compare
       <xref ref-type="fig" rid="fig0002">
        Figs 2
       </xref>
       (c) and
       <xref ref-type="fig" rid="fig0004">
        4
       </xref>
       (a)]. From a mechanistic point of view, the carboxylate group of the sialic acid of GM1 was oriented towards the cationic groups of CLQ. The rings of CLQ faced the N-acetylgalactosamine (GalNAc) residue of GM1, establishing both OH-π interaction and hydrogen bonding
       <xref ref-type="fig" rid="fig0004">
        Fig. 4
       </xref>
       (b). The second site was in a large area including both the ceramide–sugar junction and the saccharide moiety
       <xref ref-type="fig" rid="fig0004">
        Fig. 4
       </xref>
       (c). The chlorine atom of CLQ was oriented towards the ceramide axis, allowing the nitrogen-containing ring of CLQ to stack on to the pyrane ring of the first sugar residue [i.e. glucose (Glc)]. The perfect geometric complementarity of the two partners
       <xref ref-type="fig" rid="fig0004">
        Fig. 4
       </xref>
       (c,d) accounted for a particularly high energy of interaction in this case (-61 kJ.mol
       <sup>
        −1
       </sup>
       ). Interestingly, there was no overlap between the two CLQ-binding sites on GM1, so the ganglioside could accommodate two CLQ molecules
       <xref ref-type="fig" rid="fig0004">
        Fig. 4
       </xref>
       (e), reaching a global energy of interaction of -108 kJ.mol
       <sup>
        −1
       </sup>
       . A similar situation was observed with CLQ-OH, which occupies the same binding site as CLQ
       <xref ref-type="fig" rid="fig0004">
        Fig. 4
       </xref>
       (f). In this case, the energy of interaction was further increased by stabilizing contacts established between the two CLQ-OH molecules, reaching -120 kJ.mol
       <sup>
        −1
       </sup>
       . Overall, these data showed that CLQ and CLQ-OH have a good fit for sialic acids, either isolated or bound to gangliosides.
       <fig id="fig0004">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          Molecular modelling simulations of chloroquine (CLQ) and hydroxychloroquine (CLQ-OH) binding to ganglioside GM1. The surface electrostatic potential of GM1 indicates a non-polar, membrane-embedded part corresponding to ceramide (white areas), and an acidic part protruding in the extracellular space corresponding to the sialic-acid-containing saccharide part (red areas). (a) CLQ bound to the tip of the carbohydrate moiety of GM1. (b) Molecular mechanism of CLQ–ganglioside interactions. (c) Molecular dynamics simulations revealed a second site of interaction. In this case, the aromatic cycles of CLQ are positioned at the ceramide–sugar junction, whereas the nitrogen atoms interact with the acidic part of the ganglioside (not illustrated). (d,e) Surface views of GM1 complexed with one (d) or two (e) CLQ molecules (both in blue), illustrating the geometric complementarity of GM1 and CLQ molecules. (f) One GM1 molecule can also accommodate two distinct CLQ-OH molecules simultaneously, after slight rearrangement allowing increased fit due to CLQ-OH/CLQ-OH interactions. To improve clarity, CLQ-OH molecules bound to GM1 are represented in two distinct colours (blue and green).
         </p>
        </caption>
        <alt-text id="alt0004">
         Fig 4
        </alt-text>
        <graphic xlink:href="gr4_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="sec0007">
      <label>
       3.4
      </label>
      <title>
       Structural analysis of the NTD of SARS-CoV-2 S protein
      </title>
      <p id="para0015">
       The next step of this study was to determine how SARS-CoV-2 could interact with plasma membrane gangliosides, and whether such interaction could be affected by CLQ and CLQ-OH. The global structure of the SARS-CoV-2 S protein
       <xref ref-type="bibr" rid="bib0016">
        [16]
       </xref>
       is shown in
       <xref ref-type="fig" rid="fig0005">
        Fig. 5
       </xref>
       (a–d). It consists of a trimer of S proteins, each harbouring two distinct domains distant from the viral envelope: the receptor-binding region (RBD) and the NTD.
       <fig id="fig0005">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          Structural features of the SARS-CoV-2 spike (S) protein. (a) Trimeric structure (each S protein has a distinct surface colour, ‘blue’, ‘yellow’ and ‘purple’). (b) Ribbon representation of ‘blue’ S protein in the trimer (α-helix, red; β-strand, blue; coil, grey). (c) Surface structure of the ‘blue’ S protein isolated from the trimer. (d) Ribbon structure of the ‘blue’ S protein. (e) Zoom on the N-terminal domain (NTD) of the ‘blue’ S protein. (f,g) Molecular model of a minimal NTD obtained with Hyperchem [ribbon in representation in (f), surface rendering in (g)]. (h) Highlighting of the amino acid residues of the NTD that could belong to a potential ganglioside-binding domain.
         </p>
        </caption>
        <alt-text id="alt0005">
         Fig 5
        </alt-text>
        <graphic xlink:href="gr5_lrg">
        </graphic>
       </fig>
      </p>
      <p id="para0016">
       It was reasoned that if the RBD is engaged in functional interactions with the ACE-2 receptor, it would be interesting to search for potential ganglioside-binding sites on the other cell-accessible domain of the S glycoprotein (i.e. the NTD). The NTD contains approximately 290 amino acid residues. The tip of the NTD was of particular interest, as it displays a flat interface
       <xref ref-type="fig" rid="fig0005">
        Fig. 5
       </xref>
       (f) ideally positioned for targeting a ganglioside-rich plasma membrane microdomain, such as a lipid raft.
      </p>
      <p id="para0017">
       The amino acid sequence of the planar interfacial surface located at the tip of the NTD was analysed for the presence of consensus ganglioside-binding domains
       <xref ref-type="bibr" rid="bib0020">
        [20]
       </xref>
       . These motifs are constituted by a triad of mandatory amino acid residues such as (K,R)-X
       <sub>
        n
       </sub>
       -(F,Y,W)-X
       <sub>
        n
       </sub>
       -(K,R). The X
       <sub>
        n
       </sub>
       intercalating segments, usually four to five residues, may contain any amino acid, but often Gly, Pro and/or Ser residues. The strict application of this algorithm did not allow the detection of any potential ganglioside-binding domain in this region of the NTD. However, an intriguing over-representation of aromatic and basic residues was found in the 129–158 segment: 129-
       <underline>
        K
       </underline>
       VCE
       <underline>
        F
       </underline>
       Q
       <underline>
        F
       </underline>
       CNDP
       <underline>
        F
       </underline>
       LGV
       <underline>
        YY
       </underline>
       H
       <underline>
        K
       </underline>
       NN
       <underline>
        K
       </underline>
       S
       <underline>
        W
       </underline>
       MESE
       <underline>
        FR
       </underline>
       -158. This 30-amino acid stretch also contains Gly, Pro and/or Ser residues that are often found in ganglioside-binding motifs. These observations supported the notion that the tip of the NTD could display a large ganglioside-attachment interface.
      </p>
     </sec>
     <sec id="sec0008">
      <label>
       3.5
      </label>
      <title>
       Molecular interactions between gangliosides and the NTD of SARS-CoV-2 S protein
      </title>
      <p id="para0018">
       Molecular dynamic simulations of a structural motif encompassing amino acid residues 100–175 of the NTD
       <xref ref-type="fig" rid="fig0005">
        Fig. 5
       </xref>
       (f–h) merged with ganglioside GM1 further supported this concept. As shown in
       <xref ref-type="fig" rid="fig0006">
        Fig. 6
       </xref>
       , the large flat area of this structural domain fitted very well with the protruding oligosaccharide part of the ganglioside. Several amino acid residues appear to be critical for this interaction, especially Phe-135, Asn-137 and Arg-158 (
       <xref ref-type="table" rid="tbl0001">
        Table 1
       </xref>
       ). Overall, the complex involved 10 amino acid residues for a total energy of interaction of -100 kJ.mol
       <sup>
        −1
       </sup>
       . At this stage, it was observed that approximately 50% of the interface was involved in the complex, leaving the remaining 50% available for interaction with a second GM1 molecule. As expected, merging a second GM1 molecule with the preformed GM1–NTD complex led to a trimolecular complex consisting of two gangliosides in a typical symmetrical chalice-like structure into which the NTD could insert its interfacial ganglioside-binding domain (
       <xref ref-type="fig" rid="fig0007">
        Fig. 7
       </xref>
       ). The formation of this trimolecular complex was progressive, starting with a conformational rearrangement of the first ganglioside–NTD complex triggered by the second GM1 molecule. The energy of interaction of the new complex was consistently increased by 37%, reaching an estimated value of -137 kJ.mol
       <sup>
        −1
       </sup>
       . At this stage, attachment of the NTD to the ganglioside-rich microdomain involved the whole interface (i.e. 15 surface-accessible residues from Asp-111 to Ser-162). The critical residues were Asp-111, Gln-134, Phe-135, Arg-158 and Ser-161 (
       <xref ref-type="table" rid="tbl0001">
        Table 1
       </xref>
       ).
       <fig id="fig0006">
        <label>
         Fig. 6
        </label>
        <caption>
         <p>
          Molecular complex between the N-terminal domain (NTD) of SARS-CoV-2 spike protein and a single GM1 ganglioside. The NTD is represented in ribbons superposed with a transparent surface rendering (light green). Two symmetric views of the complex are shown (a,b). The amino acid residues Q-134 to D-138 located in the centre of the ganglioside-binding domain are represented as green spheres. The saccharide part of the ganglioside forms a landing surface for the tip of the NTD.
         </p>
        </caption>
        <alt-text id="alt0006">
         Fig 6
        </alt-text>
        <graphic xlink:href="gr6_lrg">
        </graphic>
       </fig>
       <table-wrap id="tbl0001" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Energy of interaction of each amino acid residue of SARS‐CoV‐2 spike protein in contact with GM1 molecules.
         </p>
        </caption>
        <alt-text id="alt0011">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th valign="top">
            Amino acid residues
           </th>
           <th valign="top">
            Energy of interaction (kJ.mol‐1)
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td valign="top">
            First step: one GM1 molecule
           </td>
           <td valign="top">
           </td>
          </tr>
          <tr>
           <td valign="top">
            Asp‐111
           </td>
           <td valign="top">
            −5.6
           </td>
          </tr>
          <tr>
           <td valign="top">
            Lys‐113
           </td>
           <td valign="top">
            −8.2
           </td>
          </tr>
          <tr>
           <td valign="top">
            Gln‐134
           </td>
           <td valign="top">
            −8.6
           </td>
          </tr>
          <tr>
           <td valign="top">
            Phe‐135
           </td>
           <td valign="top">
            −20.1
           </td>
          </tr>
          <tr>
           <td valign="top">
            Cys‐136
           </td>
           <td valign="top">
            −7.0
           </td>
          </tr>
          <tr>
           <td valign="top">
            Asn‐137
           </td>
           <td valign="top">
            −15.2
           </td>
          </tr>
          <tr>
           <td valign="top">
            Asp‐138
           </td>
           <td valign="top">
            −6.4
           </td>
          </tr>
          <tr>
           <td valign="top">
            Arg‐158
           </td>
           <td valign="top">
            −17.4
           </td>
          </tr>
          <tr>
           <td valign="top">
            Ser‐161
           </td>
           <td valign="top">
            −9.7
           </td>
          </tr>
          <tr>
           <td valign="top">
            Ser‐162
           </td>
           <td valign="top">
            −2.0
           </td>
          </tr>
          <tr>
           <td valign="top">
            Total
           </td>
           <td valign="top">
            −100.2
           </td>
          </tr>
          <tr>
           <td valign="top">
            Second step: two GM1 molecules
           </td>
           <td valign="top">
           </td>
          </tr>
          <tr>
           <td valign="top">
            Asp‐111
           </td>
           <td valign="top">
            −15.8
           </td>
          </tr>
          <tr>
           <td valign="top">
            Ser‐112
           </td>
           <td valign="top">
            −10.7
           </td>
          </tr>
          <tr>
           <td valign="top">
            Lys‐113
           </td>
           <td valign="top">
            −9.2
           </td>
          </tr>
          <tr>
           <td valign="top">
            Gln‐134
           </td>
           <td valign="top">
            −11.2
           </td>
          </tr>
          <tr>
           <td valign="top">
            Phe‐135
           </td>
           <td valign="top">
            −10.5
           </td>
          </tr>
          <tr>
           <td valign="top">
            Cys‐136
           </td>
           <td valign="top">
            −6.2
           </td>
          </tr>
          <tr>
           <td valign="top">
            Asn‐137
           </td>
           <td valign="top">
            −4.7
           </td>
          </tr>
          <tr>
           <td valign="top">
            Phe‐140
           </td>
           <td valign="top">
            −5.2
           </td>
          </tr>
          <tr>
           <td valign="top">
            Gly‐142
           </td>
           <td valign="top">
            −5.6
           </td>
          </tr>
          <tr>
           <td valign="top">
            Glu‐156
           </td>
           <td valign="top">
            −9.0
           </td>
          </tr>
          <tr>
           <td valign="top">
            Phe‐157
           </td>
           <td valign="top">
            −13.8
           </td>
          </tr>
          <tr>
           <td valign="top">
            Arg‐158
           </td>
           <td valign="top">
            −19.8
           </td>
          </tr>
          <tr>
           <td valign="top">
            Tyr‐160
           </td>
           <td valign="top">
            −3.2
           </td>
          </tr>
          <tr>
           <td valign="top">
            Ser‐161
           </td>
           <td valign="top">
            −9.7
           </td>
          </tr>
          <tr>
           <td valign="top">
            Ser‐162
           </td>
           <td valign="top">
            −2.0
           </td>
          </tr>
          <tr>
           <td valign="top">
            Total
           </td>
           <td valign="top">
            −136.6
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
       <fig id="fig0007">
        <label>
         Fig. 7
        </label>
        <caption>
         <p>
          Molecular complex between the N-terminal domain (NTD) of SARS-CoV-2 spike protein and a dimer of GM1. In (a), (c) and (d), the NTD is represented as in
          <xref ref-type="fig" rid="fig0004">
           Fig. 4
          </xref>
          . In (b), the surface of the NTD is shown without any transparency. The amino acid residues Q-134 to S-162 belonging to the ganglioside-binding domain (GBD) are represented as green spheres. Compared with a single GM1 molecule, the dimer of gangliosides forms a larger attractive surface for the NTD. In the above view of (d), the anchorage of the NTD to the gangliosides is particularly obvious. As chloroquine also interacts with the saccharide part of GM1, its presence would clearly mask most of the landing surface available for the NTD, preventing attachment of the virus to the plasma membrane of host cells.
         </p>
        </caption>
        <alt-text id="alt0007">
         Fig 7
        </alt-text>
        <graphic xlink:href="gr7_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="sec0009">
      <label>
       3.6
      </label>
      <title>
       Potential coordinated interactions between SARS-CoV-2 and the plasma membrane of a host cell: key role of gangliosides in lipid rafts
      </title>
      <p id="para0019">
       Taken together, these data strongly support the concept of a dual receptor/attachment model for SARS-CoV-2, with the RBD domain being involved in ACE-2 receptor recognition, and the NTD interface responsible for finding a ganglioside-rich landing area (lipid raft) at the cell surface.
      </p>
      <p id="para0020">
       Such a dual receptor model, consistent with the topology of the SARS-CoV-2 S protein, is proposed in
       <xref ref-type="fig" rid="fig0008">
        Fig. 8
       </xref>
       . With this model in mind, the potential effects of CLQ and CLQ-OH were studied, both of which, according to the molecular modelling data, have a high affinity for sialic acids and gangliosides.
       <fig id="fig0008">
        <label>
         Fig. 8
        </label>
        <caption>
         <p>
          Dual recognition of gangliosides and angiotensin-converting enzyme-2 (ACE-2) by SARS-CoV-2 spike (S) protein. The viral protein displays two distinct domains, the tips of which are available for distinct types of interactions. The receptor-binding domain binds to the ACE-2 receptor, and the N-terminal domain (NTD) binds to the ganglioside-rich domain of the plasma membrane. Lipid rafts, which are membrane domains enriched in gangliosides (in yellow) and cholesterol (in blue), provide a perfect attractive interface for adequately positioning the viral S protein at the first step of the infection process. These structural and molecular modelling studies suggest that amino acid residues 111–162 of the NTD form a functional ganglioside-binding domain, the interaction of which with lipid rafts can be efficiently prevented by chloroquine and hydroxychloroquine.
         </p>
        </caption>
        <alt-text id="alt0008">
         Fig 8
        </alt-text>
        <graphic xlink:href="gr8_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="sec0010">
      <label>
       3.7
      </label>
      <title>
       Molecular mechanism of CLQ and CLQ-OH antiviral effect: preventing SARS-CoV-2 S protein access to cell surface gangliosides
      </title>
      <p id="para0021">
       With the aim of establishing whether CLQ and CLQ-OH could prevent the attachment of SARS-CoV-2 to plasma membrane gangliosides, the initial NTD–GM1 complex was superposed with a drug–GM1 complex (
       <xref ref-type="fig" rid="fig0009">
        Fig. 9
       </xref>
       ). To improve clarity, the ganglioside is not presented in
       <xref ref-type="fig" rid="fig0009">
        Fig. 9
       </xref>
       . This superposition shows that the NTD and the drug (CLQ-OH in this case) share the same spatial position when bound to GM1, so GM1 cannot bind the viral protein and the drug simultaneously. This is due to the fact that the NTD and the drugs (CLQ and CLQ-OH) bind to GM1 with a similar mechanism controlled by a dyad of functional interactions: a hydrogen bond and a geometrically perfect CH-π stacking interaction. In the case of the NTD, the hydrogen bond involves Asn-167, whereas CH-π stacking is mediated by the aromatic ring of Phe-135
       <xref ref-type="fig" rid="fig0006">
        Fig. 6
       </xref>
       (b). On one hand, Asn-167 establishes a network of hydrogen bonds with the GalNAc residue of GM1. On the other hand, the flat aromatic ring of Phe-135 stacks on to the cycle of the Glc residue of GM1. In the case of CLQ and CLQ-OH, it is the nitrogen-containing ring of the drug that stacks on to the Glc ring
       <xref ref-type="fig" rid="fig0004">
        Fig. 4
       </xref>
       (c). Note that both the Phe-135 (in red) and CLQ-OH (in green) rings are located in the same position (
       <xref ref-type="fig" rid="fig0009">
        Fig. 9
       </xref>
       ). The other CLQ-OH molecule, which covers the tip of the sugar part of the ganglioside, interacts with the GalNAc ganglioside
       <xref ref-type="fig" rid="fig0004">
        Fig. 4
       </xref>
       (b). When the NTD is bound to the ganglioside, the side chain of Asn-137 is found in this exact position (
       <xref ref-type="fig" rid="fig0009">
        Fig. 9
       </xref>
       ). Thus, once two CLQ-OH (or two CLQ) molecules are bound to a ganglioside
       <xref ref-type="fig" rid="fig0004">
        Fig. 4
       </xref>
       (e,f), any binding of a SARS-Cov-2 S protein to the same ganglioside is totally prevented. The energy required to overcome this steric incompatibility is estimated to be several hundred kJ.mol
       <sup>
        −1
       </sup>
       , which is far too high to occur.
       <fig id="fig0009">
        <label>
         Fig. 9
        </label>
        <caption>
         <p>
          Mechanism of action of hydroxychloroquine (CLQ-OH). The N-terminal domain (NTD) bound to GM1 was superposed onto GM1 in interaction with two CLQ-OH molecules. The models only show the NTD and both CLQ-OH molecules (not GM1, to improve clarity). (a,b) The aromatic ring of F-135 (in red), which stacks onto the glucose cycle of GM1, overlaps the aromatic CLQ-OH rings (in green) which also bind to GM1 via a CH-π stacking mechanism. The N-137 residue of the NTD interacts with the N-acetylgalactosamine residue of GM1, but this interaction cannot occur in the presence of CLQ-OH as this part of GM1 is totally masked by the drug. (c,d) Superposition of the NTD surface (in purple) with the two CLQ-OH molecules bound to GM1, illustrating the steric impossibility that prevents NTD binding to GM1 when both CLQ-OH molecules are already interacting with the ganglioside.
         </p>
        </caption>
        <alt-text id="alt0009">
         Fig 9
        </alt-text>
        <graphic xlink:href="gr9_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="sec0011">
      <label>
       3.8
      </label>
      <title>
       Sequence alignment analysis of SARS-CoV-2 and related coronavirus: evolution of the ganglioside-binding domain at critical amino acid residues
      </title>
      <p id="para0022">
       As CLQ and CLQ-OH are potential therapies for SARS-CoV-2 infection, it is important to check whether the amino acid residues identified as critical for ganglioside binding are conserved among clinical isolates. The alignment of the 111–162 domain of 11 clinical isolates of SARS-CoV-2 from various geographic origins (including Asia and USA) is shown in
       <xref ref-type="fig" rid="fig0010">
        Fig. 10
       </xref>
       . In this region, which contains the ganglioside-binding domain identified in the present report, all amino acids are fully conserved. Interestingly, the motif is built like a giant consensus ganglioside-binding domain: a central region displaying the critical aromatic residue (Phe-135) and a basic residue at each end (Lys-113 and Arg-158). In the middle of each stretch separating this typical triad, there is a N-glycosylation site (Asn-122 and Asn-149). These last regions are not directly involved in ganglioside binding, so the oligosaccharide linked to these asparagine residues could be perfectly intercalated between the sugar head group of gangliosides.
       <fig id="fig0010">
        <label>
         Fig. 10
        </label>
        <caption>
         <p>
          Amino acid sequence alignments of the ganglioside-binding domain (GBD) of the SARS-CoV-2 spike protein. (a) Clinical SARS-CoV-2 isolates aligned with the reference sequence (6VSB_A, fragment 111–162). The amino acid residues involved in GM1 binding are indicated in red. Two asparagine residues acting as glycosylation sites are highlighted in yellow. (b) Alignments of human and animal viruses compared with SARS-CoV-2 (6VSB_A, fragment 111–162). Deletions are highlighted in green, amino acid changes in residues involved in ganglioside binding are highlighted in blue, conserved residues of the GBD are highlighted in red, and asparagine residues acting as glycosylation sites are highlighted in yellow.
         </p>
        </caption>
        <alt-text id="alt0010">
         Fig 10
        </alt-text>
        <graphic xlink:href="gr10_lrg">
        </graphic>
       </fig>
      </p>
      <p id="para0023">
       It was also noted that the ganglioside-binding domain of the NTD is fully conserved in bat RaTG13, which indicates a close relationship between the bat coronavirus and the human isolates that are currently circulating around the world. However, the motif is slightly different in other bat- and human-related coronaviruses (
       <xref ref-type="fig" rid="fig0010">
        Fig. 10
       </xref>
       ), suggesting a recent evolution which could explain, at least in part, why SARS-CoV-2 is more contagious than previously characterized human coronaviruses.
      </p>
     </sec>
    </sec>
    <sec id="sec0012">
     <label>
      4
     </label>
     <title>
      Discussion
     </title>
     <p id="para0024">
      Sialic acids linked to glycoproteins and gangliosides are used by a broad range of viruses as receptors and/or attachment factors for cell entry
      <xref ref-type="bibr" rid="bib0010">
       [10]
      </xref>
      . These viruses include major human pathogens affecting the respiratory tract, such as influenza
      <xref ref-type="bibr" rid="bib0021">
       [21]
      </xref>
      and coronaviruses
      <xref ref-type="bibr" rid="bib0022">
       [22
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0023">
       23]
      </xref>
      . The attachment to sialic-acid-containing cell surface structures is mediated by receptor-binding proteins that belong to the viral spike. In the case of coronaviruses, this function is fulfilled by the S glycoprotein
      <xref ref-type="bibr" rid="bib0009">
       [9
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0024">
       24]
      </xref>
      . SARS-CoV and SARS-CoV-2 interact with the ACE-2 protein, which has been identified as a key determinant of the contagiousness of viruses
      <xref ref-type="bibr" rid="bib0008">
       [8]
      </xref>
      . However, considering the increased transmissibility of SARS-CoV-2 compared with SARS-CoV, binding to ACE-2 alone might not be enough to ensure robust infection of the upper respiratory tract. Thus, it is likely that SARS-CoV-2 might also bind to other cell surface attachment factors, such as sialic-acid-containing glycoproteins and gangliosides. Consistent with this notion, it has been shown that depletion of cell surface sialic acids by neuraminidase treatment inhibited MERS-CoV entry of human airway cells
      <xref ref-type="bibr" rid="bib0025">
       [25]
      </xref>
      . These data, which provide direct evidence that sialic acids play a critical role in human coronavirus attachment, broaden the therapeutic options to block the replication of SARS-CoV-2 that is responsible for the COVID-19 pandemic.
     </p>
     <p id="para0025">
      Few drugs have shown consistent antiviral efficiency
      <italic>
       in vitro
      </italic>
      together with reported efficiency in patients infected with SARS-CoV-2
      <xref ref-type="bibr" rid="bib0003">
       [3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0012">
       12]
      </xref>
      . Of these, CLQ is of interest as its chemical structure is based on a combination of cationic nitrogen atoms and aromatic rings. Both features have been shown to be key determinants of the recognition of sialic acids and gangliosides by proteins
      <xref ref-type="bibr" rid="bib0020">
       [20
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0026">
       26]
      </xref>
      . Modelling approaches have been used successfully to decipher various molecular mechanisms of protein–sugar interactions accounting for the interaction of virus
      <xref ref-type="bibr" rid="bib0027">
       [27]
      </xref>
      , bacteria
      <xref ref-type="bibr" rid="bib0028">
       [28]
      </xref>
      , membrane
      <xref ref-type="bibr" rid="bib0013">
       [13]
      </xref>
      and amyloid proteins
      <xref ref-type="bibr" rid="bib0020">
       [20]
      </xref>
      with cell surface glycolipids. This in-silico strategy was applied to unravel the molecular mechanisms underlying the antiviral mechanisms of CLQ and CLQ-OH against SARS-CoV-2 infection. First, it was shown that CLQ and CLQ-OH bind readily to sialic acids with high affinity, including the typical 9-O-SIA subtype recognized by coronaviruses
      <xref ref-type="bibr" rid="bib0023">
       [23]
      </xref>
      . Next, it was shown that CLQ and CLQ-OH also bind to sialic-acid-containing gangliosides. Based on these data, the drugs may also recognize the sialic acid residues of glycoproteins. Further studies will help clarify this point.
     </p>
     <p id="para0026">
      This molecular modelling study has identified a new type of ganglioside-binding domain in the NTD of the SARS-CoV-2 S protein. This ganglioside-binding domain consists of a large flat interface enriched in aromatic and basic amino acid residues. It covers a stretch of 52 amino acid residues (111–162), which is longer than all linear ganglioside-binding domains characterized to date
      <xref ref-type="bibr" rid="bib0029">
       [29]
      </xref>
      . However, the new SARS-CoV-2 motif is organized into three distinct regions, including a central aromatic domain and two terminal basic domains (
      <xref ref-type="fig" rid="fig0010">
       Fig. 10
      </xref>
      ). Thus, this motif displays the typical features that determine optimal binding to gangliosides (i.e. CH-π stacking and electrostatic interactions).
     </p>
     <p id="para0027">
      A major outcome of this study is the demonstration that CLQ and CLQ-OH display molecular groups that fully mimic the way in which the S protein binds to gangliosides. Two CLQ (or two CLQ-OH) molecules can bind simultaneously to the polar head group of ganglioside GM1. Interestingly, these simulations indicated that CLQ-OH is more potent than CLQ, in line with the reported increased antiviral activity of CLQ-OH against SARS-CoV-2
      <xref ref-type="bibr" rid="bib0030">
       [30]
      </xref>
      . Once bound to GM1, the drugs prevent any access to the Glc and GalNAc units of the ganglioside, which are the critical binding residues for Phe-135 and Asn-137, respectively. This amino acid dyad, as well as all the other residues that mediate ganglioside binding by the SARS-CoV-2 spike, is fully conserved among clinical isolates worldwide. It is also conserved in the bat RaTG13 isolate, which reinforces the hypothesis of bat-to-human transmission. From an epidemiological point of view, it can be hypothesized that the evolution of this motif has conferred an enhanced attachment capacity of human coronaviruses to the respiratory tract through improved S–ganglioside interactions.
     </p>
    </sec>
    <sec id="sec0013">
     <label>
      5
     </label>
     <title>
      Conclusion
     </title>
     <p id="para0028">
      Given the global health emergency, drug repurposing is obviously the option of choice
      <xref ref-type="bibr" rid="bib0002">
       [2
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0003">
       3]
      </xref>
      . However, a considerable amount of time could be saved by in-silico testing to determine the capability of any potential anti-SARS-CoV-2 to disrupt the interaction of the S protein with the host cell membrane. Applied to both RBD–ACE-2 and NTD–ganglioside interactions, this molecular modelling method will help select those drugs that are likely to interfere with the initial attachment of virus particles to the respiratory tract surface epithelium. The study data support the use of CLQ, and preferentially CLQ-OH, as initial therapy for patients infected with SARS-CoV-2.
     </p>
    </sec>
    <back>
     <ref-list id="cebibl1">
      <title>
       References
      </title>
      <ref id="bib0001">
       <label>
        1
       </label>
       <element-citation id="sbref0001" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A pneumonia outbreak associated with a new coronavirus of probable bat origin
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         579
        </volume>
        <year>
         2020
        </year>
        <fpage>
         270
        </fpage>
        <lpage>
         273
        </lpage>
        <pub-id pub-id-type="pmid">
         32015507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0002">
       <label>
        2
       </label>
       <element-citation id="sbref0002" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mullard
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drug repurposing programmes get lift off
        </article-title>
        <source>
         Nat Rev Drug Discov
        </source>
        <volume>
         11
        </volume>
        <year>
         2012
        </year>
        <fpage>
         505
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="pmid">
         22743966
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0003">
       <label>
        3
       </label>
       <element-citation id="sbref0003" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine for the 2019 novel coronavirus SARS-CoV-2
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <volume>
         55
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         105923
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0004">
       <label>
        4
       </label>
       <element-citation id="sbref0004" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
        </article-title>
        <source>
         Biosci Trends
        </source>
        <year>
         2020 Feb 19
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0005">
       <label>
        5
       </label>
       <element-citation id="sbref0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Di Trani
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Donatelli
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         New insights into the antiviral effects of chloroquine
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         6
        </volume>
        <year>
         2006
        </year>
        <fpage>
         67
        </fpage>
        <lpage>
         69
        </lpage>
        <pub-id pub-id-type="pmid">
         16439323
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0006">
       <label>
        6
       </label>
       <element-citation id="sbref0006" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mauthe
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Orhon
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Rocchi
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Luhr
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hijlkema
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibits autophagic flux by decreasing autophagosome–lysosome fusion
        </article-title>
        <source>
         Autophagy
        </source>
        <volume>
         14
        </volume>
        <year>
         2018
        </year>
        <fpage>
         1435
        </fpage>
        <lpage>
         1455
        </lpage>
        <pub-id pub-id-type="pmid">
         29940786
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0007">
       <label>
        7
       </label>
       <element-citation id="sbref0007" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bergeron
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Benjannet
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Erickson
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         2
        </volume>
        <year>
         2005
        </year>
        <fpage>
         69
        </fpage>
        <pub-id pub-id-type="pmid">
         16115318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0008">
       <label>
        8
       </label>
       <element-citation id="sbref0008" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0009">
       <label>
        9
       </label>
       <element-citation id="sbref0009" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2
        </article-title>
        <source>
         Science
        </source>
        <year>
         2020 Mar 4
        </year>
        <comment>
         pii: eabb2762[Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <label>
        10
       </label>
       <element-citation id="sbref0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matrosovich
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Herrler
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Klenk
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sialic acid receptors of viruses
        </article-title>
        <source>
         Top Curr Chem
        </source>
        <volume>
         367
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         28
        </lpage>
        <pub-id pub-id-type="pmid">
         23873408
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0011">
       <label>
        11
       </label>
       <element-citation id="sbref0011" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Di Scala
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fantini
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hybrid in silico/in vitro approaches for the identification of functional cholesterol-binding domains in membrane proteins
        </article-title>
        <source>
         Methods Mol Biol
        </source>
        <volume>
         1583
        </volume>
        <year>
         2017
        </year>
        <fpage>
         7
        </fpage>
        <lpage>
         19
        </lpage>
        <pub-id pub-id-type="pmid">
         28205163
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0012">
       <label>
        12
       </label>
       <element-citation id="sbref0012" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lagier
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020 Mar 4
        </year>
        <object-id pub-id-type="publisher-id">
         105932
        </object-id>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0013">
       <label>
        13
       </label>
       <element-citation id="sbref0013" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Flores
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ramirez-Franco
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Desplantes
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Debreux
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Ferracci
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wernert
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         116
        </volume>
        <year>
         2019
        </year>
        <fpage>
         18098
        </fpage>
        <lpage>
         18108
        </lpage>
        <pub-id pub-id-type="pmid">
         31431523
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0014">
       <label>
        14
       </label>
       <element-citation id="sbref0014" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Di Scala
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wandall
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Fantini
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The glycosphingolipid MacCer promotes synaptic bouton formation in drosophila by interacting with Wnt
        </article-title>
        <source>
         Elife
        </source>
        <volume>
         7
        </volume>
        <year>
         2018
        </year>
        <comment>
         pii:e38183
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <label>
        15
       </label>
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ståhle
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kern
          </surname>
          <given-names>
           N.R.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         CHARMM-GUI membrane builder for complex biological membrane simulations with glycolipids and lipoglycans
        </article-title>
        <source>
         J Chem Theory Comput
        </source>
        <volume>
         15
        </volume>
        <year>
         2019
        </year>
        <fpage>
         775
        </fpage>
        <lpage>
         786
        </lpage>
        <pub-id pub-id-type="pmid">
         30525595
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0016">
       <label>
        16
       </label>
       <element-citation id="sbref0016" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wrapp
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Abiona
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
        </article-title>
        <source>
         Science
        </source>
        <volume>
         367
        </volume>
        <year>
         2020
        </year>
        <fpage>
         1260
        </fpage>
        <lpage>
         1263
        </lpage>
        <pub-id pub-id-type="pmid">
         32075877
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0017">
       <label>
        17
       </label>
       <element-citation id="sbref0017" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guvench
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Greene
          </surname>
          <given-names>
           S.N.
          </given-names>
         </name>
         <name>
          <surname>
           Kamath
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Brady
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Venable
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Pastor
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Additive empirical force field for hexopyranose monosaccharides
        </article-title>
        <source>
         J Comput Chem
        </source>
        <volume>
         29
        </volume>
        <year>
         2008
        </year>
        <fpage>
         2543
        </fpage>
        <lpage>
         2564
        </lpage>
        <pub-id pub-id-type="pmid">
         18470966
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0018">
       <label>
        18
       </label>
       <element-citation id="sbref0018" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Sauer
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Tortorici
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors
        </article-title>
        <source>
         Nat Struct Mol Biol
        </source>
        <volume>
         26
        </volume>
        <year>
         2019
        </year>
        <fpage>
         1151
        </fpage>
        <lpage>
         1157
        </lpage>
        <pub-id pub-id-type="pmid">
         31792450
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0019">
       <label>
        19
       </label>
       <element-citation id="sbref0019" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huta
          </surname>
          <given-names>
           B.P.
          </given-names>
         </name>
         <name>
          <surname>
           Mehlenbacher
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Nie
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zubieta
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Bou-Abdallah
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The lysosomal protein saposin B binds chloroquine
        </article-title>
        <source>
         Chem Med Chem
        </source>
        <volume>
         11
        </volume>
        <year>
         2016
        </year>
        <fpage>
         277
        </fpage>
        <lpage>
         382
        </lpage>
        <pub-id pub-id-type="pmid">
         26616259
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <label>
        20
       </label>
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yahi
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fantini
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deciphering the glycolipid code of Alzheimer's and Parkinson's amyloid proteins allowed the creation of a universal ganglioside-binding peptide
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         9
        </volume>
        <year>
         2014
        </year>
        <object-id pub-id-type="publisher-id">
         e104751
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0021">
       <label>
        21
       </label>
       <element-citation id="sbref0021" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Verma
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Gupta
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lal
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host lipid rafts play a major role in binding and endocytosis of influenza A virus
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         10
        </volume>
        <year>
         2018
        </year>
        <comment>
         pii:E650
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0022">
       <label>
        22
       </label>
       <element-citation id="sbref0022" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.X.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lipid rafts are involved in SARS-CoV entry into Vero E6 cells
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <volume>
         369
        </volume>
        <year>
         2008
        </year>
        <fpage>
         344
        </fpage>
        <lpage>
         349
        </lpage>
        <pub-id pub-id-type="pmid">
         18279660
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0023">
       <label>
        23
       </label>
       <element-citation id="sbref0023" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tortorici
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Koerhuis
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural basis for human coronavirus attachment to sialic acid receptors
        </article-title>
        <source>
         Nat Struct Mol Biol
        </source>
        <volume>
         26
        </volume>
        <year>
         2019
        </year>
        <fpage>
         481
        </fpage>
        <lpage>
         489
        </lpage>
        <pub-id pub-id-type="pmid">
         31160783
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0024">
       <label>
        24
       </label>
       <element-citation id="sbref0024" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kleine-Weber
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Schroeder
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Krüger
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Herrler
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Erichsen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
        </article-title>
        <source>
         Cell
        </source>
        <year>
         2020
        </year>
        <comment>
         pii:S0092-8674(20)30229-4[Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <label>
        25
       </label>
       <element-citation id="sbref0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Hulswit
          </surname>
          <given-names>
           R.J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Widjaja
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           McBride
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         114
        </volume>
        <year>
         2017
        </year>
        <fpage>
         E8508
        </fpage>
        <lpage>
         E8517
        </lpage>
        <pub-id pub-id-type="pmid">
         28923942
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0026">
       <label>
        26
       </label>
       <element-citation id="sbref0026" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fantini
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yahi
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases
        </article-title>
        <source>
         Expert Rev Mol Med
        </source>
        <volume>
         12
        </volume>
        <year>
         2010
        </year>
        <fpage>
         e27
        </fpage>
        <pub-id pub-id-type="pmid">
         20807455
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0027">
       <label>
        27
       </label>
       <element-citation id="sbref0027" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mahfoud
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Garmy
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Maresca
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yahi
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Puigserver
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fantini
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         277
        </volume>
        <year>
         2002
        </year>
        <fpage>
         11292
        </fpage>
        <lpage>
         11296
        </lpage>
        <pub-id pub-id-type="pmid">
         11792705
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0028">
       <label>
        28
       </label>
       <element-citation id="sbref0028" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fantini
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Garmy
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Yahi
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prediction of glycolipid-binding domains from the amino acid sequence of lipid raft-associated proteins: application to HpaA, a protein involved in the adhesion of
         <italic>
          Helicobacter pylori
         </italic>
         to gastrointestinal cells
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         45
        </volume>
        <year>
         2006
        </year>
        <fpage>
         10957
        </fpage>
        <lpage>
         10962
        </lpage>
        <pub-id pub-id-type="pmid">
         16953581
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0029">
       <label>
        29
       </label>
       <element-citation id="sbref0029" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fantini
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yahi
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Brain lipids in synaptic function and neurological disease. Clues to innovative therapeutic strategies for brain disorders
        </chapter-title>
        <year>
         2015
        </year>
        <publisher-name>
         Elsevier
        </publisher-name>
        <publisher-loc>
         San Francisco
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <label>
        30
       </label>
       <element-citation id="sbref0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2020 Mar 9
        </year>
        <comment>
         pii:ciaa237
        </comment>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0001">
      <p>
       <bold>
        Funding:
       </bold>
       None.
      </p>
      <p>
       <bold>
        Competing interests:
       </bold>
       None declared.
      </p>
      <p>
       <bold>
        Ethical approval:
       </bold>
       Not required.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="letter" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Lancet Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Lancet Infect Dis
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Lancet. Infectious Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1473-3099
      </issn>
      <issn pub-type="epub">
       1474-4457
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       16439323
      </article-id>
      <article-id pub-id-type="pmc">
       7129107
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1473-3099(06)70361-9
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/S1473-3099(06)70361-9
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        New insights into the antiviral effects of chloroquine
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Savarino
         </surname>
         <given-names>
          Andrea
         </given-names>
        </name>
        <degrees>
         Dr
        </degrees>
        <email>
         asavarino@medscape.com
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Di Trani
         </surname>
         <given-names>
          Livia
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Donatelli
         </surname>
         <given-names>
          Isabella
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cauda
         </surname>
         <given-names>
          Roberto
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cassone
         </surname>
         <given-names>
          Antonio
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Department of Infectious Diseases, Università Cattolica del Sacro Cuore, Rome, Italy
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Department of Food and Animal Health, Istituto Superiore di Sanità, Rome
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Correspondence to: Dr Andrea Savarino, Laboratory of Viral Immunology, Department of Infectious Diseases, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, I-00168 Rome, Italy. Tel +39 06 30155374; fax +39 06 3054519
        <email>
         asavarino@medscape.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        24
       </day>
       <month>
        1
       </month>
       <year>
        2006
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        2
       </month>
       <year>
        2006
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        24
       </day>
       <month>
        1
       </month>
       <year>
        2006
       </year>
      </pub-date>
      <volume>
       6
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       67
      </fpage>
      <lpage>
       69
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2006 Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2006
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
     </article-meta>
    </front>
    <p id="para10">
     In a paper published 2 years ago in this journal, some of us described the potentially therapeutic benefits of the quinoline antimalarial chloroquine in viral diseases such as HIV-1/AIDS and severe acute respiratory syndrome (SARS).
     <xref ref-type="bibr" rid="bib1">
      <sup>
       1
      </sup>
     </xref>
     Chloroquine/hydroxychloroquine has since been adopted to treat HIV-1-infected patients in clinical trials, and new insights into its antiviral activity have been obtained from in-vitro studies.
    </p>
    <p id="para20">
     On the HIV/AIDS front, chloroquine (250 mg twice daily) has been administered to HIV-1-infected patients with baseline viral loads over 50 000 copies per mL, in combination with lamivudine (150 mg twice daily) and hydroxyurea (500 mg twice daily) in an ongoing clinical trial in India.
     <xref ref-type="bibr" rid="bib2">
      <sup>
       2
      </sup>
     </xref>
     Ten out of 18 volunteers had an undetectable viral load at week 24.
     <xref ref-type="bibr" rid="bib2">
      <sup>
       2
      </sup>
     </xref>
     The median drop in viral load was more than 2·0 log,
     <xref ref-type="bibr" rid="bib2">
      <sup>
       2
      </sup>
     </xref>
     more than the median 1·5 log drop seen with a nucleoside reverse transcriptase inhibitor (NRTI) and hydroxyurea alone.
     <xref ref-type="bibr" rid="bib3">
      <sup>
       3
      </sup>
     </xref>
    </p>
    <p id="para30">
     These results are different from those of another trial in Singapore using didanosine (125–250 mg twice daily), hydroxyurea (500 mg twice daily), and hydroxychloroquine (200 mg twice daily, corresponding to 125 mg of chloroquine).
     <xref ref-type="bibr" rid="bib1">
      <sup>
       1
      </sup>
     </xref>
     The median drop in viral load was 1·3 log, similar to that induced by a NRTI plus hydroxyurea. Follow-up of these patients at week 144 suggests that the value of hydroxychloroquine may lie in the maintenance of the effects of didanosine/hydroxyurea.
     <xref ref-type="bibr" rid="bib4">
      <sup>
       4
      </sup>
     </xref>
    </p>
    <p id="para40">
     The discrepancy between the two studies, besides differences in the design and patients enrolled, probably reflects the different dosages of chloroquine/hydroxychloroquine. Drops in viral load are reported to occur using daily doses of 800 mg of hydroxychloroquine,
     <xref ref-type="bibr" rid="bib1">
      <sup>
       1
      </sup>
     </xref>
     corresponding to 500 mg of chloroquine (as used in the Indian study), but not using 250 mg of chloroquine daily,
     <xref ref-type="bibr" rid="bib5">
      <sup>
       5
      </sup>
     </xref>
     corresponding to 400 mg of hydroxychloroquine (as adopted in the Singapore study). Chloroquine/hydroxychloroquine might thus be a valuable option to be tested in low-cost antiretroviral combinations, but correct dosages should be used, considering that the study participants should be regularly monitored to prevent retinopathy. Prospective randomised double-blind placebo studies are also needed to assess the contribution of chloroquine/hydroxychloroquine as part of an antiretroviral regimen. According to new in-vitro results, the antiretroviral effects of chloroquine are attributable to the inhibition of viral particle glycosylation.
     <xref ref-type="bibr" rid="bib6">
      <sup>
       6
      </sup>
     </xref>
     These effects appeared to be specific, since the chloroquine concentrations effective in vitro neither affected any other step in HIV-1 replication nor were cytotoxic.
     <xref ref-type="bibr" rid="bib6">
      <sup>
       6
      </sup>
     </xref>
    </p>
    <p id="para50">
     Our hypothesis that chloroquine might inhibit replication of the SARS coronavirus
     <xref ref-type="bibr" rid="bib1">
      <sup>
       1
      </sup>
     </xref>
     has been confirmed in two independent in-vitro studies.
     <xref ref-type="bibr" rid="bib7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="bib8">
      8
     </xref>
     Researchers at the Belgian Catholic University of Leuven found that chloroquine inhibited SARS coronavirus replication with a 50% effective concentration of 8·8 (SE 1·2) μmol/L, within the range of blood concentrations achievable during antimalarial treatment.
     <xref ref-type="bibr" rid="bib7">
      <sup>
       7
      </sup>
     </xref>
     The dose inducing 50% cytostatic activity was much higher (261·3 [14·5] μmol/L). Time-of-addition experiments indicated that chloroquine affected an early stage of SARS coronavirus replication.
     <xref ref-type="bibr" rid="bib7">
      <sup>
       7
      </sup>
     </xref>
     Researchers at the Centers for Disease Control and Prevention (Atlanta, GA, USA) reported potent anti-SARS coronavirus effects of chloroquine in vitro, attributable to a deficit in the glycosylation of the SARS coronavirus receptor ACE2.
     <xref ref-type="bibr" rid="bib8">
      <sup>
       8
      </sup>
     </xref>
     Again, the antiviral drug concentrations were not cytotoxic. If animal models confirm these results, chloroquine might represent a valuable therapeutic option if SARS re-emerges.
    </p>
    <p id="para60">
     The broad spectrum antiviral effects of chloroquine deserve particular attention in a time in which the world is threatened by the possibility of a new influenza pandemic, and the availability of effective drugs would be fundamental during evaluation of an effective vaccine. The effect of chloroquine against replication of Orthomyxoviridae has long been known.
     <xref ref-type="bibr" rid="bib9">
      9
     </xref>
     ,
     <xref ref-type="bibr" rid="bib10">
      10
     </xref>
     Inhibitory effects of chloroquine on both type A and B influenza viruses have been described.
     <xref ref-type="bibr" rid="bib9">
      9
     </xref>
     ,
     <xref ref-type="bibr" rid="bib10">
      10
     </xref>
     We are currently investigating the inhibitory effect of chloroquine on the H5N9/A/chicken/Italy/9097/97 avian influenza virus, recently isolated from poultry in Italy.
     <xref ref-type="bibr" rid="bib11">
      <sup>
       11
      </sup>
     </xref>
     Depending on the viral challenging doses and the methods adopted to detect the antiviral effects, the inhibitory concentrations fell within the 0·5–10 μmol/L range—ie, clinically achievable in plasma during malaria treatment (LDT, AS, ID, RC, and AC, unpublished data). If these effects are confirmed, chloroquine would deserve to be tested against the H5N1 type A avian influenza virus, currently a matter of serious concern for public health.
    </p>
    <p id="para70">
     As discussed above, glycosylation inhibition might represent a major mechanism for the antiviral effects of chloroquine, suggesting that specific interactions of chloroquine with sugar-modifying enzymes or glycosyltransferases may occur within human cells (
     <xref ref-type="fig" rid="fig1">
      figure
     </xref>
     ). Chloroquine was recently shown to inhibit quinone reductase 2,
     <xref ref-type="bibr" rid="bib13">
      <sup>
       13
      </sup>
     </xref>
     a structural neighbour of UDP-N-acetylglucosamine 2-epimerases,
     <xref ref-type="bibr" rid="bib14">
      <sup>
       14
      </sup>
     </xref>
     which are involved in sialic acid biosynthesis. If chloroquine should indeed inhibit the biosynthesis of sialic acid, this effect could explain not only the effects of chloroquine on HIV and SARS coronavirus (sialic acid moieties are present in HIV-1 glycoproteins and SARS coronavirus receptor ACE2), but also the in-vitro effects on orthomyxoviruses (which use sialic acid moieties as receptors
     <xref ref-type="bibr" rid="bib15">
      <sup>
       15
      </sup>
     </xref>
     ). These effects deserve further investigation, in that they may lead to new strategies controlling the replication of several viruses.
     <fig id="fig1">
      <label>
       Figure
      </label>
      <caption>
       <p>
        Can chloroquine interact with sugar-modifying enzymes?
       </p>
       <p>
        This computer-assisted simulation of ligand/protein docking by use of the program GOLD
        <xref ref-type="bibr" rid="bib12">
         <sup>
          12
         </sup>
        </xref>
        indicates that chloroquine (red) fits to the active site of UDP-N-acetylglucosamine 2-epimerase (grey). This evidence suggests that chloroquine could inhibit the enzyme that catalyses the rate-determining step in the sialic acid biosynthetic pathway.
       </p>
      </caption>
      <graphic xlink:href="gr1_lrg">
      </graphic>
     </fig>
    </p>
    <back>
     <ref-list id="bibl10">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Boelaert
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Majori
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of chloroquine on viral infections: an old drug against today's diseases?
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         3
        </volume>
        <year>
         2003
        </year>
        <fpage>
         722
        </fpage>
        <lpage>
         727
        </lpage>
        <pub-id pub-id-type="pmid">
         14592603
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Joshi
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Butala
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Patwardhan
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Daver
          </surname>
          <given-names>
           NG
          </given-names>
         </name>
         <name>
          <surname>
           Kelkar
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy
        </article-title>
        <source>
         J Assoc Phys India
        </source>
        <volume>
         52
        </volume>
        <year>
         2004
        </year>
        <fpage>
         597
        </fpage>
        <lpage>
         598
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lori
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Foli
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Groff
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic (‘virostatic’) mechanisms
        </article-title>
        <source>
         AIDS
        </source>
        <volume>
         19
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1173
        </fpage>
        <lpage>
         1181
        </lpage>
        <pub-id pub-id-type="pmid">
         15990570
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paton
          </surname>
          <given-names>
           NI
          </given-names>
         </name>
         <name>
          <surname>
           Aboulhab
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks
        </article-title>
        <source>
         HIV Med
        </source>
        <volume>
         6
        </volume>
        <year>
         2005
        </year>
        <fpage>
         13
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="pmid">
         15670247
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <mixed-citation publication-type="other">
        Luchters SMF, Veldhuijzen NJ, Nsanzabera D. et al. A phase I/II randomised placebo controlled study to evaluate chloroquine administration to reduce HIV-1 RNA in breast milk in an HIV-1 infected breastfeeding population: the CHARGE Study. XV International Conference on AIDS; Bangkok, Thailand; July 11–16, 2004. Abstract TuPeB4499.
       </mixed-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lucia
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Rastrelli
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors
        </article-title>
        <source>
         J Acquir Immune Defic Syndr
        </source>
        <volume>
         35
        </volume>
        <year>
         1996
        </year>
        <fpage>
         223
        </fpage>
        <lpage>
         232
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Maes
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Neyts
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Van Ranst
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <volume>
         323
        </volume>
        <year>
         2004
        </year>
        <fpage>
         264
        </fpage>
        <lpage>
         268
        </lpage>
        <pub-id pub-id-type="pmid">
         15351731
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Bergeron
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Benjannet
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
        </article-title>
        <source>
         Virol J
        </source>
        <volume>
         2
        </volume>
        <year>
         2005
        </year>
        <fpage>
         69
        </fpage>
        <pub-id pub-id-type="pmid">
         16115318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           Lenard
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antihistaminics, local anesthetics, and other amines as antiviral agents
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         78
        </volume>
        <year>
         1981
        </year>
        <fpage>
         3605
        </fpage>
        <lpage>
         3609
        </lpage>
        <pub-id pub-id-type="pmid">
         6115382
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shibata
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Aoki
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Tsurumi
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         64
        </volume>
        <year>
         1983
        </year>
        <fpage>
         1149
        </fpage>
        <lpage>
         1156
        </lpage>
        <pub-id pub-id-type="pmid">
         6842189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donatelli
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Campitelli
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Di Trani
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of H5N2 influenza viruses from Italian poultry
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         82
        </volume>
        <year>
         2001
        </year>
        <fpage>
         623
        </fpage>
        <lpage>
         630
        </lpage>
        <pub-id pub-id-type="pmid">
         11172104
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Willett
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Glen
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name>
          <surname>
           Leach
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and validation of a genetic algorithm for flexible docking
        </article-title>
        <source>
         J Mol Biol
        </source>
        <volume>
         267
        </volume>
        <year>
         1997
        </year>
        <fpage>
         727
        </fpage>
        <lpage>
         748
        </lpage>
        <pub-id pub-id-type="pmid">
         9126849
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kwiek
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Haystead
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Rudolph
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         43
        </volume>
        <year>
         2004
        </year>
        <fpage>
         4538
        </fpage>
        <lpage>
         4547
        </lpage>
        <pub-id pub-id-type="pmid">
         15078100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <collab>
          National Center for Biotechnology Information
         </collab>
        </person-group>
        <article-title>
         MMDB—Entrez's Structure Database
        </article-title>
        <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/Structure/MMDB/mmdb.shtml">
         http://www.ncbi.nlm.nih.gov/Structure/MMDB/mmdb.shtml
        </ext-link>
        <comment>
         (accessed Dec 14, 2005)
        </comment>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Olofsson
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kumlin
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Dimock
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Arnberg
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Avian influenza and sialic acid receptors: more than meets the eye?
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         5
        </volume>
        <year>
         2005
        </year>
        <fpage>
         184
        </fpage>
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="pmid">
         15766653
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Clin Rheumatol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Clin. Rheumatol
      </journal-id>
      <journal-title-group>
       <journal-title>
        Clinical Rheumatology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0770-3198
      </issn>
      <issn pub-type="epub">
       1434-9949
      </issn>
      <publisher>
       <publisher-name>
        Springer London
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7145936
      </article-id>
      <article-id pub-id-type="publisher-id">
       5073
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/s10067-020-05073-9
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Perspectives in Rheumatology
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">
         https://orcid.org/0000-0002-5035-7396
        </contrib-id>
        <name>
         <surname>
          Misra
         </surname>
         <given-names>
          Durga Prasanna
         </given-names>
        </name>
        <address>
         <email>
          durgapmisra@gmail.com
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">
         https://orcid.org/0000-0002-4508-1233
        </contrib-id>
        <name>
         <surname>
          Agarwal
         </surname>
         <given-names>
          Vikas
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">
         https://orcid.org/0000-0001-8749-6018
        </contrib-id>
        <name>
         <surname>
          Gasparyan
         </surname>
         <given-names>
          Armen Yuri
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">
         https://orcid.org/0000-0002-4188-8486
        </contrib-id>
        <name>
         <surname>
          Zimba
         </surname>
         <given-names>
          Olena
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.263138.d
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0000 9346 7267
         </institution-id>
         <institution>
          Department of Clinical Immunology and Rheumatology,
         </institution>
         <institution>
          Sanjay Gandhi Postgraduate Institute of Medical Sciences,
         </institution>
        </institution-wrap>
        Lucknow, India
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.464540.7
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0004 0469 4759
         </institution-id>
         <institution>
          Departments of Rheumatology and Research and Development,
         </institution>
         <institution>
          Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK),
         </institution>
        </institution-wrap>
        Russells Hall Hospital, Dudley, West Midlands UK
       </aff>
       <aff id="Aff3">
        <label>
         3
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.411517.7
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0004 0563 0685
         </institution-id>
         <institution>
          Department of Internal Medicine #2,
         </institution>
         <institution>
          Danylo Halytsky Lviv National Medical University,
         </institution>
        </institution-wrap>
        Lviv, Ukraine
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        10
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <fpage>
       1
      </fpage>
      <lpage>
       8
      </lpage>
      <history>
       <date date-type="received">
        <day>
         24
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         29
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         31
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © International League of Associations for Rheumatology (ILAR) 2020
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p id="Par1">
        The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren’s syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still’s disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.
        <table-wrap id="Taba">
         <table frame="hsides" rules="groups">
          <tbody>
           <tr>
            <td colspan="2">
             <p>
              <bold>
               Key Points
              </bold>
             </p>
             <p>
              <italic>
               • Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.
              </italic>
             </p>
             <p>
              <italic>
               • Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.
              </italic>
             </p>
             <p>
              <italic>
               • Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.
              </italic>
             </p>
            </td>
           </tr>
          </tbody>
         </table>
        </table-wrap>
       </p>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        Epidemiology
       </kwd>
       <kwd>
        Hydroxychloroquine
       </kwd>
       <kwd>
        Hypothesis
       </kwd>
       <kwd>
        Immunity
       </kwd>
       <kwd>
        Pathogenesis
       </kwd>
       <kwd>
        Vaccines
       </kwd>
       <kwd>
        Vitamin D
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Introduction
     </title>
     <p id="Par2">
      The pandemic resulting from coronavirus disease 19 (COVID-19) caused by the ribonucleic acid (RNA) virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged a few months ago in Wuhan, China, and has claimed more than 30,000 victims worldwide [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      –
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ]. After an initial explosive outbreak of pneumonia of unknown etiology in China, the disease spread first to neighboring Asian countries and then worldwide. The trajectory of COVID-19 spread may remind us of the ancient Silk Route disease, now called Behcet’s syndrome, which affected certain ethnicities, transformed into multisystem neutrophilic disorder and migrated from Asia to Europe millennia ago. The United States of America, Italy, Spain, China, Germany and Iran are now the leading countries with most confirmed cases and related deaths [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. The detection of SARS-CoV-2 infection relies on a polymerase chain reaction (PCR) analysis of samples from throat and nasal swabs [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ]. Reporting of the results of the PCR tests to the World Health Organization (WHO) has resulted in mapping the disease transmission and distinguishing continental Europe and North America as the current hotbed of this pandemic [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. The dynamics of this pandemic raises concerns over the safety of the global human population and necessitates responsible actions of the whole society. Patients affected with rheumatic diseases represent a particularly vulnerable group, considering that they might be on immunosuppressive therapy. In this article, we provide the perspectives of a rheumatologist on COVID-19, including rheumatic manifestations associated with this disease, and special considerations for this group of patients. We also discuss potential therapeutic targets for management of COVID-19, some of which are commonly used in rheumatology practice.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Risk factors for severe COVID-19
     </title>
     <p id="Par3">
      Crude fatality rates vary globally from 5.6 to 15.2% [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ], with a greater risk of dying for elderly individuals and those with comorbid conditions such as hypertension and diabetes mellitus [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ]. A pooled analysis of 46,248 cases revealed that hypertension (17%, 95% confidence interval [CI] 14–22%), diabetes mellitus (8%, 95% CI 6–11%), cardiovascular disease (5%, 95% CI 4–7%) and respiratory morbidity (2%, 95% CI 1–3%) are the most prevalent comorbidities [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. Smoking appears to increase the risk of adverse outcomes in COVID-19 [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ]. It may increase the expression of angiotensin-converting enzyme 2 (ACE2) in Asian current smokers and make them prone to COVID-19 [
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ]. Air pollution may also increase the risk of severe COVID-19. High mortality due to COVID-19 in some countries and air pollution are possibly associated [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ]. Rheumatologists should be aware of these risk factors for severe COVID-19 as these are also likely to be operational in their patients with rheumatic diseases.
     </p>
    </sec>
    <sec id="Sec3">
     <title>
      Manifestations of COVID-19 which may mimic rheumatic diseases
     </title>
     <p id="Par4">
      Clinical presentation of COVID-19 ranges from asymptomatic to severe pneumonia. Based on the WHO analysis of 55,924 confirmed cases, fever (87.9%), dry cough (67.7%) and fatigue (38.1%) are common symptoms of the infection [
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ]. Myalgia or arthralgia (14.8%) are also among typical symptoms [
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ]. Acute bilateral interstitial pneumonia is the major cause of morbidity and mortality in COVID-19. Early diagnosis of pneumonia is preferably based on high-resolution computed tomography since chest radiography can miss pulmonary infiltrates at early stages of the disease [
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ]. The dynamics of platelet count and its low level may predict severe course and lethal outcome in COVID-19 pneumonia. A recent systematic review identified greater odds of severe COVID-19 in those patients with thrombocytopenia (odds ratio 5.1, 95% CI 1.8–14.6) [
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      ]. Also, severe course is typically associated with low lymphocyte, high leucocyte counts and elevated neutrophil-lymphocyte ratio [
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
      ]. Acute interstitial pneumonia, lymphopenia and thrombocytopenia may also be seen with disease activity in systemic lupus erythematosus and Sjogren’s syndrome. Hence, the development of such features in patients with these underlying diseases might result in clinical confusion as to whether this is infective or autoimmune in origin.
     </p>
     <p id="Par5">
      Uncontrolled release of inflammatory cytokines such as interleukin (IL)-1ß, IL-6, monocyte chemoattractant protein 1, associated with increased serum ferritin levels and decreased natural killer cell function may result in cytokine storm syndromes [
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      ]. In conjunction with profound immunosuppression, this may suggest secondary hemophagocytic lymphohistiocytosis (HLH), an entity also associated with rheumatic diseases such as systemic lupus erythematosus and systemic onset juvenile idiopathic arthritis. Emerging evidence suggests that a subset of patients (up to one-fourth of patients in some instances) with severe COVID-19 can have myocardial dysfunction or myocarditis [
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      ]. Anecdotal reports suggest benefit with intravenous immunoglobulin with resolution of myocarditis and recovery of cardiogenic shock by 3 weeks [
      <xref ref-type="bibr" rid="CR18">
       18
      </xref>
      ]. Similarly, patients with COVID-19 have been found to have elevated D-dimer levels and may be at greater risk of venous thromboembolism, although this needs to be prospectively studied and validated in the future [
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      ]. Table
      <xref ref-type="table" rid="Tab1">
       1
      </xref>
      summarizes the manifestations associated with COVID-19 which may mimic rheumatic syndromes.
      <table-wrap id="Tab1">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Manifestations associated with coronavirus disease 19 (COVID-19) mimicking rheumatic syndromes
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <tbody>
         <tr>
          <td colspan="2">
           1. Arthralgias and Myalgias
          </td>
         </tr>
         <tr>
          <td colspan="2">
           2. Cytopenias: leucopenia (predominantly lymphopenia); thrombocytopenia
          </td>
         </tr>
         <tr>
          <td colspan="2">
           3. Acute interstitial pneumonia-like presentation
          </td>
         </tr>
         <tr>
          <td colspan="2">
           4. Myocarditis
          </td>
         </tr>
         <tr>
          <td colspan="2">
           5. Secondary hemophagocytic lymphohistiocytosis and cytokine storm
          </td>
         </tr>
         <tr>
          <td colspan="2">
           6. Possible greater risk of venous thromboembolism
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
    </sec>
    <sec id="Sec4">
     <title>
      Potential drug targets for COVID-19
     </title>
     <p id="Par6">
      Various drugs are being investigated for their potential utility in COVID-19. Improved understanding of molecular mechanisms regulating infection with this virus and the subsequent immune responses can pave the way for empirical approaches and trials at this stage.
     </p>
     <p id="Par7">
      Molecular evidence suggests that SARS-CoV-2 utilizes ACE2 receptor for cellular entry (Fig.
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ). ACE2 is expressed on numerous cells, including the epithelial cells of oral mucosa and surfactant-producing type 2 pneumocytes [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      ]. Type 2 pneumocytes are targets in severe COVID-19 [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ]. Presumably, ACE2 is more expressed in Asians than in Whites or African Americans [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ]. Likewise, patients with hypertension and those treated with ACE inhibitors and angiotensin receptor blockers may have overly expressed ACE2, inviting the virus into the lower airways and resulting in severe COVID-19. In this regard, soluble recombinant human ACE2 protein may be a promising therapeutic agent in subjects contracting the virus [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ]. Also, angiotensin II receptor antagonist losartan is postulated to exert a protective action [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ]. At this stage, it must be emphasized that current evidence does not favour either addition or discontinuation of ACE inhibitors or angiotensin receptor antagonists in patients with COVID-19, as recommended presently by cardiology societies [
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      ]. From the rheumatologist’s perspective, there exists a school of thought that the commonly used non-steroidal anti-inflammatory drug ibuprofen is believed to increase the expression of ACE2 [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ] and result in severe course and complications in COVID-19 [
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
      ]. Such a belief is based on anecdotal reports, pointing to paracetamol as a safer option for those in need of non-steroidal anti-inflammatory therapy. While this is an evolving area of knowledge and contradictory opinions are expressed in the published literature [
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
      ], the authors opine that until clearer evidence emerges, it may be prudent to rely on specific circumstances and, if possible, avoid using ibuprofen during this pandemic.
      <fig id="Fig1">
       <label>
        Fig. 1
       </label>
       <caption>
        <p>
         Potential therapeutic targets for SARS-CoV-2 and COVID-19. AAK1–AP2-associated protein kinase 1; ACE–angiotensin-converting enzyme; ARB–angiotensin receptor blocker; COVID-19–coronavirus disease 19; CQ–chloroquine; HCQ–hydroxychloroquine; IL–interleukin; JAK–Janus kinase; SARS-CoV-2–severe acute respiratory syndrome coronavirus 2; TLR–toll-like receptor; TMPRSS2–serine protease enzyme
        </p>
       </caption>
       <graphic id="MO1" xlink:href="10067_2020_5073_Fig1_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par8">
      Once the SARS-COV-2 enters the cell, it utilizes the cellular machinery to generate viral proteins and RNA, synthesize and then secrete a mature virion. The maturation of the S spike on the virion (conferring its infectivity) relies on the cellular serine protease enzyme TMPRSS2. Hence, inhibitors of this enzyme such as camostat mesylate may be useful [
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      ]. Inhibitors of RNA polymerase such as remdesivir [
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ] and favipiravir [
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ] and protease inhibitors lopinavir and ritonavir [
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
      ] affect intracellular virion assembly, and there remains a rationale to further evaluate these drugs in COVID-19 [
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      ]. A recent open-label, randomized, controlled trial evaluated the role of lopinavir and ritonavir in 199 COVID-19 patients with hypoxemia (99 treated with lopinavir/ritonavir and 100 with standard of care). Those treated with lopinavir/rotinavir did not demonstrate any significant benefit in hazard ratio for earlier clinical improvement (1.24 [95%CI 0.9–1.72]) or reduction in mortality at 28 days (− 5.8% [95%CI − 17.3% to 5.7%]). Secondary outcomes revealed that those patients treated with lopinavir/ritonavir demonstrated clinical improvement 1 day earlier than the control group in a modified intention-to-treat analysis, as well as were discharged from the ICU a median of 5 days earlier [
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      ]. While the trial failed to meet its primary objective, it possibly included patients with severe disease alone, and future studies may consider evaluating the role of lopinavir/ritonavir earlier in the course of COVID-19 [
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
      ]. Also, the potential for demonstrating a beneficial effect with a larger sample size cannot be ruled out based on the findings of this study. This drug may yet merit further evaluation in clinical trials of COVID-19. Another recent small open-label clinical trial compared favipiravir (35 patients) with lopinavir/ritonavir (45 patients) on a background of interferon alpha therapy in patients from China with milder COVID-19 without hypoxemia or respiratory distress and demonstrated earlier viral clearance in those on favipiravir. Chest radiology showed better improvement in favipiravir-treated patients than those treated with lopinavir/ritonavir at day 14, but not at earlier time points [
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ].
     </p>
     <p id="Par9">
      The mature virion enters the endosome and interacts with toll-like receptors (TLR) to stimulate downstream inflammatory pathways; chloroquine and hydroxychloroquine use interferes with endosomal acidification and inhibits such TLR activation. These drugs also interfere with downstream inflammatory pathways and resultant cytokine production, as well as dampen the inflammatory response via upregulation of regulatory anti-inflammatory molecules [
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
      –
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ]. A systematic review of available expert opinion pieces and 23 ongoing trials in China supported the notion that chloroquine limits the replication of SARS-CoV-2 [
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ]. Preliminary reports suggest that chloroquine and hydroxychloroquine are probably equally beneficial in COVID-19 and that a loading dose of the drug should be followed by a maintenance dose, prescribed for a long period [
      <xref ref-type="bibr" rid="CR35">
       35
      </xref>
      ]. A recent clinical trial evaluated hydroxychloroquine (with or without azathioprine) versus placebo in severe COVID-19 and demonstrated potential benefit for reducing viral replication. The trial reported outcomes for 20 (out of 26 patients) who received active treatment, compared to 16 controls who refused such active treatment. The former group demonstrated negative PCR in 70% at day 6 of treatment (versus 12.5% in the control group). However, this trial had a limited sample size of 36 patients, allocation to active treatment or control was not randomized, only a small proportion of patients had severe disease (lower respiratory tract infection) and clinical outcomes were not reported for all patients. These considerations `potentially undermine the quality of the study [
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
      ]. Also, concerns exist regarding the potential for cardiac arrhythmias with chloroquine (and its analogs) as well as with azithromycin and protease inhibitors; hence, due care and careful monitoring for cardiac arrhythmias are essential while using these drugs alone or in combination [
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ]. Nevertheless, the rationale driving the potential benefits with hydroxychloroquine merits its exploration as a therapeutic agent in COVID-19. Another suggestion has been to provide prophylaxis with hydroxychloroquine (400 mg twice daily for a day, followed by 400 mg once a week for 7 weeks) for healthcare workers dealing with COVID-19 as well as close contacts of these patients, as recommended empirically recently by a national society [
      <xref ref-type="bibr" rid="CR38">
       38
      </xref>
      ]. There exists a need to generate evidence regarding the role of such prophylactic therapy in COVID-19. The exact clinical scenarios where chloroquine or hydroxychloroquine may be useful in COVID-19 remain to be ascertained, unlike their use in rheumatic diseases where their indications are widely understood [
      <xref ref-type="bibr" rid="CR39">
       39
      </xref>
      ].
     </p>
     <p id="Par10">
      Janus kinases (JAK) 1 and 2 are involved in inflammation, and the enzyme AP-2-associated protein kinase 1 (AAK1) plays a role in viral cellular entry. Based on information generated by bioinformatics analysis, baricitinib may help reduce SARS-CoV-2 infection by inhibiting AAK1, and also possibly dampening the resulting inflammation by JAK1/2 inhibition [
      <xref ref-type="bibr" rid="CR40">
       40
      </xref>
      ]. The resultant cytokine storm responsible for severe COVID-19 and associated secondary HLH may respond to immunosuppressive agents used for HLH such as tocilizumab (IL-6 blockade) and anakinra (IL-1 blockade) [
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      ]. A recent pre-print retrospectively evaluated the use of a single dose of intravenous tocilizumab 400 mg in 21 patients with COVID-19 from China who either had respiratory distress, hypoxemia or required intensive care support. Nineteen of these 21 patients demonstrated clinical improvement with discharge from hospital by 2 weeks. The findings of this study need to be cautiously interpreted in the context of small numbers, the lack of a control group for comparison and background treatment with antiviral therapies and corticosteroids [
      <xref ref-type="bibr" rid="CR41">
       41
      </xref>
      ]. Ongoing clinical trials are further evaluating the role of IL-6 blockade with tocilizumab and sarilumab in severe COVID-19; the former drug is also approved in China for this indication [
      <xref ref-type="bibr" rid="CR42">
       42
      </xref>
      ,
      <xref ref-type="bibr" rid="CR43">
       43
      </xref>
      ].
     </p>
     <p id="Par11">
      Cepharanthine, selamectine and mefloquine hydrochloride are other drugs that have been demonstrated to be cytopathic to viral cultures of SARS-CoV-2, but their precise mechanisms of action are unclear [
      <xref ref-type="bibr" rid="CR44">
       44
      </xref>
      ]. Related clinical research studies are warranted. Based on numerous studies of other viruses [
      <xref ref-type="bibr" rid="CR45">
       45
      </xref>
      ,
      <xref ref-type="bibr" rid="CR46">
       46
      </xref>
      ], it is reasonable to hypothesize that vitamins C and D supplementation may boost immunity and help human organism fight COVID-19 and its aggressive effects on all organ systems (Fig.
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ). High-dose vitamin D supplementation may be considered for subjects with laboratory-confirmed deficiency, particularly the elderly, obese, those with dark skin and those individuals living at higher latitudes [
      <xref ref-type="bibr" rid="CR47">
       47
      </xref>
      ]. Based on its protective effects in subjects at risk of chronic diseases, including cancers, cardiovascular disease, respiratory tract infections, diabetes mellitus and hypertension, experts hypothesize that vitamin D supplementation and associated increase of serum 25-hydroxyvitamin D concentration above 50 ng/ml (125 nmol/l) may substantially reduce the incidence and severity of various viral diseases, including COVID-19 [
      <xref ref-type="bibr" rid="CR48">
       48
      </xref>
      ]. Arguably, there is little evidence base for most of the potential drug therapies in COVID-19 (Table
      <xref ref-type="table" rid="Tab2">
       2
      </xref>
      ). More clinical trials and cohort studies are urgently needed to evaluate the efficacy of preventive and curative agents before evidence-based recommendations can be drafted by professional societies.
      <table-wrap id="Tab2">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Potential drugs for different phases of coronavirus disease 19 (COVID-19), whose role will need to be evaluated in future clinical trials
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Phase of disease
          </th>
          <th>
           Drugs meriting exploration
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           Early phase/pre-clinical phase
          </td>
          <td>
           Preventative strategies with chloroquine, hydroxychloroquine, vitamin D, vitamin C.
          </td>
         </tr>
         <tr>
          <td>
           Viremic phase
          </td>
          <td>
           Antiviral drugs (lopinavir/ritonavir, favipiravir, remdesivir), chloroquine, hydroxychloroquine
          </td>
         </tr>
         <tr>
          <td>
           Cytokine storm phase
          </td>
          <td>
           Tocilizumab, sarilumab, baricitinib.
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
    </sec>
    <sec id="Sec5">
     <title>
      Considerations for patients with rheumatic diseases on immunosuppression
     </title>
     <p id="Par12">
      Glucocorticoids have an overall immunosuppressive effect, and these are often used in patients with inflammatory and autoimmune diseases. While glucocorticoids are also often prescribed in sepsis, available evidence does not favor their use to ameliorate the deleterious effect of lung inflammation caused by viral infections [
      <xref ref-type="bibr" rid="CR49">
       49
      </xref>
      ]. On this basis, the authors opine that it may be cautiously recommended to manage patients on long-term corticosteroid therapy by gradually tapering doses to 5–7.5 mg/daily during this pandemic. It is also advisable to stick to the recommendations of rheumatology societies, warning against abrupt cessation of corticosteroid therapy. There exists little evidence to guide the course of COVID-19 in patients on immunosuppressive therapy. Until more data emerges, it is considered prudent to continue any ongoing immunosuppressive therapy. Such drugs (other than glucocorticoids) are often discontinued during an episode of infection, and it seems reasonable to pursue a similar strategy for the time being even in the case of COVID-19 infection (Table
      <xref ref-type="table" rid="Tab3">
       3
      </xref>
      ) [
      <xref ref-type="bibr" rid="CR50">
       50
      </xref>
      –
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
      ].
      <table-wrap id="Tab3">
       <label>
        Table 3
       </label>
       <caption>
        <p>
         Summary of recommendations from rheumatology societies (EULAR, ACR, BSR, ARA) for patients with rheumatic diseases during coronavirus disease 19 (COVID-19) outbreak [
         <xref ref-type="bibr" rid="CR50">
          50
         </xref>
         –
         <xref ref-type="bibr" rid="CR53">
          53
         </xref>
         ]
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <tbody>
         <tr>
          <td colspan="2">
           1. Practising sneeze/cough hygiene, regular hand washing, avoiding touching the face, keeping away from crowded places, social distancing, avoiding busy public transport and cancelling unnecessary travel is recommended.
          </td>
         </tr>
         <tr>
          <td colspan="2">
           2. Use of a mask is recommended for those with suspected and confirmed infection. In such instances, N95 respirators with appropriate fit to the face are advisable.
          </td>
         </tr>
         <tr>
          <td colspan="2">
           3. Abrupt discontinuation of glucocorticoid therapy should be avoided, even during active infection.
          </td>
         </tr>
         <tr>
          <td colspan="2">
           4. If patients are on disease-modifying antirheumatic drugs, including biologics, small molecules, and other immunosuppressive agents, standard practices may be followed to discontinue them should one develop infection.
          </td>
         </tr>
         <tr>
          <td colspan="2">
           5. Routine face-to-face appointments should be delayed until the outbreak settles. Both patients and healthcare personnel should consider substituting face-to-face appointments with video appointments if feasible.
          </td>
         </tr>
         <tr>
          <td colspan="2">
           6. Patients should be updated about appropriate flu and pneumococcal vaccination practices.
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         <italic>
          ACR
         </italic>
         American College of Rheumatology,
         <italic>
          ARA
         </italic>
         Australian Rheumatology Association,
         <italic>
          BSR
         </italic>
         British Society for Rheumatology,
         <italic>
          EULAR
         </italic>
         European League against Rheumatism
        </p>
       </table-wrap-foot>
      </table-wrap>
     </p>
    </sec>
    <sec id="Sec6">
     <title>
      Measures at a societal level and preparing for future outbreaks
     </title>
     <p id="Par13">
      It is also important to implement restrictive measures at a societal level to mitigate the spread of the virus. Emerging evidence suggests that the virus spreads by droplets and fomites [
      <xref ref-type="bibr" rid="CR54">
       54
      </xref>
      ]. Therefore, the importance of regular hand washing, sneeze and cough hygiene and the use of personal protective equipment for healthcare workers managing COVID-19 patients are likely to help mitigate the spread of this infection [
      <xref ref-type="bibr" rid="CR50">
       50
      </xref>
      –
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
      ].
     </p>
     <p id="Par14">
      Many afflicted countries are now under lockdown or have severe travel restrictions. This is an effort to break the chain of transmission of the virus. Controlling the infection by imposing severe restrictions on travel and social contacts can be viewed as the main strategy, primarily benefiting the elderly and those with chronic comorbid conditions [
      <xref ref-type="bibr" rid="CR55">
       55
      </xref>
      ]. Screening for the virus safely and enforcing isolation of confirmed cases can also prevent short- and long-term adverse outcomes of this pandemic [
      <xref ref-type="bibr" rid="CR56">
       56
      </xref>
      ]. However, an analysis of the transmission of COVID-19 in China in January–February 2020 revealed that 86% of subjects potentially contracted the virus from patients with no or minimal symptoms, pointing to the difficulties of containing the virus spread [
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
      ]. Recently, the prolonged excretion of SARS-CoV-2 in feces for a mean period of 4 weeks has been documented, which further present difficulties in attempts to limit the community spread of disease [
      <xref ref-type="bibr" rid="CR58">
       58
      </xref>
      ]. These recent findings also point to the urgent need to develop and experiment with SARS-CoV-2 vaccines that may prevent further seasonal outbreaks of the infection. Experts also proposed a hypothesis that measles and rubella vaccines may generate cross-resistance against SARS-CoV-2, which is based on the observations that Chinese children vaccinated against measles are less vulnerable to COVID-19 than the elderly; these merit further exploration [
      <xref ref-type="bibr" rid="CR59">
       59
      </xref>
      ]. Given the dynamics of the influenza outbreaks in the early twentieth century [
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
      ], it is possible to predict a temporary remission in the COVID-19 pandemic in the coming summer months. High temperatures and heat waves are expected to minimize virulence of SARS-CoV-2. Other factors such as increased daytime hours and increased ultraviolet exposure may also exert additive beneficial effects [
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ].
     </p>
     <p id="Par15">
      To sum up, rheumatologists should closely monitor current COVID-19 pandemic, raise the global awareness of the virus characteristics and its targets, and explore strategies to minimize the incidence of severe cases. While waiting for evidence-based recommendations, empirical preventive measures should be implemented. Relying on expert opinion and rapidly accumulating evidence is currently the best way to avoid major mistakes. Balanced and well-informed actions by all specialists and the whole society are urgently needed. It is also important to be aware of the ongoing postulates regarding potential immune-mediated injury in severe COVID-19 akin to secondary HLH. In such situations, rheumatologists may be called upon to decide on appropriate immunosuppressive strategies, and such decisions may need to be taken on a case-to-case basis, in the face of limited evidence to guide them.
     </p>
    </sec>
    <back>
     <fn-group>
      <fn>
       <p>
        <bold>
         Publisher’s note
        </bold>
       </p>
       <p>
        Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
       </p>
      </fn>
     </fn-group>
     <notes notes-type="author-contribution">
      <title>
       Authors’ contributions
      </title>
      <p>
       The conception and design of the study–DPM, AYG; acquisition of data, analysis and interpretation of data–DPM, VA, OZ, AYG.
      </p>
      <p>
       Drafting the article–DPM, VA; revising it critically for important intellectual content–OZ, AYG.
      </p>
      <p>
       Final approval of the version to be submitted–DPM, VA, AYG, OZ.
      </p>
      <p>
       Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved–DPM, VA, AYG, OZ.
      </p>
     </notes>
     <notes notes-type="ethics">
      <title>
       Compliance with ethical standards
      </title>
      <notes notes-type="COI-statement">
       <title>
        Conflict of interest
       </title>
       <p id="Par16">
        Durga Prasanna Misra declares that he has no conflict of interest, including no relationship with pharmaceutical companies.
       </p>
       <p id="Par17">
        Vikas Agarwal declares that he has no conflict of interest, including no relationship with pharmaceutical companies.
       </p>
       <p id="Par18">
        Olena Zimba declares that she has no conflict of interest, including no relationship with pharmaceutical companies.
       </p>
       <p id="Par19">
        Armen Yuri Gasparyan declares that he has no conflict of interest, including no relationship with pharmaceutical companies.
       </p>
      </notes>
      <notes>
       <title>
        Ethical approval
       </title>
       <p id="Par20">
        This article does not contain any studies with human participants or animals performed by any of the authors.
       </p>
      </notes>
      <notes>
       <title>
        Disclaimer
       </title>
       <p id="Par21">
        All views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any institution or association.
       </p>
      </notes>
     </notes>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="other">
        COVID-19 cases worldwide.
        <ext-link ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/">
         https://www.worldometers.info/coronavirus/
        </ext-link>
        . Accessed on 29 Mar 2020
       </mixed-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="other">
        Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 10.1056/NEJMoa2002032
       </mixed-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Habibzadeh
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Stoneman
          </surname>
          <given-names>
           EK
          </given-names>
         </name>
        </person-group>
        <article-title>
         The novel coronavirus: a Bird's eye view
        </article-title>
        <source>
         Int J Occup Environ Med
        </source>
        <year>
         2020
        </year>
        <volume>
         11
        </volume>
        <fpage>
         65
        </fpage>
        <lpage>
         71
        </lpage>
        <pub-id pub-id-type="doi">
         10.15171/ijoem.2020.1921
        </pub-id>
        <pub-id pub-id-type="pmid">
         32020915
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="other">
        COVID-19 Situation report 68 by the World Health Organization.
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200328-sitrep-68-covid-19.pdf?sfvrsn=384bc74c_2.2">
         https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200328-sitrep-68-covid-19.pdf?sfvrsn=384bc74c_2.2
        </ext-link>
        . Updated on 28 March 2020. Accessed on 29 Mar 2020
       </mixed-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="other">
        Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G (2020) Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 10.1016/s1473-3099(20)30195-x
       </mixed-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="other">
        Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 10.1016/s2213-2600(20)30116-8
       </mixed-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="other">
        Yang J, Zheng Y, Gou X et al (2020) Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 10.1016/j.ijid.2020.03.017
       </mixed-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <mixed-citation publication-type="other">
        Liu W, Tao ZW, Lei W et al (2020) Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 10.1097/cm9.0000000000000775
       </mixed-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="other">
        Cai H (2020) Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. 10.1016/s2213-2600(20)30117-x
       </mixed-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="other">
        Environmental issues in Iran.
        <ext-link ext-link-type="uri" xlink:href="https://www.theguardian.com/world/iran-blog/2014/nov/21/iran-environmental-consequences-of-sanctions">
         https://www.theguardian.com/world/iran-blog/2014/nov/21/iran-environmental-consequences-of-sanctions
        </ext-link>
        . Updated 2014. Accessed on 19 Mar 2020
       </mixed-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="other">
        Report of the WHO-China Joint Mission on Coronavirus Disease 19 (COVID-19). Available at
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19%2D%2D-final-report-1100hr-28feb2020-11mar-update.pdf?sfvrsn=1a13fda0_2&amp;download=true">
         https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19%2D%2D-final-report-1100hr-28feb2020-11mar-update.pdf?sfvrsn=1a13fda0_2&amp;download=true
        </ext-link>
        . Updated 28 February 2020. Accessed on 24 Mar 2020
       </mixed-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures
        </article-title>
        <source>
         J Korean Med Sci
        </source>
        <year>
         2020
        </year>
        <volume>
         35
        </volume>
        <fpage>
         e61
        </fpage>
        <pub-id pub-id-type="doi">
         10.3346/jkms.2020.35.e61
        </pub-id>
        <pub-id pub-id-type="pmid">
         32030925
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="other">
        Lippi G, Plebani M, Michael Henry B (2020) Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 10.1016/j.cca.2020.03.022
       </mixed-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="other">
        Qin C, Zhou L, Hu Z et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 10.1093/cid/ciaa248
       </mixed-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="other">
        Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 10.1016/s0140-6736(20)30628-0
       </mixed-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="other">
        Clerkin Kevin J, Fried Justin A, Raikhelkar J et al (2020) Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 10.1161/CIRCULATIONAHA.120.046941
       </mixed-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <mixed-citation publication-type="other">
        Driggin E, Madhavan MV, Bikdeli B et al (2020) Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 27204. 10.1016/j.jacc.2020.03.031
       </mixed-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <mixed-citation publication-type="other">
        Hu H, Ma F, Wei X, Fang Y (2020) Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 10.1093/eurheartj/ehaa190
       </mixed-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Batlle
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wysocki
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Satchell
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
        </article-title>
        <source>
         Clin Sci (Lond)
        </source>
        <year>
         2020
        </year>
        <volume>
         134
        </volume>
        <fpage>
         543
        </fpage>
        <lpage>
         545
        </lpage>
        <pub-id pub-id-type="doi">
         10.1042/cs20200163
        </pub-id>
        <pub-id pub-id-type="pmid">
         32167153
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Dan
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
        </person-group>
        <article-title>
         High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa
        </article-title>
        <source>
         Int J Oral Sci
        </source>
        <year>
         2020
        </year>
        <volume>
         12
        </volume>
        <fpage>
         8
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41368-020-0074-x
        </pub-id>
        <pub-id pub-id-type="pmid">
         32094336
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <mixed-citation publication-type="other">
        Day M (2020) Covid-19: European drugs agency to review safety of ibuprofen. 368:m1168. 10.1136/bmj.m1168
       </mixed-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists
        </article-title>
        <source>
         Bmj
        </source>
        <year>
         2020
        </year>
        <volume>
         368
        </volume>
        <fpage>
         m1086
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/bmj.m1086
        </pub-id>
        <pub-id pub-id-type="pmid">
         32184201
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <mixed-citation publication-type="other">
        Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 10.1016/j.cell.2020.02.052
       </mixed-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </article-title>
        <source>
         Cell Res
        </source>
        <year>
         2020
        </year>
        <volume>
         30
        </volume>
        <fpage>
         269
        </fpage>
        <lpage>
         271
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/s41422-020-0282-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         32020029
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Discovering drugs to treat coronavirus disease 2019 (COVID-19)
        </article-title>
        <source>
         Drug Discov Ther
        </source>
        <year>
         2020
        </year>
        <volume>
         14
        </volume>
        <fpage>
         58
        </fpage>
        <lpage>
         60
        </lpage>
        <pub-id pub-id-type="doi">
         10.5582/ddt.2020.01012
        </pub-id>
        <pub-id pub-id-type="pmid">
         32147628
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Jeon
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           HY
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Seong
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR
        </article-title>
        <source>
         J Korean Med Sci
        </source>
        <year>
         2020
        </year>
        <volume>
         35
        </volume>
        <fpage>
         e79
        </fpage>
        <pub-id pub-id-type="doi">
         10.3346/jkms.2020.35.e79
        </pub-id>
        <pub-id pub-id-type="pmid">
         32056407
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="other">
        Emanuel EJ, Persad G, Upshur R et al (2020) Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 10.1056/NEJMsb2005114
       </mixed-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <mixed-citation publication-type="other">
        Cao B, Wang Y, Wen D et al (2020) A trial of Lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 10.1056/NEJMoa2001282
       </mixed-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="other">
        Baden LR, Rubin EJ (2020) Covid-19 — the search for effective therapy. N Engl J Med. 10.1056/NEJMe2005477
       </mixed-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="other">
        Cai Q, Yang M, Liu D et al (2020) Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering. 10.1016/j.eng.2020.03.007
       </mixed-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine for the 2019 novel coronavirus SARS-CoV-2
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         55
        </volume>
        <fpage>
         105923
        </fpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ijantimicag.2020.105923
        </pub-id>
        <pub-id pub-id-type="pmid">
         32070753
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <mixed-citation publication-type="other">
        Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 10.5582/bst.2020.01047
       </mixed-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schrezenmeier
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Dörner
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
        </article-title>
        <source>
         Nat Rev Rheumatol
        </source>
        <year>
         2020
        </year>
        <volume>
         16
        </volume>
        <fpage>
         155
        </fpage>
        <lpage>
         166
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/s41584-020-0372-x
        </pub-id>
        <pub-id pub-id-type="pmid">
         32034323
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <mixed-citation publication-type="other">
        Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 10.1016/j.jcrc.2020.03.005
       </mixed-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <mixed-citation publication-type="other">
        Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D (2020) Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 105932. 10.1016/j.ijantimicag.2020.105932
       </mixed-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <mixed-citation publication-type="other">
        Gautret P, Lagier J-C, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949. 10.1016/j.ijantimicag.2020.105949
       </mixed-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mason
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimicrobials and QT prolongation
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <year>
         2017
        </year>
        <volume>
         72
        </volume>
        <fpage>
         1272
        </fpage>
        <lpage>
         1274
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/jac/dkw591
        </pub-id>
        <pub-id pub-id-type="pmid">
         28160473
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38.
       </label>
       <mixed-citation publication-type="other">
        Indian Council of Medical Research guidelines for use of empirical use of hydroxychloquine prophylaxis in COVID-19.
        <ext-link ext-link-type="uri" xlink:href="https://icmr.nic.in/sites/default/files/upload_documents/HCQ_Recommendation_22March_final_MM_V2.pdf">
         https://icmr.nic.in/sites/default/files/upload_documents/HCQ_Recommendation_22March_final_MM_V2.pdf
        </ext-link>
        . Updated 23 March 2020, Accessed on 24 Mar 2020
       </mixed-citation>
      </ref>
      <ref id="CR39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ramos-Casals
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Brito-Zeron
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Bombardieri
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies
        </article-title>
        <source>
         Ann Rheum Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         79
        </volume>
        <fpage>
         3
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/annrheumdis-2019-216114
        </pub-id>
        <pub-id pub-id-type="pmid">
         31672775
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Griffin
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Tucker
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Oechsle
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Phelan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Stebbing
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         e30
        </fpage>
        <lpage>
         e31
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s0140-6736(20)30304-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         32032529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41.
       </label>
       <mixed-citation publication-type="other">
        Xu X, Han M, Li T et al (2020) Effective treatment of severe COVID-19 patients with Tocilizumab.[ChinaXiv:202003.00026]. Available at
        <ext-link ext-link-type="uri" xlink:href="http://www.chinaxiv.org/abs/202003.00026">
         http://www.chinaxiv.org/abs/202003.00026
        </ext-link>
        . Updated on 05 March 2020. Accesed on 29 Mar 2020
       </mixed-citation>
      </ref>
      <ref id="CR42">
       <label>
        42.
       </label>
       <mixed-citation publication-type="other">
        Approval for tocilizumab use in severe Covid-19 in China.
        <ext-link ext-link-type="uri" xlink:href="https://www.pharmaceutical-technology.com/news/roche-actemra-coronavirus-complications/">
         https://www.pharmaceutical-technology.com/news/roche-actemra-coronavirus-complications/
        </ext-link>
        . Updated 05 March 2020. Accessed on 19 Mar 2020
       </mixed-citation>
      </ref>
      <ref id="CR43">
       <label>
        43.
       </label>
       <mixed-citation publication-type="other">
        Trial in interleukin-6 blockade with sarilumab for Covid-19.
        <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrialsarena.com/news/sanofi-regeneron-trial-kevzara-covid-19/">
         https://www.clinicaltrialsarena.com/news/sanofi-regeneron-trial-kevzara-covid-19/
        </ext-link>
        . Updated 16 March 2020. Accessed on 19 Mar 2020
       </mixed-citation>
      </ref>
      <ref id="CR44">
       <label>
        44.
       </label>
       <mixed-citation publication-type="other">
        Fan HH, Wang LQ, Liu WL et al (2020) Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin Med J. 10.1097/cm9.0000000000000797
       </mixed-citation>
      </ref>
      <ref id="CR45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colunga Biancatelli
          </surname>
          <given-names>
           RML
          </given-names>
         </name>
         <name>
          <surname>
           Berrill
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Marik
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
        </person-group>
        <article-title>
         The antiviral properties of vitamin C
        </article-title>
        <source>
         Expert Rev Anti-Infect Ther
        </source>
        <year>
         2020
        </year>
        <volume>
         18
        </volume>
        <fpage>
         99
        </fpage>
        <lpage>
         101
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/14787210.2020.1706483
        </pub-id>
        <pub-id pub-id-type="pmid">
         31852327
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goncalves-Mendes
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Talvas
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Duale
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Impact of vitamin D supplementation on influenza vaccine response and immune functions in deficient elderly persons: a randomized placebo-controlled trial
        </article-title>
        <source>
         Front Immunol
        </source>
        <year>
         2019
        </year>
        <volume>
         10
        </volume>
        <fpage>
         65
        </fpage>
        <pub-id pub-id-type="doi">
         10.3389/fimmu.2019.00065
        </pub-id>
        <pub-id pub-id-type="pmid">
         30800121
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <name>
          <surname>
           Al Anouti
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Moukayed
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Targeted 25-hydroxyvitamin D concentration measurements and vitamin D3 supplementation can have important patient and public health benefits
        </article-title>
        <source>
         Eur J Clin Nutr
        </source>
        <year>
         2020
        </year>
        <volume>
         74
        </volume>
        <fpage>
         366
        </fpage>
        <lpage>
         376
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/s41430-020-0564-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         31996793
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48.
       </label>
       <mixed-citation publication-type="other">
        Grant WB, Lahore H, McDonnell SL et al (2020) Vitamin D supplementation could prevent and treat influenza, coronavirus, and pneumonia infections. Preprints 2020030235 10.20944/preprints202003.0235.v1
       </mixed-citation>
      </ref>
      <ref id="CR49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <name>
          <surname>
           Millar
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Baillie
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         473
        </fpage>
        <lpage>
         475
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30317-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         32043983
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50.
       </label>
       <mixed-citation publication-type="other">
        EULAR guidance for patients during Covid-19 outbreak.
        <ext-link ext-link-type="uri" xlink:href="https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm">
         https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm
        </ext-link>
        . Updated 17 March 2020. Accessed on 19 Mar 2020
       </mixed-citation>
      </ref>
      <ref id="CR51">
       <label>
        51.
       </label>
       <mixed-citation publication-type="other">
        BSR guidance for patients during Covid-19 outbreak.
        <ext-link ext-link-type="uri" xlink:href="https://www.rheumatology.org.uk/News-Policy/Details/Covid19-Coronavirus-update-members">
         https://www.rheumatology.org.uk/News-Policy/Details/Covid19-Coronavirus-update-members
        </ext-link>
        . Updated 25 March 2020. Accessed on 29 Mar 2020
       </mixed-citation>
      </ref>
      <ref id="CR52">
       <label>
        52.
       </label>
       <mixed-citation publication-type="other">
        ACR guidance for patients during Covid-19 outbreak.
        <ext-link ext-link-type="uri" xlink:href="https://www.rheumatology.org/announcements">
         https://www.rheumatology.org/announcements
        </ext-link>
        . Updated 28 March 2020. Accessed on 29 Mar 2020
       </mixed-citation>
      </ref>
      <ref id="CR53">
       <label>
        53.
       </label>
       <mixed-citation publication-type="other">
        Australian Rheumatology Association guidance for patients during Covid-19 outbreak.
        <ext-link ext-link-type="uri" xlink:href="https://arthritisaustralia.com.au/advice-regarding-coronavirus-covid-19-from-the-australian-rheumatology-association/">
         https://arthritisaustralia.com.au/advice-regarding-coronavirus-covid-19-from-the-australian-rheumatology-association/
        </ext-link>
        . Updated 17 March 2020. Accessed on 19 Mar 2020
       </mixed-citation>
      </ref>
      <ref id="CR54">
       <label>
        54.
       </label>
       <mixed-citation publication-type="other">
        van Doremalen N, Bushmaker T, Morris DH et al (2020) Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 10.1056/NEJMc2004973
       </mixed-citation>
      </ref>
      <ref id="CR55">
       <label>
        55.
       </label>
       <mixed-citation publication-type="other">
        Wilder-Smith A, Freedman DO (2020) Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. J Travel Med 27. 10.1093/jtm/taaa020
       </mixed-citation>
      </ref>
      <ref id="CR56">
       <label>
        56.
       </label>
       <mixed-citation publication-type="other">
        Kwon KT, Ko J-H, Shin H, Sung M, Kim JY (2020) Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak. J Korean Med Sci 35:e123. 10.3346/jkms.2020.35.e123
       </mixed-citation>
      </ref>
      <ref id="CR57">
       <label>
        57.
       </label>
       <mixed-citation publication-type="other">
        Li R, Pei S, Chen B, et al. (2020) Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2) Science eabb3221. 10.1126/science.abb3221
       </mixed-citation>
      </ref>
      <ref id="CR58">
       <label>
        58.
       </label>
       <mixed-citation publication-type="other">
        Wu Y, Guo C, Tang L et al (2020) Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. 10.1016/s2468-1253(20)30083-2
       </mixed-citation>
      </ref>
      <ref id="CR59">
       <label>
        59.
       </label>
       <mixed-citation publication-type="other">
        Adnan Shereen M, Khan S, Kazmi A, Bashir N, Siddique R (2020) COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 10.1016/j.jare.2020.03.005
       </mixed-citation>
      </ref>
      <ref id="CR60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Andreasen
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Viboud
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Simonsen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiologic characterization of the 1918 influenza pandemic summer wave in Copenhagen: implications for pandemic control strategies
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2008
        </year>
        <volume>
         197
        </volume>
        <fpage>
         270
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/524065
        </pub-id>
        <pub-id pub-id-type="pmid">
         18194088
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hindawi
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Damanhouri
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         <name>
          <surname>
           el-Kafrawy
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Tolah
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inactivation of Middle East respiratory syndrome-coronavirus in human plasma using amotosalen and ultraviolet a light
        </article-title>
        <source>
         Transfusion
        </source>
        <year>
         2018
        </year>
        <volume>
         58
        </volume>
        <fpage>
         52
        </fpage>
        <lpage>
         59
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/trf.14422
        </pub-id>
        <pub-id pub-id-type="pmid">
         29239484
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Clin Med
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J Clin Med
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       jcm
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Clinical Medicine
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2077-0383
      </issn>
      <publisher>
       <publisher-name>
        MDPI
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32110875
      </article-id>
      <article-id pub-id-type="pmc">
       7141113
      </article-id>
      <article-id pub-id-type="doi">
       10.3390/jcm9030623
      </article-id>
      <article-id pub-id-type="publisher-id">
       jcm-09-00623
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0002-9788-701X
        </contrib-id>
        <name>
         <surname>
          Pang
         </surname>
         <given-names>
          Junxiong
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
        <xref ref-type="aff" rid="af2-jcm-09-00623">
         2
        </xref>
        <xref ref-type="corresp" rid="c1-jcm-09-00623">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0002-7527-1636
        </contrib-id>
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Min Xian
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
        <xref ref-type="aff" rid="af2-jcm-09-00623">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0003-1124-3764
        </contrib-id>
        <name>
         <surname>
          Ang
         </surname>
         <given-names>
          Ian Yi Han
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tan
         </surname>
         <given-names>
          Sharon Hui Xuan
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lewis
         </surname>
         <given-names>
          Ruth Frances
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          Jacinta I-Pei
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gutierrez
         </surname>
         <given-names>
          Ramona A
         </given-names>
        </name>
        <xref ref-type="aff" rid="af3-jcm-09-00623">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gwee
         </surname>
         <given-names>
          Sylvia Xiao Wei
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
        <xref ref-type="aff" rid="af2-jcm-09-00623">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chua
         </surname>
         <given-names>
          Pearleen Ee Yong
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
        <xref ref-type="aff" rid="af2-jcm-09-00623">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Qian
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ng
         </surname>
         <given-names>
          Xian Yi
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yap
         </surname>
         <given-names>
          Rowena K.S.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tan
         </surname>
         <given-names>
          Hao Yi
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Teo
         </surname>
         <given-names>
          Yik Ying
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tan
         </surname>
         <given-names>
          Chorh Chuan
         </given-names>
        </name>
        <xref ref-type="aff" rid="af4-jcm-09-00623">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0002-6271-5832
        </contrib-id>
        <name>
         <surname>
          Cook
         </surname>
         <given-names>
          Alex R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yap
         </surname>
         <given-names>
          Jason Chin-Huat
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hsu
         </surname>
         <given-names>
          Li Yang
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-jcm-09-00623">
         1
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af1-jcm-09-00623">
       <label>
        1
       </label>
       Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117549, Singapore;
       <email>
        ephwmx@nus.edu.sg
       </email>
       (M.X.W.);
       <email>
        yha2103@columbia.edu
       </email>
       (I.Y.H.A.);
       <email>
        tan.sharon@nus.edu.sg
       </email>
       (S.H.X.T.);
       <email>
        ephrfl@nus.edu.sg
       </email>
       (R.F.L.);
       <email>
        ephcij@nus.edu.sg
       </email>
       (J.I.-P.C.);
       <email>
        ephsgxw@nus.edu.sg
       </email>
       (S.X.W.G.);
       <email>
        ephceyp@nus.edu.sg
       </email>
       (P.E.Y.C.);
       <email>
        yang_qian@nus.edu.sg
       </email>
       (Q.Y.);
       <email>
        ephngx@nus.edu.sg
       </email>
       (X.Y.N.);
       <email>
        ephryks@nus.edu.sg
       </email>
       (R.K.S.Y.);
       <email>
        haoyi.tan.official@gmail.com
       </email>
       (H.Y.T.);
       <email>
        ephtyy@nus.edu.sg
       </email>
       (Y.Y.T.);
       <email>
        ephcar@nus.edu.sg
       </email>
       (A.R.C.);
       <email>
        jasonyap@nus.edu.sg
       </email>
       (J.C.-H.Y.);
       <email>
        mdchly@nus.edu.sg
       </email>
       (L.Y.H.)
      </aff>
      <aff id="af2-jcm-09-00623">
       <label>
        2
       </label>
       Centre for Infectious Disease Epidemiology and Research, National University of Singapore, Singapore 117549, Singapore
      </aff>
      <aff id="af3-jcm-09-00623">
       <label>
        3
       </label>
       National Centre for Infectious Diseases, Singapore 308442, Singapore;
       <email>
        ramona_a_gutierrez@ncid.sg
       </email>
      </aff>
      <aff id="af4-jcm-09-00623">
       <label>
        4
       </label>
       Ministry of Health, Singapore 169854, Singapore;
       <email>
        chorhchuan.tan@moht.com.sg
       </email>
      </aff>
      <author-notes>
       <corresp id="c1-jcm-09-00623">
        <label>
         *
        </label>
        Correspondence:
        <email>
         ephpjv@nus.edu.sg
        </email>
        or
        <email>
         pangv@hotmail.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        26
       </day>
       <month>
        2
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       9
      </volume>
      <issue>
       3
      </issue>
      <elocation-id>
       623
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         13
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         19
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 by the authors.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ).
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        novel coronavirus
       </kwd>
       <kwd>
        diagnostics
       </kwd>
       <kwd>
        vaccine
       </kwd>
       <kwd>
        treatments
       </kwd>
       <kwd>
        global health
       </kwd>
       <kwd>
        outbreak
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1-jcm-09-00623" sec-type="intro">
     <title>
      1. Introduction
     </title>
     <p>
      Since mid-December 2019 and as of early February 2020, the 2019 novel coronavirus (2019-nCoV) originating from Wuhan (Hubei Province, China) has infected over 25,000 laboratory-confirmed cases across 28 countries with about 500 deaths (a case-fatality rate of about 2%). More than 90% of the cases and deaths were in China [
      <xref ref-type="bibr" rid="B1-jcm-09-00623">
       1
      </xref>
      ]. Based on the initial reported surge of cases in Wuhan, the majority were males with a median age of 55 years and linked to the Huanan Seafood Wholesale Market [
      <xref ref-type="bibr" rid="B2-jcm-09-00623">
       2
      </xref>
      ]. Most of the reported cases had similar symptoms at the onset of illness such as fever, cough, and myalgia or fatigue. Most cases developed pneumonia and some severe and even fatal respiratory diseases such as acute respiratory distress syndrome [
      <xref ref-type="bibr" rid="B3-jcm-09-00623">
       3
      </xref>
      ].
     </p>
     <p>
      The 2019 novel coronavirus (2019-nCoV), a betacoronavirus, forms a clade within the subgenus sarbecovirus of the Orthocoronavirinae subfamily [
      <xref ref-type="bibr" rid="B4-jcm-09-00623">
       4
      </xref>
      ]. The severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are also betacoronaviruses that are zoonotic in origin and have been linked to potential fatal illness during the outbreaks in 2003 and 2012, respectively [
      <xref ref-type="bibr" rid="B5-jcm-09-00623">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="B6-jcm-09-00623">
       6
      </xref>
      ]. Based on current evidence, pathogenicity for 2019-nCoV is about 3%, which is significantly lower than SARS-CoV (10%) and MERS-CoV (40%) [
      <xref ref-type="bibr" rid="B7-jcm-09-00623">
       7
      </xref>
      ]. However, 2019-nCoV has potentially higher transmissibility (R
      <sub>
       0
      </sub>
      : 1.4–5.5) than both SARS-CoV (R
      <sub>
       0
      </sub>
      : 2–5) and MERS-CoV (R
      <sub>
       0
      </sub>
      : &lt;1) [
      <xref ref-type="bibr" rid="B7-jcm-09-00623">
       7
      </xref>
      ].
     </p>
     <p>
      With the possible expansion of 2019-nCoV globally [
      <xref ref-type="bibr" rid="B8-jcm-09-00623">
       8
      </xref>
      ] and the declaration of the 2019-nCoV outbreak as a Public Health Emergency of International Concern by the World Health Organization, there is an urgent need for rapid diagnostics, vaccines and therapeutics to detect, prevent and contain 2019-nCoV promptly. There is however currently a lack of understanding of what is available in the early phase of 2019-nCoV outbreak. The systematic review describes and assesses the potential rapid diagnostics, vaccines and therapeutics for 2019-nCoV, based in part on the developments for MERS-CoV and SARS-CoV.
     </p>
    </sec>
    <sec id="sec2-jcm-09-00623">
     <title>
      2. Material and Methods
     </title>
     <sec id="sec2dot1-jcm-09-00623">
      <title>
       2.1. Study Identification and Selection
      </title>
      <p>
       A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies examining the diagnosis, therapeutic drugs and vaccines for Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and the 2019 novel coronavirus (2019-nCoV), in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
      </p>
      <p>
       There were two independent reviewers each focusing on SARS, MERS, and 2019-nCoV, respectively. A third independent reviewer was engaged to resolve any conflicting article of interest. We used the key words “SARS”, “coronavirus”, “MERS”, “2019 Novel coronavirus”, “Wuhan virus” to identify the diseases in the search strategy. The systematic searches for diagnosis, therapeutic drugs and vaccines were carried out independently and the key words “drug”, “therapy”, “vaccine”, “diagnosis”, “point of care testing” and “rapid diagnostic test” were used in conjunction with the disease key words for the respective searches.
      </p>
      <p>
       Examples of search strings can be found in
       <xref ref-type="app" rid="app1-jcm-09-00623">
        Table S1
       </xref>
       . We searched for randomized controlled trials (RCTs) and validation trials (for diagnostics test) published in English, that measured (a) the sensitivity and/or specificity of a rapid diagnostic test or a point-of-care testing kit, (b) the impact of drug therapy or (c) vaccine efficacy against either of these diseases with no date restriction applied. For the 2019-nCoV, we searched for all in vitro, animal, or human studies published in English between 1 December 2019 and 6 February 2020, on the same outcomes of interest. In addition, we reviewed the references of retrieved articles in order to identify additional studies or reports not retrieved by the initial searches. Studies that examined the mechanisms of diagnostic tests, drug therapy or vaccine efficacy against SARS, MERS and 2019-nCoV were excluded.
      </p>
     </sec>
     <sec id="sec2dot2-jcm-09-00623">
      <title>
       2.2. Supplementary Strategies
      </title>
      <p>
       Given the rapidly developing and commercial nature of information regarding these developments, Google search results from the first five pages of each search term were scanned for relevance. Relevant articles were further identified through snowballing, including a search of press releases and grey literature on vaccine manufacturers’ official websites (
       <xref ref-type="app" rid="app1-jcm-09-00623">
        Table S2
       </xref>
       ). A list of potential commercial kits was also provided on 29 January 2020 by Dr. Kim J. Png (personal communication). This list was compiled by Dr. Png from web searches and review of latest business news. The list served to verify and supplement our team’s own search above for review. Clinical trials was also searched via
       <uri xlink:href="https://clinicaltrials.gov/">
        https://clinicaltrials.gov/
       </uri>
       to supplement the review of the diagnostics, vaccine and therapeutics of 2019-nCoV, SARS-CoV and MERS-CoV.
      </p>
     </sec>
    </sec>
    <sec id="sec3-jcm-09-00623" sec-type="results">
     <title>
      3. Results
     </title>
     <sec id="sec3dot1-jcm-09-00623">
      <title>
       3.1. Search Results
      </title>
      <p>
       An initial search identified a total of 1,065 articles from PubMed, Embase and Cochrane Library. There were 236, 236 and 593 articles related to diagnostics, therapeutics and vaccines, respectively (
       <xref ref-type="fig" rid="jcm-09-00623-f001">
        Figure 1
       </xref>
       ). After reviewing for inclusion and exclusion and the removal of duplications, a total of 27 studies were used for the full review (
       <xref ref-type="fig" rid="jcm-09-00623-f001">
        Figure 1
       </xref>
       ).
      </p>
      <p>
       A Google search for 2019-nCoV diagnostics (as of 6 February 2020;
       <xref ref-type="app" rid="app1-jcm-09-00623">
        Table S2
       </xref>
       ) yielded five webpage links from government and international bodies with official information and guidelines (WHO, Europe CDC, US CDC, US FDA), three webpage links on diagnostic protocols and scientific commentaries, and five webpage links on market news and press releases. Six protocols for diagnostics using reverse transcriptase polymerase chain reaction (RT-PCR) from six countries were published on WHO’s website [
       <xref ref-type="bibr" rid="B9-jcm-09-00623">
        9
       </xref>
       ]. Google search for 2019-nCoV vaccines yielded 19 relevant articles.
      </p>
     </sec>
     <sec id="sec3dot2-jcm-09-00623">
      <title>
       3.2. Diagnostics
      </title>
      <p>
       With the emergence of 2019-nCoV, real time RT-PCR remains the primary means for diagnosing the new virus strain among the many diagnostic platforms available ([
       <xref ref-type="bibr" rid="B10-jcm-09-00623">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="B11-jcm-09-00623">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="B12-jcm-09-00623">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="B13-jcm-09-00623">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="B14-jcm-09-00623">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="B15-jcm-09-00623">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="B16-jcm-09-00623">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="B17-jcm-09-00623">
        17
       </xref>
       ,
       <xref ref-type="bibr" rid="B18-jcm-09-00623">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="B19-jcm-09-00623">
        19
       </xref>
       ];
       <xref ref-type="app" rid="app1-jcm-09-00623">
        Table S3
       </xref>
       ). Among the 16 diagnostics studies selected, one study discussed the use of RT-PCR in diagnosing patients with 2019-nCoV [
       <xref ref-type="bibr" rid="B11-jcm-09-00623">
        11
       </xref>
       ] (
       <xref ref-type="table" rid="jcm-09-00623-t001">
        Table 1
       </xref>
       ). The period and type of specimen collected for RT-PCR play an important role in the diagnosis of 2019-nCoV. It was found that the respiratory specimens were positive for the virus while serum was negative in the early period. It has also suggested that in the early days of illness, patients have high levels of virus despite the mild symptoms.
      </p>
      <p>
       Apart from the commonly used RT-PCR in diagnosing MERS-CoV, four studies identified various diagnostic methods such as reverse transcription loop-mediated isothermal amplification (RT-LAMP), RT-insulated isothermal PCR (RT-iiPCR) and a one-step rRT-PCR assay based on specific TaqMan probes. RT-LAMP has similar sensitivity as real time RT-PCR. It is also highly specific and is used to detect MERS-CoV. It is comparable to the usual diagnostic tests and is rapid, simple and convenient. Likewise, RT-iiPCR and a one-step rRT-PCR assay have also shown similar sensitivity and high specificity for MER-CoV. Lastly, one study focused on the validation of the six commercial real RT-PCR kits, with high accuracy. Although real time RT-PCR is a primary method for diagnosing MERS-CoV, high levels of PCR inhibition may hinder PCR sensitivity (
       <xref ref-type="table" rid="jcm-09-00623-t001">
        Table 1
       </xref>
       ).
      </p>
      <p>
       There are eleven studies that focus on SARS-CoV diagnostic testing (
       <xref ref-type="table" rid="jcm-09-00623-t001">
        Table 1
       </xref>
       ). These papers described diagnostic methods to detect the virus with the majority of them using molecular testing for diagnosis. Comparison between the molecular test (i.e RT-PCR) and serological test (i.e., ELISA) showed that the molecular test has better sensitivity and specificity. Hence, enhancements to the current molecular test were conducted to improve the diagnosis. Studies looked at using nested PCR to include a pre-amplification step or incorporating N gene as an additional sensitive molecular marker to improve on the sensitivity (
       <xref ref-type="table" rid="jcm-09-00623-t001">
        Table 1
       </xref>
       ).
      </p>
      <p>
       In addition, there are seven potential rapid diagnostic kits (as of 24 January 2020;
       <xref ref-type="table" rid="jcm-09-00623-t002">
        Table 2
       </xref>
       ) available on the market for 2019-nCoV. Six of these are only for research purposes. Only one kit from Beijing Genome Institute (BGI) is approved for use in the clinical setting for rapid diagnosis. Most of the kits are for RT-PCR. There were two kits (BGI, China and Veredus, Singapore) with the capability to detect multiple pathogens using sequencing and microarray technologies, respectively.
      </p>
     </sec>
     <sec id="sec3dot3-jcm-09-00623">
      <title>
       3.3. Potential Vaccines
      </title>
      <p>
       With the emergence of 2019-nCoV, there are about 15 potential vaccine candidates in the pipeline globally (
       <xref ref-type="table" rid="jcm-09-00623-t003">
        Table 3
       </xref>
       ), in which a wide range of technology (such as messenger RNA, DNA-based, nanoparticle, synthetic and modified virus-like particle) was applied. It will likely take about a year for most candidates to start phase 1 clinical trials except for those funded by Coalition for Epidemic Preparedness Innovations (CEPI). However, the kit developed by the BGI have passed emergency approval procedure of the National Medical Products Administration, and are currently used in clinical and surveillance centers of China [
       <xref ref-type="bibr" rid="B40-jcm-09-00623">
        40
       </xref>
       ].
      </p>
      <p>
       Of the total of 570 unique studies on 2019-nCoV, SARS CoV or MERS-CoV vaccines screened, only four were eventually included in the review. Most studies on SARS and MERS vaccines were excluded as they were performed in cell or animal models (
       <xref ref-type="fig" rid="jcm-09-00623-f001">
        Figure 1
       </xref>
       ). The four studies included in this review were Phase I clinical trials on SARS or MERS vaccines (
       <xref ref-type="table" rid="jcm-09-00623-t004">
        Table 4
       </xref>
       ) [
       <xref ref-type="bibr" rid="B44-jcm-09-00623">
        44
       </xref>
       ,
       <xref ref-type="bibr" rid="B45-jcm-09-00623">
        45
       </xref>
       ,
       <xref ref-type="bibr" rid="B46-jcm-09-00623">
        46
       </xref>
       ,
       <xref ref-type="bibr" rid="B47-jcm-09-00623">
        47
       </xref>
       ]. There were no studies of any population type (cell, animal, human) on the 2019-nCoV at the point of screening. The published clinical trials were mostly done in United States except for one on the SARS vaccine done in China [
       <xref ref-type="bibr" rid="B44-jcm-09-00623">
        44
       </xref>
       ]. All vaccine candidates for SARS and MERS were reported to be safe, well-tolerated and able to trigger the relevant and appropriate immune responses in the participants. In addition, we highlight six ongoing Phase I clinical trials identified in the
       <uri>
        ClinicalTrials.gov
       </uri>
       register ([
       <xref ref-type="bibr" rid="B48-jcm-09-00623">
        48
       </xref>
       ,
       <xref ref-type="bibr" rid="B49-jcm-09-00623">
        49
       </xref>
       ]);
       <xref ref-type="app" rid="app1-jcm-09-00623">
        Table S4
       </xref>
       ) [
       <xref ref-type="bibr" rid="B50-jcm-09-00623">
        50
       </xref>
       ,
       <xref ref-type="bibr" rid="B51-jcm-09-00623">
        51
       </xref>
       ,
       <xref ref-type="bibr" rid="B52-jcm-09-00623">
        52
       </xref>
       ]. These trials are all testing the safety and immunogenicity of their respective MERS-CoV vaccine candidates but were excluded as there are no results published yet. The trials are projected to complete in December 2020 (two studies in Russia [
       <xref ref-type="bibr" rid="B50-jcm-09-00623">
        50
       </xref>
       ,
       <xref ref-type="bibr" rid="B51-jcm-09-00623">
        51
       </xref>
       ]) and December 2021 (in Germany [
       <xref ref-type="bibr" rid="B52-jcm-09-00623">
        52
       </xref>
       ]).
      </p>
     </sec>
     <sec id="sec3dot4-jcm-09-00623">
      <title>
       3.4. Potential Therapeutics
      </title>
      <p>
       Existing literature search did not return any results on completed 2019-nCoV trials at the time of writing. Among 23 trials found from the systematic review (
       <xref ref-type="table" rid="jcm-09-00623-t005">
        Table 5
       </xref>
       ), there are nine clinical trials registered under the clinical trials registry (
       <uri>
        ClinicalTrials.gov
       </uri>
       ) for 2019-nCoV therapeutics [
       <xref ref-type="bibr" rid="B53-jcm-09-00623">
        53
       </xref>
       ,
       <xref ref-type="bibr" rid="B54-jcm-09-00623">
        54
       </xref>
       ,
       <xref ref-type="bibr" rid="B55-jcm-09-00623">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="B56-jcm-09-00623">
        56
       </xref>
       ,
       <xref ref-type="bibr" rid="B57-jcm-09-00623">
        57
       </xref>
       ,
       <xref ref-type="bibr" rid="B58-jcm-09-00623">
        58
       </xref>
       ,
       <xref ref-type="bibr" rid="B59-jcm-09-00623">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="B60-jcm-09-00623">
        60
       </xref>
       ,
       <xref ref-type="bibr" rid="B61-jcm-09-00623">
        61
       </xref>
       ]. Of which five studies on hydroxychloroquine, lopinavir plus ritonavir and arbidol, mesenchymal stem cells, traditional Chinese medicine and glucocorticoid therapy usage have commenced recruitment. The remaining four studies encompass investigation of antivirals, interferon atomization, darunavir and cobicistat, arbidol, and remdesivir usage for 2019-nCoV patients (
       <xref ref-type="table" rid="jcm-09-00623-t005">
        Table 5
       </xref>
       ).
      </p>
      <p>
       Besides the six completed randomized controlled trials (RCT) selected from the systematic review (
       <xref ref-type="table" rid="jcm-09-00623-t006">
        Table 6
       </xref>
       ), there is only one ongoing randomized controlled trial targeted at SARS therapeutics [
       <xref ref-type="bibr" rid="B92-jcm-09-00623">
        92
       </xref>
       ]. The studies found from
       <uri>
        ClinicalTrials.gov
       </uri>
       have not been updated since 2013. While many prospective and retrospective cohort studies conducted during the epidemic centered on usage of ribavirin with lopinavir/ritonavir or ribavirin only, there has yet to be well-designed clinical trials investigating their usage. Three completed randomized controlled trials were conducted during the SARS epidemic–3 in China, 1 in Taiwan and 2 in Hong Kong [
       <xref ref-type="bibr" rid="B93-jcm-09-00623">
        93
       </xref>
       ,
       <xref ref-type="bibr" rid="B94-jcm-09-00623">
        94
       </xref>
       ,
       <xref ref-type="bibr" rid="B95-jcm-09-00623">
        95
       </xref>
       ,
       <xref ref-type="bibr" rid="B96-jcm-09-00623">
        96
       </xref>
       ,
       <xref ref-type="bibr" rid="B97-jcm-09-00623">
        97
       </xref>
       ]. The studies respectively investigated antibiotic usage involving 190 participants, combination of western and Chinese treatment vs. Chinese treatment in 123 participants, integrative Chinese and Western treatment in 49 patients, usage of a specific Chinese medicine in four participants and early use of corticosteroid in 16 participants. Another notable study was an open non-randomized study investigating ribavirin/lopinavir/ritonavir usage in 152 participants [
       <xref ref-type="bibr" rid="B98-jcm-09-00623">
        98
       </xref>
       ]. One randomized controlled trial investigating integrative western and Chinese treatment during the SARS epidemic was excluded as it was a Chinese article [
       <xref ref-type="bibr" rid="B94-jcm-09-00623">
        94
       </xref>
       ].
      </p>
      <p>
       There is only one ongoing randomized controlled trial targeted at MERS therapeutics [
       <xref ref-type="bibr" rid="B99-jcm-09-00623">
        99
       </xref>
       ]. It investigates the usage of Lopinavir/Ritonavir and Interferon Beta 1B. Likewise, many prospective and retrospective cohort studies conducted during the epidemic centered on usage of ribavirin with lopinavir/ritonavir/ribavirin, interferon, and convalescent plasma usage. To date, only one trial has been completed. One phase 1 clinical trial investigating the safety and tolerability of a fully human polyclonal IgG immunoglobulin (SAB-301) was found in available literature [
       <xref ref-type="bibr" rid="B46-jcm-09-00623">
        46
       </xref>
       ]. The trial conducted in the United States in 2017 demonstrated SAB-301 to be safe and well-tolerated at single doses. Another trial on MERS therapeutics was found on
       <uri>
        ClinicalTrials.gov
       </uri>
       —a phase 2/3 trial in the United States evaluating the safety, tolerability, pharmacokinetics (PK), and immunogenicity on co-administered MERS-CoV antibodies REGN3048 &amp; REGN3051 [
       <xref ref-type="bibr" rid="B100-jcm-09-00623">
        100
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec4-jcm-09-00623" sec-type="discussion">
     <title>
      4. Discussion
     </title>
     <sec id="sec4dot1-jcm-09-00623">
      <title>
       4.1. Rapid Diagnostics
      </title>
      <p>
       Rapid diagnostics plays an important role in disease and outbreak management. The fast and accurate diagnosis of a specific viral infection enables prompt and accurate public health surveillance, prevention and control measures. Local transmission and clusters can be prevented or delayed by isolation of laboratory-confirmed cases and their close contacts quarantined and monitored at home. Rapid diagnostic also facilitates other specific public health interventions such as closure of high-risk facilities and areas associated with the confirmed cases for prompt infection control and environmental decontamination [
       <xref ref-type="bibr" rid="B11-jcm-09-00623">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="B101-jcm-09-00623">
        101
       </xref>
       ].
      </p>
      <p>
       Laboratory diagnosis can be performed by: (a) detecting the genetic material of the virus, (b) detecting the antibodies that neutralize the viral particles of interest, (c) detecting the viral epitopes of interest with antibodies (serological testing), or (d) culture and isolation of viable virus particles. The key limitations of genetic material detection are the lack of knowledge of the presence of viable virus, the potential cross-reactivity with non-specific genetic regions and the short timeframe for accurate detection during the acute infection phase. The key limitations of serological testing is the need to collect paired serum samples (in the acute and convalescent phases) from cases under investigation for confirmation to eliminate potential cross-reactivity from non-specific antibodies from past exposure and/or infection by other coronaviruses. The limitation of virus culture and isolation is the long duration and the highly specialized skills required of the technicians to process the samples.
      </p>
      <p>
       Where the biological samples are taken from also play a role in the sensitivity of these tests. For SARS-CoV and MERS-CoV, specimens collected from the lower respiratory tract such as sputum and tracheal aspirates have higher and more prolonged levels of viral RNA because of the tropism of the virus. MERS-CoV viral loads are also higher for severe cases and have longer viral shedding compared to mild cases. Although upper respiratory tract specimens such as nasopharyngeal or oropharyngeal swabs can be used, they have potentially lower viral loads and may have higher risk of false-negatives among the mild MERS and SARS cases [
       <xref ref-type="bibr" rid="B102-jcm-09-00623">
        102
       </xref>
       ,
       <xref ref-type="bibr" rid="B103-jcm-09-00623">
        103
       </xref>
       ], and likely among the 2019-nCoV cases.
      </p>
      <sec id="sec4dot1dot1-jcm-09-00623">
       <title>
        4.1.1. Detection of Genetic Material
       </title>
       <p>
        The existing practices in detecting genetic material of coronaviruses such as SARS-CoV and MERS-CoV include (a) reverse transcription-polymerase chain reaction (RT-PCR), (b) real-time RT-PCR (rRT-PCR), (c) reverse transcription loop-mediated isothermal amplification (RT-LAMP) and (d) real-time RT-LAMP [
        <xref ref-type="bibr" rid="B104-jcm-09-00623">
         104
        </xref>
        ]. Nucleic amplification tests (NAAT) are usually preferred as in the case of MERS-CoV diagnosis as it has the highest sensitivity at the earliest time point in the acute phase of infection [
        <xref ref-type="bibr" rid="B102-jcm-09-00623">
         102
        </xref>
        ]. Chinese health authorities have recently posted the full genome of 2019-nCoV in the GenBank and in GISAID portal to facilitate in the detection of the virus [
        <xref ref-type="bibr" rid="B11-jcm-09-00623">
         11
        </xref>
        ]. Several laboratory assays have been developed to detect the novel coronavirus in Wuhan, as highlighted in WHO’s interim guidance on nCoV laboratory testing of suspected cases. These include protocols from other countries such as Thailand, Japan and China [
        <xref ref-type="bibr" rid="B105-jcm-09-00623">
         105
        </xref>
        ].
       </p>
       <p>
        The first validated diagnostic test was designed in Germany. Corman et al. had initially designed a candidate diagnostic RT-PCR assay based on the SARS or SARS-related coronavirus as it was suggested that circulating virus was SARS-like. Upon the release of the sequence, assays were selected based on the match against 2019-nCoV upon inspection of the sequence alignment. Two assays were used for the RNA dependent RNA polymerase (RdRP) gene and E gene where E gene assay acts as the first-line screening tool and RdRp gene assay as the confirmatory testing. All assays were highly sensitive and specific in that they did not cross-react with other coronavirus and also human clinical samples that contained respiratory viruses [
        <xref ref-type="bibr" rid="B11-jcm-09-00623">
         11
        </xref>
        ].
       </p>
       <p>
        The Hong Kong University used two monoplex assays which were reactive with coronaviruses under the subgenus Sarbecovirus (consisting of 2019-nCoV, SARS-CoV and SARS-like coronavirus). Viral RNA extracted from SARS-CoV can be used as the positive control for the suggested protocol assuming that SARS has been eradicated. It is proposed that the N gene RT-PCR can be used as a screening assay while the Orf1b assay acts as a confirmatory test. However, this protocol has only been evaluated with a panel of controls with the only positive control SARS-CoV RNA. Synthetic oligonucleotide positive control or 2019-nCoV have yet to be tested [
        <xref ref-type="bibr" rid="B106-jcm-09-00623">
         106
        </xref>
        ].
       </p>
       <p>
        The US CDC shared the protocol on the real time RT-PCR assay for the detection of the 2019-nCoV with the primers and probes designed for the universal detection of SARS-like coronavirus and the specific detection of 2019-nCoV. However, the protocol has not been validated on other platforms or chemistries apart from the protocol described. There are some limitations for the assay. Analysts engaged have to be trained and familiar with the testing procedure and result interpretation. False negative results may occur due to insufficient organisms in the specimen resulting from improper collection, transportation or handling. Also, RNA viruses may show substantial genetic variability. This could result in mismatch between the primer and probes with the target sequence which can diminish the assay performance or result in false negative results [
        <xref ref-type="bibr" rid="B107-jcm-09-00623">
         107
        </xref>
        ]. Point-of-care test kit can potentially minimize these limitations, which should be highly prioritized for research and development in the next few months.
       </p>
      </sec>
      <sec id="sec4dot1dot2-jcm-09-00623">
       <title>
        4.1.2. Serological Testing
       </title>
       <p>
        Serological testing such as ELISA, IIFT and neutralization tests are effective in determining the extent of infection, including estimating asymptomatic and attack rate. Compared to the detection of viral genome through molecular methods, serological testing detects antibodies and antigens. There would be a lag period as antibodies specifically targeting the virus would normally appear between 14 and 28 days after the illness onset [
        <xref ref-type="bibr" rid="B108-jcm-09-00623">
         108
        </xref>
        ]. Furthermore, studies suggest that low antibody titers in the second week or delayed antibody production could be associated with mortality with a high viral load. Hence, serological diagnoses are likely used when nucleic amplification tests (NAAT) are not available or accessible [
        <xref ref-type="bibr" rid="B102-jcm-09-00623">
         102
        </xref>
        ].
       </p>
      </sec>
     </sec>
     <sec id="sec4dot2-jcm-09-00623">
      <title>
       4.2. Vaccines
      </title>
      <p>
       Vaccines can prevent and protect against infection and disease occurrence when exposed to the specific pathogen of interest, especially in vulnerable populations who are more prone to severe outcomes. In the context of the current 2019-nCoV outbreak, vaccines will help control and reduce disease transmission by creating herd immunity in addition to protecting healthy individuals from infection. This decreases the effective R0 value of the disease. Nonetheless, there are social, clinical and economic hurdles for vaccine and vaccination programmes, including (a) the willingness of the public to undergo vaccination with a novel vaccine, (b) the side effects and severe adverse reactions of vaccination, (c) the potential difference and/or low efficacy of the vaccine in populations different from the clinical trials’ populations and (d) the accessibility of the vaccines to a given population (including the cost and availability of the vaccine).
      </p>
      <p>
       Vaccines against the 2019-nCoV are currently in development and none are in testing (at the time of writing). On 23 January 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that they will fund vaccine development programmes with Inovio, The University of Queensland and Moderna, Inc respectively, with the aim to test the experimental vaccines clinically in 16 weeks (By June 2020). The vaccine candidates will be developed by the DNA, recombinant and mRNA vaccine platforms from these organizations [
       <xref ref-type="bibr" rid="B109-jcm-09-00623">
        109
       </xref>
       ].
      </p>
      <p>
       Based on the most recent MERS-CoV outbreak, there are already a number of vaccine candidates being developed but most are still in the preclinical testing stage. The vaccines in development include viral vector-based vaccine, DNA vaccine, subunit vaccine, virus-like particles (VLPs)-based vaccine, inactivated whole-virus (IWV) vaccine and live attenuated vaccine. The latest findings for these vaccines arebased on the review by Yong et al. (2019) in August 2019 [
       <xref ref-type="bibr" rid="B110-jcm-09-00623">
        110
       </xref>
       ]. As of the date of reporting, there is only one published clinical study on the MERS-CoV vaccine by GeneOne Life Science &amp; Inovio Pharmaceuticals [
       <xref ref-type="bibr" rid="B47-jcm-09-00623">
        47
       </xref>
       ]. There was one SARS vaccine trial conducted by the US National Institute of Allergy and Infectious Diseases. Both Phase I clinical trials reported positive results, but only one has announced plans to proceed to Phase 2 trial [
       <xref ref-type="bibr" rid="B111-jcm-09-00623">
        111
       </xref>
       ].
      </p>
      <p>
       Due to the close genetic relatedness of SARS-CoV (79%) with 2019-nCoV [
       <xref ref-type="bibr" rid="B112-jcm-09-00623">
        112
       </xref>
       ], there may be potential cross-protective effect of using a safe SARS-CoV vaccine while awaiting the 2019-nCoV vaccine. However, this would require small scale phase-by-phase implementation and close monitoring of vaccinees before any large scale implementation.
      </p>
     </sec>
     <sec id="sec4dot3-jcm-09-00623">
      <title>
       4.3. Therapeutics
      </title>
      <p>
       Apart from the timely diagnosis of cases, the achievement of favorable clinical outcomes depends on the timely treatment administered. ACE2 has been reported to be the same cell entry receptor used by 2019-nCoV to infect humans as SARS-CoV [
       <xref ref-type="bibr" rid="B113-jcm-09-00623">
        113
       </xref>
       ]. Hence, clinical similarity between the two viruses is expected, particularly in severe cases. In addition, most of those who have died from MERS-CoV, SARS-CoV and 2019-nCoV were advance in age and had underlying health conditions such as hypertension, diabetes or cardiovascular disease that compromised their immune systems [
       <xref ref-type="bibr" rid="B114-jcm-09-00623">
        114
       </xref>
       ]. Coronaviruses have error-prone RNA-dependent RNA polymerases (RdRP), which result in frequent mutations and recombination events. This results in quasispecies diversity that is closely associated with adaptive evolution and the capacity to enhance viral-cell entry to cause disease over time in a specific population at-risk [
       <xref ref-type="bibr" rid="B115-jcm-09-00623">
        115
       </xref>
       ]. Since ACE2 is abundantly present in humans in the epithelia of the lung and small intestine, coronaviruses are likely to infect the upper respiratory and gastrointestinal tract and this may influence the type of therapeutics against 2019-nCoV, similarly to SAR-CoV.
      </p>
      <p>
       However, in the years following two major coronavirus outbreaks SARS-CoV in 2003 and MERS-CoV in 2012, there remains no consensus on the optimal therapy for either disease [
       <xref ref-type="bibr" rid="B116-jcm-09-00623">
        116
       </xref>
       ,
       <xref ref-type="bibr" rid="B117-jcm-09-00623">
        117
       </xref>
       ]. Well-designed clinical trials that provide the gold standard for assessing the therapeutic measures are scarce. No coronavirus protease inhibitors have successfully completed a preclinical development program despite large efforts exploring SARS-CoV inhibitors. The bulk of potential therapeutic strategies remain in the experimental phase, with only a handful crossing the in vitro hurdle. Stronger efforts are required in the research for treatment options for major coronaviruses given their pandemic potential. Effective treatment options are essential to maximize the restoration of affected populations to good health following infections. Clinical trials have commenced in China to identify effective treatments for 2019-nCoV based on the treatment evidence from SARS and MERS. There is currently no effective specific antiviral with high-level evidence; any specific antiviral therapy should be provided in the context of a clinical study/trial. Few treatments have shown real curative action against SARS and MERS and the literature generally describes isolated cases or small case series.
      </p>
      <p>
       Many interferons from the three classes have been tested for their antiviral activities against SARS-CoV both in vitro and in animal models. Interferon β has consistently been shown to be the most active, followed by interferon α. The use of corticosteroids with interferon alfacon-1 (synthetic interferon α) appeared to have improved oxygenation and faster resolution of chest radiograph abnormalities in observational studies with untreated controls. Interferon has been used in multiple observational studies to treat SARS-CoV and MERS-CoV patients [
       <xref ref-type="bibr" rid="B116-jcm-09-00623">
        116
       </xref>
       ,
       <xref ref-type="bibr" rid="B117-jcm-09-00623">
        117
       </xref>
       ]. Interferons, with or without ribavirin, and lopinavir/ritonavir are most likely to be beneficial and are being trialed in China for 2019-nCoV. This drug treatment appears to be the most advanced. Timing of treatment is likely an important factor in effectiveness. A combination of ribavirin and lopinavir/ritonavir was used as a post-exposure prophylaxis in health care workers and may have reduced the risk of infection. Ribavirin alone is unlikely to have substantial antiviral activities at clinically used dosages. Hence, ribavirin with or without corticosteroids and with lopinavir and ritonavir are among the combinations employed. This was the most common agent reported in the available literature. Its efficacy has been assessed in observational studies, retrospective case series, retrospective cohort study, a prospective observational study, a prospective cohort study and randomized controlled trial ranging from seven to 229 participants [
       <xref ref-type="bibr" rid="B117-jcm-09-00623">
        117
       </xref>
       ]. Lopinavir/ritonavir (Kaletra) was the earliest protease inhibitor combination introduced for the treatment of SARS-CoV. Its efficacy was documented in several studies, causing notably lower incidence of adverse outcomes than with ribavirin alone. Combined usage with ribavirin was also associated with lower incidence of acute respiratory distress syndrome, nosocomial infection and death, amongst other favorable outcomes. Recent in vitro studies have shown another HIV protease inhibitor, nelfinavir, to have antiviral capacity against SARS-CoV, although it has yet to show favorable outcomes in animal studies [
       <xref ref-type="bibr" rid="B118-jcm-09-00623">
        118
       </xref>
       ]. Remdesivir (Gilead Sciences, GS-5734) nucleoside analogue in vitro and in vivo data support GS-5734 development as a potential pan-coronavirus antiviral based on results against several coronaviruses (CoVs), including highly pathogenic CoVs and potentially emergent BatCoVs. The use of remdesivir may be a good candidate as an investigational treatment.
      </p>
      <p>
       Improved mortality following receipt of convalescent plasma in various doses was consistently reported in several observational studies involving cases with severe acute respiratory infections (SARIs) of viral etiology. A significant reduction in the pooled odds of mortality following treatment of 0.25 compared to placebo or no therapy was observed [
       <xref ref-type="bibr" rid="B119-jcm-09-00623">
        119
       </xref>
       ]. Studies were however at moderate to high risk of bias given their small sample sizes, allocation of treatment based on the physician’s discretion, and the availability of plasma. Factors like concomitant treatment may have also confounded the results. Associations between convalescent plasma and hospital length of stay, viral antibody levels, and viral load respectively were similarly inconsistent across available literature. Convalescent plasma, while promising, is likely not yet feasible, given the limited pool of potential donors and issues of scalability. Monoclonal antibody treatment is progressing. SARS-CoV enters host cells through the binding of their spike (S) protein to angiotensin converting enzyme 2 (ACE2) and CD209L [
       <xref ref-type="bibr" rid="B118-jcm-09-00623">
        118
       </xref>
       ]. Human monoclonal antibodies to the S protein have been shown to significantly reduce the severity of lung pathology in non-human primates following MERS-CoV infection [
       <xref ref-type="bibr" rid="B120-jcm-09-00623">
        120
       </xref>
       ]. Such neutralizing antibodies can be elicited by active or passive immunization using vaccines or convalescent plasma respectively. While such neutralizing antibodies can theoretically be harvested from individuals immunized with vaccines, there is uncertainty over the achievement of therapeutic levels of antibodies.
      </p>
      <p>
       Other therapeutic agents have also been reported. A known antimalarial agent, chloroquine, elicits antiviral effects against multiple viruses including HIV type 1, hepatitis B and HCoV-229E. Chloroquine is also immunomodulatory, capable of suppressing the production and release of factors which mediate the inflammatory complications of viral diseases (tumor necrosis factor and interleukin 6) [
       <xref ref-type="bibr" rid="B121-jcm-09-00623">
        121
       </xref>
       ]. It is postulated that chloroquine works by altering ACE2 glycosylation and endosomal pH. Its anti-inflammatory properties may be beneficial for the treatment of SARS. Niclosamide as a known drug used in antihelminthic treatment. The efficacy of niclosamide as an inhibitor of virus replication was proven in several assays. In both immunoblot analysis and immunofluorescence assays, niclosamide treatment was observed to completely inhibit viral antigen synthesis. Reduction of virus yield in infected cells was dose dependent. Niclosamide likely does not interfere in the early stages of virus attachment and entry into cells, nor does it function as a protease inhibitor. Mechanisms of niclosamide activity warrant further investigation [
       <xref ref-type="bibr" rid="B122-jcm-09-00623">
        122
       </xref>
       ]. Glycyrrhizin also reportedly inhibits virus adsorption and penetration in the early steps of virus replication. Glycyrrhizin was a significantly potent inhibitor with a low selectivity index when tested against several pathogenic flaviviruses. While preliminary results suggest production of nitrous oxide (which inhibits virus replication) through induction of nitrous oxide synthase, the mechanism of Glycyrrhizin against SARS-CoV remains unclear. The compound also has relatively lower toxicity compared to protease inhibitors like ribavirin [
       <xref ref-type="bibr" rid="B123-jcm-09-00623">
        123
       </xref>
       ]. Inhibitory activity was also detected in baicalin [
       <xref ref-type="bibr" rid="B124-jcm-09-00623">
        124
       </xref>
       ], extracted from another herb used in the treatment of SARS in China and Hong Kong. Findings on these compounds are limited to in vitro studies [
       <xref ref-type="bibr" rid="B121-jcm-09-00623">
        121
       </xref>
       ,
       <xref ref-type="bibr" rid="B122-jcm-09-00623">
        122
       </xref>
       ,
       <xref ref-type="bibr" rid="B123-jcm-09-00623">
        123
       </xref>
       ,
       <xref ref-type="bibr" rid="B124-jcm-09-00623">
        124
       </xref>
       ].
      </p>
      <p>
       Due to the rapidly evolving situation of the 2019-nCoV, there will be potential limitations to the systematic review. The systematic review is likely to have publication bias as some developments have yet to be reported while for other developments there is no intention to report publicly (or in scientific platforms) due to confidentiality concerns. However, this may be limited to only a few developments for review as publicity does help in branding to some extent for the company and/or the funder. Furthermore, due to the rapid need to share the status of these developments, there may be reporting bias in some details provided by authors of the scientific articles or commentary articles in traditional media. Lastly, while it is not viable for any form of quality assessment and meta-analysis of the selected articles due to the limited data provided and the heterogeneous style of reporting by different articles, this paper has provided a comprehensive overview of the potential developments of these pharmaceutical interventions during the early phase of the outbreak. This systematic review would be useful for cross-check when the quality assessment and meta-analysis of these developments are performed as a follow-up study.
      </p>
     </sec>
    </sec>
    <sec id="sec5-jcm-09-00623" sec-type="conclusions">
     <title>
      5. Conclusions
     </title>
     <p>
      Rapid diagnostics, vaccines and therapeutics are key pharmaceutical interventions to limit transmission of respiratory infectious diseases. Many potential developments on these pharmaceutical interventions for 2019-nCoV are ongoing in the containment phase of this outbreak, potentially due to better pandemic preparedness than before. However, lessons from MERS-CoV and SARS-CoV have shown that the journeys for these developments can still be challenging moving ahead.
     </p>
    </sec>
    <back>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       We are thankful to Kim J. Png for sharing with us valuable information on commercial diagnostic development for 2019-nCoV.
      </p>
     </ack>
     <app-group>
      <app id="app1-jcm-09-00623">
       <title>
        Supplementary Materials
       </title>
       <p>
        The following are available online at
        <uri xlink:href="https://www.mdpi.com/2077-0383/9/3/623/s1">
         https://www.mdpi.com/2077-0383/9/3/623/s1
        </uri>
        , Table S1: Example of full search strategy in Pubmed, Table S2: Google Search: 2019-nCoV diagnostics, Table S3: Summary of diagnostic assays developed for 2019-nCoV, Table S4: Summary of ongoing clinical trials on MERS-CoV vaccine.
       </p>
       <supplementary-material content-type="local-data" id="jcm-09-00623-s001">
        <media xlink:href="jcm-09-00623-s001.zip">
         <caption>
          <p>
           Click here for additional data file.
          </p>
         </caption>
        </media>
       </supplementary-material>
      </app>
     </app-group>
     <notes>
      <title>
       Author Contributions
      </title>
      <p>
       Conceptualization, Y.Y.T. and C.C.T.; methodology, J.P., M.X.W., J.C.-H.Y.; software, M.X.W., A.R.C.; validation, formal analysis, investigation, J.P., M.X.W., I.Y.H.A., S.H.X.T., R.F.L., J.I.-P.C., R.A.G., S.X.W.G., P.E.Y.C., Q.Y., X.Y.N., R.K.S.Y., H.Y.T.; resources, X.X.; data curation, I.Y.H.A., R.A.G., S.H.X.T., R.F.L., J.I.-P.C., S.X.W.G., P.E.Y.C., Q.Y., X.Y.N., R.K.S.Y., H.Y.T.; writing—original draft preparation, J.P., M.X.W.; writing—review and editing, L.Y.H., C.C.T., R.A.G., J.P., and J.C.-H.Y.; visualization, M.X.W., S.X.W.G., and P.E.Y.C.; supervision, Y.Y.T., A.R.C. and L.Y.H.; project administration, J.P. and J.C.-H.Y.; funding acquisition, J.P. and J.C.-H.Y. All authors have read and agreed to the published version of the manuscript.
      </p>
     </notes>
     <notes>
      <title>
       Funding
      </title>
      <p>
       This research was funded by Ministry of Health and Ministry of Defence, Singapore.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Conflicts of Interest
      </title>
      <p>
       The authors declare no conflict of interest.
      </p>
     </notes>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1-jcm-09-00623">
       <label>
        1.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          World Health Organization
         </collab>
        </person-group>
        <article-title>
         Novel coronavirus (2019-ncov) situation report 15
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/">
          https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-05">
         (accessed on 5 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B2-jcm-09-00623">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, china: A descriptive study
        </article-title>
        <source>
         Lancet (Lond. Engl.)
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30211-7
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3-jcm-09-00623">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in wuhan, china
        </article-title>
        <source>
         Lancet (Lond. Engl.)
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30183-5
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4-jcm-09-00623">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus from patients with pneumonia in china, 2019
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
        <volume>
         382
        </volume>
        <fpage>
         727
        </fpage>
        <lpage>
         733
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001017
        </pub-id>
        <pub-id pub-id-type="pmid">
         31978945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5-jcm-09-00623">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in saudi arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B6-jcm-09-00623">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           Z.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology and cause of severe acute respiratory syndrome (sars) in guangdong, people’s republic of china, in February, 2003
        </article-title>
        <source>
         Lancet (Lond. Engl.)
        </source>
        <year>
         2003
        </year>
        <volume>
         362
        </volume>
        <fpage>
         1353
        </fpage>
        <lpage>
         1358
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)14630-2
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7-jcm-09-00623">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenicity and transmissibility of 2019-ncov-a quick overview and comparison with other emerging viruses
        </article-title>
        <source>
         Microbes Infect.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/j.micinf.2020.01.004
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8-jcm-09-00623">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nowcasting and forecasting the potential domestic and international spread of the 2019-ncov outbreak originating in wuhan, china: A modelling study
        </article-title>
        <source>
         Lancet (Lond. Engl.)
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30260-9
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9-jcm-09-00623">
       <label>
        9.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          World Health Organization
         </collab>
        </person-group>
        <article-title>
         Novel coronavirus (2019-ncov) technical guidance: Laboratory testing for 2019-ncov in humans
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance">
          https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B10-jcm-09-00623">
       <label>
        10.
       </label>
       <element-citation publication-type="web">
        <article-title>
         Charité Virology. Diagnostic detection of wuhan coronavirus 2019 (17 January 2019)
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2">
          https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B11-jcm-09-00623">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Landt
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Kaiser
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Molenkamp
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Meijer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Bleicker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Brünink
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Schneider
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Schmidt
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Detection of 2019 novel coronavirus (2019-ncov) by real-time rt-pcr
        </article-title>
        <source>
         Eurosurveillance
        </source>
        <year>
         2020
        </year>
        <volume>
         25
        </volume>
        <fpage>
         2000045
        </fpage>
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES.2020.25.3.2000045
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B12-jcm-09-00623">
       <label>
        12.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          School of Public Health The University of Hong Kong
         </collab>
        </person-group>
        <article-title>
         Detection of 2019 novel coronavirus (2019-ncov) in suspected human cases by rt-pcr
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/peiris-protocol-16-1-20.pdf?sfvrsn=af1aac73_4">
          https://www.who.int/docs/default-source/coronaviruse/peiris-protocol-16-1-20.pdf?sfvrsn=af1aac73_4
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B13-jcm-09-00623">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           S.M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           K.P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Krishnan
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           D.Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           C.K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular diagnosis of a novel coronavirus (2019-ncov) causing an outbreak of pneumonia
        </article-title>
        <source>
         Clin. Chem.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1093/clinchem/hvaa029
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14-jcm-09-00623">
       <label>
        14.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Chinese Center for Disease Control and Prevention
         </collab>
        </person-group>
        <article-title>
         Specific primers and probes for detection 2019 novel coronavirus
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html">
          http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B15-jcm-09-00623">
       <label>
        15.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Department of Medical Sciences Ministry of Public Health Thailand
         </collab>
        </person-group>
        <article-title>
         Conventional rt-pcr for detection of ncov
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/conventional-rt-pcr-followed-by-sequencing-for-detection-of-ncov-rirl-nat-inst-health-t.pdf">
          https://www.who.int/docs/default-source/coronaviruse/conventional-rt-pcr-followed-by-sequencing-for-detection-of-ncov-rirl-nat-inst-health-t.pdf
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B16-jcm-09-00623">
       <label>
        16.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nao
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Katano
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Takeda
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of second case of 2019-ncov infection in japan (corrected version)
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/method-niid-20200123-2.pdf?sfvrsn=fbf75320_7">
          https://www.who.int/docs/default-source/coronaviruse/method-niid-20200123-2.pdf?sfvrsn=fbf75320_7
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B17-jcm-09-00623">
       <label>
        17.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          U.S. Department of Health &amp; Human Services
         </collab>
        </person-group>
        <article-title>
         Real-time rt-pcr panel for detection 2019-novel coronavirus
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-for-detection-instructions.pdf">
          https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-for-detection-instructions.pdf
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B18-jcm-09-00623">
       <label>
        18.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          U.S. Department of Health &amp; Human Services
         </collab>
        </person-group>
        <article-title>
         2019-novel coronavirus (2019-ncov) real-time rrt-pcr panel primers and probes
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-primer-probes.pdf">
          https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-primer-probes.pdf
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B19-jcm-09-00623">
       <label>
        19.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Nct
         </collab>
        </person-group>
        <article-title>
         Safety and immunogenicity of a candidate mers-cov vaccine (mers001)
        </article-title>
        <year>
         2019
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03399578?term=vaccine&amp;cond=Mers+CoV&amp;draw=2&amp;rank=2">
          https://clinicaltrials.gov/ct2/show/NCT03399578?term=vaccine&amp;cond=Mers+CoV&amp;draw=2&amp;rank=2
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B20-jcm-09-00623">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           M.N.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Seong
          </surname>
          <given-names>
           M.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           B.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analytical and clinical validation of six commercial middle east respiratory syndrome coronavirus rna detection kits based on real-time reverse-transcription pcr
        </article-title>
        <source>
         Ann. Lab. Med.
        </source>
        <year>
         2016
        </year>
        <volume>
         36
        </volume>
        <fpage>
         450
        </fpage>
        <lpage>
         456
        </lpage>
        <pub-id pub-id-type="doi">
         10.3343/alm.2016.36.5.450
        </pub-id>
        <pub-id pub-id-type="pmid">
         27374710
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21-jcm-09-00623">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yano
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Senba
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Akachi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kobayashi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Nishinaka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Notomi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of middle east respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (rt-lamp)
        </article-title>
        <source>
         Virol. J.
        </source>
        <year>
         2014
        </year>
        <volume>
         11
        </volume>
        <fpage>
         139
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1743-422X-11-139
        </pub-id>
        <pub-id pub-id-type="pmid">
         25103205
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22-jcm-09-00623">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Go
          </surname>
          <given-names>
           Y.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.-S.
          </given-names>
         </name>
         <name>
          <surname>
           Cheon
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Nam
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ku
          </surname>
          <given-names>
           K.B.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           N.H.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Alison Lee
          </surname>
          <given-names>
           P.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           Y.-C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation and clinical validation of two field–deployable reverse transcription-insulated isothermal pcr assays for the detection of the middle east respiratory syndrome–coronavirus
        </article-title>
        <source>
         J. Mol. Diagn.
        </source>
        <year>
         2017
        </year>
        <volume>
         19
        </volume>
        <fpage>
         817
        </fpage>
        <lpage>
         827
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jmoldx.2017.06.007
        </pub-id>
        <pub-id pub-id-type="pmid">
         28807812
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23-jcm-09-00623">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hashemzadeh
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Rasouli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zahraei
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Izadi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tat
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Saadat
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Najarasl
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Khansari Nejad
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Dorostkar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of dual taqman based one-step rrt-pcr assay panel for rapid and accurate diagnostic test of mers-cov: A novel human coronavirus, ahead of hajj pilgrimage
        </article-title>
        <source>
         Iran Red Crescent Med. J.
        </source>
        <year>
         2016
        </year>
        <volume>
         18
        </volume>
        <fpage>
         e23874
        </fpage>
        <pub-id pub-id-type="doi">
         10.5812/ircmj.23874
        </pub-id>
        <pub-id pub-id-type="pmid">
         28191331
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24-jcm-09-00623">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           X.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           G.K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           I.F.N.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           R.W.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.-H.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Sars coronavirus detection methods
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         1108
        </fpage>
        <lpage>
         1111
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1107.041045
        </pub-id>
        <pub-id pub-id-type="pmid">
         16022791
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B25-jcm-09-00623">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           L.T.
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           Y.-W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           F.P.-F.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           S.S.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dillon
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           J.S.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A real-time pcr for sars-coronavirus incorporating target gene pre-amplification
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2003
        </year>
        <volume>
         312
        </volume>
        <fpage>
         1290
        </fpage>
        <lpage>
         1296
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2003.11.064
        </pub-id>
        <pub-id pub-id-type="pmid">
         14652014
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B26-jcm-09-00623">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           T.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hsiung
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           I.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           P.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Juang
          </surname>
          <given-names>
           J.-L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sensitive and quantitative detection of severe acute respiratory syndrome coronavirus infection by real-time nested polymerase chain reaction
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         38
        </volume>
        <fpage>
         293
        </fpage>
        <lpage>
         296
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/380841
        </pub-id>
        <pub-id pub-id-type="pmid">
         14699465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B27-jcm-09-00623">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           H.-S.
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           S.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           T.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           S.-F.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           J.-H.
          </given-names>
         </name>
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           Y.-H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           T.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           W.-Z.
          </given-names>
         </name>
         <name>
          <surname>
           Ferng
          </surname>
          <given-names>
           T.-L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Serologic and molecular biologic methods for sars-associated coronavirus infection, taiwan
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         304
        </fpage>
        <lpage>
         310
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1002.030731
        </pub-id>
        <pub-id pub-id-type="pmid">
         15030702
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B28-jcm-09-00623">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Chong
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chng
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kwang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of a western blot assay for detection of antibodies against coronavirus causing severe acute respiratory syndrome
        </article-title>
        <source>
         Clin. Diagn Lab. Immunol.
        </source>
        <year>
         2004
        </year>
        <volume>
         11
        </volume>
        <fpage>
         417
        </fpage>
        <lpage>
         422
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CDLI.11.2.417-422.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15013997
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29-jcm-09-00623">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           O.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yam
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lo
          </surname>
          <given-names>
           Y.M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early diagnosis of sars coronavirus infection by real time rt-pcr
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <year>
         2003
        </year>
        <volume>
         28
        </volume>
        <fpage>
         233
        </fpage>
        <lpage>
         238
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jcv.2003.08.004
        </pub-id>
        <pub-id pub-id-type="pmid">
         14522060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30-jcm-09-00623">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kwan
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Phuah
          </surname>
          <given-names>
           E.B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation and validation of an enzyme-linked immunosorbent assay and an immunochromatographic test for serological diagnosis of severe acute respiratory syndrome
        </article-title>
        <source>
         Clin. Diagn Lab. Immunol.
        </source>
        <year>
         2004
        </year>
        <volume>
         11
        </volume>
        <fpage>
         699
        </fpage>
        <lpage>
         703
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CDLI.11.4.699-703.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15242944
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31-jcm-09-00623">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           R.K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.M.N.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           F.C.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reverse transcriptase pcr diagnostic assay for the coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <year>
         2004
        </year>
        <volume>
         42
        </volume>
        <fpage>
         1994
        </fpage>
        <lpage>
         1999
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JCM.42.5.1994-1999.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15131160
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B32-jcm-09-00623">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mahony
          </surname>
          <given-names>
           J.B.
          </given-names>
         </name>
         <name>
          <surname>
           Petrich
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Louie
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Chong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Smieja
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chernesky
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Loeb
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Performance and cost evaluation of one commercial and six in-house conventional and real-time reverse transcription-pcr assays for detection of severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <year>
         2004
        </year>
        <volume>
         42
        </volume>
        <fpage>
         1471
        </fpage>
        <lpage>
         1476
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JCM.42.4.1471-1476.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15070991
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33-jcm-09-00623">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           I.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Yeh
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           Y.P.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunofluorescence assay for detection of the nucleocapsid antigen of the severe acute respiratory syndrome (sars)-associated coronavirus in cells derived from throat wash samples of patients with sars
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <year>
         2005
        </year>
        <volume>
         43
        </volume>
        <fpage>
         2444
        </fpage>
        <lpage>
         2448
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JCM.43.5.2444-2448.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15872279
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34-jcm-09-00623">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hwang
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Wann
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Shih
          </surname>
          <given-names>
           Y.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Quantitation of severe acute respiratory syndrome coronavirus genome by real-time polymerase chain reaction assay using minor groove binder DNA probe technology
        </article-title>
        <source>
         J. Microbiol. Immunol. Infect.
        </source>
        <year>
         2004
        </year>
        <volume>
         37
        </volume>
        <fpage>
         258
        </fpage>
        <lpage>
         265
        </lpage>
        <pub-id pub-id-type="pmid">
         15497005
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35-jcm-09-00623">
       <label>
        35.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Genesig
         </collab>
        </person-group>
        <article-title>
         Novel coronavirus strain 2019-ncov
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.genesig.com/products/10037-novel-coronavirus-strain-2019-ncov.">
          https://www.genesig.com/products/10037-novel-coronavirus-strain-2019-ncov.
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-30">
         (accessed on 30 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B36-jcm-09-00623">
       <label>
        36.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Today
         </collab>
        </person-group>
        <article-title>
         Brief-jiangsu bioperfectus technologies develops test kit for new china coronavirus
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.todayonline.com/world/brief-jiangsu-bioperfectus-technologies-develops-test-kit-new-china-coronavirus">
          https://www.todayonline.com/world/brief-jiangsu-bioperfectus-technologies-develops-test-kit-new-china-coronavirus
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-30">
         (accessed on 30 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B37-jcm-09-00623">
       <label>
        37.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Co-Diagnostics Inc
         </collab>
        </person-group>
        <article-title>
         Co-diagnostics inc designs test for new coronavirus using coprimer platform
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://codiagnostics.com/co-diagnostics-designs-new-coronavirus-test-using-coprimers/">
          http://codiagnostics.com/co-diagnostics-designs-new-coronavirus-test-using-coprimers/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-30">
         (accessed on 30 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B38-jcm-09-00623">
       <label>
        38.
       </label>
       <element-citation publication-type="web">
        <article-title>
         Genetic Engineering &amp; Biotechnology News. Coronavirus detection test in the works for wuhan
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.genengnews.com/news/coronavirus-detection-test-in-the-works-for-wuhan/">
          https://www.genengnews.com/news/coronavirus-detection-test-in-the-works-for-wuhan/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-30">
         (accessed on 30 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B39-jcm-09-00623">
       <label>
        39.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          altona Diagnostics
         </collab>
        </person-group>
        <article-title>
         Altona diagnostics is developing a rt-pcr kit for detection of novel coronavirus (2019-ncov)
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://altona-diagnostics.com/en/news/assay-for-novel-coronavirus-under-development.html">
          https://altona-diagnostics.com/en/news/assay-for-novel-coronavirus-under-development.html
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B40-jcm-09-00623">
       <label>
        40.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          BGI
         </collab>
        </person-group>
        <article-title>
         Bgi develops real-time fluorescent rt-pcr kit for detecting the 2019 novel coronavirus
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.bgi.com/global/company/news/bgi-develops-real-time-dna-based-kit-for-detecting-the-2019-novel-coronavirus/">
          https://www.bgi.com/global/company/news/bgi-develops-real-time-dna-based-kit-for-detecting-the-2019-novel-coronavirus/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-30">
         (accessed on 30 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B41-jcm-09-00623">
       <label>
        41.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          MGI
         </collab>
        </person-group>
        <article-title>
         Bgi responds to novel coronavirus with real-time detection kits, deploys emergency team to wuhan
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://en.mgitech.cn/news/129/">
          https://en.mgitech.cn/news/129/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-30">
         (accessed on 30 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B42-jcm-09-00623">
       <label>
        42.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Singapore biotech firm veredus expects to have wuhan virus test by feb 1
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.businesstimes.com.sg/companies-markets/singapore-biotech-firm-veredus-expects-to-have-wuhan-virus-test-by-feb-1">
          https://www.businesstimes.com.sg/companies-markets/singapore-biotech-firm-veredus-expects-to-have-wuhan-virus-test-by-feb-1
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-30">
         (accessed on 30 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B43-jcm-09-00623">
       <label>
        43.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Veredus Laboratories Pte Ltd.
         </collab>
        </person-group>
        <article-title>
         Veredus laboratories announces the development of a lab-on-chip for the detection of 3 coronaviruses: Mers-cov, sars-cov and 2019-ncov
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://vereduslabs.com/wordpress/wp-content/uploads/2020/01/VereCoV-Press-Release-Final.pdf">
          http://vereduslabs.com/wordpress/wp-content/uploads/2020/01/VereCoV-Press-Release-Final.pdf
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-30">
         (accessed on 30 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B44-jcm-09-00623">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           Y.P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Safety and immunogenicity from a phase i trial of inactivated severe acute respiratory syndrome coronavirus vaccine
        </article-title>
        <source>
         Antivir. Ther.
        </source>
        <year>
         2007
        </year>
        <volume>
         12
        </volume>
        <fpage>
         1107
        </fpage>
        <lpage>
         1113
        </lpage>
        <pub-id pub-id-type="pmid">
         18018769
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B45-jcm-09-00623">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Louder
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Holman
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gordon
          </surname>
          <given-names>
           I.J.
          </given-names>
         </name>
         <name>
          <surname>
           Enama
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Larkin
          </surname>
          <given-names>
           B.D.
          </given-names>
         </name>
         <name>
          <surname>
           Andrews
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Koup
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Roederer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A sars DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase i clinical trial
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2008
        </year>
        <volume>
         26
        </volume>
        <fpage>
         6338
        </fpage>
        <lpage>
         6343
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2008.09.026
        </pub-id>
        <pub-id pub-id-type="pmid">
         18824060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B46-jcm-09-00623">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Beigel
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Voell
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raviprakash
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jiao
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Luke
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Davey
          </surname>
          <given-names>
           R.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Safety and tolerability of a novel, polyclonal human anti-mers coronavirus antibody produced from transchromosomic cattle: A phase 1 randomised, double-blind, single-dose-escalation study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2018
        </year>
        <volume>
         18
        </volume>
        <fpage>
         410
        </fpage>
        <lpage>
         418
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(18)30002-1
        </pub-id>
        <pub-id pub-id-type="pmid">
         29329957
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B47-jcm-09-00623">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Modjarrad
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Mills
          </surname>
          <given-names>
           K.T.
          </given-names>
         </name>
         <name>
          <surname>
           Castellano
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Paolino
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Muthumani
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Reuschel
          </surname>
          <given-names>
           E.L.
          </given-names>
         </name>
         <name>
          <surname>
           Robb
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Racine
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Safety and immunogenicity of an anti-middle east respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2019
        </year>
        <volume>
         19
        </volume>
        <fpage>
         1013
        </fpage>
        <lpage>
         1022
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(19)30266-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         31351922
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B48-jcm-09-00623">
       <label>
        48.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Nct
         </collab>
        </person-group>
        <article-title>
         Evaluate the safety, tolerability and immunogenicity study of gls-5300 in healthy volunteers
        </article-title>
        <year>
         2019
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT03721718?term=vaccine&amp;cond=Mers+CoV&amp;draw=2&amp;rank=7">
          https://clinicaltrials.gov/ct2/show/study/NCT03721718?term=vaccine&amp;cond=Mers+CoV&amp;draw=2&amp;rank=7
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B49-jcm-09-00623">
       <label>
        49.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Nct
         </collab>
        </person-group>
        <article-title>
         A clinical trial to determine the safety and immunogenicity of healthy candidate mers-cov vaccine (mers002)
        </article-title>
        <year>
         2019
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/record/NCT04170829">
          https://clinicaltrials.gov/ct2/show/record/NCT04170829
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B50-jcm-09-00623">
       <label>
        50.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Nct
         </collab>
        </person-group>
        <article-title>
         Study of safety and immunogenicity of bvrs-gamvac-combi
        </article-title>
        <year>
         2019
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT04128059">
          https://clinicaltrials.gov/show/NCT04128059
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B51-jcm-09-00623">
       <label>
        51.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Nct
         </collab>
        </person-group>
        <article-title>
         Study of safety and immunogenicity of bvrs-gamvac
        </article-title>
        <year>
         2019
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT04130594">
          https://clinicaltrials.gov/show/NCT04130594
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B52-jcm-09-00623">
       <label>
        52.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Nct
         </collab>
        </person-group>
        <article-title>
         Randomized, double-blind, placebo-controlled, phase ib study to assess the safety and immunogenicity of mva-mers-s_df-1
        </article-title>
        <year>
         2019
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT04119440">
          https://clinicaltrials.gov/show/NCT04119440
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B53-jcm-09-00623">
       <label>
        53.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          ClinicalTrials.gov
         </collab>
        </person-group>
        <article-title>
         Efficacy and safety of hydroxychloroquine for treatment of pneumonia caused by 2019-ncov (hc-ncov)
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04261517">
          https://clinicaltrials.gov/ct2/show/NCT04261517
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B54-jcm-09-00623">
       <label>
        54.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          ClinicalTrials.gov
         </collab>
        </person-group>
        <article-title>
         A prospective, randomized controlled clinical study of antiviral therapy in the 2019-ncov pneumonia
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04255017">
          https://clinicaltrials.gov/ct2/show/NCT04255017
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B55-jcm-09-00623">
       <label>
        55.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          ClinicalTrials.gov
         </collab>
        </person-group>
        <article-title>
         A prospective, randomized controlled clinical study of interferon atomization in the 2019-ncov pneumonia
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04254874">
          https://clinicaltrials.gov/ct2/show/NCT04254874
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B56-jcm-09-00623">
       <label>
        56.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          ClinicalTrials.gov
         </collab>
        </person-group>
        <article-title>
         The efficacy of lopinavir plus ritonavir and arbidol against novel coronavirus infection
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04252885">
          https://clinicaltrials.gov/ct2/show/NCT04252885
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B57-jcm-09-00623">
       <label>
        57.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          ClinicalTrials.gov
         </collab>
        </person-group>
        <article-title>
         Mild/moderate 2019-ncov remdesivir rct
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04252664">
          https://clinicaltrials.gov/ct2/show/NCT04252664
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B58-jcm-09-00623">
       <label>
        58.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          ClinicalTrials.gov
         </collab>
        </person-group>
        <article-title>
         Efficacy and safety of darunavir and cobicistat for treatment of pneumonia caused by 2019-ncov
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04252274">
          https://clinicaltrials.gov/ct2/show/NCT04252274
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B59-jcm-09-00623">
       <label>
        59.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          ClinicalTrials.gov
         </collab>
        </person-group>
        <article-title>
         Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04252118">
          https://clinicaltrials.gov/ct2/show/NCT04252118
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B60-jcm-09-00623">
       <label>
        60.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          ClinicalTrials.gov
         </collab>
        </person-group>
        <article-title>
         Treatment and prevention of traditional chinese medicines (tcms) on 2019-ncov infection
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03301090">
          https://clinicaltrials.gov/ct2/show/NCT03301090
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B61-jcm-09-00623">
       <label>
        61.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          ClinicalTrials.gov
         </collab>
        </person-group>
        <article-title>
         Glucocorticoid therapy for novel coronavirus critically ill patients with severe acute respiratory failure (steroids-sari)
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04244591">
          https://clinicaltrials.gov/ct2/show/NCT04244591
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B62-jcm-09-00623">
       <label>
        62.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           McKay
          </surname>
          <given-names>
           B.L.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drugmakers rush to develop vaccines against china virus the wall street journal
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.wsj.com/articles/drugmakers-rush-to-develop-vaccines-against-china-virus-11579813026">
          https://www.wsj.com/articles/drugmakers-rush-to-develop-vaccines-against-china-virus-11579813026
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B63-jcm-09-00623">
       <label>
        63.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Inovio Pharmaceuticals Inc.
         </collab>
        </person-group>
        <article-title>
         Inovio selected by cepi to develop vaccine against new coronavirus inovio
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://ir.inovio.com/news-and-media/news/press-release-details/2020/Inovio-Selected-by-CEPI-to-Develop-Vaccine-Against-New-Coronavirus/default.aspx">
          http://ir.inovio.com/news-and-media/news/press-release-details/2020/Inovio-Selected-by-CEPI-to-Develop-Vaccine-Against-New-Coronavirus/default.aspx
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B64-jcm-09-00623">
       <label>
        64.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          University of Queensland Australia
         </collab>
        </person-group>
        <article-title>
         Race to develop coronavirus vaccine
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine">
          https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B65-jcm-09-00623">
       <label>
        65.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hennessy
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Australia’s been asked to make a coronavirus vaccine at ‘unprecedented speed’ business insider
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.sciencealert.com/australian-scientists-asked-to-make-coronavirus-vaccine-at-unprecedented-speed">
          https://www.sciencealert.com/australian-scientists-asked-to-make-coronavirus-vaccine-at-unprecedented-speed
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B66-jcm-09-00623">
       <label>
        66.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reinicke
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An obscure biotech stock skyrockets 38% after saying it’s testing a coronavirus antibody (vir)
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://markets.businessinsider.com/news/stocks/vir-biotechnology-stock-price-surges-coronavirus-antibody-tests-crispr-2020-1-1028847912.">
          https://markets.businessinsider.com/news/stocks/vir-biotechnology-stock-price-surges-coronavirus-antibody-tests-crispr-2020-1-1028847912.
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B67-jcm-09-00623">
       <label>
        67.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          VIR
         </collab>
        </person-group>
        <article-title>
         Vir biotechnology applying multiple platforms to address public health risk from wuhan coronavirus
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-applying-multiple-platforms-address-public">
          https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-applying-multiple-platforms-address-public
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B68-jcm-09-00623">
       <label>
        68.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Xinhua
         </collab>
        </person-group>
        <article-title>
         China cdc developing novel coronavirus vaccine xinhua
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.xinhuanet.com/english/2020-01/26/c_138734908.htm">
          http://www.xinhuanet.com/english/2020-01/26/c_138734908.htm
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B69-jcm-09-00623">
       <label>
        69.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.-H.Z.W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chinese scientists race to develop vaccine as coronavirus death toll jumps: South china morning post
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.scmp.com/news/china/society/article/3047676/number-coronavirus-cases-china-doubles-spread-rate-accelerates">
          https://www.scmp.com/news/china/society/article/3047676/number-coronavirus-cases-china-doubles-spread-rate-accelerates
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B70-jcm-09-00623">
       <label>
        70.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         China coronavirus: Hong kong researchers have already developed vaccine but need time to test it, expert reveals: South china morning post
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hong-kong-researchers-have">
          https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hong-kong-researchers-have
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B71-jcm-09-00623">
       <label>
        71.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          China Daily
         </collab>
        </person-group>
        <article-title>
         Novel coronavirus vaccine being developed: China daily
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.chinadaily.com.cn/a/202001/26/WS5e2d1768a310128217273481.html">
          https://www.chinadaily.com.cn/a/202001/26/WS5e2d1768a310128217273481.html
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B72-jcm-09-00623">
       <label>
        72.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Xinhua
         </collab>
        </person-group>
        <article-title>
         China fast-tracks novel coronavirus vaccine development xinhua
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.xinhuanet.com/english/2020-01/28/c_138739378.htm">
          http://www.xinhuanet.com/english/2020-01/28/c_138739378.htm
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B73-jcm-09-00623">
       <label>
        73.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Berkeley
          </surname>
          <given-names>
           L.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
        </person-group>
        <article-title>
         Us health officials fast-track coronavirus vaccine, hope to start clinical trial in three months: Cnbc markets
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.cnbc.com/2020/01/28/us-fast-tracks-coronavirus-vaccine-hopes-to-start-trial-in-three-months.html">
          https://www.cnbc.com/2020/01/28/us-fast-tracks-coronavirus-vaccine-hopes-to-start-trial-in-three-months.html
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B74-jcm-09-00623">
       <label>
        74.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bursztynsky
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         J&amp;j scientific officer ‘pretty confident’ they can create coronavirus vaccine as outbreak widens: Cnbc markets
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.cnbc.com/2020/01/27/jj-pretty-confident-it-can-create-china-coronavirus-vaccine.html">
          https://www.cnbc.com/2020/01/27/jj-pretty-confident-it-can-create-china-coronavirus-vaccine.html
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B75-jcm-09-00623">
       <label>
        75.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          The Canadian Press
         </collab>
        </person-group>
        <article-title>
         Saskatchewan lab joins global effort to develop coronavirus vaccine
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.cbc.ca/news/canada/saskatchewan/vido-intervac-working-on-coronavirus-vaccine-1.5439118">
          https://www.cbc.ca/news/canada/saskatchewan/vido-intervac-working-on-coronavirus-vaccine-1.5439118
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B76-jcm-09-00623">
       <label>
        76.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          GeoVax
         </collab>
        </person-group>
        <article-title>
         Geovax and bravovax (wuhan, china) to collaborate on development of coronavirus vaccine
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.geovax.com/news/geovax-and-bravovax-wuhan-china-to-collaborate-on-development-of-coronavirus-vaccine">
          https://www.geovax.com/news/geovax-and-bravovax-wuhan-china-to-collaborate-on-development-of-coronavirus-vaccine
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B77-jcm-09-00623">
       <label>
        77.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Clover Biopharmaceuticals
         </collab>
        </person-group>
        <article-title>
         Clover initiates development of recombinant subunit- trimer vaccine for wuhan coronavirus (2019-ncov)
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.cloverbiopharma.com/index.php?m=content&amp;c=index&amp;a=show&amp;catid=11&amp;id=40">
          http://www.cloverbiopharma.com/index.php?m=content&amp;c=index&amp;a=show&amp;catid=11&amp;id=40
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B78-jcm-09-00623">
       <label>
        78.
       </label>
       <element-citation publication-type="web">
        <article-title>
         Precision Vaccinations. Mrna vaccines can induce immune responses for 2019- ncov
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.precisionvaccinations.com/curevac-mrna-platform-specifically-suitable-rapidly-provide-answer-viral-outbreak-situation-novel">
          https://www.precisionvaccinations.com/curevac-mrna-platform-specifically-suitable-rapidly-provide-answer-viral-outbreak-situation-novel
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-29">
         (accessed on 29 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B79-jcm-09-00623">
       <label>
        79.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Usdin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         J&amp;j developing coronavirus vaccine, at least nine other vaccines under development
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.biocentury.com/bc-extra/company-news/2020-01-27/jj-developing-coronavirus-vaccine-least-nine-other-vaccines-under-">
          https://www.biocentury.com/bc-extra/company-news/2020-01-27/jj-developing-coronavirus-vaccine-least-nine-other-vaccines-under-
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-29">
         (accessed on 29 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B80-jcm-09-00623">
       <label>
        80.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Chinese Clinical Trial Registry
         </collab>
        </person-group>
        <article-title>
         A randomized, open-label, blank-controlled trial for the efficacy and safety of lopinavir-ritonavir and interferon-alpha 2b in hospitalization patients with novel coronavirus infection
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/showprojen.aspx?proj=48684">
          http://www.chictr.org.cn/showprojen.aspx?proj=48684
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-29">
         (accessed on 29 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B81-jcm-09-00623">
       <label>
        81.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           N.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gilead mulls repositioning failed ebola drug in china virus
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.fiercebiotech.com/biotech/gilead-mulls-repositioning-failed-ebola-drug-china-virus">
          https://www.fiercebiotech.com/biotech/gilead-mulls-repositioning-failed-ebola-drug-china-virus
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-29">
         (accessed on 29 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B82-jcm-09-00623">
       <label>
        82.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Science Mag
         </collab>
        </person-group>
        <article-title>
         Can an anti-hiv combination or other existing drugs outwit the new coronavirus?
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.sciencemag.org/news/2020/01/can-anti-hiv-combination-or-other-existing-drugs-outwit-new-coronavirus">
          https://www.sciencemag.org/news/2020/01/can-anti-hiv-combination-or-other-existing-drugs-outwit-new-coronavirus
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-29">
         (accessed on 29 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B83-jcm-09-00623">
       <label>
        83.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Today
         </collab>
        </person-group>
        <article-title>
         Brief-ascletis pharma clarifies media reports on coronavirus treatment
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.todayonline.com/world/brief-ascletis-pharma-clarifies-media-reports-coronavirus-treatment?cid=todayInsideTodaypage">
          https://www.todayonline.com/world/brief-ascletis-pharma-clarifies-media-reports-coronavirus-treatment?cid=todayInsideTodaypage
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-29">
         (accessed on 29 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B84-jcm-09-00623">
       <label>
        84.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Speights
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         5 biotech stocks to watch with the coronavirus scare
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.fool.com/investing/2020/01/26/what-to-expect-in-pfizers-q3-earnings-update.aspx">
          https://www.fool.com/investing/2020/01/26/what-to-expect-in-pfizers-q3-earnings-update.aspx
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-29">
         (accessed on 29 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B85-jcm-09-00623">
       <label>
        85.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Pharmaceutical Tech
         </collab>
        </person-group>
        <article-title>
         Coronavirus: Gilead, purdue university explore potential treatments
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.pharmaceutical-technology.com/news/coronavirus-drugs-development/">
          https://www.pharmaceutical-technology.com/news/coronavirus-drugs-development/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-29">
         (accessed on 29 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B86-jcm-09-00623">
       <label>
        86.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Chinese Clinical Trial Registry
         </collab>
        </person-group>
        <article-title>
         A prospective comparative study for xue-bi-jing injection in the treatment of pneumonia cause by novel coronavirus infection
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/hvshowproject.aspx?id=21735">
          http://www.chictr.org.cn/hvshowproject.aspx?id=21735
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-07">
         (accessed on 7 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B87-jcm-09-00623">
       <label>
        87.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Chinese Clinical Trial Registry
         </collab>
        </person-group>
        <article-title>
         Adjunctive corticosteroid therapy for patients with severe 2019-ncov pneumonia: A randomized controlled trial
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/showprojen.aspx?proj=48777">
          http://www.chictr.org.cn/showprojen.aspx?proj=48777
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-07">
         (accessed on 7 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B88-jcm-09-00623">
       <label>
        88.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mak
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus outbreak pushes chinese biotech stocks higher despite market downturn
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.bioworld.com/articles/432890-coronavirus-outbreak-pushes-chinese-biotech-stocks-higher-despite-market-downturn">
          https://www.bioworld.com/articles/432890-coronavirus-outbreak-pushes-chinese-biotech-stocks-higher-despite-market-downturn
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-07">
         (accessed on 7 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B89-jcm-09-00623">
       <label>
        89.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus: Chinese researchers claim tcm herbal remedy could ‘inhibit’ 2019-ncov
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.bioworld.com/articles/432838-coronavirus-chinese-researchers-claim-tcm-herbal-remedy-could-inhibit-2019-ncov">
          https://www.bioworld.com/articles/432838-coronavirus-chinese-researchers-claim-tcm-herbal-remedy-could-inhibit-2019-ncov
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-07">
         (accessed on 7 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B90-jcm-09-00623">
       <label>
        90.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Chinese Clinical Trial Registry
         </collab>
        </person-group>
        <article-title>
         A randomized, open-label, blank-controlled, multicenter trial for shuang-huang-lian oral solution in the treatment of 2019-ncov pneumonia
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/showprojen.aspx?proj=49051">
          http://www.chictr.org.cn/showprojen.aspx?proj=49051
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-07">
         (accessed on 7 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B91-jcm-09-00623">
       <label>
        91.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Chinese Clinical Trial Registry
         </collab>
        </person-group>
        <article-title>
         A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with 2019-ncov pneumonia
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/showprojen.aspx?proj=49145">
          http://www.chictr.org.cn/showprojen.aspx?proj=49145
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-07">
         (accessed on 7 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B92-jcm-09-00623">
       <label>
        92.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          ClinicalTrials.gov
         </collab>
        </person-group>
        <article-title>
         A multi-centre, double-blinded, randomized, placebo-controlled trial on the efficacy and safety of lopinavir ritonavir plus ribavirin in the treatment of severe acute respiratory syndrome
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00578825">
          https://clinicaltrials.gov/ct2/show/NCT00578825
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B93-jcm-09-00623">
       <label>
        93.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Hwang
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chao
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Ker
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chien
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The lesson of supplementary treatment with chinese medicine on severe laboratory-confirmed sars patients
        </article-title>
        <source>
         Am. J. Chin. Med.
        </source>
        <year>
         2006
        </year>
        <volume>
         34
        </volume>
        <fpage>
         927
        </fpage>
        <lpage>
         935
        </lpage>
        <pub-id pub-id-type="doi">
         10.1142/S0192415X06004405
        </pub-id>
        <pub-id pub-id-type="pmid">
         17163582
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B94-jcm-09-00623">
       <label>
        94.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qiang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Biao
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Rui-lin
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Bao-guo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li-min
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Hai-jian
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yan-nan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hong-qiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ying-min
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical controlled study of integrative chinese and western medicine in treating 49 cases of sars
        </article-title>
        <source>
         Chin. J. Integr. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         9
        </volume>
        <fpage>
         175
        </fpage>
        <lpage>
         180
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/BF02838027
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B95-jcm-09-00623">
       <label>
        95.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Allen Chan
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           V.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           K.T.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Effects of early corticosteroid treatment on plasma sars-associated coronavirus rna concentrations in adult patients
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         31
        </volume>
        <fpage>
         304
        </fpage>
        <lpage>
         309
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jcv.2004.07.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         15494274
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B96-jcm-09-00623">
       <label>
        96.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Layon
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with sars
        </article-title>
        <source>
         Am. J. Chin. Med.
        </source>
        <year>
         2006
        </year>
        <volume>
         34
        </volume>
        <fpage>
         937
        </fpage>
        <lpage>
         947
        </lpage>
        <pub-id pub-id-type="doi">
         10.1142/S0192415X06004417
        </pub-id>
        <pub-id pub-id-type="pmid">
         17163583
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B97-jcm-09-00623">
       <label>
        97.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (sars) in guangzhou, pr china
        </article-title>
        <source>
         J. Med. Microbiol.
        </source>
        <year>
         2003
        </year>
        <volume>
         52
        </volume>
        <fpage>
         715
        </fpage>
        <lpage>
         720
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jmm.0.05320-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         12867568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B98-jcm-09-00623">
       <label>
        98.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           I.F.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Role of lopinavir/ritonavir in the treatment of sars: Initial virological and clinical findings
        </article-title>
        <source>
         Thorax
        </source>
        <year>
         2004
        </year>
        <volume>
         59
        </volume>
        <fpage>
         252
        </fpage>
        <lpage>
         256
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/thorax.2003.012658
        </pub-id>
        <pub-id pub-id-type="pmid">
         14985565
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B99-jcm-09-00623">
       <label>
        99.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          ClinicalTrials.gov
         </collab>
        </person-group>
        <article-title>
         Mers-cov infection treated with a combination of lopinavir ritonavir and interferon beta-1b
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02845843">
          https://clinicaltrials.gov/ct2/show/NCT02845843
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B100-jcm-09-00623">
       <label>
        100.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          ClinicalTrials.gov
         </collab>
        </person-group>
        <article-title>
         A safety, tolerability, pharmacokinetics and immunogenicity trial of co-administered mers-cov antibodies regn3048 and regn3051
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03301090">
          https://clinicaltrials.gov/ct2/show/NCT03301090
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-10">
         (accessed on 10 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B101-jcm-09-00623">
       <label>
        101.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Medical Technology
         </collab>
        </person-group>
        <article-title>
         The importance of diagnostic tests in fighting infectious diseases
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.lifechanginginnovation.org/medtech-facts/importance-diagnostic-tests-fighting-infectious-diseases">
          https://www.lifechanginginnovation.org/medtech-facts/importance-diagnostic-tests-fighting-infectious-diseases
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B102-jcm-09-00623">
       <label>
        102.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kelly-Cirino
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Mazzola
          </surname>
          <given-names>
           L.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chua
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Oxenford
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An updated roadmap for mers-cov research and product development: Focus on diagnostics
        </article-title>
        <source>
         BMJ Glob. Health
        </source>
        <year>
         2019
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e001105
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/bmjgh-2018-001105
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B103-jcm-09-00623">
       <label>
        103.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Public Health Laboratory Network
         </collab>
        </person-group>
        <article-title>
         Phln guidance on laboratory testing for 2019-ncov 2020
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.health.gov.au/sites/default/files/documents/2020/01/phln-guidance-on-laboratory-testing-for-2019-ncov-phln-guidance-on-laboratory-testing-for-novel-coronavirus-2019-ncov.pdf">
          https://www.health.gov.au/sites/default/files/documents/2020/01/phln-guidance-on-laboratory-testing-for-2019-ncov-phln-guidance-on-laboratory-testing-for-novel-coronavirus-2019-ncov.pdf
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B104-jcm-09-00623">
       <label>
        104.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recent advances in the detection of respiratory virus infection in humans
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25674
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B105-jcm-09-00623">
       <label>
        105.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          World Health Organization
         </collab>
        </person-group>
        <article-title>
         Laboratory testing for 2019 novel coronavirus (2019-ncov) in suspected human cases
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-coronavirus">
          https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-coronavirus
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B106-jcm-09-00623">
       <label>
        106.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          HKU Med
         </collab>
        </person-group>
        <article-title>
         Detection of 2019 novel coronavirus (2019-ncov) in suspected human cases by rt-pcr lks faculty of medicine school of public health
        </article-title>
        <year>
         2020
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/peiris-protocol-16-1-20.pdf?sfvrsn=af1aac73_4.">
          https://www.who.int/docs/default-source/coronaviruse/peiris-protocol-16-1-20.pdf?sfvrsn=af1aac73_4.
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B107-jcm-09-00623">
       <label>
        107.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
         <collab>
          RVB. Division of viral diseases
         </collab>
        </person-group>
        <article-title>
         Real-time rt-pcr panel for detection 2019- novel coronavirus 2020
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/uscdcrt-pcr-panel-for-detection-instructions.pdf?sfvrsn=3aa07934_2">
          https://www.who.int/docs/default-source/coronaviruse/uscdcrt-pcr-panel-for-detection-instructions.pdf?sfvrsn=3aa07934_2
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B108-jcm-09-00623">
       <label>
        108.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Johani
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hajeer
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mers-cov diagnosis: An update
        </article-title>
        <source>
         J. Infect. Public Health
        </source>
        <year>
         2016
        </year>
        <volume>
         9
        </volume>
        <fpage>
         216
        </fpage>
        <lpage>
         219
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jiph.2016.04.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         27106390
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B109-jcm-09-00623">
       <label>
        109.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          CEPI
         </collab>
        </person-group>
        <article-title>
         Cepi to fund three programmes to develop vaccines against the novel coronavirus, ncov-2019
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://cepi.net/news_cepi/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019/">
          https://cepi.net/news_cepi/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-29">
         (accessed on 29 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B110-jcm-09-00623">
       <label>
        110.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yong
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ong
          </surname>
          <given-names>
           H.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yeap
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus
        </article-title>
        <source>
         Front. Microbiol.
        </source>
        <year>
         2019
        </year>
        <volume>
         10
        </volume>
        <fpage>
         1781
        </fpage>
        <pub-id pub-id-type="doi">
         10.3389/fmicb.2019.01781
        </pub-id>
        <pub-id pub-id-type="pmid">
         31428074
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B111-jcm-09-00623">
       <label>
        111.
       </label>
       <element-citation publication-type="book">
        <source>
         Inovio’s Positive First-Inhhuman Mers Vaccine Results Published in the Lancet Infectious Diseases
        </source>
        <publisher-name>
         Athena Information Solutions Pvt. Ltd.
        </publisher-name>
        <publisher-loc>
         Mumbai, India
        </publisher-loc>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="B112-jcm-09-00623">
       <label>
        112.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding
        </article-title>
        <source>
         Lancet (Lond. Engl.)
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         565
        </fpage>
        <lpage>
         574
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30251-8
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B113-jcm-09-00623">
       <label>
        113.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Si
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A pneumonia outbreak associated with a new coronavirus of probable bat origin
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1038/s41586-020-2012-7
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B114-jcm-09-00623">
       <label>
        114.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sars and mers: Recent insights into emerging coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2016
        </year>
        <volume>
         14
        </volume>
        <fpage>
         523
        </fpage>
        <lpage>
         534
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro.2016.81
        </pub-id>
        <pub-id pub-id-type="pmid">
         27344959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B115-jcm-09-00623">
       <label>
        115.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Origin and evolution of pathogenic coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2019
        </year>
        <volume>
         17
        </volume>
        <fpage>
         181
        </fpage>
        <lpage>
         192
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/s41579-018-0118-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         30531947
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B116-jcm-09-00623">
       <label>
        116.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Momattin
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Ali
          </surname>
          <given-names>
           A.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A systematic review of therapeutic agents for the treatment of the middle east respiratory syndrome coronavirus (mers-cov)
        </article-title>
        <source>
         Travel Med. Infect. Dis.
        </source>
        <year>
         2019
        </year>
        <volume>
         30
        </volume>
        <fpage>
         9
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.tmaid.2019.06.012
        </pub-id>
        <pub-id pub-id-type="pmid">
         31252170
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B117-jcm-09-00623">
       <label>
        117.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Momattin
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Mohammed
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Therapeutic options for middle east respiratory syndrome coronavirus (mers-cov) – possible lessons from a systematic review of sars-cov therapy
        </article-title>
        <source>
         Int. J. Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         17
        </volume>
        <fpage>
         e792
        </fpage>
        <lpage>
         e798
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ijid.2013.07.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         23993766
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B118-jcm-09-00623">
       <label>
        118.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.-Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The management of coronavirus infections with particular reference to sars
        </article-title>
        <source>
         J. Antimicrob. Chemother.
        </source>
        <year>
         2008
        </year>
        <volume>
         62
        </volume>
        <fpage>
         437
        </fpage>
        <lpage>
         441
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/jac/dkn243
        </pub-id>
        <pub-id pub-id-type="pmid">
         18565970
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B119-jcm-09-00623">
       <label>
        119.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mair-Jenkins
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Saavedra-Campos
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Baillie
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Cleary
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Khaw
          </surname>
          <given-names>
           F.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.S.
          </given-names>
         </name>
         <name>
          <surname>
           Makki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rooney
          </surname>
          <given-names>
           K.D.
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen-Van-Tam
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Beck
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         211
        </volume>
        <fpage>
         80
        </fpage>
        <lpage>
         90
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiu396
        </pub-id>
        <pub-id pub-id-type="pmid">
         25030060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B120-jcm-09-00623">
       <label>
        120.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Bagci
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Keith
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Mollura
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Zeitlin
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Huzella
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bartos
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bohorova
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         3b11-n, a monoclonal antibody against mers-cov, reduces lung pathology in rhesus monkeys following intratracheal inoculation of mers-cov jordan-n3/2012
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2016
        </year>
        <volume>
         490
        </volume>
        <fpage>
         49
        </fpage>
        <lpage>
         58
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2016.01.004
        </pub-id>
        <pub-id pub-id-type="pmid">
         26828465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B121-jcm-09-00623">
       <label>
        121.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Maes
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Neyts
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ranst
          </surname>
          <given-names>
           M.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2004
        </year>
        <volume>
         323
        </volume>
        <fpage>
         264
        </fpage>
        <lpage>
         268
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2004.08.085
        </pub-id>
        <pub-id pub-id-type="pmid">
         15351731
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B122-jcm-09-00623">
       <label>
        122.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           C.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Jan
          </surname>
          <given-names>
           J.-T.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           H.-P.
          </given-names>
         </name>
         <name>
          <surname>
           Hwang
          </surname>
          <given-names>
           D.-R.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           H.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Hong
          </surname>
          <given-names>
           C.-F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide
        </article-title>
        <source>
         Antimicrob. Agents Chemother.
        </source>
        <year>
         2004
        </year>
        <volume>
         48
        </volume>
        <fpage>
         2693
        </fpage>
        <lpage>
         2696
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.48.7.2693-2696.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15215127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B123-jcm-09-00623">
       <label>
        123.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Bauer
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chandra
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rabenau
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Doerr
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Glycyrrhizin, an active component of liquorice roots, and replication of sars-associated coronavirus
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <fpage>
         2045
        </fpage>
        <lpage>
         2046
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13615-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         12814717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B124-jcm-09-00623">
       <label>
        124.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           R.Y.T.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.T.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tsui
          </surname>
          <given-names>
           W.H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           I.F.N.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           T.S.W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         In vitro susceptibility of 10 clinical isolates of sars coronavirus to selected antiviral compounds
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         31
        </volume>
        <fpage>
         69
        </fpage>
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jcv.2004.03.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         15288617
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="jcm-09-00623-f001" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        A PRISMA flow diagram of the search strategy for diagnostics, vaccine and therapeutics of 2019-nCoV, MERS-CoV and SARS-CoV.
       </p>
      </caption>
      <graphic xlink:href="jcm-09-00623-g001">
      </graphic>
     </fig>
     <table-wrap id="jcm-09-00623-t001" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       jcm-09-00623-t001_Table 1
      </object-id>
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Systematic search outcomes for diagnostic evaluation of 2019-nCoV, SARS-CoV and MERS-CoV.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          S/N
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Year
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Author (Country)
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Test
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Population/Samples
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Finding
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          References
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="7" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2019-nCoV
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2020
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Corman et al. (Germany)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          rRT-PCR; First-line screening tool: E gene assay; Confirmatory testing: RdRp gene assay.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Respiratory samples were obtained during 2019 from patients hospitalised at Charité medical Centre.
          <break>
          </break>
          Additional samples were selected from biobanks at the Rijksinstituut voor Volksgezondheid en Milieu), Bilthoven, at Erasmus University Medical Center, Rotterdam, at Public Health England, London, and at the University of Hong Kong.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preliminary finding with SARS-CoV strain Frankfurt-1 virions grown on Vero cells, E gene and RdRp gene assays produced the best result (5.2 and 3.8 copies per reaction at 95% detection probability, respectively)
          <break>
          </break>
          In vitro transcript RNA identical to 2019-nCoV target sequence, 3.9 copies per reaction for the E gene assay and 3.6 copies per reaction for the RdRp assay which were close to the 95% hit rate of 2.9 copies per reaction
          <break>
          </break>
          When tested for cross-reaction with other coronavirus, there was no reactivity with the assays.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B11-jcm-09-00623">
           11
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="7" rowspan="1" style="border-bottom:solid thin" valign="middle">
          MERS-CoV
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2016
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Kim et al. (Korea)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Six different commercial MERS-CoV RNA detection kits based on rRT-PCR:
          <break>
          </break>
          (i) PowerChek (Kogene Biotech, Korea); (ii) DiaPlexQ (SolGent, Korea); (iii) Anyplex (Seegene, Korea)
          <break>
          </break>
          Screening: envelope gene (upE)
          <break>
          </break>
          Confirmation: ORF1a
          <break>
          </break>
          (iv) AccuPower (Bioneer, Korea) (v) LightMix (Roche Molecular Diagnostics, Switzerland) (vi) UltraFast kits (Nanobiosys, Korea)
          <break>
          </break>
          detect upE and ORF1a simultaneously
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          28 nasopharyngeal swabs that were positive for other respiratory viruses were used for specificity and
          <break>
          </break>
          18 lower respiratory specimens for clinical sensitivity.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          All six kits correctly identified 8 of 8 (100%) positive clinical specimens. However, based on the findings from the high inhibition panel, PowerChek and AccuPower were the least sensitive to the presence of PCR inhibition.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B20-jcm-09-00623">
           20
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          3
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2014
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Shirato et al. (Japan)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Loopamp RNA Amplification Kit (RT-LAMP; Eiken, Tokyo, Japan)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          laboratory isolates MERS-CoV diluted with medium containing pharyngeal swabs obtained from healthy adults
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Real-time RT-PCR was able to detect at level as low as 1.6 copies of MERS-CoV RNA while RT-LAMP was also able to detect viral RNA at levels as low as 0.7 copies, showing equivalence with the RT-PCR assay.
          <break>
          </break>
          There was no cross reactivity with other respiratory viruses, for RT-LAMP
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B21-jcm-09-00623">
           21
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2017
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Go et al. (Korea)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RT-iiPCR
          <break>
          </break>
          Target upE and ORF1a gene
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          55 sequential sputum samples collected from 12 patients infected with MERS-CoV were obtained from the Chungnam National University Hospital.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Overall agreement between RT-iiPCR assays and reference RT-qPCR assays were 98.06% (95% CI, 94.43–100%) and 99.03% (95% CI, 95.88–100%) for ORF1a and upE assays, respectively.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B22-jcm-09-00623">
           22
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          5
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2015
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Hashemzadeh et al. (Iran)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          A onestep rRT-PCR assay, based on specific TaqMan probes
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          UpE and ORF1b was synthesized due to the difficulty in acquiring patient sample
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          The sensitivity obtained for upE was fewer than ten copies of RNA template per reaction and for ORF1b was 50 or fewer copies per reaction.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B23-jcm-09-00623">
           23
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="4" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SARS-CoV
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          6
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2005
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Lau et al. (Hong Kong)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Real time qRT-PCR; Antibody-based capture ELISA
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          40 SARS patients hospitalized in HK between March–May 2003
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Sensitivities for qRT-PCR (80% for fecal samples and 25% for urine samples) were higher than those of the polyclonal (50% and 5%) and monoclonal (35% and 8%) antibody-based nucleocapsid antigen capture enzyme-linked immunosorbent assays.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B24-jcm-09-00623">
           24
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          7
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2003
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Lau et al. (Hong Kong)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Enhanced real-time fluorescent PCR
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          80 suspected or probable SARS cases between 1–3 April 2003
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          The limit of detection of the enhanced real-time PCR method was 10
          <sup>
           2
          </sup>
          -fold higher than the standard real-time PCR assay and 10
          <sup>
           7
          </sup>
          -fold higher than conventional PCR methods
          <break>
          </break>
          In the clinical aspect, the enhanced real-time PCR method was able to detect 6 cases of SARS-CoV positive samples that were not confirmed by any other assay
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B25-jcm-09-00623">
           25
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          8
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2004
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Jiang et al. (Taiwan)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Quantitative, real-time, nested polymerase chain reaction
          <break>
          </break>
          (PCR)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          46 patients with suspected or reported SARS April through May 2003 in Taiwan
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          The single round PCR yielded a minor amplification signal. Nested PCR produce signal without apparent background. The single round RT-PCR detected 15 of 46 positive cases, while the nest real-time PCR detected 17 of 46 cases.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B26-jcm-09-00623">
           26
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          9
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2004
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Wu et al. (Taiwan)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Neutralization test,
          <break>
          </break>
          (ELISA), (IFA), and (ICT)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          537 probable SARS patients in Taiwan
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          With the neutralization test as a reference method, the sensitivity, specificity, positive predictive value, and negative predictive value of the test were
          <break>
          </break>
          ELISA: 98.2%, 98.7%, 98.7%, and 98.4%
          <break>
          </break>
          IFA: 99.1%, 87.8%, 88.1% and 99.1%
          <break>
          </break>
          ICT: 33.6%, 98.2%, 95.7%, and 56.1%
          <break>
          </break>
          RT-PCR: 52.2%, 78.7%, 74.5%, and 58.1%,
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B27-jcm-09-00623">
           27
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          10
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2003
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          He et al. (Singapore)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Western blot assay with N195 protein
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          274 clinical sera which were collected
          <break>
          </break>
          from patients suffering from probable or suspected SARS, dengue fever, autoimmune diseases
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          The specificity and sensitivity of this test were 98.3 and 90.9% and 40 of 44 clinical SARS samples were positive.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B28-jcm-09-00623">
           28
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          11
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2003
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Poon et al. (Hong Kong)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Real time quantitative RT-PCR modified RNA extraction method
          <break>
          </break>
          1b region of SARS-CoVCoV
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          50 NPA samples collected from days 1–3 of disease onset from SARS patients in whom SARS CoV infections was subsequently serologically confirmed
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          From the 50 NPA specimens collected during the first 3 days of illness, the first-generation RT-PCR assay identified 22% positive sample, modification in the RNA extraction method identified 44% positive samples and the combination of the modified RNA extraction method and real-time quantitative PCR technology, identified 80% positive sample.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B29-jcm-09-00623">
           29
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          12
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2004
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Guan et al. (Hong Kong)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Specific ELISA Genelabs Diagnostics Pte Ltd. utilizing two recombinant proteins (Gst-N and Gst-U274)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          227 clinical serum specimens collected from SARS patients in Hong Kong between 18 March–24 May 2003 and 385 samples from healthy donors.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          For the ELISA, the overall sensitivity was 71.8% and specificity was 99.5%
          <break>
          </break>
          For the immunocromatographic test, overall rate of detection of SARS-associated specimens by the rapid test was 70.5% and its specificity was 97.7%.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B30-jcm-09-00623">
           30
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          13
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2003
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Hui et al. (Hong Kong)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RT-PCR
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Clinical samples, NPAs (n = 131) and stool specimens (n = 5), provided by the Department of Microbiology, The University of Hong Kong.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          PCR amplifying the N gene gave an average of a 26.0% (6.3 to 60.0%) stronger intensity signal than that for the 1b gene additional sensitive molecular marker for the diagnosis of the SARS coronavirus
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B31-jcm-09-00623">
           31
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          14
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2004
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Mahony et al. (Canada)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Seven RT-PCR assays include (i) a nested assay with BNI outer and inner primers with polB gene; (ii) a two-step, non-nested assay with the BNI outer primers with polB gene; (iii) a two-step, non-nested RT-PCR assay with Cor-p-F2 and Cor-p-R1 with polB gene; (iv) a one-step RT-PCR, with BNI outer primers and polB gene with SYBR Green detection; (v) a two-step assay amplifying and nucleocapsid gene with SYBR Green detection; (vi) a one-step assay with the same nucleocapsid primers and gene with TaqMan probe and (vii) a commercial RealArt HPA CoV RT-PCR assay (Artus).
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          68 specimens, including 17 respiratory tract specimens (nasopharyngeal or throat swabs), 29 urine samples, and 22 stool samples, were collected between March–April of 2003 from hospitalized patients with a probable or suspected diagnosis of SARS at Sunnybrook and Women’s College Health Sciences Centre during the Toronto outbreak of SARS.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          There is no significant difference in the sensitivity and specificity for the 7 assays
          <break>
          </break>
          Assay 1: 94%; 100%
          <break>
          </break>
          Assay 2: 100%; 94%
          <break>
          </break>
          Assay 3: 94%; 100%
          <break>
          </break>
          Assay 4: 100%; 96%
          <break>
          </break>
          Assay 5: 94%; 100%
          <break>
          </break>
          Assay 6: 83%; 100%
          <break>
          </break>
          Assay 7: 94%; 100%
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B32-jcm-09-00623">
           32
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          15.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2004
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Liu et al. (Taiwan)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Indirect IFA
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Throat wash samples from 17 confirmed SARS adult patients, and 10 healthy controls admitted to the emergency department of the National Taiwan University Hospital between 16 April–1 May 2003.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SARS-CoV was detected in 11 of 17 (65%) samples from SARS patients from day 2 to day 9 of the illness but in none of the 10 samples from healthy controls
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B33-jcm-09-00623">
           33
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          16.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2004
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Lin et al. (Taiwan)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SARS-CoV real-time PCR assay with a TaqMan minor groove binder probe developed by Applied Biosystems (Foster City, CA, USA).
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          228 samples (137 sputum, 53 throat swabs or throat wash, 17 NPS, 19 stool specimen, 2 pleural fluid, 2 urine and 1 serum sample) from 151 patients with atypical
          <break>
          </break>
          pneumonia or symptoms mimicking SARS between 30 April–26 June 26 were recruited,
          <break>
          </break>
          In total, from 151 patients were tested.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          • The real time PCR has a threshold sensitivity of 10 genome equivalents per reaction and it has a good reproducibility with the inter-assay coefficients of variation of 1.73 to 2.72%.
          <break>
          </break>
          • 13 specimens from 6 patients were positive with viral load range from 362 to 36,240,000 genome equivalents/mL.
          <break>
          </break>
          The real-time RT-PCR reaction was more sensitive than the nested PCR reaction, as the detection limit for the nested PCR reaction was about 10
          <sup>
           3
          </sup>
          genome equivalents in the standard cDNA control.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B34-jcm-09-00623">
           34
          </xref>
          ]
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         Real-time reverse-transcription PCR (rRT-PCR); RNA-dependent RNA polymerase (RdRp); open reading frame 1a (ORF1a); Loop-mediated isothermal amplification (LAMP); enzyme-linked immunosorbent assay (ELISA); immunofluorescent assay (IFA); immunochromatographic test (ICT); nasopharyngeal aspirate (NPA).
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="jcm-09-00623-t002" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       jcm-09-00623-t002_Table 2
      </object-id>
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Potential commercial rapid diagnostic kits for 2019-nCoV.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          S/N
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Type
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Organisation
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Date
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Test
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Sensitivity
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Specificity
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Availability
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Turn Around
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Costs
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Reference
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RT-PCR
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Genesig (U.K.)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Jan 2020
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RT-PCR Kit
          <break>
          </break>
          MasterMix and q16 reaction tubes included (for genesig
          <sup>
           ®
          </sup>
          q16); PCR MasterMix Kit (for other instruments)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Sensitive to &lt; 100 copies of target
          <break>
          </break>
          Broad dynamic detection range (&gt;6 logs)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Stated to be high but with no accompanying statistics
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Sold for research use only and are not licensed for diagnostic procedures
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (no info)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          For use with genesig q16 tubes: £5.44/test; For use with others:
          <break>
          </break>
          £4.62/test
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B35-jcm-09-00623">
           35
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RT-PCR
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Bioperfectus Technologies (China)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          14 Jan 2020
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RT-PCR test kit
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not stated
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not stated
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Available as scientific research product—does not require registration
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (no info)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (no info)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B36-jcm-09-00623">
           36
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          3
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RT-PCR
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Co-Diagnostics (U.S.A.)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          23 Jan 2020
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Commercial Kit RT-PCR kit
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Stated to be high but with no accompanying statistics.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Claims with lower false positive
          <sup>
           1
          </sup>
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          By Mar 2020
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (no info)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (no info)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B37-jcm-09-00623">
           37
          </xref>
          ,
          <xref ref-type="bibr" rid="B38-jcm-09-00623">
           38
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RT-PCR
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          altona Diagnostics (Germany)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          23 Jan 2020
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Commercial Kit RT-PCR kit
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not stated
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not stated
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (no info)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (no info)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (no info)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B39-jcm-09-00623">
           39
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          5
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RT-PCR
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          BGI; Pathomics Health (distributor; China) *
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          23 Jan 2020
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Fluorescent RT-PCR kit
          <break>
          </break>
          In vitro RT-PCR combining fluorescent probing
          <sup>
           1
          </sup>
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not stated
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not stated
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Currently used in hospitals and local disease control centres in China.
          <break>
          </break>
          Potentially in Hong Kong, Taiwan, Brunei, Thailand, Nigeria, South Africa too.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No data stated but described as ‘can issue results in a few hours’.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (no info)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B40-jcm-09-00623">
           40
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          6
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Combined RT-PCR and meta- genomics detection
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          BGI; Pathomics Health (distributor; China) *
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          23 Jan 2020
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2019-nCoV PMseq Kit
          <break>
          </break>
          A metagenomics sequencing kit based on combinatorial Probe Anchor Sythesis. Able to detect both known and novel microorganisms, Enabling monitoring of evolution during transmission
          <sup>
           2
          </sup>
          .
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not stated
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not stated
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Has been
          <break>
          </break>
          Providing technical support for the scientific clinical prevention and control of the epidemic in Wuhan.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Faster than Fluoresce nt RT- PCR kit. 128 Samples with SE50 in 5 h; 128 samples with PE100 in 22 h,
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (no info)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B41-jcm-09-00623">
           41
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          7
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Microfluidic
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Veredus Laboratories (Singapore)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          24 Jan 2020
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          enVision (enzyme-assisted nanocomplexes for visual identification of nucleic acids)
          <break>
          </break>
          Lab-on-Chip platform integrating PCR and microarray
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Stated to be high but with no accompanying statistics.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Stated to be high but with no accompanying statistics.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (no info)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2 h
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          (no info)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B42-jcm-09-00623">
           42
          </xref>
          ,
          <xref ref-type="bibr" rid="B43-jcm-09-00623">
           43
          </xref>
          ]
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         <sup>
          1
         </sup>
         BGI, pathomics Health. Real-Time Flourescent RT-PCR kit for detecting 2019-nCoV. Published 2020.
         <sup>
          2
         </sup>
         BGI, pathomics Health. BGI RT-PCR Kit and PMseq
         <sup>
          ®
         </sup>
         Solution for Detecting 2019-nCoV. Published 2020. * Passed emergency approval procedure of the National Medical Products Administration.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="jcm-09-00623-t003" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       jcm-09-00623-t003_Table 3
      </object-id>
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Ongoing vaccine development for 2019-nCoV.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          S/N
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Company
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Estimated Timeline
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Technology
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Stage/Funding
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Reference
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Moderna Therapeutics—US National Institute of Allergy and Infectious Diseases
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          3 months to early stage (phase 1) clinical trial in US (earliest); much longer for full testing and regulatory approval
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Messenger RNA vaccine
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical
          <break>
          </break>
          Awaiting preclinical tests and phase 1 study by NIAID, Funding by CEPI.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B62-jcm-09-00623">
           62
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Inovio Pharmaceuticals
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Human testing in the next few months
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          INO-4800-DNA
          <break>
          </break>
          based vaccine (DNA synthesized in lab, does not require actual virus sample)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical
          <break>
          </break>
          Funding by Coalition for Epidemic Preparedness Innovations (CEPI), up to $9 million
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B62-jcm-09-00623">
           62
          </xref>
          ,
          <xref ref-type="bibr" rid="B63-jcm-09-00623">
           63
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          3
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Novavax
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          3 months
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Nanoparticle vaccine
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B62-jcm-09-00623">
           62
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          University of Queensland
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          6 months
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Rapid Response Technology, ‘Molecular clamp’ vaccine platform (gene added to viral proteins, misleads body to generate antibodies)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical
          <break>
          </break>
          Funding by Coalition for Epidemic Preparedness Innovations (CEPI)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B64-jcm-09-00623">
           64
          </xref>
          ,
          <xref ref-type="bibr" rid="B65-jcm-09-00623">
           65
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          5
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Vir Biotechnology
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not available
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Anti-coronavirus monoclonal antibodies. Additionally, using “whole-genome CRISPR-based screening capabilities to identify the host receptor for Wuhan coronavirus”
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B66-jcm-09-00623">
           66
          </xref>
          ,
          <xref ref-type="bibr" rid="B67-jcm-09-00623">
           67
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          6
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Chinese Centre for Disease Control and Prevention (CDC)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          At least 1 month for development, 2–3 years before availability for use
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not available
          <break>
          </break>
          Inactivated virus vaccine (postulated, not verified)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical; virus successfully isolated, currently selecting strain
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B68-jcm-09-00623">
           68
          </xref>
          ,
          <xref ref-type="bibr" rid="B69-jcm-09-00623">
           69
          </xref>
          ,
          <xref ref-type="bibr" rid="B70-jcm-09-00623">
           70
          </xref>
          ,
          <xref ref-type="bibr" rid="B71-jcm-09-00623">
           71
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          7
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Shanghai East Hospital (Tongji University)—Stermirna Therapeutics
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          &lt;40 days for manufacture of vaccine samples
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          mRNA technology
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B72-jcm-09-00623">
           72
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          8
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Johnson &amp; Johnson
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1 year to market
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Adenovirus—vectored technology used for Ebola vaccine (and Zika and HIV vaccine candidates)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B73-jcm-09-00623">
           73
          </xref>
          ,
          <xref ref-type="bibr" rid="B74-jcm-09-00623">
           74
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          9
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          University of Hong Kong
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Months for animal testing, At least 1 year for clinical trials on humans
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Modified nasal spray influenza vaccine (with surface antigen of coronavirus) prevents both influenza and corona virus
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical; vaccine developed
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B70-jcm-09-00623">
           70
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          10
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          University of Saskatchewan (VIDO-InterVac)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Target for animal testing in 6–8 weeks, human trials in at least a year
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not available
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B75-jcm-09-00623">
           75
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          11
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          GeoVax—BravoVax
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not available
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Modified Vaccina Ankara—Virus Like Particles (MVA-VLP) vaccine platform
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B76-jcm-09-00623">
           76
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          12
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Clover Biopharmaceuticals
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not available
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Highly purified recombinant 2019-nCoV S protein subunit-trimer vaccine (S-Trimer), produced using Trimer-Tag© technology
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B77-jcm-09-00623">
           77
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          13
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          CureVac
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not available
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          mRNA technology
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preclinical
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B78-jcm-09-00623">
           78
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          14
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not available
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not available
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not available
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B79-jcm-09-00623">
           79
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          15
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Codagenix
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not available
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not available
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not available
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B79-jcm-09-00623">
           79
          </xref>
          ]
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="jcm-09-00623-t004" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       jcm-09-00623-t004_Table 4
      </object-id>
      <label>
       Table 4
      </label>
      <caption>
       <p>
        Systematic search of completed vaccine trial of SARS-CoV and MERS-CoV.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          S/N
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Organisation; Candidate
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Country of Study; Trial Type; Study Design; Study Details
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Population
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Outcome (Safety)
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Outcome (Efficacy)
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Reference
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="7" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SARS-CoV
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Sinovac Biotech Co. Ltd.; Inactivacted SARS-CoV (ISCV)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          China (Beijing);
          <break>
          </break>
          Phase I clinical trial;
          <break>
          </break>
          Randomised, double-blind and placebo controlled;
          <break>
          </break>
          2 doses of 16 SARS-CoV units (SU) or 32 SU ISCV or placebo control vaccine, intramuscular injection of vaccines in deltoid muscle, doses were 28 days apart
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          36 healthy adults between 21 and 40 years old, free of chronic diseases, immunosuppression SARS-CoV, HCV and HIV; 12 subjects were included in each intervention arm
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No severe adverse reaction (grade 3) was reported.
          <break>
          </break>
          All local adverse events were mild and resolved within 47–72 h, while systemic adverse events were reported sporadically from all 3 groups and resolved within 24 h.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Seroconversion reached 100% for both vaccine groups on day 42, persisted at 100% in the group receiving 16 SU but decreased to 91.1% for the group receiving 32 SU on day 56.
          <break>
          </break>
          Geometric mean titres (GMT) of specific SARS-CoV neutralising antibody peaked 2 weeks after the second dose, but started to drop 4 weeks later (values not reported). Seroconversion and GMT of neutralising antibody levels were lower in subjects between 21–30 years old compared to those in the elder group, but without significant differences (35: seroconversion
          <italic>
           p
          </italic>
          = 0.444; GMT P = 0.528) on days 35 and 42.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B44-jcm-09-00623">
           44
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          National Institutes of Health, National Institute of Allergy and Infectious Diseases, Vaccine Research Center; VRC-SRSDNA015-00-VP
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          United States (Maryland)
          <break>
          </break>
          Phase I clinical trial;
          <break>
          </break>
          Open-label study;
          <break>
          </break>
          3 doses of vaccine (4 mg/dose), intramuscular injection into lateral deltoid muscle via the Biojector 2000
          <sup>
           ®
          </sup>
          Needle-Free Injection Management System™ on study days 0, 38 and 56
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          10 subjects between 21 and 29 years old (mean age 35.5) with mean BMI of 24.6 (range 19.7 to 33.9) and were Caucasians (90%) or Asian (10%); only 9 subjects completed all 3 doses
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No severe adverse reaction (grade 3), but at least 50% subjects reported at least one mild systemic symptom following vaccination.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SARS specific antibody was detected by ELISA in 8 of 10 (80%) of subjects at one or more timepoints. The neutralizing antibody response was detected in all subjects who received 3 doses of vaccine and peaked between week 8 and 12, with 6 subjects remaining positive at week 32.
          <break>
          </break>
          SARS-CoV-specific CD4+ T cell responses were detected in all vaccines between week 2 and 32, and CD8+ T cell responses in ∼20% of individuals by ICS. The peak T cell response occurred between week 8 and 12 and when present, was sustained throughout the 32 week trial.
         </td>
         <td align="left" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B45-jcm-09-00623">
           45
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="7" rowspan="1" style="border-bottom:solid thin" valign="middle">
          MERS-CoV
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          GeneOne Life Science and Inovio Pharmaceuticals; GLS-5300
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          United States (Maryland)
          <break>
          </break>
          Phase I clinical trial;
          <break>
          </break>
          Open-label, single-arm, dose-escalation study;
          <break>
          </break>
          3 doses of 0·67 mg, 2 mg, or 6 mg GLS-5300; intramuscular 1 mL injection followed immediately by co-localised intramuscular electroporation with CELLECTRA
          <sup>
           ®
          </sup>
          -5P device at week 0, 4 and 12 with follow-up through to 48 weeks after dose 3
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          75 healthy adults between 18 and 50 years old (mean age 32.2 years), with normal screening electrocardiogram, screening laboratory findings within normal limits or be grade 0–1 findings, and have no history of clinically significant immunosuppressive or autoimmune disease, HIV, hepatitis B or C virus infection; 25 subjects were randomised into each dose group and 65 subjects completed the study, and per protocol analysis was used.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          No vaccine-associated serious adverse events.
          <break>
          </break>
          97% participants reported at least one solicited adverse event, but most solicited symptoms were reported as mild and were self-limiting (19 [76%] with 0·67 mg, 20 [80%] with 2 mg, and 17 [68%] with 6 mg); injection site reactions were the most common adverse event [92%].
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Seroconversion measured by S1-ELISA occurred in 86% and 94% participants after 2 and 3 doses, respectively, and was maintained in 79% participants up to study end at week 60.
          <break>
          </break>
          Neutralising antibodies were detected in 50% participants at one or more time points during the study, but only 3% maintained neutralisation activity to end of study. T-cell responses were detected in 71% and 76% participants after 2 and 3 doses, respectively. There were no differences in immune responses between dose groups after 6 weeks and vaccine-induced humoral and cellular responses were respectively detected in 77% and 64% participants at week 60.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B47-jcm-09-00623">
           47
          </xref>
          ]
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="jcm-09-00623-t005" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       jcm-09-00623-t005_Table 5
      </object-id>
      <label>
       Table 5
      </label>
      <caption>
       <p>
        Potential &amp; ongoing therapeutics trials of 2019-nCoV infection.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          S/N
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Company
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Treatment
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Stage
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Reference
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          AbbVie
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Lopinavir-ritonavir
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Approved. Used in clinical settings.
          <break>
          </break>
          The Jin Yintan Hospital in Wuhan, China, launched a randomised, open-label, blank-controlled trial for the efficacy and safety of lopinavir-ritonavir and interferon-alpha 2b in hospitalisation of 80 patients with novel coronavirus infection. Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and 50 mg of ritonavir), twice a day, 2 tablets at a time; interferon-α2b. Assessment of effectiveness of treatment based on clinical improvement time of 28 days after randomisation.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B80-jcm-09-00623">
           80
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Sanofi-Aventis
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Teicoplanin (Targocid)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Approved. Used in clinical setting.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          3
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Gilead Science
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Remdesivir
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Gilead is in active discussions with researchers and clinicians in the United States and China regarding the ongoing Wuhan coronavirus outbreak and the potential use of remdesivir as an investigational treatment.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B81-jcm-09-00623">
           81
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Vir
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Monoclonal antibodies
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Vir is working to rapidly determine whether its previously identified anti-coronavirus monoclonal antibodies (mAbs) bind and neutralize 2019-nCoV.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B67-jcm-09-00623">
           67
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          5
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Regeneron
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Monoclonal antibodies
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Regeneron Pharmaceuticals has developed monoclonal antibodies to treat MERS that are now being tested in early human studies. A company spokesperson said that researchers have begun to identify similar antibodies that might work against 2019-nCoV. With Ebola, it took Regeneron six months to develop candidate treatments and test them in animal models.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B82-jcm-09-00623">
           82
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          6
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Ascletis
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Ritonavir + ASC09 combo
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Applied to include in national emergency channel on 25 January 2020. Not yet approved by regulators.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B83-jcm-09-00623">
           83
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          7
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Biocryst Pharmaceuticals
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Galidesivir
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Biocryst is evaluating Galidesivir to determine if it could potentially target the coronavirus. Galidesivir is currently in a phase 1 clinical study.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B84-jcm-09-00623">
           84
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          8
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Purdue University
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Molecules that inhibit 2 coronavirus enzymes
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Molecules developed by the university scientists inhibit two coronavirus enzymes and prevent its replication. The discovered drug targets are said to be more than 95% similar to enzyme targets found on the SARS virus.
          <break>
          </break>
          Researchers note that identified drugs may not be available to address the ongoing outbreak but they hope to make it accessible for future outbreaks.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B85-jcm-09-00623">
           85
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          9
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          The First Affiliated Hospital of Guangzhou Medical University
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          “xue bi jing” (TCM)
          <break>
          </break>
          -ChiCTR2000029381
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Approved. Recruitment of subjects has not started.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B86-jcm-09-00623">
           86
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          10
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Chongqing Public Health Medical Center
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Adjunctive steroids has a trial-ChiCTR2000029386
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Approved. Recruitment of subjects has not started.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B87-jcm-09-00623">
           87
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          11
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Ruijin Hospital
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Umefinovir (arbidol)- NCT04260594
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          An antiviral treatment for influenza infection. Preliminary test in the in vitro cell showed an effective inhibition of coronavirus and a significant inhibition to the cytopathic effect.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B88-jcm-09-00623">
           88
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          12
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Shanghai Public Health Clinical Center
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Darunavir-NCT04252274
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          An antiviral treatment for HIV. Study showed that it can significantly inhibit the replication of the new coronavirus.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B88-jcm-09-00623">
           88
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          13
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Harbin Pharmaceutical Group Sanjing Pharmaceutical Holding Co., Ltd.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Oral liquid traditional Chinese medicine, Shuanghuanglian
          <break>
          </break>
          -ChiCTR2000029605
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Preliminary testing identified that it can inhibit the new coronavirus. It was previously identified to have an antiviral effect for influenza virus, SARS and MERS.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B88-jcm-09-00623">
           88
          </xref>
          ,
          <xref ref-type="bibr" rid="B89-jcm-09-00623">
           89
          </xref>
          ,
          <xref ref-type="bibr" rid="B90-jcm-09-00623">
           90
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          14
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          The Fifth Affiliated Hospital of Sun Yat-Sen University
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Chloroquine phosphate
          <break>
          </break>
          -ChiCTR2000029609
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Approved. Recruitment of subjects has not started.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B88-jcm-09-00623">
           88
          </xref>
          ,
          <xref ref-type="bibr" rid="B91-jcm-09-00623">
           91
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          15
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Shanghai Public Health Clinical Center
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Hydroxychloroquine
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Recruitment in process; Interventional subjects will receive hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B53-jcm-09-00623">
           53
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          16
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Tongji Hospital
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Abidol Hydrochloride combined with Interferon atomization
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Recruitment of subjects has not started; Interventional subjects will receive standard symptomatic support therapy (SMT) plus abidol hydrochloride (0.2 g, 3 times a day) or Abidol Hydrochloride combined with Interferon (PegIFN-α-2b) atomization (45 ug)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B55-jcm-09-00623">
           55
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          17
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Tongji Hospital
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Drug: Abidol hydrochloride, Oseltamivir, Lopinavir/ritonavir
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Recruitment of subjects has not started; Interventional subjects will receive either Abidol hydrochloride 0.2 g once, 3 times a day, 2 weeks or Oseltamivir 75 mg once, twice a day, 2 weeks or Lopinavir/ritonavir 500 mg once, twice a day, 2 weeks
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B54-jcm-09-00623">
           54
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          18
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Guangzhou 8th People’s Hospital
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Lopinavir Plus Ritonavir and Arbidol
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Recruitment in process; Interventional subjects will receive either standard treatment plus a regimen of lopinavir (200 mg) and ritonavir (50 mg) (oral, q12h, every time 2 tablets of each, taking for 7–14 days) or Standard treatment plus a regimen of arbidol (100 mg) (oral, tid, 200 mg each time, taking for 7–14 days).
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B56-jcm-09-00623">
           56
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          19
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          China-Japan Friendship Hospital
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Remdesivir
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Recruitment of subjects has not started
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B57-jcm-09-00623">
           57
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          20
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Shanghai Public Health Clinical Center
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Darunavir &amp; Cobicistat
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Recruitment of subjects has not started; Interventional subjects will receive darunavir and cobicistat one tablet per day for 5 days plus conventional treatments.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B58-jcm-09-00623">
           58
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          21
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Beijing 302 Hospital
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Mesenchymal Stem Cell (MSC)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Recruitment in process; Interventional subjects will receive conventional treatment plus 3 times of MSCs (0.5–1.0 × 10E6 MSCs/kg body weight intravenously at Day 0, Day 3, Day 6).
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B59-jcm-09-00623">
           59
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          22
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Beijing 302 Hospital
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Traditional Chinese Medicine
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Recruitment in process; Interventional subjects will receive oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400 mg/100 mg, p.o, bid) for 14 days plus Traditional Chinese Medicines (TCMs) granules: one bag, p.o, bid, for 14 days.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B60-jcm-09-00623">
           60
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          23
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Medical ICU, Peking Union Medical College Hospital
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Methylprednisolone
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Recruitment in process; Interventional subjects will receive standard care plus methylprednisolone therapy (40 mg q12h for 5 days)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B61-jcm-09-00623">
           61
          </xref>
          ]
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="jcm-09-00623-t006" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       jcm-09-00623-t006_Table 6
      </object-id>
      <label>
       Table 6
      </label>
      <caption>
       <p>
        Completed Randomized Controlled Trials for SARS-CoV &amp; MERS-CoV Therapeutics.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          S/N
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Date
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Country
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          No. of Participants
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Treatment
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Outcome
         </th>
         <th align="left" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Reference
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="7" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SARS-CoV
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Recruitment: 24 March–28 April 2003
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Hong Kong
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          152/152
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Historical control: 4 g oral loading dose followed by 1.2 g every 8 h, or 8 mg/kg intravenously every 8 h if the patient could not tolerate oral treatment) with a reducing regimen of corticosteroid for 21 days
          <break>
          </break>
          Treatment group: combination of lopinavir (400 mg)/ritonavir (100 mg) orally every 12 h for 14 days
          <break>
          </break>
          Both groups given ribavirin &amp; corticosteroid according to the same protocol
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Primary outcome: composite adverse outcome at 21 days, severe hypoxaemia to fraction of inspired oxygen or death
          <break>
          </break>
          The 21 day adverse outcome rate was therefore 28.8% for the historical controls and 2.4% for the treatment group, giving an effect size of 26.4% (95% confidence interval 16.8 to 36.0,
          <italic>
           p
          </italic>
          = 0.001) for lopinavir/ritonavir treatment.
          <break>
          </break>
          Apparent reduction in also viral load, steroid dose, incidence of nocosomial infections in treatment group compared to control group.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B98-jcm-09-00623">
           98
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Recruitment: 24 April–30 June 2003
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Taiwan
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4/4
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          CM A: Composition of 13 herbs
          <break>
          </break>
          CM B: Popular health care product in Taiwan
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Death in patient 1 (placebo control), recovery in remaining 3 patients
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B93-jcm-09-00623">
           93
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          3
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Recruitment: 10 April–31 May 2003
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          China
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          115/123
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Western medicine: oxygen supplementation, hemofiltration, ribavirin, antibacterials (azithromycin, cefuroxime, metronidazole), and immunoregulation with thymosin injection.
          <break>
          </break>
          Combined treatment: Herba houttuyniae with western medicine, and when necessary, TCM treatment like heat clearing and detoxifying, qi supplementing, blood regulating prescription.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Patients with early symptoms experienced a longer hospital stay (
          <italic>
           p
          </italic>
          = 0.028), a non-statistically significant mortality rate decrease (combined treatment: 9.6% versus WM: 11.1%), and a significant improvement of arthralgia and myalgia (
          <italic>
           p
          </italic>
          &lt; 0.05) when on combined treatment compared with a strictly WM treatment.
          <break>
          </break>
          Combined treatment also improved arterial oxyhemoglobin saturation significantly at day 22 (
          <italic>
           p
          </italic>
          &lt; 0.05) compared to WM.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B96-jcm-09-00623">
           96
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          20 April 2003–30 May 2003
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Hong Kong
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          16/17
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          9 (Early hydrocortisone treatment) &amp; 7 (Saline placebo)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Median time for SARS-CoV RNA to become undetectable In plasma was 12 days vs. 8 days in the hydrocortisone and placebo groups.
          <break>
          </break>
          Corticosteroid treatment early in the treatment was associated with higher subsequent plasma viral load compared to placebo (AUC; Mann–Whitney,
          <italic>
           p
          </italic>
          = 0.023), delaying viral clearance
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B95-jcm-09-00623">
           95
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          5
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          28 January–28 February 2003
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          China
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          190/190
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          40 (A; Ribavirin, cefoperazone/sulbactam);
          <break>
          </break>
          30 (B; fluoroquinolone, azithromycin, recombinant interferon alpha and restricted steroid use);
          <break>
          </break>
          60 (C; quinolone, azithromycin, some given recombinant interferon alpha, steroid use when symptoms worsen);
          <break>
          </break>
          60 (D; levofloxacin, azithromycin, of which 45 were given recombinant interferon alpha)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Treatment D presented with the most favourable outcome. The shortest mean time to discharge, 20.7 (SD, 4.6) days, was observed in treatment group D, compared to 24.8, 24.8 and 22.4 days for treatment groups A, B and C respectively.
          <break>
          </break>
          None of the patients on treatment D needed mechanical ventilation, all recovered and were discharged from the hospital compared to 2, 2, and 7 deaths from patients on treatments A, B and C respectively
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B97-jcm-09-00623">
           97
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          6
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Not reported
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          China
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          49/52
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          29 (Control: Ribavirin, Levofloxacin, Thyopentin, Azithromycin, methylpredisolone)
          <break>
          </break>
          20 (Treatment: Control group treatment + TCM Recipes)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          All patients recovered.
          <break>
          </break>
          Significantly shorted time from the disease onset to the symptom improvement in treatment (5.10 ± 2.83 days) compared to control group (7.62 ± 2.27 days) (
          <italic>
           p
          </italic>
          &lt; 0.05) No significant difference in blood routine improvement, pulmonary chest shadow in chest film improvement and corticosteroid usgae between the 2 groups.
          <break>
          </break>
          However, particularly in the respect of improving clinical symptoms, elevating quality of life, promoting immune function recovery, promoting absorption of pulmonary inflammation, reducing the dosage of cortisteroid and shortening the therapeutic course, treatment with integrative chinese and western medicine treatment had obvious superiority compared with using control treatment alone.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B94-jcm-09-00623">
           94
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="left" colspan="7" rowspan="1" style="border-bottom:solid thin" valign="middle">
          MERS-CoV
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          7
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2 June 2016–4 January 2017
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          United States
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          38/43
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Each group comprises 6 cohorts (Escalating doses 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg &amp; 50 mg/kg in SAB-001 treatment group)
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          A total of 97 adverse events (AEs) were reported, with a mean of 2.3 AEs per participant in the SAB-301 group and a mean of 3.3 AEs per participant in the placebo group. No serious adverse event related to the study intervention was observed. Single dose pharmacokinetics demonstrated relatively linear and dose-proportional increases in maximal concentration and area-under-the-concentration-time curve. Microneutralization titres also correlated to the SAB-301 levels in serum.
          <break>
          </break>
          Single infusions of SAB-301 up to 50 mg/kg appear to be safe and well-tolerated in healthy participants.
         </td>
         <td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          [
          <xref ref-type="bibr" rid="B46-jcm-09-00623">
           46
          </xref>
          ]
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="chapter-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="publisher-id">
       978-1-4939-0597-3
      </journal-id>
      <journal-id journal-id-type="doi">
       10.1007/978-1-4939-0597-3
      </journal-id>
      <journal-id journal-id-type="nlm-ta">
       Hydroxychloroquine and Chloroquine Retinopathy
      </journal-id>
      <journal-title-group>
       <journal-title>
        Hydroxychloroquine and Chloroquine Retinopathy
       </journal-title>
      </journal-title-group>
      <isbn publication-format="print">
       978-1-4939-0596-6
      </isbn>
      <isbn publication-format="electronic">
       978-1-4939-0597-3
      </isbn>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7122276
      </article-id>
      <article-id pub-id-type="publisher-id">
       2
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/978-1-4939-0597-3_2
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Pharmacology of Chloroquine and Hydroxychloroquine
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Browning
         </surname>
         <given-names>
          David J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <aff id="Aff2">
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.490463.c
         </institution-id>
         <institution>
          Charlotte Eye Ear Nose &amp; Throat Associates,
         </institution>
        </institution-wrap>
        Charlotte, NC USA
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        4
       </day>
       <month>
        4
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <fpage>
       35
      </fpage>
      <lpage>
       63
      </lpage>
      <permissions>
       <copyright-statement>
        © Springer Science+Business Media New York 2014
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p>
        The 4-aminoquinolines are weak bases that are completely absorbed from the gastrointestinal tract, sequestered in peripheral tissues, metabolized in the liver to pharmacologically active by-products, and excreted via the kidneys and the feces. The parent drugs and metabolites are excreted with a half-life of elimination of approximately 40 days. However, slow release from sequestered stores of the drugs means that after discontinuation, they continue to be released into the plasma for years. Correct dosing is based on the ideal body weight of the patient, which depends on height. The 4AQs diminish autoimmunity without compromising immunity to infections.
       </p>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Rheumatoid Arthritis
       </kwd>
       <kwd>
        Systemic Lupus Erythematosus
       </kwd>
       <kwd>
        Blood Concentration
       </kwd>
       <kwd>
        Ideal Body Weight
       </kwd>
       <kwd>
        Therapeutic Ratio
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Springer Science+Business Media New York 2014
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <p>
     This chapter covers the pharmacology of chloroquine and hydroxychloroquine, which is similar for both drugs [
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     ], but the details are different. For example, both drugs are partially excreted in feces, but the proportions differ slightly—8–10 % for chloroquine and 15–24 % for hydroxychloroquine. Generally, whatever is said in this chapter about one drug can be assumed to apply to the other unless otherwise specified [
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
     ]. Because both drugs are derivatives of a 4-aminoquinoline (4AQ) nucleus, they are referred to as 4AQs, and the retinopathy that they can cause is termed 4-aminoquinoline retinopathy (4AQR) [
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     ]. Commonly used abbreviations in this chapter are collected in “Abbreviations” for reference. Each term will be first used in its full form, along with its abbreviation.
    </p>
    <sec id="Sec1">
     <title>
      History
     </title>
     <p>
      In the 1600s, the Jesuits who proselytized Chile discovered from the Incas that the bark of the cinchona tree can cure malaria [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ]. Additional medicinal qualities of cinchona bark were described in the 1700s, and the British and Dutch transplanted these trees to Javan plantations in the early 1900s for the production of quinine. In 1894, Payne described the use of quinine to treat systemic lupus erythematosus (SLE) [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ]. Other alkaloids contained in cinchona bark, such as pamaquine, were also successfully used to treat SLE [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ].
     </p>
     <p>
      When the Japanese army occupied Java in World War II, the natural supply of quinine was lost, and synthesis of antimalarials was pursued in the United States [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. Quinacrine, a 9-aminoacridine compound, was first used, but had the unpleasant side effect of staining the skin and sclera yellow in a manner indistinguishable from icterus [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      –
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ]. The 4AQs, chloroquine and hydroxychloroquine, were found to be effective as antimalarials and did not discolor the skin. Chloroquine was first synthesized in 1934 by Andersag of I.G. Farbenindustrie in a German effort to find drugs better than quinine [
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ]. The Germans lost interest in the drug when they judged it to be too toxic for use in man, but the Americans restudied the drug and found it to be effective against malaria and sufficiently safe [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ]. Hydroxychloroquine was synthesized in 1946 and proposed as a safer alternative to chloroquine in 1955 [
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      ]. Resistance to chloroquine as an antimalarial became a problem in some parts of the world in the 1980s.
     </p>
     <p>
      In World War II it was observed that servicemen with rashes and inflammatory arthritis who took quinacrine and chloroquine for malaria prophylaxis experienced improvement in their autoimmune conditions [
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
      ]. In 1951, Page used quinacrine to treat arthritis and autoimmune dermatologic conditions [
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      ]. Later chloroquine and then hydroxychloroquine were also noted to favorably affect patients with rheumatologic diseases. Over time, both have been widely adopted for these uses. They are commonly used in patients with rheumatoid arthritis (RA), SLE, discoid lupus erythematosus, polymorphous light eruptions, solar urticaria, recurrent basal cell carcinoma of the skin, porphyrea cutane tarda, antiphospholipid antibody syndrome, and more than 20 other rarer conditions [
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      –
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      ].
     </p>
     <p>
      The side effects other than retinopathy of the 4AQs are discussed in Chap. 10.1007/978-1-4939-0597-3_3. Chapters 10.1007/978-1-4939-0597-3_4 through 10.1007/978-1-4939-0597-3_6 cover aspects of retinopathy. The 4AQs and quinacrine can cause retinopathy with the order of frequency chloroquine &gt; hydroxychloroquine &gt; &gt; quinacrine. Chloroquine retinopathy was first described by Hobbs in 1959 [
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ]. Hydroxychloroquine retinopathy was first described by Braun-Vallon in 1963 [
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
      ,
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      ]. Quinacrine retinopathy is so rare that some have said that it does not exist [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ]. Nevertheless, it does, identical in its funduscopic appearance to 4AQR, and was described in 2004 [
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ].
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Chemistry
     </title>
     <p>
      The parent molecule for the antimalarials is quinine. Both chloroquine (C
      <sub>
       18
      </sub>
      H
      <sub>
       26
      </sub>
      ClN
      <sub>
       3
      </sub>
      ) and hydroxychloroquine (C
      <sub>
       18
      </sub>
      H
      <sub>
       26
      </sub>
      ClN
      <sub>
       3
      </sub>
      O) are alkylated 4-aminoquinolines (4AQs) (Fig.
      <xref ref-type="fig" rid="Fig1">
       2.1
      </xref>
      ) [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ]. Chloroquine is 7-chloro-4(-4-diethylamino-1-methylbutylamino) quinoline and hydroxychloroquine is its hydroxyl derivative. Chloroquine and hydroxychloroquine have molecular weights of 320 and 336, respectively [
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      ]. Both chloroquine and hydroxychloroquine are amphiphilic weak bases based on two fused aromatic rings having conjugated double bonds, the 4-aminoquinoline nucleus (Fig.
      <xref ref-type="fig" rid="Fig1">
       2.1
      </xref>
      ). Both drugs cross cell membranes well [
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      ,
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
      ]. Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ,
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
      ]. The 4AQs lack the third benzene ring that is part of the acridine nucleus of quinacrine (Fig.
      <xref ref-type="fig" rid="Fig1">
       2.1
      </xref>
      ) [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ].
      <fig id="Fig1">
       <label>
        Fig. 2.1
       </label>
       <caption>
        <p>
         Chloroquine and hydroxychloroquine are 4-aminoquinolines. Quinacrine has a side chain similar to that in chloroquine, but is based on an acridine nucleus
        </p>
       </caption>
       <graphic id="MO1" xlink:href="308936_1_En_2_Fig1_HTML">
       </graphic>
      </fig>
     </p>
     <sec id="d29e567">
      <title>
       Useful Conversion Factors
      </title>
      <p>
       In the literature on chloroquine and hydroxychloroquine, some articles express concentrations in μg/mL or ng/mL and others in M/L. The molecular weights of chloroquine and hydroxychloroquine are 320 and 336, respectively; so one mole of chloroquine weighs 320 g and one mole
of hydroxychloroquine weighs 336 g. It follows that 1 × 10
       <sup>
        −6
       </sup>
       M of chloroquine and hydroxychloroquine is equivalent to 320 ng/mL (0.320 μg/mL) and 336 ng/mL (0.320 μg/mL), respectively. Conversely, one μg/ml of chloroquine and hydroxychloroquine is equivalent to 3.125 × 10
       <sup>
        −6
       </sup>
       and 2.97 × 10
       <sup>
        −6
       </sup>
       M/L, respectively.
      </p>
      <p>
       Hydroxychloroquine is more soluble than chloroquine, but both are water-soluble [
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
       ]. Chloroquine has two basic groups corresponding to the quinoline-ring nitrogen and the diethylamino side-chain nitrogen with ionization constants of 8.1 and 10.2, respectively [
       <xref ref-type="bibr" rid="CR33">
        33
       </xref>
       –
       <xref ref-type="bibr" rid="CR36">
        36
       </xref>
       ]. At a physiologic pH of 7.4, 18 % of chloroquine is monoprotonated but still soluble in lipid and able to traverse cell membranes. However, biprotonated chloroquine, as occurs in a lysosome at a pH of 4–5, is sequestered and prevented from traversing back out to the cytoplasm (see Chap. 10.1007/978-1-4939-0597-3_1) [
       <xref ref-type="bibr" rid="CR34">
        34
       </xref>
       ,
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ]. Although the amount of free drug present in the plasma is miniscule at the physiologic pH, it is this form of the drug that determines the distribution of the drug between the plasma and the tissues [
       <xref ref-type="bibr" rid="CR36">
        36
       </xref>
       ]. Induction of acidosis increases the concentration of the drug in the plasma and erythrocytes but does not change drug concentration in the tissues, which have large reservoirs at steady state.
      </p>
      <p>
       The chemical and brand names of the antimalarial drugs are listed in Table
       <xref ref-type="table" rid="Tab1">
        2.1
       </xref>
       . Chloroquine diphosphate is the oral form of the drug, and chloroquine hydrochloride is the form used intramuscularly for malaria-induced coma [
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ]. Neither 4AQ is permitted for routine clinical use in Japan following multiple lawsuits over retinopathy in the 1970s [
       <xref ref-type="bibr" rid="CR39">
        39
       </xref>
       ]. Hydroxychloroquine is more commonly used in the United States [
       <xref ref-type="bibr" rid="CR6">
        6
       </xref>
       ]. Chloroquine is rarely used in the United States after multiple lawsuits in the 1960s led Winthrop Laboratories to withdraw the drug’s rheumatic indications, but continues to be commonly used in Canada, Mexico, Brazil, Europe, Poland, Turkey, South Africa, and Asia [
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
       ,
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="CR6">
        6
       </xref>
       ,
       <xref ref-type="bibr" rid="CR39">
        39
       </xref>
       –
       <xref ref-type="bibr" rid="CR47">
        47
       </xref>
       ].
       <table-wrap id="Tab1">
        <label>
         Table 2.1
        </label>
        <caption>
         <p>
          Chemical and brand names of antimalarial drugs
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Chemical name
           </th>
           <th>
            Brand name
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Chloroquine phosphate
           </td>
           <td>
            Aralen, Bemaphate, Chinamine, Delagil, Gontochin, Imagon, Iroquine, Klorokin, Luprochin, Resoquine, Sanoquin, Tanakan, Tresochin, Tochin
           </td>
          </tr>
          <tr>
           <td>
            Chloroquine diphosphate
           </td>
           <td>
            Avloclor and Resochin
           </td>
          </tr>
          <tr>
           <td>
            Chloroquine sulfate
           </td>
           <td>
            Amokin, Arechin Arthrochin, Artrichin Bemaco, Bemaphate, Bemasulph, Nivaquine, Resoquine
           </td>
          </tr>
          <tr>
           <td>
            Hydroxychloroquine sulfate
           </td>
           <td>
            Axenal, Dolquine, Ercoquin, Plaquenil, Polirrheumin, Quensyl
           </td>
          </tr>
          <tr>
           <td>
            Quinacrine hydrochloride
           </td>
           <td>
            Acriquine, Atabrine, Atebrin, Chinacrin, Erion, Itaichin, Mepacrine, Palacrin, Metoquine
           </td>
          </tr>
          <tr>
           <td>
            Amodiaquine dihydrochloride
           </td>
           <td>
            CAM-AQ1, Camoquinal, Camoquine, Flavoquine, Miaquin,
           </td>
          </tr>
          <tr>
           <td>
            Quinine sulfate
           </td>
           <td>
            Qualaquin
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          <italic>
           Source
          </italic>
          : Dubois [
          <xref ref-type="bibr" rid="CR10">
           10
          </xref>
          ]
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p>
       Structure-activity studies of many derivatives of the 4AQs show that halogen substitutions at any position other than seven (Fig.
       <xref ref-type="fig" rid="Fig1">
        2.1
       </xref>
       ) reduce pharmacologic activity and toxicity [
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
       ]. An aryl rather than an alkyl side chain decreases the therapeutic ratio [
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
       ]. Increasing alkyl side-chain length above five carbons decreases the therapeutic ratio and increases toxicity [
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
       ].
      </p>
      <p>
       Chloroquine binds to nucleic acids by electrostatic forces, hydrogen bonds, and van der Waals forces [
       <xref ref-type="bibr" rid="CR48">
        48
       </xref>
       ]. As a cation at physiologic pH, it binds ionically to melanin, which is a polyanion with many negatively charged carboxyl groups and ortho-semiquinone groups [
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
       –
       <xref ref-type="bibr" rid="CR52">
        52
       </xref>
       ]. Other binding forces to melanin include van der Waal’s forces between the aromatic rings of chloroquine and the indole nuclei of melanin as well as charge transfer complexes in which melanin acts as an electron acceptor [
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="CR50">
        50
       </xref>
       –
       <xref ref-type="bibr" rid="CR54">
        54
       </xref>
       ]. The interactions of hydroxychloroquine and melanin parallel those of chloroquine.
      </p>
     </sec>
     <sec id="d29e753">
      <title>
       Melanin and the 4-Aminoquinolines
      </title>
      <p>
       Melanin is a name for a family of pigments which are polyanionic polymers formed from the oxidation of tyrosine in cellular vesicles called melanosomes [
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
       ]. The term is descriptive, not chemical. Eumelanin is brown or black. Pheomelanin is red or yellow and occurs in red hair [
       <xref ref-type="bibr" rid="CR56">
        56
       </xref>
       ]. Melanins occur in the retinal pigment epithelium (RPE) of the eye, in the inner ear, and in the substantia nigra of the brain. The highest concentrations are in the eye [
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="CR56">
        56
       </xref>
       ]. The functions of melanin in the eye are to absorb light, preventing scatter, and to protect against free radicals [
       <xref ref-type="bibr" rid="CR29">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="CR56">
        56
       </xref>
       ]. Although choroidal melanin seems to be synthesized throughout life, melanin in the RPE is synthesized for a brief interval of fetal and perinatal life with little production thereafter [
       <xref ref-type="bibr" rid="CR56">
        56
       </xref>
       –
       <xref ref-type="bibr" rid="CR58">
        58
       </xref>
       ].
      </p>
      <p>
       The interaction of melanin with 4AQs is complex. Some have written that increased melanin is related to toxicity [
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
       ]. Others have denied this or maintained an agnostic viewpoint pending further evidence [
       <xref ref-type="bibr" rid="CR29">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="CR54">
        54
       </xref>
       ,
       <xref ref-type="bibr" rid="CR56">
        56
       </xref>
       ]. Also, the possibility of a protective effect has been raised. The mechanism suggested is that melanin binds the drug and prevents formation of lamellar bodies until its binding capacity is exceeded [
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="CR51">
        51
       </xref>
       ,
       <xref ref-type="bibr" rid="CR56">
        56
       </xref>
       ,
       <xref ref-type="bibr" rid="CR59">
        59
       </xref>
       –
       <xref ref-type="bibr" rid="CR62">
        62
       </xref>
       ]. It has been hypothesized that the extensive binding of 4AQs to melanin produces high local gradients of the drugs that may have importance in identifying cell types that are particularly affected [
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
       ]. For example, calculations suggest that the effective concentration of chloroquine in the cytoplasm of the RPE may be in the range of 10
       <sup>
        −5
       </sup>
       to 10
       <sup>
        −4
       </sup>
       M/L [
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
       ]. Chloroquine accumulates in the uveal tract of pigmented animals, but not albino animals, but both types of animals develop 4AQR [
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
       ].
      </p>
      <p>
       Melanin content in the RPE decreases with age [
       <xref ref-type="bibr" rid="CR58">
        58
       </xref>
       ]. In the first two decades of life, an average of 8 % of cytoplasmic volume is occupied by melanin, but only 3.5 % after age 40 [
       <xref ref-type="bibr" rid="CR66">
        66
       </xref>
       ]. The decrease is thought to occur by the degradation of melanin, after damage by light or free radicals, into complex granules containing melanolysosomes and melanolypofuscin. The relationship of decreasing melanin and increasing risk of 4AQR with increasing age is intuitive but speculative.
      </p>
      <p>
       The 4AQs have chiral carbons about which the side chains can be arranged so as to be nonsuperimposable mirror images of each other [
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
       ]. These stereoisomers, called enantiomers, are labeled as R(−) or S(+) forms. Clinically used 4AQs are racemic mixtures with equal amounts of R(−) and S(+) forms [
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
       ].
      </p>
      <p>
       Both enantiomers of chloroquine are equipotent in vitro and in a duck model of malaria. In mice and rats S(+) chloroquine was more potent than R(−) chloroquine, possibly due to stereoselectivity in distribution of drug throughout the body [
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
       ,
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
       ].
      </p>
      <p>
       S(+) chloroquine is more highly bound to plasma proteins than R(−) chloroquine (67 % versus 35 %) [
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
       ]. Sequestration of the R(−) enantiomer in ocular tissues is greater than that of the S(+) enantiomer [
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
       ]. The toxicity of the S(+) enantiomer is greater than the R(−) enantiomer in mammals [
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
       ]. The S(+) enantiomer for both chloroquine and hydroxychloroquine is excreted by the kidneys preferentially compared to the R(−) enantiomer [
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
       ,
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
       ]. Because renal failure is associated with 4AQR, it is possible that S(+) chloroquine and S(+) hydroxychloroquine are more toxic in humans than R(−) chloroquine and R(−) hydroxychloroquine, respectively [
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="Sec3">
     <title>
      Pharmacokinetics and Tissue Distribution of the 4-Aminoquinolines
     </title>
     <sec id="Sec4">
      <title>
       Absorption
      </title>
      <p>
       Nearly complete absorption of 4AQs after an oral dose occurs within 2–4 h (Fig.
       <xref ref-type="fig" rid="Fig2">
        2.2
       </xref>
       ) [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
       ]. In fasting subjects the absorption of oral chloroquine was 89 ± 16 % and of hydroxychloroquine was 74 ± 13 % [
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
       ,
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ]. Absorption is relatively unaffected by concomitant ingestion of food. However, intersubject variability of 30–100 % has been reported in extent of absorption, which may explain in part the individual variability of 4AQ effectiveness and toxicity [
       <xref ref-type="bibr" rid="CR4">
        4
       </xref>
       ,
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR72">
        72
       </xref>
       ].
       <fig id="Fig2">
        <label>
         Fig. 2.2
        </label>
        <caption>
         <p>
          Chloroquine bioavailability and elimination in man. A single dose of chloroquine was given intravenously (blue circles), as an oral solution (yellow triangles), or as tablets (purple squares). Panel A shows plasma concentration of chloroquine and panel B chloroquine metabolite. The near superposition of the three curves in panel A is evidence of near-complete absorption of chloroquine from the gastrointestinal tract. Slow elimination is also indicated. Data from Gustafsson [
          <xref ref-type="bibr" rid="CR70">
           70
          </xref>
          ]
         </p>
        </caption>
        <graphic id="MO2" xlink:href="308936_1_En_2_Fig2_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       Distribution and Pharmacokinetics
      </title>
      <p>
       The pharmacokinetics of chloroquine and hydroxychloroquine are similar [
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
       –
       <xref ref-type="bibr" rid="CR75">
        75
       </xref>
       ]. However, the explanation is complicated because of their differential sequestration in various tissues of the body and continuously evolving tests for detection of the drugs in plasma that are increasingly sensitive [
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR75">
        75
       </xref>
       ,
       <xref ref-type="bibr" rid="CR76">
        76
       </xref>
       ]. As a result, estimates of pharmacokinetic parameters have varied widely over the years [
       <xref ref-type="bibr" rid="CR53">
        53
       </xref>
       ,
       <xref ref-type="bibr" rid="CR75">
        75
       </xref>
       ]. For example, the terminal half-life of chloroquine has been reported variously to be between one and 157 days [
       <xref ref-type="bibr" rid="CR53">
        53
       </xref>
       ,
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
       ,
       <xref ref-type="bibr" rid="CR75">
        75
       </xref>
       ,
       <xref ref-type="bibr" rid="CR76">
        76
       </xref>
       ]. In addition, dose-dependent kinetics have been reported by some, while others have claimed that this interpretation arises from artifacts of insensitive detection methods [
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR75">
        75
       </xref>
       –
       <xref ref-type="bibr" rid="CR77">
        77
       </xref>
       ]. In the 1980s a two-compartment model was thought to best describe the pharmacokinetics of the 4AQs [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ]. Now a model with three compartments is considered to be more accurate [
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR75">
        75
       </xref>
       ].
      </p>
      <p>
       The 4AQs have a large volume of distribution (
       <italic>
        V
       </italic>
       ) due to extensive sequestration of the drugs by tissues. Plasma volumes of distribution up to 65,000 L for chloroquine and 44,257 L for hydroxychloroquine have been reported [
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR75">
        75
       </xref>
       ,
       <xref ref-type="bibr" rid="CR77">
        77
       </xref>
       ]. Normalized by body mass, reported volumes of distribution for chloroquine have ranged from 204 to 800 L/kg depending on the sensitivity of the method of detecting chloroquine [
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ]. Drug disposition proceeds in three phases—distribution from blood to tissues, equilibration between blood and tissues, and release from tissues back into blood [
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
       ]. These phases have half-lives of 3–8, 40–216 h, and 30–60 days, respectively [
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
       ,
       <xref ref-type="bibr" rid="CR75">
        75
       </xref>
       ,
       <xref ref-type="bibr" rid="CR78">
        78
       </xref>
       ].
      </p>
      <p>
       The peak plasma concentration after an oral dose of chloroquine is 3–12 h [
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
       ]. Thirty-three to 70 % of the drug in plasma is protein-bound [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="CR75">
        75
       </xref>
       ,
       <xref ref-type="bibr" rid="CR79">
        79
       </xref>
       ,
       <xref ref-type="bibr" rid="CR80">
        80
       </xref>
       ]. The effects of hypoalbuminemia and altered immunoglobulin composition in patients taking 4AQs are not well understood [
       <xref ref-type="bibr" rid="CR80">
        80
       </xref>
       ].
      </p>
      <p>
       The phase of terminal elimination has the greatest importance for the 4AQs as used in autoimmune diseases in which they are given for years and for which steady-state levels are the emphasis. The most commonly quoted median value for the terminal elimination half-life is 40 days [
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="CR75">
        75
       </xref>
       ,
       <xref ref-type="bibr" rid="CR81">
        81
       </xref>
       ]. The pharmacokinetics of chloroquine do not differ to a clinically important extent between black and white patients [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="CR79">
        79
       </xref>
       ]. The average melanin content of a black person is estimated to be 1 g and for a white person is estimated to be 250 mg. This implies that melanin sequestration is not a large factor in systemic pharmacokinetics although the drug continues to elute from melanin at low levels for years after cessation of ingestion [
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
       ,
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR78">
        78
       </xref>
       ,
       <xref ref-type="bibr" rid="CR82">
        82
       </xref>
       ].
      </p>
      <p>
       A lower daily dose of chloroquine and hydroxychloroquine leads to a lower plateau concentration in plasma (Fig.
       <xref ref-type="fig" rid="Fig3">
        2.3
       </xref>
       and Table
       <xref ref-type="table" rid="Tab2">
        2.2
       </xref>
       ). Doses of chloroquine of 3.5–4.0 mg/kg/day based on ideal body weight (IBW) yield serum concentrations of 6 to 9 × 10
       <sup>
        −7
       </sup>
       M/L. Doses of hydroxychloroquine of 6.0–6.5 mg/kg/day based on IBW yield serum concentrations of 1.4 to 1.5 × 10
       <sup>
        −6
       </sup>
       M/L [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ]. Daily dosing of chloroquine 250 mg/day produces plasma concentrations at equilibrium of 0.31 to 3.13 × 10
       <sup>
        −6
       </sup>
       M/L depending on body mass [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ]. The dependence of time to reach equilibrium levels on daily dosing is schematically represented in Fig.
       <xref ref-type="fig" rid="Fig3">
        2.3
       </xref>
       . Because the half-life to reach a steady-state concentration is not the same for all daily doses, one may conclude that the mechanism of drug elimination is not a first-order process, but rather more complicated with some dependence of the elimination-rate constant on plasma-drug concentration (see Chap. 10.1007/978-1-4939-0597-3_1) [
       <xref ref-type="bibr" rid="CR83">
        83
       </xref>
       , p. 314, [
       <xref ref-type="bibr" rid="CR84">
        84
       </xref>
       ].
       <fig id="Fig3">
        <label>
         Fig. 2.3
        </label>
        <caption>
         <p>
          Schematically depicted dependence of final equilibrium plasma concentration and equilibration time on daily dose of chloroquine. The dependence of the final equilibrium concentration on body mass is not shown. However, for a given daily dose the final equilibrium concentration will be lower for a higher body mass. Similar relationships apply to hydroxychloroquine dosing. Data from Mackenzie [
          <xref ref-type="bibr" rid="CR2">
           2
          </xref>
          ]
         </p>
        </caption>
        <graphic id="MO3" xlink:href="308936_1_En_2_Fig3_HTML">
        </graphic>
       </fig>
       <table-wrap id="Tab2">
        <label>
         Table 2.2
        </label>
        <caption>
         <p>
          Plateau concentrations of 4-aminoquinolines according to daily dosing
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Drug/reference
           </th>
           <th>
            Dosing
           </th>
           <th>
            Equivalent daily dosing for a subject with IBW of 60 kg (mg/kg/day)
           </th>
           <th>
            Plateau plasma concentration (M/L)
           </th>
           <th>
            Plateau blood concentration (M/L)
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            C [
            <xref ref-type="bibr" rid="CR80">
             80
            </xref>
            ]
           </td>
           <td>
            250 mg/week
           </td>
           <td>
            0.60
           </td>
           <td>
            10
            <sup>
             −8
            </sup>
           </td>
           <td>
            <sup>
             a
            </sup>
            5 × 10
            <sup>
             −8
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            C [
            <xref ref-type="bibr" rid="CR80">
             80
            </xref>
            ]
           </td>
           <td>
            500 mg/week
           </td>
           <td>
            1.19
           </td>
           <td>
            10
            <sup>
             −7
            </sup>
           </td>
           <td>
            <sup>
             a
            </sup>
            5 × 10
            <sup>
             −7
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            C [
            <xref ref-type="bibr" rid="CR80">
             80
            </xref>
            ]
           </td>
           <td>
            250 mg/day
           </td>
           <td>
            4.16
           </td>
           <td>
            10
            <sup>
             −6
            </sup>
           </td>
           <td>
            <sup>
             a
            </sup>
            5 × 10
            <sup>
             −6
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            C [
            <xref ref-type="bibr" rid="CR80">
             80
            </xref>
            ]
           </td>
           <td>
            500 mg/day
           </td>
           <td>
            8.33
           </td>
           <td>
            10
            <sup>
             −5
            </sup>
           </td>
           <td>
            <sup>
             a
            </sup>
            5 × 10
            <sup>
             −5
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            C [
            <xref ref-type="bibr" rid="CR69">
             69
            </xref>
            ]
           </td>
           <td>
            310 mg/day
           </td>
           <td>
            5.17
           </td>
           <td>
            3.9 × 10
            <sup>
             −7
            </sup>
           </td>
           <td>
            1.95 × 10
            <sup>
             −6
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            HC [
            <xref ref-type="bibr" rid="CR174">
             175
            </xref>
            ]
           </td>
           <td>
            224 mg/day
           </td>
           <td>
            3.73
           </td>
           <td>
            <sup>
             b
            </sup>
            2.5 × 10
            <sup>
             −7
            </sup>
           </td>
           <td>
            2.0 × 10
            <sup>
             −6
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            HC [
            <xref ref-type="bibr" rid="CR71">
             71
            </xref>
            ]
           </td>
           <td>
            155 mg/day
           </td>
           <td>
            2.58
           </td>
           <td>
            <sup>
             b
            </sup>
            5.88 × 10
            <sup>
             −7
            </sup>
           </td>
           <td>
            2.94 × 10
            <sup>
             −6
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            HC [
            <xref ref-type="bibr" rid="CR71">
             71
            </xref>
            ]
           </td>
           <td>
            310 mg/day
           </td>
           <td>
            5.17
           </td>
           <td>
            <sup>
             b
            </sup>
            1.18 × 10
            <sup>
             −8
            </sup>
           </td>
           <td>
            5.88 × 10
            <sup>
             −6
            </sup>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          In some rows only one plateau concentration was measured, with the other deduced (see
          <italic>
           superscripts
          </italic>
          ). Findings that whole blood concentrations are approximately five times than that of plasma concentrations are denoted by
          <italic>
           a
          </italic>
          . The finding that plasma concentrations are approximately one-fifth of whole blood concentrations is denoted by
          <italic>
           b
          </italic>
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       Steady-State Concentration of 4-Aminoquinolines in Various Organs
      </title>
      <p>
       The concentration of 4AQs in the tissues of the body after ingestion varies. In pigmented rats, the order of concentration of chloroquine after a single dose from greatest to least is uvea &gt; liver &gt; lung &gt; kidney &gt; vitreous &gt; heart &gt; skin &gt; hair &gt; brain &gt; blood &gt; serum [
       <xref ref-type="bibr" rid="CR53">
        53
       </xref>
       ]. The results are similar in rabbits and humans [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="CR82">
        82
       </xref>
       ]. Drug binding to melanin explains the differences between pigmented and albino animals [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ]. The order of concentration of hydroxychloroquine in various tissues of albino rats is similar, except that concentrations in the albinotic uvea fall to the approximate level of the heart. In pigmented mammals, the eye has the highest concentration due to binding by melanin [
       <xref ref-type="bibr" rid="CR74">
        74
       </xref>
       ]. Similar results were found after chronic oral administration of chloroquine to albino and pigmented rats (Figs.
       <xref ref-type="fig" rid="Fig4">
        2.4
       </xref>
       and
       <xref ref-type="fig" rid="Fig5">
        2.5
       </xref>
       ) [
       <xref ref-type="bibr" rid="CR74">
        74
       </xref>
       ].
       <fig id="Fig4">
        <label>
         Fig. 2.4
        </label>
        <caption>
         <p>
          Relative concentration of hydroxychloroquine in various tissues in rats. Tissue levels of hydroxychloroquine in albino rats receiving 40 mg/kg/day of hydroxychloroquine orally by stomach tube, 6 days a week, for 3 months. Groups of four or six animals were sacrificed on days 30, 61, 91, 99, and 106. Results shown project back (mathematically, at intervals) to day 1, as indicated by broken lines. The single curve labeled “Eye (hooded)” refers to pigmented rather than albino rats. The melanin in pigmented tissues sequesters hydroxychloroquine. Data from McChesney EW [
          <xref ref-type="bibr" rid="CR74">
           74
          </xref>
          ]
         </p>
        </caption>
        <graphic id="MO4" xlink:href="308936_1_En_2_Fig4_HTML">
        </graphic>
       </fig>
       <fig id="Fig5">
        <label>
         Fig. 2.5
        </label>
        <caption>
         <p>
          Concentration of chloroquine in ocular tissues of pigmented rats. Panel A—Mean concentration of radioactivity in iris/ciliary body (blue line, circles) and choroid (orange line, triangles) at 24 h after repeated oral administration of
          <sup>
           14
          </sup>
          C-chloroquine at daily doses of 28 mg (0.054 mmol)kg/L under non-fasting conditions in pigmented rats for 84 days. Each value represents the mean ± standard deviation for three rats. Compare the concentrations in iris/ciliary body and choroid to those found in the retina and cornea in panel B. Panel B—Mean concentration of radioactivity in retina (orange line, triangles), cornea (purple line, squares), and vitreous (blue line, circles) after repeated oral administration of
          <sup>
           14
          </sup>
          C-chloroquine at daily doses of 28 mg (0.054 mmol)kg/L under non-fasting conditions in pigmented rats for 84 days. The concentration of chloroquine in the choroid is approximately 12 times higher in the choroid than the retina after the 84th dose. Data from Tanaka [
          <xref ref-type="bibr" rid="CR54">
           54
          </xref>
          ]
         </p>
        </caption>
        <graphic id="MO5" xlink:href="308936_1_En_2_Fig5_HTML">
        </graphic>
       </fig>
      </p>
      <p>
       Limited information from cases of accidental death in persons taking chloroquine and suicides by chloroquine ingestion indicates similar distributions of 4AQs across various tissues in humans [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ]. Tissue uptake as a function of dosage is nonlinear. In rats, a threefold increase in dosing leads to a 20-fold increase in hydroxychloroquine deposition in liver and spleen [
       <xref ref-type="bibr" rid="CR85">
        85
       </xref>
       ].
      </p>
      <p>
       A useful way to understand the differential distribution of 4AQs across various tissues is to consider ratios of concentration in tissues compared to plasma concentration (Table
       <xref ref-type="table" rid="Tab3">
        2.3
       </xref>
       ). The concentration of chloroquine in the liver, spleen, and adrenal gland is 6,000–80,000 times that in plasma, depending on the species chosen for study—whether the species is pigmented or albinotic—and the regimen of drug administration [
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ]. Within a single organ there are large differences in drug concentration in particular tissues. For example, chloroquine concentrations in the uvea of the rat are 9–32 times that of the retina, which in turn has concentrations six to nine times that of the vitreous [
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
       ,
       <xref ref-type="bibr" rid="CR54">
        54
       </xref>
       ]. In another example, within skin the 4AQs are more concentrated in the epidermis than the corium with a concentration ratio of 5:1 to 15:1 [
       <xref ref-type="bibr" rid="CR86">
        86
       </xref>
       ]. The variation reflects sequestration of 4AQs by lysosomes and melanin [
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ]. Millimolar levels of 4AQs can be found in lysosomes, and melanin can bind a quantity of 4AQs up to 3 % of its weight [
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR87">
        87
       </xref>
       ].
       <table-wrap id="Tab3">
        <label>
         Table 2.3
        </label>
        <caption>
         <p>
          Relative distribution of chloroquine among tissues
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Model
           </th>
           <th>
            Tissue
           </th>
           <th>
            Tissue-plasma concentration ratio
           </th>
           <th>
            Study
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Human
           </td>
           <td>
            Fat, tendon, bone
           </td>
           <td>
            0.1
           </td>
           <td>
            Titus [
            <xref ref-type="bibr" rid="CR37">
             37
            </xref>
            ], McChesney [
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            Albino rat, human
           </td>
           <td>
            Erythrocytes
           </td>
           <td>
            1.9–4.0
           </td>
           <td>
            Berliner [
            <xref ref-type="bibr" rid="CR3">
             3
            </xref>
            ], Alvan [
            <xref ref-type="bibr" rid="CR175">
             176
            </xref>
            ], Titus [
            <xref ref-type="bibr" rid="CR37">
             37
            </xref>
            ,
            <xref ref-type="bibr" rid="CR70">
             70
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            Albino rat
           </td>
           <td>
            Whole blood
           </td>
           <td>
            3.7
           </td>
           <td>
            Berliner [
            <xref ref-type="bibr" rid="CR3">
             3
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            Albino rat
           </td>
           <td>
            Brain
           </td>
           <td>
            4–31
           </td>
           <td>
            Berliner [
            <xref ref-type="bibr" rid="CR3">
             3
            </xref>
            ], Titus [
            <xref ref-type="bibr" rid="CR37">
             37
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            Albino rat
           </td>
           <td>
            Muscle
           </td>
           <td>
            4–41
           </td>
           <td>
            Berliner [
            <xref ref-type="bibr" rid="CR3">
             3
            </xref>
            ], Titus [
            <xref ref-type="bibr" rid="CR37">
             37
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            Human
           </td>
           <td>
            Skin
           </td>
           <td>
            6–200
           </td>
           <td>
            Ramser [
            <xref ref-type="bibr" rid="CR87">
             87
            </xref>
            ], Tannenbaum [
            <xref ref-type="bibr" rid="CR32">
             32
            </xref>
            ], Goldman [
            <xref ref-type="bibr" rid="CR20">
             20
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            Albino rat
           </td>
           <td>
            Heart
           </td>
           <td>
            150
           </td>
           <td>
            Berliner [
            <xref ref-type="bibr" rid="CR3">
             3
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            NG
           </td>
           <td>
            Leukocytes
           </td>
           <td>
            100–300
           </td>
           <td>
            Titus [
            <xref ref-type="bibr" rid="CR37">
             37
            </xref>
            ], Dubois [
            <xref ref-type="bibr" rid="CR10">
             10
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            Albino rat
           </td>
           <td>
            Kidney
           </td>
           <td>
            670
           </td>
           <td>
            Berliner [
            <xref ref-type="bibr" rid="CR3">
             3
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            Albino rat
           </td>
           <td>
            Lung
           </td>
           <td>
            640
           </td>
           <td>
            Berliner [
            <xref ref-type="bibr" rid="CR3">
             3
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            Albino rat
           </td>
           <td>
            Liver
           </td>
           <td>
            420
           </td>
           <td>
            Berliner [
            <xref ref-type="bibr" rid="CR3">
             3
            </xref>
            ]
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          In the albino rat model chloroquine 25 mg/kg was given daily for 10 days yielding a mean plasma concentration of 157 g/L [
          <xref ref-type="bibr" rid="CR3">
           3
          </xref>
          ]. NG means not given
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p>
       There are clinically unimportant differences in tissue distribution of chloroquine and hydroxychloroquine [
       <xref ref-type="bibr" rid="CR78">
        78
       </xref>
       ]. For an identical dose of hydroxychloroquine and chloroquine, tissue levels of chloroquine are 2.5 times those of hydroxychloroquine [
       <xref ref-type="bibr" rid="CR74">
        74
       </xref>
       ]. Tissue-plasma concentration ratios for chloroquine in various albinotic animals range from 28 to 93. For hydroxychloroquine the analogous tissue-plasma concentration ratios range from 33 to 79. In contrast, for both drugs in pigmented animals the tissue-plasma concentration ratios are approximately 1,000–3,000 [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ]. The 4AQs remain in human tissues for years. Five years after last ingesting chloroquine, chloroquine and its metabolite have been measured in the urine [
       <xref ref-type="bibr" rid="CR85">
        85
       </xref>
       ,
       <xref ref-type="bibr" rid="CR88">
        88
       </xref>
       ].
      </p>
     </sec>
     <sec id="Sec7">
      <title>
       Metabolism
      </title>
      <p>
       Metabolism of 4AQs is by dealkylation in the liver (Fig.
       <xref ref-type="fig" rid="Fig6">
        2.6
       </xref>
       ) [
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
       ]. To determine metabolites of chloroquine, carbon-14-labeled chloroquine was administered to monkeys, after which 12 labeled metabolites were detected. The two most important were desethyl chloroquine and bisdesethyl chloroquine, both of which have pharmacologic activity and are thought to be approximately as toxic as the parent compounds [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ]. The differential efficacy and toxicity of the metabolites of 4AQs has not been studied, but a suggestion has been made that desethylhydroxychloroquine might have a higher therapeutic ratio than the parent compound hydroxychloroquine [
       <xref ref-type="bibr" rid="CR77">
        77
       </xref>
       ].
       <fig id="Fig6">
        <label>
         Fig. 2.6
        </label>
        <caption>
         <p>
          Metabolism of chloroquine by dealkylation. Both metabolites are found in plasma and urine and both have activity similar to the parent compound. Data from Projean [
          <xref ref-type="bibr" rid="CR89">
           89
          </xref>
          ]
         </p>
        </caption>
        <graphic id="MO6" xlink:href="308936_1_En_2_Fig6_HTML">
        </graphic>
       </fig>
      </p>
      <p>
       The quinoline ring is resistant to degradation by cytochrome P450 enzymes (CYP) CYP2C8 and CYP3A4, which mediate 80 % of the total metabolism of 4AQs [
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="CR89">
        89
       </xref>
       –
       <xref ref-type="bibr" rid="CR91">
        91
       </xref>
       ]. The metabolism of chloroquine and hydroxychloroquine differs only in the number of metabolites produced (Fig.
       <xref ref-type="fig" rid="Fig7">
        2.7
       </xref>
       ) [
       <xref ref-type="bibr" rid="CR92">
        92
       </xref>
       ]. Thirty percent to 79 % of an oral dose of a 4AQ is metabolized and 21–70 % is excreted without metabolism [
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="CR91">
        91
       </xref>
       ,
       <xref ref-type="bibr" rid="CR93">
        93
       </xref>
       ].
       <fig id="Fig7">
        <label>
         Fig. 2.7
        </label>
        <caption>
         <p>
          Chemical structures of the three major metabolites of chloroquine and hydroxychloroquine. Chloroquine has two metabolites, whereas hydroxychloroquine has three
         </p>
        </caption>
        <graphic id="MO7" xlink:href="308936_1_En_2_Fig7_HTML">
        </graphic>
       </fig>
      </p>
      <p>
       Desethylchloroquine concentration after a dose of chloroquine reaches 40–48 % of chloroquine concentration. Bisdesethylchloroquine concentration reaches 10–13 % of chloroquine concentration [
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
       ,
       <xref ref-type="bibr" rid="CR93">
        93
       </xref>
       ,
       <xref ref-type="bibr" rid="CR94">
        94
       </xref>
       ]. At steady state the ratio of chloroquine to desethylchloroquine was 7.2 ± 1.88 while the ratio of hydroxychloroquine to desethylhydroxychloroquine was 1.75 ± .37 [
       <xref ref-type="bibr" rid="CR77">
        77
       </xref>
       ].
      </p>
      <p>
       Inhibition of cytochrome P450 isoenzymes by other drugs and variation across individuals in expression of the isoforms may explain the variation in levels of the two metabolites after ingestion of the same dose of chloroquine or hydroxychloroquine [
       <xref ref-type="bibr" rid="CR77">
        77
       </xref>
       ,
       <xref ref-type="bibr" rid="CR89">
        89
       </xref>
       ]. For example, ketoconazole, an inhibitor of CYP3A4, inhibited the formation of desethylchloroquine by 33 % and 45 % at concentrations of 1 × 10
       <sup>
        −6
       </sup>
       and 1 × 10
       <sup>
        −5
       </sup>
       M/L, respectively [
       <xref ref-type="bibr" rid="CR93">
        93
       </xref>
       ]. Cimetidine, another CYP3A4 inhibitor, increased the half-life of an oral dose of chloroquine by 48 % [
       <xref ref-type="bibr" rid="CR95">
        95
       </xref>
       ]. The elimination half-lives of chloroquine, desethylchloroquine, and bisdesethylchloroquine are all from 20 to 60 days. The half-lives of elimination of the desethyl metabolites of the 4AQs are longer than those of the parent compounds. [
       <xref ref-type="bibr" rid="CR77">
        77
       </xref>
       ] Chloroquine and metabolites can be found in urine for months after a single oral dose [
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
       ].
      </p>
      <p>
       Caution should be exercised in considering the results of testing in animal models. The results may not translate directly to human metabolism. For example, the dog metabolizes chloroquine by glucuronidation in a manner unlike some other species that leads to a relatively short half-life [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ].
      </p>
     </sec>
     <sec id="Sec8">
      <title>
       Excretion and Storage
      </title>
      <p>
       4AQs are excreted by the kidney and the liver [
       <xref ref-type="bibr" rid="CR96">
        96
       </xref>
       ]. For both chloroquine and hydroxychloroquine, approximately 40–60 % is excreted as unchanged or metabolized drug through the kidneys, 8–25 % is excreted in unchanged or changed form in the feces, 5 % is sloughed off through the skin, and 25–45 % is stored long term in lean body tissues (Table
       <xref ref-type="table" rid="Tab4">
        2.4
       </xref>
       ) [
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="CR53">
        53
       </xref>
       ,
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
       ,
       <xref ref-type="bibr" rid="CR74">
        74
       </xref>
       ,
       <xref ref-type="bibr" rid="CR80">
        80
       </xref>
       ]. Kidney or liver dysfunction decreases excretion of 4AQs and leads to greater drug retention and higher risk of retinopathy [
       <xref ref-type="bibr" rid="CR80">
        80
       </xref>
       ]. In the anuric patient, compared to subject with normal renal function, the equilibrium level of chloroquine is 70 % higher and for hydroxychloroquine is 25–30 % higher [
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ]. Declining renal function may be one mechanism by which age becomes a risk factor for retinopathy.
       <table-wrap id="Tab4">
        <label>
         Table 2.4
        </label>
        <caption>
         <p>
          Excretion of 4-aminoquinolines
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Fate
           </th>
           <th>
            Chloroquine (%)
           </th>
           <th>
            Hydroxychloroquine (%)
           </th>
           <th>
            References
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Excreted unchanged in urine
           </td>
           <td>
            Range 10–60; median 38
           </td>
           <td>
            Range 6–60; median 23
           </td>
           <td>
            <p>
             Tett [
             <xref ref-type="bibr" rid="CR71">
              71
             </xref>
             ], Schultz [
             <xref ref-type="bibr" rid="CR78">
              78
             </xref>
             ], Gustafsson [
             <xref ref-type="bibr" rid="CR70">
              70
             </xref>
             ], McChesney [
             <xref ref-type="bibr" rid="CR11">
              11
             </xref>
             ], Berliner [
             <xref ref-type="bibr" rid="CR3">
              3
             </xref>
             ],
            </p>
            <p>
             Titus [
             <xref ref-type="bibr" rid="CR37">
              37
             </xref>
             ], Ono [
             <xref ref-type="bibr" rid="CR53">
              53
             </xref>
             ], McChesney [
             <xref ref-type="bibr" rid="CR74">
              74
             </xref>
             ], Albert [
             <xref ref-type="bibr" rid="CR73">
              73
             </xref>
             ]
            </p>
           </td>
          </tr>
          <tr>
           <td>
            Excreted as metabolites in urine
           </td>
           <td>
            Range 7–31; median 18
           </td>
           <td>
            17
           </td>
           <td>
            Gustafsson [
            <xref ref-type="bibr" rid="CR70">
             70
            </xref>
            ], McChesney [
            <xref ref-type="bibr" rid="CR11">
             11
            </xref>
            ], Titus [
            <xref ref-type="bibr" rid="CR37">
             37
            </xref>
            ], Ono [
            <xref ref-type="bibr" rid="CR53">
             53
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            Excreted in feces
           </td>
           <td>
            8–10
           </td>
           <td>
            24–25
           </td>
           <td>
            McChesney [
            <xref ref-type="bibr" rid="CR11">
             11
            </xref>
            ], McChesney [
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            Sloughed off in skin
           </td>
           <td>
            5
           </td>
           <td>
            5
           </td>
           <td>
            Mackenzie [
            <xref ref-type="bibr" rid="CR80">
             80
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            Stored long term in lean tissues
           </td>
           <td>
            45
           </td>
           <td>
            45
           </td>
           <td>
            Mackenzie [
            <xref ref-type="bibr" rid="CR80">
             80
            </xref>
            ]
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
      <p>
       Alkalinization of urine decreases excretion [
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
       ]. Acidification of the urine by oral ingestion of ammonium chloride can increase renal excretion 20–80 % [
       <xref ref-type="bibr" rid="CR85">
        85
       </xref>
       ]. Intramuscular injection of dimercaprol can also increase urinary excretion of chloroquine [
       <xref ref-type="bibr" rid="CR85">
        85
       </xref>
       ]. Neither of these approaches has been adopted in clinical practice as practical methods to treat chloroquine retinopathy.
      </p>
     </sec>
    </sec>
    <sec id="Sec9">
     <title>
      Clinical Uses and Dosing
     </title>
     <p>
      The 4AQs are commonly used in rheumatologic conditions because they are effective in a high proportion of cases and have fewer side effects than gold, azathioprine, penicillamine, or levamisole [
      <xref ref-type="bibr" rid="CR97">
       97
      </xref>
      –
      <xref ref-type="bibr" rid="CR100">
       100
      </xref>
      ]. The diagnoses for which 4AQs are most prescribed are rheumatoid arthritis (RA) and SLE, which together account for 82–95 % of the cases [
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="CR101">
       101
      </xref>
      ,
      <xref ref-type="bibr" rid="CR223">
       102
      </xref>
      ]. An epidemiologic survey, found that 60.1 % of patients with RA and 92.2 % of patients with SLE take hydroxychloroquine at some point in the course of their disease [
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ].
     </p>
     <p>
      Antimalarials have a different mechanism of action than other immunomodulating therapies making them useful in combination therapy [
      <xref ref-type="bibr" rid="CR42">
       42
      </xref>
      ,
      <xref ref-type="bibr" rid="CR102">
       103
      </xref>
      –
      <xref ref-type="bibr" rid="CR104">
       105
      </xref>
      ]. In RA and SLE it is commonly observed that 60–95 % of patients taking chloroquine have a clinical response measured by subjective improvement, objective responses in laboratory measurements, activities of daily living, and reductions in flares of disease [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ,
      <xref ref-type="bibr" rid="CR71">
       71
      </xref>
      ,
      <xref ref-type="bibr" rid="CR105">
       106
      </xref>
      –
      <xref ref-type="bibr" rid="CR111">
       112
      </xref>
      ]. Although initially embraced for patients with milder forms of SLE and RA [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ], the recent trend is that 4AQs are being used in a higher proportion of patients with SLE; some have advocated their use in all SLE patients [
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="CR103">
       104
      </xref>
      ]. Many reports pool all patients taking 4AQs together under the assumption that the disease for which the drug is taken is immaterial to the risk of retinopathy [
      <xref ref-type="bibr" rid="CR62">
       62
      </xref>
      ,
      <xref ref-type="bibr" rid="CR112">
       113
      </xref>
      ,
      <xref ref-type="bibr" rid="CR113">
       114
      </xref>
      ].
     </p>
     <p>
      Clinical efficacy may be greater in SLE than in RA [
      <xref ref-type="bibr" rid="CR114">
       115
      </xref>
      ]. In 15 % of patients the clinical response is dramatic [
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ]. The erythrocyte sedimentation rate, C-reactive protein, and serum IgG levels typically decrease in patients with autoimmune diseases treated with 4AQs. Occasionally, long-term remission of autoimmune disease is possible with no progression of radiologically documented joint disease [
      <xref ref-type="bibr" rid="CR115">
       116
      </xref>
      ]. In SLE, use of 4AQs has also improved survival [
      <xref ref-type="bibr" rid="CR116">
       117
      </xref>
      ]. This may be due to the antiatherogenic and antithrombotic effects of 4AQs as well as their beneficial effects on lipid profile and osteoporosis [
      <xref ref-type="bibr" rid="CR102">
       103
      </xref>
      ,
      <xref ref-type="bibr" rid="CR103">
       104
      </xref>
      ]. When the drugs are stopped, beneficial effects last for several weeks to months, but disease activity generally recurs [
      <xref ref-type="bibr" rid="CR115">
       116
      </xref>
      ]. There is typically no increase in rates of opportunistic infection. Chloroquine prevents an immunologic response to antigenic proteins requiring digestion, but not the response of T cells to predigested antigenic peptides [
      <xref ref-type="bibr" rid="CR117">
       118
      </xref>
      ].
     </p>
     <p>
      Full effects of the 4AQs may take 3–6 months to develop [
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ,
      <xref ref-type="bibr" rid="CR38">
       38
      </xref>
      ,
      <xref ref-type="bibr" rid="CR105">
       106
      </xref>
      ,
      <xref ref-type="bibr" rid="CR106">
       107
      </xref>
      ,
      <xref ref-type="bibr" rid="CR115">
       116
      </xref>
      ,
      <xref ref-type="bibr" rid="CR117">
       118
      </xref>
      –
      <xref ref-type="bibr" rid="CR119">
       120
      </xref>
      ]. Some have attributed this to a pharmacodynamic mechanism involving an immune process that requires the observed time to develop. However, the effect is predictable based on pharmacokinetics and the time required to saturate lysosomes (see Chap. 10.1007/978-1-4939-0597-3_1) [
      <xref ref-type="bibr" rid="CR83">
       83
      </xref>
      ,
      <xref ref-type="bibr" rid="CR94">
       94
      </xref>
      ,
      <xref ref-type="bibr" rid="CR120">
       121
      </xref>
      ,
      <xref ref-type="bibr" rid="CR121">
       122
      </xref>
      ]. The delayed onset of therapeutic effect of the 4AQs after initiation of therapy can be shortened by using a higher loading dose in the first weeks to months at the price of an increased frequency of gastrointestinal side effects [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="CR38">
       38
      </xref>
      ,
      <xref ref-type="bibr" rid="CR118">
       119
      </xref>
      ,
      <xref ref-type="bibr" rid="CR120">
       121
      </xref>
      ,
      <xref ref-type="bibr" rid="CR122">
       123
      </xref>
      ]. A doubling of the daily dose is common in the first part of a course of rheumatologic therapy [
      <xref ref-type="bibr" rid="CR123">
       124
      </xref>
      ]. Beginning with the maintenance dose leads to a slower onset of action [
      <xref ref-type="bibr" rid="CR120">
       121
      </xref>
      ,
      <xref ref-type="bibr" rid="CR122">
       123
      </xref>
      ].
     </p>
     <p>
      Some clinicians give patients a drug holiday during summer as a way of assessing if the drug is still required for control of disease activity [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="CR122">
       123
      </xref>
      ]. This practice should also reduce the probability of developing 4AQR. Rheumatologists frequently decrease the dosing of 4AQs over time. In one series of 758 patients, 84 % of patients begun on 400 mg/day of hydroxychloroquine had their daily doses reduced over time. This is important, since the most common intervention by ophthalmologists is to suggest dosage reductions, not cessation of 4AQs, in response to concerns of retinopathy [
      <xref ref-type="bibr" rid="CR124">
       125
      </xref>
      –
      <xref ref-type="bibr" rid="CR126">
       127
      </xref>
      ].
     </p>
     <p>
      Approximately 20–50 % of patients with SLE and 75 % of patients with RA eventually have cessation of the drug by 6–10 years of follow-up, mainly because of inefficacy in the case of RA and because of disease remission in the case of SLE [
      <xref ref-type="bibr" rid="CR97">
       97
      </xref>
      ,
      <xref ref-type="bibr" rid="CR114">
       115
      </xref>
      ,
      <xref ref-type="bibr" rid="CR124">
       125
      </xref>
      ,
      <xref ref-type="bibr" rid="CR127">
       128
      </xref>
      ,
      <xref ref-type="bibr" rid="CR128">
       129
      </xref>
      ]. The rate of discontinuation of 4AQs is highest in the first 2 years. In the case of hydroxychloroquine, by 2 years approximately 34 % of patients with SLE and 54 % of patient with RA will have discontinued the drug [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="CR124">
       125
      </xref>
      ,
      <xref ref-type="bibr" rid="CR127">
       128
      </xref>
      ]. Discontinuation of hydroxychloroquine may be less common in patients treated for SLE than RA. In one series, the overall 5-, 10-, and 15-year discontinuation rates were 20 %, 38 %, and 58 %, respectively [
      <xref ref-type="bibr" rid="CR114">
       115
      </xref>
      ]. Approximately 5 % of patients stop treatment because of ocular problems such as blurred vision or corneal deposits and 5 % stop because of gastrointestinal complaints, rashes, and other side effects. Rates of stopping 4AQs are dependent on the physician, the patient, and their relationship [
      <xref ref-type="bibr" rid="CR97">
       97
      </xref>
      ]. Some physicians and patients are more willing than others to tolerate less-than-complete control of disease activity and some degree of side effects [
      <xref ref-type="bibr" rid="CR97">
       97
      </xref>
      ].
     </p>
     <p>
      Chloroquine is commonly given in doses of 100–250 mg/day for prophylaxis against malaria [
      <xref ref-type="bibr" rid="CR129">
       130
      </xref>
      ]. It is given as 1,500 mg over 3 days as a treatment for an acute episode of malaria [
      <xref ref-type="bibr" rid="CR130">
       131
      </xref>
      ]. The most common doses of chloroquine and hydroxychloroquine in clinical use are 250 and 400 mg/day, respectively, regardless of height or weight of the patient [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="CR45">
       45
      </xref>
      ,
      <xref ref-type="bibr" rid="CR97">
       97
      </xref>
      ,
      <xref ref-type="bibr" rid="CR100">
       100
      </xref>
      ,
      <xref ref-type="bibr" rid="CR125">
       126
      </xref>
      ]. That is, cumulative doses greater than 100 times that used for prophylaxis or treatment of malaria are administered to patients with autoimmune diseases [
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="CR100">
       100
      </xref>
      ,
      <xref ref-type="bibr" rid="CR114">
       115
      </xref>
      ,
      <xref ref-type="bibr" rid="CR129">
       130
      </xref>
      ]. Before 1980, dosing of 4AQs was excessive and largely responsible for the greater prevalence of 4AQR reported in this era [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ]. For example, in 1978 it was recommended that 400 mg/day of hydroxychloroquine and 250 mg/day of chloroquine were acceptable doses for all adults weighing over 100 lb [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ]. The threshold for IBW at which these doses are now recognized to be unacceptable is now recognized to be 135 lb, not 100 lb [
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
      ,
      <xref ref-type="bibr" rid="CR126">
       127
      </xref>
      ,
      <xref ref-type="bibr" rid="CR131">
       132
      </xref>
      ]. More sophisticated regimens seek dosing not greater than 6 mg/kg/day based on actual body weight (ABW) [
      <xref ref-type="bibr" rid="CR97">
       97
      </xref>
      ] or 6.0–6.5 mg/kg/day based on IBW for hydroxychloroquine [
      <xref ref-type="bibr" rid="CR78">
       78
      </xref>
      ,
      <xref ref-type="bibr" rid="CR132">
       133
      </xref>
      ]. The analogous ceiling for chloroquine is 3.5 mg/kg/day based on IBW. The preferred dosing of 4AQs is based on IBW [
      <xref ref-type="bibr" rid="CR80">
       80
      </xref>
      ,
      <xref ref-type="bibr" rid="CR113">
       114
      </xref>
      ]. If a patient’s ABW is less than the IBW based on height, then the ABW should be used to determine dosing [
      <xref ref-type="bibr" rid="CR125">
       126
      </xref>
      ].
     </p>
     <p>
      A 250 mg dose of chloroquine phosphate contains 150 mg of chloroquine base [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ]. A 200 mg dose of hydroxychloroquine sulfate contains 155 mg of hydroxychloroquine base [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ]. The relative potency and toxicity of the two 4AQs is inconsistently portrayed. Some have written that chloroquine is more potent and more toxic than hydroxychloroquine [
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="CR133">
       134
      </xref>
      ], but others have said the reverse. For example, 400 mg of hydroxychloroquine has been assumed to be equivalent to 500 mg of chloroquine [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="CR133">
       134
      </xref>
      ,
      <xref ref-type="bibr" rid="CR134">
       135
      </xref>
      ], yet another report assumes that 400 mg of chloroquine is equivalent to 500 mg of hydroxychloroquine [
      <xref ref-type="bibr" rid="CR133">
       134
      </xref>
      ]. Other reports state that 400 mg of hydroxychloroquine is equivalent to 250 mg of chloroquine [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="CR135">
       136
      </xref>
      ].
     </p>
     <p>
      The best analysis based on multiple forms of administration in different animal models and in human trials is that chloroquine and hydroxychloroquine are equipotent and that chloroquine is approximately twice as toxic [
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ]. That is, in acute toxicity experiments in animal models, the dose at which 50 % die (LD
      <sub>
       50
      </sub>
      ) is approximately twice as high with hydroxychloroquine as with chloroquine (see Chap. 10.1007/978-1-4939-0597-3_3) [
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ]. Likewise, in subacute and chronic toxicity studies, the tolerated dose for 50 % of animals is approximately twice as high with hydroxychloroquine as with chloroquine [
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ]. Although less rigorous, clinical series in humans suggests the same with a smaller percentage of side effects with hydroxychloroquine compared to chloroquine when the two are given in comparable dosages [
      <xref ref-type="bibr" rid="CR136">
       137
      </xref>
      ,
      <xref ref-type="bibr" rid="CR137">
       138
      </xref>
      ]. Therefore, at the most commonly prescribed daily doses, chloroquine and hydroxychloroquine have been considered equally effective in treating autoimmune diseases with the therapeutic ratio favoring hydroxychloroquine (see Chap. 10.1007/978-1-4939-0597-3_1).
     </p>
     <p>
      Reports are inconsistent in the way they report drug concentrations. Plasma, serum, and whole blood concentrations have been used. They are not comparable; plasma concentrations are the lowest, and whole blood concentrations are the greatest. Serum concentrations exceed plasma concentrations because platelets concentrate 4AQs, and upon coagulation of the blood the platelet contents are released into the serum [
      <xref ref-type="bibr" rid="CR138">
       139
      </xref>
      ]. Plasma levels of chloroquine effective against malaria are 10
      <sup>
       −8
      </sup>
      to 10
      <sup>
       −7
      </sup>
      M/L [
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ,
      <xref ref-type="bibr" rid="CR139">
       140
      </xref>
      ]. For rheumatological disease higher plasma levels are required—approximately 10
      <sup>
       −6
      </sup>
      M/L [
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ,
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ,
      <xref ref-type="bibr" rid="CR71">
       71
      </xref>
      ,
      <xref ref-type="bibr" rid="CR89">
       89
      </xref>
      ,
      <xref ref-type="bibr" rid="CR139">
       140
      </xref>
      ,
      <xref ref-type="bibr" rid="CR140">
       141
      </xref>
      ]. Serum concentrations of chloroquine in patients taking chloroquine 250 mg/day for long periods are in the range 6.25 × 10
      <sup>
       −7
      </sup>
      to 1.25 × 10
      <sup>
       −6
      </sup>
      M/L [
      <xref ref-type="bibr" rid="CR141">
       142
      </xref>
      ]. Therapeutic whole blood concentrations of HC for autoimmune diseases are 8 × 10
      <sup>
       −7
      </sup>
      to 5 × 10
      <sup>
       −6
      </sup>
      M/L, approximately five times higher than plasma concentrations [
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
      ,
      <xref ref-type="bibr" rid="CR78">
       78
      </xref>
      ,
      <xref ref-type="bibr" rid="CR89">
       89
      </xref>
      ]. Using whole blood concentrations is not optimal because 4AQs are preferentially sequestered in erythrocytes and leukocytes which implies that hematocrit and white blood cell count will affect the whole blood concentration in potentially confounding ways. On the other hand, the precision of measurements is higher with whole blood than with plasma, possibly due to the technical difficulty of separating blood cells and platelets from plasma, making whole blood more suited for pharmacokinetic analyses [
      <xref ref-type="bibr" rid="CR77">
       77
      </xref>
      ].
     </p>
     <p>
      In a study of patients with rheumatoid arthritis, patients with less morning stiffness and no rheumatoid factor had significantly higher blood concentrations of hydroxychloroquine than patients with more morning stiffness and presence of rheumatoid factor [
      <xref ref-type="bibr" rid="CR142">
       143
      </xref>
      ]. Other studies have not found a correlation between plasma concentration and clinical response [
      <xref ref-type="bibr" rid="CR77">
       77
      </xref>
      ,
      <xref ref-type="bibr" rid="CR138">
       139
      </xref>
      ,
      <xref ref-type="bibr" rid="CR143">
       144
      </xref>
      ]. In patients taking hydroxychloroquine for RA and SLE, daily dosing at 400 mg/day was associated with wide variability in whole blood concentrations [
      <xref ref-type="bibr" rid="CR144">
       145
      </xref>
      ]. In a study of 143 patients with SLE, those patients with inactive disease had average whole blood concentrations of 3.37 × 10
      <sup>
       −6
      </sup>
      ± 1.64 × 10
      <sup>
       −6
      </sup>
      M/L compared to 2.17 × 10
      <sup>
       −6
      </sup>
      ± 1.40 × 10
      <sup>
       −6
      </sup>
      in those patients with active disease [
      <xref ref-type="bibr" rid="CR144">
       145
      </xref>
      ]. Higher rates of efficacy can be assured if dosing is calibrated to yield a whole blood concentration of approximately 3.1 × 10
      <sup>
       −6
      </sup>
      M/L [
      <xref ref-type="bibr" rid="CR38">
       38
      </xref>
      ,
      <xref ref-type="bibr" rid="CR144">
       145
      </xref>
      ]. Variability may be due to lack of adherence to therapy or differences in absorption or metabolism of the drugs by individuals. Because of interindividual variability, in certain patients it may not be possible to reach therapeutic concentrations of 4AQs without exceeding daily dose thresholds based on IBW that are considered high risk for causing retinopathy [
      <xref ref-type="bibr" rid="CR144">
       145
      </xref>
      ]. Patients taking hydroxychloroquine for graft-versus-host disease have higher whole blood concentration targets of 5 × 10
      <sup>
       −6
      </sup>
      to 1.5 × 10
      <sup>
       −5
      </sup>
      M/L. Concerns over retinopathy in these patients are balanced against the more serious nature of their systemic disease. Effective plasma concentrations and effective in vitro concentrations of the drugs are not necessarily closely related, as the drug concentrations may be higher locally due to intracellular organelle sequestration [
      <xref ref-type="bibr" rid="CR138">
       139
      </xref>
      ,
      <xref ref-type="bibr" rid="CR139">
       140
      </xref>
      ]. Other potential confounders include receptor concentrations, the influence of alcohol and smoking, genetic and gender influences, and age [
      <xref ref-type="bibr" rid="CR77">
       77
      </xref>
      ]. Perhaps because of inconsistency of results, few clinicians measure plasma concentrations of 4AQs to judge adequacy of a trial of drug [
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="CR138">
       139
      </xref>
      ].
     </p>
     <p>
      One therapeutic strategy used to reduce the risk of retinopathy yet obtain the beneficial disease modifying effects of antimalarial therapy is to combine chloroquine or hydroxychloroquine with quinacrine, which is not a 4-aminoquinoline and is considered to have a lesser risk of causing retinopathy. In practical terms, the patient is begun on hydroxychloroquine 400 mg/day or 6.5 mg/kg/day based on IBW, whichever is lower. After 2 months, if the autoimmune disease has not sufficiently responded, quainacrine 100 mg/day is added. After one additional month if a response has been achieved then the hydroxychloroquine is reduced to 200 mg/day [
      <xref ref-type="bibr" rid="CR38">
       38
      </xref>
      ]. Although the risk of retinopathy with quinacrine is less than with 4AQs, retinopathy has been associated infrequently with quinacrine [
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ].
     </p>
    </sec>
    <sec id="Sec10">
     <title>
      Pregnancy and Lactation
     </title>
     <p>
      Antimalarials cross the placenta and can concentrate in the eyes of fetal animals in mice and monkey models [
      <xref ref-type="bibr" rid="CR64">
       64
      </xref>
      ,
      <xref ref-type="bibr" rid="CR145">
       146
      </xref>
      ]. Cord blood concentrations of antimalarials are similar to maternal blood levels [
      <xref ref-type="bibr" rid="CR146">
       147
      </xref>
      ,
      <xref ref-type="bibr" rid="CR147">
       148
      </xref>
      ]. Toxicity in the fetus has not been reported. However, the number of mothers who have taken one of the drugs on a daily basis while pregnant and whose offspring have subsequently been examined for retinopathy has been small and the methods for checking retinopathy insensitive (Table
      <xref ref-type="table" rid="Tab5">
       2.5
      </xref>
      ) [
      <xref ref-type="bibr" rid="CR148">
       149
      </xref>
      –
      <xref ref-type="bibr" rid="CR150">
       151
      </xref>
      ]. A randomized control trial with greater than 400 pregnancies per arm would be required to detect a difference in 5 % in pregnancy loss with alpha error of 0.05 and beta error of 0.8 [
      <xref ref-type="bibr" rid="CR151">
       152
      </xref>
      ]. Such a study is unlikely to be done, and therefore practice is likely to be guided by evidence of lesser quality. In case–control studies and prospective case series, the rates of spontaneous abortion, fetal death, fetal distress, and congenital malformations have not differed, although the studies have been small with little power to detect small differences in rates [
      <xref ref-type="bibr" rid="CR151">
       152
      </xref>
      –
      <xref ref-type="bibr" rid="CR153">
       154
      </xref>
      ]. Flares of lupus among women who stop 4AQs during pregnancy are more frequent than in women who continue these drugs throughout pregnancy [
      <xref ref-type="bibr" rid="CR151">
       152
      </xref>
      ,
      <xref ref-type="bibr" rid="CR152">
       153
      </xref>
      ]. The general consensus is that mothers using antimalarial drugs during pregnancy need not stop them as they do not appear to affect fetal health [
      <xref ref-type="bibr" rid="CR146">
       147
      </xref>
      ,
      <xref ref-type="bibr" rid="CR149">
       150
      </xref>
      ,
      <xref ref-type="bibr" rid="CR152">
       153
      </xref>
      –
      <xref ref-type="bibr" rid="CR155">
       156
      </xref>
      ]. Dissenting opinion has been published, but it is based on anecdotal associations of fetal abnormalities in mothers taking 4AQs during pregnancy [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
      ,
      <xref ref-type="bibr" rid="CR71">
       71
      </xref>
      ,
      <xref ref-type="bibr" rid="CR156">
       157
      </xref>
      ].
      <table-wrap id="Tab5">
       <label>
        Table 2.5
       </label>
       <caption>
        <p>
         4-Aminoquinoline use in pregnancy and the risk of retinopathy in offspring
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Study
          </th>
          <th>
           Examinations done on offspring
          </th>
          <th>
           Number of offspring with retinopathy/number of pregnant women taking chloroquine
          </th>
          <th>
           Number of offspring with retinopathy/number of pregnant women taking hydroxychloroquine
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           Klinger [
           <xref ref-type="bibr" rid="CR148">
            149
           </xref>
           ]
          </td>
          <td>
           BCVA, SLE, DFE, CV, some GVF
          </td>
          <td rowspan="2">
           0/7
          </td>
          <td>
           0/14
          </td>
         </tr>
         <tr>
          <td>
           Motta [
           <xref ref-type="bibr" rid="CR149">
            150
           </xref>
           ]
          </td>
          <td>
           Inspect anterior segment, pupillary reaction, DFE
          </td>
          <td>
           0/35
          </td>
         </tr>
         <tr>
          <td>
           Parke [
           <xref ref-type="bibr" rid="CR155">
            156
           </xref>
           ]
          </td>
          <td>
           Funduscopy
          </td>
          <td rowspan="2">
           0/4
          </td>
          <td>
           0/4
          </td>
         </tr>
         <tr>
          <td>
           Costedoat-Chalumeau [
           <xref ref-type="bibr" rid="CR147">
            148
           </xref>
           ]
          </td>
          <td>
           NG
          </td>
          <td>
           0/11
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         <italic>
          BCVA
         </italic>
         best corrected visual acuity,
         <italic>
          SLE
         </italic>
         slit lamp examination,
         <italic>
          CV
         </italic>
         color vision,
         <italic>
          GVF
         </italic>
         Goldmann visual fields,
         <italic>
          NG
         </italic>
         not given,
         <italic>
          DFE
         </italic>
         dilated fundus examination
        </p>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p>
      Data on use of antimalarials by lactating mothers is sparse, but small amounts are excreted into breast milk [
      <xref ref-type="bibr" rid="CR146">
       147
      </xref>
      ,
      <xref ref-type="bibr" rid="CR157">
       158
      </xref>
      ]. In a woman given 800 mg of hydroxychloroquine in the course of 48 h, the concentration of drug in breast milk was 9.5 × 10
      <sup>
       −9
      </sup>
      M/L [
      <xref ref-type="bibr" rid="CR158">
       159
      </xref>
      ]. Doses delivered to breastfeeding infants have been estimated to be 0.06–0.2 mg/kg/day, far less than the threshold of 6.5 mg/kg/day used to regulate pediatric and adult dosing [
      <xref ref-type="bibr" rid="CR147">
       148
      </xref>
      ,
      <xref ref-type="bibr" rid="CR151">
       152
      </xref>
      ].The little evidence available suggests that breastfeeding mothers may continue therapy with hydroxychloroquine and chloroquine [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="CR146">
       147
      </xref>
      ,
      <xref ref-type="bibr" rid="CR149">
       150
      </xref>
      ,
      <xref ref-type="bibr" rid="CR157">
       158
      </xref>
      ]. If prescription of a 4AQ is considered during pregnancy, then hydroxychloroquine is preferred over chloroquine because it may be less toxic, because hydroxychloroquine has been used as a treatment for antiphospholipid syndrome, and because hydroxychloroquine is less concentrated in breast milk than chloroquine [
      <xref ref-type="bibr" rid="CR38">
       38
      </xref>
      ].
     </p>
    </sec>
    <sec id="Sec11">
     <title>
      Mechanism of Action
     </title>
     <sec id="Sec12">
      <title>
       Positive Studies on Mechanism of Action of 4-Aminoquinolines
      </title>
      <p>
       Mechanisms of action of chloroquine and hydroxychloroquine are thought to be the same [
       <xref ref-type="bibr" rid="CR159">
        160
       </xref>
       ]. The mechanism that has received the most attention involves lysosomotropism, that is, the property that 4AQs accumulate within lysosomes and other intracellular acidic compartments due to protonation and sequestration of the drug [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR121">
        122
       </xref>
       ,
       <xref ref-type="bibr" rid="CR160">
        161
       </xref>
       ]. Uncharged 4AQs readily diffuse into the lysosome, but once protonated at their two basic residues cannot diffuse back out into the cytoplasm [
       <xref ref-type="bibr" rid="CR33">
        33
       </xref>
       ].
      </p>
      <p>
       Lysosomes have a pH between four and five maintained by an active transport of protons from the cytosol into the lysosome [
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="CR121">
        122
       </xref>
       ,
       <xref ref-type="bibr" rid="CR161">
        162
       </xref>
       –
       <xref ref-type="bibr" rid="CR163">
        164
       </xref>
       ]. The cytosol and the extracellular milieu have a pH of approximately 7.4 [
       <xref ref-type="bibr" rid="CR121">
        122
       </xref>
       ]. Chloroquine is a weak base with p
       <italic>
        K
       </italic>
       <sub>
        1
       </sub>
       = 8.1 for the amine group at position seven and p
       <italic>
        K
       </italic>
       <sub>
        2
       </sub>
       = 10.1 for the amine group on the alkyl side chain [
       <xref ref-type="bibr" rid="CR52">
        52
       </xref>
       ]. Lysosomal concentrations of chloroquine as high as 2 × 10
       <sup>
        −2
       </sup>
       M/L have been measured. [
       <xref ref-type="bibr" rid="CR161">
        162
       </xref>
       ,
       <xref ref-type="bibr" rid="CR163">
        164
       </xref>
       ] The pH of lysosomes exposed to chloroquine increases from the baseline four to six [
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="CR162">
        163
       </xref>
       ]. If the pH gradient is abolished, chloroquine accumulation ceases [
       <xref ref-type="bibr" rid="CR163">
        164
       </xref>
       ]. Bafilomycin A1, an inhibitor of lysosomal acidification, blocks chloroquine-induced lysosomotropism and toxicity in RPE-19 cell culture [
       <xref ref-type="bibr" rid="CR160">
        161
       </xref>
       ]. At equilibrium, the ratio of distribution of diacidic bases 4AQs between lysosomes and plasma is given by the ratio (
       <italic>
        H
       </italic>
       <sub>
        L
       </sub>
       /
       <italic>
        H
       </italic>
       <sub>
        P
       </sub>
       ), [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ] where
       <italic>
        H
       </italic>
       <sub>
        L
       </sub>
       is the hydrogen ion concentration of the lysosome and
       <italic>
        H
       </italic>
       <sub>
        <italic>
         P
        </italic>
       </sub>
       is the hydrogen ion concentration of the plasma. Thus the ratio of 4AQs between lysosomes and plasma is approximately 160,000. To maintain osmotic balance as chloroquine enters the lysosome, water accompanies it, swelling the organelle [
       <xref ref-type="bibr" rid="CR161">
        162
       </xref>
       ].
      </p>
      <p>
       Although lysosomes are a small fraction of intracellular volume, the large gradient of 4AQ suggests the large volumes of distribution empirically measured in pharmacokinetic studies (see Sect.
       <xref ref-type="sec" rid="Sec5">
        2.2.3.2
       </xref>
       ) [
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ]. Besides the sequestration due to diprotonation, there is also binding to acidic polysaccharides and acidic glycolipids found in lysosomal membranes [
       <xref ref-type="bibr" rid="CR121">
        122
       </xref>
       ].
      </p>
      <p>
       The inhibition of lysosomal enzymatic function is hypothesized to be the cause of beneficial effects and retinopathy of the 4AQs [
       <xref ref-type="bibr" rid="CR29">
        29
       </xref>
       ]. Once inside lysosomes, 4AQs inhibit the lysosomal activity of cathepsin B and enzymes involved in degradation of mucopolysaccharides and proteins [
       <xref ref-type="bibr" rid="CR33">
        33
       </xref>
       ,
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR117">
        118
       </xref>
       ,
       <xref ref-type="bibr" rid="CR164">
        165
       </xref>
       ,
       <xref ref-type="bibr" rid="CR165">
        166
       </xref>
       ]. Elevation of lysosomal pH by 4AQs inhibits MHC class II-dependent antigen processing and presentation by monocytes [
       <xref ref-type="bibr" rid="CR166">
        167
       </xref>
       ]. The raised pH increases invariant chain (Ii) dissociation from the MHC class II molecule via decreased activity of aspartyl protease, cathepsin D, and cathepsin B, which cleave Ii from the MHC class II molecule [
       <xref ref-type="bibr" rid="CR78">
        78
       </xref>
       ]. This decreases antigen binding to the surface of the professional APCs (see Chap. 10.1007/978-1-4939-0597-3_1). The 4AQs also inhibit lysosomal pinocytosis which inhibits digestion of exogenous proteins into antigenic peptides. With decreased peptide loading into the groove between α and β chains of MHC class II molecules there are fewer peptide-MHC class II complexes for transport to the cell surface and presentation to CD4 T cells (see Chap. 10.1007/978-1-4939-0597-3_1) [
       <xref ref-type="bibr" rid="CR167">
        168
       </xref>
       ]. Self-antigens typically have lower affinity for MHC class II molecules than non-self-antigens, thus 4AQs have a preferential inhibitory effect on autoimmunity, and do not impair immunity to exogenous agents [
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ]. The net effect of 4AQs is dysfunctional protein processing, receptor recycling, protein secretion, reduced production of cytokines and immune mediators, reduced lymphocyte production, and reduced natural killer cell activity [
       <xref ref-type="bibr" rid="CR81">
        81
       </xref>
       ].
      </p>
      <p>
       Toxic effects occur when lysosomes exposed to 4AQs accumulate ubiquitinated proteins leading to apoptosis, disruption of autophagy, and oxidative injury [
       <xref ref-type="bibr" rid="CR160">
        161
       </xref>
       ]. Swollen lysosomes combine with phagosomes containing photoreceptor outer segments to form lamellar inclusion bodies (myeloid or myelin bodies, see Chap. 10.1007/978-1-4939-0597-3_1) [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="CR168">
        169
       </xref>
       ]. The increased lysosomal pH inhibits receptor-enzyme dissociation, which may have toxic effects [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ]. The sequestered cell membranes and included protein receptors in the myelin bodies are disrupted in their normal recycling which depletes the population of surface membrane receptors without a change in receptor affinity. Disrupted interaction of retinal neuronal and RPE cells with the local environment results in toxicity and eventually morphologic damage [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ].
      </p>
      <p>
       Although lysosomotropic effects have received the most attention, 4AQs affect many other cellular processes, and it can be confusing to tie them together in a comprehensible way. One way to do so is to organize them is by their dependence on concentration. Some authors contend that mechanisms that depend on concentrations higher than 1 × 10
       <sup>
        −6
       </sup>
       M/L in vitro are not relevant to clinical effects. They reason that such concentrations are higher than those expected to be found clinically in the plasma [
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR78">
        78
       </xref>
       ,
       <xref ref-type="bibr" rid="CR141">
        142
       </xref>
       ,
       <xref ref-type="bibr" rid="CR169">
        170
       </xref>
       ]. For example, although hydroxychloroquine at a concentration of 1 × 10
       <sup>
        −4
       </sup>
       M/L affects IL-17 and other cytokine levels produced by the peripheral blood mononuclear cells of patients with RA and SLE in vitro, we are uncertain that this is a physiologic pathway [
       <xref ref-type="bibr" rid="CR170">
        171
       </xref>
       ]. In another example, significant inhibition of immunoglobulin synthesis and secretion by rat plasma cells in vitro required concentration of 9 × 10
       <sup>
        −4
       </sup>
       M/L chloroquine [
       <xref ref-type="bibr" rid="CR171">
        172
       </xref>
       ]. These levels of drug are not present in whole blood or plasma, but it is possible that these levels are relevant in intracellular compartments, which are known to have higher concentrations than in plasma [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="CR80">
        80
       </xref>
       ,
       <xref ref-type="bibr" rid="CR89">
        89
       </xref>
       ,
       <xref ref-type="bibr" rid="CR139">
        140
       </xref>
       ,
       <xref ref-type="bibr" rid="CR141">
        142
       </xref>
       ]. Liver-to-plasma ratios of 200–500 have been recorded in rat models of chloroquine pharmacokinetics (Table
       <xref ref-type="table" rid="Tab3">
        2.3
       </xref>
       ) [
       <xref ref-type="bibr" rid="CR89">
        89
       </xref>
       ]. In this view, therefore, mechanisms operative at concentrations up to 10
       <sup>
        −4
       </sup>
       M may be clinically relevant. Given the persistence of controversy, the coverage here will include mechanisms found at higher concentrations grouped by order of magnitude [
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ]. Table
       <xref ref-type="table" rid="Tab6">
        2.6
       </xref>
       provides a non-exhaustive list of the effects of the 4AQs grouped by concentration dependence.
       <table-wrap id="Tab6">
        <label>
         Table 2.6
        </label>
        <caption>
         <p>
          Mechanisms of action of 4-aminoquinolines
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Mechanism
           </th>
           <th>
            Concentration range at which relevant (M)
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Chloroquine inhibited the interaction of memory B cells but not unprimed B cells specific for foreign antigens [
            <xref ref-type="bibr" rid="CR37">
             37
            </xref>
            ,
            <xref ref-type="bibr" rid="CR177">
             178
            </xref>
            ]
           </td>
           <td>
            10
            <sup>
             −11
            </sup>
            to 10
            <sup>
             −8
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            Chloroquine inhibited DNA synthesis and IL-6 secretion by human peripheral blood mononuclear cells stimulated by foreign antigens [
            <xref ref-type="bibr" rid="CR172">
             173
            </xref>
            ]
           </td>
           <td>
            10
            <sup>
             −8
            </sup>
            to 10
            <sup>
             −7
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            1. 4AQs attached to ferriprotoporphyrin IX (FP) to form a toxic complex that increased the membrane permeability of erythrocytes parasitized by malaria protozoans and the protozoans themselves. The erythrocytes and protozoans lost potassium, swelled and were lysed [
            <xref ref-type="bibr" rid="CR2">
             2
            </xref>
            ,
            <xref ref-type="bibr" rid="CR11">
             11
            </xref>
            ,
            <xref ref-type="bibr" rid="CR37">
             37
            </xref>
            ,
            <xref ref-type="bibr" rid="CR163">
             164
            </xref>
            ,
            <xref ref-type="bibr" rid="CR178">
             179
            </xref>
            ,
            <xref ref-type="bibr" rid="CR179">
             180
            </xref>
            ]
           </td>
           <td rowspan="10">
            10
            <sup>
             −7
            </sup>
            to 10
            <sup>
             −6
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            2. 4AQs inhibited professional APCs from stimulating primed T cells [
            <xref ref-type="bibr" rid="CR78">
             78
            </xref>
            ,
            <xref ref-type="bibr" rid="CR117">
             118
            </xref>
            ]. 4AQs decreased levels of serum IL-1β, IL-2, IL-4, IL-6, IL-17, IL-18, IL-22, IFN-γ, and TNF-α [
            <xref ref-type="bibr" rid="CR24">
             24
            </xref>
            ,
            <xref ref-type="bibr" rid="CR38">
             38
            </xref>
            ,
            <xref ref-type="bibr" rid="CR44">
             44
            </xref>
            ,
            <xref ref-type="bibr" rid="CR78">
             78
            </xref>
            ,
            <xref ref-type="bibr" rid="CR87">
             87
            </xref>
            ,
            <xref ref-type="bibr" rid="CR141">
             142
            </xref>
            ,
            <xref ref-type="bibr" rid="CR166">
             167
            </xref>
            ,
            <xref ref-type="bibr" rid="CR180">
             181
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            3. Chloroquine reduced IL-1β and IL-6 mRNA levels by reducing their stability through a pH dependent mechanism in human monocyte cell culture [
            <xref ref-type="bibr" rid="CR181">
             182
            </xref>
            ]. Transcription of DNA to RNA was not blocked [
            <xref ref-type="bibr" rid="CR181">
             182
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            4. Inhibition of TNF-α expression occurred by blocking transcription of DNA into mRNA and not by a mechanism involving sequestration of chloroquine in lysosomes as bafilomycin did not block the effect of chloroquine [
            <xref ref-type="bibr" rid="CR182">
             183
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            5. In a rat blood-vessel model for assessing prostaglandin inhibition, chloroquine inhibited prostaglandin effects [
            <xref ref-type="bibr" rid="CR183">
             184
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            6. In patients taking chloroquine for SLE and RA, circulating lymphocytes contained higher numbers of myelin bodies (see Chap. 10.1007/978-1-4939-0597-3_1) compared to lymphocytes from control patients not taking these drugs and non-rheumatoid control subjects. These were associated with inhibition of lysosomal enzymes cathepsin B
            <sub>
             1
            </sub>
            and phospholipase A
            <sub>
             2
            </sub>
            [
            <xref ref-type="bibr" rid="CR71">
             71
            </xref>
            ,
            <xref ref-type="bibr" rid="CR139">
             140
            </xref>
            ,
            <xref ref-type="bibr" rid="CR168">
             169
            </xref>
            ,
            <xref ref-type="bibr" rid="CR175">
             176
            </xref>
            ,
            <xref ref-type="bibr" rid="CR184">
             185
            </xref>
            ,
            <xref ref-type="bibr" rid="CR185">
             186
            </xref>
            ]. Chloroquine also inhibited mucopolysaccharidases, alcohol dehydrogenase, and acid phosphodiesterase within lysosomes [
            <xref ref-type="bibr" rid="CR165">
             166
            </xref>
            ,
            <xref ref-type="bibr" rid="CR186">
             187
            </xref>
            ,
            <xref ref-type="bibr" rid="CR187">
             188
            </xref>
            ]. Elevation of pH, as would occur in lysosomes exposed to chloroquine, increased the inhibitory potency [
            <xref ref-type="bibr" rid="CR184">
             185
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            7. Chloroquine inhibited leukotriene release in human lung tissue cell culture that was overcome by arachidonic acid, suggesting inhibition of phospholipase A2 [
            <xref ref-type="bibr" rid="CR139">
             140
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            8. Chloroquine inhibited the C
            <sub>
             p
            </sub>
            G-oligodeoxynucleotide (C
            <sub>
             p
            </sub>
            G-ODN)-mediated blockade of apoptosis and inhibited IL-6 secretion in a murine B cell lymphoma model [
            <xref ref-type="bibr" rid="CR172">
             173
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            9. Hydroxychloroquine decreased HIV viral RNA titers [
            <xref ref-type="bibr" rid="CR135">
             136
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            10. Chloroquine inhibited polypeptide synthesis in rat liver cell free extracts by binding to the polynucleotide and preventing subsequent formation with a polynucleotide-ribosome complex [
            <xref ref-type="bibr" rid="CR188">
             189
            </xref>
            ]. There was no effect on polypeptide chain initiation or termination [
            <xref ref-type="bibr" rid="CR189">
             190
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            1. Chloroquine inhibited chemotaxis of polymorphonuclear leukocytes [
            <xref ref-type="bibr" rid="CR71">
             71
            </xref>
            ,
            <xref ref-type="bibr" rid="CR190">
             191
            </xref>
            ,
            <xref ref-type="bibr" rid="CR191">
             192
            </xref>
            ]
           </td>
           <td rowspan="11">
            10
            <sup>
             −6
            </sup>
            to 10
            <sup>
             −5
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            2. Chloroquine inhibited production of immunoglobulin secreting cells in response to Staphylococcus aureus by interfering with monocyte secretion of IL-1 in human peripheral mononuclear cells [
            <xref ref-type="bibr" rid="CR141">
             142
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            3. Chloroquine protected lysosomes against rupture by lysolecithin, progesterone, etiocholanolone, vitamin A, streptolysin S, ultraviolet irradiation, and incubation at neutral pH [
            <xref ref-type="bibr" rid="CR192">
             193
            </xref>
            ]. 4AQs stabilized lysosomal membranes inhibiting the release of lysosomal enzymes and receptor recycling [
            <xref ref-type="bibr" rid="CR167">
             168
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            4. Chloroquine inhibited cytokine secretion by mononuclear cells and binding of inositol 1,4,5-triphosphate to its intracellular receptor [
            <xref ref-type="bibr" rid="CR172">
             173
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            5. 4AQs inhibited activation of toll-like receptors TLR-3, TLR-7, and TLR-9 by raising intralysosomal pH [
            <xref ref-type="bibr" rid="CR14">
             14
            </xref>
            ,
            <xref ref-type="bibr" rid="CR24">
             24
            </xref>
            ,
            <xref ref-type="bibr" rid="CR38">
             38
            </xref>
            ,
            <xref ref-type="bibr" rid="CR164">
             165
            </xref>
            ,
            <xref ref-type="bibr" rid="CR166">
             167
            </xref>
            ,
            <xref ref-type="bibr" rid="CR193">
             194
            </xref>
            –
            <xref ref-type="bibr" rid="CR195">
             196
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            6. Chloroquine suppressed secretion of catecholamines in bovine adrenal medullary cells by interfering with calcium uptake [
            <xref ref-type="bibr" rid="CR196">
             197
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            7. Chloroquine caused a decrease in lysosomal β-glucuronidase and arylsulfatase A activity in cultured human fibroblasts [
            <xref ref-type="bibr" rid="CR197">
             198
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            8. Hydroxychloroquine reduced binding of β2-glycoprotein by antiphospholipid antibodies on phospholipid bilayers [
            <xref ref-type="bibr" rid="CR16">
             16
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            9. 4AQs increased the activity of HMG-CoA reductase and decreased serum cholesterol and atherosclerosis in SLE [
            <xref ref-type="bibr" rid="CR60">
             60
            </xref>
            ,
            <xref ref-type="bibr" rid="CR128">
             129
            </xref>
            ,
            <xref ref-type="bibr" rid="CR198">
             199
            </xref>
            ,
            <xref ref-type="bibr" rid="CR199">
             200
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            10. 4AQs reduced serum glucose and incidence of diabetes mellitus in SLE [
            <xref ref-type="bibr" rid="CR16">
             16
            </xref>
            ,
            <xref ref-type="bibr" rid="CR128">
             129
            </xref>
            ,
            <xref ref-type="bibr" rid="CR200">
             201
            </xref>
            ,
            <xref ref-type="bibr" rid="CR224">
             202
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            11. 4AQs had an antithrombotic effect in SLE [
            <xref ref-type="bibr" rid="CR16">
             16
            </xref>
            ,
            <xref ref-type="bibr" rid="CR128">
             129
            </xref>
            ,
            <xref ref-type="bibr" rid="CR201">
             203
            </xref>
            ]. 4 AQs prevented platelet alpha-granule release in vitro [
            <xref ref-type="bibr" rid="CR169">
             170
            </xref>
            ]. They inhibited release of arachidonic acid from stimulated platelets [
            <xref ref-type="bibr" rid="CR14">
             14
            </xref>
            ,
            <xref ref-type="bibr" rid="CR24">
             24
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            1. Chloroquine inhibited human lymphocyte proliferation stimulated by phytohemagglutinin or conconavalin A [
            <xref ref-type="bibr" rid="CR71">
             71
            </xref>
            ,
            <xref ref-type="bibr" rid="CR141">
             142
            </xref>
            ]. The effect occurred when drug was added early in the culture, but not later, indicating an action involving lysosomes and not via DNA binding [
            <xref ref-type="bibr" rid="CR202">
             204
            </xref>
            ]
           </td>
           <td rowspan="11">
            10
            <sup>
             −5
            </sup>
            to 10
            <sup>
             −4
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            2. Chloroquine inhibited digestion of endocytosed proteins in mouse peritoneal macrophages [
            <xref ref-type="bibr" rid="CR203">
             205
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            3. Chloroquine inhibited proteolytic conversion of a proform of complement C3 in cultured rat hepatocytes [
            <xref ref-type="bibr" rid="CR204">
             206
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            4. Chloroquine inhibited phosphorylation of extracellular signal-regulated kinases (ERK) 1 and 2 and mitogen-activated protein kinases [
            <xref ref-type="bibr" rid="CR38">
             38
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            5. Chloroquine inhibited mitochondrial respiration [
            <xref ref-type="bibr" rid="CR12">
             12
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            6. Chloroquine inhibited DNA polymerase [
            <xref ref-type="bibr" rid="CR71">
             71
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            7. Chloroquine competitively inhibited cholinesterase in plasma and human red blood cells [
            <xref ref-type="bibr" rid="CR205">
             207
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            8. 4AQs inhibited expression on the cell surface of TNF receptors without affecting levels of TNF receptor mRNA in a human histiocytic lymphoma cell line culture and in human peripheral monocytes suggesting inhibition of transport of the receptors from the cytosol to the cell surface [
            <xref ref-type="bibr" rid="CR206">
             208
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            9. Chloroquine inhibited endotoxin-stimulated TNF-α, IL-1β, and IL-6 from human whole blood and monocytes by an effect on DNA transcription and not a lysosomotropic mechanism [
            <xref ref-type="bibr" rid="CR180">
             181
            </xref>
            ,
            <xref ref-type="bibr" rid="CR182">
             183
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            10. Hydroxychloroquine induced apoptosis in human lymphocytes from normal subjects and synoviocytes taken from RA patients [
            <xref ref-type="bibr" rid="CR207">
             209
            </xref>
            ,
            <xref ref-type="bibr" rid="CR208">
             210
            </xref>
            ]. Chloroquine inhibited extracellular signal-regulated kinase (ERK) in HeLa cells which promoted susceptibility to Fas-mediated apoptosis [
            <xref ref-type="bibr" rid="CR209">
             211
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            11. Chloroquine blocked DNA repair [
            <xref ref-type="bibr" rid="CR210">
             212
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            1. Chloroquine inhibited
            <sup>
             124
            </sup>
            I-mannose-bovine serum albumin ingestion by inhibiting receptor recycling in rat alveolar macrophages [
            <xref ref-type="bibr" rid="CR211">
             213
            </xref>
            ]
           </td>
           <td rowspan="10">
            10
            <sup>
             −4
            </sup>
            to 10
            <sup>
             −3
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            2. Chloroquine stabilized erythrocyte membranes [
            <xref ref-type="bibr" rid="CR34">
             34
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            3. Chloroquine inhibited cathepsin B and diamine oxidase enzyme activities and inhibited protein synthesis [
            <xref ref-type="bibr" rid="CR11">
             11
            </xref>
            ,
            <xref ref-type="bibr" rid="CR14">
             14
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            4. Chloroquine attached to double-stranded DNA [
            <xref ref-type="bibr" rid="CR172">
             173
            </xref>
            ,
            <xref ref-type="bibr" rid="CR225">
             214
            </xref>
            ]. Chloroquine attached to single stranded DNA less avidly [
            <xref ref-type="bibr" rid="CR172">
             173
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            5. Neutrophil phagocytosis was inhibited [
            <xref ref-type="bibr" rid="CR191">
             192
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            6. Neutrophil oxidative metabolism was inhibited [
            <xref ref-type="bibr" rid="CR191">
             192
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            7. Proteolytic processing of secretory proteins by hepatocytes was inhibited [
            <xref ref-type="bibr" rid="CR204">
             206
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            8. Chloroquine inhibited DNA and RNA biosynthesis and was associated with degradation of ribosomes and ribosomal RNA in a bacterial model [
            <xref ref-type="bibr" rid="CR212">
             215
            </xref>
            ,
            <xref ref-type="bibr" rid="CR213">
             216
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            9. Chloroquine raised the pH in the food vacuole of malaria parasites inhibiting the digestion of hemoglobin [
            <xref ref-type="bibr" rid="CR71">
             71
            </xref>
            ]. Resistant strains of malaria accumulated less chloroquine than those of nonresistant parasites [
            <xref ref-type="bibr" rid="CR34">
             34
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            10. 4AQs inhibited protein synthesis but not uptake of amino acids in beef RPE cell culture [
            <xref ref-type="bibr" rid="CR63">
             63
            </xref>
            ].
           </td>
          </tr>
          <tr>
           <td>
            1. Chloroquine decreased serum phospholipids concomitant with the appearance of multilamellar myeloid bodies in the RPE, photoreceptors, and ganglion cells in a rat model [
            <xref ref-type="bibr" rid="CR60">
             60
            </xref>
            ]
           </td>
           <td rowspan="28">
            Concentrations not reported
           </td>
          </tr>
          <tr>
           <td>
            2. 4AQs inhibited antigen presentation, chemotaxis, phagocytosis, calcium receptor signaling of T and B cells, and matrix metalloproteinase activity [
            <xref ref-type="bibr" rid="CR14">
             14
            </xref>
            ]. Chloroquine prevented T cell responses to antigenic proteins but not antigenic peptides implying a mechanism of inhibiting the cleavage of antigenic proteins by macrophages [
            <xref ref-type="bibr" rid="CR117">
             118
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            3. Hydroxychloroquine increased Fas-mediated apoptosis of synoviocytes [
            <xref ref-type="bibr" rid="CR167">
             168
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            4. 4AQs inhibited gene expression in T cells in response to immune stimuli [
            <xref ref-type="bibr" rid="CR30">
             30
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            5. Chloroquine inhibited autophagy in human RPE cells [
            <xref ref-type="bibr" rid="CR160">
             161
            </xref>
            ]. Inhibition of vacuolar H
            <sup>
             +
            </sup>
            -ATPase by bafilomycin A1 blocked this effect implying that chloroquine acted as a lysosomotropic agent. [
            <xref ref-type="bibr" rid="CR160">
             161
            </xref>
            ] In a rat pancreas model chloroquine increased the volume of autophagic vacuoles and increased proteolytic lysosomal enzyme activities [
            <xref ref-type="bibr" rid="CR214">
             217
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            6. Hydroxychloroquine inhibited collagen-induced platelet aggregation and alpha-granule release [
            <xref ref-type="bibr" rid="CR16">
             16
            </xref>
            ,
            <xref ref-type="bibr" rid="CR169">
             170
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            7. Chloroquine inhibited protein synthesis [
            <xref ref-type="bibr" rid="CR188">
             189
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            8. Chloroquine disrupted the blood-retina barrier as determined by fluorophotometry in patients with retinopathy [
            <xref ref-type="bibr" rid="CR215">
             218
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            9. Chloroquine inhibited oxidative enzymes found in the ellipsoids of the inner segments of photoreceptors [
            <xref ref-type="bibr" rid="CR216">
             219
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            10. 4AQs-induced apoptosis of umbilical vascular endothelial cells, peripheral blood lymphocytes, and rheumatoid synoviocytes [
            <xref ref-type="bibr" rid="CR87">
             87
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            11. Chloroquine decreased retinal glucose-6-phosphate dehydrogenase activity leading to decreased retinal glutathione concentration which increases retinal lipid peroxidation [
            <xref ref-type="bibr" rid="CR29">
             29
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            12. Chloroquine inhibited low-density lipoprotein uptake or binding to cell surface receptors in human fibroblasts. Degradation of low-density lipoproteins by lysosomes was inhibited [
            <xref ref-type="bibr" rid="CR217">
             220
            </xref>
            ]. Cholesterol ester formation was stimulated and 3-hydroxy-3-methylglutaryl-coenzyme A activity was inhibited. As a result LDL accumulated within the cell [
            <xref ref-type="bibr" rid="CR217">
             220
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            13. Chloroquine depleted acid hydrolase receptors on the cell surface and inhibited pinocytosis of acid hydrolases [
            <xref ref-type="bibr" rid="CR167">
             168
            </xref>
            ]. Secretion of newly synthesized acid hydrolases bearing phosphomannosyl recognition markers was increased [
            <xref ref-type="bibr" rid="CR167">
             168
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            14. Chloroquine increased nitric oxide synthase activity in endothelial cells [
            <xref ref-type="bibr" rid="CR218">
             221
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            15. Chloroquine reduced incorporation of labeled sulfate into cartilage polysaccharide sulfates in a rat model [
            <xref ref-type="bibr" rid="CR90">
             90
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            16. Chloroquine intercalated between base pairs of DNA as evidenced by the increase in viscosity of DNA exposed to chloroquine [
            <xref ref-type="bibr" rid="CR14">
             14
            </xref>
            ,
            <xref ref-type="bibr" rid="CR225">
             214
            </xref>
            ,
            <xref ref-type="bibr" rid="CR219">
             222
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            17. Chloroquine inhibited the mitogenesis in polymorphonuclear leukocytes stimulated by zymosan [
            <xref ref-type="bibr" rid="CR191">
             192
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            18. Chloroquine inhibited spontaneous and interferon-upregulated natural killer activity in patients with RA [
            <xref ref-type="bibr" rid="CR218">
             221
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            19. 4AQs interfered with the binding of antiphospholipid antibodies to annexin A5, a potent anticoagulant [
            <xref ref-type="bibr" rid="CR24">
             24
            </xref>
            ,
            <xref ref-type="bibr" rid="CR81">
             81
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            20. 4AQs reduced lipid and triglyceride levels, increased low-density lipoprotein receptor activity, and increased HMG-CoA reductase activity, reducing cardiovascular disease risk [
            <xref ref-type="bibr" rid="CR24">
             24
            </xref>
            ,
            <xref ref-type="bibr" rid="CR81">
             81
            </xref>
            ]. 4AQs decreased the incidence of diabetes and had a hypoglycemic effect, decreased glycosylated hemoglobin levels in patients with diabetes, and improved glucose tolerance in patients with type II diabetes [
            <xref ref-type="bibr" rid="CR14">
             14
            </xref>
            ,
            <xref ref-type="bibr" rid="CR81">
             81
            </xref>
            ,
            <xref ref-type="bibr" rid="CR125">
             126
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            21. 4AQs inhibited TLR9-mediated stimulation of perilipin-3 in macrophages [
            <xref ref-type="bibr" rid="CR24">
             24
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            22. Chloroquine had an antineoplastic effect producing a reduction in the incidence of Burkitt’s lymphoma among patients in Tanzania who took the drug for malaria. Chloroquine-induced apoptosis in malignant B cells in patients with chronic lymphocytic leukemia [
            <xref ref-type="bibr" rid="CR14">
             14
            </xref>
            ]. Hydroxychloroquine had an anti-breast cancer effect. Chloroquine had an anti-colon cancer effect in a mouse model, induced cell death in human A 549 lung cancer cells, and produced better survival in patients with glioblastoma multiforme [
            <xref ref-type="bibr" rid="CR14">
             14
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            23. 4AQs promoted oxidation of cysteine residues in the peripherin/rds protein leading to disorganization of photoreceptor outer segments and cell death [
            <xref ref-type="bibr" rid="CR29">
             29
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            24. Chloroquine had a direct depressant effect on smooth muscle of the gut, arteries, trachea, and ciliary body, which might explain the mild ileus and temporary presbyopia that patients often experience after starting the drug [
            <xref ref-type="bibr" rid="CR100">
             100
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            25. 4AQs inhibit replication of HIV, SARS coronavirus, and influenza [
            <xref ref-type="bibr" rid="CR10">
             10
            </xref>
            ,
            <xref ref-type="bibr" rid="CR38">
             38
            </xref>
            ,
            <xref ref-type="bibr" rid="CR135">
             136
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            26. Chloroquine blocked production of IL-1β, IL-6, and TNF-α caused by ultraviolet irradiation of skin of normal subjects but had no effect on expression of these cytokines in unirradiated skin [
            <xref ref-type="bibr" rid="CR220">
             223
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            27. Chloroquine stimulated nitric oxide production in the kidney and brain with increased vasopressin and natriuresis [
            <xref ref-type="bibr" rid="CR221">
             224
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            28. Chloroquine enhanced CD8+ T cell responses by APCs against soluble antigens [
            <xref ref-type="bibr" rid="CR222">
             225
            </xref>
            ]
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          <italic>
           4AQ
          </italic>
          4-aminoquinoline,
          <italic>
           4AQR
          </italic>
          4-aminoquinoline retinopathy,
          <italic>
           IL
          </italic>
          interleukin,
          <italic>
           IFN
          </italic>
          interferon,
          <italic>
           TNF
          </italic>
          tumor necrosis factor,
          <italic>
           DNA
          </italic>
          deoxyribonucleic acid,
          <italic>
           RNA
          </italic>
          ribonucleic acid,
          <italic>
           SLE
          </italic>
          systemic lupus erythematosus,
          <italic>
           RA
          </italic>
          rheumatoid arthritis,
          <italic>
           RPE
          </italic>
          retinal pigment epithelium,
          <italic>
           HIV
          </italic>
          human immunodeficiency virus,
          <italic>
           TLR
          </italic>
          toll-like receptor,
          <italic>
           HMG-CoA
          </italic>
          3-hydroxy-3-methylglutaryl-coenzyme A reductase,
          <italic>
           mRNA
          </italic>
          mitochondrial ribonucleic acid,
          <italic>
           LDL
          </italic>
          low-density lipoprotein,
          <italic>
           SARS
          </italic>
          severe acute respiratory syndrome,
          <italic>
           APC
          </italic>
          antigen presenting cell
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <sec id="d29e3989">
       <title>
        Pharmacologic Tools for Dissecting the Mechanism of Action of 4-Aminoquinolines
       </title>
       <p>
        A recurring theme in papers written on the mechanism of action of chloroquine and hydroxychloroquine is the use of bafilomycin and ammonium acetate. Ammonium acetate is a cation that crosses cellular membranes easily. It can be used to flatten proton gradients across cell membranes [
        <xref ref-type="bibr" rid="CR172">
         173
        </xref>
        ]. Bafilomycin is a drug that inhibits the vacuolar proton pump and can decrease the acidification of intracellular vacuoles [
        <xref ref-type="bibr" rid="CR172">
         173
        </xref>
        ]. It provides a tool for diminishing the uptake of 4AQs by lysosomes and dissecting this mechanism from several candidates.
       </p>
      </sec>
     </sec>
     <sec id="Sec13">
      <title>
       Negative Studies on Mechanism of Action of 4-Aminoquinolines
      </title>
      <p>
       A number of studies have excluded mechanisms by which 4AQs produce effects. Hydroxychloroquine does not inhibit cyclo-oxygenases or decrease prostaglandin production [
       <xref ref-type="bibr" rid="CR94">
        94
       </xref>
       ]. Binding of 4AQs to DNA is not thought to be a clinically important mechanism; mefloquine does not bind to DNA, yet is an effective antimalarial drug [
       <xref ref-type="bibr" rid="CR163">
        164
       </xref>
       ]. The beneficial effects of 4AQs on polymorphous light eruptions are not due to a light-screening effect as they did not act as a physical barrier to the passage of ultraviolet radiation [
       <xref ref-type="bibr" rid="CR86">
        86
       </xref>
       ]. Chloroquine did not affect mitochondrial respiration and oxidative phosphorylation in mouse-liver homogenates or rat-liver mitochondria [
       <xref ref-type="bibr" rid="CR90">
        90
       </xref>
       ]. Neither did it affect adenosine triphosphate activity of cow visual pigment extracts [
       <xref ref-type="bibr" rid="CR173">
        174
       </xref>
       ]. Chloroquine did not affect the internalization of oligonucleotides via acidified vesicles [
       <xref ref-type="bibr" rid="CR172">
        173
       </xref>
       ].
      </p>
     </sec>
     <sec id="Sec14">
      <title>
       Drug Interactions
      </title>
      <p>
       Proton pump inhibitors such as omeprazole may inhibit the accumulation of 4AQs in lysosomes by decreasing the pH of these organelles. A potentially antagonizing effect of such drugs on the immunomodulating effects of 4AQs has been hypothesized [
       <xref ref-type="bibr" rid="CR174">
        175
       </xref>
       ]. Drugs that inhibit CYP3A4 such as ketoconazole and cimetidine can increase plasma levels of 4AQs [
       <xref ref-type="bibr" rid="CR93">
        93
       </xref>
       ,
       <xref ref-type="bibr" rid="CR95">
        95
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="Sec15">
     <title>
      Summary of Key Points
     </title>
     <p>
      <list list-type="bullet">
       <list-item>
        <p>
         The pharmacology of chloroquine and hydroxychloroquine is similar.
        </p>
       </list-item>
       <list-item>
        <p>
         The molecular weights of chloroquine and hydroxychloroquine are 320 and 336, respectively.
        </p>
       </list-item>
       <list-item>
        <p>
         Chloroquine and hydroxychloroquine are alkylated 4AQs that are water soluble, weak, amphiphilic bases that readily cross cell membranes.
        </p>
       </list-item>
       <list-item>
        <p>
         Melanin can bind 3 % of its weight in 4AQs, but whether this protects against, exacerbates, or has no effect on the risk of retinopathy is unknown.
        </p>
       </list-item>
       <list-item>
        <p>
         The 4AQs are lysosomotropic by virtue of protonation and trapping inside acidic lysosomes.
        </p>
       </list-item>
       <list-item>
        <p>
         Absorption of 4AQs is nearly complete with a peak plasma concentration at 3–12 h after an oral dose, a volume of distribution greater than 40,000 L, and a terminal elimination half-life of approximately 40 days.
        </p>
       </list-item>
       <list-item>
        <p>
         Equilibrium plasma concentrations depend on daily dose and IBW.
        </p>
       </list-item>
       <list-item>
        <p>
         With chronic ingestion of 4AQs in non-albinotic mammals, the tissue concentration of drug is highest in the uvea and RPE with a concentration 10,000 times that of plasma. In albinotic mammals, uveal drug concentrations approximate that of the heart. The 4AQs are lipophobic with concentrations in fat that are one-tenth that of plasma.
        </p>
       </list-item>
       <list-item>
        <p>
         The major metabolites of 4AQs are the desethyl and bisdesethyl derivatives of the parent drugs. The metabolites are pharmacologically active. CYP2C3 and CYP3A4 are responsible for 80 % of the metabolism of 4AQs.
        </p>
       </list-item>
       <list-item>
        <p>
         Forty to 60 % of 4AQs is excreted by the kidneys, 8–25 % is excreted in the feces, 5 % is sloughed off with the skin, and 25–45 % is stored in lean tissues.
        </p>
       </list-item>
       <list-item>
        <p>
         Renal and hepatic insufficiency leads to higher plasma concentrations for a given daily dose and raise the risk of toxicity.
        </p>
       </list-item>
       <list-item>
        <p>
         The clinical effects of 4AQs take 3–6 months to develop when no loading doses are used. The time course follows the pharmacokinetics to steady-state concentrations.
        </p>
       </list-item>
       <list-item>
        <p>
         Four hundred milligram per day of hydroxychloroquine and 250 mg/day of chloroquine are acceptable if the lesser of a patient’s IBW and ABW is 135 lb or more.
        </p>
       </list-item>
       <list-item>
        <p>
         Hydroxychloroquine and chloroquine are equipotent but chloroquine is more toxic; thus the therapeutic ratio is higher for hydroxychloroquine.
        </p>
       </list-item>
       <list-item>
        <p>
         Whole blood concentrations of 4AQs are approximately five times the plasma concentrations, are more precise, and are favored for pharmacokinetic measurements.
        </p>
       </list-item>
       <list-item>
        <p>
         A clinically therapeutic concentration of a 4AQ is greater than 3 × 10
         <sup>
          −6
         </sup>
         M/L.
        </p>
       </list-item>
       <list-item>
        <p>
         4AQs should not be stopped during pregnancy and lactation.
        </p>
       </list-item>
       <list-item>
        <p>
         There are more than 20 actions of 4AQs. The lysosomotropic mechanisms are the most important clinically. Because of these effects, the 4AQs have a dichotomous effect on T cells. They inhibit CD4 T cell stimulation but promote CD8 T cell stimulation. The combined effect is a beneficial action in autoimmunity without a penalty of increased opportunistic infections.
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <back>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bunch
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
         <name>
          <surname>
           O’Duffy
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Disease modifying drugs for progressive rheumatoid arthritis
        </article-title>
        <source>
         Mayo Clin Proc
        </source>
        <year>
         1980
        </year>
        <volume>
         55
        </volume>
        <fpage>
         161
        </fpage>
        <lpage>
         79
        </lpage>
        <pub-id pub-id-type="pmid">
         6766523
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackenzie
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pharmacologic actions of 4-aminoquinoline compounds
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1983
        </year>
        <volume>
         75
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         7
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Berliner
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
         <name>
          <surname>
           Earle
          </surname>
          <given-names>
           DP
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Taggart
          </surname>
          <given-names>
           JV
          </given-names>
         </name>
         <name>
          <surname>
           Zubrod
          </surname>
          <given-names>
           CG
          </given-names>
         </name>
         <name>
          <surname>
           Welch
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Conan
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
         <name>
          <surname>
           Bauman
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Scudder
          </surname>
          <given-names>
           ST
          </given-names>
         </name>
         <name>
          <surname>
           Shannon
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Studies on the chemotherapy of the human malarias. VI. The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         1948
        </year>
        <volume>
         27
        </volume>
        <fpage>
         98
        </fpage>
        <lpage>
         107
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bothwell
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Furst
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           RO
          </given-names>
         </name>
         <name>
          <surname>
           Furst
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine
        </article-title>
        <source>
         Antirheumatic therapy: actions and outcomes
        </source>
        <year>
         2005
        </year>
        <publisher-loc>
         Basel
        </publisher-loc>
        <publisher-name>
         Piet L.C.M. van Riel and Barry Bresnihan
        </publisher-name>
        <fpage>
         81
        </fpage>
        <lpage>
         92
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wallace
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarials-the ‘real’ advance in lupus
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         2001
        </year>
        <volume>
         10
        </volume>
        <fpage>
         385
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         11434570
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rynes
          </surname>
          <given-names>
           RI
          </given-names>
         </name>
         <name>
          <surname>
           Parke
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Introduction to symposium on antimalarial therapy and lupus
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         1993
        </year>
        <volume>
         2
        </volume>
        <fpage>
         S1
        </fpage>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wallace
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The history of antimalarials
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         1996
        </year>
        <volume>
         5
        </volume>
        <fpage>
         S2
        </fpage>
        <lpage>
         3
        </lpage>
        <pub-id pub-id-type="pmid">
         8803902
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rynes
          </surname>
          <given-names>
           RI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial drugs in the treatment of rheumatological diseases
        </article-title>
        <source>
         Br J Rheumatol
        </source>
        <year>
         1997
        </year>
        <volume>
         36
        </volume>
        <fpage>
         799
        </fpage>
        <lpage>
         805
        </lpage>
        <pub-id pub-id-type="pmid">
         9255117
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hobbs
          </surname>
          <given-names>
           HE
          </given-names>
         </name>
         <name>
          <surname>
           Calnan
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Visual disturbances with antimalarial drugs, with particular reference to chloroquine keratopathy
        </article-title>
        <source>
         Arch Dermatol.
        </source>
        <year>
         1959
        </year>
        <volume>
         80
        </volume>
        <fpage>
         557
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="pmid">
         14402142
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dubois
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarials in the management of discoid and systemic lupus erythematosus
        </article-title>
        <source>
         Semin Arthritis Rheum
        </source>
        <year>
         1978
        </year>
        <volume>
         8
        </volume>
        <fpage>
         33
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="pmid">
         358397
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           McChesney
          </surname>
          <given-names>
           EQ
          </given-names>
         </name>
         <name>
          <surname>
           Fitch
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Peters
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Richards
          </surname>
          <given-names>
           WHG
          </given-names>
         </name>
        </person-group>
        <article-title>
         4-Aminoquinolines
        </article-title>
        <source>
         Antimalarial drugs II. Current antimalarials and new drug developments
        </source>
        <year>
         1984
        </year>
        <publisher-loc>
         Berlin
        </publisher-loc>
        <publisher-name>
         Springer
        </publisher-name>
        <fpage>
         3
        </fpage>
        <lpage>
         60
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="other">
        Thompson PE, Webel LM. Antimalarial agents: chemistry and pharmacology. New York: Academic Press; 1972. p. 150–96.
       </mixed-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tzekov
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates
        </article-title>
        <source>
         Doc Ophthalmol
        </source>
        <year>
         2005
        </year>
        <volume>
         110
        </volume>
        <fpage>
         111
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="pmid">
         16249962
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ben-Zvi
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Kivity
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Langevitz
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine: from malaria to autoimmunity
        </article-title>
        <source>
         Clin Rev Allergy Immunol.
        </source>
        <year>
         2012
        </year>
        <volume>
         42
        </volume>
        <fpage>
         145
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="pmid">
         21221847
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lozier
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Friedlander
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complications of antimalarial therapy
        </article-title>
        <source>
         Int Ophthalmol Clin
        </source>
        <year>
         1989
        </year>
        <volume>
         29
        </volume>
        <fpage>
         172
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         2666332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rand
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           XX
          </given-names>
         </name>
         <name>
          <surname>
           Quinn
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           PP
          </given-names>
         </name>
         <name>
          <surname>
           Hathcock
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Taatjes
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers
        </article-title>
        <source>
         Blood
        </source>
        <year>
         2008
        </year>
        <volume>
         112
        </volume>
        <fpage>
         1687
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="pmid">
         18577708
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pillsbury
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name>
          <surname>
           Jacobson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of chronic discoid lupus erythematosus with chloroquine (Aralen)
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         1954
        </year>
        <volume>
         154
        </volume>
        <fpage>
         1330
        </fpage>
        <lpage>
         3
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          The Canadian Hydroxychloroquine Study Group
         </collab>
        </person-group>
        <article-title>
         A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
        </article-title>
        <source>
         New Engl J Med
        </source>
        <year>
         1991
        </year>
        <volume>
         324
        </volume>
        <fpage>
         150
        </fpage>
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         1984192
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Banks
          </surname>
          <given-names>
           CN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Melanin: blackguard or red herring? Another look at chloroquine retinopathy
        </article-title>
        <source>
         Aust N Z Ophthalmol.
        </source>
        <year>
         1987
        </year>
        <volume>
         15
        </volume>
        <fpage>
         365
        </fpage>
        <lpage>
         70
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goldman
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Preston
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reactions to chloroquine observed during the treatment of various dermatologic disorders
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <year>
         1957
        </year>
        <volume>
         6
        </volume>
        <fpage>
         654
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         13458670
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hobbs
          </surname>
          <given-names>
           HE
          </given-names>
         </name>
         <name>
          <surname>
           Sorsby
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Retinopathy following chloroquine therapy
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         1959
        </year>
        <volume>
         2
        </volume>
        <fpage>
         478
        </fpage>
        <lpage>
         80
        </lpage>
        <pub-id pub-id-type="pmid">
         14402143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bernstein
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular safety of hydroxychloroquine sulfate (Plaquenil)
        </article-title>
        <source>
         South Med J
        </source>
        <year>
         1992
        </year>
        <volume>
         85
        </volume>
        <fpage>
         274
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         1546352
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shearer
          </surname>
          <given-names>
           RV
          </given-names>
         </name>
         <name>
          <surname>
           Dubois
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular changes induced by long-term hydroxychloroquine (Plaquenil) therapy
        </article-title>
        <source>
         Am J Ophthalmol
        </source>
        <year>
         1967
        </year>
        <volume>
         64
        </volume>
        <fpage>
         245
        </fpage>
        <lpage>
         52
        </lpage>
        <pub-id pub-id-type="pmid">
         6036279
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wallace
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Gudsoorkar
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Weisman
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Venuturupalli
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         New insights into mechanisms of therapeutic effects of antimalarial agents in SLE
        </article-title>
        <source>
         Nat Rev Rheumatol
        </source>
        <year>
         2012
        </year>
        <volume>
         8
        </volume>
        <fpage>
         522
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="pmid">
         22801982
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Browning
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bull’s-eye maculopathy associated with quinacrine therapy for malaria
        </article-title>
        <source>
         Am J Ophthalmol
        </source>
        <year>
         2004
        </year>
        <volume>
         137
        </volume>
        <fpage>
         577
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         15013892
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="other">
        Chloroquine. DrugBank: open data drug &amp; drug target database. 2005.
        <ext-link ext-link-type="uri" xlink:href="http://www.drugbank.ca/drugs/DB00608">
         http://www.drugbank.ca/drugs/DB00608
        </ext-link>
        . Accessed 22 Aug 2013.
       </mixed-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="other">
        Hydroxychloroquine. DrugBank: open data drug &amp; drug target database. 2007.
        <ext-link ext-link-type="uri" xlink:href="http://www.drugbank.ca/drugs/DB01611">
         http://www.drugbank.ca/drugs/DB01611
        </ext-link>
        . Accessed 22 Aug 2013.
       </mixed-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Potts
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        <article-title>
         The reaction of uveal pigment in vitro with polycyclic compounds
        </article-title>
        <source>
         Invest Ophthalmol
        </source>
        <year>
         1964
        </year>
        <volume>
         3
        </volume>
        <fpage>
         405
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="pmid">
         14203332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Toler
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy
        </article-title>
        <source>
         Exp Biol Med
        </source>
        <year>
         2004
        </year>
        <volume>
         229
        </volume>
        <fpage>
         607
        </fpage>
        <lpage>
         15
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sundelin
          </surname>
          <given-names>
           SP
          </given-names>
         </name>
         <name>
          <surname>
           Terman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells
        </article-title>
        <source>
         APMIS.
        </source>
        <year>
         2002
        </year>
        <volume>
         110
        </volume>
        <fpage>
         481
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         12193209
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferrari
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Cutler
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kinetics and thermodynamics of chloroquine and hydroxychloroquine transport across the human erythrocyte membrane
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         1991
        </year>
        <volume>
         41
        </volume>
        <fpage>
         23
        </fpage>
        <lpage>
         30
        </lpage>
        <pub-id pub-id-type="pmid">
         1986742
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tanenbaum
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Tuffanelli
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial agents: chloroquine, hydroxychloroquine, and quinacrine
        </article-title>
        <source>
         Arch Dermatol
        </source>
        <year>
         1980
        </year>
        <volume>
         116
        </volume>
        <fpage>
         587
        </fpage>
        <lpage>
         91
        </lpage>
        <pub-id pub-id-type="pmid">
         6990871
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wibo
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Poole
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1
        </article-title>
        <source>
         J Cell Biol
        </source>
        <year>
         1974
        </year>
        <volume>
         63
        </volume>
        <fpage>
         430
        </fpage>
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="pmid">
         4607946
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Homewood
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Warhurst
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Peters
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Baggaley
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lysosomes, pH, and anti-malarial action of chloroquine
        </article-title>
        <source>
         Nature
        </source>
        <year>
         1972
        </year>
        <volume>
         235
        </volume>
        <fpage>
         50
        </fpage>
        <lpage>
         2
        </lpage>
        <pub-id pub-id-type="pmid">
         4550396
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stepien
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
         <name>
          <surname>
           Wilczok
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Studies of the mechanism of chloroquine binding to synthetic dopa-melanin
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         1982
        </year>
        <volume>
         31
        </volume>
        <fpage>
         3359
        </fpage>
        <lpage>
         65
        </lpage>
        <pub-id pub-id-type="pmid">
         6816244
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jailer
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Zubrod
          </surname>
          <given-names>
           CG
          </given-names>
         </name>
         <name>
          <surname>
           Rosenfeld
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Shannon
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of acidosis and anoxia on the concentration of quinacrine and chloroquine in blood
        </article-title>
        <source>
         J Pharmacol Exp Ther
        </source>
        <year>
         1948
        </year>
        <volume>
         92
        </volume>
        <fpage>
         345
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="pmid">
         18907222
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Titus
          </surname>
          <given-names>
           EO
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine
        </article-title>
        <source>
         Ther Drug Monit
        </source>
        <year>
         1989
        </year>
        <volume>
         11
        </volume>
        <fpage>
         369
        </fpage>
        <lpage>
         79
        </lpage>
        <pub-id pub-id-type="pmid">
         2662478
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kalia
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Dutz
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
        </person-group>
        <article-title>
         New concepts in antimalarial use and mode of action in dermatology
        </article-title>
        <source>
         Dermatol Ther
        </source>
        <year>
         2007
        </year>
        <volume>
         20
        </volume>
        <fpage>
         160
        </fpage>
        <lpage>
         74
        </lpage>
        <pub-id pub-id-type="pmid">
         17970883
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kishimoto
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Deshpande
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         <name>
          <surname>
           Yokogawa
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Buyon
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Okada
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of hydroxychloroquine in Japan
        </article-title>
        <source>
         J Rheumatol
        </source>
        <year>
         2012
        </year>
        <volume>
         39
        </volume>
        <fpage>
         1296
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         22661421
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Araiza-Casillas
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Cardenas
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Morales
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Cardiel
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors associated with chloroquine-induced retinopathy in rheumatic diseases
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         2004
        </year>
        <volume>
         13
        </volume>
        <fpage>
         119
        </fpage>
        <lpage>
         24
        </lpage>
        <pub-id pub-id-type="pmid">
         14995005
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Easterbrook
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The ocular safety of hydroxychloroquine
        </article-title>
        <source>
         Semin Arthritis Rheum
        </source>
        <year>
         1993
        </year>
        <volume>
         23
        </volume>
        <fpage>
         62
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         8278820
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meinao
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name>
          <surname>
           Sato
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <name>
          <surname>
           Andrade
          </surname>
          <given-names>
           LEC
          </given-names>
         </name>
         <name>
          <surname>
           Ferraz
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Atra
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Controlled trial with chloroquine diphosphate in systemic lupus erythematosus
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         1996
        </year>
        <volume>
         5
        </volume>
        <fpage>
         237
        </fpage>
        <lpage>
         41
        </lpage>
        <pub-id pub-id-type="pmid">
         8803897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Akman
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Cerman
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Yenice
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Kazokoglu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Two cases with chloroquine and hydroxychloroquine maculopathy
        </article-title>
        <source>
         Marmara Med J
        </source>
        <year>
         2011
        </year>
        <volume>
         24
        </volume>
        <fpage>
         68
        </fpage>
        <lpage>
         72
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wozniacka
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lesiak
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Narbutt
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           McCauliffe
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name>
          <surname>
           Sysa-Jedrzejowska
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         2006
        </year>
        <volume>
         15
        </volume>
        <fpage>
         268
        </fpage>
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="pmid">
         16761500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bartel
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
         <name>
          <surname>
           Roux
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Robinson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           IF
          </given-names>
         </name>
         <name>
          <surname>
           Brighton
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Van der Hoven
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Visual function and long-term chloroquine treatment
        </article-title>
        <source>
         S Afr Med J
        </source>
        <year>
         1994
        </year>
        <volume>
         84
        </volume>
        <fpage>
         32
        </fpage>
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         8197491
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Missner
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kellner
          </surname>
          <given-names>
           U
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography
        </article-title>
        <source>
         Graefes Arch Clin Exp Ophthalmol.
        </source>
        <year>
         2012
        </year>
        <volume>
         250
        </volume>
        <fpage>
         319
        </fpage>
        <lpage>
         25
        </lpage>
        <pub-id pub-id-type="pmid">
         22215255
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Easterbrook
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular effects and safety of antimalarial agents
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1988
        </year>
        <volume>
         85
        </volume>
        <fpage>
         23
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         3177429
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parker
          </surname>
          <given-names>
           FS
          </given-names>
         </name>
         <name>
          <surname>
           Irvin
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
        </person-group>
        <article-title>
         The interaction of chloroquine with nucleic acids and nucleoproteins
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         1952
        </year>
        <volume>
         199
        </volume>
        <fpage>
         897
        </fpage>
        <lpage>
         909
        </lpage>
        <pub-id pub-id-type="pmid">
         13022698
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ono
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Absorption, distribution and excretion of 14C-levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin-related radioactivity to melanin in vivo
        </article-title>
        <source>
         J Pharm Pharmacol
        </source>
        <year>
         2004
        </year>
        <volume>
         56
        </volume>
        <fpage>
         463
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         15099441
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tjalve
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Nilsson
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Larsson
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Studies on the binding of chlorpromazine and chloroquine to melanin in vivo
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         1981
        </year>
        <volume>
         30
        </volume>
        <fpage>
         1845
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         7271873
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Larsson
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interaction between chemicals and melanin
        </article-title>
        <source>
         Pigment Cell Res
        </source>
        <year>
         1993
        </year>
        <volume>
         6
        </volume>
        <fpage>
         127
        </fpage>
        <lpage>
         44
        </lpage>
        <pub-id pub-id-type="pmid">
         8234197
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Larsson
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Tjalve
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Studies on the mechanism of drug-binding to melanin
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         1979
        </year>
        <volume>
         28
        </volume>
        <fpage>
         1181
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         36092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ono
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine-related radioactivity to melanin in-vivo
        </article-title>
        <source>
         J Pharm Pharmacol
        </source>
        <year>
         2003
        </year>
        <volume>
         55
        </volume>
        <fpage>
         1647
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="pmid">
         14738591
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Takashina
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Tsutsumi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative assessment of ocular tissue distribution of drug-related radioactivity after chronic oral administration of C14-levofloxacin and C14-chloroquine in pigmented rats
        </article-title>
        <source>
         J Pharm Pharmacol
        </source>
        <year>
         2004
        </year>
        <volume>
         56
        </volume>
        <fpage>
         977
        </fpage>
        <lpage>
         83
        </lpage>
        <pub-id pub-id-type="pmid">
         15285841
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Salazar-Bookaman
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Wainer
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Patil
          </surname>
          <given-names>
           PN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Relevance of drug-melanin interactions to ocular pharmacology and toxicology
        </article-title>
        <source>
         J Ocul Pharmacol
        </source>
        <year>
         1994
        </year>
        <volume>
         10
        </volume>
        <fpage>
         217
        </fpage>
        <lpage>
         39
        </lpage>
        <pub-id pub-id-type="pmid">
         8207328
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leblanc
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Jezequei
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Davies
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hanton
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Taradach
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Binding of drugs to eye melanin is not predictive of ocular toxicity
        </article-title>
        <source>
         Regul Toxicol Pharmacol.
        </source>
        <year>
         1998
        </year>
        <volume>
         28
        </volume>
        <fpage>
         124
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="pmid">
         9927562
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feeney
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lipofuscin and melanin of human retinal pigment epithelium. Fluorescence, enzyme cytochemical, and ultrastructural studies
        </article-title>
        <source>
         Invest Ophthalmol Vis Sci
        </source>
        <year>
         1978
        </year>
        <volume>
         17
        </volume>
        <fpage>
         583
        </fpage>
        <lpage>
         600
        </lpage>
        <pub-id pub-id-type="pmid">
         669890
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boulton
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ageing of the retinal pigment epithelium
        </article-title>
        <source>
         Prog Retin Eye Res
        </source>
        <year>
         1991
        </year>
        <volume>
         11
        </volume>
        <fpage>
         125
        </fpage>
        <lpage>
         51
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ivanina
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Zueva
          </surname>
          <given-names>
           MV
          </given-names>
         </name>
         <name>
          <surname>
           Lebedeva
          </surname>
          <given-names>
           MN
          </given-names>
         </name>
         <name>
          <surname>
           Bogoslovsky
          </surname>
          <given-names>
           AI
          </given-names>
         </name>
         <name>
          <surname>
           Bunin
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ultrastructural alterations in rat and cat retina and pigment epithelium induced by chloroquine
        </article-title>
        <source>
         Graefes Arch Clin Exp Ophthalmol.
        </source>
        <year>
         1983
        </year>
        <volume>
         220
        </volume>
        <fpage>
         32
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         6832596
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gaafar
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Abdel-Khalek
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
         <name>
          <surname>
           El-Sayed
          </surname>
          <given-names>
           NK
          </given-names>
         </name>
         <name>
          <surname>
           Ramadan
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lipidemic effect as a manifestation of chloroquine retinotoxicity
        </article-title>
        <source>
         Arzneimittelforschung
        </source>
        <year>
         1995
        </year>
        <volume>
         45
        </volume>
        <fpage>
         1231
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         8929246
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wolfe
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Marmor
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus
        </article-title>
        <source>
         Arthritis Care Res
        </source>
        <year>
         2010
        </year>
        <volume>
         62
        </volume>
        <fpage>
         775
        </fpage>
        <lpage>
         84
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marmor
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of screening procedures in hydroxychloroquine toxicity
        </article-title>
        <source>
         Arch Ophthalmol
        </source>
        <year>
         2012
        </year>
        <volume>
         130
        </volume>
        <fpage>
         461
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         22159170
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR63">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gonasun
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Potts
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro inhibition of protein synthesis in the retinal pigment epithelium by chloroquine
        </article-title>
        <source>
         Invest Ophthalmol Vis Sci
        </source>
        <year>
         1974
        </year>
        <volume>
         13
        </volume>
        <fpage>
         107
        </fpage>
        <lpage>
         15
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR64">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mason
          </surname>
          <given-names>
           CG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular accumulation and toxicity of certain systemically administered drugs
        </article-title>
        <source>
         J Toxicol Environ Health.
        </source>
        <year>
         1977
        </year>
        <volume>
         2
        </volume>
        <fpage>
         977
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="pmid">
         405503
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR65">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kasuya
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Miyata
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Toxicological studies on the chloroquine-melanin affinity in vivo and in vitro in relation to chloroquine retinopathy
        </article-title>
        <source>
         J Toxicol Stud
        </source>
        <year>
         1976
        </year>
        <volume>
         1
        </volume>
        <fpage>
         32
        </fpage>
        <lpage>
         8
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR66">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feeney-Burns
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Hilderbrand
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Eldridge
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells
        </article-title>
        <source>
         Invest Ophthalmol Vis Sci
        </source>
        <year>
         1984
        </year>
        <volume>
         25
        </volume>
        <fpage>
         195
        </fpage>
        <lpage>
         200
        </lpage>
        <pub-id pub-id-type="pmid">
         6698741
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR67">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iredale
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Fieger
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wainer
          </surname>
          <given-names>
           IW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Determination of the stereoisomers of hydroxychloroquine and its major metabolites in plasma and urine following a single oral administration of racemic hydroxychloroquine
        </article-title>
        <source>
         Semin Arthritis Rheum
        </source>
        <year>
         1993
        </year>
        <volume>
         23
        </volume>
        <fpage>
         74
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="pmid">
         8278822
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR68">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ducharme
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Farinotti
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements
        </article-title>
        <source>
         Clin Pharmacokinet
        </source>
        <year>
         1996
        </year>
        <volume>
         31
        </volume>
        <fpage>
         257
        </fpage>
        <lpage>
         74
        </lpage>
        <pub-id pub-id-type="pmid">
         8896943
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR69">
       <label>
        69.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rollo
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Goodman
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <name>
          <surname>
           Gilman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drugs used in the chemotherapy of malaria
        </article-title>
        <source>
         The pharmacological basis of therapeutics
        </source>
        <year>
         1975
        </year>
        <publisher-loc>
         New York
        </publisher-loc>
        <publisher-name>
         Macmillan
        </publisher-name>
        <fpage>
         1045
        </fpage>
        <lpage>
         68
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR70">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gustafsson
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <name>
          <surname>
           Walker
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Alvan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Beermann
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Estevez
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Gleisner
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lindstrom
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Sjoqvist
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Disposition of chloroquine in man after single intravenous and oral doses
        </article-title>
        <source>
         Br J Clin Pharmacol
        </source>
        <year>
         1983
        </year>
        <volume>
         15
        </volume>
        <fpage>
         471
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         6849784
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR71">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tett
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Cutler
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarials in rheumatic diseases
        </article-title>
        <source>
         Baillieres Clin Rheumatol
        </source>
        <year>
         1990
        </year>
        <volume>
         4
        </volume>
        <fpage>
         467
        </fpage>
        <lpage>
         89
        </lpage>
        <pub-id pub-id-type="pmid">
         2093438
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR72">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Laaksonen
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Koskiahde
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Juva
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine
        </article-title>
        <source>
         Scand J Rheumatol
        </source>
        <year>
         1974
        </year>
        <volume>
         3
        </volume>
        <fpage>
         103
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         4608161
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR73">
       <label>
        73.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Albert
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Debois
          </surname>
          <given-names>
           LKL
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           KF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial ocular toxicity, a critical appraisal
        </article-title>
        <source>
         J Clin Rheumatol
        </source>
        <year>
         1998
        </year>
        <volume>
         4
        </volume>
        <fpage>
         57
        </fpage>
        <lpage>
         62
        </lpage>
        <pub-id pub-id-type="pmid">
         19078251
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR74">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McChesney
          </surname>
          <given-names>
           EW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1983
        </year>
        <volume>
         75
        </volume>
        <fpage>
         11
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         6408923
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR75">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tett
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Cutler
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           RO
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           KF
          </given-names>
         </name>
        </person-group>
        <article-title>
         A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers
        </article-title>
        <source>
         Br J Clin Pharmacol.
        </source>
        <year>
         1988
        </year>
        <volume>
         26
        </volume>
        <fpage>
         303
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="pmid">
         3179169
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR76">
       <label>
        76.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tett
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Cutler
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Apparent dose-dependence of chloroquine pharmacokinetics due to limited assay sensitivity and short sampling times
        </article-title>
        <source>
         Eur J Clin Pharmacol
        </source>
        <year>
         1987
        </year>
        <volume>
         31
        </volume>
        <fpage>
         729
        </fpage>
        <lpage>
         31
        </lpage>
        <pub-id pub-id-type="pmid">
         3556380
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR77">
       <label>
        77.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Gibbs
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Baethge
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Botstein
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
         <name>
          <surname>
           Caldwell
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Dietz
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Ettlinger
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Golden
          </surname>
          <given-names>
           HE
          </given-names>
         </name>
         <name>
          <surname>
           Lindsley
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2002
        </year>
        <volume>
         46
        </volume>
        <fpage>
         1460
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         12115175
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR78">
       <label>
        78.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schultz
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Gilman
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
        </person-group>
        <article-title>
         The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease
        </article-title>
        <source>
         Leuk Lymphoma.
        </source>
        <year>
         1997
        </year>
        <volume>
         24
        </volume>
        <fpage>
         201
        </fpage>
        <lpage>
         10
        </lpage>
        <pub-id pub-id-type="pmid">
         9156650
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR79">
       <label>
        79.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Buchanan
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Can der Walt
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
        </person-group>
        <article-title>
         The binding of cloroquine to normal and kwashiorkor serum
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <year>
         1977
        </year>
        <volume>
         26
        </volume>
        <fpage>
         1025
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         71861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR80">
       <label>
        80.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackenzie
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1983
        </year>
        <volume>
         75
        </volume>
        <fpage>
         40
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         6869410
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR81">
       <label>
        81.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Katz
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action
        </article-title>
        <source>
         Curr Eye Res
        </source>
        <year>
         2011
        </year>
        <volume>
         23
        </volume>
        <fpage>
         278
        </fpage>
        <lpage>
         81
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR82">
       <label>
        82.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lawwill
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Appleton
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Altstatt
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine accumulation in human eyes
        </article-title>
        <source>
         Am J Ophthalmol
        </source>
        <year>
         1968
        </year>
        <volume>
         65
        </volume>
        <fpage>
         530
        </fpage>
        <lpage>
         2
        </lpage>
        <pub-id pub-id-type="pmid">
         5642904
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR83">
       <label>
        83.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goldstein
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Aronow
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Kalman
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
        </person-group>
        <source>
         Principles of drug action: the basis of pharmacology
        </source>
        <year>
         2013
        </year>
        <publisher-loc>
         New York
        </publisher-loc>
        <publisher-name>
         Wiley
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="CR84">
       <label>
        84.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rowland
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Tozer
          </surname>
          <given-names>
           TN
          </given-names>
         </name>
        </person-group>
        <source>
         Clinical pharmacokinetics and pharmacodynamics. Concepts and applications
        </source>
        <year>
         2011
        </year>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <publisher-name>
         Wolters Kluwer
        </publisher-name>
        <fpage>
         579
        </fpage>
       </element-citation>
      </ref>
      <ref id="CR85">
       <label>
        85.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Bernstein
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Zvaifler
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Studies on the pharmacology of chloroquine. Recommendations for the treatment of chloroquine retinopathy
        </article-title>
        <source>
         Arch Ophthalmol
        </source>
        <year>
         1963
        </year>
        <volume>
         70
        </volume>
        <fpage>
         474
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="pmid">
         14078869
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR86">
       <label>
        86.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shaffer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Cahn
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Levy
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Absorption of antimalarial drugs in human skin: spectroscopic and chemical analysis in epidermis and corium
        </article-title>
        <source>
         J Invest Dermatol
        </source>
        <year>
         1958
        </year>
        <volume>
         30
        </volume>
        <fpage>
         341
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         13563934
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR87">
       <label>
        87.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ramser
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Kokot
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Metze
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Weib
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Luger
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Bohm
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts
        </article-title>
        <source>
         J Invest Dermatol.
        </source>
        <year>
         2009
        </year>
        <volume>
         129
        </volume>
        <fpage>
         2419
        </fpage>
        <lpage>
         26
        </lpage>
        <pub-id pub-id-type="pmid">
         19357706
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR88">
       <label>
        88.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           O’Grady
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Experimental chloroquine myopathy
        </article-title>
        <source>
         J Neurol Neurosurg Psychiatry.
        </source>
        <year>
         1966
        </year>
        <volume>
         29
        </volume>
        <fpage>
         255
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         5937641
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR89">
       <label>
        89.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Projean
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Baune
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Farinotti
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Flinois
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Beaune
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Taburet
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Ducharme
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro metabolism of chloroquine: Identification of CYP2cb, CYP3A4, and CYP2D6 as the main isoforms catalyzing
         <italic>
          N
         </italic>
         -desethylchloroquine formation
        </article-title>
        <source>
         Am Soc Pharmacol Exp Ther
        </source>
        <year>
         2003
        </year>
        <volume>
         31
        </volume>
        <fpage>
         748
        </fpage>
        <lpage>
         54
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR90">
       <label>
        90.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Whitehouse
          </surname>
          <given-names>
           MW
          </given-names>
         </name>
         <name>
          <surname>
           Bostrom
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Biochemical properties of anti-inflammatory drugs-VI. The effects of chloroquine (Resochin) and some of their potential metabolites on cartilage metabolism and oxidative phosphorylation
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         1965
        </year>
        <volume>
         14
        </volume>
        <fpage>
         1173
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         4221789
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR91">
       <label>
        91.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuroda
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection and distribution of chloroquine metabolites in human tissues
        </article-title>
        <source>
         J Pharmacol Exp Ther
        </source>
        <year>
         1962
        </year>
        <volume>
         137
        </volume>
        <fpage>
         156
        </fpage>
        <lpage>
         61
        </lpage>
        <pub-id pub-id-type="pmid">
         14460766
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR92">
       <label>
        92.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Estes
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Ewing-Wilson
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Mitsumoto
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Hanson
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Shirey
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Ratliff
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine neuromyotoxicity. Clinical and pathological perspective
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1987
        </year>
        <volume>
         82
        </volume>
        <fpage>
         447
        </fpage>
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="pmid">
         3826099
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR93">
       <label>
        93.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes
        </article-title>
        <source>
         Arch Pharm Res
        </source>
        <year>
         2003
        </year>
        <volume>
         26
        </volume>
        <fpage>
         631
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         12967198
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR94">
       <label>
        94.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ben-Chetrit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Tischel
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Hinz
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Levy
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effects of colchicine and hydroxychloroquine on the cyclo-oxygenases COX-1 and COX-2
        </article-title>
        <source>
         Rheumatol Int
        </source>
        <year>
         2005
        </year>
        <volume>
         25
        </volume>
        <fpage>
         332
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         14963695
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR95">
       <label>
        95.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ette
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Brown-Awala
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Essien
          </surname>
          <given-names>
           EE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine elimination in humans: effect of low-dose cimetidine
        </article-title>
        <source>
         J Clin Pharmacol
        </source>
        <year>
         1987
        </year>
        <volume>
         27
        </volume>
        <fpage>
         813
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         3323258
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR96">
       <label>
        96.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bernstein
          </surname>
          <given-names>
           HN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular safety of hydroxychloroquine
        </article-title>
        <source>
         Ann Ophthalmol
        </source>
        <year>
         1991
        </year>
        <volume>
         23
        </volume>
        <fpage>
         292
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         1952638
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR97">
       <label>
        97.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Runge
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1983
        </year>
        <volume>
         75
        </volume>
        <fpage>
         52
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         6869411
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR98">
       <label>
        98.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Terrell
          </surname>
          <given-names>
           WL
          </given-names>
          <suffix>
           III
          </suffix>
         </name>
         <name>
          <surname>
           Haik
          </surname>
          <given-names>
           KG
          </given-names>
         </name>
         <name>
          <surname>
           Haik
          </surname>
          <given-names>
           GM
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine sulfate and retinopathy
        </article-title>
        <source>
         South Med J
        </source>
        <year>
         1988
        </year>
        <volume>
         81
        </volume>
        <fpage>
         1327
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         3175741
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR99">
       <label>
        99.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dwosh
          </surname>
          <given-names>
           IL
          </given-names>
         </name>
         <name>
          <surname>
           Stein
          </surname>
          <given-names>
           HB
          </given-names>
         </name>
         <name>
          <surname>
           Urowitz
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Smythe
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <name>
          <surname>
           Hunter
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Ogryzlo
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         1977
        </year>
        <volume>
         20
        </volume>
        <fpage>
         685
        </fpage>
        <lpage>
         92
        </lpage>
        <pub-id pub-id-type="pmid">
         403921
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR100">
       <label>
        100.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackenzie
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
        </person-group>
        <article-title>
         An appraisal of chloroquine
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         1970
        </year>
        <volume>
         13
        </volume>
        <fpage>
         280
        </fpage>
        <lpage>
         91
        </lpage>
        <pub-id pub-id-type="pmid">
         4912633
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR101">
       <label>
        101.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tobin
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Krohel
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Rynes
          </surname>
          <given-names>
           RI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine-seven-year experience
        </article-title>
        <source>
         Arch Ophthalmol
        </source>
        <year>
         1982
        </year>
        <volume>
         100
        </volume>
        <fpage>
         81
        </fpage>
        <lpage>
         3
        </lpage>
        <pub-id pub-id-type="pmid">
         7055472
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR223">
       <label>
        102.
       </label>
       <mixed-citation publication-type="other">
        Henkind P, Rothfield NF. Ocular abnormalities in patients treated with synthetic antimalarial drugs. New Engl J Med. 1963;269:434–9.
       </mixed-citation>
      </ref>
      <ref id="CR102">
       <label>
        103.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Molad
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Gorshtein
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wysenbeek
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Guedj
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Weinberger
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Amit-Vazina
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         2002
        </year>
        <volume>
         11
        </volume>
        <fpage>
         356
        </fpage>
        <lpage>
         61
        </lpage>
        <pub-id pub-id-type="pmid">
         12139373
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR103">
       <label>
        104.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Akhavan
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Gladman
          </surname>
          <given-names>
           DD
          </given-names>
         </name>
         <name>
          <surname>
           Urowitz
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Fortin
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
        </person-group>
        <article-title>
         The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus
        </article-title>
        <source>
         J Rheumatol
        </source>
        <year>
         2013
        </year>
        <volume>
         40
        </volume>
        <fpage>
         831
        </fpage>
        <lpage>
         41
        </lpage>
        <pub-id pub-id-type="pmid">
         23588942
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR104">
       <label>
        105.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Scull
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine therapy in rheumatoid arthritis
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         1962
        </year>
        <volume>
         5
        </volume>
        <fpage>
         30
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         13910104
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR105">
       <label>
        106.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bagnall
          </surname>
          <given-names>
           AW
          </given-names>
         </name>
        </person-group>
        <article-title>
         The value of chloroquine in rheumatoid disease. A four year study of continuous therapy
        </article-title>
        <source>
         Can Med Assoc J
        </source>
        <year>
         1957
        </year>
        <volume>
         77
        </volume>
        <fpage>
         182
        </fpage>
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="pmid">
         13446795
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR106">
       <label>
        107.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           EM
          </given-names>
         </name>
         <name>
          <surname>
           Yocum
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine in the treatment of rheumatoid arthritis
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1983
        </year>
        <volume>
         75
        </volume>
        <fpage>
         321
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         6881184
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR107">
       <label>
        108.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haydu
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rheumatoid arthritis therapy: a rationale and the use of chloroquine diphosphate
        </article-title>
        <source>
         Am J Med Sci
        </source>
        <year>
         1953
        </year>
        <volume>
         225
        </volume>
        <fpage>
         71
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         13007699
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR108">
       <label>
        109.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          The Canadian Hydroxychloroquine Study Group
         </collab>
         <name>
          <surname>
           Tsakonas
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Joseph
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Esdaile
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Choquette
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         1998
        </year>
        <volume>
         7
        </volume>
        <fpage>
         80
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         9541091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR109">
       <label>
        110.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Clark
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Cases
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Tugwell
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Medina
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Gheno
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Tenorio
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Orozco
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine compared with placebo in rheumatoid arthritis
        </article-title>
        <source>
         Ann Intern Med.
        </source>
        <year>
         1993
        </year>
        <volume>
         119
        </volume>
        <fpage>
         1067
        </fpage>
        <lpage>
         71
        </lpage>
        <pub-id pub-id-type="pmid">
         8239224
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR110">
       <label>
        111.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maksymowych
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarials in rheumatology: efficacy and safety
        </article-title>
        <source>
         Semin Arthritis Rheum
        </source>
        <year>
         1987
        </year>
        <volume>
         16
        </volume>
        <fpage>
         206
        </fpage>
        <lpage>
         21
        </lpage>
        <pub-id pub-id-type="pmid">
         3547658
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR111">
       <label>
        112.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and rheumatoid arthritis. A short-term controlled trial
        </article-title>
        <source>
         Ann Rheum Dis
        </source>
        <year>
         1956
        </year>
        <volume>
         15
        </volume>
        <fpage>
         251
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         13363258
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR112">
       <label>
        113.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rynes
          </surname>
          <given-names>
           RI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1983
        </year>
        <volume>
         75
        </volume>
        <fpage>
         35
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         6869409
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR113">
       <label>
        114.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Browning
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity
        </article-title>
        <source>
         Am J Ophthalmol
        </source>
        <year>
         2002
        </year>
        <volume>
         133
        </volume>
        <fpage>
         649
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         11992862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR114">
       <label>
        115.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Fortin
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Panaritis
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Gans
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Esdaile
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Discontinuation of antimalarial drugs in systemic lupus erythematosus
        </article-title>
        <source>
         J Rheumatol
        </source>
        <year>
         1999
        </year>
        <volume>
         26
        </volume>
        <fpage>
         808
        </fpage>
        <lpage>
         15
        </lpage>
        <pub-id pub-id-type="pmid">
         10229401
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR115">
       <label>
        116.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paulus
          </surname>
          <given-names>
           HE
          </given-names>
         </name>
        </person-group>
        <article-title>
         An overview of benefit/risk of disease modifying treatment of rheumatoid arthritis as of today
        </article-title>
        <source>
         Ann Rheum Dis
        </source>
        <year>
         1982
        </year>
        <volume>
         41
        </volume>
        <fpage>
         26
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         7065739
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR116">
       <label>
        117.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alarcon
          </surname>
          <given-names>
           GS
          </given-names>
         </name>
         <name>
          <surname>
           McGwin
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Bertoli
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Fessler
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Calvo-Alen
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Bastian
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
         <name>
          <surname>
           Vila
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Reveille
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, multiethnic US cohort (LUMINA L)
        </article-title>
        <source>
         Ann Rheum Dis
        </source>
        <year>
         2007
        </year>
        <volume>
         66
        </volume>
        <fpage>
         1168
        </fpage>
        <lpage>
         72
        </lpage>
        <pub-id pub-id-type="pmid">
         17389655
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR117">
       <label>
        118.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fox
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         1996
        </year>
        <volume>
         5
        </volume>
        <fpage>
         S4
        </fpage>
        <lpage>
         10
        </lpage>
        <pub-id pub-id-type="pmid">
         8803903
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR118">
       <label>
        119.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abarientos
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Shapiro
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Aronow
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
         <name>
          <surname>
           Chao
          </surname>
          <given-names>
           CP
          </given-names>
         </name>
         <name>
          <surname>
           Ash
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy
        </article-title>
        <source>
         Expert Opin Drug Saf
        </source>
        <year>
         2011
        </year>
        <volume>
         10
        </volume>
        <fpage>
         705
        </fpage>
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="pmid">
         21417950
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR119">
       <label>
        120.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          American College of Rheumatology Ad Hoc Committee on Clinical Guidelines
         </collab>
        </person-group>
        <article-title>
         Guidelines for the management of rheumatoid arthritis
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         1996
        </year>
        <volume>
         39
        </volume>
        <fpage>
         713
        </fpage>
        <lpage>
         22
        </lpage>
        <pub-id pub-id-type="pmid">
         8639167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR120">
       <label>
        121.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Furst
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name>
          <surname>
           Lindsley
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Baethge
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Botstein
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
         <name>
          <surname>
           Caldwell
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Dietz
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Ettlinger
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Golden
          </surname>
          <given-names>
           HE
          </given-names>
         </name>
         <name>
          <surname>
           McLaughlin
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name>
          <surname>
           Moreland
          </surname>
          <given-names>
           LW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         1999
        </year>
        <volume>
         42
        </volume>
        <fpage>
         357
        </fpage>
        <lpage>
         65
        </lpage>
        <pub-id pub-id-type="pmid">
         10025931
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR121">
       <label>
        122.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kaufmann
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Krise
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications
        </article-title>
        <source>
         J Pharm Sci.
        </source>
        <year>
         2007
        </year>
        <volume>
         96
        </volume>
        <fpage>
         729
        </fpage>
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="pmid">
         17117426
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR122">
       <label>
        123.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Elman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Gullberg
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Nillson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Rendahl
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Wachtmeister
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Choroquine retinopathy in patients with rheumatoid arthritis
        </article-title>
        <source>
         Scand J Rheumatol
        </source>
        <year>
         1976
        </year>
        <volume>
         5
        </volume>
        <fpage>
         161
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         981992
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR123">
       <label>
        124.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Percival
          </surname>
          <given-names>
           SPB
          </given-names>
         </name>
         <name>
          <surname>
           Behrman
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ophthalmological safety of chloroquine
        </article-title>
        <source>
         Br J Ophthalmol.
        </source>
        <year>
         1969
        </year>
        <volume>
         53
        </volume>
        <fpage>
         101
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         5773461
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR124">
       <label>
        125.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grierson
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine and visual screening in a rheumatology outpatient clinic
        </article-title>
        <source>
         Ann Rheum Dis
        </source>
        <year>
         1997
        </year>
        <volume>
         56
        </volume>
        <fpage>
         188
        </fpage>
        <lpage>
         90
        </lpage>
        <pub-id pub-id-type="pmid">
         9135223
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR125">
       <label>
        126.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Browning
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice
        </article-title>
        <source>
         Am J Ophthalmol
        </source>
        <year>
         2013
        </year>
        <volume>
         155
        </volume>
        <fpage>
         418
        </fpage>
        <lpage>
         28
        </lpage>
        <pub-id pub-id-type="pmid">
         23218706
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR126">
       <label>
        127.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Browning
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reply to impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice
        </article-title>
        <source>
         Am J Ophthalmol
        </source>
        <year>
         2013
        </year>
        <volume>
         156
        </volume>
        <fpage>
         410
        </fpage>
        <lpage>
         1
        </lpage>
        <pub-id pub-id-type="pmid">
         23870364
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR127">
       <label>
        128.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morand
          </surname>
          <given-names>
           EF
          </given-names>
         </name>
         <name>
          <surname>
           McCloud
          </surname>
          <given-names>
           PI
          </given-names>
         </name>
         <name>
          <surname>
           Littlejohn
          </surname>
          <given-names>
           GO
          </given-names>
         </name>
        </person-group>
        <article-title>
         Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis
        </article-title>
        <source>
         Ann Rheum Dis
        </source>
        <year>
         1992
        </year>
        <volume>
         51
        </volume>
        <fpage>
         1318
        </fpage>
        <lpage>
         21
        </lpage>
        <pub-id pub-id-type="pmid">
         1485814
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR128">
       <label>
        129.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Petri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         1996
        </year>
        <volume>
         5
        </volume>
        <fpage>
         S16
        </fpage>
        <lpage>
         22
        </lpage>
        <pub-id pub-id-type="pmid">
         8803905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR129">
       <label>
        130.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bruce-Chwatt
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine blindness?
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         1968
        </year>
        <volume>
         2
        </volume>
        <fpage>
         1039
        </fpage>
        <pub-id pub-id-type="pmid">
         4176368
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR130">
       <label>
        131.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reed
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Campbell
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Central scotomata following chloroquine therapy
        </article-title>
        <source>
         Can Med Assoc J.
        </source>
        <year>
         1962
        </year>
        <volume>
         86
        </volume>
        <fpage>
         176
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         14490965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR131">
       <label>
        132.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Easterbrook
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of hydroxychloroquine retinopathy
        </article-title>
        <source>
         Evid Based ophthalmol.
        </source>
        <year>
         2011
        </year>
        <volume>
         12
        </volume>
        <fpage>
         132
        </fpage>
        <lpage>
         3
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR132">
       <label>
        133.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mavrikakis
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Sfikakis
          </surname>
          <given-names>
           PP
          </given-names>
         </name>
         <name>
          <surname>
           Mavrikakis
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Rougas
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Nikolaou
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Kostopoulos
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Mavrikakis
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine—a reappraisal
        </article-title>
        <source>
         Ophthalmology
        </source>
        <year>
         2003
        </year>
        <volume>
         110
        </volume>
        <fpage>
         1321
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         12867385
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR133">
       <label>
        134.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arden
          </surname>
          <given-names>
           GB
          </given-names>
         </name>
         <name>
          <surname>
           Kolb
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial therapy and early retinal changes in patients with rheumatoid arthritis
        </article-title>
        <source>
         Br Med J
        </source>
        <year>
         1966
        </year>
        <volume>
         1
        </volume>
        <fpage>
         270
        </fpage>
        <lpage>
         3
        </lpage>
        <pub-id pub-id-type="pmid">
         5902055
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR134">
       <label>
        135.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Finbloom
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Silver
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Newsome
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Gunkel
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity
        </article-title>
        <source>
         J Rheumatol
        </source>
        <year>
         1985
        </year>
        <volume>
         12
        </volume>
        <fpage>
         692
        </fpage>
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         4057189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR135">
       <label>
        136.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Trani
          </surname>
          <given-names>
           LD
          </given-names>
         </name>
         <name>
          <surname>
           Donateli
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Cauda
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Cassone
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         New insights into the antiviral effects of chloroquine
        </article-title>
        <source>
         Reflection React
        </source>
        <year>
         2006
        </year>
        <volume>
         6
        </volume>
        <fpage>
         67
        </fpage>
        <lpage>
         8
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR136">
       <label>
        137.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carr
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <name>
          <surname>
           Henkind
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Rothfield
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Siegel
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular toxicity of antimalarial drugs-long-term follow-up
        </article-title>
        <source>
         Am J Ophthalmol
        </source>
        <year>
         1968
        </year>
        <volume>
         66
        </volume>
        <fpage>
         738
        </fpage>
        <lpage>
         44
        </lpage>
        <pub-id pub-id-type="pmid">
         5729592
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR137">
       <label>
        138.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Percival
          </surname>
          <given-names>
           SPB
          </given-names>
         </name>
         <name>
          <surname>
           Meanock
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine: ophthalmological safety and clinical assessment in rheumatoid arthritis
        </article-title>
        <source>
         Br Med J
        </source>
        <year>
         1968
        </year>
        <volume>
         3
        </volume>
        <fpage>
         579
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         4875645
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR138">
       <label>
        139.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Fiechtner
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Carpenter
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
         <name>
          <surname>
           Stroshane
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         1987
        </year>
        <volume>
         30
        </volume>
        <fpage>
         567
        </fpage>
        <lpage>
         71
        </lpage>
        <pub-id pub-id-type="pmid">
         3593438
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR139">
       <label>
        140.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kench
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name>
          <surname>
           Seale
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Temple
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name>
          <surname>
           Tennant
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effects of non-steroidal inhibitors of phospholipase A2 on leukotriene and histamine release from human and guinea-pig lung
        </article-title>
        <source>
         Prostaglandins
        </source>
        <year>
         1985
        </year>
        <volume>
         30
        </volume>
        <fpage>
         199
        </fpage>
        <lpage>
         208
        </lpage>
        <pub-id pub-id-type="pmid">
         2413502
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR140">
       <label>
        141.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frisk-Holmberg
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Bergqvist
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine disposition in man
        </article-title>
        <source>
         Br J Clin Pharmacol
        </source>
        <year>
         1982
        </year>
        <volume>
         14
        </volume>
        <fpage>
         624P
        </fpage>
        <lpage>
         6
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR141">
       <label>
        142.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Salmeron
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Lipsky
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunosuppressive potential of antimalarials
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1983
        </year>
        <volume>
         75
        </volume>
        <fpage>
         19
        </fpage>
        <lpage>
         24
        </lpage>
        <pub-id pub-id-type="pmid">
         6603165
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR142">
       <label>
        143.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tett
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           RO
          </given-names>
         </name>
         <name>
          <surname>
           Cutler
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis—a cross sectional study
        </article-title>
        <source>
         J Rheumatol
        </source>
        <year>
         1993
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1874
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         8308772
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR143">
       <label>
        144.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wollheim
          </surname>
          <given-names>
           FA
          </given-names>
         </name>
         <name>
          <surname>
           Hanson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Laurell
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine treatment in rheumatoid arthritis
        </article-title>
        <source>
         Scand J Rheumatol
        </source>
        <year>
         1978
        </year>
        <volume>
         7
        </volume>
        <fpage>
         171
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         364636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR144">
       <label>
        145.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Costedoat-Chalumeau
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Amoura
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Hulot
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Hummoud
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <name>
          <surname>
           Aymard
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Cacoub
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Frances
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Wechsler
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2006
        </year>
        <volume>
         65
        </volume>
        <fpage>
         3284
        </fpage>
        <lpage>
         90
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR145">
       <label>
        146.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ullberg
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lindquist
          </surname>
          <given-names>
           NG
          </given-names>
         </name>
         <name>
          <surname>
           Sjostrand
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Accumulation of chorio-retinotoxic drugs in the foetal eye
        </article-title>
        <source>
         Nature
        </source>
        <year>
         1970
        </year>
        <volume>
         227
        </volume>
        <fpage>
         1257
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         5452818
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR146">
       <label>
        147.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cimaz
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Brucato
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Meregalli
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Muscara
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Sergi
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2004
        </year>
        <volume>
         50
        </volume>
        <fpage>
         3056
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         15457485
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR147">
       <label>
        148.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Costedoat-Chalumeau
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Amoura
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Aymard
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Hong
          </surname>
          <given-names>
           DLT
          </given-names>
         </name>
         <name>
          <surname>
           Wechsler
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evidence of transplacental passage of hydroxychloroquine in humans
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2002
        </year>
        <volume>
         46
        </volume>
        <fpage>
         1123
        </fpage>
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         11953993
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR148">
       <label>
        149.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klinger
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Morad
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Westall
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Laskin
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Spitzer
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Koren
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Buncic
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2001
        </year>
        <volume>
         358
        </volume>
        <fpage>
         813
        </fpage>
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         11564493
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR149">
       <label>
        150.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Motta
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Tincani
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Faden
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Zinzini
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Chirico
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial agents in pregnancy
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2002
        </year>
        <volume>
         359
        </volume>
        <fpage>
         524
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         11853823
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR150">
       <label>
        151.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parke
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           West
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine in pregnant patients with systemic lupus erythematosus
        </article-title>
        <source>
         J Clin Rheumatol
        </source>
        <year>
         1996
        </year>
        <volume>
         23
        </volume>
        <fpage>
         1715
        </fpage>
        <lpage>
         8
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR151">
       <label>
        152.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Clowse
          </surname>
          <given-names>
           MEB
          </given-names>
         </name>
         <name>
          <surname>
           Magder
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Witter
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Petri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine in lupus pregnancy
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2006
        </year>
        <volume>
         54
        </volume>
        <fpage>
         3640
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         17075810
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR152">
       <label>
        153.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khamashta
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Buchanan
          </surname>
          <given-names>
           NMM
          </given-names>
         </name>
         <name>
          <surname>
           Hughes
          </surname>
          <given-names>
           GRV
          </given-names>
         </name>
        </person-group>
        <article-title>
         The use of hydroxychloroquine in lupus pregnancy: the British experience
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         1996
        </year>
        <volume>
         5
        </volume>
        <fpage>
         S65
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         8803914
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR153">
       <label>
        154.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Costedoat-Chalumeau
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Amoura
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Duhaut
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Huong
          </surname>
          <given-names>
           DLT
          </given-names>
         </name>
         <name>
          <surname>
           Sebbough
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wechsler
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Safety of hydroxychloroquine in pregnant patients with connective tissue disease: a study of one hundred thirty-three cases compared with a control group
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2003
        </year>
        <volume>
         48
        </volume>
        <fpage>
         3207
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="pmid">
         14613284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR154">
       <label>
        155.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Borden
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Parke
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial drugs in systemic lupus erythematosus: use in pregnancy
        </article-title>
        <source>
         Drug Saf
        </source>
        <year>
         2001
        </year>
        <volume>
         24
        </volume>
        <fpage>
         1055
        </fpage>
        <lpage>
         83
        </lpage>
        <pub-id pub-id-type="pmid">
         11735661
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR155">
       <label>
        156.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parke
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial drugs and pregnancy
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1988
        </year>
        <volume>
         85
        </volume>
        <fpage>
         30
        </fpage>
        <lpage>
         3
        </lpage>
        <pub-id pub-id-type="pmid">
         3177430
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR156">
       <label>
        157.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Naunton
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
        </person-group>
        <article-title>
         The ototoxicity of chloroquine phosphate
        </article-title>
        <source>
         Arch Otolaryngol
        </source>
        <year>
         1964
        </year>
        <volume>
         80
        </volume>
        <fpage>
         407
        </fpage>
        <lpage>
         12
        </lpage>
        <pub-id pub-id-type="pmid">
         14198705
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR157">
       <label>
        158.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Costedoat-Chalumeau
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Amoura
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Sebbough
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Piette
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reply
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2004
        </year>
        <volume>
         50
        </volume>
        <fpage>
         3057
        </fpage>
        <lpage>
         8
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR158">
       <label>
        159.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ostensen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           ND
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         <name>
          <surname>
           Aarbakke
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine in human breast milk
        </article-title>
        <source>
         Eur J Clin Pharmacol
        </source>
        <year>
         1985
        </year>
        <volume>
         28
        </volume>
        <fpage>
         357
        </fpage>
        <pub-id pub-id-type="pmid">
         4007043
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR159">
       <label>
        160.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yam
          </surname>
          <given-names>
           JCS
          </given-names>
         </name>
         <name>
          <surname>
           Kwok
          </surname>
          <given-names>
           AKH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular toxicity of hydroxychloroquine
        </article-title>
        <source>
         Hong Kong Med J
        </source>
        <year>
         2006
        </year>
        <volume>
         12
        </volume>
        <fpage>
         294
        </fpage>
        <lpage>
         304
        </lpage>
        <pub-id pub-id-type="pmid">
         16912357
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR160">
       <label>
        161.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yoon
          </surname>
          <given-names>
           YH
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Hwang
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells
        </article-title>
        <source>
         Invest Ophthalmol Vis Sci
        </source>
        <year>
         2010
        </year>
        <volume>
         51
        </volume>
        <fpage>
         6030
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         20574031
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR161">
       <label>
        162.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Duve
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           de Barsy
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Poole
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Trouet
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tulkens
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Van Hoof
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lysosomotropic agents
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         1974
        </year>
        <volume>
         23
        </volume>
        <fpage>
         2495
        </fpage>
        <lpage>
         531
        </lpage>
        <pub-id pub-id-type="pmid">
         4606365
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR162">
       <label>
        163.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohkuma
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Poole
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         1978
        </year>
        <volume>
         75
        </volume>
        <fpage>
         3327
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="pmid">
         28524
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR163">
       <label>
        164.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ginsburg
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Geary
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current concepts and new ideas on the mechanism of action of quinoline-containing antimalarials
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         1987
        </year>
        <volume>
         36
        </volume>
        <fpage>
         1567
        </fpage>
        <lpage>
         76
        </lpage>
        <pub-id pub-id-type="pmid">
         3297064
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR164">
       <label>
        165.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kyburz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Brentano
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Gay
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mode of action of hydroxychloroquine in RA—evidence of an inhibitory effect on toll-like receptor signaling
        </article-title>
        <source>
         Nat Clin Pract Rheumatol
        </source>
        <year>
         2006
        </year>
        <volume>
         2
        </volume>
        <fpage>
         458
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         16951696
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR165">
       <label>
        166.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stauber
          </surname>
          <given-names>
           WT
          </given-names>
         </name>
         <name>
          <surname>
           Hedge
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Trout
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Schottelius
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of lysosomal function in red and white skeletal muscles by chloroquine
        </article-title>
        <source>
         Exp Neurol
        </source>
        <year>
         1981
        </year>
        <volume>
         71
        </volume>
        <fpage>
         295
        </fpage>
        <lpage>
         306
        </lpage>
        <pub-id pub-id-type="pmid">
         7004885
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR166">
       <label>
        167.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lafyatis
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           York
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Marshak-Rothstein
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial agents: closing the gate on toll-like receptors?
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2006
        </year>
        <volume>
         54
        </volume>
        <fpage>
         3068
        </fpage>
        <lpage>
         70
        </lpage>
        <pub-id pub-id-type="pmid">
         17009223
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR167">
       <label>
        168.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gonzalez-Noriega
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Grubb
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Talkad
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Sly
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling
        </article-title>
        <source>
         J Cell Biol
        </source>
        <year>
         1980
        </year>
        <volume>
         85
        </volume>
        <fpage>
         839
        </fpage>
        <lpage>
         52
        </lpage>
        <pub-id pub-id-type="pmid">
         7190150
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR168">
       <label>
        169.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           CJP
          </given-names>
         </name>
         <name>
          <surname>
           Salisbury
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Jayson
          </surname>
          <given-names>
           MIV
          </given-names>
         </name>
        </person-group>
        <article-title>
         The presence of abnormal lysosomes in lumphocytes and neutrophils during chloroquine therapy: a quantitative ultrastructural study
        </article-title>
        <source>
         Ann Rheum Dis
        </source>
        <year>
         1984
        </year>
        <volume>
         43
        </volume>
        <fpage>
         710
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         6093716
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR169">
       <label>
        170.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prowse
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pepper
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Dawes
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of the platelet alpha-granule release reaction by membrane-active drugs
        </article-title>
        <source>
         Thromb Res
        </source>
        <year>
         1982
        </year>
        <volume>
         25
        </volume>
        <fpage>
         219
        </fpage>
        <lpage>
         27
        </lpage>
        <pub-id pub-id-type="pmid">
         6175045
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR170">
       <label>
        171.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cruz da Silva
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Mariz
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <name>
          <surname>
           da Rocha Jr
          </surname>
          <given-names>
           LF
          </given-names>
         </name>
         <name>
          <surname>
           de Oliveira
          </surname>
          <given-names>
           PSS
          </given-names>
         </name>
         <name>
          <surname>
           Dantas
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name>
          <surname>
           Duarte
          </surname>
          <given-names>
           ALBP
          </given-names>
         </name>
         <name>
          <surname>
           Pitta
          </surname>
          <given-names>
           IDR
          </given-names>
         </name>
         <name>
          <surname>
           Galdino
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Pitta
          </surname>
          <given-names>
           MGDR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine decreases TH17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients
        </article-title>
        <source>
         Clinics
        </source>
        <year>
         2013
        </year>
        <volume>
         68
        </volume>
        <fpage>
         766
        </fpage>
        <lpage>
         71
        </lpage>
        <pub-id pub-id-type="pmid">
         23778483
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR171">
       <label>
        172.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Antoine
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Gould
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Jovanne
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Maurice
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Feldman
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ammonium chloride, methylamine and chloroquine reversibly inhibit antibody secretion by plasma cells
        </article-title>
        <source>
         Biol Cell
        </source>
        <year>
         1985
        </year>
        <volume>
         55
        </volume>
        <fpage>
         41
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="pmid">
         2937496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR172">
       <label>
        173.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Macfarlane
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name>
          <surname>
           Manzel
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds
        </article-title>
        <source>
         J Immunol
        </source>
        <year>
         1998
        </year>
        <volume>
         160
        </volume>
        <fpage>
         1122
        </fpage>
        <lpage>
         31
        </lpage>
        <pub-id pub-id-type="pmid">
         9570525
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR173">
       <label>
        174.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McConnell
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <name>
          <surname>
           Wachtel
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Havener
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Observations on experimental chloroquine retinopathy
        </article-title>
        <source>
         Arch Ophthalmol
        </source>
        <year>
         1964
        </year>
        <volume>
         71
        </volume>
        <fpage>
         552
        </fpage>
        <lpage>
         3
        </lpage>
        <pub-id pub-id-type="pmid">
         14109043
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR174">
       <label>
        175.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Namazi
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquinere and hydroxychloroquine
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         2009
        </year>
        <volume>
         18
        </volume>
        <fpage>
         104
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         19151110
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR175">
       <label>
        176.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bondeson
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sundler
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1 beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis
        </article-title>
        <source>
         Gen Pharmacol
        </source>
        <year>
         1998
        </year>
        <volume>
         30
        </volume>
        <fpage>
         357
        </fpage>
        <lpage>
         66
        </lpage>
        <pub-id pub-id-type="pmid">
         9510087
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR176">
       <label>
        177.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alvan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromotography
        </article-title>
        <source>
         J Chromatogr
        </source>
        <year>
         1982
        </year>
        <volume>
         229
        </volume>
        <fpage>
         241
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         7085832
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR177">
       <label>
        178.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sanders
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Uhr
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Vitetta
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antigen-specific memory and virgin B cells differ in their requirements for conjugation to T cells
        </article-title>
        <source>
         Cell Immunol
        </source>
        <year>
         1987
        </year>
        <volume>
         104
        </volume>
        <fpage>
         419
        </fpage>
        <lpage>
         25
        </lpage>
        <pub-id pub-id-type="pmid">
         2949857
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR178">
       <label>
        179.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Macomber
          </surname>
          <given-names>
           PB
          </given-names>
         </name>
         <name>
          <surname>
           Sprinz
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Morphological effects of chloroquine on Plasmodium berghei in mice
        </article-title>
        <source>
         Nature
        </source>
        <year>
         1967
        </year>
        <volume>
         214
        </volume>
        <fpage>
         937
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         4861556
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR179">
       <label>
        180.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <name>
          <surname>
           Marchetti
          </surname>
          <given-names>
           RV
          </given-names>
         </name>
         <name>
          <surname>
           Cowen
          </surname>
          <given-names>
           AI
          </given-names>
         </name>
         <name>
          <surname>
           Howitt
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Broer
          </surname>
          <given-names>
           SV
          </given-names>
         </name>
         <name>
          <surname>
           Kirk
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine transport via the malaria parasite’s chloroquine resistance transporter
        </article-title>
        <source>
         Science
        </source>
        <year>
         2009
        </year>
        <volume>
         325
        </volume>
        <fpage>
         1680
        </fpage>
        <lpage>
         2
        </lpage>
        <pub-id pub-id-type="pmid">
         19779197
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR180">
       <label>
        181.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Karres
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Kremer
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Dietl
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Steckholzer
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Jochum
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ertel
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibits proinflammatory cytokine release into human whole blood
        </article-title>
        <source>
         Am J Physiol
        </source>
        <year>
         1998
        </year>
        <volume>
         274
        </volume>
        <fpage>
         R1058
        </fpage>
        <lpage>
         64
        </lpage>
        <pub-id pub-id-type="pmid">
         9575969
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR181">
       <label>
        182.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jang
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Byun
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Jue
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine inhibits production of TNF-alpha, IL-1 beta, and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes
        </article-title>
        <source>
         Rheumatology
        </source>
        <year>
         2006
        </year>
        <volume>
         45
        </volume>
        <fpage>
         703
        </fpage>
        <lpage>
         10
        </lpage>
        <pub-id pub-id-type="pmid">
         16418198
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR182">
       <label>
        183.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Levitz
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine interferes with lipopolysaccharide-induced TNF-α gene expression by a nonlysosomotropic mechanism
        </article-title>
        <source>
         J Immunol
        </source>
        <year>
         2000
        </year>
        <volume>
         165
        </volume>
        <fpage>
         1534
        </fpage>
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="pmid">
         10903761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR183">
       <label>
        184.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Manku
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Horrobin
          </surname>
          <given-names>
           DF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         1976
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1115
        </fpage>
        <lpage>
         7
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR184">
       <label>
        185.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Loffler
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Bohn
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Hesse
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Kunze
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver
        </article-title>
        <source>
         Biochim Biophys Acta.
        </source>
        <year>
         1985
        </year>
        <volume>
         835
        </volume>
        <fpage>
         448
        </fpage>
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="pmid">
         4016141
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR185">
       <label>
        186.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matsuzawa
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Hostetler
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of chloroquine and 4,4′-bis (diethylaminoethoxy)á, â-diethyldiphenylethane on the incorporation of [3H]glycerol into the phospholipids of rat liver lysosomes and other subcellular fractions, in vivo
        </article-title>
        <source>
         Biochim Biophys Acta.
        </source>
        <year>
         1980
        </year>
        <volume>
         620
        </volume>
        <fpage>
         592
        </fpage>
        <lpage>
         602
        </lpage>
        <pub-id pub-id-type="pmid">
         6263327
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR186">
       <label>
        187.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Trout
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Stauber
          </surname>
          <given-names>
           WT
          </given-names>
         </name>
         <name>
          <surname>
           Schottelius
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Increased autophagy in chloroquine treated tonic and phasic muscles: an alternative view
        </article-title>
        <source>
         Tissue Cell.
        </source>
        <year>
         1982
        </year>
        <volume>
         13
        </volume>
        <fpage>
         393
        </fpage>
        <lpage>
         401
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR187">
       <label>
        188.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fiddick
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Heath
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of alcohol dehydrogenase by chloroquine
        </article-title>
        <source>
         Nature
        </source>
        <year>
         1967
        </year>
        <volume>
         213
        </volume>
        <fpage>
         628
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         4291734
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR188">
       <label>
        189.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roskoski
          </surname>
          <given-names>
           R
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Jaskunas
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and primaquine inhibition of rat liver cell-free polynucleotide-dependent polypeptide synthesis
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         1972
        </year>
        <volume>
         21
        </volume>
        <fpage>
         391
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         5014494
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR189">
       <label>
        190.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lefler
          </surname>
          <given-names>
           CF
          </given-names>
         </name>
         <name>
          <surname>
           Lilja
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Holbrook
          </surname>
          <given-names>
           DJ
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
        </person-group>
        <article-title>
         Inhibition of aminoacylation and polypeptide synthesis by chloroquine and primaquine in rat liver in vitro
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         1973
        </year>
        <volume>
         22
        </volume>
        <fpage>
         715
        </fpage>
        <lpage>
         28
        </lpage>
        <pub-id pub-id-type="pmid">
         4693493
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR190">
       <label>
        191.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <article-title>
         The chemosuppression of chemotaxis
        </article-title>
        <source>
         J Exp Med
        </source>
        <year>
         1966
        </year>
        <volume>
         124
        </volume>
        <fpage>
         209
        </fpage>
        <lpage>
         26
        </lpage>
        <pub-id pub-id-type="pmid">
         5950689
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR191">
       <label>
        192.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Labro
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <name>
          <surname>
           Babin-Chevaye
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         1988
        </year>
        <volume>
         32
        </volume>
        <fpage>
         1124
        </fpage>
        <lpage>
         30
        </lpage>
        <pub-id pub-id-type="pmid">
         3263835
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR192">
       <label>
        193.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weissmann
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lysosomes (concluded)
        </article-title>
        <source>
         New Engl J Med
        </source>
        <year>
         1965
        </year>
        <volume>
         273
        </volume>
        <fpage>
         1143
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         5320613
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR193">
       <label>
        194.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brentano
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Schorr
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Gay
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <name>
          <surname>
           Gay
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kyburz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         2005
        </year>
        <volume>
         52
        </volume>
        <fpage>
         2656
        </fpage>
        <lpage>
         65
        </lpage>
        <pub-id pub-id-type="pmid">
         16142732
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR194">
       <label>
        195.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leadbetter
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Rifkin
          </surname>
          <given-names>
           IR
          </given-names>
         </name>
         <name>
          <surname>
           Hohlbaum
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Beaudette
          </surname>
          <given-names>
           BC
          </given-names>
         </name>
         <name>
          <surname>
           Schlomchik
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Marshak-Rothstein
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2002
        </year>
        <volume>
         416
        </volume>
        <fpage>
         603
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         11948342
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR195">
       <label>
        196.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tehrani
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Ostrowski
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Hariman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Jay
          </surname>
          <given-names>
           WM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular toxicity of hydroxychloroquine
        </article-title>
        <source>
         Semin Ophthalmol
        </source>
        <year>
         2008
        </year>
        <volume>
         23
        </volume>
        <fpage>
         201
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         18432546
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR196">
       <label>
        197.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wada
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Sakurai
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kobayashi
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Yanagihara
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Izumi
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Suppression by phospholipase A2 inhibitors of secretion of catecholamines from isolated adrenal medullary cells by suppression of cellular calcium uptake
        </article-title>
        <source>
         Biochem Pharmacol
        </source>
        <year>
         1983
        </year>
        <volume>
         32
        </volume>
        <fpage>
         1175
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         6847709
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR197">
       <label>
        198.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wiesmann
          </surname>
          <given-names>
           EN
          </given-names>
         </name>
         <name>
          <surname>
           DiDonato
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Herschkowitz
          </surname>
          <given-names>
           NN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of chloroquine on cultured fibroblasts: release of lysosomal hydrolases and inhibition of their uptake
        </article-title>
        <source>
         Biochem Biophys Res Commun.
        </source>
        <year>
         1975
        </year>
        <volume>
         66
        </volume>
        <fpage>
         1338
        </fpage>
        <lpage>
         43
        </lpage>
        <pub-id pub-id-type="pmid">
         4
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR198">
       <label>
        199.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roman
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Shanker
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lockshin
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Sammaritano
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Simantov
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Crow
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus
        </article-title>
        <source>
         N Engl J Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         349
        </volume>
        <fpage>
         2299
        </fpage>
        <lpage>
         406
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR199">
       <label>
        200.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wallace
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Metzger
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Turnbull
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Kern
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids
        </article-title>
        <source>
         Am J Med
        </source>
        <year>
         1990
        </year>
        <volume>
         89
        </volume>
        <fpage>
         322
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         2393036
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR200">
       <label>
        201.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wasko
          </surname>
          <given-names>
           MCM
          </given-names>
         </name>
         <name>
          <surname>
           Hubert
          </surname>
          <given-names>
           HB
          </given-names>
         </name>
         <name>
          <surname>
           Lingala
          </surname>
          <given-names>
           VB
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Luggen
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Fries
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2007
        </year>
        <volume>
         298
        </volume>
        <fpage>
         187
        </fpage>
        <lpage>
         93
        </lpage>
        <pub-id pub-id-type="pmid">
         17622600
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR224">
       <label>
        202.
       </label>
       <mixed-citation publication-type="other">
        Kitridou R, Rees RG, Smith MJ, Peiris A, Kissebah AH. Effect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non-insulin dependent diabetes mellitus. Br Med J. 1987;294:900–1.
       </mixed-citation>
      </ref>
      <ref id="CR201">
       <label>
        203.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ruiz-Irastorza
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Egurbide
          </surname>
          <given-names>
           MV
          </given-names>
         </name>
         <name>
          <surname>
           Pijoan
          </surname>
          <given-names>
           JI
          </given-names>
         </name>
         <name>
          <surname>
           Garmendia
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Villar
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Martinez-Berriotxoa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Erdozain
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name>
          <surname>
           Aguirre
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
        </article-title>
        <source>
         Lupus
        </source>
        <year>
         2006
        </year>
        <volume>
         15
        </volume>
        <fpage>
         577
        </fpage>
        <lpage>
         83
        </lpage>
        <pub-id pub-id-type="pmid">
         17080912
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR202">
       <label>
        204.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hurvitz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Hirschhorn
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Suppression of in vitro lymphocyte responses by chloroquine
        </article-title>
        <source>
         N Engl J Med.
        </source>
        <year>
         1965
        </year>
        <volume>
         273
        </volume>
        <fpage>
         23
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         14297090
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR203">
       <label>
        205.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohkuma
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Chudzik
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Poole
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effects of basic substances and acidic ionophores on the digestion of exogenous and endogenous proteins in mouse peritoneal macrophages
        </article-title>
        <source>
         J Cell Biol
        </source>
        <year>
         1986
        </year>
        <volume>
         102
        </volume>
        <fpage>
         959
        </fpage>
        <lpage>
         66
        </lpage>
        <pub-id pub-id-type="pmid">
         3949884
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR204">
       <label>
        206.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oda
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Koriyama
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Ikehara
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of weakly basic amines on proteolytic processing and terminal glycosylation of secretory proteins in cultured rat hepatocytes
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         1986
        </year>
        <volume>
         240
        </volume>
        <fpage>
         739
        </fpage>
        <lpage>
         45
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR205">
       <label>
        207.
       </label>
       <mixed-citation publication-type="other">
        Wright CI, Sabine JC. Cholinesterases of human erythrocytes and plasma and their inhibition by antimalarial drugs. J Pharmacol Exp Ther. 1948;93:230–9.
       </mixed-citation>
      </ref>
      <ref id="CR206">
       <label>
        208.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jeong
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Jeon
          </surname>
          <given-names>
           KI
          </given-names>
         </name>
         <name>
          <surname>
           Jue
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells
        </article-title>
        <source>
         Immunology
        </source>
        <year>
         2002
        </year>
        <volume>
         105
        </volume>
        <fpage>
         83
        </fpage>
        <lpage>
         91
        </lpage>
        <pub-id pub-id-type="pmid">
         11849318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR207">
       <label>
        209.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meng
          </surname>
          <given-names>
           XW
          </given-names>
         </name>
         <name>
          <surname>
           Feller
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Ziegler
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <name>
          <surname>
           Pittman
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Ireland
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine
        </article-title>
        <source>
         Arthritis Rheum
        </source>
        <year>
         1997
        </year>
        <volume>
         40
        </volume>
        <fpage>
         927
        </fpage>
        <lpage>
         35
        </lpage>
        <pub-id pub-id-type="pmid">
         9153556
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR208">
       <label>
        210.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           WU
          </given-names>
         </name>
         <name>
          <surname>
           Yoo
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Min
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Koh
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes
        </article-title>
        <source>
         Clin Exp Immunol
        </source>
        <year>
         2006
        </year>
        <volume>
         144
        </volume>
        <fpage>
         503
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="pmid">
         16734620
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR209">
       <label>
        211.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Levitz
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of mitogen-activated protein kinase signaling by chloroquine
        </article-title>
        <source>
         J Immunol
        </source>
        <year>
         2002
        </year>
        <volume>
         168
        </volume>
        <fpage>
         5303
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         11994488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR210">
       <label>
        212.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ghigo
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Aldieri
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Todde
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Costamagna
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Garbarino
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Pescarmona
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Bosia
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         1998
        </year>
        <volume>
         102
        </volume>
        <fpage>
         595
        </fpage>
        <lpage>
         605
        </lpage>
        <pub-id pub-id-type="pmid">
         9691096
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR211">
       <label>
        213.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tietze
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Schlesinger
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Stahl
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and ammonium ion inhibit receptor-mediated endocystosis of mannose-glyconjugates by macrophages: apparent inhibition of receptor recycling
        </article-title>
        <source>
         Biochem Biophys Res Commun.
        </source>
        <year>
         1980
        </year>
        <volume>
         93
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         7378072
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR225">
       <label>
        214.
       </label>
       <mixed-citation publication-type="other">
        Allison JL, O’Brien RL, Hahn FE. DNA: reaction with chloroquine. Science. 1965;149:1111–3.
       </mixed-citation>
      </ref>
      <ref id="CR212">
       <label>
        215.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ciak
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Hahn
          </surname>
          <given-names>
           FE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine: mode of action
        </article-title>
        <source>
         Science
        </source>
        <year>
         1966
        </year>
        <volume>
         151
        </volume>
        <fpage>
         347
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         4955293
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR213">
       <label>
        216.
       </label>
       <mixed-citation publication-type="other">
        O’Brien RL, Olenick JG, Hahn FE. Reactions of quinine, chloroquine, and quinacrine with DNA and their effects on the DNA and RNA polymerase reactions. Proc Natl Acad Sci USA. 1966;55:1511–7.
       </mixed-citation>
      </ref>
      <ref id="CR214">
       <label>
        217.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yucel-Lindberg
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Jansson
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Glaumann
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Proteolysis in isolated autophagic vacuoles from the rat pancreas. Effects of chloroquine administration
        </article-title>
        <source>
         Virchows Arch B Cell Pathol.
        </source>
        <year>
         1991
        </year>
        <volume>
         61
        </volume>
        <fpage>
         141
        </fpage>
        <lpage>
         5
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR215">
       <label>
        218.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raines
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Bhargava
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Rosen
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
        </person-group>
        <article-title>
         The blood-retinal barrier in chloroquine retinopathy
        </article-title>
        <source>
         Invest Ophthalmol Vis Sci
        </source>
        <year>
         1989
        </year>
        <volume>
         30
        </volume>
        <fpage>
         1726
        </fpage>
        <lpage>
         31
        </lpage>
        <pub-id pub-id-type="pmid">
         2759787
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR216">
       <label>
        219.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weisinger
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Pesudovs
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Collin
          </surname>
          <given-names>
           HB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Management of patients undergoing hydroxychloroquine (Plaquenil) therapy
        </article-title>
        <source>
         Clin Exp Optom
        </source>
        <year>
         2000
        </year>
        <volume>
         83
        </volume>
        <fpage>
         32
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         12472464
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR217">
       <label>
        220.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goldstein
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Brunschede
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of the proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and Triton WR 1339
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         1975
        </year>
        <volume>
         250
        </volume>
        <fpage>
         7854
        </fpage>
        <lpage>
         62
        </lpage>
        <pub-id pub-id-type="pmid">
         170273
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR218">
       <label>
        221.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ausiello
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Barbieri
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Spagnoli
          </surname>
          <given-names>
           GC
          </given-names>
         </name>
         <name>
          <surname>
           Ciompi
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Gasciani
          </surname>
          <given-names>
           CU
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vivo effects of chloroquine treatment on spontaneous and interferon-induced natural killer activities in rheumatoid arthritis patients
        </article-title>
        <source>
         Clin Exp Rheumatol
        </source>
        <year>
         1986
        </year>
        <volume>
         4
        </volume>
        <fpage>
         255
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         3769242
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR219">
       <label>
        222.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O’Brien
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Allison
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Hahn
          </surname>
          <given-names>
           FE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for intercalation of chloroquine into DNA
        </article-title>
        <source>
         Biochim Biophys Acta
        </source>
        <year>
         1966
        </year>
        <volume>
         129
        </volume>
        <fpage>
         622
        </fpage>
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         5965736
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR220">
       <label>
        223.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wozniacka
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lesiak
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Boncela
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Smolarczyk
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           McCauliffe
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name>
          <surname>
           Sysa-Jedrzejowska
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus
        </article-title>
        <source>
         Br J Dermatol
        </source>
        <year>
         2008
        </year>
        <volume>
         159
        </volume>
        <fpage>
         1124
        </fpage>
        <lpage>
         30
        </lpage>
        <pub-id pub-id-type="pmid">
         18764842
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR221">
       <label>
        224.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Ashton
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Balment
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of chloroquine on renal function and vasopressin secretion: a nitric oxide-dependent effect
        </article-title>
        <source>
         J Pharmacol Exp Ther
        </source>
        <year>
         2003
        </year>
        <volume>
         304
        </volume>
        <fpage>
         156
        </fpage>
        <lpage>
         61
        </lpage>
        <pub-id pub-id-type="pmid">
         12490586
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR222">
       <label>
        225.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Accapezzato
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Visco
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Francavilla
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Molette
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Donato
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Chloroquine enhances human CD8 T cell responses against soluble antigens in vivo
        </article-title>
        <source>
         J Exp Med
        </source>
        <year>
         2005
        </year>
        <volume>
         202
        </volume>
        <fpage>
         817
        </fpage>
        <lpage>
         28
        </lpage>
        <pub-id pub-id-type="pmid">
         16157687
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Autophagy
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Autophagy
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       KAUP
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       kaup20
      </journal-id>
      <journal-title-group>
       <journal-title>
        Autophagy
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1554-8627
      </issn>
      <issn pub-type="epub">
       1554-8635
      </issn>
      <publisher>
       <publisher-name>
        Taylor &amp; Francis
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       29940786
      </article-id>
      <article-id pub-id-type="pmc">
       6103682
      </article-id>
      <article-id pub-id-type="publisher-id">
       1474314
      </article-id>
      <article-id pub-id-type="doi">
       10.1080/15548627.2018.1474314
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Resource
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion
       </article-title>
       <alt-title alt-title-type="running-authors">
        M. MAUTHE ET AL.
       </alt-title>
       <alt-title alt-title-type="running-title">
        AUTOPHAGY
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Mauthe
         </surname>
         <given-names>
          Mario
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="AFF0002">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Orhon
         </surname>
         <given-names>
          Idil
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="FT0001">
         <sup>
          *
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Rocchi
         </surname>
         <given-names>
          Cecilia
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="AFF0003">
         <sup>
          c
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="FT0001">
         <sup>
          *
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Xingdong
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="AFF0004">
         <sup>
          d
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="FT0001">
         <sup>
          *
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Luhr
         </surname>
         <given-names>
          Morten
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF0005">
         <sup>
          e
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hijlkema
         </surname>
         <given-names>
          Kerst-Jan
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Coppes
         </surname>
         <given-names>
          Robert P.
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="AFF0003">
         <sup>
          c
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Engedal
         </surname>
         <given-names>
          Nikolai
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF0005">
         <sup>
          e
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Mari
         </surname>
         <given-names>
          Muriel
         </given-names>
        </name>
        <xref ref-type="corresp" rid="AN0001">
        </xref>
        <xref ref-type="aff" rid="AFF0001">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="AFF0002">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Reggiori
         </surname>
         <given-names>
          Fulvio
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="AFF0002">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <aff id="AFF0001">
        <label>
         a
        </label>
        <institution>
         Department of Cell Biology, University of Groningen, University Medical Center Groningen
        </institution>
        , Groningen,
        <country>
         The Netherlands
        </country>
       </aff>
       <aff id="AFF0002">
        <label>
         b
        </label>
        <institution>
         Department of Cell Biology, University Medical Center Utrecht, Center for Molecular Medicine
        </institution>
        , Utrecht,
        <country>
         The Netherlands
        </country>
       </aff>
       <aff id="AFF0003">
        <label>
         c
        </label>
        <institution>
         Department of Radiation Oncology, University of Groningen, University Medical Center Groningen
        </institution>
        , Groningen,
        <country>
         The Netherlands
        </country>
       </aff>
       <aff id="AFF0004">
        <label>
         d
        </label>
        <institution>
         Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Northeast Agricultural University
        </institution>
        , Harbin,
        <country>
         People’s Republic of China
        </country>
       </aff>
       <aff id="AFF0005">
        <label>
         e
        </label>
        <institution>
         Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership for Molecular Medicine, University of Oslo
        </institution>
        , Oslo,
        <country>
         Norway
        </country>
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="AN0001">
        CONTACT Muriel Mari
        <email xlink:href="m.c.mari@umcg.nl">
         m.c.mari@umcg.nl
        </email>
        <institution>
         Department of Cell Biology, University of Groningen, University Medical Center Groningen
        </institution>
        ,
        <addr-line>
         A. Deusinglaan 1, 9713 AV
        </addr-line>
        , Groningen,
        <country>
         The Netherlands
        </country>
        ; Fulvio Reggiori
        <email xlink:href="f.m.reggiori@umcg.nl">
         f.m.reggiori@umcg.nl
        </email>
        <institution>
         Department of Cell Biology, University Medical Center Utrecht, Center for Molecular Medicine
        </institution>
        ,
        <addr-line>
         Heidelberglaan 100
        </addr-line>
        , 3584 CX Utrecht,
        <country>
         The Netherlands
        </country>
       </corresp>
       <fn id="FT0001">
        <label>
         *
        </label>
        <p>
         These authors contributed equally to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="collection">
       <year>
        2018
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        20
       </day>
       <month>
        7
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <volume>
       14
      </volume>
      <issue>
       8
      </issue>
      <fpage seq="12">
       1435
      </fpage>
      <lpage>
       1455
      </lpage>
      <history>
       <date date-type="received">
        <day>
         2
        </day>
        <month>
         10
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="accepted">
        <day>
         2
        </day>
        <month>
         5
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         1
        </day>
        <month>
         5
        </month>
        <year>
         2018
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2018 Informa UK Limited, trading as Taylor &amp; Francis Group
       </copyright-statement>
       <copyright-year>
        2018
       </copyright-year>
       <copyright-holder>
        Informa UK Limited, trading as Taylor &amp; Francis Group
       </copyright-holder>
      </permissions>
      <self-uri content-type="pdf" xlink:href="kaup-14-08-1474314.pdf">
      </self-uri>
      <abstract>
       <title>
        ABSTRACT
       </title>
       <p>
        Macroautophagy/autophagy is a conserved transport pathway where targeted structures are sequestered by phagophores, which mature into autophagosomes, and then delivered into lysosomes for degradation. Autophagy is involved in the pathophysiology of numerous diseases and its modulation is beneficial for the outcome of numerous specific diseases. Several lysosomal inhibitors such as bafilomycin A
        <sub>
         1
        </sub>
        (BafA
        <sub>
         1
        </sub>
        ), protease inhibitors and chloroquine (CQ), have been used interchangeably to block autophagy in
        <italic>
         in vitro
        </italic>
        experiments assuming that they all primarily block lysosomal degradation. Among them, only CQ and its derivate hydroxychloroquine (HCQ) are FDA-approved drugs and are thus currently the principal compounds used in clinical trials aimed to treat tumors through autophagy inhibition. However, the precise mechanism of how CQ blocks autophagy remains to be firmly demonstrated. In this study, we focus on how CQ inhibits autophagy and directly compare its effects to those of BafA
        <sub>
         1
        </sub>
        . We show that CQ mainly inhibits autophagy by impairing autophagosome fusion with lysosomes rather than by affecting the acidity and/or degradative activity of this organelle. Furthermore, CQ induces an autophagy-independent severe disorganization of the Golgi and endo-lysosomal systems, which might contribute to the fusion impairment. Strikingly, HCQ-treated mice also show a Golgi disorganization in kidney and intestinal tissues. Altogether, our data reveal that CQ and HCQ are not
        <italic>
         bona fide
        </italic>
        surrogates for other types of late stage lysosomal inhibitors for
        <italic>
         in vivo
        </italic>
        experiments. Moreover, the multiple cellular alterations caused by CQ and HCQ call for caution when interpreting results obtained by blocking autophagy with this drug.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <title>
        KEYWORDS
       </title>
       <kwd>
        Autophagy
       </kwd>
       <kwd>
        bafilomycin A
        <sub>
         1
        </sub>
       </kwd>
       <kwd>
        degradative compartments
       </kwd>
       <kwd>
        fusion
       </kwd>
       <kwd>
        Golgi
       </kwd>
       <kwd>
        lysosomal degradation
       </kwd>
       <kwd>
        lysosomal inhibitors
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          H2020 Marie Skłodowska-Curie Actions
         </named-content>
         <named-content content-type="funder-identifier">
          10.13039/100010665
         </named-content>
        </funding-source>
        <award-id>
         713660
        </award-id>
       </award-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          KWF Kankerbestrijding
         </named-content>
         <named-content content-type="funder-identifier">
          10.13039/501100004622
         </named-content>
        </funding-source>
        <award-id>
         RUG2013-5792
        </award-id>
       </award-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          Nederlandse Organisatie voor Wetenschappelijk Onderzoek
         </named-content>
         <named-content content-type="funder-identifier">
          10.13039/501100003246
         </named-content>
        </funding-source>
        <award-id>
         DN82-303
        </award-id>
       </award-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          Norges Forskningsråd
         </named-content>
         <named-content content-type="funder-identifier">
          10.13039/501100005416
         </named-content>
        </funding-source>
        <award-id>
         230686/F20
        </award-id>
       </award-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
         </named-content>
         <named-content content-type="funder-identifier">
          10.13039/501100001711
         </named-content>
        </funding-source>
        <award-id>
         CRSII3_154421
        </award-id>
       </award-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          ZonMw
         </named-content>
         <named-content content-type="funder-identifier">
          10.13039/501100001826
         </named-content>
        </funding-source>
        <award-id>
         016.130.606
        </award-id>
       </award-group>
       <funding-statement>
        This work was supported by the H2020 Marie Skłodowska-Curie Actions [713660];KWF Kankerbestrijding [RUG2013-5792];Nederlandse Organisatie voor Wetenschappelijk Onderzoek [DN82-303];Norges Forskningsråd [230686/F20];Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung [CRSII3_154421];ZonMw [016.130.606];
       </funding-statement>
      </funding-group>
      <counts>
       <fig-count count="9">
       </fig-count>
       <ref-count count="93">
       </ref-count>
       <page-count count="21">
       </page-count>
      </counts>
     </article-meta>
    </front>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Open Forum Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Open Forum Infect Dis
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       ofid
      </journal-id>
      <journal-title-group>
       <journal-title>
        Open Forum Infectious Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2328-8957
      </issn>
      <publisher>
       <publisher-name>
        Oxford University Press
       </publisher-name>
       <publisher-loc>
        US
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32284951
      </article-id>
      <article-id pub-id-type="pmc">
       7144823
      </article-id>
      <article-id pub-id-type="doi">
       10.1093/ofid/ofaa105
      </article-id>
      <article-id pub-id-type="publisher-id">
       ofaa105
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review Article
        </subject>
       </subj-group>
       <subj-group subj-group-type="category-taxonomy-collection">
        <subject>
         AcademicSubjects/MED00290
        </subject>
       </subj-group>
       <subj-group subj-group-type="category-oup-series">
        <subject>
         Editor's Choice
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <contrib-id authenticated="false" contrib-id-type="orcid">
         http://orcid.org/0000-0001-6705-2225
        </contrib-id>
        <name>
         <surname>
          McCreary
         </surname>
         <given-names>
          Erin K
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0001">
         1
        </xref>
        <xref ref-type="author-notes" rid="fn-0001">
        </xref>
        <xref ref-type="corresp" rid="c1">
        </xref>
        <!--<email>mccrearye3@upmc.edu</email>-->
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Pogue
         </surname>
         <given-names>
          Jason M
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
        <xref ref-type="author-notes" rid="fn-0001">
        </xref>
       </contrib>
       <on-behalf-of>
        on behalf of the Society of Infectious Diseases Pharmacists
       </on-behalf-of>
      </contrib-group>
      <aff id="AF0001">
       <label>
        1
       </label>
       <institution>
        Department of Pharmacy, University of Pittsburgh Medical Center
       </institution>
       , Pittsburgh, Pennsylvania,
       <country country="US">
        USA
       </country>
      </aff>
      <aff id="AF0002">
       <label>
        2
       </label>
       <institution>
        Department of Clinical Pharmacy, University of Michigan College of Pharmacy
       </institution>
       , Ann Arbor, Michigan,
       <country country="US">
        USA
       </country>
      </aff>
      <author-notes>
       <corresp id="c1">
        Correspondence: Erin Kristin McCreary, PharmD, BCPS, BCIDP, Department of Pharmacy, UPMC Presbyterian, 200 Lothrop Street, Pittsburgh, PA 15213 (
        <email>
         mccrearye3@upmc.edu
        </email>
        ).
       </corresp>
       <fn id="fn-0001">
        <p>
         E. K. M. and J. M. P. contributed equally to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="collection">
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date iso-8601-date="2020-03-23" pub-type="epub">
       <day>
        23
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        23
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>
       7
      </volume>
      <issue>
       4
      </issue>
      <elocation-id>
       ofaa105
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         18
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="editorial-decision">
        <day>
         20
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         23
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="corrected-typeset">
        <day>
         09
        </day>
        <month>
         4
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
         This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
          http://creativecommons.org/licenses/by-nc-nd/4.0/
         </ext-link>
         ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
        </license-p>
       </license>
      </permissions>
      <self-uri xlink:href="ofaa105.pdf">
      </self-uri>
      <abstract>
       <title>
        Abstract
       </title>
       <p>
        Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization).
       </p>
       <p>
        On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation.
       </p>
       <p>
        Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness.
       </p>
       <p>
        We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.
       </p>
      </abstract>
      <abstract abstract-type="teaser">
       <p>
        In-progress (collecting post-transmittal)
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        lopinavir/ritonavir
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        hydroxychloroquine
       </kwd>
       <kwd>
        remdesivir
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
      </kwd-group>
      <counts>
       <page-count count="11">
       </page-count>
      </counts>
     </article-meta>
    </front>
    <p>
     In December 2019, several patients in Wuhan, Hubei, China were diagnosed with pneumonia secondary to an unknown virus. In response, an epidemiological alert was placed with the World Health Organization (WHO) dated December 31, 2019. By January 7, 2020 Chinese scientists had isolated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [
     <xref ref-type="bibr" rid="CIT0001">
      1
     </xref>
     ]. In the months that followed, SARS-CoV-2, the cause of coronavirus disease 2019 (COVID-19), spread across the globe resulting in the current pandemic. At the time of this review, COVID-19 has been diagnosed in more than 245 000 patients and associated with over 10 000 deaths (Centers for Disease Control and Prevention [CDC], WHO).
    </p>
    <p>
     On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 19, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges approximately every hour regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Most existing preclinical and clinical data on antiviral therapy are derived from other viruses, including SARS-CoV-1 (first reported in 2003), Middle East respiratory syndrome coronavirus ([MERS-CoV] first reported in 2012), and non-coronaviruses (eg, Ebola virus disease). It is unclear how well these data can be extrapolated to SARS-CoV-2. Furthermore, the clinical relevance of antiviral in vitro activity (defined as half-maximal effective concentration [EC
     <sub>
      50
     </sub>
     ] values) remains unclear given an absence of pharmacokinetic/pharmacodynamic or clinical data that equates achievable exposures relative to these values to a treatment effect. Finally, in vitro data should be compared cautiously across studies given the potential variability in testing methodologies that could impact perceived activity.
    </p>
    <p>
     Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness [
     <xref ref-type="bibr" rid="CIT0002">
      2
     </xref>
     ]. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community, preferentially evaluating these agents in the context of randomized, controlled trials.
    </p>
    <sec id="s1">
     <title>
      PHARMACOLOGICAL TREATMENTS WITH POTENTIAL CLINICAL BENEFIT
     </title>
     <sec id="s2">
      <title>
       Remdesivir
      </title>
      <p>
       Remdesivir (GS-5734) is an investigational monophosphoramidate prodrug of an adenosine analog that was developed by Gilead Sciences, Inc. in response to the Ebola outbreak in West Africa from 2014 to 2016. In its active triphosphate nucleoside form, remdesivir binds to ribonucleic acid (RNA)-dependent RNA polymerase and acts as an RNA-chain terminator. It displays potent in vitro activity against SARS-CoV-2 with an EC
       <sub>
        50
       </sub>
       at 48 hours of 0.77 µM in Vero E6 cells [
       <xref ref-type="bibr" rid="CIT0003">
        3
       </xref>
       ]. Similar activity has been demonstrated against other zoonotic coronaviruses with EC
       <sub>
        50
       </sub>
       values of 0.07 µM demonstrated for both SARS-CoV-1 and MERS-CoV [
       <xref ref-type="bibr" rid="CIT0003">
        3–6
       </xref>
       ]. Remdesivir is highly selective for viral polymerases and is therefore expected to have a low propensity to cause human toxicity. Accordingly, Sheahan et al [
       <xref ref-type="bibr" rid="CIT0006">
        6
       </xref>
       ] demonstrated a wide therapeutic index for remdesivir in a human airway epithelial cell model. The drug also displays a high genetic barrier to resistance in coronaviruses and has a long intracellular half-life that allows for once-daily dosing [
       <xref ref-type="bibr" rid="CIT0007">
        7
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0008">
        8
       </xref>
       ]. The dose under investigation for treatment of COVID-19 is 200 mg intravenously (IV) on day 1 followed by 100 mg IV daily for up to 10 days, infused over 30–60 minutes (
       <xref ref-type="table" rid="T1">
        Table 1
       </xref>
       ).
      </p>
      <table-wrap id="T1" orientation="portrait" position="float">
       <label>
        Table 1.
       </label>
       <caption>
        <p>
         Summary of Remdesivir Clinical Trials Currently Enrolling Patients in the United States as of March 18th
        </p>
       </caption>
       <table frame="vsides" rules="groups">
        <thead>
         <tr>
          <th colspan="1" rowspan="1">
           Identifier
          </th>
          <th colspan="1" rowspan="1">
           Population, Design
          </th>
          <th colspan="1" rowspan="1">
           Inclusion/Exclusion
          </th>
          <th colspan="1" rowspan="1">
           Primary Outcome
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td colspan="1" rowspan="1">
           NCT04302766
          </td>
          <td colspan="1" rowspan="1">
           Expanded access protocol for Department of Defense-affiliated personnel with COVID-19 diagnosis
          </td>
          <td colspan="1" rowspan="1">
           Not available
          </td>
          <td colspan="1" rowspan="1">
           Not available
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           NCT04292899
          </td>
          <td colspan="1" rowspan="1">
           Phase 3, randomized trial of 5 versus 10 days of remdesivir for treatment of severe COVID-19 Target enrollment: 400 participants
          </td>
          <td colspan="1" rowspan="1">
           Inclusion: Adults, PCR positive ≤4 days before randomization (severe disease), oral temperature ≥37.2°C, SpO
           <sub>
            2
           </sub>
           ≤94% on room air, radiographic evidence of pulmonary infiltrates Exclusion: Receipt of concurrent antiviral &lt;24 hours before study drug initiation
           <sup>
            a
           </sup>
           , multiorgan failure, mechanical ventilator support at screening, creatine clearance &lt;50 mL/min, ALT or AST 5 × ULN
          </td>
          <td colspan="1" rowspan="1">
           Proportion of patients with normalization of fever and oxygen saturation through day 14
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           NCT04292730
          </td>
          <td colspan="1" rowspan="1">
           Phase 3, randomized trial of remdesivir for 5 or 10 days compared with standard of care for treatment of moderate COVID-19 Target enrollment: 600 participants
          </td>
          <td colspan="1" rowspan="1">
           Same as NCT04292899 except this study is for patients with moderate disease
          </td>
          <td colspan="1" rowspan="1">
           Proportion of patients discharged by day 14
          </td>
         </tr>
         <tr>
          <td colspan="1" rowspan="1">
           NCT04280705
          </td>
          <td colspan="1" rowspan="1">
           Adaptive, randomized, placebo-controlled trial of 394 patients at 50 sites globally for up to 10 days (all sites have been recruited)
          </td>
          <td colspan="1" rowspan="1">
           Inclusion: Adult (must agree to use contraception if of childbearing age for study duration), PCR positive &lt;72 hours before randomization, illness of any duration and at least one of the following: radiographic infiltrates by imaging, clinical assessment, and SpO
           <sub>
            2
           </sub>
           ≤94% on room air, requiring mechanical ventilation and/or supplemental oxygen Exclusion: ALT or AST 5 × ULN, eGFR &lt;30 mL/min, pregnancy or breast feeding, anticipated transfer to nonstudy site within 72 hours, allergy to study medication
          </td>
          <td colspan="1" rowspan="1">
           Percentage of subjects reporting each severity rating by day 15 (death, hospitalized/ventilated or ECMO, hospitalized/HFNC, hospitalized/on O
           <sub>
            2
           </sub>
           , hospitalized/not on O
           <sub>
            2
           </sub>
           , not hospitalized/limited activity, not hospitalized/no limitations)
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="fn-0100">
         <p>
          Abbreviations: ALT, alanine aminotransferase; AST, aspartate transaminase; °C, degrees Celsius; COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomerular filtration rate; HFNC, high flow nasal cannula; O
          <sub>
           2
          </sub>
          , oxygen; PCR, polymerase chain reaction; SpO
          <sub>
           2
          </sub>
          , peripheral capillary oxygen saturation; ULN, upper limit of normal.
         </p>
        </fn>
        <fn id="fn-0101">
         <p>
          <sup>
           a
          </sup>
          It is currently unclear what this means with regards to repurposed drugs; however, study protocols use lopinavir/ritonavir as an example of “antiviral therapy”.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <p>
       The therapeutic efficacy of remdesivir was first described in an animal model against Ebola among infected rhesus monkeys in which once-daily dosing resulted in suppression of viral replication and protection from lethal disease [
       <xref ref-type="bibr" rid="CIT0009">
        9
       </xref>
       ]. However, in a human study, remdesivir-treated patients with Ebola experienced a 28-day mortality rate of 53% in a randomized controlled trial of 4 experimental therapies conducted in response to the Democratic Republic of Congo outbreak of 2018, resulting in early termination of this study arm [
       <xref ref-type="bibr" rid="CIT0010">
        10
       </xref>
       ]. It is worth noting that this trial did not have an active control arm, and mortality rates for the other experimental treatments were 49.7% (ZMapp), 35.1% (Mab114), and 33.5% (REGN-EB3). Against MERS-CoV, Sheahan et al [
       <xref ref-type="bibr" rid="CIT0005">
        5
       </xref>
       ] evaluated the therapeutic efficacy of remdesivir among infected mice and found treatment significantly reduced virus lung titers, weight loss, lung hemorrhage, and lung injury scores. The authors proposed the importance of early therapy initiation to diminish virus replication and promote pulmonary repair because remdesivir demonstrated less clinical benefit with high-titer virus inoculum. Most notably, the authors also noted that prophylactic remdesivir diminished MERS-CoV replication and disease, which was similar to their findings in a murine model with SARS-CoV-1 [
       <xref ref-type="bibr" rid="CIT0005">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0006">
        6
       </xref>
       ].
      </p>
      <p>
       The first report of a remdesivir-treated patient with COVID-19 in the United States was a 35-year-old male in Snohomish County, Washington who received treatment on hospital day 7 (illness day 11) due to developing pneumonia and persistent fevers [
       <xref ref-type="bibr" rid="CIT0011">
        11
       </xref>
       ]. The patient experienced clinical improvement and negativity of oropharyngeal swab on hospital day 8, although nasopharyngeal swab remained positive. No adverse events to remdesivir were reported for the patient, which is consistent with previous case reports of use in other viruses [
       <xref ref-type="bibr" rid="CIT0012">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0013">
        13
       </xref>
       ]. Among the first 12 patients confirmed by the CDC to have COVID-19 in the United States, 3 were treated with remdesivir via compassionate use protocol [
       <xref ref-type="bibr" rid="CIT0014">
        14
       </xref>
       ]. All patients reported transient gastrointestinal symptoms and aminotransferase elevation. All patients are reportedly recovering, but the authors were unable to assess the efficacy or safety of remdesivir based on the lack of comparator and confounding treatments, including concomitant use of corticosteroids in one patient.
      </p>
      <p>
       There are 4 clinical trials currently enrolling patients in the United States (
       <xref ref-type="table" rid="T1">
        Table 1
       </xref>
       ). Two additional trials recruiting only in China have been registered on ClinicalTrials.gov NCT04257656 (severe disease) and NCT04252664 (mild/moderate disease). Remdesivir may also be obtained through compassionate use and the emergency Investigational New Drug (eIND) application process. At the time of this review, requests for compassionate use must be submitted online via
       <ext-link ext-link-type="uri" xlink:href="https://rdvcu.gilead.com/">
        https://rdvcu.gilead.com/
       </ext-link>
       . Compassionate use is only considered for hospitalized patients with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 requiring mechanical ventilation in whom enrollment in a clinical trial is not feasible. Patients are excluded from the compassionate use program if they do not meet the above criteria, have evidence of multiorgan failure, are receiving vasopressors for hypotension, have liver disease defined as alanine aminotransferase (ALT) &gt;5 × upper limit of normal (ULN) or renal impairment defined as
       <italic>
        creatinine clearance (
       </italic>
       CrCl) &lt;30 mL/min, or receiving dialysis or continuous venovenous hemofiltration. Inclusion and exclusion criteria for compassionate use may change, so applicants are encouraged to review the most up to date criteria for all potential patients. Clinicians should be cognizant that it typically takes a minimum of 72 hours for institutions to receive emergency institutional review board authorization (if required), protocol, and consent forms from Gilead, US Food and Drug Administration (FDA)-approval for the eIND, and eventual drug shipment. Clinicians should coordinate with their local information technology teams to build a medication order sentence into the electronic health record during this time. Patients may receive other antiviral therapies during the waiting period but must immediately discontinue them if they receive remdesivir for compassionate use.
      </p>
      <p>
       It is interesting to note that the adaptive clinical trial protocol originally stated “remdesivir is a prodrug that is metabolized to its active form as a substrate of CYP-3A4”. This implies the existence of a drug-drug interaction with CYP3A4 substrate inhibitors such as ritonavir or voriconazole. However, the protocol also stated “although remdesivir is a substrate for CYP2C8, CYP2D6, and CYP3A4 in vitro, coadministration with inhibitors of these CYP isoforms is unlikely to markedly increase remdesivir levels, as its metabolism is likely to be predominantly mediated by hydrolase activity.” Unlike the former, the latter statement is substantiated by well described chemistry of the molecule. The National Institute of Allergy and Infectious Diseases was contacted about this discrepancy and in collaboration with Gilead, this has been corrected. There is no reason to believe that any significant drug interactions between remdesivir and CYP3A4 inhibitors or inducers are likely [
       <xref ref-type="bibr" rid="CIT0008">
        8
       </xref>
       ].
      </p>
      <p>
       Emerging clinical evidence and available in vitro data suggest remdesivir is a promising agent for the treatment of COVID-19. Institutions should explore clinical trial enrollment or compassionate use remdesivir for moderate-to-severe patients. Additional clinical data are eagerly anticipated and should help further define the role of this agent in COVID-19.
      </p>
     </sec>
     <sec id="s3">
      <title>
       Chloroquine and Hydroxychloroquine
      </title>
      <p>
       Chloroquine, an antimalarial agent with anti-inflammatory and immunomodulatory activities, has gained significant interest as a potential therapeutic option for the management of COVID-19. In early February, Wang et al [
       <xref ref-type="bibr" rid="CIT0003">
        3
       </xref>
       ] demonstrated potent in vitro activity of chloroquine against SARS-CoV-2 with an EC
       <sub>
        50
       </sub>
       at 48 hours of 1.13 µM in Vero E6 cells. These data were consistent with previous data for chloroquine’s inhibitory activity against SARS-CoV-1 and MERS-CoV in various cell lines, where EC
       <sub>
        50
       </sub>
       values of 1–8.8 and 3.0 µM were demonstrated, respectively [
       <xref ref-type="bibr" rid="CIT0015">
        15
       </xref>
       ]. These findings have supported the clinical use of chloroquine, at a dose of 500 mg by mouth twice daily, in numerous clinical trials in China during this outbreak. Although the rationale for this dosing regimen remains unclear, and peer reviewed data from the trials are currently unavailable, it was announced in mid-February that promising early results have been demonstrated. Per Gao et al [
       <xref ref-type="bibr" rid="CIT0016">
        16
       </xref>
       ], “thus far, results from more than 100 patients have demonstrated that chloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course according to the news briefing. Severe adverse reactions to chloroquine phosphate were not noted in the aforementioned patients.”
      </p>
      <p>
       Although this development has been encouraging, supply issues in the United States and cardiovascular toxicity concerns limit the use of chloroquine. As an alternative, hydroxychloroquine, a compound that differs from chloroquine only by a single hydroxyl group, has garnered interest. Hydroxychloroquine is perceived as having better tolerability than chloroquine, which has led to long-term usage in rheumatological disorders. Historically, very limited data were published assessing the activity of hydroxychloroquine against coronaviruses. In 2006, Biot et al [
       <xref ref-type="bibr" rid="CIT0017">
        17
       </xref>
       ] assessed the comparative inhibitory activity of chloroquine and hydroxychloroquine against SARS-CoV-1 in Vero cells. The authors demonstrated that chloroquine had an approximately 5-fold increased potency (EC
       <sub>
        50
       </sub>
       of 6.5 ± 3.2 µM) compared with that of hydroxychloroquine (EC
       <sub>
        50
       </sub>
       of 34 ± 5 µM).
      </p>
      <p>
       Against SARS-CoV-2, Yao et al [
       <xref ref-type="bibr" rid="CIT0018">
        18
       </xref>
       ] performed a 2-part study assessing the comparative in vitro activity of chloroquine and hydroxychloroquine and performed pharmacology-based pharmacokinetic (PBPK) modeling to assess comparative exposure and predicted activity of these 2 compounds in the lung. In vitro analyses in Vero cells demonstrated that the potency of hydroxychloroquine (EC
       <sub>
        50
       </sub>
       of 0.72 µM) was greater than that of chloroquine (EC
       <sub>
        50
       </sub>
       of 5.47 µM) against SARS-CoV-2 [
       <xref ref-type="bibr" rid="CIT0018">
        18
       </xref>
       ].
      </p>
      <p>
       To inform optimal dosing of hydroxychloroquine, the investigators then performed PBPK modeling. In this analysis, the investigators utilized human population pharmacokinetic and rat lung penetration data for each compound to estimate free trough concentrations in the lung to EC
       <sub>
        50
       </sub>
       ratios (R
       <sub>
        LTEC
       </sub>
       ) [
       <xref ref-type="bibr" rid="CIT0018">
        18
       </xref>
       ]. Because 500 mg of chloroquine by mouth twice daily has been reported to demonstrate efficacy against SARS-CoV-2, the target R
       <sub>
        LTEC
       </sub>
       for hydroxychloroquine regimens was set to ≥2.38 (day 1), 5.92 (day 3), and 18.9 (day 5), which were the R
       <sub>
        LTEC
       </sub>
       values predicted with the “efficacious” 500 mg by mouth twice-daily dosing of chloroquine [
       <xref ref-type="bibr" rid="CIT0016">
        16
       </xref>
       ]. Various dosing regimens were simulated, but 2 are particularly notable. The first was an oral loading dose of 1200 mg (divided 800 mg then 400 mg) on day 1, followed by 400 mg daily. This regimen led to significantly higher R
       <sub>
        LTEC
       </sub>
       on day 1 (33.3), day 3 (55.1), and day 5 (103) than those values demonstrated with chloroquine. The second regimen was a loading dose of 800 mg (400 mg × 2) on day 1 followed by 200 mg twice daily. This was also associated with higher R
       <sub>
        LTEC
       </sub>
       values than chloroquine on day 1, 3, and 5 (corresponding to 21.0, 38.9, and 85.4, respectively) [
       <xref ref-type="bibr" rid="CIT0018">
        18
       </xref>
       ]. The authors concluded that these data support the lower dose regimen because R
       <sub>
        LTEC
       </sub>
       values were significantly higher than those with the “proven efficacious” regimen of 500 mg of chloroquine by mouth twice daily. Clinicians should note that both chloroquine and hydroxychloroquine have half-lives of ~40 days [
       <xref ref-type="bibr" rid="CIT0019">
        19
       </xref>
       ], and therefore short durations would likely provide prolonged courses of therapy. This was exemplified in the PBPK modeling in which R
       <sub>
        LTEC
       </sub>
       values with hydroxychloroquine were predicted to still be above the targeted efficacy threshold on day 10, even with a 5-day course of therapy.
      </p>
      <p>
       Although these data are encouraging for the potential role of hydroxychloroquine against SARS-CoV-2, we caution against solely relying on these data to support dosing regimens for patients. The use of 500 mg of chloroquine by mouth twice daily as the reference for efficacy is rational given initial reports from China [
       <xref ref-type="bibr" rid="CIT0016">
        16
       </xref>
       ], but it is important to note that this dosing still requires validation, and the improved R
       <sub>
        LTEC
       </sub>
       values reported are largely driven by the finding that hydroxychloroquine was 7.6 times more potent than chloroquine in vitro. Although this enhanced potency may very well prove true as more data become available, this report is counter to the relative potency demonstrated with the structurally similar SARS-CoV-1 strain in 2006 in which chloroquine was approximately 5 times more potent than hydroxychloroquine. In addition, a recently published study has demonstrated that the EC
       <sub>
        50
       </sub>
       value for chloroquine is 1.13 µM [
       <xref ref-type="bibr" rid="CIT0003">
        3
       </xref>
       ], similar to the value reported for hydroxychloroquine in the analysis by Yao et al [
       <xref ref-type="bibr" rid="CIT0018">
        18
       </xref>
       ].
      </p>
      <p>
       Because there are currently no efficacy data available for hydroxychloroquine in COVID-19, additional consideration should be given to the optimal dosing strategy. We use the following example to illustrate this point. If one were to consider these 2 compounds to be equally potent (identical EC
       <sub>
        50
       </sub>
       values) and utilize the PBPK data from Yao et al [
       <xref ref-type="bibr" rid="CIT0018">
        18
       </xref>
       ], the 800 mg load, 400 mg daily regimen for hydroxychloroquine would yield R
       <sub>
        LTEC
       </sub>
       values of 2.76, 5.11, and 11.2 on day 1, 3, and 5, respectively. These R
       <sub>
        LTEC
       </sub>
       values would be slightly lower than those achieved with 500 mg by mouth twice daily of chloroquine on day 3 and significantly lower than those on day 5, suggesting the potential need for a higher dose to have similar activity. Although the 400 mg daily regimen is the most common regimen currently being assessed in clinical trials, the rationale for that dose is currently unclear, and at least 1 clinical trial in China is using a higher dose of 800 mg by mouth daily.
      </p>
      <p>
       To this point, Gautret et al [
       <xref ref-type="bibr" rid="CIT0020">
        20
       </xref>
       ] recently published their initial experience on the impact of 200 mg of hydroxychloroquine by mouth every 8 hours on viral eradication in patients with COVID-19. The authors reported on 36 patients (20 hydroxychloroquine and 16 control) who were COVID-19 positive and able to have nasopharyngeal sampling for the first 6 days of therapy (in the treated arm). The investigators demonstrated that hydroxychloroquine (14 of 20, 70%) was superior to standard of care (2 of 16, 12.5%;
       <italic>
        P
       </italic>
       = .001) in eradicating SARS-CoV-2 from the nasopharynx. It is interesting to note that 6 patients were prescribed azithromycin “to prevent bacterial super-infection” and the investigators found that viral eradication was numerically superior in this subgroup (6 of 6, 100%) compared with those who received hydroxychloroquine alone (8 of 14, 57%). The authors concluded that azithromycin “reinforced” the SARS-CoV-2 viral load achieved by hydroxychloroquine. Although these data are intriguing, certain limitations to this data set must be acknowledged. First, although viral eradication is an important endpoint, the authors did not report clinical outcomes in these patients. Second, the cohort initially contained 26 hydroxychloroquine patients, but 6 of them were removed from the analysis due to early cessation of hydroxychloroquine therapy including 3 PCR-positive patients who were transferred to the intensive care unit (ICU), 1 PCR-negative patient who passed away, and 1 PCR-positive patient who discontinued hydroxychloroquine due to nausea. Finally, the hydroxychloroquine monotherapy arm included patients with significantly higher viral loads, represented by lower cycle threshold (C
       <sub>
        T
       </sub>
       ) values than those who received combination therapy. If the hydroxychloroquine monotherapy patients with C
       <sub>
        T
       </sub>
       values &lt;23 are separated from those with C
       <sub>
        T
       </sub>
       values ≥23, there is a notable discordance in viral eradication rates (1 of 5, 20% vs 7 of 9, 78%), with this latter number approaching the 6 of 6 demonstrated with hydroxychloroquine and azithromycin combination therapy in which all patients had C
       <sub>
        T
       </sub>
       values ≥23. Given this finding, the small numbers in this study, the lack of clinical outcomes presented, the potential for additive toxicity with hydroxychloroquine and azithromycin, and the desperate need to practice good antimicrobial stewardship during the COVID-19 pandemic, we would caution clinicians against using these data to support combination therapy.
      </p>
      <p>
       Despite all of the unknowns, the initial experience in China is encouraging for the potential role of chloroquine, or alternatively hydroxychloroquine, for the management of COVID-19. Clinicians are encouraged to closely follow subsequent peer-reviewed publications from the ongoing chloroquine and hydroxychloroquine trials, because others have raised concerns regarding the apparent in vitro and/or in vivo discordance witnessed with chloroquine in other viral infections [
       <xref ref-type="bibr" rid="CIT0021">
        21
       </xref>
       ]. Furthermore, if hydroxychloroquine is utilized, careful consideration for dose selection should be given in accordance with the aforementioned data, as well as considerations for when to initiate during the course of illness.
      </p>
     </sec>
     <sec id="s4">
      <title>
       Lopinavir/Ritonavir
      </title>
      <p>
       Lopinavir is a human immunodeficiency virus (HIV)-1 protease inhibitor administered in fixed-dose combination with ritonavir (LPV/r), a potent CYP3A4 inhibitor that “boosts” lopinavir concentrations. Lopinavir seems to block the main protease of SARS-CoV-1, inhibiting viral replication [
       <xref ref-type="bibr" rid="CIT0022">
        22
       </xref>
       ]. In 2003, Chu et al [
       <xref ref-type="bibr" rid="CIT0023">
        23
       </xref>
       ] evaluated a series of antivirals for in vitro activity against SARS-CoV-1. They reported lopinavir at 4 µg/mL and ribavirin at 50 µg/mL inhibited SARS-CoV-1 after 48 hours of incubation and that the agents were synergistic when used together [
       <xref ref-type="bibr" rid="CIT0023">
        23
       </xref>
       ]. de Wilde et al [
       <xref ref-type="bibr" rid="CIT0024">
        24
       </xref>
       ] later described the antiviral activity of lopinavir against SARS-CoV-1 and demonstrated an EC
       <sub>
        50
       </sub>
       17.1 ± 1 in Vero E6 cells, which is near the upper range of LPV plasma concentrations previously measured in patients with HIV [
       <xref ref-type="bibr" rid="CIT0025">
        25
       </xref>
       ]. Sheahan et al [
       <xref ref-type="bibr" rid="CIT0005">
        5
       </xref>
       ] evaluated the in vitro efficacy of LPV/r in combination with interferon beta (INFb) against MERS-CoV and found the addition of LPV/r did not significantly enhance antiviral activity of INFb alone (EC
       <sub>
        50
       </sub>
       = 160 vs 175 IU/mL, respectively). They also described the EC
       <sub>
        50
       </sub>
       of LPV/r (8.5 µM) and LPV alone (11.6 µM), suggesting similar activity to that described for SARS CoV-1. Despite in vitro activity against MERS-CoV, therapeutic doses of LPV/r + INFb in mice models failed to reduce virus titer and exacerbated lung disease [
       <xref ref-type="bibr" rid="CIT0005">
        5
       </xref>
       ]. This is notable because this was the same study in which remdesivir demonstrated both more potent in vitro activity as well as in vivo efficacy. However, the in vivo animal data for MERS-CoV appears equivocal given that a nonhuman primate model demonstrated improved clinical and pathological features after LPV/r treatment [
       <xref ref-type="bibr" rid="CIT0026">
        26
       </xref>
       ]. A randomized controlled trial of LPV/r and recombinant interferon-β1b versus placebo is currently enrolling for patients with MERS-CoV, which might help clarify the apparent discrepancy between in vitro and animal models [
       <xref ref-type="bibr" rid="CIT0027">
        27
       </xref>
       ].
      </p>
      <p>
       Based on in vitro findings, Chu et al [
       <xref ref-type="bibr" rid="CIT0023">
        23
       </xref>
       ] utilized combination therapy with LPV/r, ribavirin, and corticosteroids for any newly diagnosed patient with SARS-CoV-1 without acute respiratory distress syndrome (ARDS) starting in April 2003. Patients receiving LPV/r combination therapy (N = 41) were matched to historical patients receiving ribavirin plus corticosteroids (N = 111), and a significant reduction in the development of ARDS or death at 21 days was observed (2.4% vs 28.8%,
       <italic>
        P
       </italic>
       &lt; .001). This was corroborated by an expanded case-control matched study of 75 LPV/r-treated patients from the same center that demonstrated a significant reduction in pulse steroid use (27.3% vs 55.4%), intubation (0% vs 11%), and mortality (2.3% vs 15.6%) among patients who received LPV/r combination versus no LPV/r, respectively, as initial therapy [
       <xref ref-type="bibr" rid="CIT0028">
        28
       </xref>
       ]. More important, the benefits of LPV/r were only demonstrated in patients who received initial treatment with LPV/r (defined as initiation of drug at time of SARS-CoV-1 diagnosis). There was no observed benefit when LPV/r was added as rescue or salvage therapy (death rate 12.9% vs 14%).
      </p>
      <p>
       This compelling mortality difference in SARS-CoV-1 and continued investigation in MERS-CoV led to inclusion of LPV/r in the Chinese SARS-CoV-2 guidelines at a dose of 400 mg/100 mg (2 capsules/tablets) by mouth twice a day for no more than 10 days even though to our knowledge, no in vitro data for LPV/r in SARS-CoV-2 exist [
       <xref ref-type="bibr" rid="CIT0029">
        29
       </xref>
       ]. In pediatric patients weighing 15–40 kg, the recommended dose in the United States is 10 mg/kg suspension by mouth twice daily. There are 10 ongoing registered clinical trials in China, Korea, Thailand, and Hong Kong evaluating LPV/r as monotherapy or in combination with other antivirals (eg, ribavirin, interferon beta-1b) or traditional Chinese medicine for treatment of COVID-19.
      </p>
      <p>
       Real-world data for treatment of COVID-19 with LPV/r are emerging. Young et al [
       <xref ref-type="bibr" rid="CIT0030">
        30
       </xref>
       ] reported outcomes of the first 18 patients infected with SARS-CoV-2 in Singapore, 5 of whom received LPV/r monotherapy. Three patients had reduction in oxygen requirements after treatment initiation; 2 deteriorated to respiratory failure. Two of 5 patients (40%) experienced clearance of viral shedding on treatment, and 4 of 5 (80%) experienced adverse events that precluded completion of the planned 14-day treatment course. Other published case reports or case series from Korea and China comprising 6 total patients describe decreased viral load and clinical improvement after LPV/r initiation. These data are difficult to interpret in light of concomitant drug therapies, varied time points of therapy initiation, heterogeneous severity of illness amongst patients, and the lack of comparator treatments [
       <xref ref-type="bibr" rid="CIT0031">
        31–33
       </xref>
       ]. Finally, early reports from Wuhan have described some patients receiving LPV/r in addition to other therapies (including corticosteroids), but clinical outcomes and adverse events are either not described or not delineated by treatment group [
       <xref ref-type="bibr" rid="CIT0034">
        34–36
       </xref>
       ].
      </p>
      <p>
       Most recently, Cao [
       <xref ref-type="bibr" rid="CIT0037">
        37
       </xref>
       ] et al reported the results of an open-label randomized trial comparing LPV/r 400/100 mg twice daily (n = 99) to standard care (n = 100) for the treatment of COVID-19 pneumonia. The primary endpoint was defined as the time from randomization to an improvement of 2 points on a 7-category ordinal scale or discharge from the hospital. Secondary outcomes included 28-day mortality, time until discharge, and virologic response on repeat oropharyngeal swabs over the course of the study. The median time from symptom onset to randomization was 13 (interquartile range [IQR], 11–16) days, and this did not differ between the groups. There was no significant difference in time to clinical improvement (16 [IQR, 13–17] days vs 16 [IQR, 15–17] days), time from randomization until discharge (12 [IQR, 10–16] days vs 14 [IQR, 11–16] days), or mortality (19.2 % vs 25.0%; absolute difference, −5.8; 95% confidence interval [CI], −17.3% to 5.7%) between patients receiving LPV/r and standard care. When the 3 patients who died after randomization but before receiving LPV/r were removed, there remained no difference in mortality (16.7% vs 25.0%; absolute difference, −8.3 percentage points; 95% CI, −19.6 to 3.0). More important, there was no difference between treatment arms in reduction of viral loads over time between the 2 groups.
      </p>
      <p>
       With the available data, it is difficult to assess whether LPV/r has a role for the treatment of COVID-19 either as monotherapy or in combination. The data from SARS-CoV-1 are encouraging, but this must be weighed against the inferior performance in mouse models against MERS-CoV, the less potent in vitro activity compared with remdesivir and chloroquine for SARS-CoV-1, and limited data suggesting no advantage over standard care for SARS-CoV-2. More important, it warrants comment that in the recent randomized controlled trial in COVID-19 pneumonia, the median time from symptom onset to initiation of therapy was 13 days, and in the SARS-CoV-1 experience, therapy appeared effective if started early, but not as rescue and/or salvage. If used, drug interactions must be screened, and gastrointestinal toxicities, including diarrhea, nausea, and vomiting, and hepatotoxicity, require close monitoring, particularly because elevated aspartate transaminase or ALT may exclude patients with COVID-19 from clinical trials. The LPV/r tablets can be taken without regard to food but should not be crushed because this decreases systemic exposure; solution should be used in patients who cannot receive intact tablets [
       <xref ref-type="bibr" rid="CIT0038">
        38
       </xref>
       ].
      </p>
     </sec>
     <sec id="s5">
      <title>
       Nitazoxanide
      </title>
      <p>
       Nitazoxanide has demonstrated potent in vitro activity against SARS CoV-2, with an EC
       <sub>
        50
       </sub>
       at 48 hours of 2.12 µM in Vero E6 cells [
       <xref ref-type="bibr" rid="CIT0003">
        3
       </xref>
       ]. This potent activity is consistent with EC
       <sub>
        50
       </sub>
       values for nitazoxanide and its active metabolite, tizoxanide, against MERS-CoV in LLC-MK2 cells in which EC
       <sub>
        50
       </sub>
       values of 0.92 and 0.83 µM, respectively, have been demonstrated [
       <xref ref-type="bibr" rid="CIT0039">
        39
       </xref>
       ]. Nitazoxanide displays broad-spectrum in vitro antiviral activity against influenza, respiratory syncytial virus, parainfluenza, rotavirus, and norovirus among others in addition to coronaviruses [
       <xref ref-type="bibr" rid="CIT0039">
        39
       </xref>
       ]. This broad-spectrum antiviral activity is believed to be due to the fact that the mechanism of action is based on interference with host-regulated pathways involved in viral replication rather than virus-specific pathways [
       <xref ref-type="bibr" rid="CIT0039">
        39
       </xref>
       ].
      </p>
      <p>
       Due to its broad-spectrum antiviral activity, nitazoxanide is being investigated for the management of influenza and other acute respiratory infections. Positive results were demonstrated in a phase 2b/3 study for the outpatient management of influenza, in which a dose of 600 mg by mouth BID of nitazoxanide was associated with a ~1-day improvement in time to resolution of symptoms when compared with placebo (
       <italic>
        P
       </italic>
       = .008) [
       <xref ref-type="bibr" rid="CIT0040">
        40
       </xref>
       ]. Three phase 3 randomized controlled trials in uncomplicated influenza have since been completed (ClinicalTrials.gov Identifier NCT01610245 [March 2018], NCT02612922 [April 2018], and NCT03336619 [September 2019]), although results are unavailable. Nitazoxanide failed to reduce the duration of hospitalization or the time to symptom alleviation in a phase 2 randomized controlled trial in patients with severe acute respiratory illnesses requiring hospitalization, predominantly caused by respiratory viruses [
       <xref ref-type="bibr" rid="CIT0041">
        41
       </xref>
       ]. Although the in vitro activity of nitazoxanide against SARS-CoV-2 is encouraging, more data are clearly needed to determine its role in the management of COVID-19.
      </p>
     </sec>
    </sec>
    <sec id="s6">
     <title>
      ADJUNCTIVE PHARMACOLOGICAL TREATMENTS
     </title>
     <sec id="s7">
      <title>
       Tocilizumab
      </title>
      <p>
       Tocilizumab is a humanized monoclonal antibody that inhibits both membrane-bound and soluble interleukin-6 (IL-6) receptors. Interleukin-6, which is secreted by monocytes and macrophages, is one of the main drivers of immunologic response and symptoms in patients with cytokine-release syndrome (CRS). Although tocilizumab was first approved by the FDA in 2010 for the treatment of rheumatoid arthritis, it has gained traction in recent years for treatment of patients with CRS following chimeric antigen receptor T-cell (CAR T) therapy as a corticosteroid-sparing agent [
       <xref ref-type="bibr" rid="CIT0042">
        42
       </xref>
       ]. Indeed, it received FDA approval for severe or life-threatening CAR T-associated CRS in 2017 due to its efficacy and safety profile. Although criteria for grading CRS severity varies by cancer center, it has been proposed to administer tocilizumab to CRS patients with any of the following: oxygen requirement &lt;40%, hypotension responsive to fluids or a low dose of a single vasoactive agent, or Grade 2 organ toxicity as defined by the Common Terminology Criteria for Adverse Events [
       <xref ref-type="bibr" rid="CIT0043">
        43
       </xref>
       ]. Interleukin-6 antagonism may make a patient more susceptible to bacterial infection and has been associated with neutropenia and thrombocytopenia in patients receiving chronic therapy with tocilizumab for giant cell arteritis or rheumatoid arthritis. In a case series of 53 adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, Grade 3 CRS or higher was associated with increased risk of subsequent infection, but it was unclear whether tocilizumab or corticosteroid use promoted this risk [
       <xref ref-type="bibr" rid="CIT0044">
        44
       </xref>
       ]. There were no reported adverse events in the 60 tocilizumab-treated patients submitted to the FDA for the CRS indication, which recommends a maximum of 4 doses for treatment [
       <xref ref-type="bibr" rid="CIT0045">
        45
       </xref>
       ].
      </p>
      <p>
       Hyperinflammatory states and cytokine storming, including elevated IL-6, has been reported in severe COVID-19 and were associated with increased mortality in patients in China [
       <xref ref-type="bibr" rid="CIT0036">
        36
       </xref>
       ]. A preprint (nonpeer reviewed) case series of 21 patients treated with tocilizumab between February 5 and 14, 2020 in China reported marked success, including rapid resolution of fever and C-reactive protein, decreased oxygen requirements, and resolution of lung opacities on computerized tomography imaging [
       <xref ref-type="bibr" rid="CIT0046">
        46
       </xref>
       ]. The authors state the patients all had “routine treatment for a week” before tocilizumab, which was described as “standard care according to national treatment guidelines” including lopinavir, methylprednisolone, and other supportive care. All patients had IL-6 analyzed before tocilizumab administration with a mean value of 132.38 ± 278.54 pg/mL (normal &lt;7 pg/mL). It should be noted that in the United States, IL-6 monitoring is a send-out laboratory for most institutions with a turnaround time of 3–7 days. No adverse events were described in the Chinese cohort; however, long-term assessment was not done.
      </p>
      <p>
       Immunotherapy with tocilizumab is listed as a treatment option for severe or critical cases of COVID-19 with elevated IL-6 in the 7th edition of the National Health Commission of the People’s Republic of China COVID-19 Diagnosis and Treatment Guide [
       <xref ref-type="bibr" rid="CIT0029">
        29
       </xref>
       ]. The recommended dose is 4–8 mg/kg or 400 mg standard dose IV once, with the option to repeat a dose in 12 hours (not to exceed a total dose of 800 mg). There are 2 ongoing trials in China evaluating safety and efficacy of tocilizumab for patients with COVID-19 pneumonia, but none registered in the United States.
      </p>
      <p>
       We anticipate that more data regarding tocilizumab use in patients with COVID-19 will emerge, and it will be imperative for clinicians to evaluate it closely. The optimal timing of tocilizumab administration during the disease course is not yet defined, nor is there a known IL-6 threshold for progression to severe disease. It is imperative to continue to follow the long-term outcomes in these patients to assess the risk versus benefit of tocilizumab.
      </p>
     </sec>
     <sec id="s8">
      <title>
       Corticosteroids
      </title>
      <p>
       Similar to other severe respiratory tract infections, there is significant interest and controversy surrounding the role of corticosteroids for the management of severe pneumonia due to coronaviruses. The potential benefit of these agents to blunt the inflammatory cascade seen in severe disease needs to be carefully weighed against the concerns for secondary infections, adverse events, and other complications of corticosteroid therapy. The data assessing the role of corticosteroids as adjunctive care for severe coronavirus (SARS-CoV-1, MERS-CoV, and SARS-CoV-2) pneumonia are difficult to interpret. Given the retrospective observational nature of these analyses, there is significant confounding by indication that is difficult to control or correct for in addition to limited sample sizes. Patients who receive corticosteroids have a higher severity of illness, are more likely to require invasive interventions, and are more likely to be receiving intensive care. In addition, there is significant heterogeneity with regard to timing of corticosteroid initiation, which can significantly impact disease progression and likelihood of response. All of these features lead to patients who receive steroids being at increased risk for poor outcomes. In addition, there is great variation in agent and dosage used, which can impact both safety and efficacy. Therefore, clinicians making any therapeutic decisions based on the literature for corticosteroids need to keep these considerations in mind.
      </p>
      <p>
       The clinical data for use of corticosteroids in SARS-CoV-1 infections are mixed. Multiple analyses show no impact on outcomes [
       <xref ref-type="bibr" rid="CIT0047">
        47
       </xref>
       ], one report demonstrates decreased mortality in critically ill patients [
       <xref ref-type="bibr" rid="CIT0048">
        48
       </xref>
       ], and others have documented worse outcomes for patients receiving steroids, including increased time to viral clearance [
       <xref ref-type="bibr" rid="CIT0049">
        49
       </xref>
       ] or an increase in the composite endpoint of ICU admission or death [
       <xref ref-type="bibr" rid="CIT0050">
        50
       </xref>
       ]. In MERS-CoV, receipt of corticosteroids has been associated with a delayed time until viral clearance in a large cohort (n = 309) of infected patients [
       <xref ref-type="bibr" rid="CIT0051">
        51
       </xref>
       ]. However, this same data set showed a nonsignificant reduction in 90-day mortality in patients receiving corticosteroids (adjusted odds ratio = 0.75; 95% CI, 0.52–1.07) after accounting for differences between the groups in a regression model accounting for time-varying exposures. Finally, recent evidence in SARS-CoV-2 suggested a decrease in mortality in patients with ARDS with the receipt of corticosteroids (23 of 50 [46%] vs 21 of 34 [62%] without; hazard ratio, 0.38; 95% CI, 0.20–0.72) [
       <xref ref-type="bibr" rid="CIT0052">
        52
       </xref>
       ].
      </p>
      <p>
       As demonstrated, the data for corticosteroids are inconsistent, confusing, and inconclusive. Although target patients in whom corticosteroids will improve outcomes may exist (eg, those with cytokine-related lung injury who may develop rapidly progressive pneumonia), that population remains ill-defined [
       <xref ref-type="bibr" rid="CIT0053">
        53
       </xref>
       ]. Clinicians need to carefully weigh the risks and benefits of corticosteroids on the individual patient level. This need for a risk-benefit assessment in individual patients and careful consideration of dose is exemplified in the COVID-19 Diagnosis and Treatment Guide from the National Health Commission of the People’s Republic of China where the authors state, “Based on respiratory distress and chest imaging, may consider glucocorticoid that is equivalent to methylprednisolone 1–2 mg/kg/day for 3–5 days or less. Note that large-dose glucocorticoid suppresses immune system and could delay clearance of SARS-CoV-2.” [
       <xref ref-type="bibr" rid="CIT0029">
        29
       </xref>
       ] A recent consensus statement from the Chinese Thoracic Society recommends a lower dose, ≤0.5–1 mg/kg per day methylprednisolone for ≤7 days in select patients, after careful consideration of risks and benefits [
       <xref ref-type="bibr" rid="CIT0053">
        53
       </xref>
       ]. Randomized controlled trial data are urgently needed to clearly define the role of corticosteroids in COVID-19.
      </p>
     </sec>
    </sec>
    <sec id="s9">
     <title>
      PHARMACOLOGICAL TREATMENTS IN WHICH RISKS OUTWEIGH BENEFITS
     </title>
     <sec id="s10">
      <title>
       Ribavirin With or Without Interferon
      </title>
      <p>
       Ribavirin, a guanosine analog that terminates RNA synthesis, was first approved in the 1980s and has been used clinically for respiratory syncytial virus, viral hemorrhagic fever, and in combination with interferon for hepatitis C. As mentioned previously (see LPV/r section), it was evaluated against SARS-CoV-1 in 2003 and used clinically in combination with corticosteroids and/or interferon in the absence of other treatment options; however, outcomes were either poor or ill-defined [
       <xref ref-type="bibr" rid="CIT0054">
        54
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0055">
        55
       </xref>
       ]. The doses required for antiviral activity against SARS range from 1.2 to 2.4 grams by mouth every 8 hours, which are associated with excessive toxicity to patients [
       <xref ref-type="bibr" rid="CIT0056">
        56
       </xref>
       ]. Wang et al [
       <xref ref-type="bibr" rid="CIT0003">
        3
       </xref>
       ] evaluated the in vitro activity of ribavirin against SARS-CoV-2 and found an EC
       <sub>
        50
       </sub>
       of 109.5 µM, which was over 100 times less potent than remdesivir. The risk of hematologic toxicity at high doses likely outweighs potential clinical benefit, and therefore ribavirin was not considered a viable candidate for further investigation by the WHO research and development plan for SARS-CoV-2 given its lack of in vitro efficacy, toxicity profile, and poor outcomes.
      </p>
      <p>
       Interferons (α, β) may stimulate innate antiviral responses and are expected to have in vitro activity against SARS-CoV-2, given the previously described activity demonstrated against MERS-CoV (EC
       <sub>
        50
       </sub>
       175 IU/mL). However, toxicities are substantial including severe cytopenias, hepatotoxicity (including fatality), neuropsychiatric events, and risk of developing fatal or life-threatening ischemia or infection, particularly when combined with ribavirin. This combination was not associated with improved mortality or enhanced viral clearance in a retrospective analysis of patients infected with MERS-CoV who were initiated on combination therapy within 1–3 days of ICU admission [
       <xref ref-type="bibr" rid="CIT0057">
        57
       </xref>
       ]. Despite the limited to poor data, Chinese guidelines recommend ribavirin 500 mg IV 2–3 times daily in combination with LPV/r or inhaled interferon-α (5 million units nebulized twice daily) as one of the “standard treatment” options for COVID-19. Various combinations of ribavirin, interferon, and other antiviral agents are currently being studied in several clinical trials.
      </p>
      <p>
       Based on the poor in vitro activity, an absence of animal or human data supporting its use, and a significant toxicity profile, we recommend avoiding use of ribavirin in patients with COVID-19 at this time. Although interferons may be useful as adjunctive care, they pose a significant risk to critically ill patients, and in the absence of supportive data they also cannot be currently recommended.
      </p>
     </sec>
     <sec id="s11">
      <title>
       Oseltamivir and Baloxavir
      </title>
      <p>
       Given their antiviral activity against influenza, considerable attention has been paid to oseltamivir, and to a lesser degree baloxavir, as potential treatment options for COVID-19. This was exacerbated by the initial report from Huang et al [
       <xref ref-type="bibr" rid="CIT0001">
        1
       </xref>
       ] in Wuhan where patients managed with COVID-19 received oseltamivir in addition to broad-spectrum antimicrobials. It is important to note that use of oseltamivir was not as targeted therapy of SARS-CoV-2 but rather driven by the lack of a knowledge of the causative pathogen at the time of treatment and the desire to empirically treat influenza. The authors do not suggest the use of oseltamivir for COVID-19 in that publication, and there are no data that suggest in vitro activity of oseltamivir against SARS-CoV-2. In fact, the only data assessing oseltamivir activity against coronaviruses demonstrated it to be ineffective at inhibiting SARS-CoV-1, even at a concentration of 10 000 µM/L [
       <xref ref-type="bibr" rid="CIT0056">
        56
       </xref>
       ]. Coronaviruses do not utilize neuraminidase, and thus there is no enzyme to be inhibited by oseltamivir. This would hold true for zanamivir, peramivir, or any other neuraminidase inhibitor agents. Similarly, neither a defined mechanism nor in vitro data have suggested that baloxavir would demonstrate activity against SARS-CoV-2 or other coronaviruses. Therefore, given the critical need for these agents in the management of influenza and concern for drug shortages with oseltamivir, these agents should be avoided in patients with COVID-19 once influenza has been ruled out.
      </p>
     </sec>
    </sec>
    <sec id="s12">
     <title>
      AGENTS UNDER INVESTIGATION FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
     </title>
     <p>
      <xref ref-type="table" rid="T2">
       Table 2
      </xref>
      lists agents that are being investigated and/or theoretically considered for the management of SARS-CoV-2-infected patients. At this time, no recommendation can be made for any of these agents. In general, they should be avoided without additional supporting evidence.
     </p>
     <table-wrap id="T2" orientation="portrait" position="float">
      <label>
       Table 2.
      </label>
      <caption>
       <p>
        Agents Under Investigation for SARS-COV-2
       </p>
      </caption>
      <table frame="vsides" rules="groups">
       <thead>
        <tr>
         <th colspan="1" rowspan="1">
          Agent
         </th>
         <th colspan="1" rowspan="1">
          Comments
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="1" rowspan="1">
          Anakinra
         </td>
         <td colspan="1" rowspan="1">
          Interleukin-1 (IL-1) receptor antagonist hypothesized to quell cytokine storming. No data for use as adjunctive therapy for COVID-19 currently. No clinical trials are enrolling in China or the United States exploring this agent.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Arbidol (Umifenovir)
         </td>
         <td colspan="1" rowspan="1">
          Antiviral used in Russia and China for influenza, being studied in Chinese clinical trials (200 mg by mouth 3 times daily for no more than 10 days) for COVID-19 claiming potent in vitro activity. No clinical data exist currently; not available in the United States.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Baricitinib
         </td>
         <td colspan="1" rowspan="1">
          A Janus kinase family (JAK) enzyme inhibitor, suggested as a COVID-19 treatment from artificial intelligence [
          <xref ref-type="bibr" rid="CIT0058">
           58
          </xref>
          ]. No clinical data exist.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Bevacizumab
         </td>
         <td colspan="1" rowspan="1">
          Recombinant humanized monoclonal antibody that prevents vascular endothelial growth factor (VEGF) association with endothelial receptors Flt-1 and KDR approved for multiple cancers in the United States. Is on critical, national shortage. Being evaluated in a clinical trial in China for COVID-19 (NCT04275414), no data exist at this time to support use.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Brilacidin
         </td>
         <td colspan="1" rowspan="1">
          A host defense peptide mimetic in clinical development by Innovation Pharmaceuticals. The company recently announced they will begin testing the molecule against SARS-CoV-2 beginning the week of March 16, 2020.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Convalescent plasma
         </td>
         <td colspan="1" rowspan="1">
          Convalescent plasma from patients who have recovered from viral infections has been used previously for SARS-CoV-1, Middle East respiratory syndrome, Ebola, and H1N1 influenza with reported success [
          <xref ref-type="bibr" rid="CIT0059">
           59
          </xref>
          ]. The safety and efficacy of convalescent plasma transfusion in SARS-CoV-2-infected patients has not been established, and no protocols exist currently in the United States. Protocols are reportedly being developed at The Johns Hopkins University Hospital.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Darunavir/cobicistat
         </td>
         <td colspan="1" rowspan="1">
          HIV-1 protease inhibitor currently being evaluated in a clinical trial (NCT04252274), but no in vitro or human data exist to support use at this time.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Disulfiram
         </td>
         <td colspan="1" rowspan="1">
          Thiuram derivative that blocks alcohol oxidation. Demonstrated ability to competitively inhibit the papain-like proteases of SARS; however, no clinical data exist [
          <xref ref-type="bibr" rid="CIT0060">
           60
          </xref>
          ]. No in vitro or clinical data exist for COVID-19.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Eculizumab
         </td>
         <td colspan="1" rowspan="1">
          Humanized, monoclonal IgG antibody that binds to complement protein C5 and prevents formation of membrane attack complex (MAC). Being evaluated in a clinical trial (NCT04288713) for COVID-19 to quell immune response, no data exist at this time to support use.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Favipiravir
         </td>
         <td colspan="1" rowspan="1">
          RNA-dependent RNA polymerase inhibitor with broad-spectrum antiviral activity; however, demonstrated high EC
          <sub>
           50
          </sub>
          (decreased potency) against SARS-CoV-2 but was effective in protecting mice against Ebola virus despite similarly high EC
          <sub>
           50
          </sub>
          values [
          <xref ref-type="bibr" rid="CIT0003">
           3
          </xref>
          ]. Currently being evaluated in Clinical Trial NCT04273763 for patients with COVID-19. This agent is not FDA approved or available in the United States.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Galidesivir (BCX4430)
         </td>
         <td colspan="1" rowspan="1">
          Nucleoside RNA polymerase inhibitor with reported wide spectrum of antiviral activity, currently in pipeline of Biocryst Pharma and previously evaluated for Ebola and other hemorrhagic fever virus infections.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Griffithsin
         </td>
         <td colspan="1" rowspan="1">
          Algae-derived lectin and potent HIV entry inhibitor agent that demonstrated in vitro activity against SARS-CoV-1 [
          <xref ref-type="bibr" rid="CIT0061">
           61
          </xref>
          ].
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          IVIG
         </td>
         <td colspan="1" rowspan="1">
          IVIG remains on critical national shortage in the United States. The benefit in patients with COVID-19 is unclear.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Nelfinavir
         </td>
         <td colspan="1" rowspan="1">
          Nelfinavir, an HIV-1 protease inhibitor, might be active against SARS-CoV-2 based on a preprint publication that utilized homology modeling [
          <xref ref-type="bibr" rid="CIT0062">
           62
          </xref>
          ]. No clinical data exist.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Niclosamide
         </td>
         <td colspan="1" rowspan="1">
          Anthelminthic drug with in vitro efficacy against SARS-CoV-1; however, low absorption and oral bioavailability resulting in a wide range of serum concentrations in healthy volunteers after a single dose may limit utility as antiviral treatment [
          <xref ref-type="bibr" rid="CIT0063">
           63
          </xref>
          ].
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          REGN3048
         </td>
         <td colspan="1" rowspan="1">
          Human monoclonal antibody discovered by Regeneron that reportedly binds to the S protein of MERS-CoV. Currently in phase 1 trial in healthy volunteers (NCT03301090). The company reportedly announced recruitment for phase 2 and 3 trials for SARS-CoV-2; however, these are not registered on ClinicalTrials.gov.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Sarilumab
         </td>
         <td colspan="1" rowspan="1">
          IL-6 receptor antagonist FDA-approved for rheumatoid arthritis. Recently announced a US-based trial will begin enrolling at medical centers in New York for patients with severe COVID-19 disease.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Sofosbuvir
         </td>
         <td colspan="1" rowspan="1">
          Antiviral used to treat hepatitis C, in vitro activity against SARS-CoV-1, no clinical data exist [
          <xref ref-type="bibr" rid="CIT0064">
           64
          </xref>
          ].
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          TZLS-501
         </td>
         <td colspan="1" rowspan="1">
          A novel, fully human anti-IL6R by Tiziana Life Sciences. The company recently announced they are moving forward with clinical development for patient use in patients with COVID-19 and excessive IL-6 production.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Vitamin C
         </td>
         <td colspan="1" rowspan="1">
          There is an ongoing clinical trial of 12 grams IV BID vitamin C in China for treatment of COVID-19 (NCT04264533). Use of this agent is not recommended at this time.
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          XueBiJing
         </td>
         <td colspan="1" rowspan="1">
          Chinese herbal medicine extract infusion formulation given at 100 mL IV twice daily, suggested as a “may consider” treatment for severe and critical cases in the National Health Commission of the People’s Republic of China: the COVID-19 Diagnosis and Treatment Guide, 7th Edition. This previously demonstrated improved mortality in patients with severe community acquired pneumonia in China [
          <xref ref-type="bibr" rid="CIT0065">
           65
          </xref>
          ].
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="fn-0102">
        <p>
         Abbreviations: BID, twice a day; COVID-19, coronavirus disease 2019; EC
         <sub>
          50
         </sub>
         , half-maximal effective concentration; FDA, US Food and Drug Administration; HIV, human immunodeficiency virus; IgG, immunoglobulin G; IL6R, IL-6 receptor; IV, intravenous; IVIG, intravenous immunoglobulin; MERS-CoV, Middle East respiratory syndrome coronavirus; RNA, ribonucleic acid; SARS-CoV, severe acute respiratory syndrome coronavirus.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
    </sec>
    <sec id="s13">
     <title>
      CONCLUSIONS
     </title>
     <p>
      Appropriate management strategies for patients with COVID-19 are a rapidly evolving therapeutic challenge, and the optimal agents (if any) to treat infection or prevent progression to critical illness remain ill-defined. Although certain agents listed in this review are encouraging, and the potential benefit of therapy likely outweighs the relatively minor risk of adverse events from short-course therapy, the evidence remains inconclusive and changes almost daily.
     </p>
     <p>
      Patient populations who warrant therapy and the timing of initiation of therapy need to be defined. Given that disease progression can occur rapidly in stable patients and that viral loads are highest early in the infection course, the authors of this review opine that rapid initiation of therapy in high-risk populations (patients who are hospitalized or outpatients who are at high risk of complications) is rational and should be considered, ideally in the context of a well-controlled, adequately powered trial. More important, however, this strategy is not without risk and needs to be weighed against potential adverse events (that remain poorly defined) and impending drug shortages with increases in use of these agents. To help address these concerns, careful consideration should be given to duration of therapy with many clinical trials and institutional protocols recommending 5–7 days for uncomplicated disease. Duration of therapy should be individualized to the patient and the progression of disease.
     </p>
     <p>
      Clinicians must continually monitor and adapt as new literature becomes available. Caution should be applied because the bulk of the available clinical data are uncontrolled, not peer reviewed, or even unpublished. Given these limitations, it is critical that institutions and clinicians report their experiences with the management and treatment of COVID-19 to the medical community so that we may further modify and optimize treatment recommendations and pathways.
     </p>
    </sec>
    <back>
     <ack id="a1">
      <title>
       Acknowledgments
      </title>
      <p>
       We acknowledge and thank Jovan Borjan, Julie Ann Justo, Liza Vaezi, Ryan Shields, and Jason Gallagher for thorough review of this manuscript.
      </p>
      <p>
       <bold>
        <italic>
         Potential conflicts of interest.
        </italic>
       </bold>
       All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
      </p>
     </ack>
     <ref-list id="r1">
      <title>
       References
      </title>
      <ref id="CIT0001">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         395
        </volume>
        :
        <fpage>
         497
        </fpage>
        –
        <lpage>
         506
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0002">
       <label>
        2.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Stevens
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Patel
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nori
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Involving antimicrobial stewardship programs in COVID-19 response efforts: all hands on deck
        </article-title>
        .
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2020
        </year>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         2
        </lpage>
        . doi:
        <pub-id pub-id-type="doi">
         10.1017/ice.2020.69
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0003">
       <label>
        3.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cao
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </article-title>
        .
        <source>
         Cell Res
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         30
        </volume>
        :
        <fpage>
         269
        </fpage>
        –
        <lpage>
         71
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32020029
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0004">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gordon
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tchesnokov
          </surname>
          <given-names>
           EP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Feng
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         ,
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <year>
         2020
        </year>
        :jbc.AC120.013056. DOI:
        <pub-id pub-id-type="doi">
         10.1074/jbc.AC120.013056
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0005">
       <label>
        5.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sheahan
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Leist
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
        </article-title>
        .
        <source>
         Nat Commun
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         11
        </volume>
        :
        <fpage>
         222
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         31924756
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0006">
       <label>
        6.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sheahan
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Graham
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
        </article-title>
        .
        <source>
         Sci Transl Med
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         eaal3653
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         28659436
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0007">
       <label>
        7.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Agostini
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Andres
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease
        </article-title>
        .
        <source>
         mBio
        </source>
        <year>
         2018
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         e00221-18
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29511076
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0008">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Siegel
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hui
          </surname>
          <given-names>
           HC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Doerffler
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         60
        </volume>
        :
        <fpage>
         1648
        </fpage>
        –
        <lpage>
         61
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28124907
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0009">
       <label>
        9.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Warren
          </surname>
          <given-names>
           TK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jordan
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lo
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
        </article-title>
        .
        <source>
         Nature
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         531
        </volume>
        :
        <fpage>
         381
        </fpage>
        –
        <lpage>
         5
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26934220
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0010">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Mulangu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dodd
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Davey
          </surname>
          <given-names>
           RT
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         A randomized, controlled trial of Ebola virus disease therapeutics
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2019
        </year>
        ;
        <volume>
         381
        </volume>
        :
        <fpage>
         2293
        </fpage>
        –
        <lpage>
         303
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31774950
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0011">
       <label>
        11.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Holshue
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           DeBolt
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lindquist
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        ;
        <person-group>
         <collab>
          Washington State 2019-nCoV Case Investigation Team
         </collab>
        </person-group>
        <article-title>
         First case of 2019 novel coronavirus in the United States
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         382
        </volume>
        :
        <fpage>
         929
        </fpage>
        –
        <lpage>
         36
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32004427
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0012">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jacobs
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rodger
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bell
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Late Ebola virus relapse causing meningoencephalitis: a case report
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         388
        </volume>
        :
        <fpage>
         498
        </fpage>
        –
        <lpage>
         503
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27209148
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0013">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Dörnemann
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Burzio
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ronsse
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         First newborn baby to receive experimental therapies survives Ebola virus disease
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         215
        </volume>
        :
        <fpage>
         171
        </fpage>
        –
        <lpage>
         4
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28073857
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0014">
       <label>
        14.
       </label>
       <mixed-citation publication-type="other">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Midgley
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         First 12 patients with coronavirus disease 2019 (COVID-19) in the United States.
        </article-title>
        Available at:
        <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2020.03.09.20032896v1.full.pdf">
         https://www.medrxiv.org/content/10.1101/2020.03.09.20032896v1.full.pdf
        </ext-link>
        . Accessed
        <comment>
         14 March 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0015">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Colson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rolain
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lagier
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         ,
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
        </article-title>
        .
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         55
        </volume>
        :
        <fpage>
         105932
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0016">
       <label>
        16.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tian
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
        </article-title>
        .
        <source>
         Bioscience Trends
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         72
        </fpage>
        –
        <lpage>
         3
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32074550
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0017">
       <label>
        17.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Biot
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Daher
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chavain
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         49
        </volume>
        :
        <fpage>
         2845
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16640347
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0018">
       <label>
        18.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ye
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2020
        </year>
        :
        <fpage>
         ciaa237
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         32150618
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0019">
       <label>
        19.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tett
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical pharmacokinetics of slow-acting antirheumatic drugs
        </article-title>
        .
        <source>
         Clin Pharmacokinet
        </source>
        <year>
         1993
        </year>
        ;
        <volume>
         25
        </volume>
        :
        <fpage>
         392
        </fpage>
        –
        <lpage>
         407
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7904547
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0020">
       <label>
        20.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gautret
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lagier
          </surname>
          <given-names>
           J-C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Parola
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial
        </article-title>
        .
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2020
        </year>
        ; DOI:
        <pub-id pub-id-type="doi">
         10.1016/j.ijantimicag.2020.105949
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0021">
       <label>
        21.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Touret
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           de Lamballerie
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Of chloroquine and COVID-19
        </article-title>
        .
        <source>
         Antiviral Res
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         177
        </volume>
        :
        <fpage>
         104762
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         32147496
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0022">
       <label>
        22.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ratia
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pegan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Takayama
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         105
        </volume>
        :
        <fpage>
         16119
        </fpage>
        –
        <lpage>
         24
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18852458
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0023">
       <label>
        23.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hung
          </surname>
          <given-names>
           IF
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        ;
        <person-group>
         <collab>
          HKU/UCH SARS Study Group
         </collab>
        </person-group>
        <article-title>
         Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
        </article-title>
        .
        <source>
         Thorax
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         59
        </volume>
        :
        <fpage>
         252
        </fpage>
        –
        <lpage>
         6
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14985565
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0024">
       <label>
        24.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           de Wilde
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jochmans
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Posthuma
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture
        </article-title>
        .
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         4875
        </fpage>
        –
        <lpage>
         84
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24841269
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0025">
       <label>
        25.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           López Aspiroz
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Santos Buelga
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cabrera Figueroa
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients
        </article-title>
        .
        <source>
         Ther Drug Monit
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         33
        </volume>
        :
        <fpage>
         573
        </fpage>
        –
        <lpage>
         82
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21912331
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0026">
       <label>
        26.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yeung
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         212
        </volume>
        :
        <fpage>
         1904
        </fpage>
        –
        <lpage>
         13
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0027">
       <label>
        27.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Arabi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Asiri
          </surname>
          <given-names>
           AY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Assiri
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial
        </article-title>
        .
        <source>
         Trials
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         8
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         31900204
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0028">
       <label>
        28.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lai
          </surname>
          <given-names>
           ST
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study
        </article-title>
        .
        <source>
         Hong Kong Med J
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         399
        </fpage>
        –
        <lpage>
         406
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14660806
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0029">
       <label>
        29.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         National Health Commission (NHC) of the People’s Republic of China
        </collab>
        .
        <article-title>
         The diagnosis and treatment guide of COVID-19 pneumonia caused by new coronavirus infection 7th Edition, published March 3rd, 2020.
        </article-title>
        Translanted to English. Available at:
        <ext-link ext-link-type="uri" xlink:href="http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm">
         http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm
        </ext-link>
        . Accessed 6 March 2020.
       </mixed-citation>
      </ref>
      <ref id="CIT0030">
       <label>
        30.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Young
          </surname>
          <given-names>
           BE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ong
          </surname>
          <given-names>
           SWX
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kalimuddin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore
        </article-title>
        .
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        :
        <fpage>
         e203204
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0031">
       <label>
        31.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lim
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jeon
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shin
          </surname>
          <given-names>
           HY
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR
        </article-title>
        .
        <source>
         J Korean Med Sci
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         35
        </volume>
        :
        <fpage>
         e79
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         32056407
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0032">
       <label>
        32.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Han
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Quan
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Guo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019
        </article-title>
        .
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         92
        </volume>
        :
        <fpage>
         461
        </fpage>
        –
        <lpage>
         3
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32073161
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0033">
       <label>
        33.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment
        </article-title>
        .
        <source>
         Biosci Trends
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         64
        </fpage>
        –
        <lpage>
         8
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32037389
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0034">
       <label>
        34.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hu
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China
        </article-title>
        .
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         323
        </volume>
        :
        <fpage>
         1061
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0035">
       <label>
        35.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         395
        </volume>
        :
        <fpage>
         507
        </fpage>
        –
        <lpage>
         13
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0036">
       <label>
        36.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tu
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Du
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         395
        </volume>
        :
        <fpage>
         1054
        </fpage>
        –
        <lpage>
         62
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32171076
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0037">
       <label>
        37.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cao
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19
        </article-title>
        .
        <source>
         New Engl J Med
        </source>
        <year>
         2020
        </year>
        ; DOI:
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001282
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0038">
       <label>
        38.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Best
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Capparelli
          </surname>
          <given-names>
           EV
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Diep
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children
        </article-title>
        .
        <source>
         J Acquir Immune Defic Syndr (1999)
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         385
        </fpage>
        –
        <lpage>
         91
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0039">
       <label>
        39.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rossignol
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Infect Public Health
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         227
        </fpage>
        –
        <lpage>
         30
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27095301
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0040">
       <label>
        40.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Haffizulla
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hartman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hoppers
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         609
        </fpage>
        –
        <lpage>
         18
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24852376
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0041">
       <label>
        41.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gamiño-Arroyo
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Guerrero
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           McCarthy
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2019
        </year>
        ;
        <volume>
         69
        </volume>
        :
        <fpage>
         1903
        </fpage>
        –
        <lpage>
         11
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30753384
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0042">
       <label>
        42.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kotch
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Barrett
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Teachey
          </surname>
          <given-names>
           DT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
        </article-title>
        .
        <source>
         Expert Rev Clin Immunol
        </source>
        <year>
         2019
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         813
        </fpage>
        –
        <lpage>
         22
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31219357
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0043">
       <label>
        43.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lee
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Santomasso
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Locke
          </surname>
          <given-names>
           FL
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
        </article-title>
        .
        <source>
         Biol Blood Marrow Transplant
        </source>
        <year>
         2019
        </year>
        ;
        <volume>
         25
        </volume>
        :
        <fpage>
         625
        </fpage>
        –
        <lpage>
         38
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30592986
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0044">
       <label>
        44.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Park
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Romero
          </surname>
          <given-names>
           FA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Taur
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2018
        </year>
        ;
        <volume>
         67
        </volume>
        :
        <fpage>
         533
        </fpage>
        –
        <lpage>
         40
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29481659
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0045">
       <label>
        45.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Le
          </surname>
          <given-names>
           RQ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yuan
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome
        </article-title>
        .
        <source>
         Oncologist
        </source>
        <year>
         2018
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         943
        </fpage>
        –
        <lpage>
         7
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29622697
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0046">
       <label>
        46.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Xu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Han
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Effective treatment of severe COVID-19 patients with tocilizumab
        </article-title>
        .
        <source>
         ChinaXiv
        </source>
        <year>
         2020
        </year>
        ; DOI:
        <pub-id pub-id-type="doi">
         10.12074/202003.00026
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0047">
       <label>
        47.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Stockman
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bellamy
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Garner
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: systematic review of treatment effects
        </article-title>
        .
        <source>
         PLoS Med
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         e343
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         16968120
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0048">
       <label>
        48.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tang
          </surname>
          <given-names>
           XP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tan
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience
        </article-title>
        .
        <source>
         Chest
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         129
        </volume>
        :
        <fpage>
         1441
        </fpage>
        –
        <lpage>
         52
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16778260
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0049">
       <label>
        49.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lee
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Allen Chan
          </surname>
          <given-names>
           KC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients
        </article-title>
        .
        <source>
         J Clin Virol
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         31
        </volume>
        :
        <fpage>
         304
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15494274
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0050">
       <label>
        50.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Auyeung
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lee
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lai
          </surname>
          <given-names>
           WK
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study
        </article-title>
        .
        <source>
         J Infect
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         51
        </volume>
        :
        <fpage>
         98
        </fpage>
        –
        <lpage>
         102
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16038758
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0051">
       <label>
        51.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Arabi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mandourah
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al-Hameed
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome
        </article-title>
        .
        <source>
         Am J Respir Crit Care Med
        </source>
        <year>
         2018
        </year>
        ;
        <volume>
         197
        </volume>
        :
        <fpage>
         757
        </fpage>
        –
        <lpage>
         67
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29161116
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0052">
       <label>
        52.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cai
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China
        </article-title>
        .
        <source>
         JAMA Intern Med
        </source>
        <year>
         2020
        </year>
        ; DOI:
        <pub-id pub-id-type="doi">
         10.1001/jamainternmed.2020.0994
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0053">
       <label>
        53.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Shang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         On the use of corticosteroids for 2019-nCoV pneumonia
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         395
        </volume>
        :
        <fpage>
         683
        </fpage>
        –
        <lpage>
         4
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32122468
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0054">
       <label>
        54.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Booth
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Matukas
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tomlinson
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
        </article-title>
        .
        <source>
         JAMA
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         289
        </volume>
        :
        <fpage>
         2801
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12734147
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0055">
       <label>
        55.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lee
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hui
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wu
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         A major outbreak of severe acute respiratory syndrome in Hong Kong
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         348
        </volume>
        :
        <fpage>
         1986
        </fpage>
        –
        <lpage>
         94
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12682352
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0056">
       <label>
        56.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tan
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ooi
          </surname>
          <given-names>
           EE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lin
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         581
        </fpage>
        –
        <lpage>
         6
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15200845
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0057">
       <label>
        57.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Arabi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shalhoub
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mandourah
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study
        </article-title>
        .
        <source>
         Clin Infect Dis
        </source>
        <year>
         2019
        </year>
        ; DOI:
        <pub-id pub-id-type="doi">
         10.1093/cid/ciz544
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0058">
       <label>
        58.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Richardson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Griffin
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tucker
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         395
        </volume>
        :
        <fpage>
         e30
        </fpage>
        –
        <lpage>
         1
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32032529
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0059">
       <label>
        59.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Xiong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Convalescent plasma as a potential therapy for COVID-19
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         398
        </fpage>
        –
        <lpage>
         400
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32113510
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0060">
       <label>
        60.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lin
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Moses
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hsieh
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
        </article-title>
        .
        <source>
         Antiviral Res
        </source>
        <year>
         2018
        </year>
        ;
        <volume>
         150
        </volume>
        :
        <fpage>
         155
        </fpage>
        –
        <lpage>
         63
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29289665
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0061">
       <label>
        61.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           O’Keefe
          </surname>
          <given-names>
           BR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Giomarelli
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family
         <italic>
          Coronaviridae
         </italic>
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         84
        </volume>
        :
        <fpage>
         2511
        </fpage>
        –
        <lpage>
         21
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20032190
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0062">
       <label>
        62.
       </label>
       <mixed-citation publication-type="other">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Xu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Peng
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation
        </article-title>
        .
        <year>
         2010
        </year>
        ; DOI:
        <pub-id pub-id-type="doi">
         10.1101/2020.01.27.921627
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0063">
       <label>
        63.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Xu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           PY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Broad spectrum antiviral agent niclosamide and its therapeutic potential
        </article-title>
        .
        <source>
         ACS Infect Dis
        </source>
        <year>
         2020
        </year>
        ; DOI:
        <pub-id pub-id-type="doi">
         10.1021/acsinfecdis.0c00052
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0064">
       <label>
        64.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Elfiky
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
        </article-title>
        .
        <source>
         Life Sci
        </source>
        <year>
         2020
        </year>
        ;
        <volume>
         248
        </volume>
        :
        <fpage>
         117477
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         32119961
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0065">
       <label>
        65.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Song
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yao
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <etal>
          et al.
         </etal>
        </person-group>
        <article-title>
         XueBiJing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial
        </article-title>
        .
        <source>
         Crit Care Med
        </source>
        <year>
         2019
        </year>
        ;
        <volume>
         47
        </volume>
        :
        <fpage>
         e735
        </fpage>
        –
        <lpage>
         43
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31162191
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="editorial" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       One Health
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       One Health
      </journal-id>
      <journal-title-group>
       <journal-title>
        One Health
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2352-7714
      </issn>
      <publisher>
       <publisher-name>
        Published by Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32292817
      </article-id>
      <article-id pub-id-type="pmc">
       7128742
      </article-id>
      <article-id pub-id-type="publisher-id">
       S2352-7714(20)30062-8
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.onehlt.2020.100131
      </article-id>
      <article-id pub-id-type="publisher-id">
       100131
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Picot
         </surname>
         <given-names>
          Stephane
         </given-names>
        </name>
        <email>
         stephane.picot@univ-lyon1.fr
        </email>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
        <xref ref-type="aff" rid="af0010">
         b
        </xref>
        <xref ref-type="corresp" rid="cr0005">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0010">
        <name>
         <surname>
          Marty
         </surname>
         <given-names>
          Aileen
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0015">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0015">
        <name>
         <surname>
          Bienvenu
         </surname>
         <given-names>
          Anne-Lise
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
        <xref ref-type="aff" rid="af0020">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0020">
        <name>
         <surname>
          Blumberg
         </surname>
         <given-names>
          Lucille H.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0025">
         e
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0025">
        <name>
         <surname>
          Dupouy-Camet
         </surname>
         <given-names>
          Jean
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0030">
         f
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0030">
        <name>
         <surname>
          Carnevale
         </surname>
         <given-names>
          Pierre
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0035">
         g
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0035">
        <name>
         <surname>
          Kano
         </surname>
         <given-names>
          Shigeyuki
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0040">
         h
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0040">
        <name>
         <surname>
          Jones
         </surname>
         <given-names>
          Malcolm K.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0045">
         i
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0045">
        <name>
         <surname>
          Daniel-Ribeiro
         </surname>
         <given-names>
          Cláudio Tadeu
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0050">
         j
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0050">
        <name>
         <surname>
          Mas-Coma
         </surname>
         <given-names>
          Santiago
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0055">
         k
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af0005">
       <label>
        a
       </label>
       Malaria Research Unit, , UMR 5246, CNRS, INSA, CPE University Lyon, 69100 Lyon, France
      </aff>
      <aff id="af0010">
       <label>
        b
       </label>
       Institute of Parasitology and Medical Mycology, Croix-Rousse Hospital, Hospices Civils de Lyon, 69004 Lyon, France
      </aff>
      <aff id="af0015">
       <label>
        c
       </label>
       Translational Medicine, HWCOM, FIU Health Travel Medicine Program and Vaccine Clinic Commander, Emergency Response Team Development, Miami, FL, United States
      </aff>
      <aff id="af0020">
       <label>
        d
       </label>
       Groupement Hospitalier Nord, Service Pharmacie, Hospices Civils de Lyon, Lyon, France
      </aff>
      <aff id="af0025">
       <label>
        e
       </label>
       Division of Public Health Surveillance and Response, National Institute for Communicable Diseases, 2131 Johannesburg, South Africa
      </aff>
      <aff id="af0030">
       <label>
        f
       </label>
       Faculté de Médecine Paris Descartes, Académie Vétérinaire de France, Paris, France
      </aff>
      <aff id="af0035">
       <label>
        g
       </label>
       Institute of Research for Development (former), Montpellier Centre, BP 64501, 34394 Montpellier, France
      </aff>
      <aff id="af0040">
       <label>
        h
       </label>
       Department of Tropical Medicine and Malaria, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan
      </aff>
      <aff id="af0045">
       <label>
        i
       </label>
       School of Veterinary Science, The University of Queensland, Brisbane, QLD, Australia
      </aff>
      <aff id="af0050">
       <label>
        j
       </label>
       Laboratório de Pesquisa em Malária, Instituto Oswaldo Cruz, Fiocruz. Av. Brasil 4365. CEP 21.040-360, Rio de Janeiro, Brazil.
      </aff>
      <aff id="af0055">
       <label>
        k
       </label>
       Departamento de Parasitología, Facultad de Farmacia, Universidad de Valencia, 46100, Valencia, Spain
      </aff>
      <author-notes>
       <corresp id="cr0005">
        <label>
         ⁎
        </label>
        Corresponding author at: ICBMS CNRS 5246, Campus Lyon-Tech La Doua, Université de Lyon, Villeurbanne 69100, France.
        <email>
         stephane.picot@univ-lyon1.fr
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        4
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        4
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       100131
      </elocation-id>
      <permissions>
       <copyright-statement>
        © 2020 Published by Elsevier B.V.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ab0005">
       <p>
        Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people, meaning people with close contact with positive tested patients, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at does matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6 mg/kg/day 1 (loading dose) followed by 5 mg/kg/day, with a maximum limit of 600 mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people.
       </p>
      </abstract>
      <kwd-group id="ks0005">
       <title>
        Keywords
       </title>
       <kwd>
        COVID19
       </kwd>
       <kwd>
        SARS-CoV2
       </kwd>
       <kwd>
        Hydroxychloroquine
       </kwd>
       <kwd>
        Chloroquine
       </kwd>
       <kwd>
        Systemic lupus erythematosus
       </kwd>
       <kwd>
        Immunomodulation
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="s0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0005">
      The world is facing significant challenges because of COVID-19. Briefly, these include [
      <xref ref-type="bibr" rid="bb0005">
       1
      </xref>
      ] how to prevent the disease, [
      <xref ref-type="bibr" rid="bb0010">
       2
      </xref>
      ] how to treat severe cases, [
      <xref ref-type="bibr" rid="bb0015">
       3
      </xref>
      ] how to reduce the medical, social, and economic impact of the illness, and [
      <xref ref-type="bibr" rid="bb0020">
       4
      </xref>
      ] how to end the pandemic. Social distancing measures were rapidly implemented, albeit not uniformly, and other known public health measures such as contact tracing are also variably implemented. Clinical trials are underway using repurposed drugs, new drugs, and new technologically developed antibody drugs. Review of the recently shared preliminary results reveals that most of the data, while valuable, fail to provide definitive evidence of effective lead compounds. Mainly this is because most of these initial studies are observational and not controlled studies. Thus, documented treatment is still lacking. In spite of the paucity of clinical evidences of an unequivocal beneficial effect of chloroquine on COVID-19, the absence of an effective treatment so far, the untimely publicity given to the potential effect of chloroquine and the consequent social and political pressure raised the demand for urgent clinical trials and even resulted in the simultaneous release of the drug for its compassionate use in the treatment of severe cases.
     </p>
     <p id="p0010">
      Meanwhile, the development of a safe and effective vaccine is likely to take many months or years.
     </p>
     <p id="p0015">
      A crucial issue that has not yet been adequately addressed is the pharmacological control of virus replication in contact cases before individuals show symptoms. Use of drugs has the potential to both reduce the risk of disease manifestation and to decrease the presymptomatic spread of SARS-CoV2.
     </p>
     <p id="p0020">
      Considering the incredible amount of conflicting medical, political and social debates, not always scientifically based, about the use of drugs for COVID-19 treatment, it is time to implement prospective clinical trials to answer the question: can prophylactic doses of hydroxychloroquine decrease the risk of clinical infection in documented exposed people? Considering the ongoing world tragedy, no option should be discarded even if more robust scientific evidences are still lacking.
     </p>
     <p id="p0025">
      We want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as post-exposure drug for exposed people, meaning people with close contact with positive tested patients, including home and medical caregivers.
     </p>
     <p id="p0030">
      Here we provide information that justifies a clinical trial of hydroxychloroquine [
      <xref ref-type="bibr" rid="bb0005">
       1
      </xref>
      ] as a post-exposure drug together with the background needed to safely and properly design such a clinical trial, taking into consideration the PK/PD of hydroxychloroquine, its action against virus including
      <italic>
       Coronaviridae
      </italic>
      , its potential toxicity in humans and the impact of repurposing for patients with inflammatory diseases.
     </p>
    </sec>
    <sec id="s0010">
     <label>
      2
     </label>
     <title>
      Hydroxychloroquine post-COVID-19 exposure: for whom, when, how, why?
     </title>
     <sec id="s0015">
      <label>
       2.1
      </label>
      <title>
       For whom
      </title>
      <p id="p0035">
       Millions of people are currently exposed to a high risk of contamination. Among them, adults taking care of family members who tested positive for SARS-CoV-2 at home, and medical and paramedical staffs treating hospitalized patients with symptomatic COVID-19, are highly susceptible to infection and may represent a second wave of extreme importance in the next few weeks. If those people get sick, we'll face another significant problem. Those highly exposed people should be protected. In that case, social distancing measures do not apply. In the absence of a vaccine, post-exposure pharmacological protection is the only way to prevent caregivers from becoming symptomatic.
      </p>
      <p id="p0040">
       We do not promote the general use of HCQ as prophylaxis in the general population for four main reasons: (1) There is evidence that HCQ may kill the virus
       <italic>
        in vitro
       </italic>
       , but there is as yet, no data regarding the use of HCQ as a post-exposure for asymptomatic people.
      </p>
      <p id="p0045">
       (2) Such recommendation will favor uncontrolled use of HCQ leading to risks of inappropriate use that could cause serious side effect, inefficacy, supply shortage and non-authorized speculation.
      </p>
      <p id="p0050">
       (3) Designing prospective clinical trials to test general use would be difficult because of the challenge of establishing a control population of unexposed persons, leading to difficulties in data analysis and lack of evidence.
      </p>
      <p id="p0055">
       (4) The risk of side-effects required close follow-up and clinical monitoring.
      </p>
     </sec>
     <sec id="s0020">
      <label>
       2.2
      </label>
      <title>
       When
      </title>
      <p id="p0060">
       We recommend the post-exposure regimen of HCQ for asymptomatic people, whether or not they have been tested for SARS-CoV-2, in close contact with symptomatic patients positive for SARS-CoV-2 and to start the regimen as soon as possible. For HCQ blood concentration to reach a steady-state takes time (approximately six days), while the incubation period of COVID-19 before symptoms is also approximately six days; thus, the regimen should be started on the first day of exposure to the risk.
      </p>
     </sec>
     <sec id="s0025">
      <label>
       2.3
      </label>
      <title>
       How
      </title>
      <p id="p0065">
       We promote the use of the HCQ to match that of the standard treatment of Systemic Lupus erythematous which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight [
       <xref ref-type="bibr" rid="bb0010">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0015">
        3
       </xref>
       ], at 6 mg/kg/day 1 (loading dose) followed by 5 mg/kg/day, with a maximum limit of 600 mg/day in all cases. The duration of the post-exposure regimen should last as long as the contact with a positive patient last or in case of repeated exposure, with a minimum of 10 days to reach a blood concentration at steady state. The terminal elimination half-life is approximately 50 days [
       <xref ref-type="bibr" rid="bb0020">
        4
       </xref>
       ] leading to a long term efficacy.
      </p>
      <p id="p0070">
       Considering the highly documented safety of orally administered HCQ for a short time, we consider that the highest possible dose should be used, under the control of competent medical staff, in order to reach the minimum HCQ tissue level required to inactivate a clinically significant proportion of the virus.
      </p>
     </sec>
     <sec id="s0030">
      <label>
       2.4
      </label>
      <title>
       Why
      </title>
      <p id="p0075">
       Hydroxychloroquine is a more soluble hydroxy-analogue of chloroquine (CQ), which was first synthesized by Hans Andersag in 1934, and proven by military testing during World War II as a safe antimalarial used successfully during the 20th century to prevent and treat malaria in endemic areas [
       <xref ref-type="bibr" rid="bb0025">
        5
       </xref>
       ]. In the 1990s studies revealed that hydroxychloroquine (HCQ), has immunomodulatory properties; leading to its use in the treatment of autoimmune diseases such as Lupus and rheumatoid arthritis [
       <xref ref-type="bibr" rid="bb0025">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0030">
        6
       </xref>
       ].
      </p>
      <p id="p0080">
       As early as the 1990s, researchers noted the antiviral effect of hydroxychloroquine [
       <xref ref-type="bibr" rid="bb0035">
        7
       </xref>
       ]. Currently, there are over 123 references on PubMed obtained using the keywords: “virus, hydroxychloroquine” similarly, web of science reveals a high interest in hydroxychloroquine and its role in viral diseases since the early 1990s.
      </p>
      <p id="p0085">
       Hydroxychloroquine and chloroquine have demonstrated
       <italic>
        in vitro
       </italic>
       antiviral effectiveness against Herpes simplex virus type 1 [
       <xref ref-type="bibr" rid="bb0040">
        8
       </xref>
       ], Zika [
       <xref ref-type="bibr" rid="bb0045">
        9
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0050">
        10
       </xref>
       ], HIV [
       <xref ref-type="bibr" rid="bb0055">
        11
       </xref>
       ], MERS [
       <xref ref-type="bibr" rid="bb0060">
        12
       </xref>
       ], SARS-CoV [
       <xref ref-type="bibr" rid="bb0060">
        12
       </xref>
       ], HCoV-OC43 [
       <xref ref-type="bibr" rid="bb0065">
        13
       </xref>
       ], Chikungunya [
       <xref ref-type="bibr" rid="bb0070">
        14
       </xref>
       ], Hepatitis C [
       <xref ref-type="bibr" rid="bb0075">
        15
       </xref>
       ], and several other viruses [
       <xref ref-type="bibr" rid="bb0055">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0080">
        16
       </xref>
       ]. For coronavirus, some studies suggested, at least
       <italic>
        in vitro
       </italic>
       , some efficacy of chloroquine on the SARS-CoV virus [
       <xref ref-type="bibr" rid="bb0060">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0065">
        13
       </xref>
       ] or MERS-CoV [
       <xref ref-type="bibr" rid="bb0085">
        17
       </xref>
       ].
      </p>
      <p id="p0090">
       Using Vero E6 cells infected with nCoV-2019BetaCoV/Wuhan/WIV04/2019, Wang et al. [
       <xref ref-type="bibr" rid="bb0090">
        18
       </xref>
       ] conducted standard assays to determine the potency (half-maximal effective concentration or EC
       <sub>
        50
       </sub>
       ) and the cytotoxicity at 50% (the half-maximal cytotoxic concentration or CC
       <sub>
        50
       </sub>
       ) of Chloroquine. Wang's study showed CQ has potency against SARS-CoV-2 at 1.13 μM (EC
       <sub>
        50
       </sub>
       of 1.13 μM) and great safety at therapeutic doses since CQ did not show significant toxicity until the concentration exceeded 100 μM (CC
       <sub>
        50
       </sub>
       greater than 100 μM). A previous study showed that CQ had an IC
       <sub>
        50
       </sub>
       of 2.5 ± 0.7 μM with a CC
       <sub>
        50
       </sub>
       of 31.5 ± 14.8 [
       <xref ref-type="bibr" rid="bb0095">
        19
       </xref>
       ]. More recently, Yao et al. showed that Hydroxychloroquine (HCQ) was more potent than chloroquine (EC
       <sub>
        50
       </sub>
       = 0.72 and EC
       <sub>
        50
       </sub>
       = 5.47 μM respectively) at 48 h [
       <xref ref-type="bibr" rid="bb0100">
        20
       </xref>
       ].
      </p>
      <p id="p0095">
       Hydroxychloroquine shows a high partitioning in tissue, including lung and brain. This chemical property offers a key clinical advantage in the case of COVID-19.
      </p>
      <p id="p0100">
       HCQ has a ten-fold concentration ratio in the lungs [
       <xref ref-type="bibr" rid="bb0105">
        21
       </xref>
       ]. A recent review described a series of 85 case reports of children presenting interstitial lung diseases and treated with HCQ or CQ at doses ranging from 3.5 to 10 mg/kg body weight/day with a maximum of 600 mg/day. HCQ was well-tolerated in most cases with relatively few side effect. Of the 16 patients who were treated exclusively with HCQ or CQ, the symptoms improved in 14 cases [
       <xref ref-type="bibr" rid="bb0105">
        21
       </xref>
       ].
      </p>
      <p id="p0105">
       Signs of anosmia and hyposmia are common in coronaviruses, and currently, loss of smell is noted in as many as 30% of patients with COVID-19 [
       <xref ref-type="bibr" rid="bb0110">
        22
       </xref>
       ], even those who are otherwise asymptomatic (
       <ext-link ext-link-type="uri" id="ir0005" xlink:href="http://www.entuk.org/sites/default/files/files/LossofsenseofsmellasmarkerofCOVID">
        www.entuk.org/sites/default/files/files/LossofsenseofsmellasmarkerofCOVID
       </ext-link>
       ). These signs likely arise as a consequence of the SARS-CoV2 passing through the olfactory epithelium to the olfactory areas of the brain, a concept supported by studies of other coronaviruses [
       <xref ref-type="bibr" rid="bb0115">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0120">
        24
       </xref>
       ]. Previous work with SARS-CoV1 indicated that it could cross the cribriform plate of the ethmoid bone which can produce cerebral involvement [
       <xref ref-type="bibr" rid="bb0125">
        25
       </xref>
       ]. A study of the neurological manifestations of 214 hospitalized patients with COVID19 revealed neurologic symptoms in 36.4% which fell into three categories [
       <xref ref-type="bibr" rid="bb0005">
        1
       </xref>
       ] central nervous system (CNS) symptoms or diseases (headache, dizziness, impaired consciousness, ataxia, acute cerebrovascular disease, and epilepsy), [
       <xref ref-type="bibr" rid="bb0010">
        2
       </xref>
       ] peripheral nervous system (PNS) symptoms (hypogeusia, hyposmia, and neuralgia), and [
       <xref ref-type="bibr" rid="bb0015">
        3
       </xref>
       ] skeletal muscular changes (Mao L, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study: pre-print, medRxiv not yet peer-reviewed] 25 Feb, 2020).
      </p>
      <p id="p0110">
       Hydroxychloroquine penetrates the central nervous system. Patients with glioblastoma were safely treated with HCQ (600 mg/day) used in conjunction with radiation and adjuvants [
       <xref ref-type="bibr" rid="bb0130">
        26
       </xref>
       ]. The correlation between brain and plasma concentrations showed a 4 to 30-fold difference for HCQ, demonstrating its ability to diffuse in the brain [
       <xref ref-type="bibr" rid="bb0135">
        27
       </xref>
       ]. Based on this observation, hydroxychloroquine may reach antiviral concentrations in the brain, leading to an expected preventive effect on early symptoms such as anosmia, which may persist after recovery from COVID-19.
      </p>
     </sec>
    </sec>
    <sec id="s0035">
     <label>
      3
     </label>
     <title>
      Benefits/risks of hydroxychloroquine against the virus
     </title>
     <sec id="s0040">
      <label>
       3.1
      </label>
      <title>
       Benefits
      </title>
      <p id="p0115">
       Hydroxychloroquine has a wide range of indications, including rheumatoid arthritis, systemic lupus erythematosus, and polymorphous light eruption (Physicians' Desk Reference. Hydroxychloroquine sulfate - Drug Summary.
       <ext-link ext-link-type="uri" id="ir0010" xlink:href="https://www.pdr.net/drug-summary/Plaquenil-hydroxychloroquine-sulfate-1911">
        https://www.pdr.net/drug-summary/Plaquenil-hydroxychloroquine-sulfate-1911
       </ext-link>
       (accessed 29 March 2020)). HCQ is administered orally in doses ranging from 100 to 600 mg daily. HCQ has also been tested for other indications such as cancers [
       <xref ref-type="bibr" rid="bb0140">
        28
       </xref>
       ], multiple sclerosis, and diabetes mellitus [
       <xref ref-type="bibr" rid="bb0145">
        29
       </xref>
       ]. In the current context of this extreme worldwide emergency, it is reasonable to propose that even if we could only reduce 10 to 30% in virus replication there would likely be a significantly reduce the transmission and severity of COVID19, and improve the clinical outcome. By using EC50, we are describing the proposed thresholds of efficacy at values that exceed those values, specifically, we are describing that these 4-aminoquinoline drugs could decrease virus replication or viral survival by 50%. Based on that proposal, lower plasma concentrations of HCQ, which we can easily obtain from a standard dosage regimen, is likely to be of significant clinically and public health impact.
      </p>
     </sec>
     <sec id="s0045">
      <label>
       3.2
      </label>
      <title>
       Risks
      </title>
      <p id="p0120">
       The antiviral activity of HCQ is thus, demonstrably higher than its cytotoxic side effects, which permits a high selectivity index. Currently, CQ and HCQ are denigrated by some because of their potential side effects. But toxicity is described as a feature of transiently high and dangerous peak concentrations that may develop during parenteral not appropriate oral, administration [
       <xref ref-type="bibr" rid="bb0150">
        30
       </xref>
       ].
      </p>
      <p id="p0125">
       The risk of retinopathy associated with hydroxychloroquine treatment has been well documented for decades. It was recently shown that the prevalence of retinopathy ranged from 5.2 to 7.5% in patients who were treated for &gt;5 years [
       <xref ref-type="bibr" rid="bb0155">
        31
       </xref>
       ]. There is no need to use HCQ for such extended periods for as a post-exposure medication for COVID-19.
      </p>
      <p id="p0130">
       The risk of cardiomyopathy, including cardiac conduction disorders, is reduced with this drug regimen. However, we recommend ECG before initiation of treatment in case of cardiac antecedents; but this should not delay the start of the post-exposure regimen.
      </p>
      <p id="p0135">
       There is evidence for the lack of significant risk of retinal toxicity after exposure to HCQ
       <italic>
        in utero
       </italic>
       [
       <xref ref-type="bibr" rid="bb0160">
        32
       </xref>
       ], but considering the lack of evidence for safety of post-exposure hydroxychloroquine during pregnancy, we consider that pregnant women should be excluded from the future clinical trials.
      </p>
     </sec>
    </sec>
    <sec id="s0050">
     <label>
      4
     </label>
     <title>
      Mechanisms of antiviral effect of chloroquine/hydroxychloroquine
     </title>
     <p id="p0140">
      The exact mechanism of action of chloroquine and hydroxychloroquine against the virus has not been clearly depicted; however, laboratory data show that 4-aminoquinoline compounds (Chloroquine and hydroxychloroquine) have four mechanisms by which they act against diverse RNA viruses including SARS-CoV1 and reduce the cytokine storm that these viruses can generate.
      <list id="l0005" list-type="simple">
       <list-item id="li0005">
        <label>
         1.
        </label>
        <p id="p0145">
         <bold>
          Inhibition of viral entry
         </bold>
         : Chloroquine interferes with terminal glycosylation of angiotensin-converting enzyme 2 which serves as the cellular receptor for SARS-CoV-1 and SARS-CoV-2. In cell culture chloroquine effectively prevents the spread of SARS CoV and works as a prophylactic [
         <xref ref-type="bibr" rid="bb0060">
          12
         </xref>
         ].
        </p>
       </list-item>
       <list-item id="li0010">
        <label>
         2.
        </label>
        <p id="p0150">
         <bold>
          Inhibition of viral release into the host cell
         </bold>
         : HCQ is a weak base which rapidly diffuses across membranes of cells and organelles to acidic cytoplasmic vesicles such as endosomes, lysosomes, or Golgi vesicles causing an increase in pH of the organelles. Unlike other enveloped viruses, Coronaviruses bud and assemble at the endoplasmic reticulum (ER)-Golgi intermediate compartment (ERGIC). 4-aminoquinoline compounds become highly concentrated in organelles causing dysfunction of enzymes including enzymes needed for proteolytic processing and post-translational modification of viral proteins [
         <xref ref-type="bibr" rid="bb0165">
          33
         </xref>
         ]. Experimental data from the Wuhan Institute of Virology demonstrated that chloroquine inhibits the replication of the SARS-CoV-2, in part because of its ability to alkalinize endosomal organelles [
         <xref ref-type="bibr" rid="bb0090">
          18
         </xref>
         ]. Hu et al. [
         <xref ref-type="bibr" rid="bb0170">
          34
         </xref>
         ] have proposed that CQ suppresses phosphatidylinositol binding clathrin assembly protein (PICALM) and thereby prevents endocytosis-mediated uptake of SARS-CoV-2. There is also data that chloroquine interferes with organelle acidification, which may lead to hindering fusion of viral particles, when chloroquine treatment was used for different emerging or non-emerging virus over the previous five decades: Mouse hepatitis virus (MHV-3) [
         <xref ref-type="bibr" rid="bb0175">
          35
         </xref>
         ], Feline infectious peritonitis virus (FIPV) [
         <xref ref-type="bibr" rid="bb0180">
          36
         </xref>
         ], or H5N1 strain of Influenza A [
         <xref ref-type="bibr" rid="bb0185">
          37
         </xref>
         ].
        </p>
       </list-item>
       <list-item id="li0015">
        <label>
         3.
        </label>
        <p id="p0155">
         <bold>
          Reduction of viral infectivity
         </bold>
         : Chloroquine inhibits viral particle glycosylation [
         <xref ref-type="bibr" rid="bb0190">
          38
         </xref>
         ]. The envelopes of coronavirus contain two major glycoproteins the Spike (S) [
         <xref ref-type="bibr" rid="bb0195">
          39
         </xref>
         ] and the Membrane (M) proteins. Lack of proper glycosylation damages the S protein [
         <xref ref-type="bibr" rid="bb0200">
          40
         </xref>
         ], needed for receptor binding.
        </p>
       </list-item>
       <list-item id="li0020">
        <label>
         4.
        </label>
        <p id="p0160">
         <bold>
          Immunomodulation
         </bold>
         : At the cellular level, chloroquine and hydroxychloroquine inhibit immune activation by reducing signaling by Pattern Recognition Receptors (Toll-like receptor signaling) and cytokine production [
         <xref ref-type="bibr" rid="bb0005">
          1
         </xref>
         ]. Hydroxychloroquine also inhibits the activity of the nucleic acid sensor cyclic GMP-AMP (cGAMP) synthase (cGAS) by interfering with its binding to cytosolic DNA. By preventing TLR signaling and cGAS–stimulator of interferon genes (STING) signaling, hydroxychloroquine can reduce the production of pro-inflammatory cytokines, including type I interferons [
         <xref ref-type="bibr" rid="bb0005">
          1
         </xref>
         ]. These drugs also reduce the expression of CD154 (CD40L) on helper T-cells which is essential for a successful antibody response and class switching [
         <xref ref-type="bibr" rid="bb0205">
          41
         </xref>
         ]. These immunomodulatory actions could help prevent the transition from mild or moderate disease to the dreadful acute respiratory distress syndrome by reducing the cytokine storm [
         <xref ref-type="bibr" rid="bb0210">
          42
         </xref>
         ] .
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec id="s0055">
     <label>
      5
     </label>
     <title>
      Conclusion
     </title>
     <p id="p0165">
      Non-pharmaceutical measures such as social distancing, school closure and teleworking (Di Domenico et al. Expected impact of school closure and telework to mitigate COVID-19 epidemic in France. Report #8, 14 March 2020
      <ext-link ext-link-type="uri" id="ir0015" xlink:href="http://Epicx-lab.com">
       Epicx-lab.com
      </ext-link>
      ,
      <ext-link ext-link-type="uri" id="ir0020" xlink:href="https://www.epicx-lab.com/uploads/9/6/9/4/9694133/inserm_covid-19-school-closure-french-regions_20200313.pdf">
       https://www.epicx-lab.com/uploads/9/6/9/4/9694133/inserm_covid-19-school-closure-french-regions_20200313.pdf
      </ext-link>
      ) are expected to delay and reduce the peak incidence and to achieve a reduction of the final attack rate of 15% (Additional Epicx-lab Reports
      <ext-link ext-link-type="uri" id="ir0025" xlink:href="http://www.epicx-lab.com/covid-19.html">
       www.epicx-lab.com/covid-19.html
      </ext-link>
      ). Reasonable interventions that can lead to a significant reduction in the impact of the epidemic profile and should be considered and evaluated without any delay.
     </p>
     <p id="p0170">
      As we observe the logarithmic increase in the number of cases and death, as well as the social and economic impact of COVID-19, measures for prevention and means to control the outbreak become urgent. The use of hydroxychloroquine as a post-exposure means to reduce sickness and transmission of COVID-19 demands immediate attention and should be taken into consideration.
     </p>
     <p id="p0175">
      It is of utmost importance to promote the design of prospective clinical trials to test the hypothesis: ‘Does a post-exposure non-toxic dose of hydroxychloroquine significantly alter Sars-Cov-2 replication in people exposed to a documented infective contact; and does it reduce the severity of subsequent disease? These futures clinical trials should document the benefit/risk ratio of this strategy rapidly.
     </p>
     <p id="p0180">
      This strategy for prevention is clearly achievable considering the safety of hydroxychloroquine for a short period of time, its demonstrated antiviral effect and its low cost and accessibility. In the context of the COVID-19 epidemic, if clinical evidence from prospective controlled clinical trials confirms the positive impact, its implementation will be urgently needed. Supply shortage of hydroxychloroquine, which remains needed for standard indications such as Lupus or rheumatoid arthritis should be prevented by a significant effort of pharmaceutical companies, already ongoing, for increasing the production of hydroxychloroquine specifically for COVID-19. Other initiative such as the “Defense Production Act” in the US may be activated.
     </p>
     <p id="p0185">
      Using post-exposure HCQ is in line with WHO's strategic objectives to limit human-to-human transmission. If we do not seriously consider using this easy and safe option, we are taking the risk of allowing the pandemic to sore further out of control. As recently stated, the urgency of the epidemic necessitates choices about which interventions to employ. Early HCQ administration to all people at risk of infection from close contact with a positive patient is one of the most reasonable choices. Moreover, it is a choice that could potentially have a considerable impact on the early termination of the COVID-19 epidemic. However, its administration should be done under medical control to avoid potential side effects and to prevent an uncontrolled use leading to supply shortages.
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Declaration of Competing Interest
     </title>
     <p id="p0190">
      The authors declare no conflict of interest.
     </p>
    </sec>
    <back>
     <ref-list id="bi0005">
      <title>
       References
      </title>
      <ref id="bb0005">
       <label>
        1
       </label>
       <element-citation id="rf0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Dai
          </surname>
          <given-names>
           S.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression
        </article-title>
        <source>
         J Antimicrob Chemother.
        </source>
        <year>
         20 mars 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0010">
       <label>
        2
       </label>
       <element-citation id="rf0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fanouriakis
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kostopoulou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cheema
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Anders
          </surname>
          <given-names>
           H.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Aringer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bajema
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Update of the joint European league against rheumatism and European renal association-European Dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis
        </article-title>
        <source>
         Ann Rheum Dis.
        </source>
        <year>
         2019
        </year>
        <comment>
         27 mars 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0015">
       <label>
        3
       </label>
       <element-citation id="rf0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fanouriakis
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bertsias
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Boumpas
          </surname>
          <given-names>
           D.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine dosing in systemic lupus erythematosus: response to « Letter in response to the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al » by Costedoat-Chalumeau et al
        </article-title>
        <source>
         Ann Rheum Dis.
        </source>
        <year>
         14 juin 2019
        </year>
       </element-citation>
      </ref>
      <ref id="bb0020">
       <label>
        4
       </label>
       <element-citation id="rf0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tett
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Cutler
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Beck
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           R.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis--a prospective, dose ranging study
        </article-title>
        <source>
         J Rheumatol. juill
        </source>
        <volume>
         27
        </volume>
        <issue>
         7
        </issue>
        <year>
         2000
        </year>
        <fpage>
         1656
        </fpage>
        <lpage>
         1660
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0025">
       <label>
        5
       </label>
       <element-citation id="rf0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coatney
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pitfalls in a discovery: the chronicle of chloroquine
        </article-title>
        <source>
         Am J Trop Med Hyg. mars
        </source>
        <volume>
         12
        </volume>
        <year>
         1963
        </year>
        <fpage>
         121
        </fpage>
        <lpage>
         128
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0030">
       <label>
        6
       </label>
       <element-citation id="rf0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Landewé
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
         <name>
          <surname>
           Goei Thè
          </surname>
          <given-names>
           H.S.
          </given-names>
         </name>
         <name>
          <surname>
           van Rijthoven
          </surname>
          <given-names>
           A.W.
          </given-names>
         </name>
         <name>
          <surname>
           Breedveld
          </surname>
          <given-names>
           F.C.
          </given-names>
         </name>
         <name>
          <surname>
           Dijkmans
          </surname>
          <given-names>
           B.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis
        </article-title>
        <source>
         Arthritis Rheum. mai
        </source>
        <volume>
         37
        </volume>
        <issue>
         5
        </issue>
        <year>
         1994
        </year>
        <fpage>
         637
        </fpage>
        <lpage>
         643
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0035">
       <label>
        7
       </label>
       <element-citation id="rf0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goldring
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Nemaorani
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial drugs modulate the expression of monocyte receptors
        </article-title>
        <source>
         Int J Immunopharmacol. sept
        </source>
        <volume>
         21
        </volume>
        <issue>
         9
        </issue>
        <year>
         1999
        </year>
        <fpage>
         599
        </fpage>
        <lpage>
         607
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0040">
       <label>
        8
       </label>
       <element-citation id="rf0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lima
          </surname>
          <given-names>
           T.L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Feitosa De
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Dos Santos-Silva
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Dos Santos-Silva
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Da
          </surname>
          <given-names>
           Siqueira E.M.
          </given-names>
         </name>
         <name>
          <surname>
           PRL
          </surname>
          <given-names>
           Machado
          </given-names>
         </name>
        </person-group>
        <article-title>
         Improving Encapsulation of Hydrophilic Chloroquine Diphosphate into Biodegradable Nanoparticles: A Promising Approach against Herpes Virus Simplex-1 Infection
        </article-title>
        <source>
         Pharmaceutics.
        </source>
        <volume>
         10
        </volume>
        <issue>
         4
        </issue>
        <year>
         3 déc 2018
        </year>
       </element-citation>
      </ref>
      <ref id="bb0045">
       <label>
        9
       </label>
       <element-citation id="rf0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Delvecchio
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Higa
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Pezzuto
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Valadão
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Garcez
          </surname>
          <given-names>
           P.P.
          </given-names>
         </name>
         <name>
          <surname>
           Monteiro
          </surname>
          <given-names>
           F.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         29
        </volume>
        <year>
         2016
        </year>
        <comment>
         8(12)
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0050">
       <label>
        10
       </label>
       <element-citation id="rf0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Pham
          </surname>
          <given-names>
           H.T.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Quan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Mesplède
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimalarial drugs and their metabolites are potent Zika virus inhibitors
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         91
        </volume>
        <issue>
         7
        </issue>
        <year>
         2019
        </year>
        <fpage>
         1182
        </fpage>
        <lpage>
         1190
        </lpage>
        <pub-id pub-id-type="pmid">
         30801742
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0055">
       <label>
        11
       </label>
       <element-citation id="rf0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of chloroquine in viral diseases
        </article-title>
        <source>
         Lancet Infect Dis. sept
        </source>
        <volume>
         11
        </volume>
        <issue>
         9
        </issue>
        <year>
         2011
        </year>
        <fpage>
         653
        </fpage>
        <lpage>
         654
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0060">
       <label>
        12
       </label>
       <element-citation id="rf0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bergeron
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Benjannet
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Erickson
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
        </article-title>
        <source>
         Virol J.
        </source>
        <volume>
         2
        </volume>
        <year>
         22 août 2005
        </year>
        <fpage>
         69
        </fpage>
        <pub-id pub-id-type="pmid">
         16115318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0065">
       <label>
        13
       </label>
       <element-citation id="rf0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Rysman
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Verbeeck
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Van Ranst
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice
        </article-title>
        <source>
         Antimicrob Agents Chemother. août
        </source>
        <volume>
         53
        </volume>
        <issue>
         8
        </issue>
        <year>
         2009
        </year>
        <fpage>
         3416
        </fpage>
        <lpage>
         3421
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0070">
       <label>
        14
       </label>
       <element-citation id="rf0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Topno
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Dikhit
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bhawana null, Sahoo GC, Madhukar M, et al.
          </surname>
         </name>
        </person-group>
        <article-title>
         Molecular docking studies of chloroquine and its derivatives against P23pro-zbd domain of chikungunya virus: implication in designing of novel therapeutic strategies
        </article-title>
        <source>
         J Cell Biochem. oct
        </source>
        <volume>
         120
        </volume>
        <issue>
         10
        </issue>
        <year>
         2019
        </year>
        <fpage>
         18298
        </fpage>
        <lpage>
         18308
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0075">
       <label>
        15
       </label>
       <element-citation id="rf0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Helal
          </surname>
          <given-names>
           G.K.
          </given-names>
         </name>
         <name>
          <surname>
           Gad
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Abd-Ellah
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Eid
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         88
        </volume>
        <issue>
         12
        </issue>
        <year>
         2016
        </year>
        <fpage>
         2170
        </fpage>
        <lpage>
         2178
        </lpage>
        <pub-id pub-id-type="pmid">
         27183377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0080">
       <label>
        16
       </label>
       <element-citation id="rf0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Salata
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Calistri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Parolin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Baritussio
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Palù
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antiviral activity of cationic amphiphilic drugs
        </article-title>
        <source>
         Expert Rev. Anti-Infect. Ther.
        </source>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <year>
         2017
        </year>
        <fpage>
         483
        </fpage>
        <lpage>
         492
        </lpage>
        <pub-id pub-id-type="pmid">
         28286997
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0085">
       <label>
        17
       </label>
       <element-citation id="rf0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gross
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bollinger
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         13
        </volume>
        <issue>
         3
        </issue>
        <year>
         2018
        </year>
        <object-id pub-id-type="publisher-id">
         e0194868
        </object-id>
       </element-citation>
      </ref>
      <ref id="bb0090">
       <label>
        18
       </label>
       <element-citation id="rf0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </article-title>
        <source>
         Cell Res.
        </source>
        <volume>
         30
        </volume>
        <issue>
         3
        </issue>
        <year>
         2020
        </year>
        <fpage>
         269
        </fpage>
        <lpage>
         271
        </lpage>
        <pub-id pub-id-type="pmid">
         32020029
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0095">
       <label>
        19
       </label>
       <element-citation id="rf0095" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Bailey
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Heiner
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Montgomery
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Lauridsen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice
        </article-title>
        <source>
         Antivir Chem Chemother.
        </source>
        <volume>
         17
        </volume>
        <issue>
         5
        </issue>
        <year>
         2006
        </year>
        <fpage>
         275
        </fpage>
        <lpage>
         284
        </lpage>
        <pub-id pub-id-type="pmid">
         17176632
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0100">
       <label>
        20
       </label>
       <element-citation id="rf0100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
        </article-title>
        <source>
         Clin Infect Dis.
        </source>
        <year>
         9 mars 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0105">
       <label>
        21
       </label>
       <element-citation id="rf0105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Braun
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ferner
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kronfeld
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Griese
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases
        </article-title>
        <source>
         Pediatr Pulmonol. avr
        </source>
        <volume>
         50
        </volume>
        <issue>
         4
        </issue>
        <year>
         2015
        </year>
        <fpage>
         410
        </fpage>
        <lpage>
         419
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0110">
       <label>
        22
       </label>
       <element-citation id="rf0110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lüers
          </surname>
          <given-names>
           J.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Klußmann
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Guntinas-Lichius
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Covid-19 pandemic and otolaryngology: What it comes down to?
        </article-title>
        <source>
         Laryngorhinootologie
        </source>
        <year>
         26 mars 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0115">
       <label>
        23
       </label>
       <element-citation id="rf0115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnett
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The olfactory nerve and not the trigeminal nerve is the major site of CNS entry for mouse hepatitis virus, strain JHM
        </article-title>
        <source>
         Virology. mai
        </source>
        <volume>
         194
        </volume>
        <issue>
         1
        </issue>
        <year>
         1993
        </year>
        <fpage>
         185
        </fpage>
        <lpage>
         191
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0120">
       <label>
        24
       </label>
       <element-citation id="rf0120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Youngentob
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Schwob
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Saha
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Manglapus
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Jubelt
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Functional consequences following infection of the olfactory system by intranasal infusion of the olfactory bulb line variant (OBLV) of mouse hepatitis strain JHM
        </article-title>
        <source>
         Chem Senses. oct
        </source>
        <volume>
         26
        </volume>
        <issue>
         8
        </issue>
        <year>
         2001
        </year>
        <fpage>
         953
        </fpage>
        <lpage>
         963
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0125">
       <label>
        25
       </label>
       <element-citation id="rf0125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Netland
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ferraro
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pewe
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Olivares
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enhancement of murine coronavirus replication by severe acute respiratory syndrome coronavirus protein 6 requires the N-terminal hydrophobic region but not C-terminal sorting motifs
        </article-title>
        <source>
         J Virol. oct
        </source>
        <volume>
         81
        </volume>
        <issue>
         20
        </issue>
        <year>
         2007
        </year>
        <fpage>
         11520
        </fpage>
        <lpage>
         11525
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0130">
       <label>
        26
       </label>
       <element-citation id="rf0130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rosenfeld
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Supko
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Desideri
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Grossman
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brem
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
        </article-title>
        <source>
         Autophagy. août
        </source>
        <volume>
         10
        </volume>
        <issue>
         8
        </issue>
        <year>
         2014
        </year>
        <fpage>
         1359
        </fpage>
        <lpage>
         1368
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0135">
       <label>
        27
       </label>
       <element-citation id="rf0135" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Olafuyi
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Badhan
          </surname>
          <given-names>
           R.K.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dose optimization of chloroquine by pharmacokinetic modeling during pregnancy for the treatment of Zika virus infection
        </article-title>
        <source>
         J Pharm Sci. janv
        </source>
        <volume>
         108
        </volume>
        <issue>
         1
        </issue>
        <year>
         2019
        </year>
        <fpage>
         661
        </fpage>
        <lpage>
         673
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0140">
       <label>
        28
       </label>
       <element-citation id="rf0140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gustafson
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation
        </article-title>
        <source>
         J. Pharmacol. Exp. Ther.
        </source>
        <volume>
         365
        </volume>
        <issue>
         3
        </issue>
        <year>
         2018
        </year>
        <fpage>
         447
        </fpage>
        <lpage>
         459
        </lpage>
        <pub-id pub-id-type="pmid">
         29438998
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0145">
       <label>
        29
       </label>
       <element-citation id="rf0145" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           T.-H.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           T.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.-H.
          </given-names>
         </name>
         <name>
          <surname>
           Chiou
          </surname>
          <given-names>
           J.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           Y.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           J.C.-C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome
        </article-title>
        <source>
         QJM
        </source>
        <volume>
         112
        </volume>
        <issue>
         10
        </issue>
        <year>
         1 oct 2019
        </year>
        <fpage>
         757
        </fpage>
        <lpage>
         762
        </lpage>
        <pub-id pub-id-type="pmid">
         31218368
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0150">
       <label>
        30
       </label>
       <element-citation id="rf0150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Krishna
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           White
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pharmacokinetics of quinine, chloroquine and amodiaquine
        </article-title>
        <source>
         Clinical implications. Clin Pharmacokinet. avr
        </source>
        <volume>
         30
        </volume>
        <issue>
         4
        </issue>
        <year>
         1996
        </year>
        <fpage>
         263
        </fpage>
        <lpage>
         299
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0155">
       <label>
        31
       </label>
       <element-citation id="rf0155" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jorge
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ung
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Young
          </surname>
          <given-names>
           L.H.
          </given-names>
         </name>
         <name>
          <surname>
           Melles
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           H.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine retinopathy - implications of research advances for rheumatology care
        </article-title>
        <source>
         Nat. Rev. Rheumatol.
        </source>
        <volume>
         14
        </volume>
        <issue>
         12
        </issue>
        <year>
         2018
        </year>
        <fpage>
         693
        </fpage>
        <lpage>
         703
        </lpage>
        <pub-id pub-id-type="pmid">
         30401979
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0160">
       <label>
        32
       </label>
       <element-citation id="rf0160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Osadchy
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ratnapalan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Koren
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature
        </article-title>
        <source>
         J Rheumatol. déc
        </source>
        <volume>
         38
        </volume>
        <issue>
         12
        </issue>
        <year>
         2011
        </year>
        <fpage>
         2504
        </fpage>
        <lpage>
         2508
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0165">
       <label>
        33
       </label>
       <element-citation id="rf0165" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Bari
          </surname>
          <given-names>
           M.A.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases
        </article-title>
        <source>
         Pharmacol. Res. Perspect.
        </source>
        <volume>
         5
        </volume>
        <issue>
         1
        </issue>
        <year>
         2017
        </year>
        <object-id pub-id-type="publisher-id">
         e00293
        </object-id>
       </element-citation>
      </ref>
      <ref id="bb0170">
       <label>
        34
       </label>
       <element-citation id="rf0170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wolfram
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Insights from nanomedicine into chloroquine efficacy against COVID-19
        </article-title>
        <source>
         Nat Nanotechnol.
        </source>
        <year>
         23 mars 2020
        </year>
       </element-citation>
      </ref>
      <ref id="bb0175">
       <label>
        35
       </label>
       <element-citation id="rf0175" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mallucci
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of chloroquine on lysosomes and on growth of mouse hepatitis virus (MHV-3)
        </article-title>
        <source>
         Virology. mars
        </source>
        <volume>
         28
        </volume>
        <issue>
         3
        </issue>
        <year>
         1966
        </year>
        <fpage>
         355
        </fpage>
        <lpage>
         362
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0180">
       <label>
        36
       </label>
       <element-citation id="rf0180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takano
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Katoh
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Doki
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Hohdatsu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo
        </article-title>
        <source>
         Antiviral Res. août
        </source>
        <volume>
         99
        </volume>
        <issue>
         2
        </issue>
        <year>
         2013
        </year>
        <fpage>
         100
        </fpage>
        <lpage>
         107
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0185">
       <label>
        37
       </label>
       <element-citation id="rf0185" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           K.-F.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-malaria drug chloroquine is highly effective in treating avian influenza a H5N1 virus infection in an animal model
        </article-title>
        <source>
         Cell Res. févr
        </source>
        <volume>
         23
        </volume>
        <issue>
         2
        </issue>
        <year>
         2013
        </year>
        <fpage>
         300
        </fpage>
        <lpage>
         302
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0190">
       <label>
        38
       </label>
       <element-citation id="rf0190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lucia
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
         <name>
          <surname>
           Rastrelli
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Rutella
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Golotta
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Morra
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors
        </article-title>
        <source>
         J Acquir Immune Defic Syndr.
        </source>
        <volume>
         35
        </volume>
        <issue>
         3
        </issue>
        <year>
         1 mars 2004
        </year>
        <fpage>
         223
        </fpage>
        <lpage>
         232
        </lpage>
        <pub-id pub-id-type="pmid">
         15076236
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0195">
       <label>
        39
       </label>
       <element-citation id="rf0195" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kirchdoerfer
          </surname>
          <given-names>
           R.N.
          </given-names>
         </name>
         <name>
          <surname>
           Cottrell
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Pallesen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yassine
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pre-fusion structure of a human coronavirus spike protein
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         531
        </volume>
        <issue>
         7592
        </issue>
        <year>
         3 mars 2016
        </year>
        <fpage>
         118
        </fpage>
        <lpage>
         121
        </lpage>
        <pub-id pub-id-type="pmid">
         26935699
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0200">
       <label>
        40
       </label>
       <element-citation id="rf0200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ujike
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Taguchi
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incorporation of spike and membrane glycoproteins into coronavirus virions
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         7
        </volume>
        <issue>
         4
        </issue>
        <year>
         3 avr 2015
        </year>
        <fpage>
         1700
        </fpage>
        <lpage>
         1725
        </lpage>
        <pub-id pub-id-type="pmid">
         25855243
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0205">
       <label>
        41
       </label>
       <element-citation id="rf0205" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schrezenmeier
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Dörner
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
        </article-title>
        <source>
         Nat Rev Rheumatol. mars
        </source>
        <volume>
         16
        </volume>
        <issue>
         3
        </issue>
        <year>
         2020
        </year>
        <fpage>
         155
        </fpage>
        <lpage>
         166
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0210">
       <label>
        42
       </label>
       <element-citation id="rf0210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
        </article-title>
        <source>
         Cell Discov.
        </source>
        <volume>
         6
        </volume>
        <year>
         2020
        </year>
        <fpage>
         16
        </fpage>
        <pub-id pub-id-type="pmid">
         32194981
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
  </pmc-articleset>
 </body>
</html>